U.S. patent application number 16/014231 was filed with the patent office on 2018-10-18 for pyrazolo[1,5a]pyrimidine derivatives as irak4 modulators.
This patent application is currently assigned to Genentech, Inc.. The applicant listed for this patent is Genentech, Inc.. Invention is credited to Marian C. Bryan, Joy Drobnick, Jianwen Feng, Alberto Gobbi, James Richard Kiefer, JR., Aleksandr Kolesnikov, Jun Liang, Chudi Ndubaku, Alan G. Olivero, Naomi Rajapaksa.
Application Number | 20180298015 16/014231 |
Document ID | / |
Family ID | 57755272 |
Filed Date | 2018-10-18 |
United States Patent
Application |
20180298015 |
Kind Code |
A1 |
Bryan; Marian C. ; et
al. |
October 18, 2018 |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
Abstract
Compounds of Formula 0, Formula I, and Formula II and methods of
use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors
are described herein.
Inventors: |
Bryan; Marian C.; (San
Francisco, CA) ; Gobbi; Alberto; (San Francisco,
CA) ; Kiefer, JR.; James Richard; (Belmont, CA)
; Kolesnikov; Aleksandr; (San Francisco, CA) ;
Olivero; Alan G.; (Half Moon Bay, CA) ; Drobnick;
Joy; (Daly City, CA) ; Liang; Jun; (Los Altos
Hills, CA) ; Rajapaksa; Naomi; (San Mateo, CA)
; Ndubaku; Chudi; (Oakland, CA) ; Feng;
Jianwen; (Millbrae, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Genentech, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
Genentech, Inc.
South San Francisco
CA
|
Family ID: |
57755272 |
Appl. No.: |
16/014231 |
Filed: |
June 21, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/EP2016/081810 |
Dec 19, 2016 |
|
|
|
16014231 |
|
|
|
|
62271171 |
Dec 22, 2015 |
|
|
|
62279459 |
Jan 15, 2016 |
|
|
|
62398341 |
Sep 22, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
A61P 37/02 20180101; C07D 519/00 20130101; A61P 29/00 20180101;
C07D 487/04 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; C07D 519/00 20060101 C07D519/00; A61P 29/00 20060101
A61P029/00; A61P 35/00 20060101 A61P035/00; A61P 37/02 20060101
A61P037/02 |
Claims
1. A compound of Formula 0: ##STR01840## or a stereoisomer or
pharmaceutically acceptable salt thereof, wherein: R.sup.1 is
hydrogen or halogen; R.sup.3 is hydrogen, halogen, CN, OH,
C.sub.1-3alkyl, C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.1-2NR.sup.6R.sup.7, --NR.sup.8R.sup.9,
--O--C.sub.1-3alkyl, a 3-7 membered monocyclic saturated or
partially saturated heterocyclic group, a 5-6 membered monocyclic
heteroaryl ring, or a 5-6 membered monocyclic aryl ring, wherein
any alkyl, alkanoyl, or alkenyl is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and wherein any cycloalkyl group, heterocyclic
group, heteroaryl ring, or aryl ring is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, a 3-7 membered monocyclic saturated
or partially saturated heterocyclic group, --C(O)NR.sup.8R.sup.9,
or --NR.sup.8R.sup.9, wherein any alkyl, alkenyl, or heterocyclic
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, or a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group that
may be optionally substituted with oxo; R.sup.5 is hydrogen, --CN,
C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.3-10cycloalkyl group,
--NR.sup.8R.sup.9, --C(O)NR.sup.8R.sup.9, --O(C.sub.3-7cycloalkyl
group), --O(C.sub.1-3alkyl)-3-8 membered cycloalkyl group,
--O(C.sub.0-3alkyl)-3-8 membered saturated or partially saturated
heterocyclic group, --O(C.sub.1-3alkyl)-phenyl, a --O(C.sub.1-3
alkyl)-5-6 membered heteroaryl ring, a 3-11 membered saturated or
partially saturated heterocyclic group, or a 5-6 membered
monocyclic heteroaryl ring, wherein any alkyl or alkoxy is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, or a 3-11 membered saturated
or partially saturated heterocyclic group that may be optionally
substituted with (i) --C(O)(C.sub.1-3alkyl) optionally substituted
with halogen or (ii) with C.sub.1-3alkyl optionally substituted
with halogen, and wherein any cycloalkyl group, heterocyclic group,
phenyl, or heteroaryl ring is optionally substituted by halogen;
oxo; CN; OH; C.sub.1-6alkoxy; --NR.sup.8R.sup.9;
--C(O)(C.sub.1-3alkyl); --(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.12NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl; A is a 3-11 membered heterocyclic
group optionally substituted by halogen, oxo, CN, OH,
C.sub.1-6alkyl, --(C.sub.0-3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-3alkyl)-3-11 membered heterocyclic group,
--NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.1-2NR.sup.10R.sup.11, or
--(C.sub.0-3alkyl)-OP(O)(OC.sub.1-3alkyl).sub.2, wherein any alkyl,
cycloalkyl group, or heterocyclic group is independently optionally
substituted by halogen; oxo; CN; OR.sup.13; C.sub.1-3haloalkoxy;
--C(O)(C.sub.1-3alkyl); --S--C.sub.1-3alkyl; or C.sub.1-3alkyl
optionally substituted with OH, halogen, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, or a 3-8 membered
heterocyclic group, and wherein when A is a 5-membered nitrogen
containing heterocyclic group, the nitrogen atom is substituted;
R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group, wherein any
alkyl or cycloalkyl group is independently optionally substituted
by halogen, oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy; R.sup.8, R.sup.9, R.sup.10
and R.sup.11 are, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl group,
--(C.sub.0-3alkyl)-phenyl, a 3-11 membered saturated heterocyclic
group, a 5-6 membered monocyclic heteroaryl ring, --C(O)R.sup.13,
--C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or --S(O).sub.1-2R.sup.13,
or R.sup.10 and R.sup.11 are taken together to form a 5-8 membered
heterocyclic group, wherein any alkyl, cycloalkyl group, phenyl,
heterocyclic group, or heteroaryl ring is independently optionally
substituted by halogen, oxo, CN, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, C.sub.1-3haloalkoxy,
--OR.sup.13, --NR.sup.6R.sup.7, or a 5-6 membered monocyclic
heteroaryl ring; R.sup.12 is, independently at each occurrence,
hydrogen, C.sub.1-6alkyl or C.sub.3-6cycloalkyl group, wherein any
alkyl or cycloalkyl group is independently optionally substituted
by halogen, oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy; R.sup.13 is, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-10cycloalkyl
group, or a 3-11 membered saturated heterocyclic group, wherein any
alkyl, cycloalkyl group, or heterocyclic group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, C.sub.1-3haloalkoxy,
--OR.sup.12, or --NR.sup.6R.sup.7; and R.sup.16 is hydrogen,
halogen, CN, or C.sub.1-3alkyl optionally substituted with
--NH.sub.2, halogen, or CN.
2. The compound of claim 1, further defined as a compound of
Formula I: ##STR01841## or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein: R.sup.1 is hydrogen or halogen;
R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.1-2NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring, wherein any alkyl, alkanoyl, or alkenyl is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy, and any cycloalkyl group
or other ring is independently optionally substituted by halogen,
oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl; R.sup.4 is
hydrogen, halogen, C.sub.1-3alkyl, C.sub.2-3alkenyl,
--(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9; wherein any
alkyl or alkenyl is independently optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), --O(C.sub.1-3alkyl)-3-8 membered
cycloalkyl group, --O(C.sub.1-3alkyl)-3-8 membered saturated or
partially saturated heterocyclic group, --O(C.sub.1-3alkyl)-phenyl,
a --O(C.sub.1-3alkyl)-5-6 membered heteroaryl ring, a 3-11 membered
saturated or partially saturated heterocyclic group, or a 5-6
membered monocyclic heteroaryl ring, wherein any alkyl or alkoxy is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy, and any cycloalkyl group
or other ring is optionally substituted by halogen, oxo, CN, OH,
C.sub.1-6alkoxy, --C(O)(C.sub.1-3alkyl),
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.8R.sup.9, --OP(O)(OC.sub.1-3alkyl).sub.2, a 5-6
membered monocyclic heteroaryl ring optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl, or
C.sub.1-3alkyl optionally substituted by halogen, oxo, CN, OH,
phenyl, a 3-8 membered saturated heterocyclic group, a 5-6 membered
monocyclic heteroaryl ring, or --NR.sup.8R.sup.9; A is a 3-11
membered heterocyclic group optionally substituted by halogen, oxo,
CN, OH, C.sub.1-6alkyl,
--(C.sub.0-C.sub.3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-C.sub.3alkyl)-3-11 membered heterocyclic group
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl, --NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.12NR.sup.10R.sup.11, or --OP(O)(OC.sub.1-3alkyl).sub.2,
wherein any alkyl, cycloalkyl group, or heterocyclic group is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-8 membered heterocyclic group; wherein
when A is a 5-membered nitrogen containing heterocyclic group, the
nitrogen atom is substituted; R.sup.6 and R.sup.7 are,
independently at each occurrence, hydrogen, C.sub.1-3alkyl, or
C.sub.3-6cycloalkyl group, wherein any alkyl or cycloalkyl group is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy; R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are,
independently at each occurrence, hydrogen, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl group, --(C.sub.0-3alkyl)-phenyl, a 3-11
membered saturated heterocyclic group, --C(O)R.sup.13,
--C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or --S(O).sub.1-2R.sup.13,
or R.sup.10 and R.sup.11 are taken together to form a 5-8 membered
heterocyclic group optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy; wherein any alkyl, cycloalkyl group, or other
ring is independently optionally substituted by halogen, oxo, CN,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.13, or --NR.sup.6R.sup.7; R.sup.12
is, independently at each occurrence, hydrogen, C.sub.1-6alkyl or
C.sub.3-6cycloalkyl group, wherein any alkyl or cycloalkyl group is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy; R.sup.13 is, independently at each occurrence,
hydrogen, C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11
membered saturated heterocyclic group, wherein any alkyl,
cycloalkyl group, or other ring is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, C.sub.1-3haloalkoxy,
--OR.sup.12, or --NR.sup.6R.sup.7; and R.sup.16 is H, --Cl, --CN,
or --CH.sub.3.
3. The compound of claim 1, further defined as a compound of
Formula II: ##STR01842## or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein: R.sup.1 is hydrogen or halogen;
R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.1-2NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring, wherein any alkyl, alkanoyl, or alkenyl is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy, and any cycloalkyl group
or other ring is independently optionally substituted by halogen,
oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl; R.sup.4 is
hydrogen, halogen, C.sub.1-3alkyl, C.sub.2-3alkenyl,
--(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9; wherein any
alkyl or alkenyl is independently optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), a 3-11 membered saturated or
partially saturated heterocyclic group, or a 5-6 membered
monocyclic heteroaryl ring, wherein any alkyl or alkoxy is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy, and any cycloalkyl group
or other ring is optionally substituted by halogen, oxo, CN, OH,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9; A is a
3-11 membered heterocyclic group optionally substituted by halogen,
oxo, CN, OH, C.sub.1-6alkyl, C.sub.3-6cycloalkyl group,
--NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)NR.sup.10R.sup.11,
--C(O)OR.sup.13, or --S(O).sub.1-2NR.sup.10R.sup.11, wherein any
alkyl or cycloalkyl group is independently optionally substituted
by halogen, oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy; wherein when A is a
5-membered nitrogen containing heterocyclic group, the nitrogen
atom is substituted; R.sup.6 and R.sup.7 are, independently at each
occurrence, hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
wherein any alkyl or cycloalkyl group is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently at each
occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl group, a
3-11 membered saturated heterocyclic group, --C(O)R.sup.13,
--C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or --S(O).sub.1-2R.sup.13,
wherein any alkyl, cycloalkyl group or other ring is independently
optionally substituted by halogen, oxo, CN, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, C.sub.1-3haloalkoxy,
--OR.sup.13, or --NR.sup.6R.sup.7; R.sup.12 is, independently at
each occurrence, hydrogen, C.sub.1-6alkyl or C.sub.3-6cycloalkyl
group, wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group, wherein any alkyl, cycloalkyl group,
or other ring is independently optionally substituted by halogen,
oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
R.sup.16 is H, --Cl, --CN, or --CH.sub.3.
4. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1 and R.sup.4 are each
hydrogen, and R.sup.3 is hydrogen, OH, halogen, CH.sub.3,
CH.sub.2OH, CH.sub.2F, OCHF.sub.2, CHF.sub.2, CF.sub.3,
cyclopropyl, azetidinyl, CN, --C(O)CH.sub.3, --C(O)NH.sub.2,
--C(O)NHCH.sub.3, --NHCH.sub.3, --SO.sub.2--NH.sub.2, or
--SO.sub.2--NHCH.sub.3.
5. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1 and R.sup.4 are each
hydrogen, and R.sup.3 is hydrogen, OH, CH.sub.3, or CH.sub.2OH.
6. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1 and R.sup.4 are each
hydrogen, and R.sup.3 is Br, Cl, F, OCHF.sub.2, CHF.sub.2, or
CF.sub.3.
7. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1 and R.sup.4 are each
hydrogen, and R.sup.3 is cyclopropyl, azetidinyl, CN,
--C(O)CH.sub.3, --C(O)NH.sub.2, --C(O)NHCH.sub.3, --NHCH.sub.3,
--SO.sub.2--NH.sub.2, or --SO.sub.2--NHCH.sub.3.
8. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1 and R.sup.3 are each
hydrogen, and R.sup.4 is Cl, CHF.sub.2, ##STR01843## or a
stereoisomer thereof.
9. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.1, R.sup.3, and R.sup.4 are
each hydrogen.
10. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is a 3-11 membered
saturated or partially saturated heterocyclic group optionally
substituted by halogen, oxo, CN, OH,
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9.
11. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is an N-linked 3-11
membered saturated heterocyclic group optionally substituted by
halogen, oxo, CN, OH, --(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9.
12. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the ring heteroatoms of the 3-11
membered saturated or partially saturated heterocyclic group of
R.sup.5 are selected from nitrogen and oxygen.
13. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is piperidinyl,
piperazinyl, or morpholinyl, wherein any R.sup.5 is optionally
substituted by halogen; oxo; CN; OH; C.sub.1-6alkoxy;
--NR.sup.8R.sup.9; --C(O)(C.sub.1-3alkyl);
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.1-2NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl.
14. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is N-linked piperidinyl,
N-linked piperazinyl, or N-linked morpholinyl, wherein any R.sup.5
is optionally substituted by halogen, oxo, CN, OH, or
C.sub.1-3alkyl optionally substituted by halogen, oxo, CN, or
OH.
15. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is --CH.sub.2CH.sub.3,
--C(CH.sub.3).sub.2, Cl, CN, cyclopropyl, --C(O)NH.sub.2,
--OCH.sub.3, --OCH.sub.2CF.sub.3, --OCH.sub.2CHF.sub.2, --CF.sub.3,
--CHF.sub.2, --OCF.sub.3, --OCHF.sub.2, --NHCH.sub.3,
--N(CH.sub.3).sub.2, ##STR01844## ##STR01845## ##STR01846##
##STR01847## ##STR01848## ##STR01849## ##STR01850## ##STR01851##
##STR01852## ##STR01853## ##STR01854## ##STR01855## ##STR01856##
##STR01857## or a stereoisomer thereof.
16. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is ##STR01858##
##STR01859## ##STR01860## or a stereoisomer thereof.
17. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein R.sup.5 is ##STR01861##
18. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein A is a 3-11 membered, non-aromatic
heterocyclic group.
19. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein A is a 3-11 membered heterocyclic
group comprising at least one oxygen as a ring atom and is
optionally substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11, wherein any alkyl or cycloalkyl
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy.
20. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the following portion of Formula
0, Formula I, or Formula II ##STR01862## is further defined as 0-A,
I-A, or II-A: ##STR01863## wherein A is a 5 or 6 membered ring
optionally containing an additional ring heteroatom and wherein A
is optionally substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.1-2R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11, wherein any alkyl or cycloalkyl
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy.
21. The compound of claim 20, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein 0-A, I-A, or II-A is further
defined as 0-B, I--B, or II-B: ##STR01864## wherein R.sup.14 and
R.sup.15 are each selected from halogen, oxo, CN, OH,
C.sub.1-6alkyl, C.sub.3-6 cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, and
--S(O).sub.1-2NR.sup.10R.sup.11, wherein any alkyl or cycloalkyl
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy; or R.sup.14 and R.sup.15 together form a
C.sub.3-6cycloalkyl group or saturated or partially saturated 3-6
membered heterocyclic group, wherein any cycloalkyl group or other
ring is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy.
22. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein A does not contain oxygen as a
ring atom and is optionally substituted by halogen, oxo, CN, OH,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.1-2R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11, wherein any alkyl or cycloalkyl
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3 alkoxy, or
C.sub.1-3haloalkoxy.
23. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the following portion of Formula
0, Formula I, or Formula II ##STR01865## is further defined as 0-C,
I-C, or II-C: ##STR01866## wherein the nitrogen comprises a
substituent as defined in claim 1.
24. The compound of claim 23, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the following portion of Formula
0, Formula I, or Formula II ##STR01867## is further defined as 0-C,
I-C, or II-C: ##STR01868## wherein the nitrogen of A is substituted
by C.sub.1-6alkyl or C.sub.3-6cycloalkyl group, wherein any alkyl
or cycloalkyl group is independently optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy.
25. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the following portion of Formula
0, Formula I, or Formula II ##STR01869## is selected from
##STR01870## ##STR01871## ##STR01872## ##STR01873## ##STR01874##
##STR01875## ##STR01876## ##STR01877## ##STR01878## ##STR01879##
##STR01880## ##STR01881## ##STR01882## ##STR01883## ##STR01884##
##STR01885## ##STR01886## or a stereoisomer thereof.
26. The compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof, wherein the following portion of Formula
0, Formula I, or Formula II ##STR01887## is selected from
##STR01888## ##STR01889## ##STR01890## ##STR01891## ##STR01892##
and stereoisomers thereof.
27. The compound of claim 1, wherein the compound is not
##STR01893##
28. The compound of claim 1, selected from the group consisting of
the compounds of Tables 1, 2 and 3, or a stereoisomer or
pharmaceutically acceptable salt thereof.
29. A pharmaceutical composition comprising a compound of claim 1,
or a stereoisomer or pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable excipient, carrier or diluent.
30. A method of preventing, treating, or lessening the severity of
a disease or condition responsive to the inhibition of IRAK4 in a
patient, comprising administering to the patient a therapeutically
effective amount of a compound of claim 1, or a stereoisomer or
pharmaceutically acceptable salt thereof.
31. A method for treating cancer in a patient, comprising
administering to the patient a therapeutically effective amount of
a compound of claim 1, or a stereoisomer or pharmaceutically
acceptable salt thereof.
32. A method for treating an inflammatory or autoimmune disease in
a patient, comprising administering to the patient a
therapeutically effective amount of a compound of claim 1, or a
stereoisomer or pharmaceutically acceptable salt thereof.
33. The method of claim 32, wherein the disease is selected from
the group consisting of Crohn's disease, ulcerative colitis,
Irritable Bowel Disorder (IBD), asthma, graft versus host disease,
allograft rejection, chronic obstructive pulmonary disease (COPD),
rheumatoid arthritis, systemic lupus erythematosus, lupus
nephritis, cutaneous lupus, psoriasis, systemic onset juvenile
idiopathic arthritis, multiple sclerosis, neuropathic pain, gout,
and gouty arthritis.
34. A method of inhibiting IRAK4 in a cell, ex vivo, comprising
contacting the cell with an effective amount of a compound of claim
1, or a stereoisomer or salt thereof.
35. A method of inhibiting IRAK4 in a patient in need of therapy,
comprising administering to the patient a therapeutically effective
amount of a compound of claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of International
Application No. PCT/EP2016/081810, filed Dec. 19, 2016, which
claims priority to U.S. provisional application Ser. No.
62/271,171, filed Dec. 22, 2015; U.S. provisional application Ser.
No. 62/279,459, filed Jan. 15, 2016; and U.S. provisional
application Ser. No. 62/398,341, filed Sep. 22, 2016, each of which
is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention pertains to compounds useful for inhibition
of Interleukin-1 Receptor Associated Kinase 4 (IRAK4).
BACKGROUND OF THE INVENTION
[0003] TIR-domain (Toll-Interleukin 1 Receptor-domain) containing
cell surface receptors such as the Toll-like receptors (TLR) and
the IL-1 and IL-18 receptors play critical roles in innate immunity
and have been implicated in the pathogenesis of autoimmunity. TLRs,
for example, recognize pathogenic or endogenous ligands and provide
a requisite signal for dendritic cell maturation and antigen
presentation to T cell. Similarly, proteins that mediate signaling
from these receptors have also been shown to play important roles
in the pathogenesis of autoimmune disorders. For example mice
deficient in MyD88, an adaptor protein that directly interacts with
the TIR domain, are more susceptible to bacterial, fungal and
parasitic infections. In addition, MyD88 deficient mice are
resistant to experimental autoimmune encephalomyelitis (EAE) and
streptococcal cell wall-induced arthritis.
[0004] The Interleukin-1 Receptor Associated Kinase (IRAK) family
is comprised of four family members IRAK1, IRAK2, IRAK3 (also
termed IRAK-M), and IRAK4. These proteins are characterized by a
typical N-terminal death domain that mediates interaction with
MyD88-family adaptor proteins and a centrally located kinase
domain. Whereas IRAK1 and IRAK4 have kinase activity, IRAK2 and
IRAK3 are catalytically inactive. Upon activation of their upstream
cognate receptors, IRAK4 is thought to phosphorylate IRAK1,
resulting in the activation and autophosphorylation of IRAK1 and
subsequent phosphorylation of downstream substrates. The
hyperphosphorylation of IRAK1 directs its dissociation from the
receptor complex and its eventual ubiquitylation and proteasomal
degradation. Phosphorylation of downstream substrates such as
Pellino-2 ultimately leads to the activation of the MAPKs such as
p38 and c-Jun N-terminal kinase (JNK) and NF-kB followed by
production of pro-inflammatory cytokines, chemokines, and
destructive enzyme.
[0005] The role of IRAK4 in innate immunity and in the pathogenesis
of autoimmune diseases is emerging. See, e.g., Li et al., "IRAK-4:
A novel member of the IRAK family with the properties of an
IRAK-kinase," PNAS 2002, 99(8), 5567-5572; Flannery et al., "The
interleukin-1 receptor-associated kinases: Critical regulators of
innate immune signaling," Biochem Pharm 2010, 80(12), 1981-1991.
Patients with destabilizing or null mutations in IRAK4 demonstrate
defects in TLR signaling and the production of pro-inflammatory
cytokines such as IL-1 and TNF as well as antiviral cytokines such
as IFN.alpha. and IFN.beta.. These patients demonstrate an
increased susceptibility to gram-positive bacterial infections
although they are generally resistant to gram-negative bacterial,
viral, and fungal infections. Similarly, IRAK4 deficient mice have
defects in TLR- and IL-1-mediated cytokine production and exhibit
an increased susceptibility to infection. IRAK1 deficient mice
demonstrate a loss of responsiveness to lipopolysaccharides (LPS),
IL-1, and IL-18 as well as impaired Th1 development. These mice
were resistant to experimental autoimmune encephalomyelitis,
exhibiting little or no CNS inflammation.
[0006] Accordingly, compounds that modulate the function of IRAK4
represent an attractive approach to the development of therapeutic
agents for the treatment of diseases such as inflammatory, cell
proliferative and immune-related conditions and diseases associated
with IRAK-mediated signal transduction, such as rheumatoid
arthritis, inflammatory bowel disease, multiple sclerosis, lupus,
diabetes, obesity, allergic disease, psoriasis, asthma, graft
rejection, cancer and sepsis.
SUMMARY OF THE INVENTION
[0007] One aspect of the invention includes a compound of Formula
0:
##STR00001##
[0008] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0009] wherein:
[0010] R.sup.1 is hydrogen or halogen; R.sup.3 is hydrogen,
halogen, CN, OH, C.sub.1-3alkyl, C.sub.2-3alkenyl,
C.sub.3-7cycloalkyl group, C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.12NR.sup.6R.sup.7, --NR.sup.8R.sup.9,
--O--C.sub.1-3alkyl, a 3-7 membered monocyclic saturated or
partially saturated heterocyclic group, a 5-6 membered monocyclic
heteroaryl ring, or a 5-6 membered monocyclic aryl ring,
[0011] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0012] wherein any cycloalkyl group, heterocyclic group, heteroaryl
ring, or aryl ring is independently optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl;
[0013] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl,
--(C.sub.0-C.sub.3alkyl)C(O)R.sup.13--(C.sub.2-3alkenyl)C(O)NR.sup.10R.su-
p.11, --S(O).sub.12NR.sup.10R.sup.11, a 3-7 membered monocyclic
saturated or partially saturated heterocyclic group,
--C(O)NR.sup.8R.sup.9, or --NR.sup.8R.sup.9,
[0014] wherein any alkyl, alkenyl, or heterocyclic group is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, or a 3-7 membered monocyclic
saturated or partially saturated heterocyclic group that may be
optionally substituted with oxo;
[0015] R.sup.5 is hydrogen, --CN, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, --O(C.sub.3-7cycloalkyl group),
--O(C.sub.1-3alkyl)-3-8 membered cycloalkyl group,
--O(C.sub.0-C.sub.3alkyl)-3-8 membered saturated or partially
saturated heterocyclic group, --O(C.sub.1-3alkyl)-phenyl, a
--O(C.sub.1-3 alkyl)-5-6 membered heteroaryl ring, a 3-11 membered
saturated or partially saturated heterocyclic group, or a 5-6
membered monocyclic heteroaryl ring,
[0016] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-11 membered saturated or partially
saturated heterocyclic group that may be optionally substituted
with (i) --C(O)(C.sub.1-3alkyl) optionally substituted with halogen
or (ii) with C.sub.1-3alkyl optionally substituted with halogen,
and
[0017] wherein any cycloalkyl group, heterocyclic group, phenyl, or
heteroaryl ring is optionally substituted by halogen; oxo; CN; OH;
C.sub.1-6alkoxy; --NR.sup.8R.sup.9; --C(O)(C.sub.1-3alkyl);
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.12NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl;
[0018] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
--(C.sub.0-3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-3alkyl)-3-11 membered heterocyclic group,
--NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.1-2R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.1-2N.sup.10R.sup.11, or
--(C.sub.0-3alkyl)-OP(O)(OC.sub.1-3alkyl).sub.2,
[0019] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen; oxo; CN;
OR.sup.13; C.sub.1-3haloalkoxy; --C(O)(C.sub.1-3alkyl);
--S--C.sub.1-3alkyl; or C.sub.1-3alkyl optionally substituted with
OH, halogen, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-8 membered heterocyclic group, and
[0020] wherein when A is a 5-membered nitrogen containing
heterocyclic group, the nitrogen atom is substituted;
[0021] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0022] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0023] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, --(C.sub.0-3alkyl)-phenyl, a 3-11 membered saturated
heterocyclic group, a 5-6 membered monocyclic heteroaryl ring,
--C(O)R.sup.13, --C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or
--S(O).sub.1-2R.sup.13, or R.sup.10 and R.sup.11 are taken together
to form a 5-8 membered heterocyclic group,
[0024] wherein any alkyl, cycloalkyl group, phenyl, heterocyclic
group, or heteroaryl ring is independently optionally substituted
by halogen, oxo, CN, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, --OR.sup.13,
--NR.sup.6R.sup.7, or a 5-6 membered monocyclic heteroaryl
ring;
[0025] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0026] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0027] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0028] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0029] R.sup.16 is hydrogen, halogen, CN, or C.sub.1-3alkyl
optionally substituted with --NH.sub.2, halogen, or CN.
[0030] Another aspect of the invention includes a compound of
Formula I:
##STR00002##
[0031] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0032] wherein:
[0033] R.sup.1 is hydrogen or halogen;
[0034] R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.12NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring,
[0035] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and any cycloalkyl group or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, or C.sub.1-3haloalkyl;
[0036] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9;
[0037] wherein any alkyl or alkenyl is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0038] R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), --O(C.sub.1-3alkyl)-3-8 membered
cycloalkyl group, --O(C.sub.1-3alkyl)-3-8 membered saturated or
partially saturated heterocyclic group, --O(C.sub.1-3alkyl)-phenyl,
a --O(C.sub.1-3alkyl)-5-6 membered heteroaryl ring, a 3-11 membered
saturated or partially saturated heterocyclic group, or a 5-6
membered monocyclic heteroaryl ring,
[0039] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0040] any cycloalkyl group or other ring is optionally substituted
by halogen, oxo, CN, OH, C.sub.1-6alkoxy, --C(O)(C.sub.1-3alkyl),
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.8R.sup.9, --OP(O)(OC.sub.1-3alkyl).sub.2, a 5-6
membered monocyclic heteroaryl ring optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl, or
C.sub.1-3alkyl optionally substituted by halogen, oxo, CN, OH,
phenyl, a 3-8 membered saturated heterocyclic group, a 5-6 membered
monocyclic heteroaryl ring, or --NR.sup.8R.sup.9;
[0041] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
--(C.sub.0-C.sub.3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-C.sub.3alkyl)-3-11 membered heterocyclic group
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl, --NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.1-2NR.sup.10R.sup.11, or
--OP(O)(OC.sub.1-3alkyl).sub.2,
[0042] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-8 membered heterocyclic group;
[0043] wherein when A is a 5-membered nitrogen containing
heterocyclic group, the nitrogen atom is substituted;
[0044] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0045] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0046] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, --(C.sub.0-3alkyl)-phenyl, a 3-11 membered saturated
heterocyclic group, --C(O)R.sup.13, --C(O)OR.sup.13,
--C(O)NR.sup.6R.sup.7, or --S(O).sub.1-2R.sup.13, or R.sup.10 and
R.sup.11 are taken together to form a 5-8 membered heterocyclic
group optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0047] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.13, or --NR.sup.6R.sup.7;
[0048] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0049] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0050] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0051] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0052] R.sup.16 is H, --Cl, --CN, or --CH.sub.3.
[0053] Yet another aspect of the invention includes a compound of
Formula II:
##STR00003##
[0054] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0055] wherein:
[0056] R.sup.1 is hydrogen or halogen;
[0057] R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.12NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring,
[0058] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and any cycloalkyl group or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, or C.sub.1-3haloalkyl;
[0059] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9;
[0060] wherein any alkyl or alkenyl is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0061] R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), a 3-11 membered saturated or
partially saturated heterocyclic group, or a 5-6 membered
monocyclic heteroaryl ring,
[0062] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0063] any cycloalkyl group or other ring is optionally substituted
by halogen, oxo, CN, OH, --(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9;
[0064] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11,
[0065] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
wherein when A is a 5-membered nitrogen containing heterocyclic
group, the nitrogen atom is substituted;
[0066] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0067] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0068] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, a 3-11 membered saturated heterocyclic group,
--C(O)R.sup.13, --C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or
--S(O).sub.1-2R.sup.13
[0069] wherein any alkyl, cycloalkyl group or other ring is
independently optionally substituted by halogen, oxo, CN,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.13, or --NR.sup.6R.sup.7;
[0070] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0071] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0072] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0073] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0074] R.sup.16 is H, --Cl, --CN, or --CH.sub.3.
[0075] Also provided is a pharmaceutical composition that comprises
a compound of the invention and a pharmaceutically acceptable
carrier, diluent or excipient.
[0076] Another aspect includes a compound of the invention for use
in therapy, such as the treatment of an inflammatory disease, an
autoimmune disease or cancer.
[0077] Another aspect includes a method of preventing, treating or
lessening the severity of a disease or condition responsive to the
inhibition of IRAK4, in a patient. The method can comprise
administering to the patient a therapeutically effective amount of
a compound of the invention.
[0078] Another aspect includes the use of a compound of the
invention in the manufacture of a medicament for the treatment of a
disease responsive to the inhibition of IRAK4.
[0079] Another aspect includes a kit for treating a disease or
disorder responsive to the inhibition of IRAK4. The kit can
comprise a first pharmaceutical composition comprising a compound
of the invention, and instructions for use.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0080] "Halogen" or "halo" refers to F, Cl, Br or I. Additionally,
terms such as "haloalkyl," are meant to include monohaloalkyl and
polyhaloalkyl.
[0081] The term "alkyl" refers to a saturated linear or
branched-chain monovalent hydrocarbon radical, wherein the alkyl
radical may be optionally substituted. In one example, the alkyl
radical is one to eighteen carbon atoms (C.sub.1-C.sub.18). In
other examples, the alkyl radical is C.sub.0-C.sub.6,
C.sub.0-C.sub.5, C.sub.0-C.sub.3, C.sub.1-C.sub.12,
C.sub.1-C.sub.10, C.sub.1-C.sub.8, C.sub.1-C.sub.6,
C.sub.1-C.sub.5, C.sub.1-C.sub.4, or C.sub.1-C.sub.3. C.sub.0 alkyl
refers to a bond. Examples of alkyl groups include methyl (Me,
--CH.sub.3), ethyl (Et, --CH.sub.2CH.sub.3), 1-propyl (n-Pr,
n-propyl, --CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, 1-heptyl and
1-octyl. In some embodiments, substituents for "optionally
substituted alkyls" include one to four instances of F, Cl, Br, I,
OH, SH, CN, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, NO.sub.2,
N.sub.3, C(O)CH.sub.3, COOH, CO.sub.2CH.sub.3, methyl, ethyl,
propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy,
propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and
heterocyclic portions thereof may be optionally substituted, such
as by one to four instances of substituents selected from this same
list.
[0082] "Aryl" refers to a carbocyclic aromatic group, whether or
not fused to one or more groups, having the number of carbon atoms
designated, or if no number is designated, up to 14 carbon atoms.
One example includes aryl groups having 6-14 carbon atoms. Another
example includes aryl groups having 6-10 carbon atoms. Examples of
aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl,
naphthacenyl, 1,2,3,4-tetrahydronaphthalenyl, 1H-indenyl,
2,3-dihydro-1H-indenyl, and the like (see, e.g., Lang's Handbook of
Chemistry (Dean, J. A., ed.) 13.sup.th ed. Table 7-2 [1985]). A
particular aryl is phenyl. Substituted phenyl or substituted aryl
means a phenyl group or aryl group substituted with one, two,
three, four or five substituents, for example, 1-2, 1-3 or 1-4
substituents, such as chosen from groups specified herein (see
"optionally substituted" definition), such as F, Cl, Br, I, OH, SH,
CN, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, NO.sub.2, N.sub.3,
C(O)CH.sub.3, COOH, CO.sub.2CH.sub.3, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and
heterocyclic portions thereof may be optionally substituted, such
as by one to four instances of substituents selected from this same
list. Examples of the term "substituted phenyl" include a mono- or
di(halo)phenyl group such as 2-chlorophenyl, 2-bromophenyl,
4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl,
3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl,
3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl,
2,4-difluorophenyl and the like; a mono- or di(hydroxy)phenyl group
such as 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, the
protected-hydroxy derivatives thereof and the like; a nitrophenyl
group such as 3- or 4-nitrophenyl; a cyanophenyl group, for
example, 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as
4-methylphenyl, 2,4-dimethylphenyl, 2-methylphenyl,
4-(isopropyl)phenyl, 4-ethylphenyl, 3-(n-propyl)phenyl and the
like; a mono or di(alkoxy)phenyl group, for example,
3,4-dimethoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 3-ethoxyphenyl,
4-(isopropoxy)phenyl, 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl
and the like; 3- or 4-trifluoromethylphenyl; a mono- or
dicarboxyphenyl or (protected carboxy)phenyl group such
4-carboxyphenyl, a mono- or di(hydroxymethyl)phenyl or (protected
hydroxymethyl)phenyl such as 3-(protected hydroxymethyl)phenyl or
3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or
(protected aminomethyl)phenyl such as 2-(aminomethyl)phenyl or
2,4-(protected aminomethyl)phenyl; or a mono- or
di(N-(methylsulfonylamino))phenyl such as
3-(N-methylsulfonylamino))phenyl. Also, the term "substituted
phenyl" represents disubstituted phenyl groups where the
substituents are different, for example, 3-methyl-4-hydroxyphenyl,
3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl,
4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl,
2-hydroxy-4-chlorophenyl, 2-chloro-5-difluoromethoxy and the like,
as well as trisubstituted phenyl groups where the substituents are
different, for example 3-methoxy-4-benzyloxy-6-methyl
sulfonylamino, 3-methoxy-4-benzyloxy-6-phenyl sulfonylamino, and
tetrasubstituted phenyl groups where the substituents are different
such as 3-methoxy-4-benzyloxy-5-methyl-6-phenyl sulfonylamino.
[0083] The terms "compound(s) of the invention," and "compound(s)
of the present invention" and the like, unless otherwise indicated,
include compounds of Formula 0, Formula I, Formula II, and the
compounds of Tables 1, 2 and 3 herein, including stereoisomers
(including atropisomers), geometric isomers, tautomers, solvates,
metabolites, isotopes, salts (e.g., pharmaceutically acceptable
salts), and prodrugs thereof. In some embodiments, solvates,
metabolites, isotopes or prodrugs are excluded, or any combination
thereof.
[0084] "Cycloalkyl" refers to a non-aromatic, saturated or
partially unsaturated hydrocarbon ring group wherein the cycloalkyl
group may be optionally substituted independently with one or more
substituents described herein. In one example, the cycloalkyl group
is 3 to 12 carbon atoms (C.sub.3-C.sub.12). In other examples,
cycloalkyl is C.sub.3-C.sub.8, C.sub.3-C.sub.10 or
C.sub.5-C.sub.10. In other examples, the cycloalkyl group, as a
monocycle, is C.sub.3-C.sub.8, C.sub.3-C.sub.6 or C.sub.5-C.sub.6.
In another example, the cycloalkyl group, as a bicycle, is
C.sub.7-C.sub.12. In another example, the cycloalkyl group, as a
spiro system, is C.sub.5-C.sub.12. Examples of monocyclic
cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl,
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-1-enyl,
1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl,
cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl.
Exemplary arrangements of bicyclic cycloalkyls having 7 to 12 ring
atoms include, but are not limited to, [4,4], [4,5], [5,5], [5,6]
or [6,6] ring systems. Exemplary bridged bicyclic cycloalkyls
include, but are not limited to, bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane. Examples of spiro
cycloalkyl include, spiro[2.2]pentane, spiro[2.3]hexane,
spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane. In some
embodiments, substituents for "optionally substituted cycloalkyls"
include one to four instances of F, Cl, Br, I, OH, SH, CN,
NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, NO.sub.2, N.sub.3,
C(O)CH.sub.3, COOH, CO.sub.2CH.sub.3, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted, such
as by one to four instances of substituents selected from this same
list.
[0085] "Heterocyclic group", "heterocyclic", "heterocycle",
"heterocyclyl", or "heterocyclo" are used interchangeably and refer
to any mono-, bi-, tricyclic or spiro, saturated, partially
saturated or unsaturated, aromatic (heteroaryl) or non-aromatic
(e.g., heterocycloalkyl), ring system, having 3 to 20 ring atoms,
where the ring atoms are carbon, and at least one atom in the ring
or ring system is a heteroatom selected from nitrogen, sulfur or
oxygen. If any ring atom of a cyclic system is a heteroatom, that
system is a heterocycle, regardless of the point of attachment of
the cyclic system to the rest of the molecule. In one example,
heterocyclyl includes 3-11 ring atoms ("members") and includes
monocycles, bicycles, tricycles and spiro ring systems, wherein the
ring atoms are carbon, where at least one atom in the ring or ring
system is a heteroatom selected from nitrogen, sulfur or oxygen. In
one example, heterocyclyl includes 1 to 4 heteroatoms. In one
example, heterocyclyl includes 1 to 3 heteroatoms. In another
example, heterocyclyl includes 3- to 7-membered monocycles having
1-2, 1-3 or 1-4 heteroatoms selected from nitrogen, sulfur or
oxygen. In another example, heterocyclyl includes 4- to 6-membered
monocycles having 1-2, 1-3 or 1-4 heteroatoms selected from
nitrogen, sulfur or oxygen. In another example, heterocyclyl
includes 3-membered monocycles. In another example, heterocyclyl
includes 4-membered monocycles. In another example, heterocyclyl
includes 5-6 membered monocycles, e.g., 5-6 membered heteroaryl. In
another example, heterocyclyl includes 3-11 membered
heterocycloyalkyls, such as 4-11 membered heterocycloalkyls. In
some embodiments, a heterocycloalkyl includes at least one
nitrogen. In one example, the heterocyclyl group includes 0 to 3
double bonds. Any nitrogen or sulfur heteroatom may optionally be
oxidized (e.g., NO, SO, SO.sub.2), and any nitrogen heteroatom may
optionally be quaternized (e.g., [NR.sub.4].sup.+Cl.sup.-,
[NR.sub.4].sup.+OH.sup.-). Example heterocycles are oxiranyl,
aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl,
1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl,
dihydro-1H-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl,
dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl,
piperazinyl, isoquinolinyl, tetrahydroisoquinolinyl, morpholinyl,
thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl,
tetrahydropyranyl, hexahydrothiopyranyl, hexahydropyrimidinyl,
oxazinanyl, thiazinanyl, thioxanyl, homopiperazinyl,
homopiperidinyl, azepanyl, oxepanyl, thiepanyl, oxazepinyl,
oxazepanyl, diazepanyl, 1,4-diazepanyl, diazepinyl, thiazepinyl,
thiazepanyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl,
isothiazolidinyl, 1,1-dioxoisothiazolidinonyl, oxazolidinonyl,
imidazolidinonyl, 4,5,6,7-tetrahydro[2H]indazolyl,
tetrahydrobenzoimidazolyl, 4,5,6,7-tetrahydrobenzo[d]imidazolyl,
1,6-dihydroimidazol[4,5-d]pyrrolo[2,3-b]pyridinyl, thiazinyl,
oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl,
oxathiazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl,
imidazolinyl, dihydropyrimidyl, tetrahydropyrimidyl, 1-pyrrolinyl,
2-pyrrolinyl, 3-pyrrolinyl, indolinyl, thiapyranyl, 2H-pyranyl,
4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl,
dithianyl, dithiolanyl, pyrimidinonyl, pyrimidindionyl,
pyrimidin-2,4-dionyl, piperazinonyl, piperazindionyl,
pyrazolidinylimidazolinyl, 3-azabicyclo[3.1.0]hexanyl,
3,6-diazabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl,
3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl,
azabicyclo[2.2.2]hexanyl, 2-azabicyclo[3.2.1]octanyl,
8-azabicyclo[3.2.1]octanyl, 2-azabicyclo[2.2.2]octanyl,
8-azabicyclo[2.2.2]octanyl, 7-oxabicyclo[2.2.1]heptane,
azaspiro[3.5]nonanyl, azaspiro[2.5]octanyl, azaspiro[4.5]decanyl,
1-azaspiro[4.5]decan-2-only, azaspiro[5.5]undecanyl,
tetrahydroindolyl, octahydroindolyl, tetrahydroisoindolyl,
tetrahydroindazolyl, 1,1-dioxohexahydrothiopyranyl. Examples of
5-membered heterocycles containing a sulfur or oxygen atom and one
to three nitrogen atoms are thiazolyl, including thiazol-2-yl and
thiazol-2-yl N-oxide, thiadiazolyl, including 1,3,4-thiadiazol-5-yl
and 1,2,4-thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and
oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and
1,2,4-oxadiazol-5-yl. Example 5-membered ring heterocycles
containing 2 to 4 nitrogen atoms include imidazolyl, such as
imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl;
1,2,3-triazol-5-yl, 1,2,4-triazol-5-yl, and tetrazolyl, such as
1H-tetrazol-5-yl. Example benzo-fused 5-membered heterocycles are
benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl. Example
6-membered heterocycles contain one to three nitrogen atoms and
optionally a sulfur or oxygen atom, for example pyridyl, such as
pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as
pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as
1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in
particular pyridazin-3-yl, and pyrazinyl. The pyridine N-oxides and
pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl,
pyridazinyl and the 1,3,4-triazin-2-yl groups, are other example
heterocycle groups. Heterocycles may be optionally substituted. For
example, substituents for "optionally substituted heterocycles"
include one to four instances of F, Cl, Br, I, OH, SH, CN,
NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, NO.sub.2, N.sub.3,
C(O)CH.sub.3, COOH, CO.sub.2CH.sub.3, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted, such
as by one to four instances of substituents selected from this same
list.
[0086] "Heteroaryl" refers to any mono-, bi-, or tricyclic ring
system where at least one ring is a 5- or 6-membered aromatic ring
containing from 1 to 4 heteroatoms selected from nitrogen, oxygen,
and sulfur, and in an example embodiment, at least one heteroatom
is nitrogen. See, for example, Lang's Handbook of Chemistry (Dean,
J. A., ed.) 13.sup.th ed. Table 7-2 [1985]. Included in the
definition are any bicyclic groups where any of the above
heteroaryl rings are fused to an aryl ring, wherein the aryl ring
or the heteroaryl ring is joined to the remainder of the molecule.
In one embodiment, heteroaryl includes 5-6 membered monocyclic
aromatic groups where one or more ring atoms is nitrogen, sulfur or
oxygen. Example heteroaryl groups include thienyl, furyl,
imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl,
isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl,
thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl,
pyridazinyl, triazinyl, tetrazinyl, tetrazolo[1,5-b]pyridazinyl,
imidazol[1,2-a]pyrimidinyl and purinyl, as well as benzo-fused
derivatives, for example benzoxazolyl, benzofuryl, benzothiazolyl,
benzothiadiazolyl, benzotriazolyl, benzoimidazolyl and indolyl.
Heteroaryl groups can be optionally substituted. In some
embodiments, substituents for "optionally substituted heteroaryls"
include one to four instances of F, Cl, Br, I, OH, SH, CN,
NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, NO.sub.2, N.sub.3,
C(O)CH.sub.3, COOH, CO.sub.2CH.sub.3, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and
heterocyclic portions thereof may be optionally substituted, such
as by one to four instances of substituents selected from this same
list.
[0087] In particular embodiments, a heterocyclyl group is attached
at a carbon atom of the heterocyclyl group. By way of example,
carbon bonded heterocyclyl groups include bonding arrangements at
position 2, 3, 4, 5, or 6 of a pyridine ring, position 3, 4, 5, or
6 of a pyridazine ring, position 2, 4, 5, or 6 of a pyrimidine
ring, position 2, 3, 5, or 6 of a pyrazine ring, position 2, 3, 4,
or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole ring, position 2, 4, or 5 of an oxazole,
imidazole or thiazole ring, position 3, 4, or 5 of an isoxazole,
pyrazole, or isothiazole ring, position 2 or 3 of an aziridine
ring, position 2, 3, or 4 of an azetidine ring, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline ring or position 1, 3, 4, 5, 6, 7, or
8 of an isoquinoline ring.
[0088] In certain embodiments, the heterocyclyl group is
N-attached. By way of example, nitrogen bonded heterocyclyl or
heteroaryl groups include bonding arrangements at position 1 of an
aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline,
3-pyrroline, imidazole, imidazolidine, 2-imidazoline,
3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine, indole, indoline, 1H-indazole, position 2
of a isoindole, or isoindoline, position 4 of a morpholine, and
position 9 of a carbazole, or .beta.-carboline.
[0089] The term "alkoxy" refers to a linear or branched monovalent
radical represented by the formula --OR in which R is alkyl, as
defined herein. Alkoxy groups include methoxy, ethoxy, propoxy,
isopropoxy, mono-, di- and tri-fluoromethoxy and cyclopropoxy.
"Haloalkoxy" refers to a haloalkyl group, as that term is defined
herein, as R.
[0090] The term "alkanoyl" refers to group (alkyl)-C(.dbd.O)--,
wherein alkyl is as defined herein. For example,
C.sub.1-C.sub.6alkanoyl refers to a group of formula
(C.sub.1-C.sub.5alkyl)-C(.dbd.O)--. Alkanoyl groups include,
formyl, acetyl, propanoyl, isopropanoyl, butanoyl, isobutanoyl,
pentanoyl, 3-methylpentanoyl, and hexanoyl.
[0091] "Optionally substituted" unless otherwise specified means
that a group may be unsubstituted or substituted by one or more
(e.g., 0, 1, 2, 3, 4, or 5 or more, or any range derivable therein)
of the substituents listed for that group in which said
substituents may be the same or different. In an embodiment, an
optionally substituted group has 1 substituent. In another
embodiment an optionally substituted group has 2 substituents. In
another embodiment an optionally substituted group has 3
substituents. In another embodiment an optionally substituted group
has 4 substituents. In another embodiment an optionally substituted
group has 5 substituents.
[0092] As used herein a wavy line "" that intersects a bond in a
chemical structure indicate the point of attachment of the atom to
which the wavy bond is connected in the chemical structure to the
remainder of a molecule, or to the remainder of a fragment of a
molecule. In some embodiments, an arrow together with an asterisk
is used in the manner of a wavy line to indicate a point of
attachment.
[0093] In certain embodiments, divalent groups are described
generically without specific bonding configurations. It is
understood that the generic description is meant to include both
bonding configurations, unless specified otherwise. For example, in
the group R.sup.1--R.sup.2--R.sup.3, if the group R.sup.2 is
described as --CH.sub.2C(O)--, then it is understood that this
group can be bonded both as R.sup.1--CH.sub.2C(O)--R.sup.3, and as
R.sup.1--C(O)CH.sub.2--R.sup.3, unless specified otherwise.
[0094] The phrase "pharmaceutically acceptable" refers to molecular
entities and compositions that do not produce an adverse, allergic
or other untoward reaction when administered to an animal, such as,
for example, a human, as appropriate.
[0095] Compounds of the invention may be in the form of a salt,
such as a pharmaceutically acceptable salt. "Pharmaceutically
acceptable salts" include both acid and base addition salts.
"Pharmaceutically acceptable acid addition salt" refers to those
salts which retain the biological effectiveness and properties of
the free bases and which are not biologically or otherwise
undesirable, formed with inorganic acids such as hydrochloric acid,
hydrobromic acid, sulfuric acid, nitric acid, carbonic acid,
phosphoric acid and the like, and organic acids may be selected
from aliphatic, cycloaliphatic, aromatic, araliphatic,
heterocyclic, carboxylic, and sulfonic classes of organic acids
such as formic acid, acetic acid, propionic acid, glycolic acid,
gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid,
maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, aspartic acid, ascorbic acid, glutamic acid,
anthranilic acid, benzoic acid, cinnamic acid, mandelic acid,
embonic acid, phenylacetic acid, methanesulfonic acid,
ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid,
salicylic acid and the like.
[0096] "Pharmaceutically acceptable base addition salts" include
those derived from inorganic bases such as sodium, potassium,
lithium, ammonium, calcium, magnesium, iron, zinc, copper,
manganese, aluminum salts and the like. Particular base addition
salts are the ammonium, potassium, sodium, calcium and magnesium
salts. Salts derived from pharmaceutically acceptable organic
nontoxic bases include salts of primary, secondary, and tertiary
amines, substituted amines including naturally occurring
substituted amines, cyclic amines and basic ion exchange resins,
such as isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol,
tromethamine, dicyclohexylamine, lysine, arginine, histidine,
caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine,
glucosamine, methylglucamine, theobromine, purines, piperizine,
piperidine, N-ethylpiperidine, polyamine resins and the like.
Particular organic non-toxic bases include isopropylamine,
diethylamine, ethanolamine, tromethamine, dicyclohexylamine,
choline, and caffeine.
[0097] In some embodiments, a salt is selected from a
hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate,
acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate,
succinate, oxalate, methanesulphonate, p-toluenesulphonate,
bisulphate, benzenesulphonate, ethanesulphonate, malonate,
xinafoate, ascorbate, oleate, nicotinate, saccharinate, adipate,
formate, glycolate, palmitate, L-lactate, D-lactate, aspartate,
malate, L-tartrate, D-tartrate, stearate, furoate (e.g., 2-furoate
or 3-furoate), napadisylate (naphthalene-1,5-disulfonate or
naphthalene-1-(sulfonic acid)-5-sulfonate), edisylate
(ethane-1,2-disulfonate or ethane-1-(sulfonic acid)-2-sulfonate),
isothionate (2-hydroxyethylsulfonate), 2-mesitylenesulphonate,
2-naphthalenesulphonate, 2,5-dichlorobenzenesulphonate,
D-mandelate, L-mandelate, cinnamate, benzoate, adipate, esylate,
malonate, mesitylate (2-mesitylenesulphonate), napsylate
(2-naphthalenesulfonate), camsylate (camphor-10-sulphonate, for
example (1S)-(+)-10-camphorsulfonic acid salt), glutamate,
glutarate, hippurate (2-(b enzoylamino)acetate), orotate, xylate
(p-xylene-2-sulphonate), and pamoic
(2,2'-dihydroxy-1,1'-dinaphthylmethane-3,3'-dicarboxylate).
[0098] A "sterile" formulation is aseptic or free from all living
microorganisms and their spores.
[0099] "Stereoisomers" refer to compounds that have identical
chemical constitution, but differ with regard to the arrangement of
the atoms or groups in space. Stereoisomers include diastereomers,
enantiomers, conformers and the like.
[0100] "Chiral" refers to molecules which have the property of
non-superimposability of the mirror image partner, while the term
"achiral" refers to molecules which are superimposable on their
mirror image partner.
[0101] "Diastereomer" refers to a stereoisomer with two or more
centers of chirality and whose molecules are not mirror images of
one another. Diastereomers have different physical properties,
e.g., melting points, boiling points, spectral properties or
biological activities. Mixtures of diastereomers may separate under
high resolution analytical procedures such as electrophoresis and
chromatography such as HPLC.
[0102] "Enantiomers" refer to two stereoisomers of a compound which
are non-superimposable mirror images of one another.
[0103] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds",
John Wiley & Sons, Inc., New York, 1994. Many organic compounds
exist in optically active forms, i.e., they have the ability to
rotate the plane of plane-polarized light. In describing an
optically active compound, the prefixes D and L, or R and S, are
used to denote the absolute configuration of the molecule about its
chiral center(s). The prefixes d and l or (+) and (-) are employed
to designate the sign of rotation of plane-polarized light by the
compound, with (-) or l meaning that the compound is levorotatory.
A compound prefixed with (+) or d is dextrorotatory. For a given
chemical structure, these stereoisomers are identical except that
they are mirror images of one another. A specific stereoisomer may
also be referred to as an enantiomer, and a mixture of such isomers
is often called an enantiomeric mixture. A 50:50 mixture of
enantiomers is referred to as a racemic mixture or a racemate,
which may occur where there has been no stereoselection or
stereospecificity in a chemical reaction or process. The terms
"racemic mixture" and "racemate" refer to an equimolar mixture of
two enantiomeric species, devoid of optical activity.
[0104] The term "tautomer" or "tautomeric form" refers to
structural isomers of different energies which are interconvertible
via a low energy barrier. For example, proton tautomers (also known
as prototropic tautomers) include interconversions via migration of
a proton, such as keto-enol and imine-enamine isomerizations.
Valence tautomers include interconversions by reorganization of
some of the bonding electrons.
[0105] Certain compounds of the invention can exist in unsolvated
forms as well as solvated forms, including hydrated forms. A
"solvate" refers to an association or complex of one or more
solvent molecules and a compound of the present invention. Examples
of solvents that form solvates include water, isopropanol, ethanol,
methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
Certain compounds of the invention can exist in multiple
crystalline or amorphous forms. In general, all physical forms are
intended to be within the scope of the present invention. The term
"hydrate" refers to the complex where the solvent molecule is
water.
[0106] A "metabolite" refers to a product produced through
metabolism in the body of a specified compound or salt thereof.
Such products can result, for example, from the oxidation,
reduction, hydrolysis, amidation, deamidation, esterification,
deesterification, enzymatic cleavage, and the like, of the
administered compound.
[0107] Metabolite products typically are identified by preparing a
radiolabelled (e.g., .sup.14C or .sup.3H) isotope of a compound of
the invention, administering it in a detectable dose (e.g., greater
than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig,
monkey, or to a human, allowing sufficient time for metabolism to
occur (typically about 30 seconds to 30 hours) and isolating its
conversion products from the urine, blood or other biological
samples. These products are easily isolated since they are labeled
(others are isolated by the use of antibodies capable of binding
epitopes surviving in the metabolite). The metabolite structures
are determined in conventional fashion, e.g., by MS, LC/MS or NMR
analysis. In general, analysis of metabolites is done in the same
way as conventional drug metabolism studies well known to those
skilled in the art. The metabolite products, so long as they are
not otherwise found in vivo, are useful in diagnostic assays for
therapeutic dosing of the compounds of the invention.
[0108] "Amino-protecting group" as used herein refers to a
derivative of the groups commonly employed to block or protect an
amino group while reactions are carried out on other functional
groups on the compound. Examples of such protecting groups include
carbamates, amides, alkyl and aryl groups, and imines, as well as
many N-heteroatom derivatives which can be removed to regenerate
the desired amine group. Particular amino protecting groups are Pmb
(p-Methoxybenzyl), Boc (tert-Butyloxycarbonyl), Fmoc
(9-Fluorenylmethyloxycarbonyl) and Cbz (Carbobenzyloxy). Further
examples of these groups are found in T. W. Greene and P. G. M.
Wuts, "Protecting Groups in Organic Synthesis, 3.sup.rd ed., John
Wiley & Sons, Inc., 1999. The term "protected amino" refers to
an amino group substituted with one of the above amino-protecting
groups.
[0109] "Carboxy-protecting group" as used herein refers to those
groups that are stable to the conditions of subsequent reaction(s)
at other positions of the molecule, which may be removed at the
appropriate point without disrupting the remainder of the molecule,
to give the unprotected carboxy-group. Examples of carboxy
protecting groups include, ester groups and heterocyclyl groups.
Ester derivatives of the carboxylic acid group may be employed to
block or protect the carboxylic acid group while reactions are
carried out on other functional groups on the compound. Examples of
such ester groups include substituted arylalkyl, including
substituted benzyls, such as 4-nitrobenzyl, 4-methoxybenzyl,
3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl,
2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl,
benzhydryl, 4,4'-dimethoxybenzhydryl,
2,2',4,4'-tetramethoxybenzhydryl, alkyl or substituted alkyl esters
such as methyl, ethyl, t-butyl allyl or t-amyl, triphenylmethyl
(trityl), 4-methoxytrityl, 4,4'-dimethoxytrityl,
4,4',4''-trimethoxytrityl, 2-phenylprop-2-yl, thioesters such as
t-butyl thioester, silyl esters such as trimethylsilyl,
t-butyldimethylsilyl esters, phenacyl, 2,2,2-trichloroethyl,
beta-(trimethylsilyl)ethyl, beta-(di(n-butyl)methylsilyl)ethyl,
p-toluenesulfonylethyl, 4-nitrobenzyl sulfonylethyl, allyl,
cinnamyl, 1-(trimethylsilylmethyl)prop-1-en-3-yl, and like
moieties. Another example of carboxy-protecting groups are
heterocyclyl groups such as 1,3-oxazolinyl. Further examples of
these groups are found in T. W. Greene and P. G. M. Wuts,
"Protecting Groups in Organic Synthesis, 3.sup.rd ed., John Wiley
& Sons, Inc., 1999. The term "protected carboxy" refers to a
carboxy group substituted with one of the above carboxy-protecting
groups.
[0110] "Hydroxy-protecting group" as used herein refers to a
derivative of the hydroxy group commonly employed to block or
protect the hydroxy group while reactions are carried out on other
functional groups on the compound. Examples of such protecting
groups include tetrahydropyranyloxy, benzoyl, acetoxy,
carbamoyloxy, benzyl, and silylethers (e.g., TBS, TBDPS) groups.
Further examples of these groups are found in T. W. Greene and P.
G. M. Wuts, "Protecting Groups in Organic Synthesis, 3.sup.rd ed.,
John Wiley & Sons, Inc., 1999. The term "protected hydroxy"
refers to a hydroxy group substituted with one of the above
hydroxy-protecting groups.
[0111] Compounds of the invention may contain one or more
asymmetric carbon atoms. Accordingly, the compounds may exist as
diastereomers, enantiomers or mixtures thereof. The syntheses of
the compounds may employ racemates, diastereomers or enantiomers as
starting materials or as intermediates. Mixtures of particular
diastereomeric compounds may be separated, or enriched in one or
more particular diastereomers, by chromatographic or
crystallization methods. Similarly, enantiomeric mixtures may be
separated, or enantiomerically enriched, using the same techniques
or others known in the art. Each of the asymmetric carbon or
nitrogen atoms may be in the R or S configuration and both of these
configurations are within the scope of the invention.
[0112] In the structures shown herein, where the stereochemistry of
any particular chiral atom is not specified, then all stereoisomers
are contemplated and included as the compounds of the invention.
Where stereochemistry is specified by a solid wedge or dashed line
representing a particular configuration, then that stereoisomer is
so specified and defined. Unless otherwise specified, if solid
wedges or dashed lines are used, relative stereochemistry is
intended.
[0113] Another aspect includes prodrugs of the compounds of the
invention including known amino-protecting and carboxy-protecting
groups which are released, for example hydrolyzed, to yield the
compound of the present invention under physiologic conditions.
[0114] The term "prodrug" refers to a precursor or derivative form
of a pharmaceutically active substance that is less efficacious to
the patient compared to the parent drug and is capable of being
enzymatically or hydrolytically activated or converted into the
more active parent form. See, e.g., Wilman, "Prodrugs in Cancer
Chemotherapy" Biochemical Society Transactions, 14, pp. 375-382,
615th Meeting Belfast (1986) and Stella et al., "Prodrugs: A
Chemical Approach to Targeted Drug Delivery," Directed Drug
Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press
(1985). Prodrugs include, but are not limited to,
phosphate-containing prodrugs, thiophosphate-containing prodrugs,
sulfate-containing prodrugs, peptide-containing prodrugs, D-amino
acid-modified prodrugs, glycosylated prodrugs,
.beta.-lactam-containing prodrugs, optionally substituted
phenoxyacetamide-containing prodrugs or optionally substituted
phenylacetamide-containing prodrugs, and 5-fluorocytosine and
5-fluorouridine prodrugs.
[0115] A particular class of prodrugs are compounds in which a
nitrogen atom in an amino, amidino, aminoalkyleneamino,
iminoalkyleneamino or guanidino group is substituted with a hydroxy
group, an alkylcarbonyl (--CO--R) group, an alkoxycarbonyl
(--CO--OR), or an acyloxyalkyl-alkoxycarbonyl
(--CO--O--R--O--CO--R) group where R is a monovalent or divalent
group, for example alkyl, alkylene or aryl, or a group having the
Formula --C(O)--O--CP1P2-haloalkyl, where P1 and P2 are the same or
different and are hydrogen, alkyl, alkoxy, cyano, halogen, alkyl or
aryl. In a particular embodiment, the nitrogen atom is one of the
nitrogen atoms of the amidino group of the compounds of the
invention. Prodrugs may be prepared by reacting a compound of the
present invention with an activated group, such as acyl groups, to
bond, for example, a nitrogen atom in the compound to the exemplary
carbonyl of the activated acyl group. Examples of activated
carbonyl compounds are those containing a leaving group bonded to
the carbonyl group, and include, for example, acyl halides, acyl
amines, acyl pyridinium salts, acyl alkoxides, acyl phenoxides such
as p-nitrophenoxy acyl, dinitrophenoxy acyl, fluorophenoxy acyl,
and difluorophenoxy acyl. The reactions are generally carried out
in inert solvents at reduced temperatures such as -78 to about
50.degree. C. The reactions may also be carried out in the presence
of an inorganic base, for example potassium carbonate or sodium
bicarbonate, or an organic base such as an amine, including
pyridine, trimethylamine, triethylamine, triethanolamine, or the
like.
[0116] Additional types of prodrugs are also encompassed. For
instance, a free carboxyl group of a compound of the invention can
be derivatized as an amide or alkyl ester. As another example,
compounds of the invention comprising free hydroxy groups can be
derivatized as prodrugs by converting the hydroxy group into a
group such as, but not limited to, a phosphate ester,
hemisuccinate, dimethylaminoacetate, or
phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D.
et al., (1996) Improved oral drug delivery: solubility limitations
overcome by the use of prodrugs Advanced Drug Delivery Reviews,
19:115. Carbamate prodrugs of hydroxy and amino groups are also
included, as are carbonate prodrugs, sulfonate esters and sulfate
esters of hydroxy groups. Derivatization of hydroxy groups as
(acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group
can be an alkyl ester optionally substituted with groups including,
but not limited to, ether, amine and carboxylic acid
functionalities, or where the acyl group is an amino acid ester as
described above, are also encompassed. Prodrugs of this type are
described in J. Med. Chem., (1996), 39:10. More specific examples
include replacement of the hydrogen atom of the alcohol group with
a group such as (C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylaminomethyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, alpha-amino(C.sub.1-C.sub.4)alkanoyl,
arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl,
where each alpha-aminoacyl group is independently selected from the
naturally occurring L-amino acids, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from the removal of a hydroxyl group of the hemiacetal
form of a carbohydrate).
[0117] "Leaving group" refers to a portion of a first reactant in a
chemical reaction that is displaced from the first reactant in the
chemical reaction. Examples of leaving groups include, but are not
limited to, halogen atoms, alkoxy and sulfonyloxy groups. Example
sulfonyloxy groups include, but are not limited to,
alkylsulfonyloxy groups (for example methyl sulfonyloxy (mesylate
group) and trifluoromethylsulfonyloxy (triflate group)) and
arylsulfonyloxy groups (for example p-toluenesulfonyloxy (tosylate
group) and p-nitrosulfonyloxy (nosylate group)).
[0118] A "subject," "individual," or "patient" is a vertebrate. In
certain embodiments, the vertebrate is a mammal. Mammals include,
but are not limited to, farm animals (such as cows), sport animals,
pets (such as guinea pigs, cats, dogs, rabbits and horses),
primates, mice and rats. In certain embodiments, a mammal is a
human. In embodiments comprising administration of a compound of to
a patient, the patient is typically in need thereof.
[0119] The terms "inhibiting" and "reducing," or any variation of
these terms, includes any measurable decrease or complete
inhibition to achieve a desired result. For example, there may be a
decrease of about, at most about, or at least about 5%, 10%, 15%,
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 99%, or more, or any range derivable therein,
reduction of activity (e.g., IRAK4 activity) compared to
normal.
[0120] In some embodiments, a compound of Formula 0, Formula I, or
Formula II, such as a compound of Tables 1, 2 or 3, is selective
for inhibition of IRAK4 over IRAK1. By "selective for inhibition"
it is meant that the compound is at least a 5%, 10%, 15%, 20%, 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 99%, or more, or any range derivable therein, better inhibitor
of IRAK4 activity compared to IRAK1 activity, or is at least a 2-,
3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-, or 500-fold better inhibitor
of IRAK4 activity compared to IRAK1 activity.
[0121] A "therapeutically effective amount" means an amount of a
compound of the present invention, such as a compound of Formula 0,
Formula I, or Formula II (e.g., a compound of Tables 1, 2 or 3),
that (i) treats or prevents the particular disease, condition or
disorder, or (ii) attenuates, ameliorates or eliminates one or more
symptoms of the particular disease, condition, or disorder, and
optionally (iii) prevents or delays the onset of one or more
symptoms of the particular disease, condition or disorder described
herein. In some embodiments, the therapeutically effective amount
is an amount sufficient to decrease or alleviate the symptoms of an
autoimmune or inflammatory disease (e.g., lupus). In some
embodiments, a therapeutically effective amount is an amount of a
chemical entity described herein sufficient to significantly
decrease the activity or number of B-cells. In the case of cancer,
the therapeutically effective amount of the drug may reduce the
number of cancer cells; reduce the tumor size; inhibit (i.e., slow
to some extent and preferably stop) cancer cell infiltration into
peripheral organs; inhibit (i.e., slow to some extent and
preferably stop) tumor metastasis; inhibit, to some extent, tumor
growth; or relieve to some extent one or more of the symptoms
associated with the cancer. To the extent the drug may prevent
growth or kill existing cancer cells, it may be cytostatic or
cytotoxic. For cancer therapy, efficacy can, for example, be
measured by assessing the time to disease progression (TTP) or
determining the response rate (RR).
[0122] "Treatment" (and variations such as "treat" or "treating")
refers to clinical intervention in an attempt to alter the natural
course of the individual or cell being treated, and can be
performed either for prophylaxis or during the course of clinical
pathology. Desirable effects of treatment include preventing
occurrence or recurrence of disease, alleviation of symptoms,
diminishment of any direct or indirect pathological consequences of
the disease, stabilized (i.e., not worsening) state of disease,
decreasing the rate of disease progression, amelioration or
palliation of the disease state, prolonging survival as compared to
expected survival if not receiving treatment and remission or
improved prognosis. In some embodiments, compounds of the
invention, are used to delay development of a disease or disorder
or to slow the progression of a disease or disorder. Those in need
of treatment include those already with the condition or disorder
as well as those prone to have the condition or disorder, (for
example, through a genetic mutation) or those in which the
condition or disorder is to be prevented.
[0123] "Inflammatory disorder" refers to any disease, disorder or
syndrome in which an excessive or unregulated inflammatory response
leads to excessive inflammatory symptoms, host tissue damage, or
loss of tissue function. "Inflammatory disorder" also refers to a
pathological state mediated by influx of leukocytes or neutrophil
chemotaxis.
[0124] "Inflammation" refers to a localized, protective response
elicited by injury or destruction of tissues, which serves to
destroy, dilute, or wall off (sequester) both the injurious agent
and the injured tissue. Inflammation is notably associated with
influx of leukocytes or neutrophil chemotaxis. Inflammation can
result from infection with pathogenic organisms and viruses and
from noninfectious means such as trauma or reperfusion following
myocardial infarction or stroke, immune responses to foreign
antigens, and autoimmune responses. Accordingly, inflammatory
disorders amenable to treatment with a compound of the present
invention, such as a compound of Formula 0, Formula I, or Formula
II (e.g., a compound of Tables 1, 2 or 3), encompass disorders
associated with reactions of the specific defense system as well as
with reactions of the nonspecific defense system.
[0125] "Specific defense system" refers to the component of the
immune system that reacts to the presence of specific antigens.
Examples of inflammation resulting from a response of the specific
defense system include the classical response to foreign antigens,
autoimmune diseases, and delayed type hypersensitivity responses
mediated by T-cells. Chronic inflammatory diseases, the rejection
of solid transplanted tissue and organs, e.g., kidney and bone
marrow transplants, and graft versus host disease (GVHD), are
further examples of inflammatory reactions of the specific defense
system.
[0126] The term "nonspecific defense system" refers to inflammatory
disorders that are mediated by leukocytes that are incapable of
immunological memory (e.g., granulocytes, and macrophages).
Examples of inflammation that result, at least in part, from a
reaction of the nonspecific defense system include inflammation
associated with conditions such as adult (acute) respiratory
distress syndrome (ARDS) or multiple organ injury syndromes;
reperfusion injury; acute glomerulonephritis; reactive arthritis;
dermatoses with acute inflammatory components; acute purulent
meningitis or other central nervous system inflammatory disorders
such as stroke; thermal injury; inflammatory bowel disease;
granulocyte transfusion associated syndromes; and cytokine-induced
toxicity.
[0127] "Autoimmune disease" refers to any group of disorders in
which tissue injury is associated with humoral or cell-mediated
responses to the body's own constituents. Non-limiting examples of
autoimmune diseases include rheumatoid arthritis, lupus and
multiple sclerosis.
[0128] "Allergic disease" as used herein refers to any symptoms,
tissue damage, or loss of tissue function resulting from allergy.
"Arthritic disease" as used herein refers to any disease that is
characterized by inflammatory lesions of the joints attributable to
a variety of etiologies. "Dermatitis" as used herein refers to any
of a large family of diseases of the skin that are characterized by
inflammation of the skin attributable to a variety of etiologies.
"Transplant rejection" as used herein refers to any immune reaction
directed against grafted tissue, such as organs or cells (e.g.,
bone marrow), characterized by a loss of function of the grafted
and surrounding tissues, pain, swelling, leukocytosis, and
thrombocytopenia. The therapeutic methods of the present invention
include methods for the treatment of disorders associated with
inflammatory cell activation.
[0129] "Inflammatory cell activation" refers to the induction by a
stimulus (including, but not limited to, cytokines, antigens or
auto-antibodies) of a proliferative cellular response, the
production of soluble mediators (including but not limited to
cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive
amines), or cell surface expression of new or increased numbers of
mediators (including, but not limited to, major histocompatability
antigens or cell adhesion molecules) in inflammatory cells
(including but not limited to monocytes, macrophages, T
lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclear
leukocytes such as neutrophils, basophils, and eosinophils), mast
cells, dendritic cells, Langerhans cells, and endothelial cells).
It will be appreciated by persons skilled in the art that the
activation of one or a combination of these phenotypes in these
cells can contribute to the initiation, perpetuation, or
exacerbation of an inflammatory disorder.
[0130] In some embodiments, inflammatory disorders which can be
treated according to the methods of this invention include, but are
not limited to, asthma, rhinitis (e.g., allergic rhinitis),
allergic airway syndrome, atopic dermatitis, bronchitis, rheumatoid
arthritis, psoriasis, lupus, chronic obstructive pulmonary disease
(COPD), contact dermatitis, chronic obstructive pulmonary disease
and delayed hypersensitivity reactions.
[0131] The terms "cancer" and "cancerous", "neoplasm", and "tumor"
and related terms refer to or describe the physiological condition
in mammals that is typically characterized by unregulated cell
growth. A "tumor" comprises one or more cancerous cells. Examples
of cancer include carcinoma, blastoma, sarcoma, seminoma,
glioblastoma, melanoma, leukemia, and myeloid or lymphoid
malignancies. More particular examples of such cancers include
squamous cell cancer (e.g., epithelial squamous cell cancer) and
lung cancer including small-cell lung cancer, non-small cell lung
cancer ("NSCLC"), adenocarcinoma of the lung and squamous carcinoma
of the lung. Other cancers include skin, keratoacanthoma,
follicular carcinoma, hairy cell leukemia, buccal cavity, pharynx
(oral), lip, tongue, mouth, salivary gland, esophageal, larynx,
hepatocellular, gastric, stomach, gastrointestinal, small
intestine, large intestine, pancreatic, cervical, ovarian, liver,
bladder, hepatoma, breast, colon, rectal, colorectal,
genitourinary, biliary passage, thyroid, papillary, hepatic,
endometrial, uterine, salivary gland, kidney or renal, prostate,
testis, vulval, peritoneum, anal, penile, bone, multiple myeloma,
B-cell lymphoma, diffuse large B-Cell lymphoma (DLBCL), central
nervous system, brain, head and neck, Hodgkin's, and associated
metastases. Examples of neoplastic disorders include
myeloproliferative disorders, such as polycythemia vera, essential
thrombocytosis, myelofibrosis, such as primary myelofibrosis, and
chronic myelogenous leukemia (CML).
[0132] A "chemotherapeutic agent" is an agent useful in the
treatment of a given disorder, for example, cancer or inflammatory
disorders. Examples of chemotherapeutic agents are well-known in
the art and include examples such as those disclosed in U.S. Publ.
Appl. No. 2010/0048557, incorporated herein by reference.
Additionally, chemotherapeutic agents include pharmaceutically
acceptable salts, acids or derivatives of any of chemotherapeutic
agents, as well as combinations of two or more of them.
[0133] Unless otherwise stated, structures depicted herein are also
meant to include compounds that differ only in the presence of one
or more isotopically enriched atoms. Exemplary isotopes that can be
incorporated into compounds of the invention, include isotopes of
hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine,
chlorine, and iodine, such as .sup.2H, .sup.3H, .sup.11C, .sup.13C,
.sup.14C, .sup.13N, .sup.15N, .sup.15O, .sup.17O, .sup.18O,
.sup.32P, .sup.33P, .sup.35S, .sup.18F, .sup.36Cl, .sup.123I, and
.sup.125I, respectively. Isotopically-labeled compounds (e.g.,
those labeled with .sup.3H and .sup.14C) can be useful in compound
or substrate tissue distribution assays. Tritiated (i.e., .sup.3H)
and carbon-14 (i.e., .sup.14C) isotopes can be useful for their
ease of preparation and detectability. Further, substitution with
heavier isotopes such as deuterium (i.e., .sup.2H) may afford
certain therapeutic advantages resulting from greater metabolic
stability (e.g., increased in vivo half-life or reduced dosage
requirements). In some embodiments, in compounds of the invention,
one or more carbon atoms are replaced by .sup.13C- or
.sup.14C-enriched carbon. Positron emitting isotopes such as
.sup.15O, .sup.13N, .sup.11C, and .sup.18F are useful for positron
emission tomography (PET) studies to examine substrate receptor
occupancy. Isotopically labeled compounds can generally be prepared
by following procedures analogous to those disclosed in the Schemes
or in the Examples herein, by substituting an isotopically labeled
reagent for a non-isotopically labeled reagent.
[0134] It is specifically contemplated that any limitation
discussed with respect to one embodiment of the invention may apply
to any other embodiment of the invention. Furthermore, any compound
or composition of the invention may be used in any method of the
invention, and any method of the invention may be used to produce
or to utilize any compound or composition of the invention.
[0135] If any discrepancy exists between a structure and its name,
the structure prevails.
[0136] The use of the term "or" is used to mean "and/or" unless
explicitly indicated to refer to alternatives only or the
alternative are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or."
[0137] Throughout this application, the term "about" is used to
indicate that a value includes the standard deviation of error for
the device or method being employed to determine the value.
[0138] As used herein, "a" or "an" means one or more, unless
clearly indicated otherwise. As used herein, "another" means at
least a second or more.
[0139] Headings used herein are intended only for organizational
purposes.
IRAK4 Inhibitors
[0140] As noted, one aspect of the invention includes a compound of
Formula 0:
##STR00004##
[0141] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0142] wherein:
[0143] R.sup.1 is hydrogen or halogen;
[0144] R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.12NR.sup.6R.sup.7, --NR.sup.8R.sup.9,
--O--C.sub.1-3alkyl, a 3-7 membered monocyclic saturated or
partially saturated heterocyclic group, a 5-6 membered monocyclic
heteroaryl ring, or a 5-6 membered monocyclic aryl ring,
[0145] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0146] wherein any cycloalkyl group, heterocyclic group, heteroaryl
ring, or aryl ring is independently optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl;
[0147] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.1-2NR.sup.10R.sup.11, a 3-7 membered monocyclic
saturated or partially saturated heterocyclic group,
--C(O)NR.sup.8R.sup.9, or --NR.sup.8R.sup.9,
[0148] wherein any alkyl, alkenyl, or heterocyclic group is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, or a 3-7 membered monocyclic
saturated or partially saturated heterocyclic group that may be
optionally substituted with oxo;
[0149] R.sup.5 is hydrogen, --CN, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, --O(C.sub.3-7cycloalkyl group),
--O(C.sub.1-3alkyl)-3-8 membered cycloalkyl group,
--O(C.sub.0-3alkyl)-3-8 membered saturated or partially saturated
heterocyclic group, --O(C.sub.1-3alkyl)-phenyl, a --O(C.sub.1-3
alkyl)-5-6 membered heteroaryl ring, a 3-11 membered saturated or
partially saturated heterocyclic group, or a 5-6 membered
monocyclic heteroaryl ring,
[0150] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-11 membered saturated or partially
saturated heterocyclic group that may be optionally substituted
with (i) --C(O)(C.sub.1-3alkyl) optionally substituted with halogen
or (ii) with C.sub.1-3alkyl optionally substituted with halogen,
and
[0151] wherein any cycloalkyl group, heterocyclic group, phenyl, or
heteroaryl ring is optionally substituted by halogen; oxo; CN; OH;
C.sub.1-6alkoxy; --NR.sup.8R.sup.9; --C(O)(C.sub.1-3alkyl);
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.12NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl;
[0152] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
--(C.sub.0-3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-3alkyl)-3-11 membered heterocyclic group,
--NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.1-2R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.1-2N.sup.10R.sup.11, or
--(C.sub.0-3alkyl)-OP(O)(OC.sub.1-3alkyl).sub.2,
[0153] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen; oxo; CN;
OR.sup.13; C.sub.1-3haloalkoxy; --C(O)(C.sub.1-3alkyl);
--S--C.sub.1-3alkyl; or C.sub.1-3alkyl optionally substituted with
OH, halogen, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-8 membered heterocyclic group, and
[0154] wherein when A is a 5-membered nitrogen containing
heterocyclic group, the nitrogen atom is substituted;
[0155] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0156] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0157] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, --(C.sub.0-3alkyl)-phenyl, a 3-11 membered saturated
heterocyclic group, a 5-6 membered monocyclic heteroaryl ring,
--C(O)R.sup.13, --C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or
--S(O).sub.12R.sup.13, or R.sup.10 and R.sup.11 are taken together
to form a 5-8 membered heterocyclic group,
[0158] wherein any alkyl, cycloalkyl group, phenyl, heterocyclic
group, or heteroaryl ring is independently optionally substituted
by halogen, oxo, CN, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, C.sub.1-3haloalkoxy, --OR.sup.13,
--NR.sup.6R.sup.7, or a 5-6 membered monocyclic heteroaryl
ring;
[0159] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0160] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0161] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0162] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0163] R.sup.16 is hydrogen, halogen, CN, or C.sub.1-3alkyl
optionally substituted with --NH.sub.2, halogen, or CN.
[0164] Another aspect of the invention includes a compound of
Formula I:
##STR00005##
[0165] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0166] wherein:
[0167] R.sup.1 is hydrogen or halogen;
[0168] R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.1-2NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring,
[0169] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0170] any cycloalkyl group or other ring is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl;
[0171] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9;
[0172] wherein any alkyl or alkenyl is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0173] R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), --O(C.sub.1-3alkyl)-3-8 membered
cycloalkyl group, --O(C.sub.1-3alkyl)-3-8 membered saturated or
partially saturated heterocyclic group, --O(C.sub.1-3alkyl)-phenyl,
a --O(C.sub.1-3alkyl)-5-6 membered heteroaryl ring, a 3-11 membered
saturated or partially saturated heterocyclic group, or a 5-6
membered monocyclic heteroaryl ring,
[0174] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0175] any cycloalkyl group or other ring is optionally substituted
by halogen, oxo, CN, OH, C.sub.1-6 alkoxy, --C(O)(C.sub.1-3alkyl),
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.1-2NR.sup.8R.sup.9, --OP(O)(OC.sub.1-3alkyl).sub.2, a
5-6 membered monocyclic heteroaryl ring optionally substituted by
halogen, oxo, CN, OH, C.sub.1-3alkyl, or C.sub.1-3haloalkyl, or
C.sub.1-3alkyl optionally substituted by halogen, oxo, CN, OH,
phenyl, a 3-8 membered saturated heterocyclic group, a 5-6 membered
monocyclic heteroaryl ring, or --NR.sup.8R.sup.9;
[0176] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
--(C.sub.0-3alkyl)-C.sub.3-6cycloalkyl group, a
--(C.sub.0-C.sub.3alkyl)-3-11 membered heterocyclic group
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl, --NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)(C.sub.1-3alkyl),
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13,
--S(O).sub.12NR.sup.10R.sup.11, or
--OP(O)(OC.sub.1-3alkyl).sub.2,
[0177] wherein any alkyl, cycloalkyl group, or heterocyclic group
is independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, or a 3-8 membered heterocyclic group;
[0178] wherein when A is a 5-membered nitrogen containing
heterocyclic group, the nitrogen atom is substituted;
[0179] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0180] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0181] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, --(C.sub.0-3alkyl)-phenyl, a 3-11 membered saturated
heterocyclic group, --C(O)R.sup.13, --C(O)OR.sup.13,
--C(O)NR.sup.6R.sup.7, or --S(O).sub.1-2R.sup.13, or R.sup.10 and
R.sup.11 are taken together to form a 5-8 membered heterocyclic
group optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0182] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.13, or --NR.sup.6R.sup.7;
[0183] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0184] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0185] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0186] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0187] R.sup.16 is H, --Cl, --CN, or --CH.sub.3.
[0188] Another aspect of the invention includes a compound of
Formula II:
##STR00006##
[0189] or a stereoisomer or pharmaceutically acceptable salt
thereof,
[0190] wherein:
[0191] R.sup.1 is hydrogen or halogen;
[0192] R.sup.3 is hydrogen, halogen, CN, OH, C.sub.1-3alkyl,
C.sub.2-3alkenyl, C.sub.3-7cycloalkyl group,
C.sub.1-C.sub.3alkanoyl,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.6R.sup.7,
--(C.sub.2-3alkenyl)C(O)NR.sup.6R.sup.7,
--S(O).sub.12NR.sup.6R.sup.7, --NR.sup.8R.sup.9, a 3-7 membered
monocyclic saturated or partially saturated heterocyclic group, a
5-6 membered monocyclic heteroaryl ring, or a 5-6 membered
monocyclic aryl ring,
[0193] wherein any alkyl, alkanoyl, or alkenyl is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0194] any cycloalkyl group or other ring is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl;
[0195] R.sup.4 is hydrogen, halogen, C.sub.1-3alkyl,
C.sub.2-3alkenyl, --(C.sub.0-C.sub.3alkyl)C(O)R.sup.13
--(C.sub.2-3alkenyl)C(O)NR.sup.10R.sup.11,
--S(O).sub.12NR.sup.10R.sup.11, or --NR.sup.8R.sup.9;
[0196] wherein any alkyl or alkenyl is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy;
[0197] R.sup.5 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.3-10cycloalkyl group, --NR.sup.8R.sup.9,
--O(C.sub.3-7cycloalkyl group), a 3-11 membered saturated or
partially saturated heterocyclic group, or a 5-6 membered
monocyclic heteroaryl ring,
[0198] wherein any alkyl or alkoxy is independently optionally
substituted by halogen, oxo, CN, OH, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy, and
[0199] any cycloalkyl group or other ring is optionally substituted
by halogen, oxo, CN, OH,
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9;
[0200] A is a 3-11 membered heterocyclic group optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11
[0201] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0202] wherein when A is a 5-membered nitrogen containing
heterocyclic group, the nitrogen atom is substituted;
[0203] R.sup.6 and R.sup.7 are, independently at each occurrence,
hydrogen, C.sub.1-3alkyl, or C.sub.3-6cycloalkyl group,
[0204] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0205] R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently
at each occurrence, hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl
group, a 3-11 membered saturated heterocyclic group,
--C(O)R.sup.13, --C(O)OR.sup.13, --C(O)NR.sup.6R.sup.7, or
--S(O).sub.1-2R.sup.13
[0206] wherein any alkyl, cycloalkyl group or other ring is
independently optionally substituted by halogen, oxo, CN,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.13, or --NR.sup.6R.sup.7;
[0207] R.sup.12 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl or C.sub.3-6cycloalkyl group,
[0208] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy;
[0209] R.sup.13 is, independently at each occurrence, hydrogen,
C.sub.1-6alkyl, C.sub.3-10cycloalkyl group, or a 3-11 membered
saturated heterocyclic group,
[0210] wherein any alkyl, cycloalkyl group, or other ring is
independently optionally substituted by halogen, oxo, CN, OH,
C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy,
C.sub.1-3haloalkoxy, --OR.sup.12, or --NR.sup.6R.sup.7; and
[0211] R.sup.16 is H, --Cl, --CN, or --CH.sub.3.
[0212] In some embodiments, R.sup.1 and R.sup.4 are each hydrogen,
and R.sup.3 is hydrogen, OH, halogen, CH.sub.3, CH.sub.2OH,
CH.sub.2F, OCHF.sub.2, CHF.sub.2, CF.sub.3, cyclopropyl,
azetidinyl, CN, --C(O)CH.sub.3, --C(O)NH.sub.2, --C(O)NHCH.sub.3,
--NHCH.sub.3, --SO.sub.2--NH.sub.2, or --SO.sub.2--NHCH.sub.3.
[0213] In some embodiments, R.sup.1 and R.sup.4 are each hydrogen,
and R.sup.3 is hydrogen, halogen, CH.sub.3, CH.sub.2F, CHF.sub.2,
CF.sub.3, cyclopropyl, or --C(O)CH.sub.3.
[0214] In some embodiments, R.sup.1 and R.sup.4 are each hydrogen,
and R.sup.3 is hydrogen, OH, CH.sub.3, or CH.sub.2OH.
[0215] In some embodiments, R.sup.1 and R.sup.4 are each hydrogen,
and R.sup.3 is Br, Cl, F, OCHF.sub.2, CHF.sub.2, or CF.sub.3.
[0216] In some embodiments, R.sup.1 and R.sup.4 are each hydrogen,
and R.sup.3 is cyclopropyl, azetidinyl, CN, --C(O)CH.sub.3,
--C(O)NH.sub.2, --C(O)NHCH.sub.3, --NHCH.sub.3,
--SO.sub.2--NH.sub.2, or --SO.sub.2--NHCH.sub.3.
[0217] In some embodiments, R.sup.1 and R.sup.3 are each hydrogen,
and R.sup.4 is Cl, CHF.sub.2,
##STR00007##
or a stereoisomer thereof.
[0218] In some embodiments, R.sup.1 and R.sup.3 are each hydrogen,
and R.sup.4 is hydrogen or CH.sub.3.
[0219] In some embodiments, R.sup.1, R.sup.4 and R.sup.3 are each
hydrogen.
[0220] In some embodiments, R.sup.16 is H. In some embodiments,
R.sup.16 is --Cl, --CN, or --CH.sub.3.
[0221] In some embodiments, R.sup.5 is a 3-11 membered saturated or
partially saturated heterocyclic group optionally substituted by
halogen; oxo; CN; OH; C.sub.1-6alkoxy; --NR.sup.8R.sup.9;
--C(O)(C.sub.1-3alkyl);
--(C.sub.0-C.sub.3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.12NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl.
[0222] In some embodiments, R.sup.5 is a 3-11 membered saturated or
partially saturated heterocyclic group optionally substituted by
halogen, oxo, CN, OH, --(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9. In some
embodiments, R.sup.5 is an N-linked 3-11 membered saturated
heterocyclic group optionally substituted by halogen, oxo, CN, OH,
--(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11,
--OP(O)(OC.sub.1-3alkyl).sub.2, or C.sub.1-3 alkyl optionally
substituted by halogen, oxo, CN, OH, or --NR.sup.8R.sup.9.
[0223] In some embodiments, the ring heteroatoms of the 3-11
membered saturated or partially saturated heterocyclic group of
R.sup.5 are selected from nitrogen and oxygen.
[0224] In some embodiments, R.sup.5 is piperidinyl, piperazinyl, or
morpholinyl, wherein any R.sup.5 is optionally substituted by
halogen; oxo; CN; OH; C.sub.1-6alkoxy; --NR.sup.8R.sup.9;
--C(O)(C.sub.1-3alkyl); --(C.sub.0-3alkyl)C(O)NR.sup.10R.sup.11;
--S(O).sub.12NR.sup.8R.sup.9; --OP(O)(OC.sub.1-3alkyl).sub.2;
C.sub.3-10cycloalkyl group optionally substituted with OH or
halogen; a 3-11 membered saturated or partially saturated
heterocyclic group optionally substituted with oxo or
C.sub.1-3alkyl; a 5-6 membered monocyclic heteroaryl ring
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl, or
C.sub.1-3haloalkyl; or C.sub.1-4alkyl optionally substituted by
halogen, oxo, CN, OH, --O--C.sub.1-3 alkyl, --S--C.sub.1-3alkyl,
--SO.sub.2--C.sub.1-3alkyl, --NR.sup.8R.sup.9,
--C(O)NR.sup.8R.sup.9, phenyl, C.sub.3-10cycloalkyl, a 3-11
membered saturated or partially saturated heterocyclic group
optionally substituted with oxo or C.sub.1-3 alkyl, or a 5-6
membered monocyclic heteroaryl ring optionally substituted with
oxo, halogen, or C.sub.1-3alkyl.
[0225] In some embodiments, R.sup.5 is N-linked piperidinyl,
N-linked piperazinyl, or N-linked morpholinyl, wherein any R.sup.5
is optionally substituted by halogen, oxo, CN, OH, or
C.sub.1-3alkyl optionally substituted by halogen, oxo, CN, or
OH.
[0226] In some embodiments, R.sup.5 is:
[0227] --CH.sub.2CH.sub.3, --C(CH.sub.3).sub.2, Cl, CN,
cyclopropyl, --C(O)NH.sub.2, --OCH.sub.3, --OCH.sub.2CF.sub.3,
--OCH.sub.2CHF.sub.2, --CF.sub.3, --CHF.sub.2, --OCF.sub.3,
--OCHF.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2,
##STR00008## ##STR00009## ##STR00010## ##STR00011## ##STR00012##
##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017##
##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022##
or a stereoisomer thereof.
[0228] In some embodiments, R.sup.5 is:
##STR00023## ##STR00024## ##STR00025##
or a stereoisomer thereof.
[0229] In some embodiments, R.sup.5 is
##STR00026##
[0230] As previously noted, when A is a 5-membered nitrogen
containing heterocyclic ring, the nitrogen atom is substituted. In
embodiments wherein A comprises one or more nitrogen atoms, e.g.,
2, 3, or more nitrogen atoms, each nitrogen atom is substituted.
More particularly, in some embodiments, the compound is not
##STR00027##
[0231] In some embodiments, A is a 3-11 membered, non-aromatic
heterocyclic group.
[0232] In some embodiments, A is a 3-11 membered heterocyclic group
comprising at least one oxygen as a ring atom and is optionally
substituted by halogen, oxo, CN, OH, C.sub.1-6alkyl, C.sub.3-6
cycloalkyl group, --NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)NR.sup.10R.sup.11,
--C(O)OR.sup.13, or --S(O).sub.12NR.sup.10R.sup.11, wherein any
alkyl or cycloalkyl group is independently optionally substituted
by halogen, oxo, CN, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl,
C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy.
[0233] In some embodiments, the following portion of Formula 0,
Formula I, or Formula II,
##STR00028##
is further defined as 0-A, I-A, or II-A:
##STR00029##
[0234] wherein A is a 5 or 6 membered ring optionally containing an
additional ring heteroatom and
[0235] wherein A is optionally substituted by halogen, oxo, CN, OH,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or --S(O).sub.1-2
NR.sup.10R.sup.11,
[0236] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy.
[0237] In some embodiments, 0-A, I-A, or II-A is further defined as
0-B, I-B, or II-B:
##STR00030##
wherein R.sup.14 and R.sup.15 are each selected from halogen, oxo,
CN, OH, C.sub.1-6alkyl, C.sub.3-6 cycloalkyl group,
--NR.sup.8R.sup.9, --NR.sup.12C(O)R.sup.13,
--NR.sup.12S(O).sub.12R.sup.13, --C(O)NR.sup.10R.sup.11,
--C(O)OR.sup.13, and --S(O).sub.1-2NR.sup.10R.sup.11,
[0238] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy; or
R.sup.14 and R.sup.15 together form a C.sub.3-6cycloalkyl group or
saturated or partially saturated 3-6 membered heterocyclic
group,
[0239] wherein any cycloalkyl group or other ring is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy.
[0240] In some embodiments, A does not contain oxygen as a ring
atom and is optionally substituted by halogen, oxo, CN, OH,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl group, --NR.sup.8R.sup.9,
--NR.sup.12C(O)R.sup.13, --NR.sup.12S(O).sub.12R.sup.13,
--C(O)NR.sup.10R.sup.11, --C(O)OR.sup.13, or
--S(O).sub.1-2NR.sup.10R.sup.11 wherein any alkyl or cycloalkyl
group is independently optionally substituted by halogen, oxo, CN,
OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or
C.sub.1-3haloalkoxy.
[0241] In some embodiments, the following portion of Formula 0,
Formula I, or Formula II,
##STR00031##
[0242] is further defined as 0-C, I-C, or II-C:
##STR00032##
[0243] wherein the nitrogen comprises a substituent as defined
herein.
[0244] In some embodiments, the following portion of Formula 0,
Formula I, or Formula II,
##STR00033##
[0245] is further defined as 0-C, I-C, or II-C:
##STR00034##
[0246] wherein the nitrogen of A is substituted by C.sub.1-6alkyl
or C.sub.3-6cycloalkyl group,
[0247] wherein any alkyl or cycloalkyl group is independently
optionally substituted by halogen, oxo, CN, OH, C.sub.1-3alkyl,
C.sub.1-3haloalkyl, C.sub.1-3alkoxy, or C.sub.1-3haloalkoxy.
[0248] In some embodiments, the following portion of Formula 0,
Formula I, or Formula II,
##STR00035##
[0249] is selected from
##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041## ##STR00042## ##STR00043## ##STR00044## ##STR00045##
##STR00046## ##STR00047## ##STR00048## ##STR00049## ##STR00050##
##STR00051## ##STR00052##
and stereoisomers thereof.
[0250] In some embodiments, the following portion of Formula 0,
Formula I, or Formula II,
##STR00053##
is selected from
##STR00054## ##STR00055## ##STR00056## ##STR00057##
##STR00058##
and stereoisomers thereof.
[0251] In some embodiments, a compound is selected from the group
consisting of the compounds of Tables 1, 2 and 3, shown below, or a
stereoisomer or pharmaceutically acceptable salt thereof.
TABLE-US-00001 TABLE 1 Exemplary compounds of the present
invention. Salts of such compounds are also contemplated. See the
Examples section for preparation of such compounds. Ex. Structure
Name 1 ##STR00059## N-[7-[4-(hydroxymethyl)-1-piperidyl]-
3,4-dihydro-2H-1,4-benzoxazin-6- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 2 ##STR00060## N-[7-[4-(hydroxymethyl)-1-piperidyl]-
3-oxo-4H-1,4-benzoxazin-6- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 3 ##STR00061## N-[2,2-dimethyl-6-[2-
(methylaminomethyl)-1,3-dioxan-5-yl]-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 4
##STR00062## N-[6-[4-(hydroxymethyl)-1-piperidyl]-
2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 5 ##STR00063## N-(2,2-dimethyl-7-morpholino-3,4-
dihydro-1,4-benzoxazin-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 6 ##STR00064## N-[2-(hydroxymethyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 7 ##STR00065## N-[7-[4-(hydroxymethyl)-1-piperidyl]-
3,4-dihydro-2H-1,4-benzoxazin-6-yl]-6-
methyl-pyrazolo[1,5-a]pyrimidine-3- carboxamide 8 ##STR00066##
N-[6-[4-(2,2-difluoroethyl)piperazin-1-
yl]-2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 9 ##STR00067## N-(7-morpholino-3,4-dihydro-2H-1,4-
benzoxazin-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 10
##STR00068## N-(3-methyl-7-morpholino-3,4-dihydro-
2H-1,4-benzoxazin-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 11
##STR00069## N-(2-methyl-7-morpholino-3,4-dihydro-
2H-1,4-benzoxazin-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 12
##STR00070## N-[6-[4-(hydroxymethyl)-1-piperidyl]-
2,2-dimethyl-3H-benzofuran-5-yl]-6-
methyl-pyrazolo[1,5-a]pyrimidine-3- carboxamide 13 ##STR00071##
N-[6-[(3S)-3- (hydroxymethyl)pyrrolidin-1-yl]-2,2-
dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 14 ##STR00072## N-(2-methyl-6-morpholino-2,3-
dihydrobenzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 15
##STR00073## N-[6-[(3R)-3- (hydroxymethyl)pyrrolidin-1-yl]-2,2-
dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 16 ##STR00074## N-[2-(hydroxymethyl)-6-[4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine-3-
carboxamide 17 ##STR00075## N-[6-(2,2-dimethylmorpholin-4-yl)-2-
(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 18 ##STR00076##
N-[6-[3-(hydroxymethyl)-3-methyl- pyrrolidin-1-yl]-2,2-dimethyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 19
##STR00077## N-[6-[4-(2,2-difluoroethyl)piperazin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 20 ##STR00078## N-[2,2-dimethyl-6-[2-
(methylaminomethyl)-1,3-dioxan-5-yl]-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 21
##STR00079## N-(2-ethyl-2-methyl-6-morpholino-3H-
benzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 22
##STR00080## N-(2-cyclopropyl-2-methyl-6-
morpholino-3H-benzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 23 ##STR00081## N-[2-(dimethylcarbamoyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 24 ##STR00082##
N-[6-[4-(1-amino-2,2,2-trifluoro-ethyl)-
1-piperidyl]-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 25 ##STR00083##
N-[2-(methoxymethyl)-2-methyl-6- morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 26 ##STR00084##
N-[6-(4,4-difluoro-1-piperidyl)-2- (hydroxymethyl)-2-methyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 27 and 28
##STR00085## N-(3-hydroxy-3-methyl-7-morpholino-
chroman-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-(3-hydroxy-3-methyl-7-morpholino- chroman-6-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00086## 29 and 30 ##STR00087##
N-[2-(hydroxymethyl)-2-methyl-6- morpholino-3H-benzofuran-5-yl]-6-
methyl-pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[2-(hydroxymethyl)-2-methyl-6- morpholino-3H-benzofuran-5-yl]-6-
methyl-pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00088## 31 and
32 ##STR00089## N-[(2R)-2-(hydroxymethyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00090## 33 ##STR00091##
N-(2,2-dimethyl-6-morpholino-3H- benzofuran-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 34 ##STR00092##
N-(6-methoxy-2,2-dimethyl-3H- benzofuran-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 35 ##STR00093##
N-(8-morpholino-2,3,4,5-tetrahydro-1,5-
benzoxazepin-7-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 36 and
37 ##STR00094## N-[(2R)-6-(2,2-dimethylmorpholin-4-
yl)-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and N-[(2S)-6-(2,2-dimethylmorpholin-4-
yl)-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00095## 38 ##STR00096##
2-methyl-6-morpholino-5- (pyrazolo[1,5-a]pyrimidine-3-
carbonylamino)-3H-benzofuran-2- carboxylic acid 39 ##STR00097##
N-(6-morpholinospiro[3H-benzofuran-
2,4'-tetrahydropyran]-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
40 ##STR00098## N-[6-[4-fluoro-4-(hydroxymethyl)-1-
piperidyl]-2,2-dimethyl-3H-benzofuran-
5-yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 41 ##STR00099##
N-[6-(1,1-dioxo-1,4-thiazinan-4-yl)-2,2- dimethyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 42 and 43 ##STR00100##
N-[(2S)-2-(hydroxymethyl)-2-methyl-6- [(1R,4R)-2-oxa-5-
azabicyclo[2.2.1]heptan-5-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2R)-2-(hydroxymethyl)-2-methyl-6- [(1R,4R)-2-oxa-5-
azabicyclo[2.2.1]heptan-5-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00101## 44 and 45 ##STR00102##
N-[(2R)-6-[4-fluoro-4-(hydroxymethyl)-
1-piperidyl]-2-(hydroxymethyl)-2- methyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2S)-6-[4-fluoro-4-(hydroxymethyl)-
1-piperidyl]-2-(hydroxymethyl)-2- methyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00103## 46 and 47
##STR00104## N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
[(1S,4S)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl]-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2R)-2-(hydroxymethyl)-2-methyl-6- [(1S,4S)-2-oxa-5-
azabicyclo[2.2.1]heptan-5-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00105## 48 and 49 ##STR00106##
N-[(2S)-2-methyl-2-(methylcarbamoyl)- 6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2R)-2-methyl-2-(methylcarbamoyl)- 6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00107## 50 and 51
##STR00108## N-[(2R)-2-(difluoromethyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[(2S)-2-(difluoromethyl)-2-methyl-6-
morpholino-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00109## 52 and 53 ##STR00110##
N-[(2R)-2-(hydroxymethyl)-6-[4-(1-
hydroxy-1-methyl-ethyl)-1-piperidyl]-2-
methyl-3H-benzofuran-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[(2S)-2-(hydroxymethyl)-6-[4-(1-
hydroxy-1-methyl-ethyl)-1-piperidyl]-2-
methyl-3H-benzofuran-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00111## 54 and 55 ##STR00112##
6-fluoro-N-[(2R)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
6-fluoro-N-[(2S)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00113## 56 and 57
##STR00114## N-[(2S)-6-[(3S)-3-fluoropyrrolidin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2R)-6-[(3S)-3-fluoropyrrolidin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00115## 58 and 59 ##STR00116##
N-[(2R)-6-[(3R)-3-fluoropyrrolidin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2S)-6-[(3R)-3-fluoropyrrolidin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00117## 60 ##STR00118##
N-[6-[4-(2-hydroxyethyl)piperazin-1-
yl]-2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 61 ##STR00119## 6-cyclopropyl-N-(2,2-dimethyl-6-
morpholino-3H-benzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 62 ##STR00120## N-[2,2-dimethyl-6-(4-piperidyl)-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 63
##STR00121## N-[2,2-dimethyl-6-(1-methyl-4-
piperidyl)-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 64 and 65 ##STR00122## N-[6-(4-hydroxycyclohexoxy)-2,2-
dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[6-(4-hydroxycyclohexoxy)-2,2-
dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00123## 66 and 67 ##STR00124##
N-[(2R)-6-(3,3-difluoropyrrolidin-1-yl)-
2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2S)-6-(3,3-difluoropyrrolidin-1-yl)-
2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide
##STR00125## 68 ##STR00126## N-[6-(3,3-difluoro-4-hydroxy-
pyrrolidin-1-yl)-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 69 ##STR00127##
N-(2,2-dimethyl-6-morpholino-3H- benzofuran-5-yl)-6-
(trifluoromethyl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 70
##STR00128## N-[2,2-dimethyl-6-(2,2,2-
trifluoroethoxy)-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 71 and 72 ##STR00129##
N-[(2R)-2-(hydroxymethyl)-2-methyl-6-
(trifluoromethyl)-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
(trifluoromethyl)-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00130## 73 and 74 ##STR00131##
N-[(2R)-6-(difluoromethyl)-2- (hydroxymethyl)-2-methyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2S)-6-(difluoromethyl)-2- (hydroxymethyl)-2-methyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00132## 75 ##STR00133## 6-(difluoromethyl)-N-[2-
(hydroxymethyl)-2-methyl-6- morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 76 and 77 ##STR00134##
N-[(2R)-2-methyl-6-morpholino-2- (trifluoromethyl)-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2S)-2-methyl-6-morpholino-2- (trifluoromethyl)-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00135## 78 and 79
##STR00136## N-[(2R)-2-(hydroxymethyl)-2-methyl-6-
[(1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-
diazabicyclo[2.2.1]heptan-2-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
[(1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-
diazabicyclo[2.2.1]heptan-2-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00137## 80 and 81 ##STR00138##
N-[(2R)-7-chloro-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2S)-7-chloro-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00139## 82
##STR00140## N-(3,3-dimethyl-7-morpholino-2,4-
dihydro-1,4-benzoxazin-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 83 and 84 ##STR00141## N-[(2R)-2-(hydroxymethyl)-2,7-
dimethyl-6-morpholino-3H-benzofuran-
5-yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2S)-2-(hydroxymethyl)-2,7- dimethyl-6-morpholino-3H-benzofuran-
5-yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00142## 85 and
86 ##STR00143## 6-acetyl-N-[(2R)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
6-acetyl-N-[(2S)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00144## 87 and 88
##STR00145## N-[(2R)-6-[4-(2- hydroxyethyl)piperazin-1-yl]-2-
(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2S)-6-[4-(2-hydroxyethyl)piperazin-
1-yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00146## 89 ##STR00147##
N-[6-[1-(2,2-difluoroethyl)-4-piperidyl]-
2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 90 ##STR00148## N-[2,2-dimethyl-6-[1-(2,2,2-
trifluoroethyl)-4-piperidyl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 91 ##STR00149##
6-(difluoromethyl)-N-(2,2-dimethyl-6- morpholino-3H-benzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 92 and 93 ##STR00150##
N-[(2S)-2-(hydroxymethyl)-6-[4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-[(2R)-2-(hydroxymethyl)-6-[4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00151## 94 and 95 ##STR00152##
N-[6-[(3S)-3-(hydroxymethyl)-3-
methyl-pyrrolidin-1-yl]-2,2-dimethyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[6-[(3R)-3-(hydroxymethyl)-3-
methyl-pyrrolidin-1-yl]-2,2-dimethyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00153## 96 and 97 ##STR00154##
N-(2-ethyl-2-methyl-6-morpholino-3H- benzofuran-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide and N-(2-ethyl-2-methyl-6-morpholino-3H-
benzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00155## 98 and 99 ##STR00156##
N-[6-[4-(2,2-difluoroethyl)piperazin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[6-[4-(2,2-difluoroethyl)piperazin-1-
yl]-2-(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00157## 100 ##STR00158##
N-[6-(6,8-dihydro-5H-imidazo[1,5- a]pyrazin-7-yl)-2,2-dimethyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyridine-3-carboxamide 101
##STR00159## N-[2,2-dimethyl-6-(5,6,8,9-
tetrahydroimidazo[1,5-d][1,4]diazepin-
7-yl)-3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
102 ##STR00160## N-[6-[4-(hydroxymethyl)imidazol-1-yl]-
2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 103 ##STR00161## N-(6-imidazol-1-yl-2,2-dimethyl-3H-
benzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 104
##STR00162## N-[2,2-dimethyl-6-(2-methylpyrrolidin-
1-yl)-3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
105 ##STR00163## N-[6-(3-hydroxy-3-methyl-azetidin-1-
yl)-2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 106 ##STR00164## N-[2,2-dimethyl-6-(2-oxa-8-
azaspiro[4.5]decan-8-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 107 ##STR00165##
N-[2,2-dimethyl-6-(2-oxa-7- azaspiro[3.4]octan-7-yl)-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 108
##STR00166## N-[2,2-dimethyl-6-(2-oxa-7-
azaspiro[4.4]nonan-7-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 109 ##STR00167##
N-[6-(4-hydroxy-8-azaspiro[4.5]decan-
8-yl)-2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 110 ##STR00168## N-[6-(2-hydroxy-7-azaspiro[3.5]nonan-
7-yl)-2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 111 ##STR00169## N-[2,2-dimethyl-6-(3-oxo-2,7-
diazaspiro[3.5]nonan-7-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 112 ##STR00170## N-[6-(6,6-difluoro-3-
azabicyclo[3.1.0]hexan-3-yl)-2,2- dimethyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 113 ##STR00171##
N-[2,2-dimethyl-6-(6-oxo-1H-pyridin-3-
yl)-3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 114
##STR00172## N-[2,2-dimethyl-6-(2-oxa-7-
azaspiro[3.5]nonan-7-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 115 ##STR00173##
N-[6-(3-fluoro-4-hydroxy-1-piperidyl)-
2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 116 ##STR00174## N-[6-(1,4-diazepan-1-yl)-2,2-dimethyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 117
##STR00175## N-[2,2-dimethyl-6-(1,4-oxazepan-4-yl)-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 118
##STR00176## N-(2,2-dimethyl-6-morpholino-1,1-
dioxo-3H-benzothiophen-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 119 and 120 ##STR00177##
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
[(1R,4R)-5-(2,2,2-trifluoroethyl)-2,5-
diazabicyclo[2.2.1]heptan-2-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and N-[3-[3-(2-hydroxyethyl)-2-oxo-
imidazolidin-1-yl]-1-methyl-pyrazol-4-
yl]-2-[2-(2,2,2-trifluoroethylamino)-4-
pyridyl]oxazole-4-carboxamide ##STR00178## 121 and 122 ##STR00179##
N-[(2R)-6-(4,4-difluoro-1-piperidyl)-2-
(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2S)-6-(4,4-difluoro-1-piperidyl)-2-
(hydroxymethyl)-2-methyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00180## 123 and 124 ##STR00181##
N-[(2R)-6-[(1R,4R)-5-(2,2- difluoroethyl)-2,5-
diazabicyclo[2.2.1]heptan-2-yl]-2- (hydroxymethyl)-2-methyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2S)-6-[(1R,4R)-5-(2,2- difluoroethyl)-2,5-
diazabicyclo[2.2.1]heptan-2-yl]-2- (hydroxymethyl)-2-methyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00182## 125 and 126 ##STR00183##
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-
(2-oxa-8-azaspiro[4.5]decan-8-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and
N-[(2R)-2-(hydroxymethyl)-2-methyl-6-
(2-oxa-8-azaspiro[4.5]decan-8-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00184## 127 and 128 ##STR00185##
N-[(2R)-2-(hydroxymethyl)-2-methyl-6- (4-methylpiperazin-1-yl)-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2S)-2-(hydroxymethyl)-2-methyl-6- (4-methylpiperazin-1-yl)-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00186## 129 and 130 ##STR00187##
N-[(2S)-2-(hydroxymethyl)-6-[4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2R)-2-(hydroxymethyl)-6-[4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00188## 131 ##STR00189##
N-(6-(4-(2,2-difluoroethyl)piperazin-1-
yl)-2-(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
fluoropyrazolo[1,5-a]pyrimidine-3- carboxamide 132 and 133
##STR00190## (S)-N-(6-(4-(2,2-
Difluoroethyl)piperazin-1-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5-yl)-6- fluoropyrazolo[1,5-a]pyrimidine-3-
carboxamide and (R)-N-(6-(4-(2,2- Difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
fluoropyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00191## 134 and
135 ##STR00192## (R)-N-(2-isopropyl-2-methyl-6-
morpholino-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and (S)-N-(2-isopropyl-2-methyl-6-
morpholino-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00193## 136 ##STR00194##
N-(6-Methyl-2-morpholino-7-oxo-6,7-
dihydro-5H-pyrrolo[3,4-b]pyridin-3- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 137 ##STR00195## N-[6-[4-(2-Hydroxy-1,1-dimethyl-
ethyl)piperazin-1-yl]-2,2-dimethyl-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 138
##STR00196## N-(2-isopropyl-6-morpholino-1-oxo-
isoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 139
##STR00197## N-[2-[(2R)-2-fluoro-3-hydroxy-3-
methyl-butyl]-6-morpholino-1-oxo- isoindolin-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 140 ##STR00198##
N-(2-methyl-6-morpholino-1-oxo- isoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 141 ##STR00199##
N-[2-(hydroxymethyl)-2-methyl-7-
morpholino-chroman-6-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
142 ##STR00200## N-(6-morpholinospiro[3H-benzofuran-
2,4'-piperidine]-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 143
##STR00201## N-(7-cyano-2,2-dimethyl-6-morpholino-
3H-benzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 144
##STR00202## N-[2-(difluoromethyl)-2-methyl-6-
morpholino-3H-benzofuran-5-yl]-6-
methyl-pyrazolo[1,5-a]pyrimidine-3- carboxamide 145 ##STR00203##
[1-[2,2-dimethyl-5-(pyrazolo[1,5- a]pyrimidine-3-carbonylamino)-3H-
benzofuran-6-yl]-4-piperidyl]methyldiethyl phosphate 146
##STR00204## N-(1-methyl-6'-morpholino-3'H-
spiro[azetidine-3,2'-benzofuran]-5'-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 147 ##STR00205##
N-[1'-(2,2-difluoroethyl)-6-morpholino-
spiro[3H-benzofuran-2,3'-azetidine]-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 148 ##STR00206##
N-[6-morpholino-1'-(2,2,2- trifluoroethyl)spiro[3H-benzofuran-2,3'-
azetidine]-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 149
##STR00207## N-[6-[4-(2,2-difluoroethyl)-1,4-
diazepan-1-yl]-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 150 ##STR00208##
N-(2-isopropyl-2-methyl-6-morpholino-
3H-benzofuran-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 151
##STR00209## N-[2-(hydroxymethyl)-6-[4-(2-hydroxy-
2-methyl-propyl)piperazin-1-yl]-2- methyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 152 ##STR00210##
N-(1'-methyl-6-morpholino-spiro[3H- benzofuran-2,4'-piperidine]-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 153 and 154
##STR00211## N-[(2R)-2-(hydroxymethyl)-6-
morpholino-2-(trifluoromethyl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and N-[(2S)-2-(hydroxymethyl)-6-
morpholino-2-(trifluoromethyl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00212## 155 and 156 ##STR00213##
N-[(2S)-2-(difluoromethoxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5- yl]pyrazol[1,5-a]pyrimidine-3-
carboxamide and N-[(2R)-2-(difluoromethoxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00214## 157 and
158 ##STR00215## N-[(2R)-2-(1-hydroxy-1-methyl-ethyl)-
2-methyl-6-morpholino-3H-benzofuran-
5-yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-[(2S)-2-(1-hydroxy-1-methyl-ethyl)-
2-methyl-6-morpholino-3H-benzofuran-
5-yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00216## 159 and
160 ##STR00217## N-[(2R)-2-cyclopropyl-6-[4-(2,2-
difluoroethyl)piperazin-1-yl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2S)-2-cyclopropyl-6-[4-(2,2-
difluoroethyl)piperazin-1-yl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00218## 161 and 162 ##STR00219##
N-[(2R)-2-cyclopropyl-6-[4-fluoro-4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
N-[(2S)-2-cyclopropyl-6-[4-fluoro-4-
(hydroxymethyl)-1-piperidyl]-2-methyl-
3H-benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR00220## 163 and 164 ##STR00221##
6-chloro-N-[(2S)-2-(hydroxymethyl)-6-
[4-(hydroxymethyl)-1-piperidyl]-2- methyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
6-chloro-N-[(2R)-2-(hydroxymethyl)-6-
[4-(hydroxymethyl)-1-piperidyl]-2- methyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00222## 165 and
166 ##STR00223## 6-chloro-N-[(2S)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide and
6-chloro-N-[(2R)-2-(hydroxymethyl)-2-
methyl-6-morpholino-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00224## 167
##STR00225## 6-chloro-N-[2,2-dimethyl-6-(2-oxa-8-
azaspiro[4.5]decan-8-yl)-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide
TABLE-US-00002 TABLE 2 Additional exemplary compounds of the
present invention. Salts of such compounds are also contemplated.
See the Examples section for preparation of such compounds. 168
##STR00226## N-(6-(4-(2,2- Difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
methylpyrazolo[1,5- a]pyrimidine-3-carboxamide 169 and 170
##STR00227## (S)-6-Chloro-N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamide and
(R)-6-Chloro-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)pyrazolo
[1,5-a]pyrimidine-3-carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR00228## 171 and 172 ##STR00229##
(R)-N-(2-(Hydroxymethyl)-2- methyl-6-(trifluoromethoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (S)-N-(2-(hydroxymethyl)-2- methyl-6-(trifluoromethoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00230## 173 ##STR00231## N-[6-Morpholino-1-oxo-2-(2,2,2-
trifluoroethyl)isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 174 ##STR00232## N-[2-(2,2-difluoroethyl)-6-
morpholino-1-oxo-isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 175 ##STR00233## N-[2-(3-hydroxy-3-methyl-
butyl)-6-morpholino-1-oxo- isoindolin-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 176 ##STR00234##
N-[2-(2-hydroxy-2-methyl- propyl)-6-morpholino-1-oxo-
isoindolin-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 177
##STR00235## N-[6-[4-(2-amino-2-oxo- ethyl)piperazin-1-yl]-1-oxo-2-
tetrahydropyran-4-yl-isoindolin- 5-yl]pyrazolo[1,5-a]pyrimidine-
3-carboxamide 178 ##STR00236## N-[2-(2-methoxyethyl)-6-
morpholino-1-oxo-isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 179 ##STR00237## N-[2-(2-hydroxyethyl)-6-
morpholino-1-oxo-isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 180 ##STR00238## N-[2-(1-methyl-4-piperidyl)-6-
morpholino-1-oxo-isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 181 ##STR00239## N-[2-(4-hydroxycyclohexyl)-6-
morpholino-1-oxo-isoindolin-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 182 ##STR00240## N-[2,2-dimethyl-6-[(1S,5R)-6-
(methylcarbamoyl)-3- azabicyclo[3.1.0]hexan-3-yl]-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 183
##STR00241## N-[2,2-dimethyl-6-[4-[2- (methylamino)-2-oxo-ethyl]-1-
piperidyl]-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 184 ##STR00242## N-[6-(4-carbamoyl-4-methyl-1-
piperidyl)-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 185 ##STR00243##
N-[6-(4-hydroxyazepan-1-yl)-2,2- dimethyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 186 ##STR00244##
N-[6-[(1S,5R)-6-carbamoyl-3- azabicyclo[3.1.0]hexan-3-yl]-2,2-
dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 187 ##STR00245## N-[6-[4-(2-amino-2-oxo-
ethyl)piperazin-1-yl]-2,2- dimethyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 188 ##STR00246##
N-[2,2-dimethyl-6-[3-(3- methylimidazol-4-yl)pyrrolidin-
1-yl]-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide
189 ##STR00247## N-[6-(5,7-dihydropyrrolo[3,4-
b]pyridin-6-yl)-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 190 ##STR00248##
N-[2,2-dimethyl-6-[3-(1H- pyrazol-5-yl)-1-piperidyl]-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 191
##STR00249## N-[6-(1,3,3a,4,6,6a- hexahydrofuro[3,4-c]pyrrol-5-yl)-
2,2-dimethyl-3H-benzofuran-5- yl]pyrazolo[1,5-a]pyrimidine-3-
carboxamide 192 ##STR00250## N-[2,2-dimethyl-6-[3-(1H-
pyrazol-3-yl)pyrrolidin-1-yl]-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 193 ##STR00251## N-[6-(5,5-difluoro-2-
azabicyclo[2.2.1]heptan-2-yl)- 2,2-dimethyl-3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 194 ##STR00252##
N-[2,2-dimethyl-6-(6-oxa-2- azaspiro[3.5]nonan-2-yl)-3H-
benzofuran-5-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide 195
##STR00253## N-[2,2-dimethyl-6-[3-
(trifluoromethyl)pyrrolidin-1-yl]- 3H-benzofuran-5-
yl]pyrazolo[1,5-a]pyrimidine-3- carboxamide 196 ##STR00254##
N-(6-(3,3-difluoropiperidin-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
197 ##STR00255## N-(6-((3aR,6aS)-5,5- difluorohexahydrocyclopenta
[c]pyrrol-2(1H)-yl)-2,2-dimethyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 198 ##STR00256##
N-(6-(2- (methoxymethyl)morpholino)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
199 ##STR00257## N-(6-(6,6-difluoro-3-
azabicyclo[3.2.0]heptan-3-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
200 ##STR00258## N-(6-((3aR,6aS)-4,4-
difluorohexahydrocyclopenta[c] pyrrol-2(1H)-yl)-2,2-dimethyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 201 ##STR00259## N-(6-(2-
(hydroxymethyl)pyrrolidin-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
202 ##STR00260## N-(6-(3-(1H-imidazol-2-
yl)piperidin-1-yl)-2,2-dimethyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 203 ##STR00261##
N-(6-((3R,4S)-3,4- difluoropyrrolidin-1-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 204 ##STR00262## N-(6-(5,5-difluoro-2-
azaspiro[3.3]heptan-2-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 205 ##STR00263##
N-(6-((4- cyanobenzyl)(methyl)amino)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 206 ##STR00264## N-(6-(4-(1H-imidazol-1-
yl)piperidin-1-yl)-2,2-dimethyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 207 ##STR00265##
N-(6-(4,4-difluoroazepan-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
208 ##STR00266## N-(6-((1R,5S,6r)-6-carbamoyl-3-
azabicyclo[3.1.0]hexan-3-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 209 ##STR00267##
N-(6-(4-hydroxyazepan-1-yl)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 210 ##STR00268##
N-(6-(4-carbamoyl-4- methylpiperidin-1-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 211 ##STR00269## N-(2,2-dimethyl-6-(4-(2-
(methylamino)-2- oxoethyl)piperidin-1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 212 ##STR00270##
N-(2,2-dimethyl-6-((1R,5S,6r)-6- (methylcarbamoyl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 213 ##STR00271##
N-(2,2-dimethyl-6-(3-oxo-2,8- diazaspiro[4.5]decan-8-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
214 ##STR00272## N-(2,2-dimethyl-6-(pyrrolidin-1-
yl)-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 215 ##STR00273## N-(6-(6-(hydroxymethyl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 216 ##STR00274##
N-(6-(4-cyanopiperidin-1-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 217 ##STR00275##
N-(6-(3,3-difluoropyrrolidin-1- yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
218 ##STR00276## N-(2,2-dimethyl-6-(4-
(trifluoromethyl)piperidin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 219 ##STR00277##
N-(6-(4-isobutyrylpiperazin-1- yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
220 ##STR00278## N-(6-(4-acetyl-1,4-diazepan-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 221 ##STR00279##
N-(2,2-dimethyl-6-(3-oxo-2,8- diazaspiro[4.5]decan-8-yl)-2,3-
dihydrobenzofuran-5-yl) pyrazolo[1,5-a]pyrimidine-3- carboxamide
222 and 223 ##STR00280## (R)-N-(2,2-dimethyl-6-(2-oxa-7-
azaspiro[4.4]nonan-7-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(S)-N-(2,2-dimethyl-6-(2-oxa-7- azaspiro[4.4]nonan-7-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
(stereochemistry assigned arbitrarily) ##STR00281## 224
##STR00282## N-[6-(6-hydroxy-4-methyl-1,4-
diazepan-1-yl)-2,2-dimethyl-3H- benzofuran-5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide 225 ##STR00283##
N-(6-(4-(2-(Isopropylamino)-2- oxoethyl)piperazin-1-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 226 ##STR00284## N-(6-(4-(1-Amino-2-methyl-1-
oxopropan-2-yl)piperazin-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
227 ##STR00285## N-(6-((3R,5S)-4-(2-Amino-2-
oxoethyl)-3,5-dimethylpiperazin- 1-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
228 ##STR00286## N-(2,2-Dimethyl-6-(4-(2- morpholino-2-
oxoethyl)piperazin-1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 229 ##STR00287##
N-(2,2-Dimethyl-6-(3-(2- methylpyrimidin-4-yl)pyrrolidin-
1-yl)-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 230 ##STR00288## N-(2,2-Dimethyl-6-(4-
((tetrahydrofuran-2- yl)methyl)piperazin-1-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
231 ##STR00289## N-(6-(4-(2-(1H-Imidazol-1-
yl)ethyl)piperazin-1-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 232 ##STR00290##
N-(6-(4-(2-(Dimethylamino)-2-
oxoethyl)piperazin-1-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 233 ##STR00291##
N-(6-(5,6-Dihydroimidazo[1,2- a]pyrazin-7(8H)-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 234 ##STR00292## N-(6-(Hexahydro-5H-furo[2,3-
c]pyrrol-5-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 235 ##STR00293##
N-(6-(4-(1,3,4-Oxadiazol-2- yl)piperidin-1-yl)-2,2-dimethyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 236 ##STR00294## N-(6-(3-Carbamoylpyrrolidin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 237 ##STR00295##
N-(6-(9-Hydroxy-3-oxa-7- azabicyclo[3.3.1]nonan-7-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 238 ##STR00296## N-(2,2-Dimethyl-6-(1,4,6,7-
tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-2,3-
dihydrobenzofuran-5-yl) pyrazolo[1,5-a]pyrimidine-3- carboxamide
239 ##STR00297## N-(6-(7-Methoxy-2- azabicyclo[2.2.1]heptan-2-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 240 ##STR00298##
N-(6-(2-Azabicyclo[3.1.0]hexan- 2-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
241 ##STR00299## N-(2,2-Dimethyl-6-(3-
sulfamoylpyrrolidin-1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 242 ##STR00300##
N-(6-(4-(2-(Cyclopropylamino)- 2-oxoethyl)piperazin-1-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 243 ##STR00301## N-(2,2-Dimethyl-6-(4-(2-oxo-2-
(pyrrolidin-1-yl)ethyl)piperazin- 1-yl)-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 244 ##STR00302##
N-(6-(4-(1-(Cyclopropylamino)- 1-oxopropan-2-yl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 245 ##STR00303##
N-(2,2-Dimethyl-6-(4-(2,2,2- trifluoro-1-
hydroxyethyl)piperidin-1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 246 ##STR00304##
N-(6-(4,6-dihydropyrrolo[3,4- c]pyrazol-5(1H)-yl)-2,2-
dimethyl-2,2-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 247 ##STR00305## N-(2,2-dimethyl-6-(3-methyl-4,6-
dihydropyrrolo[3,4-c]pyrazol- 5(1H)-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 248 ##STR00306##
N-(6-(2-(2,2-Difluoroethyl)-2,7- diazaspiro[3.5]nonan-7-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 249 ##STR00307## N-(2,2-dimethyl-6-(2-(2,2,2-
trifluoroethyl)-2,7- diazaspiro[3.5]nonan-7-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
250 ##STR00308## N-[2-(2-Hydroxy-1,1-dimethyl-
ethyl)-6-morpholino-1-oxo- isoindolin-5-yl]pyrazolo[1,5-a]
pyrimidine-3-carboxamide 251 ##STR00309##
N-(6-morpholino-2-(oxetan-3-yl)- 1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 252 ##STR00310##
N-(6-morpholino-2-(2-(oxetan-3- yl)ethyl)-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 253 ##STR00311##
N-(2-(cyanomethyl)-6- morpholino-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 254 ##STR00312##
N-(6-morpholino-1-oxo-2- (tetrahydrofuran-3-yl)isoindolin-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 255 ##STR00313##
N-(6-morpholino-1-oxo-2- (tetrahydro-2H-pyran-4-
yl)isoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 256
##STR00314## N-(2-(3-methoxy-3-methylbutyl)-
6-morpholino-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 257 ##STR00315## N-(6-morpholino-1-oxo-2-
((tetrahydro-2H-pyran-2- yl)methyl)isoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 258 ##STR00316##
(R)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(2-fluoro-3-hydroxy-3- methylbutyl)-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 259 and 260
##STR00317## N-(2-((R)-2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxo-6-(4-((S)- 2,2,2-trifluoro-1-
hydroxyethyl)piperidin-1- yl)isoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide and N-(2-((R)-2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxo-6-(4-((R)- 2,2,2-trifluoro-1-
hydroxyethyl)piperidin-1- yl)isoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00318## 261 ##STR00319##
(R)-N-(6-(3,3-difluoropyrrolidin- 1-yl)-2-(2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 262 ##STR00320## N-(2-(((1r,3r)-3-
hydroxycyclobutyl)methyl)-6- morpholino-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 263 ##STR00321##
N-(6-(4- (hydroxymethyl)piperidin-1-yl)- 1-oxo-2-(2,2,2-
trifluoroethyl)isoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 264 ##STR00322## (R)-N-(2-(2-fluoro-3-hydroxy-3-
methylbutyl)-6-morpholino-1- oxoisoindolin-5-yl)-6-
methylpyrazolo[1,5- a]pyrimidine-3-carboxamide 265 ##STR00323##
N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-1-oxo-
2-(2,2,2-trifluoroethyl)isoindolin- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 266 ##STR00324## N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-1- oxo-2-(2,2,2-
trifluoroethyl)isoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 267 ##STR00325## N-(2-(3-hydroxy-2,2-
dimethylpropyl)-6-morpholino-1- oxoisoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 268 ##STR00326##
N-(2-((3-(hydroxymethyl)oxetan- 3-yl)methyl)-6-morpholino-1-
oxoisoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 269
##STR00327## (R)-6-bromo-N-(2-(2-fluoro-3-
hydroxy-3-methylbutyl)-6- morpholino-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 270 ##STR00328##
N-(2-(2,2-difluoro-3-hydroxy-3- methylbutyl)-6-morpholino-1-
oxoisoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 271
##STR00329## (R)-6-chloro-N-(2-(2-fluoro-3-
hydroxy-3-methylbutyl)-6- morpholino-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 272 ##STR00330##
N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-2-
isopropyl-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 273 ##STR00331## N-(2-(2,2-difluoro-3-
hydroxypropyl)-6-morpholino-1- oxoisoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 274 ##STR00332##
(R)-N-(6-(4-cyanopiperidin-1-yl)- 2-(2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 275 and 276 ##STR00333## (S)-N-(6-morpholino-1-oxo-2-
(tetrahydrofuran-3-yl)isoindolin- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide and (R)-N-(6-morpholino-1-oxo-2-
(tetrahydrofuran-3-yl)isoindolin- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide ##STR00334## 277 and 278 ##STR00335##
(R)-N-(6-morpholino-1-oxo-2- ((tetrahydro-2H-pyran-2-
yl)methyl)isoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (S)-N-(6-morpholino-1-oxo-2- ((tetrahydro-2H-pyran-2-
yl)methyl)isoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00336## 279 ##STR00337## N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-2- (3-hydroxy-3-methylbutyl)-1-
oxoisoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 280
##STR00338## N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-2-(3-
hydroxy-3-methylbutyl)-1- oxoisoindolin-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 281 ##STR00339## N-(6-(4-(2-amino-2-
oxoethyl)piperazin-1-yl)-2-(1- methylpiperidin-4-yl)-1-
oxoisoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 282 and
283 ##STR00340## N-(6-(4-((R)-2,2-difluoro-1-
hydroxyethyl)piperidin-1-yl)-2- ((R)-2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-(6-(4-((S)-2,2-difluoro-1-
hydroxyethyl)piperidin-1-yl)-2- ((R)-2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00341## 284 ##STR00342## (R)-N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-2- (2-fluoro-3-hydroxy-3-
methylbutyl)-1-oxoisoindolin-5- yl)-6-methylpyrazolo[1,5-
a]pyrimidine-3-carboxamide 285 ##STR00343##
(R)-6-chloro-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(2-fluoro-3-hydroxy-3- methylbutyl)-1-oxoisoindolin-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 286 ##STR00344##
(R)-N.sup.3-(2-(2-fluoro-3-hydroxy-3- methylbutyl)-6-morpholino-1-
oxoisoindolin-5-yl)pyrazolo[1,5- a]pyrimidine-3,6-dicarboxamide 287
##STR00345## N-(2-isopropyl-6-morpholino- 1,1-dioxido-2,3-
dihydrobenzo[d]isothiazol-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 288 ##STR00346## N-(2-(2-hydroxy-2-
methylpropyl)-6-morpholino-1,1- dioxido-2,3-
dihydrobenzo[d]isothiazol-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 289 ##STR00347## (R)-N-(2-(2-fluoro-3-hydroxy-3-
methylbutyl)-6-morpholino-1,1- dioxido-2,3-
dihydrobenzo[d]isothiazol-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 290 ##STR00348## diethyl ((2-methyl-6-morpholino- 5-
(pyrazolo[1,5-a]pyrimidine-3- carboxamido)-2,3-
dihydrobenzofuran-2-yl)methyl) phosphate 291 ##STR00349##
(R)-N-(2,2-dimethyl-6- (pyrrolidin-2-ylmethoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
292 ##STR00350## (R)-N-(6-((1-(2,2- difluoroethyl)pyrrolidin-2-
yl)methoxy)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 293 ##STR00351##
N-(6-(((1S,3S,5S)-2-(2,2- difluoroethyl)-2-
azabicyclo[3.1.0]hexan-3- yl)methoxy)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
294 ##STR00352## N-(6-(((1R,5S,6r)-3-(2,2- difluoroethyl)-3-
azabicyclo[3.1.0]hexan-6- yl)methoxy)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
295 ##STR00353## N-(6-(((1R,5S,6r)-3- azabicyclo[3.1.0]hexan-6-
yl)methoxy)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 296 ##STR00354##
N-(2,2-dimethyl-6- ((tetrahydrofuran-3-yl)methoxy)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 297 ##STR00355## N-(2,2-dimethyl-6-(pyridin-3-
ylmethoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
298 ##STR00356## N-(6-(cyclopropylmethoxy)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 299 ##STR00357## N-(2,2-dimethyl-6-((3-
methyloxetan-3-yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 300 ##STR00358##
N-(2,2-dimethyl-6-((1-methyl- 1H-pyrazol-4-yl)methoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
301 ##STR00359## N-(2,2-dimethyl-6-(pyridin-4- ylmethoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
302 ##STR00360## N-(6-(2,2-difluoroethoxy)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 303 ##STR00361## N-(2,2-dimethyl-6-(1-(1-methyl-
1H-pyrazol-4-yl)ethoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 304 ##STR00362##
N-(2,2-dimethyl-6-((1- methylpiperidin-3-yl)oxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
305 and 306 ##STR00363## (S)-N-(2,2-dimethyl-6-((2-
oxopiperidin-4-yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(2,2-dimethyl-6-((2- oxopiperidin-4-yl)methoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00364## 307 and 308 ##STR00365## (R)-N-(2,2-dimethyl-6-((5-
oxopyrrolidin-3-yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(S)-N-(2,2-dimethyl-6-((5- oxopyrrolidin-3-yl)methoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00366## 309 ##STR00367## N-(2,2-dimethyl-6-(piperidin-4-
ylmethoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 310 and 311
##STR00368## (S)-N-(6-(2,2-difluoroethoxy)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(6-(2,2-difluoroethoxy)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00369## 312 and 313 ##STR00370## N-((S)-6-(((1S,4R)-4-
hydroxycyclohexyl)oxy)-2-(2- hydroxypropan-2-yl)-2-methyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-((R)-6-(((1S,4S)-4- hydroxycyclohexyl)oxy)-2-(2-
hydroxypropan-2-yl)-2-methyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00371## 314 and
315 ##STR00372## N-((S)-6-(((1r,4S)-4- hydroxycyclohexyl)oxy)-2-(2-
hydroxypropan-2-yl)-2-methyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-((R)-6-(((1r,4R)-4- hydroxycyclohexyl)oxy)-2-(2-
hydroxypropan-2-yl)-2-methyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00373## 316 and
317 ##STR00374## (R)-N-(2-(hydroxymethyl)-6-(4-
(hydroxymethyl)piperidin-1-yl)- 2-(trifluoromethyl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (S)-N-(2-(hydroxymethyl)-6-(4- (hydroxymethyl)piperidin-1-yl)-
2-(trifluoromethyl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00375## 318 and
319 ##STR00376## (S)-N-(6-(4-fluoro-4-
(hydroxymethyl)piperidin-1-yl)- 2-(hydroxymethyl)-2-
(trifluoromethyl)-2,3- dihydrobenzofuran-5-yl)
pyrazolo[1,5-a]pyrimidine-3- carboxamide and (R)-N-(6-(4-fluoro-4-
(hydroxymethyl)piperidin-1-yl)- 2-(hydroxymethyl)-2-
(trifluoromethyl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00377## 320 and
321 ##STR00378## (R)-N-(2-hydroxymethyl)-2- methyl-6-(1-oxo-2,7-
diazaspiro[3.5]nonan-7-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(S)-N-(2-(hydroxymethyl)-2- methyl-6-(1-oxo-2,7-
diazaspiro[3.5]nonan-7-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00379## 322
##STR00380## N-(2-(hydroxymethyl)-6-(6- (hydroxymethyl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 323 and 324
##STR00381## (S)-N-(2-(hydroxymethyl)-6-(4-
(2-hydroxypropan-2-yl)piperidin- 1-yl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(2-(hydroxymethyl)-6-(4- (2-hydroxypropan-2-yl)piperidin-
1-yl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00382## 325
##STR00383## N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(1-hydroxypropan-2-yl)-2,3- dihydrobenzofuran-5-yl)-6-
methylpyrazolo[1,5- a]pyrimidine-3-carboxamide 326 and 327
##STR00384## (S)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
methylpyrazolo[1,5-a] pyrimidine-3-carboxamide and
(R)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
methylpyrazolo[1,5-a] pyrimidine-3-carboxamide ##STR00385## 328
##STR00386## N-(6-(4-fluoro-4- (hydroxymethyl)piperidin-1-yl)-
2-(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
methylpyrazolo[1,5-a] pyrimidine-3-carboxamide 329, 330, 331, and
332 ##STR00387## N-((R)-6-((S)-4-hydroxy-4- methylazepan-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00388##
N-((R)-6-((R)-4-hydroxy-4- methylazepan-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00389##
N-((S)-6-((S)-4-hydroxy-4- methylazepan-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00390##
N-((S)-6-((R)-4-hydroxy-4- methylazepan-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 333 and 334
##STR00391## (S)-N-(6-(4-(2-amino-2- oxoethyl)piperidin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(6-(4-(2-amino-2- oxoethyl)piperidin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00392## 335 and
336 ##STR00393## (S)-N-(6-(4-cyanopiperidin-1-yl)-
2-(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(6-(4-cyanopiperidin-1-yl)- 2-(hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00394## 337, 338, 339, and 340 ##STR00395##
N-((S)-6-((S)-4-hydroxyazepan-1- yl)-2-(hydroxymethyl)-2-methyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide; ##STR00396## N-((R)-6-((S)-4-hydroxyazepan-
1-yl)-6-(hydroxymethyl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00397##
N-((S)-6-((R)-4-hydroxyazepan- 1-yl)-2-(hydroxymethyl)-2-
methyl-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide; ##STR00398## N-((R)-6-((R)-4-hydroxyazepan-
1-yl)-2-(hydroxymethyl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 341 and 342
##STR00399## (R)-N-(6-(4-(1- hydroxycyclopropyl)piperidin-1-
yl)-2-(hydroxymethyl)-2-methyl- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and (S)-N-(6-(4-(1-
hydroxycyclopropyl)piperidin-1- yl)-2-(hydroxymethyl)-2-methyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00400## 343 ##STR00401##
N-(2-(hydroxymethyl)-2-methyl- 6-(4-propionylpiperidin-1-yl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 344 and 345 ##STR00402## (S)-N-(6-(4-(1H-imidazol-1-
yl)piperidin-1-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(6-(4-(1H-imidazol-1- yl)piperidin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00403## 346 and
347 ##STR00404## (S)-N-(6-(4-fluoro-4-
(hydroxymethyl)piperidin-1-yl)- 2-(hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(6-(4-fluoro-4- (hydroxymethyl)piperidin-1-yl)-
2-(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00405## 348 and
349 ##STR00406## N-((S)-6-((1R,5S,6R)-6- carbamoyl-3-
azabicyclo[3.1.0]hexan-3-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and N-((R)-6-((1R,5S,6S)-6- carbamoyl-3-
azabicyclo[3.1.0]hexan-3-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00407## 350 and 351 ##STR00408## (R)-N-(2-(hydroxymethyl)-2-
methyl-6-((1-methyl-1H-pyrazol- 4-yl)methoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (S)-N-(2-(hydroxymethyl)-2- methyl-6-((1-methyl-1H-pyrazol-
4-yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00409## 352
##STR00410## N-(6-(4-(2,2-difluoro-1-
hydroxyethyl)piperidin-1-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
353 ##STR00411## N-(6-(4-fluoro-4- (hydroxymethyl)piperidin-1-yl)-
2-(2-hydroxypropan-2-yl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 354 and 355
##STR00412## (S)-N-(6-(4- (hydroxymethyl)piperidin-1-yl)-
2-(2-hydroxypropan-2-yl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and (R)-N-(6-(4-
(hydroxymethyl)piperidin-1-yl)- 2-(2-hydroxypropan-2-yl)-2-
methyl-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00413## 356 ##STR00414## N-(6-(4-(2-amino-2-
oxoethyl)piperazin-1-yl)-2-(2- hydroxypropan-2-yl)-2-methyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 357 ##STR00415## N-(6-(1-(2-
hydroxyethyl)piperidin-4-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide
358 ##STR00416## N-(3-hydroxy-2,2-dimethyl-5- morpholino-2,3-
dihydrobenzofuran-6- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
359 ##STR00417## N-(2,2-dimethyl-5-morpholino-3-
oxo-2,3-dihydrobenzofuran-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 360 and 361 ##STR00418## (S)-N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-2- (2-hydroxypropan-2-yl)-2-
methyl-2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and (R)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(2-hydroxypropan-2-yl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00419## 362
##STR00420## N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
((difluoromethoxy)methyl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 363 ##STR00421##
N-(6-(4- (hydroxymethyl)piperidin-1-yl)-
2-(2-hydroxypropan-2-yl)-2- methyl-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 364 ##STR00422##
N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(difluoromethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 365 and 366
##STR00423## (R)-N-(6-(4-(2,2-difluoroethyl)
piperazin-1-yl)-2-(hydroxy- methyl)-2-(trifluoromethyl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and (S)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2- (trifluoromethyl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00424## 367 and
368 ##STR00425## (S)-N-(2-(2,2-difluoroethyl)-2-
methyl-6-morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(2-(2,2-difluoroethyl)-2- methyl-6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00426## 369 ##STR00427## N-(1'-(2-hydroxyethyl)-6-
morpholino-3H- spiro[benzofuran-2,4'-piperidin]-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 370 ##STR00428##
N-(1'-(2,2-difluoroethyl)-6- morpholino-3H-
spiro[benzofuran-2,4'-piperidin]- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 371 ##STR00429## N-(6-(4-
(hydroxymethyl)piperidin-1-yl)- 1'-methyl-3H-spiro[benzofuran-
2,4'-piperidin]-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 372
##STR00430## N-(1'-isopropyl-6-morpholino-
3H-spiro[benzofuran-2,4'- piperidin]-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 373 ##STR00431## N-(6-(4-(2-amino-2-
oxoethyl)piperazin-1-yl)-1'- methyl-3H-spiro[benzofuran-2,4'-
piperidin]-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 374
##STR00432## N-(1'-acetyl-6-(4-(2-amino-2-
oxoethyl)piperazin-1-yl)-3H- spiro[benzofuran-2,4'-piperidin]-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 375 ##STR00433##
N-(6-(4-(2-(cyclopropylamino)-2- oxoethyl)piperazin-1-yl)-3H-
spiro[benzofuran-2,4'-piperidin]- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 376 ##STR00434## N-(6-(4-(2-(cyclopropylamino)-2-
oxoethyl)piperazin-1-yl)-1'- methyl-3H-spiro[benzofuran-2,4'-
piperidin]-5-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide 377
##STR00435## N-(6-(2,2-difluoroethoxy)-3H-
spiro[benzofuran-2,4'-piperidin]- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 378 ##STR00436## N-(6-(2,2-difluoroethoxy)-1'-
methyl-3H-spiro[benzofuran-2,4'- piperidin]-5-yl)pyrazolo[1,5-a]
pyrimidine-3-carboxamide 379 ##STR00437## N-(6-(4-(2,2-
difluoroethyl)piperazin-1-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)-6- (methylamino)pyrazolo[1,5-a] pyrimidine-3-carboxamide 380
##STR00438## N-(1'-methyl-6-morpholino-3H-
spiro[benzofuran-2,4'-piperidin]- 5-yl)-6-
(methylamino)pyrazolo[1,5-a] pyrimidine-3-carboxamide 381 and 382
##STR00439## (S)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
(methylamino)pyrazolo[1,5-a] pyrimidine-3-carboxamide and
(R)-N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-yl)-6-
(methylamino)pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR00440##
383 ##STR00441## N-(6-(4-(2,2- difluoroethyl)piperazin-1-yl)-
2',3',5',6'-tetrahydro-3H- spiro[benzofuran-2,4'-pyran]-5-
yl)-6-(methylamino)pyrazolo[1,5- a]pyrimidine-3-carboxamide 384
##STR00442## N-(6-cyclopropyl-2,2-dimethyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 385 ##STR00443## N-(2-methyl-6-morpholino-1,1-
dioxido-2,3- dihydrobenzo[d]isothiazol-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 386 ##STR00444##
N-(2-(cyanomethyl)-2-methyl-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 387 and 388
##STR00445## (S)-N-(2-(2-hydroxyethyl)-2- methyl-6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(2-(2-hydroxyethyl)-2- methyl-6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00446## 389 ##STR00447## N-(6-(4-aminomethyl)-4-
fluoropiperidin-1-yl)-2,2- dimethyl-2,2-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 390 and 391
##STR00448## (R)-N-(1'-methyl-6-morpholino-
3H-spiro[benzofuran-2,3'- pyrrolidin]-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide and (S)-N-(1'-methyl-6-morpholino-
3H-spiro[benzofuran-2,3'- pyrrolidin]-5-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR00449## 392 ##STR00450##
N-(2-(1-fluoro-2-hydroxy-2- methylpropyl)-2-methyl-6-
morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 393 ##STR00451##
N-(6-morpholino-3H- spiro[benzofuran-2,3'-pyrrolidin]-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 394 ##STR00452##
N-(2,2-bis(hydroxymethyl)-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 395 ##STR00453##
N-(2,2-dimethyl-6-(2- (methylcarbamoyl)cyclopropyl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide 396 ##STR00454## N-(6-((1R,2R)-2-
carbamoylcyclopropyl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 397 ##STR00455##
N-(6-((1R,2R)-2- (hydroxymethyl)cyclopropyl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
398 ##STR00456## N-(2-isopropyl-6-morpholino-1-
oxoisoindolin-5-yl)-6- (methylamino)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 399 and 400 ##STR00457##
N-(2-((3R,4S)-3- fluorotetrahydro-2H-pyran-4-yl)-
6-morpholino-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and N-(2-((3S,4R)-3- fluorotetrahydro-2H-pyran-4-yl)-
6-morpholino-1-oxoisoindolin-5- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00458## 401 ##STR00459##
N-(2-methyl-7-morpholino-1- oxo-1,2,3,4- tetrahydroisoquinolin-6-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 402 ##STR00460##
N-(7-morpholino-1,1-dioxido- 3,4-dihydro-2H-
benzo[b][1,4]thiazin-6- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
403 ##STR00461## N-(3,3-dimethyl-7-morpholino-
1,1-dioxido-3,4-dihydro-2H- benzo[b][1,4]thiazin-6-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 404 ##STR00462##
N-(2,2-dimethyl-6-(1-methyl-1H- pyrazol-4-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
405 ##STR00463## N-(6-(5-cyanopyridin-3-yl)-2,2-
dimethyl-2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide 406 ##STR00464## N-(2,2-dimethyl-6-(1-methyl-1H-
imidazol-2-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 407 ##STR00465##
6-cyano-N-(2,2-dimethyl-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 408 ##STR00466##
1-(2-amino-2-oxoethyl)-4-(2,2- dimethyl-5-(pyrazolo[1,5-
a]pyrimidine-3-carboxamido)- 2,3-dihydrobenzofuran-6-yl)-1-
methylpiperazin-1-ium 409, 410, 411, and 412 ##STR00467##
N-((R)-2-(hydroxymethyl)-2- methyl-6-(4-((R)-1,1,1-trifluoro-
2-hydroxypropan-2-yl)piperidin- 1-yl)-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00468##
N-((R)-2-(hydroxymethyl)-2- methyl-6-(4-((S)-1,1,1-trifluoro-
2-hydroxypropan-2-yl)piperidin- 1-yl)-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00469##
N-((S)-2-(hydroxymethyl)-2- methyl-6-(4-((R)-1,1,1-trifluoro-
2-hydroxypropan-2-yl)piperidin- 1-yl)-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide; ##STR00470##
N-((S)-2-(hydroxymethyl)-2- methyl-6-(4-((S)-1,1,1-trifluoro-
2-hydroxypropan-2-yl)piperidin- 1-yl)-2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide 413 and 414
##STR00471## N-((S)-6-((1R,5S,6S)-6- carbamoyl-3-azabicyclo[3.1.0]
hexan-3-yl)-2-(hydroxymethyl)- 2-methyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
N-((R)-6-((1R,5S,6R)-6- carbamoyl-3-
azabicyclo[3.1.0]hexan-3-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00472## 415 and 416 ##STR00473## (S)-N-(6-(4-(2-amino-2-
oxoethyl)piperazin-1-yl)-2- (hydroxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00474## 417 and
418 ##STR00475## (S)-N-(2-(hydroxymethyl)-2- methyl-6-(3-oxa-2,8-
diazaspiro[4.5]decan-8-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(R)-N-(2-(hydroxymethyl)-2- methyl-6-(3-oxo-2,8-
diazaspiro[4.5]decan-8-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00476## 419 and
420 ##STR00477## (S)-N-(6-(5,7-dihydro-6H-
pyrrolo[3,4-b]pyridin-6-yl)-2- (hydoxymethyl)-2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(6-(5,7-dihydro-6H- pyrrolo[3,4-b]pyridin-6-yl)-2-
(hydroxymethyl)-2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00478## 421, 422,
and 423 ##STR00479## N-((S)-3-hydroxy-3-methyl-7-(4-
((S)-1,1,1-trifluoro-2- hydroxypropan-2-yl)piperidin-1-
yl)chroman-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide;
##STR00480## N-((R)-3-hydroxy-3-methyl-7-(4-
((S)-1,1,1-trifluoro-2- hydroxypropan-2-yl)piperidin-1-
yl)chroman-6-yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide;
##STR00481## N-(3-hydroxy-3-methyl-7-(4- ((R)-1,1,1-trifluoro-2-
hydroxypropan-2-yl)piperidin-1- yl)chroman-6-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 424 and 425 ##STR00482##
(R)-N-(7-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-3-
hydroxy-3-methylchroman-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and (S)-N-(7-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-3-
hydroxy-3-methylchroman-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00483## 426 and 427 ##STR00484##
(R)-N-(7-(4-cyanopiperidin-1-yl)- 3-hydroxy-3-methylchroman-6-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(S)-N-(7-(4-cyanopiperidin-1-yl)- 3-hydroxy-3-methylchroman-6-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide ##STR00485## 428 and
429 ##STR00486## (R)-N-(7-(4-(1H-imidazol-1-
yl)piperidin-1-yl)-3-hydroxy-3- methylchroman-6-
yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide and
(S)-N-(7-(4-(1H-imidazol-1- yl)piperidin-1-yl)-3-hydroxy-3-
methylchroman-6- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00487## 430 and 431 ##STR00488##
(S)-N-(3-hydroxy-3-methyl-7-((1- methyl-1H-pyrazol-4-
yl)methoxy)chroman-6- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
and (R)-N-(3-hydroxy-3-methyl-7- ((1-methyl-1H-pyrazol-4-
yl)methoxy)chroman-6- yl)pyrazolo[1,5-a]pyrimidine-3- carboxamide
##STR00489## 432 and 433 ##STR00490## (S)-N-(2-(hydroxymethyl)-2-
methyl-7-morpholinochroman-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide and (R)-N-(2-(hydroxymethyl)-2-
methyl-7-morpholinochroman-6- yl)pyrazolo[1,5-a]pyrimidine-3-
carboxamide ##STR00491## 434 ##STR00492## N-(6-(4-(2-hydroxy-2-
methylpropyl)piperazin-1-yl)-2,2- dimethyl-2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5-a]pyrimidine- 3-carboxamide 435 ##STR00493##
N-(6-(4-(2-ethyl-2- hydroxybutyl)piperazin-1-yl)-2,2-
dimethyl-2,2-dihydrobenzofuran- 5-yl)pyrazolo[1,5-a]pyrimidine-
3-carboxamide
TABLE-US-00003 TABLE 3 Additional exemplary compounds of the
present invention. Salts of such compounds are also contemplated.
See the Examples section for preparation of such compounds. Ex.
Structure Name 436 ##STR00494## (S)-N-(2- (hydroxymethyl)-2-
methyl-7- morpholinochroman-6- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 437 ##STR00495## (R)-N-(2- (hydroxymethyl)-2- methyl-7-
morpholinochroman-6- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
438 ##STR00496## (S)-N-(2- (dimethylcarbamoyl)-2-
methyl-6-morpholino-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 439 ##STR00497## (R)-N-(2-
(dimethylcarbamoyl)-2- methyl-6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
440 ##STR00498## N-(2,2-dimethyl-6-(4-(2- oxo-2-(((tetrahydrofuran-
2- yl)methyl)amino)ethyl) piperazin-1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 441 ##STR00499##
N-(2,2-dimethyl-6-(4-(2- oxo-2-(thiazol-2- ylamino)ethyl)piperazin-
1-yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 442 ##STR00500## (S)-N-(6- (hexahydropyrrolo[1,2-
a]pyrazin-2(1H)-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 443 ##STR00501##
(R)-N-(6- (hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)-2,2-
dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 444 ##STR00502## (R)-N-(2-methyl-2-(2-
(methylthio)ethyl)-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 445 ##STR00503##
(R)-N-(6-((1-(2-amino-2- oxoethyl)pyrrolidin-3-
yl)oxy)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 446 ##STR00504## N-(6-((1-(2-
hydroxyethyl)azetidin-3- yl)oxy)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
447 ##STR00505## (S)-N-(6-((1-(2-amino-2- oxoethyl)pyrrolidin-3-
yl)oxy)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 448 ##STR00506## N-(6-((1-ethyl-1H-
pyrazol-4-yl)methoxy)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 449 ##STR00507##
N-(2-(((2R,5R)-5-amino- 1,3-dioxan-2-yl)methyl)- 6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 450
##STR00508## N-(2,2-dimethyl-6-(4-(2- (methylsulfonyl)ethyl)
piperazin-1-yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 451 ##STR00509## 5-(((1R,2S)-2-
aminocyclohexyl)amino)- N-(6-methoxy-2,2- dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
452 ##STR00510## N-(6-carbamoyl-2,2- dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
453 ##STR00511## N-(6-(4-ethylpiperazin-1- yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
454 ##STR00512## N-(2,2-dimethyl-6-(4-(2-
(methylthio)ethyl)piperazin- 1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 455 ##STR00513##
N-(6-(4-(3-amino-3- oxopropyl)piperazin-1- yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
456 ##STR00514## N-(6-(4- (cyanomethyl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 457 ##STR00515## N-(6-(4-(2-
cyanoethyl)piperazin-1- yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 458 ##STR00516##
N-(6-(4- (cyclopropylmethyl)piperazin- 1-yl)-2,2-dimethyl-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 459 ##STR00517## N-(2,2-dimethyl-6-(4-((3-
methyl-1,2,4-oxadiazol-5- yl)methyl)piperazin-1-yl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 460 ##STR00518## N-(2,2-dimethyl-6-(4-((1-
methyl-1H-pyrazol-4- yl)methyl)piperazin-1-yl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 461 ##STR00519## N-(2,2-dimethyl-6-(4-((5-
methyl-1,2,4-oxadiazol-3- yl)methyl)piperazin-1-yl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 462 ##STR00520## N-(6-(4-(2-(1H-pyrazol-1-
yl)ethyl)piperazin-1-yl)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 463 ##STR00521##
N-(2,2-dimethyl-6-(4-((5- methyl-1,3,4-oxadiazol-2-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 464 ##STR00522##
N-(2,2-dimethyl-6-(4- ((tetrahydro-2H-pyran-4-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 465 ##STR00523##
N-(6-(4-(3- methoxypropyl)piperazin- 1-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
466 ##STR00524## N-(6-(4- (cyclobutylmethyl)piperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 467 ##STR00525##
N-(2,2-dimethyl-6-(4-(2- oxopyrrolidin-3- yl)piperazin-1-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
468 ##STR00526## N-(2,2-dimethyl-6-(4-((5- oxopyrrolidin-2-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 469 ##STR00527##
N-(6-(4-(2,3- dihydroxypropyl)piperazin- 1-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
470 ##STR00528## N-(2,2-dimethyl-6-(4-(2- (2-oxopyrrolidin-1-
yl)ethyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 471 ##STR00529## N-(2,2-dimethyl-6-
morpholino-2,3- dihydrobenzofuran-5-yl)- 6- (hydroxymethyl)pyrazolo
[1,5-a]pyrimidine-3- carboxamide 472 ##STR00530##
(R)-N-(6-(4-(1-amino-1- oxopropan-2-yl)piperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 473 ##STR00531##
(S)-N-(6-(4-(1-amino-1- oxopropan-2-yl)piperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 474 ##STR00532## (S)-N-(6-(4-(2-
hydroxypropyl)piperazin- 1-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
475 ##STR00533## (R)-N-(6-(4-(2- hydroxypropyl)piperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 476 ##STR00534## N-(6-(4-(2-amino-2-
methylpropyl)piperazin-1- yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
477 ##STR00535## (R)-N-(6-(4-(2- aminopropyl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 478 ##STR00536## (S)-N-(6-(4-(2-
aminopropyl)piperazin-1- yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 479 ##STR00537##
N-(2,2-dimethyl-6-(4-((5- methyl-2-oxo-2,3- dihydrooxazol-4-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 480 ##STR00538##
(S)-N-(2,2-dimethyl-6-(4- (1-(methylamino)-1-
oxopropan-2-yl)piperazin- 1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 481 ##STR00539##
(R)-N-(2,2-dimethyl-6-(4- (1-(methylamino)-1-
oxopropan-2-yl)piperazin- 1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 482 ##STR00540##
(S)-N-(6-(4-(1-amino-4- hydroxy-1-oxobutan-2-
yl)piperazin-1-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 483 ##STR00541##
(R)-N-(6-(4-(1-amino-4- hydroxy-1-oxobutan-2-
yl)piperazin-1-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 484 ##STR00542##
5-(difluoromethyl)-N-(2- isopropyl-6-morpholino- 1-oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 485 ##STR00543##
6-cyano-N-(2-isopropyl-6- morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 486 ##STR00544##
N.sup.3-(2-isopropyl-6- morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3,6- dicarboxamide 487 ##STR00545##
(R)-N-(6-cyclopropyl-2- (2-fluoro-3-hydroxy-3- methylbutyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 488
##STR00546## N-(2,2-dimethyl-6-(1- methyl-1H-imidazol-4- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
489 ##STR00547## N-(2,2-dimethyl-6-(1- methyl-1H-pyrazol-3-yl)-
2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 490 ##STR00548## 6-(azetidin-3-yl)-N-(2,2-
dimethyl-6-morpholino- 2,3-dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide hydrochloride 491 ##STR00549##
N.sup.3-(2,2-dimethyl-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3,6- dicarboxamide 492 ##STR00550##
(R)-N.sup.3-(2-(2-fluoro-3- hydroxy-3-methylbutyl)- 6-morpholino-1-
oxoisoindolin-5-yl)-N.sup.6- methylpyrazolo[1,5- a]pyrimidine-3,6-
dicarboxamide 493 ##STR00551## 6-(difluoromethoxy)-N-
(2,2-dimethyl-6- morpholino-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 494 ##STR00552##
(R)-6-fluoro-N-(2- (hydroxymethyl)-2- methyl-6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
495 ##STR00553## (S)-6-fluoro-N-(2- (hydroxymethyl)-2-
methyl-6-morpholino-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 496 ##STR00554## (R)-N-(6-
(cyclopropylmethoxy)-2- (2-fluoro-3-hydroxy-3- methylbutyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 497
##STR00555## N-((2R,3'S)-1',3'-dimethyl- 6-morpholino-3H-
spiro[benzofuran-2,4'- piperidin]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 498 ##STR00556## N-((2R,3'R)-1',3'-
dimethyl-6-morpholino- 3H-spiro[benzofuran-2,4'- piperidin]-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 499 ##STR00557##
N-(2,2-dimethyl-6- morpholino-1-oxo-2,3-
dihydro-1H-inden-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
500 ##STR00558## (R)-N-(2-(2-fluoro-3- hydroxy-3-methylbutyl)-
1-oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 501
##STR00559## N-(1'-(2-fluoroethyl)-6- morpholino-3H-
spiro[benzofuran-2,4'- piperidin]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 502 ##STR00560##
N-(1'-ethyl-6-morpholino- 3H-spiro[benzofuran-2,4'- piperidin]-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 503 ##STR00561##
N-(6-(4-((1H-imidazol-2- yl)methyl)piperazin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 504 ##STR00562## N-(6-(4-(isoxazol-4-
ylmethyl)piperazin-1-yl)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 505 ##STR00563##
N-(6-(4-((1H-pyrazol-5- yl)methyl)piperazin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 506 ##STR00564##
N-(2,2-dimethyl-6-(4-((1- methyl-1H-imidazol-5-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 507 ##STR00565##
N-(2,2-dimethyl-6-(4-((2- methyl-1H-imidazol-4-
yl)methyl)piperazin-1-yl)- 2,3-dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 508 ##STR00566##
N-(6-(4- isopropylpiperazin-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
509 ##STR00567## N-(6-(4-((1H-imidazol-4-
yl)methyl)piperazin-1-yl)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 510 ##STR00568##
(R)-N-(7-(4-(2,2- difluoroethyl)piperazin-1- yl)-3-hydroxy-3-
methylchroman-6- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 511
##STR00569## (S)-N-(7-(4-(2,2- difluoroethyl)piperazin-1-
yl)-3-hydroxy-3- methylchroman-6- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 512 ##STR00570## (S)-N-(6-cyclopropyl-2,2-
dimethyl-2,3- dihydrobenzofuran-5-yl)- 5-((5-oxopyrrolidin-3-
yl)methyl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 513
##STR00571## (R)-N-(6-cyclopropyl-2,2- dimethyl-2,3-
dihydrobenzofuran-5-yl)- 5-((5-oxopyrrolidin-3-
yl)methyl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 514
##STR00572## (R)-N-(6-cyclopropyl-2,2- dimethyl-2,3-
dihydrobenzofuran-5-yl)- 5-((2-oxopyrrolidin-3-
yl)methyl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 515
##STR00573## (S)-N-(6-cyclopropyl-2,2- dimethyl-2,3-
dihydrobenzofuran-5-yl)- 5-((2-oxopyrrolidin-3-
yl)methyl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 516
##STR00574## (S)-N-(1-hydroxy-2,2- dimethyl-6-morpholino-
2,3-dihydro-1H-inden-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 517 ##STR00575## (R)-N-(1-hydroxy-2,2-
dimethyl-6-morpholino- 2,3-dihydro-1H-inden-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 518 ##STR00576## N-(4-
(dimethylphosphoryl)-2- morpholinophenyl)pyrazolo
[1,5-a]pyrimidine-3- carboxamide 519 ##STR00577##
(R)-N-(3-(cyanomethyl)- 3-methyl-7- morpholinochroman-6-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 520 ##STR00578##
(S)-N-(3-(cyanomethyl)-3- methyl-7- morpholinochroman-6-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 521 ##STR00579##
(R)-N-(6-chloro-2-(2- fluoro-3-hydroxy-3- methylbutyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 522
##STR00580## (R)-N-(6-(4-((1H- imidazol-4-
yl)methyl)piperazin-1-yl)- 2-(2-hydroxypropan-2-yl)- 2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
523 ##STR00581## (S)-N-(6-(4-((1H- imidazol-4-
yl)methyl)piperazin-1-yl)- 2-(2-hydroxypropan-2-yl)- 2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
524 ##STR00582## (S)-N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-
2-(2-hydroxypropan-2-yl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 525 ##STR00583##
(R)-N-(6-(4-(2-amino-2- oxoethyl)piperazin-1-yl)-
2-(2-hydroxypropan-2-yl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 526 ##STR00584##
(R)-N-(2-(2-hydroxy-2- methylpropyl)-2-methyl- 6-morpholino-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
527 ##STR00585## (S)-N-(2-(2-hydroxy-2- methylpropyl)-2-methyl-
6-morpholino-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 528 ##STR00586## (R)-N-(6-ethyl-2-(2-
fluoro-3-hydroxy-3- methylbutyl)-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 529 ##STR00587##
(R)-N-(2-(2-fluoro-3- hydroxy-3-methylbutyl)- 6-isopropyl-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 530
##STR00588## N-(2,2-dimethyl-6- morpholino-2,3-
dihydrobenzofuran-5-yl)- 6-hydroxypyrazolo[1,5- a]pyrimidine-3-
carboxamide 531 ##STR00589## N-(6-(4- carbamoylpiperidin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 532 ##STR00590## N-(6-(4-
(dimethylamino)piperidin- 1-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
533 ##STR00591## N-(2,2-dimethyl-6- (piperazin-1-yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
534 ##STR00592## N-(6-(4-carbamoyl-4- fluoropiperidin-1-yl)-2,2-
dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 535 ##STR00593## N-(6-(4-(2-amino-2- oxoethyl)-4-
methylpiperidin-1-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 536 ##STR00594##
N-(6-(4-(2-amino-2- oxoethyl)-4- hydroxypiperidin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 537 ##STR00595## N-(6-(dimethylamino)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 538 ##STR00596## N-(2,2-dimethyl-6-((1-
methyl-1H-imidazol-4- yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 539 ##STR00597##
N-(6-((1H-imidazol-4- yl)methoxy)-2,2- dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
540 ##STR00598## (R)-N-(2,2-dimethyl-6- ((5-oxopyrrolidin-2-
yl)methoxy)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 541 ##STR00599##
(S)-N-(2,2-dimethyl-6-((5- oxopyrrolidin-2- yl)methoxy)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
542 ##STR00600## N-(2,2-dimethyl-6-((5- methyl-1H-pyrazol-3-
yl)methoxy)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 543 ##STR00601## N-(2,2-dimethyl-6-((2-
methyl-1H-imidazol-4- yl)methoxy)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 544 ##STR00602##
(R)-N-(2-(4-hydroxy-4- methylpentan-2-yl)-6- morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 545
##STR00603## (S)-N-(2-(4-hydroxy-4- methylpentan-2-yl)-6-
morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 546 ##STR00604## N-(2-(1-methylazetidin-3-
yl)-6-morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 547 ##STR00605## N-(2-((1S,4S)-4-(2-
hydroxypropan-2- yl)cyclohexyl)-6- morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 548 ##STR00606##
N-(2-((1R,4R)-4-(2- hydroxypropan-2- yl)cyclohexyl)-6-
morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 549 ##STR00607## N-(2-(((1R,2S)-2-
hydroxycyclopentyl)methyl)- 6-morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 550 ##STR00608##
N-(2-(((1S,2R)-2- hydroxycyclopentyl) methyl)-6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 551
##STR00609## (S)-N-(6-morpholino-2-(2- morpholinopropyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 552
##STR00610## (R)-N-(6-morpholino-2- (2-morpholinopropyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 553
##STR00611## (R)-N-(2-(1-methyl-2- oxopyrrolidin-3-yl)-6-
morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 554 ##STR00612## (S)-N-(2-(1-methyl-2-
oxopyrrolidin-3-yl)-6- morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 555 ##STR00613##
(S)-N-(6-morpholino-1- oxo-2-((tetrahydrofuran-3-
yl)methyl)isoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 556 ##STR00614## (R)-N-(6-morpholino-1-
oxo-2-((tetrahydrofuran-3- yl)methyl)isoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 557 ##STR00615##
N-(2-((2R,3S)-2-fluoro-3- hydroxybutyl)-6- morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 558
##STR00616## N-(2-((2S,3R)-2-fluoro-3- hydroxybutyl)-6-
morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 559 ##STR00617## N-(2-(((1S,2S)-2-
hydroxycyclopentyl)methyl)- 6-morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 560 ##STR00618##
N-(2-(((1R,2R)-2- hydroxycyclopentyl)methyl)- 6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 561
##STR00619## N-(2-((2S,3S)-2-fluoro-3- hydroxybutyl)-6-
morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 562 ##STR00620## N-(2-((2R,3R)-2-fluoro-3-
hydroxybutyl)-6- morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 563 ##STR00621##
(R)-N-(6-(azetidin-1-yl)-2- (2-fluoro-3-hydroxy-3- methylbutyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 564
##STR00622## N-(2-((1S,2R)-2- (hydroxymethyl)cyclopentyl)-
6-morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 565 ##STR00623## N-(2-((1R,2S)-2-
(hydroxymethyl)cyclopentyl)- 6-morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 566 ##STR00624##
N-(2-((1S,2S)-2- (hydroxymethyl)cyclopentyl)- 6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide 567 ##STR00625## N-(2-((1R,2R)-2-
(hydroxymethyl)cyclopentyl)- 6-morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 568 ##STR00626##
(R)-N-(2-(2-fluoro-3- hydroxy-3-methylbutyl)- 6-((2-
hydroxyethyl)(methyl)amino)- 1-oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide 569 ##STR00627## (R)-N-(6-(4-cyano-4-
methylpiperidin-1-yl)-2- (2-fluoro-3-hydroxy-3- methylbutyl)-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide 570
##STR00628## (R)-N-(6- (dimethylamino)-2-(2- fluoro-3-hydroxy-3-
methylbutyl)-1- oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide
Synthesis of IRAK4 Inhibitors
[0252] Compounds of the present invention can be made by a variety
of methods depicted in the illustrative synthetic reaction schemes
shown and described below. The starting materials and reagents used
in preparing these compounds generally are either available from
commercial suppliers, such as Aldrich Chemical Co., or are prepared
by methods known to those skilled in the art following procedures
set forth in references such as Fieser and Fieser's Reagents for
Organic Synthesis; Wiley & Sons: New York, vol. 1-21; R. C.
LaRock, Comprehensive Organic Transformations, 2nd edition
Wiley-VCH, New York 1999; Comprehensive Organic Synthesis, B. Trost
and I. Fleming (Eds.) vol. 1-9 Pergamon, Oxford, 1991;
Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W.
Rees (Eds.) Pergamon, Oxford 1984, vol. 1-9; Comprehensive
Heterocyclic Chemistry II, A. R. Katritzky and C. W. Rees (Eds)
Pergamon, Oxford 1996, vol. 1-11; and Organic Reactions, Wiley
& Sons: New York, 1991, vol. 1-40. The following synthetic
reaction schemes are merely illustrative of some methods by which
the compounds of the present invention can be synthesized, and
various modifications to these synthetic reaction schemes can be
made and will be suggested to one skilled in the art having
referred to the disclosure contained in this Application.
[0253] For illustrative purposes, reaction Schemes below provide
routes for synthesizing the compounds of the invention as well as
key intermediates. For a more detailed description of the
individual reaction steps, see the Examples section below. Those
skilled in the art will appreciate that other synthetic routes may
be used. Although some specific starting materials and reagents are
depicted in the Schemes and discussed below, other starting
materials and reagents can be substituted to provide a variety of
derivatives or reaction conditions. In addition, many of the
compounds prepared by the methods described below can be further
modified in light of this disclosure using conventional chemistry
well known to those skilled in the art.
[0254] The starting materials and the intermediates of the
synthetic reaction schemes can be isolated and purified if desired
using conventional techniques, including but not limited to,
filtration, distillation, crystallization, chromatography, and the
like. Such materials can be characterized using conventional means,
including physical constants and spectral data.
[0255] Unless specified to the contrary, the reactions described
herein preferably are conducted under an inert atmosphere at
atmospheric pressure at a reaction temperature range of from about
-78.degree. C. to about 150.degree. C., more preferably from about
0.degree. C. to about 125.degree. C., and most preferably and
conveniently at about room (or ambient) temperature, or, about
20.degree. C.
[0256] Some compounds in following schemes are depicted with
generalized substituents; however, one skilled in the art will
immediately appreciate that the nature of the R groups can varied
to afford the various compounds contemplated in this invention.
Moreover, the reaction conditions are exemplary and alternative
conditions are well known. The reaction sequences in the following
examples are not meant to limit the scope of the invention as set
forth in the claims.
[0257] Some compounds in following schemes are depicted with
generalized substituents; however, one skilled in the art will
immediately appreciate that the nature of the R groups can varied
to afford the various compounds contemplated in this invention.
Moreover, the reaction conditions are exemplary and alternative
conditions are well known. The reaction sequences in the following
examples are not meant to limit the scope of the invention as set
forth in the claims.
##STR00629##
[0258] Regarding Scheme I, requisite
3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl derivatives can be prepared
by nitration of 7-halo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl
derivatives I-la to afford I-1b followed by displacement of the
halogen with an amine to afford I-2a. Typical amines include
morpholine and 3-hydroxymethyl piperidine. Reduction of the nitro
group and condensation with pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (1-3), or an activated derivative thereof, affords the desired
amides. The requisite precursors are commercially available or are
prepared as described herein.
[0259] Aromatic nitration is well known and can be conducted under
a variety of conditions known in the art. Nitration can be carried
out, for example, by exposing an aromatic compound to concentrated
nitric acid and sulfuric acid. Active substrates can be nitrated
with HNO.sub.3 alone or in H.sub.2O, HOAc and acetic anhydride and
active compounds may be oxidized by mixtures of HNO.sub.3 and
H.sub.2SO.sub.4. Other nitrating reagents include NaNO.sub.3/TFA,
Cu(NO.sub.3).sub.2/HOAc/Ac.sub.2O, N.sub.2O.sub.4,
NO.sub.2.sup.+BF.sub.4.sup.-, NO.sub.2+PF.sub.6.sup.- and
NO.sub.2.sup.+CF.sub.3SO.sup.4-. See, e.g., J. March, Advanced
Organic Chemistry, John Wiley & Sons: New York, N.Y., 1992, pp.
522-23.
[0260] Reduction of the nitro group can be carried out with a
variety of well-known reducing agents. For example, the nitro can
be reduced under a hydrogen atmosphere in the presence of an inert
solvent and in the presence of a metal effective to catalyze
hydrogenation reactions such as platinum or palladium. The
reduction can also be carried out with an activated metal such as
activated iron, zinc or tin (produced for example by washing iron
powder with a dilute acid solution such as dilute hydrochloric
acid).
[0261] Coupling of the amine 2b intermediate with 3 is achieved
with commonly used coupling reagents or, alternatively, 3 can be
converted to the corresponding acid chloride and condensed with
2b.
[0262] Acylation of a primary amine with an acid chloride is
typically carried out in an inert solvent such as DMF, DCM, THF,
pyridine with or without water as a co-solvent, at temperatures
between 0.degree. C. and 60.degree. C. generally in the presence of
a base such as Na.sub.2CO.sub.3, NaHCO.sub.3, K.sub.2CO.sub.3,
DIPEA, TEA or pyridine and the like to afford the corresponding
amide.
[0263] Carboxylic acids can be converted into their acid chlorides
using standard reagents well known to someone skilled in the art,
such as thionyl chloride, oxalyl chloride, phosphoryl chloride and
the like. Those reagents can be used in presence of bases such as
DIPEA, TEA or pyridine.
[0264] Alternatively a carboxylic acid can be converted in situ
into activated derivatives by utilizing reagents developed for
peptide synthesis which are well known to those skilled in the art.
These activated acids were reacted directly with the amines as
described to afford the corresponding amide. Common coupling
reagents include EDC, DCC, benzotriazol-1-yloxy-tri
s(dimethylamino)-phosphonium hexafluorophosphate (BOP),
bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrOP),
2-fluoro-1-methylpyridinium p-toluenesulphonate (Mukaiyama's
reagent), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU), 1-hydroxy-7-azabenzotriazole (HOAt) or
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (PyAOP) optionally in the presence of
modifiers such as HOBt, with or without a base such NMM, TEA or
DIPEA in an inert solvent such as DMF or DCM at temperatures
between 0.degree. C. and 60.degree. C. Acylation of amines (see,
e.g., J. March, supra pp. 417-425; H. G. Benz, Synthesis of Amides
and Related Compounds in Comprehensive Organic Synthesis, E.
Winterfeldt, ed., vol. 6, Pergamon Press, Oxford 1991 pp. 381-411;
R. C. Larock, Comprehensive Organic Transformations--A Guide to
Functional Group Preparations, 1989, VCH Publishers Inc., New York;
pp. 972-976) has been reviewed.
##STR00630## ##STR00631##
[0265] 5,6-Diamino-2,2-dimethyl-3H-benzofuran derivatives
exemplified herein can be prepared utilizing a
2,2-dimethyl-5-nitro-6-halo-3H-benzofuran II-3b as the key
intermediate as depicted in Scheme II. Addition of a methyl
Grignard to methyl 5-chloro-2-fluoro-phenylacetate affords the
tertiary alcohol II-2 which undergoes an intra-molecular
cyclization to afford the II-3a. Nitration and displacement of the
chloride with an amine followed by reduction of the nitro and
acylation with I-3 is carried out in analogy with Scheme I. One
skilled in the art will appreciate that the corresponding 5-fluoro
and 5-bromo derivatives are readily available from methyl
2,5-difluorophenylacetate and methyl 5-bromo-2-fluorophenylacetate,
respectively.
##STR00632##
[0266] With respect to Scheme III, introduction of substituents
other than amines at the 2-position can be easily accomplished by
addition of an organometallic to
1-(4-chloro-2-fluorophenyl)propan-2-one, or a derivative thereof,
and carry on further transformations as described herein. Compounds
wherein the 5-amino-2,2-dimethyl-3H-benzofuran-6-yl moiety is
linked to a substituent by a carbon-carbon bond were prepared by a
palladium-catalyzed coupling of II-3b with a boric acid derivative
or a boronic ester. Similarly ether substituents can be readily
prepared by reacting 5-amino-2,2-dimethyl-6-fluoro-3H-benzofuran
(III-2b) with a alcohol in the presence of potassium tert-butoxide
or other suitable strong base. Subsequent reduction of the nitro
group, acylation of the resulting amine and any subsequent
deprotection which may be required are carried out using standard
methodology.
##STR00633##
[0267] Compounds with a hydroxymethyl substituent attached to the
dihydrofuran ring are accessible by condensation of
5-chloro-2-fluorobenzyl magnesium bromide with methyl pyruvate
which afforded IV-2. (Scheme IV) Intramolecular cyclization and
reduction of the pendant carboxylic acid affords IV-b which is
transformed to the final compounds using protocols analogous to
those previously described.
##STR00634##
[0268] With respect to Scheme V, 3H-benzothiophene-1,1-dioxide
derivatives can be prepared by intramolecular cyclization methyl
2-methylsulfonyl-4-morpholino-5-nitro-benzoate (V-3b) to afford
morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one (V-4) which is
subsequently reduced to V-6b utilizing a two-step sequence
comprising sodium borohydride reduction followed by
triethylsilane/TFA reduction that is carried on as previously
described. Reduction of the nitro group and acylation of the
resulting amine is carried out as described previously.
Methods of Treatment with and Uses of IRAK4 Inhibitors
[0269] Compounds of the present invention are useful as IRAK4
inhibitors. Accordingly, in one embodiment is provided a method of
contacting a cell, such as an ex vivo cell, with a compound of the
present invention to inhibit IRAK4 activity in the cell.
[0270] Also provided is a pharmaceutical composition comprising a
compound of Formula 0, Formula I, or Formula II, or a stereoisomer
or pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable excipient, carrier or diluent. Compounds of the
invention, including pharmaceutical compositions comprising such
compounds, may be used in the methods described herein.
[0271] Further provided is a method of preventing, treating, or
lessening the severity of a disease or condition responsive to the
inhibition of IRAK4 in a patient, comprising administering to the
patient a therapeutically effective amount of a compound of the
present invention, or a stereoisomer or pharmaceutically acceptable
salt thereof.
[0272] Also provided is a method for treating cancer in a patient,
comprising administering to the patient a therapeutically effective
amount of a compound of the present invention, or a stereoisomer or
pharmaceutically acceptable salt thereof.
[0273] Further provided is a method for treating an inflammatory or
autoimmune disease in a patient, comprising administering to the
patient a therapeutically effective amount of a compound of the
present invention, or a stereoisomer or pharmaceutically acceptable
salt thereof. In some embodiments, the disease is selected from the
group consisting of Crohn's disease, ulcerative colitis, Irritable
Bowel Disorder (IBD), asthma, graft versus host disease, allograft
rejection, chronic obstructive pulmonary disease (COPD), rheumatoid
arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous
lupus, psoriasis, systemic onset juvenile idiopathic arthritis,
multiple sclerosis, neuropathic pain, gout, and gouty
arthritis.
[0274] In some embodiments, other diseases and conditions
responsive to the inhibition of IRAK4 that can be treated using a
compound of the present invention include metabolic syndromes,
atherosclerosis, and neurodegeneration.
[0275] Further provided is the use of a compound of the present
invention, or a stereoisomer or pharmaceutically acceptable salt
thereof, in therapy. In some embodiments, use of a compound of the
present invention, or a stereoisomer or pharmaceutically acceptable
salt thereof, is provided in the treatment of an inflammatory
disease. In some embodiments, use of a compound of the present
invention, or a stereoisomer or pharmaceutically acceptable salt
thereof, is provided for the preparation of a medicament for the
treatment of an inflammatory disease. Furthermore, in some
embodiments, a compound of the present invention, or a stereoisomer
or pharmaceutically acceptable salt thereof, is provided for use in
the treatment of an inflammatory disease.
[0276] Also provided is a method of inhibiting IRAK4 in a patient
in need of therapy, comprising administering to the patient a
compound of the present invention.
Dosage & Administration
[0277] The present invention provides pharmaceutical compositions
or medicaments containing the compounds of the invention and at
least one therapeutically inert carrier, diluent or excipient, as
well as methods of using the compounds of the invention to prepare
such compositions and medicaments. In one example, compounds of
Formula 0, Formula I, or Formula II, or a stereoisomer or
pharmaceutically acceptable salt thereof, with the desired degree
of purity may be formulated by mixing with physiologically
acceptable carriers, i.e., carriers that are non-toxic to
recipients at the dosages and concentrations employed into a dosage
form at ambient temperature and at the appropriate pH. The pH of
the formulation depends mainly on the particular use and the
concentration of compound, but typically ranges anywhere from about
3 to about 8. In one example, a compound of Formula 0, Formula I,
or Formula II is formulated in an acetate buffer, at pH 5. In
another embodiment, the compounds of Formula 0, Formula I, or
Formula II are sterile. The compound may be stored, for example, as
a solid or amorphous composition, as a lyophilized formulation or
as an aqueous solution.
[0278] Compositions are formulated, dosed, and administered in a
fashion consistent with good medical practice. Factors for
consideration in this context include the particular disorder being
treated, the severity of the disorder, the particular patient being
treated, the clinical condition of the individual patient, the
cause of the disorder, the site of delivery of the agent, the
method of administration, the scheduling of administration, and
other factors known to medical practitioners. The "effective
amount" of the compound to be administered will be governed by such
considerations, and is the minimum amount necessary to inhibit
IRAK4 activity. Typically such amount may be below the amount that
is toxic to normal cells, or the patient as a whole.
[0279] The pharmaceutical composition (or formulation) for
application may be packaged in a variety of ways depending upon the
method used for administering the drug. Generally, an article for
distribution includes a container having deposited therein the
pharmaceutical formulation in an appropriate form. Suitable
containers are well-known to those skilled in the art and include
materials such as bottles (plastic and glass), sachets, ampoules,
plastic bags, metal cylinders, and the like. The container may also
include a tamper-proof assemblage to prevent indiscreet access to
the contents of the package. In addition, the container has
deposited thereon a label that describes the contents of the
container. The label may also include appropriate warnings.
[0280] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing a compound of
Formula 0, Formula I, or Formula II, or a stereoisomer or
pharmaceutically acceptable salt thereof, which matrices are in the
form of shaped articles, e.g. films, or microcapsules. Examples of
sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides, copolymers of L-glutamic acid and
gamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,
degradable lactic acid-glycolic acid copolymers such as the LUPRON
DEPOT.TM. (injectable microspheres composed of lactic acid-glycolic
acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid.
[0281] A dose to treat human patients may range from about 0.1 mg
to about 1000 mg of a compound of Formula 0, Formula I, or Formula
II, or a stereoisomer or pharmaceutically acceptable salt thereof.
A typical dose may be about 1 mg to about 300 mg of the compound. A
dose may be administered once a day (QD), twice per day (BID), or
more frequently, depending on the pharmacokinetic and
pharmacodynamic properties, including absorption, distribution,
metabolism, and excretion of the particular compound. In addition,
toxicity factors may influence the dosage and administration
regimen. When administered orally, the pill, capsule, or tablet may
be ingested daily or less frequently for a specified period of
time. The regimen may be repeated for a number of cycles of
therapy.
[0282] The compounds of the invention may be administered by any
suitable means, including oral, topical (including buccal and
sublingual), rectal, vaginal, transdermal, parenteral,
subcutaneous, intraperitoneal, intrapulmonary, intradermal,
intrathecal, epidural and intranasal, and, if desired for local
treatment, intralesional administration. Parenteral infusions
include intramuscular, intravenous, intraarterial, intraperitoneal,
or subcutaneous administration.
[0283] The compounds of the present invention may be administered
in any convenient administrative form, e.g., tablets, powders,
capsules, solutions, dispersions, suspensions, syrups, sprays,
suppositories, gels, emulsions, patches, etc. Such compositions may
contain components conventional in pharmaceutical preparations,
e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents,
and further active agents.
[0284] A typical formulation is prepared by mixing a compound of
the present invention and a carrier or excipient. Suitable carriers
and excipients are well known to those skilled in the art and are
described in detail in, e.g., Ansel, H. C., et al., Ansel's
Pharmaceutical Dosage Forms and Drug Delivery Systems.
Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro,
Alfonso R., et al. Remington: The Science and Practice of Pharmacy.
Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe,
R. C., Handbook of Pharmaceutical Excipients, Chicago,
Pharmaceutical Press, 2005. The formulations may also include one
or more buffers, stabilizing agents, surfactants, wetting agents,
lubricating agents, emulsifiers, suspending agents, preservatives,
antioxidants, opaquing agents, glidants, processing aids,
colorants, sweeteners, perfuming agents, flavoring agents, diluents
and other known additives to provide an elegant presentation of the
drug (i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament).
[0285] For oral administration, tablets containing various
excipients, such as citric acid may be employed together with
various disintegrants such as starch, alginic acid and certain
complex silicates and with binding agents such as sucrose, gelatin
and acacia. Additionally, lubricating agents such as magnesium
stearate, sodium lauryl sulfate and talc are often useful for
tableting purposes. Solid compositions of a similar type may also
be employed in soft and hard filled gelatin capsules. Preferred
materials, therefore, include lactose or milk sugar and high
molecular weight polyethylene glycols. When aqueous suspensions or
elixirs are desired for oral administration the active compound
therein may be combined with various sweetening or flavoring
agents, coloring matters or dyes and, if desired, emulsifying
agents or suspending agents, together with diluents such as water,
ethanol, propylene glycol, glycerin, or combinations thereof.
[0286] An example of a suitable oral dosage form is a tablet
containing about 25 mg, 50 mg, 100 mg, 250 mg or 500 mg of the
compound of the invention compounded with about 90-30 mg anhydrous
lactose, about 5-40 mg sodium croscarmellose, about 5-30 mg
polyvinylpyrrolidone (PVP) K30, and about 1-10 mg magnesium
stearate. The powdered ingredients are first mixed together and
then mixed with a solution of the PVP. The resulting composition
can be dried, granulated, mixed with the magnesium stearate and
compressed to tablet form using conventional equipment. An example
of an aerosol formulation can be prepared by dissolving the
compound, for example 5-400 mg, of the invention in a suitable
buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g.
a salt such as sodium chloride, if desired. The solution may be
filtered, e.g., using a 0.2 micron filter, to remove impurities and
contaminants.
[0287] In one embodiment, the pharmaceutical composition also
includes at least one additional anti-proliferative agent.
[0288] An embodiment, therefore, includes a pharmaceutical
composition comprising a compound of Formula 0, Formula I, or
Formula II, or a stereoisomer or pharmaceutically acceptable salt
thereof. A further embodiment includes a pharmaceutical composition
comprising a compound of Formula 0, Formula I, or Formula II, or a
stereoisomer or pharmaceutically acceptable salt thereof, together
with a pharmaceutically acceptable carrier or excipient.
[0289] The invention further provides veterinary compositions
comprising at least one active ingredient as above defined together
with a veterinary carrier therefore. Veterinary carriers are
materials useful for the purpose of administering the composition
and may be solid, liquid or gaseous materials which are otherwise
inert or acceptable in the veterinary art and are compatible with
the active ingredient. These veterinary compositions may be
administered parenterally, orally or by any other desired
route.
Combination Therapy
[0290] The compounds of Formula 0, Formula I, or Formula II may be
employed alone or in combination with other therapeutic agents for
the treatment of a disease or disorder described herein. The second
compound of the pharmaceutical combination formulation or dosing
regimen preferably has complementary activities to the compound of
Formula 0, Formula I, or Formula II such that they do not adversely
affect each other. The combination therapy may provide "synergy"
and prove "synergistic", i.e., the effect achieved when the active
ingredients used together is greater than the sum of the effects
that results from using the compounds separately.
[0291] The combination therapy may be administered as a
simultaneous or sequential regimen. When administered sequentially,
the combination may be administered in two or more administrations.
The combined administration includes co-administration, using
separate formulations or a single pharmaceutical formulation, and
consecutive administration in either order, wherein preferably
there is a time period while both (or all) active agents
simultaneously exert their biological activities.
[0292] Combination therapies according to the present invention
thus comprise the administration of at least one compound of
Formula 0, Formula I, or Formula II, or a stereoisomer or
pharmaceutically acceptable salt thereof, and the use of at least
one other treatment method. The amounts of the compound(s) of
Formula 0, Formula I, or Formula II and the other pharmaceutically
active agent(s) and the relative timings of administration will be
selected in order to achieve the desired combined therapeutic
effect.
Articles of Manufacture
[0293] In another embodiment of the invention, an article of
manufacture, or "kit", containing materials useful for the
treatment of the diseases and disorders described above is
provided. In one embodiment, the kit comprises a container
comprising a compound of Formula 0, Formula I, or Formula II, or a
stereoisomer or pharmaceutically acceptable salt thereof. The kit
may further comprise a label or package insert on or associated
with the container. The term "package insert" is used to refer to
instructions customarily included in commercial packages of
therapeutic products, that contain information about the
indications, usage, dosage, administration, contraindications
and/or warnings concerning the use of such therapeutic products.
Suitable containers include, for example, bottles, vials, syringes,
blister pack, etc. The container may be formed from a variety of
materials such as glass or plastic. The container may hold a
compound of Formula 0, Formula I, or Formula II or a formulation
thereof which is effective for treating the condition and may have
a sterile access port (for example, the container may be an
intravenous solution bag or a vial having a stopper pierceable by a
hypodermic injection needle).
[0294] At least one active agent in the composition is a compound
of Formula 0, Formula I, or Formula II. Alternatively, or
additionally, the article of manufacture may further comprise a
second container comprising a pharmaceutical diluent, such as
bacteriostatic water for injection (BWFI), phosphate-buffered
saline, Ringer's solution and dextrose solution. It may further
include other materials desirable from a commercial and user
standpoint, including other buffers, diluents, filters, needles,
and syringes.
[0295] In another embodiment, the kits are suitable for the
delivery of solid oral forms of a compound of Formula 0, Formula I,
or Formula II, such as tablets or capsules. Such a kit can include
a number of unit dosages. An example of such a kit is a "blister
pack". Blister packs are well known in the packaging industry and
are widely used for packaging pharmaceutical unit dosage forms.
Examples
[0296] The following examples illustrate the preparation and
biological evaluation of compounds within the scope of the
invention. These examples and preparations which follow are
provided to enable those skilled in the art to more clearly
understand and to practice the present invention. They should not
be considered as limiting the scope of the invention, but merely as
being illustrative and representative thereof.
Intermediate 1. 6-Chloro-2,2-dimethyl-5-nitro-3H-benzofuran
##STR00635##
[0297] Step A. Methyl 2-(4-chloro-2-fluoro-phenyl)acetate
##STR00636##
[0299] A mixture of 2-(4-chloro-2-fluoro-phenyl)acetic acid (8.4 g,
44.5 mmol) and concentrated sulfuric acid (3.0 mL) in methanol (50
mL) was stirred at reflux for 18 h. After concentration under
reduced pressure, the residue was dissolved in DCM (200 ml). The
organic phase was washed with sodium bicarbonate saturated
solution, brine and dried over sodium sulfate After concentration
under reduced pressure, it was afforded crude methyl
2-(4-chloro-2-fluoro-phenyl)acetate (7.6 g) as a yellow oil, which
was used without further purification. MS (ESI): m/z=203.1
[M+1].sup.+.
Step B. 1-(4-Chloro-2-fluoro-phenyl)-2-methyl-propan-2-ol
##STR00637##
[0301] To a solution of methyl 2-(4-chloro-2-fluoro-phenyl)acetate
(7.6 g, 37.51 mmol) in anhydrous THF (70 mL) was added methyl
magnesium bromide (3 m in ethyl ether, 37.5 mL, 112.5 mmol) drop
wise at -78.degree. C. The reaction was warmed to room temperature
and stirred for 30 min. Saturated ammonium chloride solution was
added. The aqueous phase was extracted with ethyl acetate
(2.times.200 mL). The combined organic phases were washed with
brine and dried over sodium sulfate. The crude was concentrated
under reduced pressure to afford
1-(4-chloro-2-fluoro-phenyl)-2-methyl-propan-2-ol (6.9 g) as a
yellow oil, which was used without further purification. MS (ESI):
m/z=185.1 [M-OH].sup.+.
Step C. 6-Chloro-2,2-dimethyl-3H-benzofuran
##STR00638##
[0303] A mixture of
1-(4-chloro-2-fluoro-phenyl)-2-methyl-propan-2-ol (6.9 g, 34.05
mmol) and potassium tert-butanolate (9.55 g, 85.12 mmol) in THF
(170 mL) was stirred at 65.degree. C. for 18 h. IN hydrogen
chloride solution was added until pH=3.0. Ethyl acetate (200 mL)
was added. The organic phase was separated and dried over sodium
sulfate. After concentration under reduced pressure, the residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:20 to 1:10) as eluting solvents to
afford 6-chloro-2,2-dimethyl-3H-benzofuran (4.3 g, 69%) as a
colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 6.99 (d,
J=8.0 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 6.88 (s, 1H), 2.93 (s, 2H),
1.44 (s, 3H).
Step D. 6-Chloro-2,2-dimethyl-5-nitro-3H-benzofuran
##STR00639##
[0305] To a solution of 6-chloro-2,2-dimethyl-3H-benzofuran (4.3 g,
23.54 mmol) in DCM (45 mL) at 25.degree. C. was slowly added fuming
nitric acid (4.5 mL) until starting material was disappeared. Water
and ethyl acetate (100 mL) were added. The organic phase was
separated and dried over sodium sulfate. After concentration under
reduced pressure, it was afforded
6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran (5.0 g) as orange
solid, which was used without further purification. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 7.84 (s, 1H), 6.83 (s, 1H), 3.04 (s,
2H), 1.52 (s, 3H).
Intermediate 2.
(6-Chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00640##
[0306] Step A. Methyl
3-(4-chloro-2-fluoro-phenyl)-2-hydroxy-2-methyl-propanoate
##STR00641##
[0308] To a solution of magnesium (1350.0 mg, 56.25 mmol) and
iodine (100.0 mg, 0.39 mmol) in diethyl ether (50 mL) at reflux was
added 1-(bromomethyl)-4-chloro-2-fluoro-benzene (5.0 g, 22.4 mmol)
drop wise. The reaction was stirred for 30 min. This solution was
then added to a solution of methyl pyruvate (2.3 g, 22.5 mmol) in
diethyl ether (50 mL) at -78.degree. C. and stirred for 30 min
followed by warming to room temperature for 2 h. Saturated ammonium
chloride solution and ethyl acetate (200 mL) was added. The organic
phase was separated and dried over sodium sulfate. After
concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (from 1:20 to
1:10) as eluting solvents to afford methyl
3-(4-chloro-2-fluoro-phenyl)-2-hydroxy-2-methyl-propanoate (2.8 g,
51%) as a yellow oil. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
7.33-7.25 (m, 1H), 7.18-7.09 (m, 2H), 3.73 (s, 3H), 3.03 (s, 2H),
1.39 (s, 3H).
Step B. 6-Chloro-2-methyl-3H-benzofuran-2-carboxylic acid
##STR00642##
[0310] The mixture of methyl
3-(4-chloro-2-fluoro-phenyl)-2-hydroxy-2-methyl-propanoate (493.0
mg, 2 mmol) and potassium tert-butanolate (561.0 mg, 5 mmol) in THF
(10 mL) was stirred at 60.degree. C. for 18 h. After cooling to
room temperature, water and 1N hydrogen chloride solution was added
until pH=3.0. Ethyl acetate (20 mL) was added. The organic phase
was separated and dried over sodium sulfate. After concentration,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:1 to 2:1) as eluting solvents to
afford 6-chloro-2-methyl-3H-benzofuran-2-carboxylic acid (271 mg,
64%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.95-10.24 (m, 1H), 7.04 (d, J=8.0 Hz, 1H), 6.87 (dd, J=1.6, 9.2
Hz, 1H), 6.85 (s, 1H), 3.59 (d, J=16 Hz, 1H), 3.13 (d, J=16 Hz,
1H), 1.73, (s, 3H).
Step C. 6-Chloro-2-methyl-5-nitro-3H-benzofuran-2-carboxylic
acid
##STR00643##
[0312] To a solution of
6-chloro-2-methyl-3H-benzofuran-2-carboxylic acid (230.0 mg, 1.08
mmol) in DCM (10 mL) at 25.degree. C. was slowly added fuming
nitric acid (0.5 mL) and stirred for 5 min. Water and ethyl acetate
(20 mL) were added. The organic phase was separated and dried over
sodium sulfate. After concentration, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether (from
1:4 to 1:3) as eluting solvents to afford
6-chloro-2-methyl-5-nitro-3H-benzofuran-2-carboxylic acid (150 mg,
54%) as orange solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.84 (s, 1H), 6.99 (s, 1H), 3.68 (d, J=16.8 Hz, 1H), 3.23 (d,
J=16.8 Hz, 1H), 1.80 (s, 3H).
Step D. (6-Chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
##STR00644##
[0314] The mixture of
6-chloro-2-methyl-5-nitro-3H-benzofuran-2-carboxylic acid (1.93 g,
7.5 mmol) and borane (1 M in THF, 14.0 mL, 14 mmol) in THF (75 mL)
was stirred at 25.degree. C. for 2 h. After slowly adding methanol
(10 mL) and then concentration, the residue was purified by silica
gel chromatography using ethyl acetate:petroleum ether (1:1) as
eluting solvents to afford
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol (580 mg,
32%) as a yellow oil. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.84 (s, 1H), 6.99 (s, 1H), 6.60-5.80 (m, 1H), 3.68 (d, J=16.8 Hz,
1H), 3.23 (d, J=16.8 Hz, 1H), 1.80 (s, 3H). MS (ESI): m/z=244.1
[M+1].sup.+.
Intermediate 3.
(6-Fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00645##
[0315] Step A. Methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate
##STR00646##
[0317] To a solution of magnesium (3290.81 mg, 137.12 mmol) and
iodine (243.76 mg, 0.96 mmol) in diethyl ether (50 mL) at reflux
was added 2,4-difluorobenzyl bromide (11291.0 mg, 54.54 mmol) drop
wise and stirred for 30 min. This solution was then added to a
solution of methyl pyruvate (5606.57 mg, 54.92 mmol) in diethyl
ether (50 mL) at -78.degree. C. and stirred for 30 min followed by
room temperature for 2 h. Saturated ammonium chloride solution and
ethyl acetate (200 mL) was added. The organic phase was separated
and dried over sodium sulfate. After concentration, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether from 1:20 to 1:10 as eluting solvents to afford methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate (8.9 g, 71%)
as a yellow oil. MS (ESI): m/z=231.1 [M+1].sup.+.
Step B. 6-Fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR00647##
[0319] A mixture of methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate (8.0 g, 34.75
mmol) and potassium tert-butanolate (9.73 g, 86.9 mmol) in THF (200
mL) was stirred at room temperature for 18 h. Another portion of
potassium tert-butanolate (9.73 g, 86.9 mmol) was added. The
mixture was stirred at 50.degree. C. for 10 h. After cooling to
room temperature, the mixture was brought to pH 3 with 2N HCl. The
organic phase was separated and concentrated under reduced pressure
to afford 6-fluoro-2-methyl-3H-benzofuran-2-carboxylic acid (8.0 g)
as a yellow solid, which was used directly to next step without
further purification. MS (ESI): m/z=197.1 [M+1].sup.+.
Step C. Methyl
6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylate
##STR00648##
[0321] A mixture of 6-fluoro-2-methyl-3H-benzofuran-2-carboxylic
acid (8 g, 40.81 mmol) and cesium carbonate (19.8 g, 60.7 mmol) in
DMF (150 mL) was added methyl iodide (6.92 g, 48.7 mmol). The
mixture was stirred at room temperature for 18 h. The mixture was
extracted with ethyl acetate (200 mL). The organic phase was washed
with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel
chromatography using petroleum ether to afford methyl
6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylate (5 g) as a
brown oil, which was used directly to next step without further
purification. MS (ESI): m/z=211.1 [M+1].sup.+.
Step D. Methyl
6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
##STR00649##
[0323] A mixture of methyl
6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylate (5 g, 23.7
mmol) in DCM (70 mL) was added drop wise fuming nitric acid (5 mL)
at room temperature. The mixture was stirred at room temperature
for 30 min, poured into ice water and extracted with ethyl acetate
(150 mL). The organic phase was concentrated to afford methyl
6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate as a
brown oil (5 g) as orange oil, which was used directly to next step
without further purification. MS (ESI): m/z=256.1 [M+1].sup.+.
Step E.
(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00650##
[0325] To a mixture of methyl
6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate (5 g,
19.53 mmol) in THF (100 mL) and ethanol (25 mL) was added sodium
borohydride (2.22 g, 58.6 mmol) followed by lithium chloride (2.5
g, 58.6 mmol) at 0.degree. C. The mixture was stirred at room
temperature for 3 h, quenched with saturated ammonium chloride and
extracted with DCM. The organic phase was dried over sodium sulfate
and concentrated under reduced pressure. The residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:1) as eluting solvents to afford
(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (3.0
g, 98%) as a brown oil. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.94 (d, J=8.0 Hz, 1H), 6.60 (d, J=11.6 Hz, 1H), 3.78 (dd,
J=5.6, 12.0 Hz, 1H), 3.66 (dd, J=7.2, 12.0 Hz, 1H), 3.34 (d, J=15.6
Hz, 1H), 2.93 (d, J=15.6 Hz, 1H), 1.84 (t, J=6.4 Hz, 1H), 1.49 (s,
3H). MS (ESI): m/z=228.1 [M+1].sup.+.
Intermediate 4.
6-Bromo-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran
##STR00651##
[0326] Step A. Methyl 2-(4-bromo-2-fluorophenyl)acetate
##STR00652##
[0328] A mixture of 2-(4-bromo-2-fluorophenyl)acetic acid (20.2 g,
86.6 mmol) and concentrated sulfuric acid (7 mL) in methanol (200
mL) was heated to reflux for 18 h. After removal of solvent, the
residue was diluted with DCM (200 mL) and washed with saturated
sodium bicarbonate, brine and dried over sodium sulfate. After
concentration, it was afforded methyl
2-(4-bromo-2-fluorophenyl)acetate (21.1 g, 99%) as a brown oil. MS
(ESI): m/z=280.1 [M+1].sup.+.
Step B. 1-(4-Bromo-2-fluorophenyl)-2-methylpropan-2-ol
##STR00653##
[0330] To a solution of methyl 2-(4-bromo-2-fluorophenyl)acetate
(16.0 g, 64.8 mmol) in THF (160 mL) at -78.degree. C. was added
methyl magnesium bromide (3 M in diethyl ether, 225 mmol, 75 mL)
drop-wise under nitrogen atmosphere. The reaction was stirred at
-78.degree. C. for 30 min followed by room temperature for 2 h. The
reaction was quenched with saturated ammonium chloride solution.
The aqueous phase was extracted with ethyl acetate (3.times.100
mL). The combined organic phases were dried over sodium sulfate.
After filtration and removal of solvent, the residue was purified
by silica gel chromatography using ethyl acetate:hexane (from 0 to
1:20) as eluting solvents to afford
1-(4-bromo-2-fluorophenyl)-2-methylpropan-2-ol as a colorless oil
(15.5 g), which was used directly to next step without further
purification. MS (ESI): m/z=263.1 [M+1].sup.+.
Step C. 1-(4-Bromo-2-fluorophenyl)-2-methylpropan-2-ol
##STR00654##
[0332] To a solution of
1-(4-bromo-2-fluorophenyl)-2-methylpropan-2-ol (15.5 g, 52.7 mmol)
in anhydrous THF (300 mL) was added potassium tert-butanolate (17.6
g, 156.8 mmol). The mixture was heated at 65.degree. C. for 18 h.
The reaction was brought to pH 3 with 2N HCl. The aqueous phase was
extracted with ethyl acetate (100 mL). The organic phase was dried
over sodium sulfate. After filtration and removal of solvent, the
residue was purified by silica gel chromatography using ethyl
acetate:hexane (from 0 to 1:20) as eluting solvents to afford
1-(4-bromo-2-fluorophenyl)-2-methylpropan-2-ol (8.9 g, 63%) as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 6.98 (d,
J=8.0 Hz, 1H), 6.93 (dd, J=1.6, 8.0 Hz, 1H), 6.87 (d, J=1.6 Hz,
1H), 2.94 (s, 2H), 1.46 (s, 6H).
Step D. 6-Bromo-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran
##STR00655##
[0334] To a solution of
1-(4-bromo-2-fluorophenyl)-2-methylpropan-2-ol (2.88 g, 12.7 mmol)
in DCM (60 mL) was added concentrated nitric acid (60 mL) slowly.
The mixture was stirred at room temperature for 30 min. The
reaction was quenched with water (100 mL) and the aqueous phase was
extracted with ethyl acetate (100 mL). The organic solution was
dried over sodium sulfate After filtration and removal of solvent,
the residue was purified by silica gel chromatography using ethyl
acetate:hexane (3:50) as eluting solvents to afford
6-bromo-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran (2.83 g, 78%) as
a yellowish solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.83
(s, 1H), 7.03 (s, 1H), 3.03 (d, J=1.6, 1.2 Hz, 2H), 1.53 (s, 6H).
MS (ESI): m/z=274.0 [M+1].sup.+.
Example 1.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][-
1,4]oxazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00656##
[0335] Step A.
(1-(6-Nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol
##STR00657##
[0337] A mixture of commercial available
7-fluoro-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (300 mg, 1.51
mmol), piperidin-4-ylmethanol (183 mg, 1.59 mmol) and
N-ethyl-N-isopropylpropan-2-amine (391 mg, 3.03 mmol) in
N-methyl-2-pyrrolidone (5 mL) was stirred at 120.degree. C. for 18
h. After cooling to room temperature, the mixture was poured into
water and the aqueous phase was extracted with ethyl acetate
(2.times.50 mL). The organic phases were combined and washed with
water and brine. After concentration under reduced pressure, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
(1-(6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol(300 mg, 67%) as a yellow solid. MS (ESI): m/z=294.1
[M+1].sup.+.
Step B.
(1-(6-Amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl-
)methanol
##STR00658##
[0339] A mixture of
(1-(6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol(300 mg, 1.02 mmol) and 10% palladium on carbon (30 mg) in
2-methylpropan-2-ol (10 mL) was stirred at 50.degree. C. for 18 h
under an atmosphere of hydrogen. After the mixture was cooled to
room temperature and filtered, the filtrate was concentrated under
reduced pressure to afford
(1-(6-amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol as a white solid (260 mg), which was used directly in the next
step without purification. MS (ESI): m/z=264.1 [M+1].sup.+.
Step C.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][1,4-
]oxazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00659##
[0341] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(322 mg, 1.97 mmol),
(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(1.03 g, 1.97 mmol) and N-ethyl-N-isopropylpropan-2-amine (510 mg,
3.95 mmol) in DMF (10 mL) was stirred at room temperature for 30
min.
(1-(6-amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol (260 mg, 0.99 mmol) was added. The resulting mixture was stirred
at room temperature for 18 h. After concentration, the residue was
purified by preparative HPLC ((Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 10-20%; B: 10 mM ammonium bicarbonate in water) to
afford
N-(7-(4-(hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide as a white solid (165
mg, 41%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.58 (s,
1H), 9.36 (d, J=7.2 Hz, 1H), 8.89 (d, J=4.0 Hz, 1H), 8.66 (s, 1H),
7.89 (s, 1H), 7.33 (dd, J=4.0, 6.8 Hz, 1H), 6.62 (s, 1H), 5.71 (s,
1H), 4.58 (t, J=5.2 Hz, 1H), 4.21-3.95 (m, 2H), 3.41 (t, J=4.5 Hz,
2H), 3.29-3.15 (m, 2H), 2.95-2.74 (m, 2H), 2.71-2.54 (m, 2H),
1.85-1.29 (m, 5H). MS (ESI): m/z=409.1 [M+1].sup.+.
Example 2.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3-oxo-3,4-dihydro-2H-ben-
zo[b][1,4]oxazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00660##
[0342] Step A.
7-(4-(Hydroxymethyl)piperidin-1-yl)-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)--
one
##STR00661##
[0344] A mixture of 7-fluoro-6-nitro-4H-1,4-benzoxazin-3-one (300
mg, 1.41 mmol), 4-piperidinylmethanol (162 mg, 1.41 mmol) and
N,N-diisopropylethylamine (342 mg, 2.82 mmol) in
4-methyl-2-pentanone (5 mL) was stirred at 30.degree. C. for 16 h
in a sealed tube. Water and ethyl acetate (2.times.30 mL) were
added. The organic phases were combined and washed with water,
dried over sodium sulfate and concentrated in vacuo. The residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:5) as eluting solvents to afford
7-(4-(hydroxymethyl)piperidin-1-yl)-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)--
one (400 mg, 92%) as a yellow solid. MS (ESI): m/z=308.2
[M+1].sup.+.
Step B.
6-Amino-7-(4-(hydroxymethyl)piperidin-1-yl)-2H-benzo[b][1,4]oxazin-
-3(4H)-one
##STR00662##
[0346] A mixture of
7-(4-(hydroxymethyl)piperidin-1-yl)-6-nitro-2H-benzo[b][1,4]oxazin-3
(4H)-one (350 mg, 1.14 mmol) and 10% palladium on carbon (35 mg) in
methanol (10 mL) was stirred at room temperature under an
atmosphere of hydrogen for 1 h. The solid was filtered off and the
filtrate was concentrated under reduced pressure to afford
6-amino-7-(4-(hydroxymethyl)piperidin-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)--
one (300 mg) as a colorless oil, which was used directly to next
step without further purification. MS (ESI): m/z=278.2
[M+1].sup.+.
Step C.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3-oxo-3,4-dihydro-2H-benzo[-
b][1,4]oxazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00663##
[0348] A mixture of
6-amino-7-[4-(hydroxymethyl)-1-piperidyl]-4H-1,4-benzoxazin-3-one
(250 mg, 0.90 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (100 mg, 0.19 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (145 mg, 0.89 mmol) and
N,N-diisopropylethylamine (23 mg, 0.19 mmol) in DMF (5 mL) was
stirred at room temperature for 18 h. The crude reaction was
purified by preparative HPLC ((Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 15-30%; B: 10 mM ammonium bicarbonate in water)) to
afford
N-(7-(4-(hydroxymethyl)piperidin-1-yl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]-
oxazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (68 mg, 18%) as
a white solid. H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.72 (s,
1H), 10.62 (s, 1H), 9.38 (d, J=6.0 Hz, 1H), 8.91 (d, J=4.0 Hz, 1H),
8.70 (s, 1H), 8.25 (s, 1H), 7.53 (dd, J=4.0, 6.8 Hz, 1H), 6.93 (s,
1H), 4.59 (t, J=5.6 Hz, 1H), 4.53 (s, 2H), 3.41 (d, J=5.2 Hz, 2H),
2.92-2.89 (m, 2H), 2.67-2.61 (m, 2H), 1.73-1.51 (m, 5H). MS (ESI):
m/z=423.2 [M+1].sup.+.
Example 3.
Trans-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-
-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00664##
[0349] Step A. 2-Trimethylsilylethyl
N-(2,2-dimethoxyethyl)carbamate
##STR00665##
[0351] To the mixture of 2,2-dimethoxyethanamine (608.0 mg, 5.78
mmol) and triethylamine (1.07 mL, 7.71 mmol) in THF (10 mL) was
added 1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione
(1.0 g, 3.86 mmol) at 0.degree. C. and the mixture was stirred at
room temperature for 1 h. The reaction was concentrated to dryness
under reduced pressure. The residue was dissolved in DCM (150 mL)
and the organic phase was washed with water and brine, dried over
sodium sulfate and concentrated to afford 2-trimethylsilylethyl
N-(2,2-dimethoxyethyl)carbamate (945 mg) as a colorless oil, which
was used directly in the next step without further purification.
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 4.76 (brs, 1H), 4.33 (t,
J=5.6 Hz, 1H), 4.12 (t, J=8.4 Hz, 2H), 3.36 (s, 6H), 3.27 (t, J=5.6
Hz, 2H), 0.94 (t, J=8.4 Hz, 2H), 0.00 (s, 9H).
Step B. Pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
##STR00666##
[0353] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (500.0 mg, 3.07 mmol) in DCM (12 mL) was added oxalyl chloride
(0.65 mL, 7.64 mmol) and DMF (100.0 mg, 1.37 mmol) at 0.degree. C.
followed by room temperature for 2 h. The mixture was concentrated
to dryness to afford pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(550 mg) as brown solid, which was used directly to the next step
without further purification. MS (ESI): m/z=178.1
[M-Cl+MeO].sup.+.
Step C. Methyl 2-(2,4-difluorophenyl)acetate
##STR00667##
[0355] The mixture of 2-(2,4-difluorophenyl)acetic acid (2.0 g,
11.62 mmol) and concentrated sulfuric acid (2 mL) in methanol (40
mL) was stirred at 70.degree. C. for 16 h. After concentration, the
residue was dissolved in ethyl acetate (300 mL). The organic phase
was washed with saturated sodium bicarbonate, water and brine,
dried over sodium sulfate and concentrated to afford methyl 2-(2,
4-difluorophenyl)acetate (2.1 g) as a colorless oil, which was used
directly to the next step without further purification. MS (ESI):
m/z=187.1 [M+1].sup.+.
Step D. 1-(2,4-Difluorophenyl)-2-methyl-propan-2-ol
##STR00668##
[0357] To a mixture of methyl 2-(2,4-difluorophenyl)acetate (1.8 g,
9.67 mmol) in THF (20 mL) was drop-wise added methyl magnesium
bromide (3.0 m in diethyl ether, 9.67 mL, 29.01 mmol) under an
atmosphere of nitrogen at -78.degree. C. The mixture was warmed and
stirred at room temperature for 1 h. The reaction was quenched by
saturated ammonium chloride solution. The aqueous phase was
extracted with ethyl acetate (2.times.200 mL). The combined organic
phases were washed with water and brine, dried over sodium sulfate
and concentrated under reduced pressure to afford
1-(2,4-difluorophenyl)-2-methyl-propan-2-ol (1.8 g) as a yellow
oil, which was used directly to the next step without further
purification. MS (ESI): m/z=169.1 [M-OH].sup.+.
Step E. 6-Fluoro-2,2-dimethyl-3H-benzofuran
##STR00669##
[0359] A mixture of 1-(2,4-difluorophenyl)-2-methyl-propan-2-ol
(1.8 g, 9.67 mmol) and potassium tert-butanolate (2720.0 mg, 24.24
mmol) in THF (50 mL) was stirred at 65.degree. C. for 90 min. After
concentration, the residue was dissolved in ethyl acetate (150 mL).
The organic phase was washed with water and brine, dried over
sodium sulfate and concentrated under reduced pressure. The residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:100) as eluting solvents to afford
6-fluoro-2,2-dimethyl-3H-benzofuran (1.14 g, 71%) as a colorless
oil. MS (ESI): m/z=167.1 [M+1].sup.+.
Step F. 6-Fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
##STR00670##
[0361] To a solution of 6-fluoro-2,2-dimethyl-3H-benzofuran (1.1 g,
6.9 mmol) in DCM (20 mL) was added into nitric acid (1.0 mL)
drop-wise over 10 min at 25.degree. C. and stirred for 20 min. The
mixture was poured into ice water. The aqueous phase was extracted
with ethyl acetate (150 mL). The organic phase was washed with
saturated sodium bicarbonate solution, water and brine and dried
over sodium sulfate before concentration under reduced pressure.
The residue was purified by silica gel chromatography eluting using
ethyl acetate:petroleum ether (1:10) as eluting solvents to afford
6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran (1.04 g, 72%) as gray
solid. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 7.92 (d, J=7.6 Hz,
1.2 Hz, 1H), 6.55 (d, J=11.6 Hz, 1H), 3.03 (s, 2H), 1.56 (s, 6H).
MS (ESI): m/z=212.1 [M+1].sup.+.
Step G. Dimethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propanedioate
##STR00671##
[0363] To the mixture of
6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran (420.0 mg, 1.99 mmol)
and dimethyl malonate (0.68 mL, 5.96 mmol) in DMF (8 mL) was added
cesium carbonate (1296.0 mg, 3.98 mmol) and stirred at 20.degree.
C. for 16 h. The mixture was poured into water (30 mL) and
extracted with ethyl acetate (200 mL). The organic phase was washed
with water and brine and dried over sodium sulfate before
concentration to dryness. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:5) as eluting
solvents to afford dimethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propanedioate (280 mg,
44%) as a yellow oil. MS (ESI): m/z=324.1 [M+1].sup.+.
Step H.
2-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)propane-1,3-diol
##STR00672##
[0365] To a solution of diisobutylaluminium hydride (1 M in
toluene, 5.2 mL, 5.2 mmol) in THF (2.5 mL) was drop-wise added the
solution of dimethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propanedioate (280.0 mg,
0.87 mmol) in THF (10 mL) under an atmosphere of nitrogen at
0.degree. C. and maintained there for 1 h followed by 1 h at room
temperature. To the mixture was added sodium sulfate decahydrate
and the mixture was stirred for 1 h. After filtration and
concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:3) as eluting
solvents to afford
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propane-1,3-diol (75 mg,
32%) as yellow oil. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 7.78
(s, 1H), 6.81 (s, 1H), 4.02 (d, J=1.2 Hz, 2H), 4.00 (s, 2H),
3.83-3.75 (m, 1H), 3.04 (s, 2H), 1.51 (s, 6H). MS (ESI): m/z=290.0
[M+Na].sup.+.
Step I. Trans-2-trimethylsilylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]ca-
rbamate
##STR00673##
[0367] The mixture of
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propane-1,3-diol (80.0
mg, 0.30 mmol), 2-trimethylsilylethyl
N-(2,2-dimethoxyethyl)carbamate (223.99 mg, 0.90 mmol) and
4-toluene sulfonic acid (3.0 mg, 0.02 mmol) in toluene (5 mL) was
stirred at 110.degree. C. in a sealed tube for 72 h. The mixture
was neutralized with triethylamine then concentrated to dryness.
The residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:5) as eluting solvents to afford
trans-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]ca-
rbamate (61 mg, 45%) as a yellow oil. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 7.72 (s, 1H), 6.53 (s, 1H), 4.92 (brs, 1H),
4.65 (t, J=4.0 Hz, 1H), 4.26-4.17 (m, 2H), 4.18-4.07 (m, 2H),
3.84-3.68 (m, 3H), 3.35 (t, J=4.8 Hz, 2H), 3.00 (s, 2H), 1.47 (s,
6H), 0.95 (t, J=8.4 Hz, 2H), 0.00 (s, 9H).
Step J. Trans-2-trimethylsilylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate
##STR00674##
[0369] To the mixture of trans-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,
3-dioxan-2-yl]methyl]carbamate (61.0 mg, 0.13 mmol) in DMF (2.5 mL)
was added sodium hydride (35.0 mg, 0.88 mmol) in ice water bath and
stirred for 10 min. To the mixture was added methyl iodide (0.02
mL, 0.35 mmol) and stirred at 20.degree. C. for 1 h. The mixture
was poured into water and the aqueous phase was extracted with
ethyl acetate (50 mL). The organics was washed with water and brine
and dried over sodium sulfate before concentration under reduced
pressure. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:5) as eluting solvents to
afford trans-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate (47 mg, 75%) as a yellow solid. MS (ESI):
m/z=489.2 [M+Na].sup.+.
Step K. Trans-2-trimethylsilylethyl
N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate
##STR00675##
[0371] A mixture of trans-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate (47.0 mg, 0.10 mmol) and 10% palladium on carbon
(20.0 mg) in methanol (8 mL) was stirred under a hydrogen
atmosphere at 20.degree. C. for 1 h. After filtration and
concentration, it was afforded trans-2-trimethylsilylethyl
N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate (42 mg) as a colorless oil, which was used
directly to the next step without further purification. MS (ESI):
m/z=437.2 [M+1].sup.+.
Step L. Trans-2-trimethylsilylethyl
N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate
##STR00676##
[0373] To the mixture of trans-2-trimethylsilylethyl
N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-1,
3-dioxan-2-yl]methyl]-N-methyl-carbamate (42.0 mg, 0.10 mmol),
triethylamine (0.04 mL, 0.30 mmol) and 4-dimethylaminopyridine (3.0
mg, 0.02 mmol) in THF (5 mL) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (25.0 mg, 0.14 mmol)
and stirred for 1 h. To the mixture was added methanol (2 mL).
After concentration, the residue was purified by silica gel
chromatography using ethyl actate:petroleum ether (1:1) as eluting
solvents to afford trans-2-trimethylsilylethyl
N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate (31 mg,
55%) as a yellow oil. MS (ESI): m/z=604.2 [M+Na].sup.+.
Step M.
Trans-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-3H-
-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00677##
[0375] To the mixture of trans-2-trimethyl silylethyl
N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate (31.0 mg,
0.05 mmol) in DCM (0.50 mL) was added trifluoroacetic acid (250
.mu.L) at 0.degree. C. and stirred for 1 h. The mixture was
neutralized with triethylamine. After concentration, the residue
was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 m; A:
acetonitrile 25-55%; B: 10 mM ammonium bicarbonatein water) to
afford
trans-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-3H-benzof-
uran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (17.8 mg, 76%) as
a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.73 (s,
1H), 8.84 (dd, J=1.6, 6.8 Hz, 1H), 8.75 (s, 1H), 8.74 (dd, J=1.6,
4.0 Hz, 1H), 7.72 (s, 1H), 7.06 (dd, J=3.6, 7.2 Hz, 1H), 6.55 (s,
1H), 4.75 (t, J=4.8 Hz, 1H), 4.28 (dd, J=4.4, 11.2 Hz, 2H), 3.84
(t, J=7.2 Hz, 2H), 3.65-3.55 (m, 1H), 3.03 (s, 2H), 2.76 (d, J=4.8
Hz, 2H), 2.46 (s, 3H), 1.48 (s, 6H). MS (ESI): m/z=438.2
[M+1].sup.+.
Example 4.
N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00678##
[0376] Step A.
(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperidin-4-yl)methan-
ol
##STR00679##
[0378] A mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 1) (1.14 g, 5.01 mmol) and 4-piperidinylmethanol
(5.77 g, 50.08 mmol) was stirred at 110.degree. C. for 18 h. The
reaction was concentrated to dryness. The residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether (from
1:4 to 2:3) to afford
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methanol
(1.53 g, 97%) as orange oil. MS (ESI): m/z=307.2 [M+1].sup.+.
Step B.
(1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperidin-4-yl-
)methanol
##STR00680##
[0380] A mixture of
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methanol
(1.16 g, 3.75 mmol) and 10% palladium on carbon (116 mg) in
methanol (30 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 2 h. After filtration and concentration under
reduced pressure,
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methanol
was afforded (1.29 g) as an orange oil, which was used directly to
next step without further purification. MS (ESI): m/z=277.2
[M+1].sup.+.
Step C.
N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00681##
[0382] A mixture of
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methanol
(990.0 mg, 3.58 mmol) and triethylamine (1087.4 mg, 10.75 mmol) in
DCM (10 mL) was stirred at 0.degree. C. To the mixture was a added
solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example
3, Step B) (975.67 mg, 5.37 mmol) in DCM (10 mL) and the reaction
was stirred at 25.degree. C. for 1 h. After concentration, the
residue was purified by preparative HPLC (Xbridge 21.2*250 mm c18,
10 um; A: acetonitrile 45-55%; B: 10 mM ammonium bicarbonate in
water) to afford
N-[6-[4-(hydroxymethyl)-1-piperidyl]-2,2-dimethyl-3H-benzofuran-5-yl]pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (916 mg, 61%) as a yellow
solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 10.50 (s, 1H),
8.82-8.72 (m, 3H), 8.43 (s, 1H), 7.01 (dd, J=4, 6.8 Hz, 1H), 6.65
(s, 1H), 3.67-3.57 (m, 2H), 3.14-3.06 (m, 2H), 3.03 (s, 2H),
2.72-2.61 (m, 2H), 1.82-1.61 (m, 5H), 1.48 (s, 6H). MS (ESI):
m/z=422.1 [M+1].sup.+.
Example 5.
N-(2,2-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00682##
[0383] Step A.
7-Fluoro-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00683##
[0385] A mixture of 2-amino-5-fluorophenol (150 mg, 1.18 mmol),
ethyl 2-bromo-2-methylpropanoate (345 mg, 1.77 mmol), cesium
carbonate (1.1 g, 3.54 mmol) in 1,4-dioxane (8 mL) was stirred at
110.degree. C. for 4 h. The reaction was filtered, concentrated
under reduced pressure and purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:4) to afford
7-fluoro-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (95 mg, 39%)
as grey solid. MS (ESI): m/z=196.1 [M+1].sup.+.
Step B.
7-Fluoro-2,2-dimethyl-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00684##
[0387] To a solution of
7-fluoro-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (95 mg, 0.49
mmol) in sulfuric acid (4 mL) was added guanidine nitrate (59 mg,
0.49 mmol) drop-wise at 0.degree. C. and stirred for 30 min. The
mixture was poured into ice water and the aqueous was extracted
with ethyl acetate (30 mL). The organic phase was dried over sodium
sulfate and concentrated to afford
7-fluoro-2,2-dimethyl-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one as
grey solid (108 mg), which was used directly to next step without
further purification. MS (ESI): m/z=241.1 [M+1].sup.+.
Step C.
2,2-Dimethyl-7-morpholino-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00685##
[0389] A mixture of
7-fluoro-2,2-dimethyl-6-nitro-2H-benzo[b][1,4]oxazin-3 (4H)-one
(100 mg, 0.41 mmol), morpholine (43 mg, 0.50 mmol) and
N,N-diisopropylethylamine (86 mg, 0.67 mmol) in acetonitrile (10
mL) was stirred at room temperature for 18 h. After concentration,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
2,2-dimethyl-7-morpholino-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
(122 mg, 97%) as grey oil. MS (ESI): m/z=308.1 [M+1].sup.+.
Step D.
2,2-Dimethyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxaz-
ine
##STR00686##
[0391] To a solution of
2,2-dimethyl-7-morpholino-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
(122 mg, 0.40 mmol) in THF (4 mL) was added borane (1M in THF, 1.59
mL, 1.59 mmol) at room temperature. Then the mixture was stirred at
65.degree. C. for 2 h. The mixture was cooled to 0.degree. C.
Methanol (10 mL) was added drop wise. The mixture was stirred at
reflux for 1 h. After concentration, it was afforded
2-methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
(120 mg) as red oil, which was used to next step without further
purification. MS (ESI): m/z=294.2 [M+1].sup.+.
Step E.
2,2-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ami-
ne
##STR00687##
[0393] A mixture of
2-methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
(120 mg, 0.41 mmol) and 10% palladium on carbon (30.0 mg) in ethyl
acetate (30 mL) was stirred at 40.degree. C. under hydrogen
atmosphere for 2 h. The solid was filtered off and the filtrate was
concentrated under reduced pressure to afford
2,2-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
(110 mg) as black oil, which was used to next step without further
purification. MS (ESI): m/z=264.1 [M+1].sup.+.
Step F.
N-(2,2-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00688##
[0395] A mixture of
2,2-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
as black oil (110 mg, 0.42 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (82 mg, 0.50 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (327 mg, 0.63 mmol) and
diisopropylethylamine (152 mg, 1.25 mmol) in DMF (10 mL) was
stirred at 25.degree. C. for 4 h. The mixture was purified by
preparative HPLC (phenomenex, Gemini C18, 21.2.times.100 mm. 5 um,
110 A, A: acetonitrile 30-40%; B: 0.05% formic acid in water) to
afford
N-(2,2-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (70 mg, 41%) as a yellow solid.
.sup.1HNMR (400 MHz, DMSO-d6): .delta. 10.51 (s, 1H), 9.36 (dd,
J=1.6, 7.2 Hz, 1H), 8.92 (dd, J=1.6, 4.4 Hz, 1H), 8.66 (s, 1H),
7.89 (s, 1H), 7.33 (dd, J=4.4, 7.2 Hz, 1H), 6.61 (s, 1H), 5.82 (s,
1H), 3.89-3.73 (m, 4H), 2.95 (s, 2H), 2.82-2.69 (m, 4.0 Hz, 4H),
1.24 (s, 6H). MS (ESI): m/z=409.1 [M+1].sup.+.
Example 6.
N-(2-(Hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofura-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00689##
[0396] Step A.
(2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00690##
[0398] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (900
mg, 3.70 mmol) in morpholine (5 mL) was stirred at 120.degree. C.
for 18 h. The mixture was concentrated under reduced pressure and
the residue purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(780 mg, 72%) as a yellow oil. MS (ESI): m/z=295.1 [M+1].sup.+.
Step B.
(5-Amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
##STR00691##
[0400] A mixture of
(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)methanol (780 mg,
2.65 mmol) and 10% palladium on carbon (200 mg) in methanol (30 mL)
was stirred at 25.degree. C. under hydrogen atmosphere for 1 h. The
reaction was filtered and the filtrate was concentrated under
reduced pressure to afford
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(550 mg) as light green oil, which was used directly to next step
without further purification. MS (ESI): m/z=265.1 [M+1].sup.+.
Step C.
N-(2-(Hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00692##
[0402] A mixture of
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(550 mg, 2.08 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(407 mg, 2.5 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinyl-
phosphonium hexafluorophosphate (1.63 g, 3.12 mmol) and
diisopropyethylamine (756 mg, 6.24 mmol) in DMF (10 mL) was stirred
at 25.degree. C. for 3 h. Water was added. The aqueous phase was
extracted with ethyl acetate (2.times.50 mL). The combined organic
phases were washed with brine, dried over sodium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel chromatography using methanol: DCM (3:100) as eluting
solvents to afford
N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyrazolo[1,-
5-a]pyrimidine-3-carboxamide (490 mg, 58%) as a yellow solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.47 (s, 1H), 8.83 (dd,
J=1.5, 7.2 Hz, 1H), 8.78 (s, 1H), 8.77 (dd, J=1.6, 4.0 Hz, 1H),
7.07 (dd, J=4.0, 7.2 Hz, 1H), 6.67 (s, 1H), 3.94-3.96 (m, 4H), 3.67
(d, J=5.6 Hz, 2H), 3.25 (d, J=15.6 Hz, 1H), 2.95 (d, J=15.6 Hz,
1H), 2.91-2.93 (m, 4H), 1.46 (s, 3H).
[0403] MS (ESI): m/z=410.1 [M+1].sup.+.
Example 7.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][-
1,4]oxazin-6-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00693##
[0404] Step A. 6-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00694##
[0406] A solution of 5-amino-1H-pyrazole-4-carboxylic acid (2000
mg, 15.74 mmol) and (E)-3-(dimethylamino)-2-methylacrylaldehyde
(1780 mg, 15.74 mmol) in acetic acid (3 mL) and ethanol (1 mL) was
heated at 70.degree. C. for 1 h. The resulting mixture was cooled
to room temperature and the solid was collected by filtration,
washed with water and dried in vacuum to afford
6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1610 mg, 58%)
as a white solid. MS (ESI): m/z=178.1 [M+1].sup.+.
Step B.
(1-(6-Nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl-
)methanol
##STR00695##
[0408] A mixture of
7-fluoro-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (300 mg, 1.51
mmol), piperidin-4-ylmethanol (183 mg, 1.59 mmol) and
N-ethyl-N-isopropylpropan-2-amine (391 mg, 3.03 mmol) in
N-methyl-2-pyrrolidone (5 mL) was stirred at 120.degree. C. for 18
h. After cooling to room temperature, the mixture was poured into
water and the aqueous phase was extracted with ethyl acetate
(2.times.50 mL). The organic phases were combined and washed with
water, brine and dried over sodium sulfate. After concentration
under reduced pressure, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:1) as eluting
solvents to afford
(1-(6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol (300 mg, 67%) as a yellow solid. MS (ESI): m/z=294.1
[M+1].sup.+.
Step C.
(1-(6-Amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl-
)methanol
##STR00696##
[0410] A mixture of
(1-(6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol (300 mg, 1.02 mmol) and 10% palladium on carbon (30 mg) in
2-methylpropan-2-ol (10 mL) was stirred at 50.degree. C. for 18 h
under hydrogen atmosphere. After the mixture was cooled down to
room temperature, the reaction was filtered and the filtrate was
concentrated under reduced pressure to afford
(1-(6-amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol(260 mg) as a white solid, which was used directly to the next
step without purification. MS (ESI): m/z=264.1 [M+1].sup.+.
Step D.
N-(7-(4-(Hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][1,4-
]oxazin-6-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00697##
[0412] A mixture of 6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (58 mg, 0.33 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(215 mg, 0.41 mmol),
(1-(6-amino-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)piperidin-4-yl)methan-
ol (85 mg, 0.27 mmol) and N-ethyl-N-isopropylpropan-2-amine (71 mg,
0.55 mmol) in DMF (5 mL) was stirred at room temperature for 18 h.
After filtration and concentration, the residue was purified by
preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate in water) to afford
N-(7-(4-(hydroxymethyl)piperidin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-
-6-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 30%)
as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
10.55 (s, 1H), 9.21 (s, 1H), 8.83 (d, J=2.8 Hz, 1H), 8.57 (s, 1H),
7.88 (s, 1H), 6.61 (s, 1H), 5.68 (s, 1H), 4.6 (t, J=2.8 Hz, 2H),
4.08 (t, J=4.4 Hz, 2H), 3.43 (t, J=5.2 Hz, 2H), 3.25-3.22 (m, 2H),
2.86-2.83 (m, 2H), 2.62-2.56 (m, 2H), 2.42 (s, 3H), 1.73-1.63 (m,
4H), 1.51-1.47 (m, 1H).
[0413] MS (ESI): m/z=423.1 [M+1].sup.+.
Example 8.
N-[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00698##
[0414] Step A.
1-(2,2-Difluoroethyl)-4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazi-
ne
##STR00699##
[0416] A mixture of 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
(80.0 mg, 0.38 mmol), 1-(2,2-difluoroethyl)piperazine hydrochloride
(212.0 mg, 1.14 mmol) and cesium carbonate (556.0 mg, 1.71 mmol) in
DMF (4 mL) was stirred at 20.degree. C. for 5 h. The mixture was
poured into water (20 mL) and the aqueous phase was extracted with
ethyl acetate (50 mL). The organic phase was washed with water and
brine and dried over sodium sulfate before concentration to
dryness. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:6) as eluting solvents to
afford
1-(2,2-difluoroethyl)-4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazi-
ne (88 mg, 68%) as yellow oil. MS (ESI): m/z=342.1 [M+1].sup.+.
Step B.
6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-
-5-amine
##STR00700##
[0418] A mixture of
1-(2,2-difluoroethyl)-4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazi-
ne (84.0 mg, 0.25 mmol) and 10% palladium on carbon (50.0 mg) in
methanol (12 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration and concentration under
reduced pressure, it was afforded
6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofur-
an-5-amine (75 mg) as a yellow oil, which was used directly in the
next step without further purification. MS (ESI): m/z=312.2
[M+1].sup.+.
Step C.
N-[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofu-
ran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00701##
[0420] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (63.0 mg, 0.35 mmol), triethylamine (0.1 mL, 0.69 mmol)
and 4-dimethylaminopyridine (7.0 mg, 0.06 mmol) in THF (10 mL) was
added
6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-amin-
e (70.0 mg, 0.22 mmol) and the mixture was stirred at 25.degree. C.
for 1 h. To the mixture was added methanol (4 mL) and stirred for
30 min. After concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether: DCM (2:1:1) as
eluting solvents to afford
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofu-
ran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (84.1 mg, 82%) as
a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.40
(brs, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.95 (dd, J=1.2, 4.4 Hz,
1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.35 (dd, J=4.0, 6.8 Hz, 1H), 6.71
(s, 1H), 6.20 (tt, J=4.4, 55.6 Hz, 1H), 3.00 (s, 2H), 2.94-2.73 (m,
10H), 1.41 (s, 6H). MS (ESI): m/z=457.2 [M+1].sup.+.
Example 9.
N-(7-Morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR00702##
[0421] Step A.
7-Morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00703##
[0423] A mixture of morpholine (176 mg, 2.02 mmol),
7-fluoro-6-nitro-3,4-dihydro-2H-1,4-benzoxazine (200 mg, 1.01
mmol), potassium carbonate (488 mg, 3.53 mmol) and sodium iodide
(530 mg, 3.53 mmol) in acetonitrile (20 mL) was stirred at
85.degree. C. for 16 h. After filtration and concentration under
reduced pressure, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:1) as eluting
solvents to afford
7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine as
red-brown oil (250 mg, 93%). MS (ESI): m/z=266.2 [M+1].sup.+.
Step B. 7-Morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
##STR00704##
[0425] A mixture of
7-morpholino-6-nitro-3,4-dihydro-2H-1,4-benzoxazine (125 mg, 0.47
mmol) and 10% palladium on carbon (50.0 mg) in ethyl acetate (20
mL) was stirred at 45.degree. C. under an atmosphere of hydrogen
for 3 h. After filtration and concentration, it was afforded
7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine as a brown
solid (100 mg), which was used directly to next step without
further purification. MS (ESI): m/z=236.2 [M+1].sup.+.
Step C.
N-(7-Morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide
##STR00705##
[0427] A mixture of
7-morpholino-3,4-dihydro-2H-1,4-benzoxazin-6-amine (95.0 mg, 0.40
mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (79.0 mg, 0.48
mmol), and
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (307 mg, 0.810 mmol) in DMF (5 mL) and
diisopropyethylamine (260 mg, 2.02 mmol) was stirred at 25.degree.
C. for 16 h. After concentration, the residue was purified by
preparative HPLC (Boston ODS 40 g flash, A: MeCN25-35%; B: 0.5%
ammonium bicarbonate in H.sub.2O) to afford
N-(7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (22.9 mg, 15%) as pale yellow solid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 10.52 (s, 1H), 9.36 (dd,
J=1.6, 6.8 Hz, 1H), 8.93 (dd, J=1.2, 4.0 Hz, 1H), 8.66 (s, 1H),
7.87 (s, 1H), 7.33 (dd, J=4.0, 6.8 Hz, 1H), 6.64 (s, 1H), 5.76 (s,
1H), 4.10-4.08 (m, 2H), 3.89-3.74 (m, 4H), 3.28-3.22 (m, 2H),
2.79-2.69 (m, 4H).
[0428] MS (ESI): m/z=381.2 [M+1].sup.+.
Example 10.
N-(3-Methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide
##STR00706##
[0429] Step A.
4-Benzyl-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00707##
[0431] A mixture of 7-fluoro-4H-1,4-benzoxazin-3-one (200 mg, 1.2
mmol), (chloromethyl)benzene (159 mg, 1.26 mmol) and cesium
carbonate (1.95 g, 5.98 mmol) in 1,4-dioxane (10 mL) was stirred at
110.degree. C. for 4 h. After filtration, the filtrate was
concentrated and purified by silica gel chromatography using ethyl
acetate:petroleum ether(1:4) as eluting solvents to afford
4-benzyl-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one (250 mg, 75%) as
a white solid. MS (ESI): m/z=258.1 [M+1].sup.+.
Step B.
4-Benzyl-7-fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00708##
[0433] To a mixture of
4-benzyl-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one (250 mg, 0.97
mmol) in THF (10 mL) was added methyl magnesium bromide (3M in
diethyl ether, 1.3 mL, 3.89 mmol) drop-wise at 0.degree. C. The
mixture was stirred at room temperature for 2 h. The reaction
mixture was cooled to 0.degree. C. and acetic acid (2 mL) was added
followed by addition of sodium borohydride (92 mg, 2.43 mmol). The
reaction mixture was stirred at room temperature for 12 h and then
poured into ice water. The aqueous phase was extracted with ethyl
acetate (10 mL). The organic phase was dried over sodium sulfate
and concentrated under reduced pressure. The residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:4) as eluting solvents to afford
4-benzyl-7-fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (220
mg, 67%) as a white solid. MS (ESI): m/z=258.2 [M+1].sup.+.
Step C. 7-Fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00709##
[0435] A mixture of
4-benzyl-7-fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (220
mg, 0.86 mmol) and 10% palladium on carbon (40 mg) in ethanol (20
mL) was stirred at 40.degree. C. under hydrogen atmosphere for 4 h.
The solid was filtered off and the filtrate was concentrated under
reduced pressure to afford
7-fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (100 mg) as a
light oil, which was used directly in the next step without
purification. MS (ESI): m/z=168.2 [M+1].sup.+.
Step D.
7-Fluoro-3-methyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00710##
[0437] To a solution of
7-fluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (100 mg, 0.60
mmol) in concentrated sulfuric acid (4 mL) was added guanidine
nitrate (73 mg, 0.60 mmol) at 0.degree. C. Then the mixture was
stirred at 0.degree. C. for 30 min and poured into ice water. The
aqueous phase was extracted with ethyl acetate (30 mL). The organic
phase was dried over sodium sulfate and concentrated to afford
7-fluoro-3-methyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (80
mg) as red solid, which was used directly in the next step without
purification. MS (ESI): m/z=213.2 [M+1].sup.+.
Step E.
3-Methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00711##
[0439] A mixture of
7-fluoro-3-methyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine (80
mg, 0.38 mmol), morpholine (49 mg, 0.57 mmol) and cesium carbonate
(246 mg, 0.75 mmol) in acetonitrile (5 mL) was stirred at
85.degree. C. for 18 h. The mixture was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:4) as eluting
solvents to afford
3-methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
(80 mg, 61%) as a red oil. MS (ESI): m/z=280.1 [M+1].sup.+.
Step F.
N-(3-Methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00712##
[0441] A mixture of
3-methyl-7-morpholino-3,4-dihydro-2H-1,4-benzoxazin-6-amine (43 mg,
0.17 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (33 mg,
0.21 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (107 mg, 0.21 mmol) and
diisopropyethylamine (44 mg, 0.34 mmol) in DMF (5 mL) was stirred
at 20.degree. C. for 16 h. The crude was purified by preparative
HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10
mM ammonium bicarbonate in water) to afford
N-(3-methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide (15 mg, 22%) as a white solid. H
NMR (400 MHz, DMSO-d.sub.6): .delta. 10.52 (s, 1H), 9.36 (dd,
J=1.2, 6.8 Hz, 1H), 8.93 (dd, J=1.6, 4 Hz, 1H), 8.67 (s, 1H), 7.78
(s, 1H), 7.33 (dd, J=4.4, 7.2 Hz, 1H), 6.66 (s, 1H), 5.81 (s, 1H),
4.13-4.08 (m, 1H), 3.87-3.80 (m, 4H), 3.61 (dd, J=8, 10 Hz, 1H),
3.41-3.33 (m, 1H), 2.78-2.71 (m, 4H), 1.08 (d, J=6.4 Hz, 3H). MS
(ESI): m/z=395.2 [M+1].sup.+.
Example 11.
N-(2-Methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide
##STR00713##
[0442] Step A.
7-Chloro-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00714##
[0444] A mixture of 2-amino-5-chlorophenol (2.26 g, 15.73 mmol),
ethyl 2-bromopropanoate (4.27 g, 23.6 mmol) and cesium carbonate
(15.39 g, 47.2 mmol) in 1,4-dioxane (20 mL) was stirred at
20.degree. C. for 18 h. After filtration and concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:4) as eluting solvents to afford
7-chloro-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one as grey solid
(1.4 g, 42%). MS (ESI): m/z=198.1 [M+1].sup.+.
Step B.
7-Chloro-2-methyl-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00715##
[0446] To a solution of
7-chloro-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one (664 mg, 3.36
mmol) in concentrated sulfuric acid (10 mL) was added guanidine
nitrate (410 mg, 3.36 mmol) at 0.degree. C. The mixture was stirred
for 30 min then poured to ice water. The aqueous phase was
extracted with ethyl acetate (100 mL). The organic phase was dried
over sodium sulfate and concentrated under reduced pressure to
afford 7-chloro-2-methyl-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
(660 mg) as a grey solid, which was used directly to next step
without further purification. MS (ESI): m/z=243.1 [M+1].sup.+.
Step C.
2-Methyl-7-morpholino-6-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one
##STR00716##
[0448] A mixture of
7-chloro-2-methyl-6-nitro-4H-1,4-benzoxazin-3-one (151 mg, 0.62
mmol) in morpholine (2 mL) was stirred at 120.degree. C. in a
sealed tube for 16 h. The mixture was concentrated and the residue
was purified by silica gel chromatography using ethyl acetate:
petroleum ether (1:1) as eluting solvents to afford
2-methyl-7-morpholino-6-nitro-4H-1,4-benzoxazin-3-one (180 mg, 78%)
as red oil. MS (ESI): m/z=294.2 [M+1].sup.+.
Step D.
2-Methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00717##
[0450] To a solution of
2-methyl-7-morpholino-6-nitro-4H-1,4-benzoxazin-3-one (183.0 mg,
0.62 mmol) in THF (4 mL) was added borane (1M in THF, 2.5 mL, 2.5
mmol). The mixture was stirred at 65.degree. C. for 2 h. The
mixture was cooled to 0.degree. C. and methanol (10 mL) was added
drop wise. The mixture was stirred at reflux for 1 h. After
concentration, it was afforded
2-methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
(180 mg) as red oil, which was used directly to next step without
further purification. MS (ESI): m z=280.2 [M+1].sup.+.
Step E.
2-Methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
##STR00718##
[0452] A mixture of
2-methyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
(180 mg, 0.64 mmol) and 10% palladium on carbon (40.0 mg) in ethyl
acetate (30 mL) was stirred at 40.degree. C. under hydrogen
atmosphere for 2 h. After filtration, the filtrate was concentrated
under reduced pressure to afford
2-methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine as
dark grey oil (162 mg), which was used directly to next step
without further purification. MS (ESI): m/z=250.2 [M+1].sup.+.
Step F.
N-(2-Methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00719##
[0454] A mixture of
2-methyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
(162 mg, 0.65 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(127 mg, 0.78 mmol), diisopropyethylamine (236 mg, 1.95 mmol) and
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (508 mg, 0.97 mmol) in DMF (10 mL) was
stirred at 25.degree. C. for 4 h. The residue was purified by
preparative HPLC (phenomenex, Gemini C18, 21.2.times.100 mm. 5 um,
110 A; A: acetonitrile 25-35%; B: 0.05% TFA in water) to afford
N-(2-methyl-7-morpholino-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)pyrazolo[1,-
5-a]pyrimidine-3-carboxamide (100 mg, 39%) as a yellow solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.51 (s, 1H), 9.35
(dd, J=1.6, 6.8 Hz, 1H), 8.92 (dd, J=1.6, 4.0 Hz, 1H), 8.66 (s,
1H), 7.87 (s, 1H), 7.33 (dd, J=4.0, 6.8 Hz, 1H), 6.65 (s, 1H), 5.76
(s, 1H), 4.05-4.08 (m, 1H), 3.82-3.84 (m, 4H), 3.26-3.29 (m, 1H),
2.87-2.92 (m, 1H), 2.74-2.76 (m, 4H), 1.26 (d, J=5.6 Hz, 3H). MS
(ESI): m/z=395.1 [M+1].sup.+.
Example 12.
N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-
-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00720##
[0456] A flask equipped with a stir bar was charged with the
6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Example 7,
Step A) (127.53 mg, 0.72 mmol) and charged with nitrogen
atmosphere. DMF (10 mL) was added and the mixture was cooled
0.degree. C. (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (359.01 mg, 0.69 mmol) was added followed by
addition of 2,4,6-trimethylpyridine (83.44 mg, 0.69 mmol).
[1-(5-Amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methanol
(Example 4, Step B) (173.0 mg, 0.63 mmol) was added and the ice
bath was removed allowing the reaction to stir at room temperature
for 3 h.
[0457] After concentration, the residue was purified by preparative
HPLC (Xbridge Prep C18 10 um OBD, 19*250 mm, A: acetonitrile 45-75%
and 0.01% NH.sub.3; B: 10 mM ammonium bicarbonate in water) to
afford
N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-
-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (173.0 mg,
63%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
10.45 (s, 1H), 8.69 (s, 1H), 8.63 (d, J=2 Hz, 1H), 8.59-8.56 (m,
1H), 8.42 (s, 1H), 6.64 (s, 1H), 3.64 (s, 2H), 3.14-3.06 (m, 2H),
3.03 (s, 2H), 2.72-2.63 (m, 2H), 2.46 (s, 2H), 1.83-1.62 (m, 5H),
1.48 (s, 6H). MS (ESI): m/z=436.3 [M+1].sup.+.
Example 13.
(S)--N-(6-(3-(hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00721##
[0458] Step A.
(S)-(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)pyrrolidin-3-yl)m-
ethanol
##STR00722##
[0460] A mixture of 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
(Example 3, Step F) (133.0 mg, 0.62 mmol),
(S)-pyrrolidin-3-ylmethanol (94.83 mg, 0.94 mmol) and potassium
carbonate (215.5 mg, 3.15 mmol) in acetonitrile (30 mL) was stirred
at 25.degree. C. for 18 h. After filtration and concentration under
reduced pressure, it was afforded [(3
S)-1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(254 mg) as a yellow oil, which was used directly to next step
without further purification. MS (ESI): m/z=293.2 [M+1].sup.+.
Step B.
(S)-(1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrrolidin-
-3-yl)methanol
##STR00723##
[0462] A mixture of [(3
S)-1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(254.0 mg, 0.87 mmol) and 10% palladium on carbon (25 mg) in
methanol (10 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration and concentration, the residue
was purified on silica gel chromatography using ethyl
acetate:petroleum ether (2:1) as eluting solvents to afford [(3
S)-1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(102 mg, 44%) as red oil. MS (ESI): m/z=263.2 [M+1].sup.+.
Step C.
(S)--N-(6-(3-(Hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihy-
drobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00724##
[0464] A mixture of [(3
S)-1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(78.0 mg, 0.30 mmol) and trimethylamine (90.26 mg, 0.89 mmol) in
DCM (15 mL) was stirred at 0.degree. C. To the mixture was added
the solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(Example 3, Step B) (80.98 mg, 0.45 mmol) in DCM (10 mL). The
reaction was stirred at 25.degree. C. for 1 h. The residue was
purified by preparative HPLC (Xbridge Prep C18 10 um OBD, 19*250
mm, A: acetonitrile 45-75% and 0.01% ammonia; B: 10 mM ammonium
bicarbonate in water) to afford
(S)--N-(6-(3-(hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (78.5 mg, 68%)
as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.97
(s, 1H), 8.04 (dd, J=2.0, 7.2 Hz, 1H), 8.78 (s, 1H), 8.75 (dd,
J=1.6, 4.0 Hz, 1H), 8.20 (s, 1H), 7.02 (dd, J=4.0, 6.8 Hz, 1H),
6.58 (s, 1H), 3.74 (d, J=6.4 Hz, 2H), 3.56-3.22 (m, 2H), 3.02 (s,
2H), 2.97-2.82 (m, 2H), 2.61-2.48 (m, 1H), 2.16-2.05 (m, 1H),
1.84-1.68 (m, 2H), 1.48 (s, 6H). MS (ESI): m/z=408.3
[M+1].sup.+.
Example 14.
N-(2-Methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide
##STR00725##
[0465] Step A.
2-(4-Chloro-2-fluorophenyl)-N-methoxy-N-methylacetamide
##STR00726##
[0467] A mixture of 2-(4-chloro-2-fluoro-phenyl)acetic acid (5.00
g, 26.51 mmol), N, O-dimethylhydroxylamine hydrochloride (7.76 g,
79.54 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (7.62 g, 39.77 mmol) and 4-dimethylaminopyridine
(4.85 g, 39.77 mmol) in DCM (100 mL) was stirred at 20.degree. C.
for 16 h. The reaction mixture was concentrated in vacuo and the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:5) as eluting solvents to afford
2-(4-chloro-2-fluoro-phenyl)-N-methoxy-N-methyl-acetamide (4.65 g,
73%) as a colorless oil. MS (ESI): m/z=232.1 [M+1].sup.+.
Step B. 1-(4-Chloro-2-fluorophenyl)propan-2-one
##STR00727##
[0469] To a mixture of
2-(4-chloro-2-fluoro-phenyl)-N-methoxy-N-methyl-acetamide (4.65 g,
20.07 mmol) in DCM (50 mL) at -78.degree. C. under nitrogen gas,
was added methyl magnesium bromide (3.0 m in diethyl ether, 8.03
mL, 24.09 mmol) drop-wise. The reaction mixture was stirred at
25.degree. C. for 30 min. The reaction was quenched by addition of
50 mL of water. The aqueous phase was extracted with ethyl acetate
(2.times.50 mL). The combined organic phases were washed with
water, dried over sodium sulfate and concentrated in vacuo. The
residue was purified on silica gel chromatography using ethyl
acetate:petroleum ether (1:3) as eluting solvents to afford
1-(4-chloro-2-fluoro-phenyl)propan-2-one (2.65 g, 67.2%) as light
yellow foam. MS (ESI): m/z=187.1 [M+1].sup.+.
Step C. 1-(4-Chloro-2-fluoro-5-nitrophenyl)propan-2-one
##STR00728##
[0471] To a solution of 1-(4-chloro-2-fluoro-phenyl)propan-2-one
(373.22 mg, 2 mmol) in sulfuric acid (1 mL) at 0.degree. C. was
added 2-oxohydrazinecarboximidamide 2-oxide (229.0 mg, 2.20 mmol).
The resultant mixture was stirred at 0.degree. C. for 2 h. The
mixture was poured into ice water and ethyl acetate (50 mL) was
added. The organic phase was separated, dried over sodium sulfate
and concentrated in vacuo to afford
1-(4-chloro-2-fluoro-5-nitro-phenyl)propan-2-one (400 mg, 78%) as a
yellow solid. MS (ESI): m/z=232.1 [M+1].sup.+.
Step D. 1-(4-Chloro-2-fluoro-5-nitrophenyl)propan-2-ol
##STR00729##
[0473] To a solution of
1-(4-chloro-2-fluoro-5-nitro-phenyl)propan-2-one (200 mg, 0.86
mmol) in methanol (4 mL) at 0.degree. C. was added sodium
borohydride (65 mg, 1.72 mmol). The resultant mixture was stirred
at 0.degree. C. for 1 h. The reaction was quenched by addition of
saturated ammonium chloride solution. The aqueous phase was
extracted with ethyl acetate (2.times.50 mL). The combined organic
phases were washed with water, dried over sodium sulfate and
concentrated in vacuo to afford
1-(4-chloro-2-fluoro-5-nitrophenyl)propan-2-ol (160 mg) as light
yellow solid, which was used directly to next step without further
purification. MS (ESI): m/z=234.2 [M+1].sup.-.
Step E. 6-Chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran
##STR00730##
[0475] A mixture of 1-(4-chloro-2-fluoro-5-nitro-phenyl)propan-2-ol
(105 mg, 0.45 mmol) and potassium tert-butanolate (100 mg, 0.90
mmol) in THF (5 mL) was stirred at 60.degree. C. for 16 h. After
cooling to room temperature, the reaction was concentrated in vacuo
and the residue was purified by silica gel chromatography using
ethyl acetate:petroleum ether(1:5) as eluting solvents to afford
6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran (50 mg, 52.1%) as
light yellow foam.
[0476] MS (ESI): m/z=214.2 [M+1].sup.+.
Step F.
4-(2-Methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
##STR00731##
[0478] A mixture of 6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran
(100.0 mg, 0.47 mmol) in morpholine (2 mL) was stirred at
110.degree. C. for 16 h in a sealed tube. After cooling to room
temperature, the reaction was concentrated in vacuo and the residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether(5:1) as eluting solvents to afford
4-(2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine (85 mg,
65%) as light yellow solid. MS (ESI): m/z=265.2 [M+1].sup.+.
Step G. 2-Methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
##STR00732##
[0480] A mixture of
4-(2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine (85 mg,
0.32 mmol) and 10% palladium on carbon (8.5 mg) in methanol (5 mL)
was stirred at room temperature under hydrogen atmosphere for 1 h.
The solid was filtered off and the filtrate was concentrated under
reduced pressure to afford
2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine (55 mg) as a
colorless foam, which was used directly to next step without
further purification. MS (ESI): m/z=235.2 [M+1].sup.+.
Step H.
N-(2-Methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
##STR00733##
[0482] To a solution of
2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine (55 mg, 0.23
mmol) and triethylamine (23 mg, 0.23 mmol) in DCM (4 mL) was
stirred at 0.degree. C. A solution of
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(42 mg, 0.23 mmol) in DCM (2 mL) was added. The resultant mixture
was stirred at 20.degree. C. for 1 h. Methanol (2 mL) was added.
After concentration, the residue was purified by preparative
HPLC((Xbridge Prep C18 10 um OBD, 19*250 mm, A: acetonitrile 45-75%
and 0.01% NH3; B: 10 mM ammonium bicarbonate in water) to afford
N-(2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide (45 mg, 51%) as a yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 10.47 (s, 1H), 8.83 (dd, J=1.6, 6.8 Hz,
1H), 8.78 (s, 1H), 8.77 (dd, J=2, 4.4 Hz, 1H), 8.45 (s, 1H), 7.07
(dd, J=4.0, 6.8 Hz, 1H), 6.67 (s, 1H), 4.97-4.92 (m, 1H), 3.96-3.94
(m, 4H), 3.34 (dd, J=8.8, 15.6 Hz, 1H), 2.93-2.91 (m, 4H), 2.84
(dd, J=7.6, 15.6 Hz, 1H), 1.47 (d, J=6.4 Hz, 3H). MS (ESI):
m/z=380.2 [M+1].sup.+.
Example 15.
(R)--N-(6-(3-(Hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00734##
[0483] Step A.
(R)-(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)pyrrolidin-3-yl)m-
ethanol
##STR00735##
[0485] A mixture of 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
(141.0 mg, 0.67 mmol), (R)-pyrrolidin-3-ylmethanol (101.3 mg, 1
mmol) and potassium carbonate (230.19 mg, 1.67 mmol) in
acetonitrile (30 mL) was stirred at 25.degree. C. for 18 h. After
filtration and concentration under reduced pressure, it was
afforded
[(3R)-1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(272 mg) as a yellow oil, which was used directly to next step
without further purification. MS (ESI): m/z=293.2 [M+1].sup.+.
Step B.
(R)-(1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)pyrrolidin-
-3-yl)methanol
##STR00736##
[0487] A mixture of
[(3R)-1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(272.0 mg, 0.93 mmol) and 10% palladium on carbon (27 mg) in
methanol (10 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration and concentration under
reduced pressure, the residue was purified on silica gel column
eluted ethyl acetate/petroleum ether (2:1) to afford
[(3R)-1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)pyrrolidin-3-y-
l]methanol (108 mg, 43%) as red oil. MS (ESI): m/z=263.2
[M+1].sup.+.
Step C.
(R)--N-(6-(3-(Hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihy-
drobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00737##
[0489] A mixture of
[(3R)-1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)pyrrolidin-3-yl]methanol
(108.0 mg, 0.41 mmol) and trimethylamine (124.97 mg, 1.23 mmol) in
DCM (15 mL) was stirred at 0.degree. C. To the mixture was added a
solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example
3, Step B) (112.12 mg, 0.62 mmol) in DCM (10 mL). The reaction was
stirred at 25.degree. C. for 1 h. The residue was purified by
preparative HPLC (Xbridge Prep C18 10 um OBD, 19*250 mm, A:
acetonitrile 45-75% and 0.01% NH3; B: 10 mM ammonium bicarbonate in
water) to afford
(R)--N-(6-(3-(hydroxymethyl)pyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (101.3 mg 60%)
as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.90
(s, 1H), 8.73 (dd, J=1.2, 6.7 Hz, 1H), 8.70 (s, 1H), 8.68 (dd,
J=1.6, 4.4 Hz, 1H), 8.12 (s, 1H), 6.95 (dd, J=4.0, 6.8 Hz, 1H),
6.51 (s, 1H), 3.67 (d, J=6.4 Hz, 2H), 3.28-3.16 (m, 2H), 2.95 (s,
2H), 2.91-2.75 (m, 2H), 2.53-2.42 (m, 1H), 2.08-1.98 (m, 1H),
1.78-1.63 (m, 2H), 1.41 (s, 6H). MS (ESI): m/z=408.2
[M+1].sup.+.
Example 16.
N-(2-(Hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,3-dih-
ydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00738##
[0490] Step A.
(1-(2-(Hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperid-
in-4-yl)methanol
##STR00739##
[0492] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol,
piperidin-4-ylmethanol (Intermediate 2) (150 mg, 0.62 mmol) in
piperidin-4-ylmethanol (1.42 g, 12.31 mmol) was stirred at
110.degree. C. for 18 h. The mixture was concentrated and the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
(1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperid-
in-4-yl)methanol (100 mg, 50%) as a yellow oil. MS (ESI): m/z=323.1
[M+1].sup.+.
Step B.
(1-(5-Amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)-
piperidin-4-yl)methanol
##STR00740##
[0494] A mixture of
(1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperid-
in-4-yl)methanol (100 mg, 0.31 mmol) and 10% palladium on carbon
(25 mg) in methanol (10 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 1 h. The solid was filtered. The filtrate
was concentrated under reduced pressure to afford
(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piperid-
in-4-yl)methanol (80 mg) as light green oil, which was used
directly to next step without further purification. MS (ESI):
m/z=293.2 [M+1].sup.+.
Step C.
N-(2-(Hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl--
2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamid-
e
##STR00741##
[0496] A mixture of
(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piperid-
in-4-yl)methanol (80 mg, 0.27 mmol),
6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (69 mg, 0.39
mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (255 mg, 0.49 mmol) and
diisopropyethylamine (118 mg, 0.98 mmol) in DMF (10 mL) was stirred
at 25.degree. C. for 3 h. The mixture was purified by preparative
HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10
mM ammonium bicarbonate in water) to afford
N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,3-dih-
ydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
(65 mg, 53%) as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 8.69 (s, 1H), 8.63 (d, J=2.0 Hz, 1H),
8.57-8.58 (m, 1H), 8.43 (s, 1H), 6.65 (s, 1H), 3.64-3.66 (m, 4H),
3.23 (d, J=16.0 Hz, 1H), 3.07-3.10 (m, 2H), 2.93 (d, J=15.6 Hz,
1H), 2.63-2.69 (m, 2H), 2.45 (s, 3H), 2.00-2.02 (m, 1H), 1.64-1.80
(m, 5H), 1.54 (s, 1H), 1.46 (s, 3H). MS (ESI): m/z=452.2
[M+1].sup.+.
Example 17.
N-(6-(2,2-Dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00742##
[0497] Step A.
(6-(2,2-Dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol
##STR00743##
[0499] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Intermediate 2) (130 mg, 0.53 mmol) in 2,2-dimethylmorpholine (1
mL) was stirred at 100.degree. C. for 18 h in a sealed tube. After
cooling to room temperature and concentration under reduced
pressure, the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (2:1) as eluting solvents to
afford
(6-(2,2-dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol (95 mg, 55%) as a yellow solid. MS (ESI): m/z=323.2
[M+1].sup.+.
Step B.
(5-Amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-
-2-yl)methanol
##STR00744##
[0501] A mixture of
(6-(2,2-dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol (95 mg, 0.29 mmol) and 10% palladium on carbon (9.5 mg) in
methanol (10 mL) was stirred at room temperature under hydrogen
atmosphere for 1 h. The solid was filtered off and the filtrate was
concentrated under reduced pressure to afford
(5-amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-2-yl)m-
ethanol(55 mg) as a colorless foam, which was used directly to the
next step without purification. MS (ESI): m/z=293.2
[M+1].sup.+.
Step C.
N-(6-(2,2-Dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihyd-
robenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00745##
[0503] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid(34
mg, 0.21 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (109 mg, 0.21 mmol) and
2,3,4-trimethylpyridine (46 mg, 0.38 mmol) in DMF (5 mL) was
stirred at room temperature for 30 min.
(5-Amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-2-
-yl)methanol (55 mg, 0.19 mmol) was added and stirred for 18 h. To
the reaction was added water. The aqueous phase was extracted with
ethyl acetate (2.times.30 mL). The combined phases were washed with
brine, dried over sulfate and concentrated in vacuo. The residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (20:1) as eluting solvents to afford
desired product. The product was further purified by preparative
HPLC ((Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 15-30%; B:
10 mM ammonium bicarbonate in water)) to afford
N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (48 mg, 58%) as
a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.97
(s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.84 (dd, J=1.6, 4.4 Hz,
1H), 8.70 (s, 1H), 8.20 (s, 1H), 7.33 (dd, J=4.4, 6.8 Hz, 1H), 6.61
(s, 1H), 5.05 (t, J=6.0 Hz, 1H), 3.82-3.74 (m, 2H), 3.48-3.40 (m,
2H), 3.20 (d, J=16 Hz, 1H), 2.83 (d, J=15.6 Hz, 1H), 2.73-2.69 (m,
2H), 2.67-2.62 (m, 2H), 1.35 (s, 6H), 1.34 (s, 3H). MS (ESI):
m/z=438.3 [M+1].sup.+.
Example 18.
N-(6-(3-(Hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00746##
[0504] Step A.
(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-3-methylpyrrolidin-3-
-yl)methanol
##STR00747##
[0506] A mixture of 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
(100 mg, 0.47 mmol), (3-methylpyrrolidin-3-yl)methanol
hydrochloride (144 mg, 0.95 mmol) and cesium carbonate (308 mg,
0.94 mmol) in DMF (6 mL) was stirred at 25.degree. C. for 18 h.
Water was added. The aqueous phase was extracted with ethyl acetate
(30 mL). The organic phase was washed with brine, dried over sodium
sulfate and concentrated under reduced pressure. The residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:1) to afford
(1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-3-methylpyrrolidin-3-
-yl)methanol (149 mg, 95%) as a yellow oil.
[0507] MS (ESI): m/z=307.1 [M+1].sup.+.
Step B.
(1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-3-methylpyrro-
lidin-3-yl)methanol
##STR00748##
[0509] A mixture of
(1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-3-methylpyrrolidin-3-
-yl)methanol (100 mg, 0.33 mmol) and 10% palladium on carbon (40
mg) in methanol (10 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. The reaction was filtered and the filtrate was
concentrated under reduced pressure to afford
(1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-3-methylpyrrolidin-3-
-yl)methanol (90 mg, 49%) as a light green oil.
[0510] MS (ESI): m/z=277.1 [M+1].sup.+.
Step C.
N-(6-(3-(Hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3--
dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00749##
[0512] A mixture of
(1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-3-methylpyrrolidin-3-
-yl)methanol (90 mg, 0.32 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (64 mg, 0.39 mmol) and
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1l-pyrrolidinylphosph-
onium hexafluorophosphate (118 mg, 0.98 mmol) in DMF (10 mL) was
stirred at 25.degree. C. for 2 h. After concentration under reduced
pressure, the residue was purified by preparative HPLC (Xbridge
Prep C18 10 um, 19*250 mm, A: acetonitrile 25-55%; B: 10 mM
ammonium bicarbonatein water) to afford
N-(6-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3--
dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (50
mg, 36%) as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.82 (s, 1H), 8.76-8.80 (m, 3H), 8.12 (s, 1H), 7.01 (dd,
J=4.0, 6.8 Hz, 1H), 6.55 (s, 1H), 3.63-3.66 (m, 2H), 3.34-3.39 (m,
1H), 3.10 (d, J=9.2 Hz, 1H), 3.00 (s, 2H), 2.86-2.93 (m, 2H), 2.39
(s, 1H), 1.94-2.01 (m, 1H), 1.60-1.66 (m, 1H), 1.47 (s, 6H), 1.20
(s, 3H). MS (ESI): m/z=422.2 [M+1].sup.+.
Example 19.
N-[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3H--
benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00750##
[0513] Step A.
[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-
-yl]methanol
##STR00751##
[0515] The mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol (120.0 mg,
0.49 mmol), 1-(2,2-difluoroethyl)piperazine hydrochloride (720.0
mg, 3.86 mmol) and cesium carbonate (820.0 mg, 2.52 mmol) in DMSO
(5 mL) was stirred at 90.degree. C. for 5 d. The reaction mixture
was diluted with ethyl acetate (30 mL) and water. The organic phase
was isolated and dried over sodium sulfate and concentrated in
vacuo. The residue was purified by silica gel chromatography using
ethyl acetate:petroleum ether (1:1) as eluting solvents to afford
[6-[4-(2,
2-difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]metha-
nol (65 mg, 37%) as a yellow oil. MS (ESI): m/z=358.2
[M+1].sup.+.
Step B.
[5-Amino-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzo-
furan-2-yl]methanol
##STR00752##
[0517] A mixture of
[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-
-yl]methanol (65.0 mg, 0.18 mmol) and 10% palladium on carbon (25.0
mg) in methanol (8 mL) was stirred under hydrogen atmosphere at
25.degree. C. for 1 h. After filtration and concentration, it was
afforded
[5-amino-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzofuran-2-
-yl]methanol (55 mg, 92%) as a brown oil, which was used directly
to the next step without purification. MS (ESI): m/z=328.1
[M+1].sup.+.
Step C.
N-[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-met-
hyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00753##
[0519] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (44.0 mg, 0.27 mmol) and diisopropyethylamine (0.08 mL, 0.51
mmol) in DMF (2 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (130.0 mg, 0.34 mmol). The mixture was stirred
at 25.degree. C. for 30 min. To the mixture was added a solution of
[5-amino-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzofuran-2-
-yl]methanol (55.0 mg, 0.17 mmol) in DMF (2 mL) and the mixture was
stirred at 25.degree. C. for 3 h. After concentration, the residue
was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um;
A: acetonitrile 25-55%; B: 10 mM ammonium bicarbonate in water) to
afford
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3H--
benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (36.4 mg,
46%) as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.41 (s, 1H), 9.37 (dd, J=2.0, 7.2 Hz, 1H), 8.95 (dd, J=1.6, 4.0
Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.35 (dd, J=4, 6.8 Hz, 1H),
6.70 (s, 1H), 6.20 (tt, J=4.4, 14 Hz, 1H), 5.05 (t, J=5.6 Hz, 1H),
3.49-3.37 (m, 2H), 3.19 (d, J=16 Hz, 1H), 2.94-2.72 (m, 11H), 1.34
(s, 3H). MS (ESI): m/z=473.2 [M+1].sup.+.
Example 20.
Cis-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-3H-benzofur-
an-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00754##
[0520] Step A. Cis-2-trimethylsilylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]ca-
rbamate
##STR00755##
[0522] The mixture of
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)propane-1,3-diol (80.0
mg, 0.30 mmol), 2-trimethylsilylethyl
N-(2,2-dimethoxyethyl)carbamate (223.99 mg, 0.90 mmol) and
4-toluene sulfonic acid(3.0 mg, 0.02 mmol) in toluene (5 mL) was
stirred at 110.degree. C. in a sealed tube for 72 h. The mixture
was neutralized with triethylamine. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:5) as eluting solvents to afford
cis-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,
3-dioxan-2-yl]methyl]carbamate (40 mg, 30%) as a yellow oil.
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 7.83 (s, 1H), 7.57 (s,
1H), 4.90 (brs, 1H), 4.70 (t, J=4.4 Hz, 1H), 4.24-4.06 (m, 6H),
3.40-3.37 (m, 1H), 3.33-3.29 (m, 2H), 3.01 (s, 2H), 1.49 (s, 6H),
0.94 (t, J=8.4 Hz, 2H), 0.00 (s, 9H). MS (ESI): m/z=475.1
[M+Na].sup.+.
Step B.
Cis-2-trimethylsilylethyl-N-[[5-(2,2-dimethyl-5-nitro-3H-benzofura-
n-6-yl)-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate
##STR00756##
[0524] To the mixture of cis-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,
3-dioxan-2-yl]methyl]carbamate (45.0 mg, 0.10 mmol) in DMF (2 mL)
was added sodium hydride (30.0 mg, 0.75 mmol) at 0.degree. C. and
stirred for 10 min. To the mixture was added methyl iodide (0.02
mL, 0.28 mmol) and reaction was stirred at 20.degree. C. for 1 h.
The mixture was poured into water. The aqueous phase was extracted
with ethyl acetate (50 mL). The organics washed with water, brine
and dried over sodium sulfate before concentration under reduced
pressure. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:5) as eluting solvents to
afford cis-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate (37 mg, 80%) as a yellow oil. MS (ESI): m/z=489.1
[M+Na].sup.+.
Step C. Cis-2-trimethylsilylethyl
N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-1,
3-dioxan-2-yl]methyl]-N-methyl-carbamate
##STR00757##
[0526] The mixture of cis-2-trimethyl silylethyl
N-[[5-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1,3-dioxan-2-yl]methyl]-N-
-methyl-carbamate (37.0 mg, 0.08 mmol) and 10% palladium on carbon
(15.0 mg) in methanol (8 mL) was stirred under hydrogen atmosphere
at 20.degree. C. for 1 h. After filtration and concentration, it
was afforded cis-2-trimethyl
silylethyl-N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-1,3-dioxan-2-y-
l]methyl]-N-methyl-carbamate (33 mg, 95%) as a colorless oil, which
was used directly to next step without further purification. MS
(ESI): m/z=437.2 [M+1].sup.+.
Step D.
Cis-2-trimethylsilylethyl-N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]py-
rimidine-3-carbonylamino)-3H-benzofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-me-
thyl-carbamate
##STR00758##
[0528] To the mixture of
cis-2-trimethylsilylethyl-N-[[5-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-
-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate (32.0 mg, 0.07 mmol),
triethylamine (25.0 mg, 0.25 mmol) and 4-dimethylaminopyridine (2.0
mg, 0.02 mmol) in THF (5 mL) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (20.0 mg, 0.11 mmol)
and stirred at 20.degree. C. for 1 h. To the mixture was added
methanol (2 mL) then the mixture was concentrated to dryness. The
residue was purified by silica gel chromatography using methanol:
DCM (1:20) as eluting solvents to afford
cis-2-trimethylsilylethyl-N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidin-
e-3-carbonylamino)-3H-benzofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-methyl-ca-
rbamate (17 mg, 40%) as a yellow oil. MS (ESI): m/z=604.2
[M+Na].sup.+.
Step E.
Cis-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-3H-b-
enzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00759##
[0530] To the mixture of cis-2-trimethylsilylethyl
N-[[5-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-1,3-dioxan-2-yl]methyl]-N-methyl-carbamate (17.0 mg,
0.03 mmol) in DCM (0.40 mL) was added trifluoroacetic acid (200.0
uL) at 0.degree. C. and stirred for 1 h. The mixture was
neutralized with triethylamine. After concentration, the residue
was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um,
A: acetonitrile 25-55%; B: 10 mM ammonium bicarbonate in water) to
afford
cis-N-[2,2-dimethyl-6-[2-(methylaminomethyl)-1,3-dioxan-5-yl]-3H-benzofur-
an-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (7.9 mg, 62%) as a
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.31 (s,
1H), 8.84 (dd, J=1.6, 6.8 Hz, 1H), 8.74 (s, 1H), 8.65 (dd, J=1.6,
4.0 Hz, 1H), 7.53 (s, 1H), 7.50 (s, 1H), 7.05 (dd, J=4.4, 7.2 Hz,
1H), 4.81 (t, J=5.2 Hz, 1H), 4.31 (d, J=11.6 Hz, 2H), 4.18 (dd,
J=3.2, 11.6 Hz, 2H), 3.04 (s, 2H), 2.98-2.93 (m, 1H), 2.81 (d,
J=4.8 Hz, 2H), 2.46 (s, 3H), 1.50 (s, 6H). MS (ESI): m/z=438.3
[M+1].sup.+.
Example 21.
N-(2-Ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00760##
[0531] Step A. 1-(4-Chloro-2-fluorophenyl)-2-methylbutan-2-ol
##STR00761##
[0533] To a solution of 1-(4-chloro-2-fluoro-phenyl)propan-2-one
(300 mg, 1.61 mmol) in THF (10 mL) was added ethyl magnesium
bromide (1 m in THF, 1.93 mL, 1.93 mmol) drop-wise at -78.degree.
C. under nitrogen atmosphere. The mixture was stirred at room
temperature for 1 h. The reaction was quenched with saturated
ammonium chloride solution. The aqueous phase was extracted with
ethyl acetate (30 mL). The organic phase was dried over sodium
sulfate and concentrated to afford
1-(4-chloro-2-fluoro-phenyl)-2-methyl-butan-2-ol (300 mg) as a
colorless oil, which was used directly to next step without further
purification. MS (ESI): m/z=199.1 [M-OH].sup.+.
Step B. 6-Chloro-2-ethyl-2-methyl-2,3-dihydrobenzofuran
##STR00762##
[0535] A mixture of
1-(4-chloro-2-fluoro-phenyl)-2-methyl-butan-2-ol (300 mg, 1.38
mmol) and potassium tert-butanolate (387 mg, 3.46 mmol) in THF (20
mL) was stirred at 65.degree. C. for 3 h. Water was added and the
aqueous was extracted with ethyl acetate (20 mL). The organic phase
was washed with brine, dried over sodium sulfate and concentrated
under reduced pressure. The residue was purified by silica
chromatography using ethyl acetate:petroleum ether (1:100) to
afford 6-chloro-2-ethyl-2-methyl-3H-benzofuran (132 mg, 49%) as a
colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.01 (d,
J=8.0 Hz, 1H), 6.77 (dd, J=1.6, 7.6 Hz, 1H), 6.71 (d, J=1.6 Hz,
1H), 3.02 (d, J=15.6 Hz, 1H), 2.86 (d, J=15.6 Hz, 1H), 1.74 (t,
J=7.2 Hz, 2H), 1.41 (s, 3H), 0.95 (q, J=7.2 Hz, 3H).
Step C.
4-(2-Ethyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
##STR00763##
[0537] A mixture of 6-chloro-2-ethyl-2-methyl-3H-benzofuran (132
mg, 0.67 mmol) in DCM (10 mL) was added nitric acid (0.5 mL)
drop-wise and the mixture was stirred for 30 min. The mixture was
poured into ice water. The aqueous phase was extracted with ethyl
acetate (30 mL). The organic phase was washed with saturated sodium
bicarbonate solution, dried over sodium sulfate and concentrated
under reduced pressure to afford
6-chloro-2-ethyl-2-methyl-5-nitro-3H-benzofuran (126 mg, 67%) as
black solid. MS (ESI): m/z=242.1 [M+1].sup.+.
Step D.
4-(2-Ethyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
##STR00764##
[0539] A mixture of 6-chloro-2-ethyl-2-methyl-5-nitro-3H-benzofuran
(132 mg, 0.55 mmol) in morpholine (2 mL) was stirred at 120.degree.
C. for 18 h. After concentration, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether
(15:100) to afford
4-(2-ethyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(106 mg, 42%) as a yellow oil. MS (ESI): m/z=293.2 [M+1].sup.+.
Step E.
2-Ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
##STR00765##
[0541] A mixture of
4-(2-ethyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(106 mg, 0.35 mmol) and 10% palladium on carbon (40 mg) in methanol
(10 mL) was stirred at 25.degree. C. under hydrogen atmosphere for
1 h. The reaction was filtered and the filtrate was concentrated
under reduced pressure to afford
(2-ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine (77
mg, 68%) as light green oil. MS (ESI): m/z=263.3 [M+1].sup.+.
Step F.
N-(2-Ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide
##STR00766##
[0543] To a mixture of
2-ethyl-2-methyl-6-morpholino-3H-benzofuran-5-amine (80 mg, 0.30
mmol) and triethylamine (92 mg, 0.91 mmol) in DCM (15 mL) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(83 mg, 0.46 mmol). The mixture was stirred at room temperature for
3 h, concentrated and purified by preparative HPLC (Xbridge Prep
C18 10 um OBD, 19*250 mm, A: acetonitrile 45-75% and 0.01% ammonia;
B: 10 mM ammonium bicarbonate in water) to yield
N-(2-ethyl-2-methyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide as a yellow solid (70 mg, 56%). .sup.1HNMR (400
MHz, CDCl.sub.3): .delta. 10.46 (s, 1H), 8.83 (dd, J=1.6, 6.8 Hz,
1H), 8.78 (s, 1H), 8.75 (dd, J=2.0, 4.0 Hz, 1H), 8.42 (s, 1H), 7.06
(dd, J=1.6, 6.8 Hz, 1H), 3.94-3.96 (m, 4H), 3.09 (d, J=15.2 Hz,
1H), 2.94 (d, J=15.2 Hz, 1H) 2.91-2.93 (m, 4H), 1.78 (q, J=7.6 Hz,
2H), 0.98 (t, J=7.2 Hz, 3H). MS (ESI): m/z=408.2 [M+1].sup.+.
Example 22.
N-(2-Cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR00767##
[0544] Step A.
1-(4-Chloro-2-fluorophenyl)-2-cyclopropylpropan-2-ol
##STR00768##
[0546] A mixture of 1-(4-chloro-2-fluoro-phenyl)propan-2-one (300
mg, 1.61 mmol) in THF (10 mL) was added drop-wise cyclopropyl
magnesium bromide (0.5 M in THF, 3.86 mL, 1.93 mmol) at -78.degree.
C. under nitrogen atmosphere. The mixture was stirred at room
temperature for 1 h. The mixture was quenched with saturated
ammonium chloride solution (20 mL) and extracted with ethyl acetate
(30 mL). The organic phase was dried over sodium sulfate and
concentrated to afford
1-(4-chloro-2-fluorophenyl)-2-cyclopropylpropan-2-ol as light oil
(350 mg), which was used directly to next step without further
purification. MS (ESI): m/z=211.1 [M-OH]+
Step B. 6-Chloro-2-cyclopropyl-2-methyl-2,3-dihydrobenzofuran
##STR00769##
[0548] A mixture of
1-(4-chloro-2-fluorophenyl)-2-cyclopropylpropan-2-ol (317 mg, 1.38
mmol) and potassium tert-butanolate (387 mg, 3.46 mmol) in THF (20
mL) was stirred at 65.degree. C. for 3 h. Water was added and the
aqueous phase was extracted with ethyl acetate (20 mL). The organic
phase was washed with brine, dried over sodium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether
(1:100) to afford
6-chloro-2-cyclopropyl-2-methyl-2,3-dihydrobenzofuran (82 mg, 28%)
as light oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.00 (d,
J=7.6 Hz, 1H), 6.77 (dd, J=1.6, 8.0 Hz, 1H), 6.69 (d, J=1.6 Hz,
1H), 3.02 (d, J=15.6 Hz, 1H), 2.90 (d, J=15.6 Hz, 1H), 1.42 (s,
3H), 1.11-1.16 (m, 1H), 0.44-0.49 (m, 3H), 0.33-0.37 (m, 1H).
Step C.
6-Chloro-2-cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran
##STR00770##
[0550] To a solution of
6-chloro-2-cyclopropyl-2-methyl-2,3-dihydrobenzofuran (82 mg, 0.38
mmol) in DCM (10 mL) was added drop-wise nitric acid (0.5 mL) at
25.degree. C. and the mixture was stirred for 30 min. The mixture
was poured into ice water and extracted with ethyl acetate (30 mL).
The organic phase was washed with saturated sodium bicarbonate
solution, dried over sodium sulfate and concentrated under reduced
pressure to afford
6-chloro-2-cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran as
black solid (100 mg, crude). MS (ESI): m/z=254.1 [M+1].sup.+.
Step D.
4-(2-Cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morph-
oline
##STR00771##
[0552] A mixture of
6-chloro-2-cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran (100
mg, 0.39 mmol) in morpholine (2 mL) was stirred at 120.degree. C.
for 18 h. The mixture was concentrated and the residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(15:100) as eluting solvents to afford
4-(2-cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(130 mg, 49%) as a yellow oil. MS (ESI): m/z=305.1 [M+1].sup.+.
Step E.
2-Cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
##STR00772##
[0554] A mixture of
4-(2-cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(130 mg, 0.35 mmol) and 10% palladium on carbon (40 mg) in methanol
(10 mL) was stirred at 25.degree. C. under H.sub.2 atmosphere for 1
h. The reaction was filtered and the filtrate was concentrated
under reduced pressure to afford
2-cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
(63 mg) as light green oil, which was used directly to next step
without further purification. MS (ESI): m/z=275.2 [M+1].sup.+.
Step F.
N-(2-Cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00773##
[0556] A mixture of
2-cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
(63 mg, 0.23 mmol) and triethylamine (70 mg, 0.69 mmol) in DCM (15
mL) was added pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(Example 3, Step B) (63 mg, 0.34 mmol). The mixture was stirred at
25.degree. C. for 3 h. After concentration, the residue was
purified by preparative HPLC (Xbridge Prep C18 10 um OBD, 19*250
mm, A: acetonitrile 45-75% and 0.01% NH.sub.3; B: 10 mM ammonium
bicarbonate in water) to afford
N-(2-cyclopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide as a yellow solid (30 mg, 31%).
.sup.1HNMR (400 MHz, CDCl.sub.3): .delta. 10.45 (s, 1H), 8.82 (dd,
J=2.0, 7.2 Hz, 1H), 8.78 (s, 1H), 8.76 (dd, J=2.0, 4.0 Hz, 1H),
8.40 (s, 1H), 7.06 (d, J=4.0, 6.8 Hz), 6.63 (s, 1H), 3.93-3.95 (m,
4H), 3.12 (d, J=16.4 Hz, 1H), 2.96 (d, J=16.4 Hz, 1H), 2.89-2.92
(m, 4H), 1.43 (s, 3H), 1.15-1.19 (m, 1H), 0.40-0.49 (m, 4H). MS
(ESI): m/z=420.2 [M+1].sup.+.
Example 23.
N-(2-(Dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00774##
[0557] Step A.
3-(2,4-Difluorophenyl)-2-hydroxy-2-methyl-propanoate
##STR00775##
[0559] To a solution of magnesium (1206.62 mg, 50.28 mmol) and
iodine (89.38 mg, 0.35 mmol) in diethyl ether (50 mL) at reflux was
added 2,4-difluorobenzyl bromide (4140.0 mg, 20 mmol) drop-wise and
the resulting mixture was stirred for 30 min. This solution was
then added to a solution of methyl pyruvate (2055.73 mg, 20.14
mmol) in diethyl ether (50 mL) at -78.degree. C. followed by 2 h at
room temperature. Saturated ammonium chloride and ethyl acetate
(200 mL) were added. The organic phase was separated and dried over
ethyl acetate. After concentration, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether (1:20
to 1:10) as eluting solvent to afford methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate (4000 mg, 87%)
as a yellow oil. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
7.25-7.10 (m, 1H) 6.84-6.70 (m, 2H), 3.75 (s, 3H), 3.09 (d, J=14
Hz, 1H), 2.92 (d, d, J=13.6 Hz, 1H), 1.47 (s, 3H).
Step B. 6-Fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR00776##
[0561] A mixture of methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate (4000.0 mg,
17.38 mmol) and potassium tert-butanolate (4874.2 mg, 43.44 mmol)
was stirred in THF (180 mL) at 65.degree. C. for 18 h. After
cooling to room temperature, the reaction was acidified to pH 3
with 1N HCl. Ethyl acetate (200 mL) was added and the organic phase
was separated, dried over sodium sulfate and concentration. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (3:2) to afford
6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-carboxylic acid (650 mg,
18%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta.7.11-6.98 (m, 1H), 6.66-6.50 (m, 2H), 3.60 (d, J=16 Hz, 1H),
3.14 (d, J=16 Hz), 1.77 (s, 3H).
Step C.
6-Fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR00777##
[0563] To a solution of
6-fluoro-2-methyl-3H-benzofuran-2-carboxylic acid (500.0 mg, 2.55
mmol) in DCM (20 mL) was added fuming nitric acid (845.23 mg, 12.74
mmol) drop-wise at 20.degree. C. The mixture was stirred for 30
min. The mixture was poured into ice water. The aqueous phase was
extracted with ethyl acetate (2.times.100 mL). The combined organic
phases were washed with water, dried over sodium sulfate and
concentrated in vacuo to afford
6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-carboxylic acid (580 mg)
as light yellow foam, which was used directly to next step without
further purification. MS (ESI): m/z=242.0 [M+1].sup.+.
Step D.
2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR00778##
[0565] A mixture of
6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-carboxylic acid (280.00
mg, 1.16 mmol), morpholine (202.29 mg, 2.32 mmol) and cesium
carbonate (1513.12 mg, 4.64 mmol) in acetonitrile (5 mL) was
stirred at 20.degree. C. for 16 h. The mixture was filtered and the
filtrate was concentrated in vacuo to obtain
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylic acid (300
mg) as a brown oil, which was used directly to next step without
further purification. MS (ESI): m/z=309.1 [M+1].sup.+.
Step E.
N,N,2-Trimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carbo-
xamide
##STR00779##
[0567] A mixture of
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylic acid
(120.0 mg, 0.39 mmol), N,N-dimethylamine hydrochloride (63.48 mg,
0.78 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (296.0 mg, 0.78 mmol) and diisopropyethylamine
(201.10 mg, 1.56 mmol) in DMF (5 mL) was stirred at 20.degree. C.
for 2 h. Water was added and the aqueous phase was extracted with
ethyl acetate (2.times.50 mL). The combined organic phases were
washed with water, dried over sodium sulfate and concentrated in
vacuo.
[0568] The residue was purified by silica gel chromatography using
ethyl acetate:petroleum ether (1:1) to afford
N,N,2-trimethyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxamide
(100 mg, 69%) as light yellow solid. MS (ESI): m/z=336.2
[M+1].sup.+.
Step F. 5-Amino-N,N,
2-trimethyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxamide
##STR00780##
[0570] A mixture of
N,N,2-trimethyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxamide
(100.00 mg, 0.30 mmol) and 10% palladium on carbon (10 mg) in
methanol (10 mL) was stirred at room temperature under hydrogen
atmosphere for 1 h. The reaction was filtered and the filtrate was
concentrated under reduced pressure to afford
5-amino-N,N,2-trimethyl-6-morpholino-3H-benzofuran-2-carboxamide
(100 mg, crude) as a colorless oil, which was used directly to next
step without further purification. MS (ESI): m/z=306.2
[M+1].sup.+.
Step G.
N-(2-(Dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofur-
an-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00781##
[0572] A mixture of
5-amino-N,N,2-trimethyl-6-morpholino-3H-benzofuran-2-carboxamide
(100.00 mg, 0.33 mmol) and triethylamine (66.27 mg, 0.65 mmol) in
DCM (5 mL) was stirred at 0.degree. C. The solution of
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(71.36 mg, 0.39 mmol) in DCM (5 mL) was added drop-wise. The
mixture was stirred at 20.degree. C. for 1 h. Methanol (3 mL) was
added. After concentration, the residue was purified by preparative
HPLC ((Xbridge Prep C18 10 um OBD, 19*250 mm, A: acetonitrile
50-70% and 0.01% NH.sub.3; B: 10 mM ammonium bicarbonate in water)
to afford
N-[2-(dimethylcarbamoyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyrazol-
o[1,5-a]pyrimidine-3-carboxamide (60 mg, 41%) as an off-white
solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.46 (s, 1H),
9.38 (d, J=6.8 Hz, 1H), 8.95 (d, J=1.6, 4 Hz, 1H), 8.69 (s, 1H),
8.35 (s, 1H), 7.35 (dd, J=4.4, 6.8 Hz, 1H), 6.85 (s, 1H), 3.90 (d,
J=16 Hz, 1H), 3.86-3.83 (m, 4H), 3.16 (s, 3H), 3.05 (d, J=16.4 Hz,
1H), 2.88 (s, 3H), 2.84-2.81 (m, 4H), 1.58 (s, 3H). MS (ESI):
m/z=451.2 [M+1].sup.+.
Example 24.
N-[6-[4-(1-Amino-2,2,2-trifluoro-ethyl)-1-piperidyl]-2,2-dimethyl-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00782##
[0573] Step A. tert-Butyl
4-((4-methoxybenzylimino)methyl)piperidine-1-carboxylate
##STR00783##
[0575] The mixture of tert-butyl 4-formyl-1-piperidinecarboxylate
(1.07 g, 5 mmol) 4-methoxybenzylamine (685.9 mg, 5 mmol) 4 .ANG.
molecular sieves (1.00 g, 5 mmol) in methanol (10 mL) was stirred
for 18 h. After filtration and concentration, it was afforded
tert-butyl 4-((4-methoxybenzylimino)methyl)piperidine-1-carboxylate
(1.66 g) as a colorless oil, which used directly to next step
without further purification. MS (ESI): m/z=333.3 [M+1].sup.+.
Step B. tert-Butyl
4-(2,2,2-trifluoro-1-(4-methoxybenzylamino)ethyl)piperidine-1-carboxylate
##STR00784##
[0577] To the mixture of tert-butyl
4-[(Z)-(4-methoxyphenyl)methyliminomethyl]piperidine-1-carboxylate
(1.66 g, 5 mmol), (trifluoromethyl)trimethylsilane (1.07 g, 7.5
mmol) and potassium hydrogen fluoride (585.0 mg, 7.5 mmol) in
acetonitrile (10 mL) was added trifluoroacetic acid (427.5 mg, 3.75
mmol) drop-wise at room temperature. The mixture was stirred at
room temperature for 18 h. Water was added and the aqueous phase
was extracted by ethyl acetate (3.times.20 mL). The combined
organic phases were dried over sodium sulfate and concentrated
under reduced pressure. The residue was purified by silica gel
chromatography using ethyl acetate: petroleum ether (from 1:10 to
1:6) as eluting solvents to afford tert-butyl
4-[2,2,2-trifluoro-1-[(4-methoxyphenyl)methylamino]ethyl]piperidine-1-car-
boxylate (1.08 g, 50%) as a colorless oil. MS (ESI): m/z=303.2
[M-100].sup.+.
Step C.
2,2,2-Trifluoro-N-[(4-methoxyphenyl)methyl]-1-(4-piperidyl)ethanam-
ine trifluoroacetic acid salt
##STR00785##
[0579] To a solution of tert-butyl
4-[2,2,2-trifluoro-1-[(4-methoxyphenyl)methylamino]ethyl]piperidine-1-car-
boxylate (150 mg, 0.37 mmol) in DCM (5 mL) was added
2,2,2-trifluoroacetic acid (0.3 mL) and the resulting mixture was
stirred at 25.degree. C. for 2 h. The reaction mixture was
concentrated to dryness to afford
2,2-trifluoro-N-[(4-methoxyphenyl)methyl]-1-(4-piperidyl)ethanamine
(100 mg) as the trifluoroacetic acid salt, which was used directly
to the next step without further purification. MS (ESI): m/z=303.1
[M+1].sup.+.
Step D.
1-[1-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]-2,2,2--
trifluoro-N-[(4-methoxyphenyl)methyl]ethanamine
##STR00786##
[0581] A mixture of 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran
(100 mg, 0.47 mmol),
2,2,2-trifluoro-N-[(4-methoxyphenyl)methyl]-1-(4-piperidyl)ethanamine
trifluoroacetic acid salt (170 mg, 0.56 mmol) and cesium carbonate
(490 mg, 1.5 mmol) in DMF (5 mL) was stirred at 25.degree. C. for
18 h. Then water was added and the aqueous phase was extracted with
ethyl acetate (3.times.20 mL). The combined organic phases were
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography using ethyl acetate:petroleum ether (0-25%) as
eluting solvents to afford
1-[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]-2,2,2-trifluo-
ro-N-[(4-methoxyphenyl)methyl]ethanamine (190 mg, 74%) as a yellow
oil. MS (ESI): m/z=494.3 [M+1].sup.+.
Step E. tert-Butyl
4-[(4-amino-3-pyridyl)oxy]piperidine-1-carboxylate
##STR00787##
[0583] A mixture of
1-[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]-2,2,2-trifluo-
ro-N-[(4-methoxyphenyl)methyl]ethanamine (180 mg, 0.36 mmol), iron
powder (420 mg, 7.52 mmol) and ammonium chloride (396 mg, 7.4 mmol)
in ethanol (10 mL) and water (2 mL) was stirred at 80.degree. C.
for 2 h. After filtration and concentration, the residue was
purified by silica gel column chromatography using ethyl
acetate:petroleum ether (20%-50%) to afford tert-butyl
4-[(4-amino-3-pyridyl)oxy]piperidine-1-carboxylate as a yellow
solid (110 mg, 97%). MS (ESI): m/z=464.3 [M+1].sup.+.
Step F.
N-(2,2-Dimethyl-6-(4-(2,2,2-trifluoro-1-((4-methoxybenzyl)amino)et-
hyl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxamide
##STR00788##
[0585] A mixture of
2,2-dimethyl-6-[4-[2,2,2-trifluoro-1-[(4-methoxyphenyl)methylamino]ethyl]-
-1-piperidyl]-3H-benzofuran-5-amine (105 mg, 0.23 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (60 mg, 0.37 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (140 mg, 0.37 mmol) and diisopropyethylamine
(165 mg, 1.28 mmol) in DMF (5 mL) was stirred at 25.degree. C. for
3 h. The mixture was purified by preparative HPLC to afford
N-[2,2-dimethyl-6-[4-[2,2,2-trifluoro-1-[(4-methoxyphenyl)methylamino]eth-
yl]-1-piperidyl]-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e (95 mg, 66%) as a yellow solid. MS (ESI): m/z=609.3
[M+1].sup.+.
Step G.
N-[6-[4-(1-Amino-2,2,2-trifluoro-ethyl)-1-piperidyl]-2,2-dimethyl--
3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00789##
[0587] A mixture of
N-[2,2-dimethyl-6-[4-[2,2,2-trifluoro-1-[(4-methoxyphenyl)
methylamino]ethyl]-1-piperidyl]-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (90 mg, 0.15 mmol) and 2,2,2-trifluoroacetic acid
(1.5 mL) was stirred at 85.degree. C. for 1 h. The reaction was
basified to pH 8 with 2N ammonia in methanol. Upon concentration,
the residue was purified by preparative HPLC (Xbridge 21.2*250 mm
c18, 10 um; A: acetonitrile 25-55%; B: 10 mM ammonium bicarbonate
in water) to afford
N-[6-[4-(1-amino-2,2,2-trifluoro-ethyl)-1-piperidyl]-2,2-dimethyl-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (29.4 mg, 41%)
as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.47 (s, 1H), 9.35 (dd, J=1.6, 7.2 Hz, 1H), 9.13 (dd, J=1.6, 4.4
Hz, 1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.30 (dd, J=4.4, 7.2 Hz, 1H),
6.69 (s, 1H), 3.24-3.12 (m, 1H), 3.03-2.90 (m, 4H), 2.74-2.56 (m,
2H), 2.10-1.87 (m, 3H), 1.84-1.55 (m, 4H), 1.408 (s, 6H). MS (ESI):
m/z=489.3 [M+1].sup.+.
Example 25.
N-(2-(Methoxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyr-
azolo[1,5-a]pyrimidine-3-carboxamide
##STR00790##
[0588] Step A.
(2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00791##
[0590] A mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 2) (310.0 mg, 1.27 mmol) and morpholine (10 mL) was
stirred at 120.degree. C. for 18 h. The reaction was concentrated
to dryness. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:4 to 2:3) to afford
(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)methanol (239 mg,
64%) as an orange oil. MS (ESI): m/z=295.1 [M+1].sup.+.
Step B.
4-(2-(Methoxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)m-
orpholine
##STR00792##
[0592] To a solution of
(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)methanol (81.0
mg, 0.28 mmol) in THF (3 mL) was added sodium hydride (9.91 mg,
0.41 mmol) at 0.degree. C. The mixture was stirred for 20 min.
Methyl iodide (87.9 mg, 0.62 mmol) was added and the mixture was
warmed to room temperature while stirring for 18 h. Ethyl acetate
(10 mL) and saturated ammonium chloride were added. The organic
phase was separated and dried over sodium sulfate before
concentration to afford
4-[2-(methoxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(121 mg), which was used directly to next step without further
purification. MS (ESI): m/z=309.1 [M+1].sup.+.
Step C.
2-(Methoxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-am-
ine
##STR00793##
[0594] A mixture of
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methanol
(121.0 mg, 0.39 mmol) and 10% palladium on carbon (10 mg) in
methanol (30 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 2 h. The reaction was filtered and the filtrate was
concentrated in vacuo to afford
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methanol
(106 mg) as a red oil, which was used directly to next step without
further purification. MS (ESI): m/z=279.3 [M+1].sup.-.
Step D.
N-(2-(Methoxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00794##
[0596] To a solution of
2-(methoxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine
(106.0 mg, 0.38 mmol) in DMF (10 mL) under nitrogen atmosphere at
0.degree. C. was added
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylp-
hosphonium hexafluorophosphate (218.4 mg, 0.42 mmol) followed by
2,4,6-trimethylpyridine (50.76 mg, 0.42 mmol).
Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (71.44 mg, 0.44 mmol)
was then introduced and the ice bath was removed allowing the
reaction to stir at room temperature for 18 h. After concentration,
the residue was purified by preparative HPLC (Xbridge Prep C18 10
um OBD, 19*250 mm, A: acetonitrile 45-75% and 0.01% NH.sub.3; B: 10
mM ammonium bicarbonate in water) to afford
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methanol
(34.9 mg, 22%) as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 10.47 (s, 1H), 8.61 (dd, J=1.6, 5.6 Hz, 1H),
8.78 (s, 1H), 8.75 (dd, J=1.6, 3.6 Hz, 1H), 8.42 (s, 1H), 7.07 (dd,
J=3.6, 5.6 Hz, 1H), 6.69 (s, 1H), 3.98-3.90 (m, 4H), 3.47 (s, 2H),
3.43 (s, 3H), 3.22 (d, J=12.8 Hz, 1H), 2.95-2.88 (m, 5H), 1.48 (s,
3H). MS (ESI): m/z=424.1 [M+1].sup.+.
Example 26.
N-[6-(4,4-Difluoro-1-piperidyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00795##
[0597] Step A.
[6-(4,4-Difluoro-1-piperidyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methano-
l
##STR00796##
[0599] The mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 2) (104.0 mg, 0.43 mmol), 4,4-difluoropiperidine
hydrochloride (670.0 mg, 4.25 mmol) and cesium carbonate (920.0 mg,
2.82 mmol) in DMSO (5 mL) was stirred at 90.degree. C. for 16 h.
The mixture was poured into water and the aqueous phase was
extracted with ethyl acetate (150 mL). The organic phase was washed
with water and brine and dried over sodium sulfate before
concentration to dryness. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:3) as eluting
solvents to afford
[6-(4,4-difluoro-1-piperidyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methano-
l(100 mg, 71%) as a brown oil. MS (ESI): m/z=329.1 [M+1].sup.+.
Step B.
[5-Amino-6-(4,4-difluoro-1-piperidyl)-2-methyl-3H-benzofuran-2-yl]-
methanol
##STR00797##
[0601] The mixture of
[6-(4,4-difluoro-1-piperidyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methano-
l (63.0 mg, 0.19 mmol) and 10% palladium on carbon (28.0 mg) in
methanol (8 mL) was stirred under hydrogen atmosphere at 20.degree.
C. for 1 h. After filtration and concentration, it was afforded
[5-amino-6-(4,4-difluoro-1-piperidyl)-2-methyl-3H-benzofuran-2-yl]methano-
l (55 mg) as a brown oil, which was used directly in the next step
without purification. MS (ESI): m/z=299.1 [M+1].sup.+.
Step C.
N-[6-(4,4-Difluoro-1-piperidyl)-2-(hydroxymethyl)-2-methyl-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00798##
[0603] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (45.0 mg, 0.28 mmol) and diisopropyethylamine (0.09 mL, 0.56
mmol) in DMF (2 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (141.0 mg, 0.37 mmol) and the mixture was
stirred at 20.degree. C. for 30 min. To the mixture was added the
solution of
[5-amino-6-(4,4-difluoro-1-piperidyl)-2-methyl-3H-benzofuran-2-yl]methano-
l (55.0 mg, 0.18 mmol) in DMF (2 mL) and the mixture was stirred at
20.degree. C. for 16 h. After concentration, the residue was
purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 5-75%; B: 10 mM ammonium bicarbonate in water) to
afford
N-[6-(4,4-difluoro-1-piperidyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 43%) as a
yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.43 (s,
1H), 9.39 (dd, J=2.0, 6.8 Hz, 1H), 8.75 (dd, J=2.0, 4.4 Hz, 1H),
8.70 (s, 1H), 8.32 (s, 1H), 7.37 (dd, J=4.0, 6.8 Hz, 1H), 6.73 (s,
1H), 5.05 (t, J=6.0 Hz, 1H), 3.49-3.37 (m, 2H), 3.20 (d, J=16.0 Hz,
1H), 2.98-2.90 (m, 4H), 2.83 (d, J=16.0 Hz, 1H), 2.34-2.14 (m, 4H),
1.34 (s, 3H). MS (ESI): m/z=444.1 [M+1].sup.+.
Examples 27 and 28.
(R)--N-(3-hydroxy-3-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide and
(S)--N-(3-hydroxy-3-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide
##STR00799##
[0604] Step A. 2-Chloro-4-((2-methylallyl)oxy)-1-nitrobenzene
##STR00800##
[0606] To a solution of 3-chloro-4-nitrophenol (25.2 g, 145 mmol)
in acetonitrile (184 mL) was added 3-bromo-2-methylpropene (16.1
mL, 159 mmol) and potassium carbonate (28.0 g, 203 mmol). The
reaction mixture was stirred at 55.degree. C. for 18 h. The mixture
was diluted with isopropyl acetate, filtered and the precipitate
was washed with isopropyl acetate and dichloromethane. The combined
filtrates were concentrated under reduced pressure and purified by
silica gel chromatography eluting using (3:1) isopropyl
acetate/MeOH in heptanes (0-40%) as eluting solvents to afford the
title compound as a light yellow oil (32.712 g, 99%). .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.10 (d, J=9.1 Hz, 1H), 7.34 (d, J=2.7
Hz, 1H), 7.14 (dd, J=9.2, 2.7 Hz, 1H), 5.13-5.03 (m, 1H), 5.05-4.97
(m, 1H), 4.66 (s, 2H), 1.83-1.68 (m, 3H).
Step B. 4-(5-((2-Methylallyl)oxy)-2-nitrophenyl)morpholine
##STR00801##
[0608] To a mixture of
2-chloro-4-((2-methylallyl)oxy)-1-nitrobenzene (3.01 g, 13.2 mmol),
and potassium carbonate (6.03 g, 43.7 mmol) in dimethyl sulfoxide
(20.1 mL, 280 mmol) was added morpholine (1.15 g, 13.2 mmol) and
the mixture was heated to 100.degree. C. in a sealed tube for 1 h.
The mixture was cooled to room temperature and diluted with water
and ethyl acetate. The organic phase was washed with saturated
sodium bicarbonate solution, water and brine and dried over sodium
sulfate before concentration under reduced pressure. The crude
residue was purified by silica gel chromatography using 0-50%
isopropyl acetate in heptane as the eluting solvents to afford the
title compound as a bright yellow solid (3.22 g, 11.6 mmol, 88%).
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.90 (d, J=9.0 Hz, 1H), 6.71
(d, J=2.6 Hz, 1H), 6.68 (dd, J=9.0, 2.6 Hz, 1H), 5.08 (d, J=0.8 Hz,
1H), 4.99 (s, 1H), 4.59 (s, 2H), 3.76-3.63 (m, 4H), 3.06-2.95 (m,
4H), 1.82-1.72 (m, 3H).
Step C. 2-(2-methylallyl)-5-morpholino-4-nitrophenol
##STR00802##
[0610] 4-(5-((2-Methylallyl)oxy)-2-nitrophenyl)morpholine (5.0 g,
18 mmol) was dissolved in DMF (15 mL, 190 mmol) and heated at
220.degree. C. in the microwave for 60 min in quintuplicate. The
reaction mixtures were combined, concentrated under reduced
pressure and brought up in isopropyl acetate and washed with water
and brine. The aqueous layer was extracted with isopropyl acetate.
The combined organic phases were dried over sodium sulfate before
concentration under reduced pressure. The crude residue was
purified by silica gel chromatography using 0-50% isopropyl acetate
in heptane to afford the title compound as a dark orange oil (3.53
g, 12.7 mmol, 12%). .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.72
(s, 1H), 7.74 (s, 1H), 6.59 (s, 1H), 4.80-4.74 (m, 1H), 4.67-4.60
(m, 1H), 3.71 (q, J=4.0, 3.6 Hz, 4H), 3.20 (s, 2H), 2.95-2.90 (m,
4H), 1.66 (s, 3H). .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.82
(s, 1H), 6.54 (s, 1H), 6.02 (s, 1H), 5.03-4.96 (m, 1H), 4.94-4.92
(m, 1H), 3.92-3.83 (m, 4H), 3.36 (s, 2H), 3.04 (dd, J=5.5, 3.7 Hz,
4H), 1.75 (s, 3H).
Step D. 1-(2-Hydroxy-4-morpholino-5-nitrophenyl)propan-2-one
##STR00803##
[0612] To a solution of
2-(2-methylallyl)-5-morpholino-4-nitrophenol (3.77 g, 13.5 mmol) in
water (169 mL, 9.40 mol) and dioxane (521 mL, 6.1 mol) was first
added osmium tetroxide (0.08 mol/L, catalytic) in tert-butyl
alcohol (700 mg, 0.677 mml) followed by sodium periodate (5.79 g,
27.1 mmol). The suspension formed was stirred overnight at room
temperature and poured onto water. The aqueous layer was acidified
to neutral pH with 1M HCl and extracted into DCM. The organic phase
was dried over sodium sulfate before concentration under reduced
pressure. The crude residue was purified by silica gel
chromatography using 0-100% isopropyl acetate in heptane to afford
the title compound (1.95 g, 6.94 mmol, 51%). .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.26 (s, 1H), 7.78 (s, 1H), 6.61 (s, 1H),
3.89-3.79 (m, 4H), 3.73 (s, 2H), 3.08-2.99 (m, 4H), 2.36 (s,
3H).
Step E. 1-(2-Methoxy-4-morpholino-5-nitrophenyl)propan-2-one
##STR00804##
[0614] A suspension of sodium hydride (60% in oil, 319 mg, 7.98
mmol) in anhydrous tetrahydrofuran (19.8 mL, 243 mmol) was heated
to reflux. Dimethylsulfoxide (19.8 mL, 280 mmol) was slowly added
and the reaction was continued for 15 min at reflux. The mixture
was then cooled to ambient temperature and trimethylsulfoxonium
iodide (1.70 g, 243 mmol) was added. Stirring was continued for 30
min at room temperature. A solution of
1-(2-Hydroxy-4-morpholino-5-nitrophenyl)propan-2-one (1.44 g, 5.15
mmol) dissolved in tetrahydrofuran (5.48 mL) was added and the
reaction mixture was stirred at room temperature for 30 min
followed by heating at 50.degree. C. for 18 h. Water was then added
and the mixture was extracted with DCM (6.times.). The combined
organic phases were washed water (3.times.), and dried over sodium
sulfate before concentration under reduced pressure. The crude
residue was purified by silica gel chromatography using 0-100%
isopropyl acetate in heptane to afford the crude product as a
yellow foam/oil residue.
Step F. 1-(5-Amino-2-methoxy-4-morpholinophenyl)propan-2-one
##STR00805##
[0616] 1-(2-Methoxy-4-morpholino-5-nitrophenyl)propan-2-one (1.03
g, 3.51 mmol) was dissolved in ethanol (17.2 mL, 295 mmol) and
treated with 10% palladium activated carbon (373 mg, 0.3509 mmol)
and the flask was put under a hydrogen atmosphere. After 4 h the
reaction mixture was filtered through celite and concentrated under
reduced pressure. The crude material was carried on without further
purification.
Step G.
(R)--N-(3-hydroxy-3-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide and
(S)--N-(3-hydroxy-3-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide
##STR00806##
[0618] A 100 mL RBF equipped with a stir bar was charged with
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (745 mg, 4.335 mmol)
and purged with nitrogen. DMF (12.4 mL, 161 mmol) was added and the
mixture was cooled 0.degree. C.
(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (2.28 g, 4.146 mmol) was then added, followed
by 2,4,6-trimethylpyridine (0.55 mL, 4.146 mmol). Crude
1-(5-amino-2-methoxy-4-morpholinophenyl)propan-2-one (1.000 g, 3.77
mmol) was then introduced and the reaction was allowed to stir at
room temperature for 18 h. The reaction mixture was filtered
through a plug of silica and concentrated under reduced pressure.
The crude material was purified and resolved via Chiral SFC to
afford the title compounds as yellow solids. Stereochemistry was
arbitrarily assigned based on peak elution.
[0619] Example 27, Peak 1 (37 mg, 2.5%): Purified via Chiral SFC
(Thar 350 SFC (Lux Cellulose-1, 30.times.250 mm, 5 um), 40% MeOH
isocratic (0.10% NH.sub.4OH) in CO2). .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.37 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95
(dd, J=4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.16 (s, 1H), 7.34 (dd,
J=7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 4.83 (s, 1H), 3.90-3.80 (m, 4H),
3.76 (s, 2H), 2.87-2.79 (m, 4H), 2.76-2.60 (m, 2H), 1.20 (s, 3H).
MS (ESI): m/z=410.2 [M+1].sup.+.
[0620] Example 28, Peak 2 (41 mg, 2.7%): Purified via Chiral SFC
(Thar 350 SFC (Chiral Technologies AD-H, 50.times.250 mm, 5 um),
40% MeOH isocratic (0.1% NH.sub.4OH) in CO2) .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.37 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95
(dd, J=4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.16 (s, 1H), 7.34 (dd,
J=7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 4.83 (s, 1H), 3.88-3.79 (m, 4H),
3.76 (s, 2H), 2.89-2.76 (m, 4H), 2.76-2.58 (m, 2H), 1.20 (s, 3H).
MS (ESI): m/z=410.2 [M+1].sup.+.
Examples 29 and 30.
(R)--N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-y-
l)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-y-
l)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00807##
[0622] A solution of 6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (58 mg, 0.33 mmol) in DMF (1.0 mL) was purged with nitrogen
and cooled to 0.degree. C.
(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (170 mg, 0.31 mmol) was then added followed by
2,4,6-trimethylpyridine (0.04 mL, 0.31 mmol).
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(75 mg, 0.28 mmol) was then introduced and the reaction was allowed
to warm to ambient temperature and stirred for 18 h. The reaction
mixture was filtered through a plug of silica, washed with a
solution of 20% methanol in DCM. The filtrate was then concentrated
and purified and resolved via chiral SFC (PIC 100 SFC (Lux
Cellulose-3, 21.1*150 mm, 5 um), 25% MeOH isocratic (0.1%
NH.sub.4OH) in CO2) to afford the title compounds as solids.
Stereochemistry was arbitrarily assigned based on peak elution.
[0623] Example 29, Peak 1: (23 mg, 20%): .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.37 (s, 1H), 9.23 (dd, J=2.0, 1.1 Hz, 1H), 8.86
(d, J=2.0 Hz, 1H), 8.59 (s, 1H), 8.29 (s, 1H), 6.69 (s, 1H), 5.03
(t, J=5.8 Hz, 1H), 3.89-3.80 (m, 4H), 3.42 (q, J=5.5 Hz, 2H), 3.20
(d, J=16.5 Hz, 1H), 2.88-2.77 (m, 5H), 2.47-2.41 (m, 3H), 1.34 (s,
3H). MS (ESI): m/z=424.2[M+1].sup.+.
[0624] Example 30, Peak 2: (23 mg, 20%): .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.37 (s, 1H), 9.23 (dd, J=2.0, 1.1 Hz, 1H), 8.86
(d, J=2.0 Hz, 1H), 8.59 (s, 1H), 8.29 (s, 1H), 6.69 (s, 1H), 5.03
(t, J=5.8 Hz, 1H), 3.89-3.80 (m, 4H), 3.42 (q, J=5.5 Hz, 2H), 3.20
(d, J=16.5 Hz, 1H), 2.88-2.77 (m, 5H), 2.47-2.41 (m, 3H), 1.34 (s,
3H). MS (ESI): m/z=424.2[M+1].sup.+.
Examples 31 and 32.
(R)--N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-y-
l)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-y-
l)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00808##
[0626]
N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 6) was resolved
via chiral SFC (PIC 100 SFC (Lux Cellulose-3, 21.1*150 mm, 5 um),
25% MeOH isocratic (0.1% NH.sub.4OH) in CO.sub.2) to afford the
title compounds as solids. Stereochemistry was arbitrarily assigned
based on peak elution.
[0627] Example 31, Peak 1: .sup.1HNMR (400 MHz, DMSO-d6) .delta.
10.43 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.94 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.29 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H),
6.70 (s, 1H), 5.10-4.98 (m, 1H), 3.91-3.74 (m, 4H), 3.43 (t, J=5.7
Hz, 2H), 3.20 (dd, J=15.9, 0.7 Hz, 1H), 2.90-2.73 (m, 5H), 1.34 (s,
3H). MS (ESI): m/z=410.2 [M+1].sup.+. Example 32, Peak 2: .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 10.43 (s, 1H), 9.37 (dd, J=7.0, 1.6
Hz, 1H), 8.94 (dd, J=4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.29 (s, 1H),
7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 5.10-4.98 (m, 1H),
3.91-3.74 (m, 4H), 3.43 (t, J=5.7 Hz, 2H), 3.20 (dd, J=15.9, 0.7
Hz, 1H), 2.90-2.73 (m, 5H), 1.34 (s, 3H). MS (ESI): m/z=410.2
[M+1].sup.+.
Example 33.
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide
##STR00809##
[0628] Step A.
4-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
##STR00810##
[0630] 2-(2-Methylallyl)-5-morpholino-4-nitrophenol (1.0 g, 3.6
mmol) was dissolved in MeOH (12 mL) and cooled to 0.degree. C. A
solution of 35% aqueous HCl (12 mL) was added and the reaction
mixture was allowed to warm to ambient temperature and then heated
at reflux for 60 h. The reaction was cooled to room temperature,
neutralized with saturated sodium bicarbonate and extracted with
isopropyl acetate. The organic phase was dried over sodium sulfate,
filtered, and absorbed onto celite under reduced pressure. The
crude residue was purified by silica gel chromatography using
(0-30%) isopropyl acetate in heptane to afford the title compound
as a yellow foam/oil residue (520 mg, 1.87 mmol, 52%). .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 7.85 (t, J=1.2 Hz, 1H), 6.60 (s, 1H),
3.76-3.61 (m, 4H), 3.01 (d, J=1.1 Hz, 2H), 2.98-2.90 (m, 4H), 1.44
(s, 6H). .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.85 (t, J=1.2
Hz, 1H), 6.44 (s, 1H), 3.90-3.79 (m, 4H), 3.05-3.01 (m, 4H), 3.00
(d, J=1.1 Hz, 2H), 1.51 (s, 6H).
Step B. 2,2-Dimethyl-6-morpholino-3H-benzofuran-5-amine
##STR00811##
[0632] The mixture of
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)morpholine (60 mg, 0.22
mmol) and 10% palladium on carbon (30 mg) in methanol (8 mL) was
stirred under hydrogen atmosphere at 25.degree. C. for 1 h. After
filtration through a plug of celite and concentration, it was
afforded 2,2-dimethyl-6-morpholino-3H-benzofuran-5-amine (50 mg) as
a yellow oil, which was directly used in the next step without
purification. MS (ESI): m/z=249.2[M+1].sup.+.
Step C.
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide
##STR00812##
[0634] A solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(370 mg, 2.1 mmol) in DMF (6.2 mL) was purged with nitrogen and
cooled to 0.degree. C.
(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (1.1 g, 2.1 mmol) was then added followed by
2,4,6-trimethylpyridine (0.27 mL, 2.1 mmol).
2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-amine (460 mg,
1.9 mmol) was then introduced and the reaction was allowed to warm
to ambient temperature and stirred for 18 h. The reaction mixture
was filtered through a plug of silica, washed with 20% methanol in
DCM and the filtrate was then concentrated and purified via
Prep-HPLC ((Gemini-NX 50*30 mm c18, 5 um, 110 A), acetonitrile
20-60% (0.1% NH.sub.4OH) in water) to afford 330 mg of the title
compound as a solid. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.43
(s, 1H), 9.41-9.32 (m, 1H), 8.98-8.91 (m, 1H), 8.68 (s, 1H), 8.31
(s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.89-3.77 (m,
4H), 3.04-2.96 (m, 2H), 2.86-2.78 (m, 4H), 1.42 (s, 6H). MS (ESI):
m/z=394.2 [M+1].sup.+.
Example 34.
N-(6-Methoxy-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrim-
idine-3-carboxamide
##STR00813##
[0635] Step A.
6-Methoxy-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran
##STR00814##
[0637] The mixture of cesium carbonate (300.0 mg, 0.92 mmol),
palladium diacetate (12.8 mg, 0.06 mmol),
6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran (Intermediate 1) (156.0
mg, 0.57 mmol) and
racemic-2-(di-tert-butylphosphino)-1,1'-binaphthyl (228.2 mg, 0.57
mmol) in methanol (0.50 mL) and toluene (5.0 mL) was heated in a
sealed tube at 80.degree. C. under microwave condition for 3 h. The
reaction was concentrated to dryness under reduced pressure and
then purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:10) to afford
6-methoxy-2,2-dimethyl-5-nitro-3H-benzofuran (155 mg, 97%) as red
solid. MS (ESI): m/z=224.2 [M+1].sup.+.
Step B. 6-Methoxy-2,2-dimethyl-2,3-dihydrobenzofuran-5-amine
##STR00815##
[0639] A mixture of 10% palladium on carbon (31.0 mg) and
6-methoxy-2,2-dimethyl-5-nitro-3H-benzofuran (155.0 mg, 0.69 mmol)
in methanol (15 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 2 h. After filtration over a plug of celite and
concentration under reduced pressure,
6-methoxy-2,2-dimethyl-3H-benzofuran-5-amine (111 mg, 62%) was
afforded as a yellow oil.
[0640] MS (ESI): m/z=194.2 [M+1].sup.+.
Step C.
N-(6-Methoxy-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00816##
[0642] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(107.76 mg, 0.66 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(329.44 mg, 0.63 mmol), N-ethyl-N-isopropylpropan-2-amine (222.72
mg, 1.72 mmol) and 6-methoxy-2,2-dimethyl-3H-benzofuran-5-amine
(111.0 mg, 0.57 mmol) in DMF (10 mL) was stirred at room
temperature for 18 h. After filtration and concentration, the
residue was purified by preparative HPLC reverse phase
chromatography (phenomenex, Gemini C18, 21.2.times.100 mm. 5 um,
110 A, A: acetonitrile 25-45%; B: 0.05% formic acid in water) to
afford
N-(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyr-
imidine-3-carboxamide (110 mg, 57%) as a yellow solid. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 10.04 (s, 1H), 8.80 (dd, J=1.6, 7.2
Hz, 1H), 8.75 (s, 1H), 8.71 (dd, J=1.6, 4.0 Hz, 1H), 8.29 (s, 1H),
7.02 (dd, J=4.0, 7.2 Hz, 1H), 6.43 (s, 2H), 3.91 (s, 3H), 3.02 (s,
2H), 1.49 (s, 6H). MS (ESI): m/z=339.2 [M+1].sup.+.
Example 35.
N-(8-Morpholino-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR00817##
[0643] Step A. N-(4-Chloro-2-hydroxyphenyl)benzamide
##STR00818##
[0645] To a solution of 2-amino-5-chlorophenol (1.45 g, 10.1 mmol)
in ethyl acetate (30 mL) and water (30 mL) was added sodium
bicarbonate (1.27 g, 15.15 mmol) and benzoyl chloride (1.42 g, 10.1
mmol). The mixture was stirred at room temperature for 1 h. The
organic phase was washed with brine, dried over sodium sulfate and
concentrated in vacuo. The residue was washed with petroleum ether
to afford N-(4-chloro-2-hydroxy-phenyl)benzamide (2.34 g, 94%) as a
brown solid. MS (ESI): m/z=248.1 [M+1].sup.+.
Step B.
(8-Chloro-3,4-dihydrobenzo[b][1,4]oxazepin-5(2H)-yl)(phenyl)methan-
one
##STR00819##
[0647] To a solution of N-(4-chloro-2-hydroxy-phenyl)benzamide
(2.08 g, 8.4 mmol) in acetonitrile (16 mL) and DCM (24 mL) was
added 1,3-dibromopropane (6781.83 mg, 33.59 mmol) and aliquot 336
(tri-n-octylmethylammonium chloride) (339.41 mg, 0.84 mmol). Then
sodium hydride (1343.67 mg, 33.59 mmol, 60% wt with mineral oil)
were added. The mixture was heated at 60.degree. C. for 3 h.
Saturated ammonium chloride solution was added. The aqueous phase
was extracted with ethyl acetate (2.times.200 mL). The combined
organic phases were washed with brine and dried over sodium
sulfate. After filtration and concentration, the residue was
purified by silica gel column eluted ethyl acetate:petroleum ether
(1:1) to afford
(8-chloro-3,4-dihydro-2H-1,5-benzoxazepin-5-yl)-phenyl-methanone
(1.3 g, 54%) as off-white solid. MS (ESI): m/z=288.1
[M+1].sup.+.
Step C. 8-Chloro-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine
##STR00820##
[0649]
(8-Chloro-3,4-dihydro-2H-1,5-benzoxazepin-5-yl)-phenyl-methanone
(1.0 g, 3.48 mmol) was dissolved in 1,4-dioxane (20 mL) and 6 m
hydrogen chloride solution (87.11 mL, 522.66 mmol) was added. The
mixture was heated at reflux for 20 h. Saturated ammonium chloride
solution was added and the aqueous phase was extracted with ethyl
acetate (100 mL). The organic extract was washed with brine and
dried over sodium sulfate. After filtration and concentration under
reduced pressure, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:3) as eluting
solvents to afford
(8-chloro-3,4-dihydro-2H-1,5-benzoxazepin-5-yl)-phenyl-methanone
(808 mg, 100%) as a brown solid. MS (ESI): m/z=184.1
[M+1].sup.+.
Step D.
8-Chloro-7-nitro-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine
##STR00821##
[0651] To a solution of
8-chloro-2,3,4,5-tetrahydro-1,5-benzoxazepine (183.0 mg, 1 mmol) in
concentrated sulfuric acid (4 mL) was slowly added guanidine
nitrate (121.58 mg, 1 mmol) at 0.degree. C. The reaction was
stirred for 30 min. The mixture was poured into ice water. The
solution was adjusted to pH=7.0 by saturated aqueous sodium
carbonate. The aqueous phase was extracted with ethyl acetate (30
mL). The organic phase wash was concentrated under reduced pressure
to afford 8-chloro-7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine
(185 mg) as a red solid, which was used directly to next step
without further purification. MS (ESI): m/z=229.0 [M+1].sup.+.
Step E.
8-Morpholino-7-nitro-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine
##STR00822##
[0653] A mixture of
8-chloro-7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine (185.0 mg,
0.81 mmol) and morpholine (10 mL) was stirred at 120.degree. C. for
18 h. After concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:5 to 1:3) to
afford 8-morpholino-7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine
(193 mg, 64.1%) as orange solid. MS (ESI): m/z=280.1
[M+1].sup.+.
Step F.
8-Morpholino-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-amine
##STR00823##
[0655] A mixture of 10% palladium on carbon (40.0 mg) and
8-morpholino-7-nitro-2,3,4,5-tetrahydro-1,5-benzoxazepine (193.0
mg, 0.69 mmol) in methanol (15 mL) was stirred at 25.degree. C.
under hydrogen atmosphere for 2 h. After filtration and
concentration in vacuo, it was afforded
8-morpholino-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-amine (154 mg,
89%) as a red oil. MS (ESI): m/z=20.1 [M+1].sup.+.
Step G.
N-(8-Morpholino-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR00824##
[0657] A mixture of
8-morpholino-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-amine (193.0 mg,
0.77 mmol) and triethylamine (235.0 mg, 2.32 mmol) in DCM (10 mL)
was stirred at 0.degree. C. To this mixture was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(210.85 mg, 1.16 mmol) and then the reaction was stirred at
25.degree. C. for 1 h. After concentration under reduced pressure,
the residue was purified by preparative HPLC (Phenomenex, Gemini
C18, 21.2.times.100 mm. 5 um, 110 A, A: acetonitrile 25-45%; B:
0.05% formic acid in water) to afford
N-(8-morpholino-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide (35 mg, 12%) as dark yellow solid. .sup.1H
NMR (400 MHz, CDCl3): .delta. 10.60 (s, 1H), 8.83 (dd, J=1.6, 7.2
Hz, 1H), 8.79-8.76 (m, 1H), 8.20 (s, 1H), 7.07 (dd, J=4.0, 7.2 Hz,
1H), 6.88 (s, 1H), 4.07 (t, J=5.6 Hz, 2H), 3.98-3.93 (m, 4H), 3.22
(t, J=5.6 Hz, 2H), 2.92-2.85 (m, 4H), 2.04-1.96 (m, 2H). m/z=395.1
[M+1].sup.+.
Example 36 and 37.
(R)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00825##
[0658] Step A.
(6-(2,2-Dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol
##STR00826##
[0660] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Intermediate 2) (130 mg, 0.53 mmol) in 2,2-dimethylmorpholine (0.5
mL) was stirred at 100.degree. C. for 18 h in a sealed tube. After
concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:1) as eluting
solvents to afford
(6-(2,2-dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol (95 mg, 55%) as a yellow solid. MS (ESI): m/z=323.3
[M+1].sup.+.
Step B.
(5-Amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-
-2-yl)methanol
##STR00827##
[0662] A mixture of
(6-(2,2-dimethylmorpholino)-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)m-
ethanol (95 mg, 0.29 mmol) and 10% palladium on carbon (10 mg) in
methanol (5 mL) was stirred at room temperature for 1 h under an
atmosphere of hydrogen. The reaction was then filtered over a plug
of celite and the filtrate was concentrated under reduced pressure
to afford
(5-amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-2-yl)m-
ethanol (55 mg), which was used directly in the next step without
purification. MS (ESI): m/z=293.1 [M+1].sup.+.
Step C.
(R)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3--
dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00828##
[0664] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (31
mg, 0.19 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(98 mg, 0.19 mmol) and collidine (68 mg, 0.57 mmol) in DMF (5 mL)
was stirred at room temperature for 30 min.
(5-amino-6-(2,2-dimethylmorpholino)-2-methyl-2,3-dihydrobenzofuran-2-yl)m-
ethanol (55 mg, 0.19 mmol) was added. The resulting mixture was
stirred at room temperature for 18 h. After concentration, the
residue was purified by preparative HPLC(Xbridge Prep C.sub.18 10
um OBD, 19*250 mm, 10 um; A: acetonitrile 45-75% and 0.01%
NH.sub.3; B: 10 mM ammonium bicarbonate in water) to afford
N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide as a yellow
solid (50 mg, 0.11 mmol, 61%). The enantiomers were then resolved
by chiral SFC to give
(R)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-di-
hydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide with
absolute stereochemistry assigned arbitrarily.
[0665] Example 36, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.97 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.84 (dd,
J=4.2, 1.7 Hz, 1H), 8.69 (s, 1H), 8.19 (d, J=0.9 Hz, 1H), 7.33 (dd,
J=7.0, 4.2 Hz, 1H), 6.60 (s, 1H), 5.07-4.99 (m, 1H), 3.79 (d, J=4.6
Hz, 2H), 3.43 (t, J=5.8 Hz, 2H), 3.23-3.16 (m, 1H), 2.82 (dd,
J=15.6, 1.1 Hz, 1H), 2.71 (s, 2H), 2.65 (s, 2H), 1.38-1.32 (m, 9H).
MS (ESI): m/z=438.2 [M+1].sup.+.
[0666] Example 37, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.97 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.84 (dd,
J=4.2, 1.7 Hz, 1H), 8.69 (s, 1H), 8.19 (d, J=0.9 Hz, 1H), 7.33 (dd,
J=7.0, 4.2 Hz, 1H), 6.60 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.79 (d,
J=5.8 Hz, 2H), 3.48-3.38 (m, 2H), 3.20 (ddt, J=15.6, 0.9, 0.5 Hz,
1H), 2.86-2.77 (m, 1H), 2.71 (s, 2H), 2.65 (d, J=5.3 Hz, 2H), 1.35
(d, J=4.4 Hz, 9H). MS (ESI): m/z=438.2 [M+1].sup.+.
Example 38.
2-Methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-2-carboxylic acid
##STR00829##
[0667] Step A. Methyl
6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
##STR00830##
[0669] A mixture of
6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylic acid
(Intermediate 2, Step C) (1.60 g, 6.21 mol), methyl iodide (1.76 g,
12.42 mmol) and potassium carbonate (1.72 g, 12.42 mmol) in DMF (10
mL) was stirred at room temperature. Water and ethyl acetate (50
mL) was added upon consumption of starting material. The organic
phase was separated and dried over sodium sulfate. After filtration
and concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (from 1:6 to
1:4) as eluting solvents to afford methyl
6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate (550
mg, 33%) as orange solid. MS (ESI): m/z=272.1 [M+1].sup.+.
Step B.
2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR00831##
[0671] A mixture of methyl
6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-carboxylate (550
mg, 2.02 mmol) in morpholine (3 mL) was stirred at 110.degree. C.
for 18 h in a sealed tube. The mixture was concentrated under
reduced pressure to afford
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid (260 mg) as a yellow oil, which was used directly in the next
step without purification. MS (ESI): m/z=309.1 [M+1].sup.+.
Step C. Methyl
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
##STR00832##
[0673] A mixture of
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid (260 mg, 0.84 mol), iodomethane (239 mg, 1.69 mmol) and
potassium carbonate (233 mg, 1.69 mmol) in DMF (10 mL) was stirred
at room temperature. Upon consumption of starting material, water
and ethyl acetate (50 mL) were added. The organic phase was
separated and dried over sodium sulfate. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:4 to 1:2) as eluting solvents to
afford methyl
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
(200 mg, 74%) as orange solid. MS (ESI): m/z=323.2 [M+1].sup.+.
Step D. Methyl
5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxylate
##STR00833##
[0675] A mixture of methyl
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
(200 mg, 0.62 mmol) and 10% palladium on carbon (20 mg) in methanol
(10 mL) was stirred at room temperature for 1 h under an atmosphere
of hydrogen. The reaction was then filtered over a plug of celite
and the filtrate was concentrated under reduced pressure to afford
methyl
5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxylate
as a white solid (150 mg), which was used directly to the next step
without purification. MS (ESI): m/z=292.3 [M+1].sup.+.
Step E. Methyl
2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-2-carboxylate
##STR00834##
[0677] A mixture of methyl
5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxylate
(150 mg, 0.51 mmol) and triethylamine (103 mg, 1.02 mmol) in DCM
(10 mL) was stirred at 0.degree. C. To the mixture was added a
solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example
3, Step B) (93 mg, 0.51 mmol) in DCM (10 mL) and then the reaction
was stirred at 25.degree. C. for 1 h. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:1 to 10:1) as eluting solvents to
afford methyl
2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-2-carboxylates a white solid (160 mg, 71%). MS
(ESI): m/z=438.1 [M+1].sup.+.
Step F.
2-Methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)--
2,3-dihydrobenzofuran-2-carboxylic acid
##STR00835##
[0679] A mixture of methyl
2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-2-carboxylate (70 mg, 0.16 mmol) and sodium
hydroxide (13 mg, 0.32 mmol) in THF (5 mL) and water(1 mL) was
stirred at 25.degree. C. for 1 h. The reaction was then purified by
preparative HPLC (Xbridge Prep C18 10 um OBD, 19*250 mm, 10 um; A:
acetonitrile 35-65% and 0.01% NH3; B: 10 mM ammonium bicarbonate in
water) to afford
2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-2-carboxylic acid (10 mg, 15%) as a yellow solid.
.sup.1HNMR (400 MHz, DMSO-d.sub.6): .delta. 10.45 (s, 1H), 9.37
(dd, J=1.6, 7.2 Hz, 1H), 8.95 (dd, J=1.6, 4.0 Hz, 1H), 8.68 (s,
1H), 8.30 (s, 1H), 7.34 (dd, J=4.0, 7.2 Hz, 1H), 6.80 (s, 1H),
3.89-3.78 (m, 4H), 3.54-3.48 (m, 1H), 3.13-3.07 (m, 1H), 2.88-2.75
(m, 4H), 1.57 (s, 3H). MS (ESI): m/z=424.2 [M+1].sup.+.
Example 39.
N-(6-Morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00836##
[0680] Step A. 4-(2,4-Difluorobenzyl)tetrahydro-2H-pyran-4-ol
##STR00837##
[0682] To a solution of magnesium (1.20 g, 45.59 mmol) and iodine
(90.0 mg, 0.35 mmol) in diethyl ether (20 mL) at 40.degree. C. was
slowly added 1-(bromomethyl)-2,4-difluorobenzene (4.10 g, 19.8
mmol). The solution was then cooled to room temperature and added
to dihydro-2H-pyran-4(3H)-one (3.00 g, 29.96 mmol) in diethyl ether
(50 mL) at -78.degree. C. and the reaction was stirred at room
temperature for 18 h. After quenching with saturated ammonium
chloride solution, ethyl acetate (100 mL) was added. The organic
phase was separated and dried over sodium sulfate. After
concentration, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:10) as
eluting solvents to afford
4-(2,4-difluorobenzyl)tetrahydro-2H-pyran-4-ol (1.80 g, 40%) as a
colorless oil. MS (ESI): m/z=229.1 [M+1].sup.+.
Step B.
6-Fluoro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]
##STR00838##
[0684] A mixture of methyl
4-(2,4-difluorobenzyl)tetrahydro-2H-pyran-4-ol (1.81 g, 7.93 mmol)
and potassium tert-butoxide (2.67 g, 23.79 mmol) in THF (50 mL) was
stirred at 60.degree. C. for 18 h. After cooling to room
temperature, IN hydrogen chloride solution was added to reach
pH=3.0. Ethyl acetate (100 mL) was added and the organic phase was
separated and dried over sodium sulfate. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether(from 1:3 to 1:2) as eluting solvents to
afford
6-fluoro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]
(1.53 g, 93%) as a yellow solid. MS (ESI): m/z=209.1
[M+1].sup.+.
Step C.
6-Fluoro-5-nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-p-
yran]
##STR00839##
[0686] To a solution of
6-fluoro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]
(1.53 g, 7.35 mmol) in DCM (50 mL) at 25.degree. C. was slowly
added fuming nitric acid (2 mL) and the reaction was stirred for 15
min. Water and ethyl acetate (100 mL) was added. The organic phase
was separated and dried over sodium sulfate. After concentration,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:6 to 1:4) as eluting solvents to
afford
6-fluoro-5-nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]
(1.29 g, 69%) as orange solid. MS (ESI): m/z=254.3 [M+1].sup.+.
Step D.
4-(5-Nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]--
6-yl)morpholine
##STR00840##
[0688] A mixture of
6-fluoro-5-nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]
(150 mg, 0.59 mmol), morpholine (103 mg, 1.18 mmol) and cesium
carbonate (579 mg, 1.78 mmol) in acetonitrile (5 mL) was stirred at
room temperature for 18 h. Upon consumption of starting material,
the mixture was poured into water and the aqueous phase was
extracted with ethyl acetate (2.times.50 mL). The organic phases
were combined and washed with water and brine. After concentration
under reduced pressure, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:2) as eluting
solvents to afford
(4-(5-nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-6-yl)m-
orpholine (180 mg, 95%) as a yellow solid.
[0689] MS (ESI): m/z=321.1 [M+1].sup.+.
Step E.
6-Morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran-
]-5-amine
##STR00841##
[0691] A mixture of
4-(5-nitro-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-6-yl)mo-
rpholine (180 mg, 0.56 mmol) and 10% palladium on carbon (18 mg) in
methanol (10 mL) was stirred at room temperature for 1 h under an
atmosphere of hydrogen. Upon filtration through a plug of celite,
the filtrate was concentrated under reduced pressure to afford
(6-morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-5-am-
ine as a white solid (150 mg), which was used directly in the next
step without purification. MS (ESI): m/z=291.1 [M+1].sup.+.
Step F.
N-(6-Morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-py-
ran]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00842##
[0693] A mixture of
6-morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-5-ami-
ne (150 mg, 0.52 mmol) and triethylamine (157 mg, 1.55 mmol) in DCM
(5 mL) was stirred at 0.degree. C. To the mixture was added a
solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example
3, Step B) (113 mg, 0.62 mmol) in DCM (5 mL) and the reaction was
stirred at 25.degree. C. for 1 h. After filtration, the residue was
purified by preparative HPLC(Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 25-55%; B: 10 mM ammonium bicarbonate in water) to
afford
N-(6-morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (60 mg, 27%) as a white
solid. H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.45 (s, 1H), 9.37
(dd, J=2.0, 7.2 Hz, 1H), 8.94 (dd, J=1.6, 4.0 Hz, 1H), 8.68 (s,
1H), 8.33 (s, 1H), 7.35 (dd, J=4.0, 7.2 Hz, 1H), 6.79 (s, 1H),
3.83-3.85 (m, 4H), 3.74-3.80 (m, 2H), 3.61-3.66 (m, 2H), 3.06 (s,
2H), 2.81-2.82 (m, 4H), 1.79-1.81 (m, 4H). MS (ESI): m/z=436.2
[M+1].sup.+.
Example 40.
N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydrob-
enzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00843##
[0694] Step A. 4-Fluoropiperidin-4-yl)methanol
2,2,2-trifluoroacetate
##STR00844##
[0696] A mixture of tert-butyl
4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (300 mg, 1.29
mmol) in trifluoroacetic acid (1 mL) and DCM (2 mL) was stirred at
20.degree. C. for 1 h. The mixture was concentrated under reduced
pressure to afford (4-fluoropiperidin-4-yl)methanol trifluoroacetic
acid salt (300 mg) as a colorless oil, which was used directly
without purification.
[0697] MS (ESI): m/z=134.1 [M+1].sup.+.
Step B.
(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-fluoropiper-
idin-4-yl)methanol
##STR00845##
[0699] A mixture of
6-chloro-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran (Intermediate
2) (107 mg, 0.47 mmol), (4-fluoropiperidin-4-yl)methanol
2,2,2-trifluoroacetate (232 mg, 0.94 mmol) and cesium carbonate
(459 mg, 1.41 mmol) in acetonitrile (1 mL) was stirred at
100.degree. C. for 18 h in a sealed tube. The mixture was poured
into water and the aqueous phase was extracted with ethyl acetate
(2.times.50 mL). The organic phases were combined, washed with
water and brine, concentrated under reduced pressure and purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:1) as eluting solvents to afford
(1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-fluoropiperidin-4--
yl)methanol (95 mg, 62%) as a yellow solid. MS (ESI): m/z=325.3
[M+1].sup.+.
Step C.
(1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4-fluoropiper-
idin-4-yl)methanol
##STR00846##
[0701] A mixture of
(1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-fluoropiperidin-4--
yl)methanol (95 mg, 0.29 mmol) and 10% palladium on carbon (10 mg)
in methanol (5 mL) was stirred at room temperature for 1 h under an
atmosphere of hydrogen. Upon filtration over a plug of celite, the
filtrate was concentrated under reduced pressure to afford
(1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4-fluoropiperidin-4--
yl)methanol (60 mg), which was used directly in the next step
without purification. MS (ESI): m/z=295.1 [M+1].sup.+.
Step D.
N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-d-
ihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00847##
[0703] A mixture of
(1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4-fluoropiperidin-4--
yl)methanol (60 mg, 0.20 mmol) and triethylamine (61 mg, 0.60 mmol)
in DCM (10 mL) was stirred at 0.degree. C. To the mixture was added
a solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(Example 3, Step B) (54 mg, 0.30 mmol) in DCM (10 mL) and the
reaction was stirred at 25.degree. C. for 1 h. The crude reaction
was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um;
A: acetonitrile 35-55%; B: 10 mM ammonium bicarbonate in water) to
afford
N-(6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydrob-
enzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (55 mg, 65%)
as a white solid. H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.43 (s,
1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.89 (dd, J=1.6, 4.0 Hz, 1H),
8.68 (s, 1H), 8.34 (s, 1H), 7.53 (dd, J=4.0, 7.2 Hz, 1H), 6.71 (s,
1H), 5.18 (br, 1H), 3.53 (d, J=17.6 Hz, 2H), 3.37 (s, 2H),
2.81-2.91 (m, 4H), 1.98-2.10 (m, 2H). 1.83-1.88 (m, 2H). 1.42 (s,
6H). MS (ESI): m/z=440.2 [M+1].sup.+.
Example 41.
N-[6-(1,1-Dioxo-thiomorpholin-4-yl)-2,2-dimethyl-2,3-dihydro-1-benzofuran-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00848##
[0704] Step A.
4-(2,2-Dimethyl-5-nitro-2,3-dihydro-1-benzofuran-6-yl)-thiomorpholine-1,1-
-dione
##STR00849##
[0706] A mixture of
6-chloro-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran (Intermediate
1) (100 mg, 0.44 mmol), thiomorpholine-1,1-dione (119 mg, 0.88
mmol) and cesium carbonate (429 mg, 1.32 mmol) in acetonitrile (5
mL) was stirred 100.degree. C. for 18 h. Upon consumption of
starting material, the mixture was poured into water and the
aqueous phase was extracted with ethyl acetate (2.times.50 mL). The
organic phases were combined and washed with water and brine. After
concentration under reduced pressure, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether (1:2)
as eluting solvents to afford
4-(2,2-dimethyl-5-nitro-2,3-dihydro-1-benzofuran-6-yl)-thiomorpholine-1,1-
-dione (70 mg, 49%) as a yellow solid. MS (ESI): m/z=327.1
[M+1].
Step B.
4-(5-Amino-2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)-thiomorphol-
ine-1,1-dione
##STR00850##
[0708] A mixture of
4-(2,2-dimethyl-5-nitro-2,3-dihydro-1-benzofuran-6-yl)-thiomorpholine-1,1-
-dione (70 mg, 0.21 mmol) and 15% palladium on carbon(10 mg) in
methanol (10 mL) was stirred at room temperature for 1 h under an
atmosphere of hydrogen. Upon filtration over a plug of celite, the
filtrate was concentrated under reduced pressure to afford
4-(5-amino-2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)-thiomorpholine-1,1-
-dione (50 mg, 81%), which was used directly to the next step
without purification. MS (ESI): m/z=297.1 [M+1].sup.+.
Step C.
N-[6-(1,1-Dioxo-thiomorpholin-4-yl)-2,2-dimethyl-2,3-dihydro-1-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00851##
[0710] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (28
mg, 0.17 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(88 mg, 0.17 mmol) and N-ethyl-N-isopropylpropan-2-amine (65 mg,
0.51 mmol) in DMF (5 mL) was stirred at room temperature for 30
min.
4-(5-Amino-2,2-dimethyl-2,3-dihydro-1-benzofuran-6-yl)-thiomorpholine-1,1-
-dione (50 mg, 0.17 mmol) was added and the resulting mixture was
stirred at room temperature for 18 h. The residue was purified by
preparative HPLC(Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate in water) to afford
N-[6-(1,1-dioxo-thiomorpholin-4-yl)-2,2-dimethyl-2,3-dihydro-1-benzofuran-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide as a white solid (25
mg, 34%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.43 (s,
1H), 9.39 (dd, J=1.2, 6.8 Hz, 1H), 8.84 (dd, J=1.6, 4.4 Hz, 1H),
8.69 (s, 1H), 8.36 (s, 1H), 7.42 (dd, J=4.4, 7.2 Hz, 1H), 6.83 (s,
1H), 3.46-3.47 (m, 4H), 3.34-3.35 (m, 4H), 3.01 (s, 2H), 1.41 (s,
6H). MS (ESI): m/z=442.2 [M+1].sup.+.
Examples 42 and 43.
N--((R)-6-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide and
N--((S)-6-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydrox-
ymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
##STR00852##
[0711] Step A.
(6-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol
##STR00853##
[0713] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Intermediate 2) (85 mg, 0.35 mmol),
(1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (95 mg, 0.70
mmol) and cesium carbonate (455 mg, 1.40 mmol) in acetonitrile (1
mL) was stirred 100.degree. C. for 18 h in sealed tube. After
filtered and concentrated, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:2) as eluting
solvents to afford
(6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol(60 mg, 56%) as a yellow solid. MS
(ESI): m/z=307.3 [M+1].sup.+.
Step B.
(5-Amino-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-
-2,3-dihydrobenzofuran-2-yl)methanol
##STR00854##
[0715] A mixture of
(6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol (60 mg, 0.20 mmol) and 10% palladium
on carbon (12 mg) in methanol (5 mL) was stirred at room
temperature for 1 h under an atmosphere of hydrogen. Upon
filtration over a plug of celite, the filtrate was concentrated
under reduced pressure to afford
(5-amino-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-2,3-di-
hydrobenzofuran-2-yl)methanol(50 mg) as a yellow oil, which was
used directly to the next step without purification. MS (ESI):
m/z=277.1 [M+1].sup.+.
Step C.
N--((R)-6-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydrox-
ymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide and
N--((S)-6-((1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR00855##
[0717] A mixture of
(5-amino-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-2,3-di-
hydrobenzofuran-2-yl)methanol (50 mg, 0.18 mmol) and triethylamine
(55 mg, 0.54 mmol) in DCM (5 mL) was stirred at 0.degree. C. To the
mixture was added a solution of
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(49 mg, 0.27 mmol) in DCM (5 mL) and then the reaction was stirred
at 25.degree. C. for 1 h. After concentration under reduced
pressure the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (15:1) as eluting solvents to
afford the desired product and then it was separated by preparative
HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10
mM ammonium bicarbonate in water) to obtain
[0718]
N--((R)-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxy-
methyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-ca-
rboxamide and
N--((S)-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide (10 mg each, 12% each) as a yellow solids with absolute
stereochemistry assigned arbitrarily.
[0719] Example 42, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 10.10 (s, 1H), 8.82 (dd, J=1.6, 7.2 Hz, 1H), 8.77 (s, 1H),
8.71 (dd, J=1.6, 4.0 Hz, 1H), 8.14 (s, 1H), 7.04 (dd, J=4.0, 7.2
Hz, 1H), 6.57 (s, 1H), 4.57 (s, 1H), 4.13 (d, J=7.2 Hz, 1H), 4.04
(s, 1H), 3.78 (dd, J=1.6 7.2 Hz, 1H), 3.67 (d, J=4.0 Hz, 2H), 3.60
(d, J=9.6 Hz, 1H), 3.22 (d, J=15.2 Hz, 1H), 3.08 (dd, J=1.6, 9.6
Hz, 1H), 2.93 (d, J=15.6 Hz, 1H), 2.10 (dd, J=1.6, 9.6 Hz, 1H),
1.96-1.89 (m, 2H), 1.47 (s, 3H). MS (ESI):
m/z=422.2[M+1].sup.+.
[0720] Example 43, Peak 2. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 10.09 (s, 1H), 8.82 (dd, J=1.6, 7.2 Hz, 1H), 8.77 (s, 1H),
8.72 (dd, J=1.6, 4.0 Hz, 1H), 8.14 (s, 1H), 7.04 (dd, J=4.0, 7.2
Hz, 1H), 6.57 (s, 1H), 4.57 (s, 1H), 4.13 (d, J=7.6 Hz, 1H), 4.05
(s, 1H), 3.78 (dd, J=2.0, 7.2 Hz, 1H), 3.67 (d, J=5.6 Hz, 2H), 3.59
(d, J=9.6 Hz, 1H), 3.22 (d, J=16.0 Hz, 1H), 3.10 (dd, J=1.6, 9.6
Hz, 1H), 2.92 (d, J=16.0 Hz, 1H), 2.10 (dd, J=1.6, 9.6 Hz, 1H),
1.96-1.89 (m, 2H), 1.46 (s, 3H). MS (ESI): m/z=422.1
[M+1].sup.+.
Examples 44 and 45.
(R)--N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxymethyl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR00856##
[0721] Step A. (4-Fluoropiperidin-4-yl)methanol
2,2,2-trifluoroacetate
##STR00857##
[0723] A mixture of tert-butyl
4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (300 mg, 1.29
mmol in trifluoroacetic acid (1 mL) and DCM (2 mL) was stirred
20.degree. C. for 1 h. Upon consumption of starting material, the
mixture was concentrated under reduced pressure to afford
(4-fluoropiperidin-4-yl)methanol trifluoroacetic acid salt (300 mg)
as a colorless oil, which was used directly to next step without
further purification MS (ESI): m/z=134.1 [M+1].sup.+.
Step B.
(4-Fluoro-1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofu-
ran-6-yl)piperidin-4-yl)methanol
##STR00858##
[0725] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (80
mg, 0.33 mmol), (4-fluoropiperidin-4-yl)methanol
2,2,2-trifluoroacetate (162 mg, 0.66 mmol) and cesium carbonate
(428 mg, 1.32 mmol) in acetonitrile (1 mL) was stirred 100.degree.
C. for 18 h in sealed tube. Upon filtration and concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:2) as eluting solvents to afford
(4-fluoro-1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-y-
l)piperidin-4-yl)methanol (100 mg, 90%) as a yellow solid. MS
(ESI): m/z=341.1 [M+1].sup.+.
Step C.
(1-(5-Amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)-
-4-fluoropiperidin-4-yl)methanol
##STR00859##
[0727] A mixture of
(4-fluoro-1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-y-
l)piperidin-4-yl)methanol(100 mg, 0.29 mmol) and 10% palladium on
carbon (10 mg) in methanol (5 mL) was stirred at room temperature
for 1 h under an atmosphere of hydrogen. Upon filtration over a
plug of celite, the filtrate was concentrated under reduced
pressure to afford
(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)-4-fluo-
ropiperidin-4-yl)methanol(90 mg) as a yellow oil, which was used
directly in the next step without purification. MS (ESI): m/z=311.1
[M+1].sup.+.
Step D.
(R)--N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxymet-
hyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbo-
xamide and
(S)--N-(6-(4-Fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxy-
methyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-ca-
rboxamide
##STR00860##
[0729] A mixture of
(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)-4-fluo-
ropiperidin-4-yl)methanol(90 mg, 0.29 mmol) and triethylamine (88
mg, 0.87 mmol) in DCM (5 mL) was stirred at 0.degree. C. To the
mixture was added a solution of
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(105 mg, 0.58 mmol) in DCM (5 mL) and the reaction was stirred at
25.degree. C. for 1 h. After concentration under reduced pressure,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (15:1) as eluting solvents to afford the
desired product then it was separated by chiral HPLC (OJ 20*250 mm,
5 u at CO.sub.2/methanol{0.2% Ammonia (7 m methanol)}=80/20, 80
g/min, 100 bar, 35.degree. C.) to obtain
[0730]
(R)--N-(6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxymeth-
yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbox-
amide and
(S)--N-(6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-(hydroxym-
ethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-car-
boxamide (15 mg, 11%) (10 mg, 8%) as a yellow solids with absolute
stereochemistry assigned arbitrarily.
[0731] Example 44, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 10.42 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.89 (dd,
J=1.6, 4.4 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.33 (dd, J=4.4,
7.2 Hz, 1H), 6.69 (s, 1H), 5.16 (t, J=6.0 Hz, 1H), 5.05 (t, J=5.6
Hz, 1H), 3.57-3.49 (m, 2H), 3.43 (t, J=6.0 Hz, 2H), 3.23-3.16 (m,
1H), 2.93-2.77 (m, 5H), 2.15-1.95 (m, 2H), 1.90-1.79 (m, 2H), 1.34
(s, 3H). MS (ESI): m/z=456.2 [M+1].sup.+.
[0732] Example 45, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.43 (s, 1H), 9.36 (dd, J=1.6, 6.8 Hz, 1H), 8.89 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.32 (dd, J=4.0,
6.8 Hz, 1H), 6.69 (s, 1H), 5.16 (t, J=6.0 Hz, 1H), 5.05 (t, J=5.6
Hz, 1H), 3.57-3.49 (m, 2H), 3.43 (t, J=6.0 Hz, 2H), 3.23-3.16 (m,
1H), 2.93-2.77 (m, 5H), 2.15-1.94 (m, 2H), 1.91-1.79 (m, 2H), 1.34
(s, 3H). MS (ESI): m/z=456.2 [M+1].sup.+.
Examples 46 and 47.
N--((S)-6-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide and
N--((R)-6-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydrox-
ymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
##STR00861##
[0733] Step A.
(6-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol
##STR00862##
[0735] A mixture of
(6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol(Intermedia-
te 2) (126 mg, 0.52 mmol), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane
hydrochloride (140 mg, 1.03 mmol) and cesium carbonate (674 mg,
2.07 mmol) in acetonitrile (2 mL) was stirred 100.degree. C. for 18
h in a sealed tube. After filtered and concentrated, the residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:2) as eluting solvents to afford
(6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol (120 mg, 76%) as a yellow solid. MS
(ESI): m/z=307.3 [M+1].sup.+.
Step B.
(5-Amino-6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-
-2,3-dihydrobenzofuran-2-yl)methanol
##STR00863##
[0737] A mixture of
(6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-5-nitro-2,3-di-
hydrobenzofuran-2-yl)methanol (120 mg, 0.39 mmol) and 10% palladium
on carbon (12 mg) in methanol (5 mL) was stirred at room
temperature for 1 h under an atmosphere of hydrogen. Upon
filtration over a plug of celite, the filtrate was concentrated
under reduced pressure to afford
(5-amino-6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-2,3-di-
hydrobenzofuran-2-yl)methanol(100 mg) as a yellow oil, which was
used directly to the next step without purification. MS (ESI):
m/z=277.1 [M+1].sup.-.
Step C.
N--((S)-6-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydrox-
ymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide and
N--((R)-6-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR00864##
[0739] A mixture of
(5-amino-6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-methyl-2,3-di-
hydrobenzofuran-2-yl)methanol(100 mg, 0.36 mmol) and triethylamine
(109 mg, 1.08 mmol) in DCM (5 mL) was stirred at 0.degree. C. To
the mixture was added a solution of
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (Example 3, Step B)
(98 mg, 0.54 mmol) in DCM (5 mL) and the reaction was stirred at
25.degree. C. for 1 h. After filtration, the residue was purified
by preparative HPLC(Xbridge 21.2*250 mm c18, 10 um, acenitrile
25-55% (10 mM ammonium bicarbonate) in water) to afford
N-(6-morpholino-2',3',5',6'-tetrahydro-3H-spiro[benzofuran-2,4'-pyran]-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (120 mg, 0.24 mmol, 79%)
as a yellow solid and it was separated by chiral pre-SFC(Column: AD
20*250 mm, 5 um (Dacel), Mobile phase: CO2/methanol {0.5% Ammonia
(7 m methanol)}=60/40) to obtain
N--((S)-6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide and
N--((R)-6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-(hydrox-
ymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide (42 mg, 28%) (45 mg, 31%) as a yellow solids with
absolute stereochemistry assigned arbitrarily.
[0740] Example 46, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 9.89 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.85 (dd,
J=1.6, 4.0 Hz, 1H), 8.67 (s, 1H), 7.88 (s, 1H), 7.32 (dd, J=4.0,
7.2 Hz, 1H), 6.52 (s, 1H), 5.04 (t, J=6.0 Hz, 1H), 4.49 (s, 1H),
4.10 (s, 1H), 3.90 (d, J=7.6 Hz, 1H), 3.66 (d, J=6.0 Hz, 1H),
3.48-3.38 (m, 2H), 3.30 (d, J=8.8 Hz, 1H), 3.20-3.07 (m, 2H), 2.79
(d, J=15.6 Hz, 1H), 2.00 (d, J=9.6 Hz, 1H), 1.80 (d, J=8.8 Hz, 1H),
1.34 (s, 3H). MS (ESI): m/z=422.1 [M+1].sup.+.
[0741] Example 47, Peak 2: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 9.87 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.85 (dd,
J=1.6, 4.0 Hz, 1H), 8.67 (s, 1H), 7.86 (s, 1H), 7.32 (dd, J=4.0,
7.2 Hz, 1H), 6.51 (s, 1H), 5.05 (t, J=6.0 Hz, 1H), 4.49 (s, 1H),
4.10 (s, 1H), 3.93 (d, J=7.6 Hz, 1H), 3.67 (d, J=7.2 Hz, 1H),
3.48-3.38 (m, 2H), 3.25 (d, J=9.2 Hz, 1H), 3.20-3.10 (m, 2H), 2.79
(d, J=16.0 Hz, 1H), 2.00 (d, J=8.0 Hz, 1H), 1.80 (d, J=9.2 Hz, 1H),
1.34 (s, 3H). MS (ESI): m/z=422.1 [M+1].sup.+.
Examples 48 and 49.
(S)--N-(2-Methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-Methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00865##
[0742] Step A.
N,2-Dimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxamide
##STR00866##
[0744] A mixture of
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylic
acid (100 mg, 0.32 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(338 mg, 0.65 mmol) and N-ethyl-N-isopropylpropan-2-amine (168 mg,
1.30 mmol) in DMF (10 mL) was stirred at room temperature for 30
min. Then methyl amine hydrochloride (44 mg, 0.65 mmol) was added.
The resulting mixture was stirred at room temperature for 18 h.
Water and ethyl acetate (50 mL) was added. The organic phase was
separated and dried over sodium sulfate. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:3 to 1:1) as eluting solvents to
afford
N,2-dimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxamide
(80 mg, 77%) as orange solid. MS (ESI): m/z=322.1 [M+1].sup.+.
Step B.
5-Amino-N,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxam-
ide
##STR00867##
[0746] A mixture of
N,2-dimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxamide
(80 mg, 0.25 mmol) and 10% palladium on carbon(8 mg) in methanol
(10 mL) was stirred at room temperature for 1 h under an atmosphere
of hydrogen. Upon filtration over a plug of celite, the filtrate
was concentrated under reduced pressure to afford
5-amino-N,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxamide
as a white solid (60 mg), which was used directly in the next step
without purification. MS (ESI): m/z=292.1 [M+1].sup.-.
Step C.
(S)--N-(2-Methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-Methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00868##
[0748] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (34
mg, 0.21 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(107 mg, 0.21 mmol) and N-ethyl-N-isopropylpropan-2-amine (53 mg,
0.42 mmol) in DMF (5 mL) was stirred at room temperature for 30
min.
5-Amino-N,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-carboxamide
(The absolute structure was assigned arbitrarily) (60 mg, 0.21
mmol) was then added and the resulting mixture was stirred at room
temperature for 18 h. After concentration, the residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(15:1) as eluting solvents to afford the desired product separated
by chiral SFC (AS 20*250 mm, 5 um (Dacel), CO2/methanol {0.2%
Ammonia (7 m methanol)}=70/30) to obtain
(S)--N-(2-methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-methyl-2-(methylcarbamoyl)-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (12 mg, 13%) (10 mg,
11%) as a yellow solid with absolute stereochemistry assigned
arbitrarily.
[0749] Example 48, Peak 1: .sup.1HNMR (400 MHz, MeOD-d.sub.4):
.delta. 9.14 (dd, J=1.6, 6.8 Hz, 1H), 8.94 (dd, J=1.6, 4.4 Hz, 1H),
8.67 (s, 1H), 8.27 (s, 1H), 7.30 (dd, J=4.4, 7.2 Hz, 1H), 6.90 (s,
1H), 3.95-3.97 (m, 4H), 3.55 (d, J=16.0 Hz, 1H), 3.19 (d, J=16.0
Hz, 1H), 2.92-2.94 (m, 4H), 2.78 (s, 3H), 1.65 (s, 3H). MS (ESI):
m/z=437.2 [M+1].sup.+.
[0750] Example 49, Peak 2: .sup.1H NMR (400 MHz, MeOD-d.sub.4):
.delta. 9.03 (dd, J=1.5, 7.2 Hz, 1H), 8.81 (dd, J=1.6, 4.4 Hz, 1H),
8.56 (s, 1H), 8.15 (s, 1H), 7.18 (dd, J=4.4, 7.2 Hz, 1H), 6.78 (s,
1H), 3.83-3.86 (m, 4H), 3.43 (d, J=16.4 Hz, 1H), 3.06 (d, J=16.4
Hz, 1H), 2.80-2.82 (m, 4H), 2.62 (s, 3H), 1.20 (s, 3H). MS (ESI):
m/z=437.1 [M+1].sup.+.
Examples 50 and 51.
(R)--N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00869##
[0751] Step A. Methyl
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
##STR00870##
[0753] A mixture of morpholine (270 mg, 3.1 mmol), methyl
6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-carboxylate (Intermediate
3, Step D) (500 mg, 1.55 mmol) and potassium carbonate (427 mg, 3.1
mmol) in acetonitrile (10 mL) was stirred at 25.degree. C. for 18
h. Water was added. The aqueous phase was extracted with ethyl
acetate (50 mL). The organic phase was dried over sodium sulfate
and concentrated to afford methyl
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylate (382 mg)
as a yellow oil, which was used directly to next step without
further purification.
[0754] MS (ESI): m/z=323.1 [M+1].sup.+.
Step B.
2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carbaldehyde
##STR00871##
[0756] To a mixture of methyl
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylate (382 mg,
1.08 mmol) in DCM (10 mL) was added diisobutylaluminium hydride
(1.62 mL, 1 m in hexane, 1.62 mmol) drop wise at -78.degree. C.
over 5 min and the reaction was maintained at -78.degree. C. for 2
h with stirring. The mixture was quenched with sodium sulfate
decahydrate and filtered. The filtrate was concentrated under
reduced pressure and the residue was purified by silica gel
chromatography eluting with using ethyl acetate:petroleum ether
(1:1) as eluting solvents to afford
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carbaldehyde (230 mg,
73%) as a yellow solid. MS (ESI): m/z=325.1 [M+methanol].sup.+.
Step C.
4-(2-(Difluoromethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-
morpholine
##STR00872##
[0758] To a mixture of
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carbaldehyde (180 mg,
0.62 mmol) in DCM (30 mL) was added drop wise diethylaminosulfur
trifluoride (620 mg, 80%, 3.08 mmol) at -78.degree. C. The mixture
was stirred at 25.degree. C. for 18 h. The mixture was concentrated
and purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:3 to 2:3) as eluting solvents to
afford
4-[2-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(110 mg, 53% yield) as a yellow solid. MS (ESI): m/z=323.1
[M+1].sup.+.
Step D.
2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-a-
mine
##STR00873##
[0760] A mixture of
4-[2-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(110 mg, 0.35 mmol) and 10% palladium on carbon (40 mg) in methanol
(20 mL) was stirred at 25.degree. C. under an atmosphere of
hydrogen for 1 h. Upon filtration over a plug of celite, the
filtrate was concentrated under reduced pressure to afford
2-(difluoromethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine (140
mg) as light green oil, which was used directly to next step
without further purification. MS (ESI): m/z=285.1 [M+1].sup.+.
Step E.
N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran--
5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00874##
[0762] A mixture of
2-(difluoromethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine (90
mg, 0.32 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (62 mg,
0.38 mmol)
(3-Hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylp-
hosphonium hexafluorophosphate (247 mg, 0.47 mmol) and
diisopropylethylamine (115 mg, 0.95 mmol) in DMF (5 mL) was stirred
at 25.degree. C. for 2 h. Water was added. The aqueous was
extracted with ethyl acetate (70 mL). The organic phase was washed
with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (9:1) as eluting
solvents to afford
N-(2-(difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)py-
razolo[1,5-a]pyrimidine-3-carboxamide (100 mg, 73%) as a yellow
solid.
[0763] MS (ESI): m/z=430.1 [M+1].sup.+.
Step F.
(R)--N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00875##
[0765] The
N-(2-(difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofur-
an-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (100 mg, 0.23 mmol)
was purified by chiral separation (OJ 20*250 mm, 5 u at
CO.sub.2/methanol {0.2% Ammonia (7 m methanol)}=80/20, 80 g/min,
100 bar, 35.degree. C.) to afford
(R)--N-(2-(difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (30 mg, 30%) (40 mg,
40%) as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[0766] Example 50, Peak 1: .sup.1HNMR (400 MHz, CDCl3) .delta.
10.47 (s, 1H), 8.84 (dd, J=1.6, 6.8 Hz, 1H), 8.78 (s, 1H), 8.77
(dd, J=1.6, 4.0 Hz, 1H), 8.46 (s, 1H), 7.07 (dd, J=4.0, 6.8 Hz,
1H), 5.75 (t, J=56.0 Hz, 1H), 3.94-3.96 (m, 4H), 3.43 (d, J=16.0
Hz, 1H), 3.03 (d, J=16.0 Hz, 1H), 2.90-2.93 (m, 4H), 1.54 (s, 3H).
MS (ESI): m/z=430.1 [M+1].sup.+.
[0767] Example 51, Peak 2: .sup.1H NMR (400 MHz, CDCl3) .delta.
10.48 (s, 1H), 8.84 (dd, J=1.6, 6.8 Hz, 1H), 8.78 (s, 1H), 8.77
(dd, J=1.6, 4.0 Hz, 1H), 8.46 (s, 1H), 7.07 (dd, J=4.0, 6.8 Hz,
1H), 5.75 (t, J=56.0 Hz, 1H), 3.94-3.96 (m, 4H), 3.43 (d, J=16.0
Hz, 1H), 3.03 (d, J=16.0 Hz, 1H), 2.90-2.93 (m, 4H), 1.54 (s, 3H).
MS (ESI): m/z=430.1 [M+1].sup.+.
Examples 52 and 53.
(R)--N-(2-(Hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbo-
xamide and
(S)--N-(2-(Hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin--
1-yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidi-
ne-3-carboxamide
##STR00876##
[0768] Step A.
(2-(1-(2-(Hydroxymethyl)-2-methyl-5-nitro-2,3-dihydro-3H-benzofuran-6-yl)-
piperidin-4-yl)propan-2-ol
##STR00877##
[0770] A mixture of 2-(4-piperidyl)-2-propanol (76 mg, 0.53 mmol)
(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol (100 mg,
0.44 mmol) and potassium (91 mg, 0.66 mmol) in acetonitrile (10 mL)
was stirred at 25.degree. C. for 18 h. Water was added. The aqueous
phase was extracted with ethyl acetate (30 mL). The organic phase
dried over sodium sulfate and concentrated to afford
2-[1-[2-(hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]-4-piperidyl]-
propan-2-ol (150 mg) as a yellow oil, which was used directly to
next step without further purification. MS (ESI): m/z=351.1
[M+1].sup.+.
Step B.
2-(1-(5-Amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-y-
l)piperidin-4-yl)propan-2-ol
##STR00878##
[0772] A mixture of
2-[1-[2-(hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]-4-piperidyl]-
propan-2-ol (150 mg, 0.43 mmol) and 10% palladium on carbon (40 mg,
0.43 mmol) in methanol (30 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 1 h. After filtration, the filtrate was
concentrated under reduced pressure to afford
2-[1-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]-4-piperidyl]-
propan-2-ol (160 mg, 82%) as a brown oil. MS (ESI): m/z=321.1
[M+1].sup.+.
Step C.
N-(2-(Hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-car-
boxamide
##STR00879##
[0774] A mixture of
2-[1-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]-4-piperidyl]-
propan-2-ol (160 mg, 0.50 mmol),
6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (106 mg, 0.60
mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (390 mg, 0.75 mmol) and
diisopropylethylamine (181 mg, 1.50 mmol) in DMF (5 mL) was stirred
at 25.degree. C. for 2 h. Water was added. The aqueous phase was
extracted with ethyl acetate (70 mL). The organic phase was washed
with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (9:1) as eluting
solvents to afford
N-(2-(hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-2-methyl--
2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamid-
e (100 mg, 42%) as a yellow solid. MS (ESI): m/z=480.1
[M+1].sup.+.
Step D.
(R)--N-(2-(Hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-y-
l)-2-methyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine--
3-carboxamide and
(S)--N-(2-(Hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbo-
xamide
##STR00880##
[0776] The
N-(2-(hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-
-2-methyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3--
carboxamide was purified by chiral separation (OJ 20*250 mm, 5 u at
CO.sub.2/methanol{0.2% Ammonia (7 m methanol)}=80/20, 80 g/min, 100
bar, 35.degree. C.) to afford
(R)--N-(2-(hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbo-
xamide and
(S)--N-(2-(hydroxymethyl)-6-(4-(2-hydroxypropan-2-yl)piperidin--
1-yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidi-
ne-3-carboxamide (40 mg, 40%) (50 mg, 50%) as a yellow solids with
absolute stereochemistry assigned arbitrarily.
[0777] Example 52, Peak 1: .sup.1H NMR (400 MHz, CDCl3) .delta.
10.42 (s, 1H), 8.69 (d, J=2.0 Hz, 1H), 8.68 (s, 1H), 8.57-8.58 (m,
1H), 8.39 (s, 1H), 6.64 (s, 1H), 3.65-3.67 (m, 2H), 3.23 (d, J=16.0
Hz, 1H), 3.12-3.15 (m, 2H), 2.94 (d, J=16.0 Hz, 1H), 2.58-2.64 (m,
2H), 2.42 (s, 3H), 2.02-2.06 (m, 2H), 1.71-1.84 (m, 4H), 1.46 (s,
3H), 1.25 (s, 6H).
[0778] MS (ESI): m/z=480.2 [M+1].sup.+.
[0779] Example 53, Peak 2: .sup.1H NMR (400 MHz, CDCl3) .delta.
10.43 (s, 1H), 8.69 (d, J=2.0 Hz, 1H), 8.68 (s, 1H), 8.57-8.58 (m,
1H), 8.39 (s, 1H), 6.64 (s, 1H), 3.65-3.67 (m, 2H), 3.23 (d, J=16.0
Hz, 1H), 3.12-3.15 (m, 2H), 2.94 (d, J=16.0 Hz, 1H), 2.58-2.64 (m,
2H), 2.42 (s, 3H), 2.02-2.06 (m, 2H), 1.71-1.84 (m, 4H), 1.46 (s,
3H), 1.25 (s, 6H). MS (ESI): m/z=480.2 [M+1].sup.+.
Examples 54 and 55.
(R)-6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00881##
[0780] Step A. (Z)-2,3,3-Trifluoroprop-1-enyl
4-methylbenzenesulfonate
##STR00882##
[0782] A mixture of 2,2,3,3-tetrafluoropropyl
4-methylbenzenesulfonate (3.0 g, 10.49 mmol) in THF (30 mL), was
cooled to -78.degree. C. n-butyllithium (9.23 mL, 23.08 mmol, 2.5 M
in hexane) was added drop wise and the reaction was stirred at
-78.degree. C. for 10 min. The reaction was quenched with water and
allowed to warm to room temperature. The aqueous phase was
extracted with DCM (2.times.50 mL). The organic phases were dried
over sodium sulfate and concentrated in vacuo to afford
(Z)-2,3,3-trifluoroprop-1-enyl 4-methylbenzenesulfonate (1.96 g,
70%) as a yellow oil, which was used directly to next step without
further purification. MS (ESI): m/z=267.0 [M+1].sup.+
Step B. (Z)-3-(Diethylamino)-2-fluoroacrylaldehyde
##STR00883##
[0784] To a solution of diethylamine (362 mg, 1.96 mmol),
triethylamine (456 mg, 4.51 mmol), and a catalytic amount of
tetrabutylammonium fluoride (0.45 mmol, 0.45 mL, 1 m in THF) in
acetonitrile (3 mL), was added a solution of
(Z)-2,3,3-trifluoroprop-1-enyl 4-methylbenzenesulfonate (1200 mg,
4.51 mmol) in acetonitrile (6 mL) at 0.degree. C. The mixture was
stirred at room temperature for 3 h and quenched with brine. The
aqueous phase was extracted with DCM (2.times.30 mL), dried over
sodium sulfate and concentrated in vacuo. The residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:4 to 1:1) as eluting solvents to afford
(Z)-3-(diethylamino)-2-fluoroacrylaldehyde (558 mg, 85%) as a
yellow oil.
[0785] MS (ESI): m/z=146.1 [M+1].sup.+
Step C. Ethyl 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00884##
[0787] A mixture of (Z)-3-(diethylamino)-2-fluoroacrylaldehyde (400
mg, 2.76 mmol) and ethyl 5-amino-1H-pyrazole-4-carboxylate (428 mg,
2.76 mmol) in acetic acid (5 mL) was stirred at 80.degree. C. for 1
h. After concentration in vacuo, the residue was purified by silica
gel chromatography using ethyl acetate:petroleum ether(1:5) as
eluting solvents to afford ethyl
6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate (180 mg, 26%) as a
yellow solid. MS (ESI): m/z=210.1 [M+1].sup.+.
Step D. 6-Fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid
##STR00885##
[0789] A mixture of ethyl
6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate (70 mg, 0.33 mmol)
and hydroxyl lithium hydrate (13 mg, 0.33 mmol) in methanol (1 mL),
THF (1 mL) and water (1 mL), was stirred at 100.degree. C. under
microwave for 10 min. After concentration in vacuo, it was afforded
6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic acid (47 mg) as a
yellow solid, which as used directly to next step without further
purification. MS (ESI): m/z=204.0 [M+1].sup.+.
Step E.
(5-Amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
##STR00886##
[0791] A mixture of
(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Example 6, Step B) (128 mg, 0.44 mmol) and 10% palladium on carbon
(30 mg) in methanol (5 mL) was stirred at 20.degree. C. under
hydrogen atmosphere for 2 h. Upon filtration through a plug of
celite, the filtrate was concentrated under reduced pressure to
afford
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(102 mg, 89%) as a brown solid. MS (ESI): m/z=265.1
[M+1].sup.+.
Step F.
6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00887##
[0793] A mixture of 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (47 mg, 0.26 mmol),
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(82 mg, 0.31 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (148 mg, 0.39 mmol) and diisopropylethylamine
(101 mg, 0.78 mmol) in DMF (5 mL) was stirred at 20.degree. C. for
2 h. The crude reaction was purified by preparative HPLC(Xbridge
21.2*250 mm c18, 10 um, A: acetonitrile 15-40%; B: 10 mM ammonium
bicarbonate in water) to afford
6-fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (46 mg, 42%)
as a yellow solid.
Step G.
(R)-6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydr-
obenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00888##
[0795]
6-Fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (46 mg, 0.11
mmol) was separated by chiral separation(SFC-80 (Thar, Waters), OJ
20*250 mm, 5 um (Dacel), C Mobile phase: CO2/methanol{0.5% Ammonia
(7 m methanol)}=70/30) to afford
(R)-6-fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-fluoro-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (8.4 mg each, 37%
each) as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[0796] Example 54, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.28 (s, 1H), 9.82 (dd, J=2.4, 4.4 Hz, 1H), 9.20 (d, J=2.4
Hz, 1H), 8.70 (s, 1H), 8.26 (s, 1H), 6.70 (s, 1H), 5.04 (t, J=6.0
Hz, 1H), 3.83-3.81 (m, 4H), 3.47-3.38 (m, 2H), 3.22-3.18 (m, 1H),
2.84-2.79 (m, 5H), 1.34 (s, 3H). MS (ESI): m/z=428.2
[M+1].sup.+.
[0797] Example 55, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.28 (s, 1H), 9.82 (dd, J=2.4, 4.4 Hz, 1H), 9.20 (d, J=2.4
Hz, 1H), 8.70 (s, 1H), 8.26 (s, 1H), 6.70 (s, 1H), 5.04 (t, J=6.0
Hz, 1H), 3.83-3.81 (m, 4H), 3.47-3.38 (m, 2H), 3.22-3.18 (m, 1H),
2.84-2.79 (m, 5H), 1.34 (s, 3H). MS (ESI): m/z=428.2
[M+1].sup.+.
Examples 56 and 57.
N-[(2S)-6-[(3S)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2R)-6-[(3
S)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl-
]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00889##
[0798] Step A.
[6-[(3S)-3-Fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]met-
hanol
##STR00890##
[0800] A mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 2) (150 mg, 0.62 mmol), (S)-3-fluoropyrrolidine
hydrochloride (110 mg, 1.23 mmol) and cesium carbonate (600 mg,
1.84 mmol) in DMSO (2 mL) was stirred at 90.degree. C. for 3 h. The
mixture was then poured into water and the aqueous phase was
extracted with ethyl acetate (2.times.30 mL). The organic phases
were combined and washed with water, brine and dried over sodium
sulfate before concentration to dryness. The residue was purified
by preparative TLC using ethyl acetate:petroleum ether (1:3) as
eluting solvents to afford [6-[(3
S)-3-fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]methanol
(102 mg, 55%) as a yellow oil. MS (ESI): m/z=297.1 [M+1].
Step B.
[5-Amino-6-[(3S)-3-Fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-2-
-yl]methanol
##STR00891##
[0802] A mixture of [6-[(3
S)-3-fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]methanol
(102 mg, 0.34 mmol) and 10% palladium on carbon (10 mg) in methanol
(10 mL) was stirred at room temperature under hydrogen atmosphere
for 1 h. The reaction was filtered through a plug of celite and the
filtrate was concentrated under reduced pressure to
afford[5-amino-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-2--
yl]methanol (96 mg) as a brown oil, which was used directly to next
step without further purification. MS (ESI): m/z=297.1 [M+1].
Step C.
N-[(2S)-6-[(3S)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2R)-6-[(3S)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00892##
[0804] A solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(118 mg, 0.72 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (340 mg, 0.89 mmol) and diisopropylethylamine
(0.24 mL, 1.45 mmol) was stirred in DMF (3 mL) at room temperature
for 10 min. To this mixture was added
[5-amino-6-[(3S)-3-fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-2-yl]met-
hanol (96 mg, 0.36 mmol) in DMF (2 mL) and stirred for 16 h. The
final products was purified by preparative HPLC (Xbridge 21.2*250
mm c18, 10 um, A: acetonitrile 25-70%; B: 10 mM ammonium
bicarbonate in water) and then the product was resolved by chiral
separation (SFC (AD-H 20*250 mm, 5 um, CO.sub.2/methanol(0.5%
Ammonia (7 m methanol))=50/50, 35.degree. C.) to afford
N-[(2S)-6-[(3
S)-3-fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl-
]pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-[(2R)-6-[(3
S)-3-fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl-
]pyrazol[1,5-a]pyrimidine-3-carboxamide (16 mg, 11%) (19 mg, 13%)
as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[0805] Example 56, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.25 (s, 1H), 8.81 (dd, J=1.6, 6.8 Hz, 1H), 8.77 (s, 1H),
8.69 (dd, J=2.0, 4.0, Hz, 1H), 8.26 (s, 1H), 7.02 (dd, J=4.4, 7.2,
Hz, 1H), 6.59 (s, 1H), 5.42-5.25 (m, 1H), 3.67 (s, 2H), 355-3.44
(m, 1H), 3.43-3.40 (m, 1H), 3.36-3.32 (m, 1H), 3.24 (d, J=15.5 Hz,
1H), 2.95-2.86 (m, 2H), 2.34-2.21 (m, 2H), 2.08-1.89 (m, 1H), 1.46
(s, 3H). MS (ESI): m/z=412.1 [M+1]
[0806] Example 57, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.24 (s, 1H), 8.81 (dd, J=2.0, 7.2 Hz, 1H), 8.76 (s, 1H),
8.67 (dd, J=1.6, 4.0 Hz, 1H), 8.25 (s, 1H), 7.02 (dd, J=4.0, 7.2
Hz, 1H), 6.59 (s, 1H), 5.46-5.23 (m, 1H), 3.67 (s, 2H), 3.54-3.46
(m, 1H), 3.44-3.39 (m, 1H), 3.36-3.32 (m, 1H), 3.23 (d, J=16.0 Hz,
1H), 2.94 (d, J=16.0 Hz, 1H), 2.93-2.85 (m, 1H), 2.40-2.13 (m, 2H),
2.08-1.85 (m, 1H), 1.46 (s, 3H). MS (ESI): m/z=412.2 [M+1]
Examples 58 and 59.
N-[(2R)-6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazol[1,5-a]pyrimidine-3-carboxamide
##STR00893##
[0807] Step A.
[6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]met-
hanol
##STR00894##
[0809] A mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 1) (150 mg, 0.62 mmol), (3R)-3-fluoropyrrolidine
hydrochloride (440 mg, 3.5 mmol) and cesium carbonate (780 mg, 2.4
mmol) in DMSO (2 mL) was stirred at 90.degree. C. for 7 h. The
mixture was poured into water and extracted ethyl acetate (100 mL)
and the organics washed with water brine and dried over sodium
sulfate before concentration to dryness. The residue was then
purified by preparative TLC using ethyl acetate:petroleum ether
(1:3) as eluting solvents to afford
[6-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-
-yl]methanol(135 mg, 74%) as a yellow oil. MS (ESI): m/z=297.1
[M+1].sup.-.
Step B.
[5-Amino-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-2-
-yl]methanol
##STR00895##
[0811] A mixture of
[6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]met-
hanol (135 mg, 0.46 mmol) and 10% palladium on carbon (50 mg) in
methanol (12 mL) was stirred under hydrogen atmosphere at
25.degree. C. for 1 h. After filtration through a plug of celite
and concentration, it was afforded
[5-amino-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-
-2-yl]methanol (110 mg) as a brown oil which was directly used to
the next step without further purification. MS (ESI): m/z=267.1
[M+1].sup.+.
Step C.
N-[(2R)-6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[(3R)-3-Fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00896##
[0813] To a solution of diisopropylethylamine (0.2 mL, 1.24 mmol)
and pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (102 mg, 0.63 mmol)
was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (314 mg, 0.83 mmol) then was stirred at
25.degree. C. for 20 min. To the mixture was added the solution of
[5-amino-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-3H-benzofuran-2-yl]met-
hanol (110 mg, 0.41 mmol) in DMF (3 mL) and the mixture was stirred
at 25.degree. C. for 16 h. The crude was purified by preparative
HPLC (Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile 25-55%; B: 10
mM ammonium bicarbonate in water) and resolved by chiral
separation(SFC-80 (Thar, Waters), AD 20*250 mm, 5 um (Dacel),
CO.sub.2/methanol{0.5% Ammonia (7 m methanol)}=50/50) to afford
N-[(2R)-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[(3R)-3-fluoropyrrolidin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-be-
nzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (24 mg, 14%)
(29 mg, 17%) as a yellow solids with absolute stereochemistry
assigned arbitrarily.
[0814] Example 58, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 10.11 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.81 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.05 (s, 1H), 7.31 (dd, J=4.0,
7.2 Hz, 1H), 6.59 (s, 1H), 5.39 (td, J=4.4, 55.2 Hz, 1H), 5.04 (t,
J=5.6 Hz, 1H), 3.56-3.34 (m, 4H), 3.22-3.07 (m, 2H), 2.93-2.85 (m,
1H), 2.81 (d, J=16.0 Hz, 1H), 2.36-2.05 (m, 2H), 1.34 (s, 3H). MS
(ESI): m/z=412.1 [M+1].sup.+.
[0815] Example 59, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 10.11 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.81 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.05 (s, 1H), 7.31 (dd, J=4.0,
7.2 Hz, 1H), 6.60 (s, 1H), 5.39 (td, J=4.4, 54.4 Hz, 1H), 5.04 (t,
J=5.6 Hz, 1H), 3.56-3.34 (m, 4H), 3.22-3.07 (m, 2H), 2.93-2.85 (m,
1H), 2.81 (d, J=16.0 Hz, 1H), 2.36-2.07 (m, 2H), 1.34 (s, 3H). MS
(ESI): m/z=412.2 [M+1].sup.+.
Example 60.
N-[6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-yl]p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00897##
[0816] Step A.
2-[4-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]ethanol
##STR00898##
[0818] A mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 1) (100 mg, 0.44 mmol) and 1-piperazineethanol (572
mg, 4.39 mmol) in DMSO (1 mL) was stirred at 110.degree. C. for 16
h. The mixture was poured into water and the aqueous phase was
extracted by ethyl acetate (100 mL). The organic phase was washed
with water, brine and dried over sodium sulfate before
concentration to dryness. The residue was purified by preparative
TLC using methanol:DCM=1:20 as eluting solvents to afford
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]ethanol
(110 mg, 78%) as a brown oil. MS (ESI): m/z=322.1 [M+1].sup.+.
Step B.
2-[4-(5-Amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]ethan-
ol
##STR00899##
[0820] A mixture of
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]ethanol
(59 mg, 0.18 mmol) and 10% palladium on carbon (29 mg) in methanol
(8 mL) was stirred under hydrogen atmosphere at 20.degree. C. for 1
h. After filtration and concentration,
2-[4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]ethanol
(50 mg) was afforded as a brown oil, which was used to the next
step without further purification. MS (ESI): m/z=392.2
[M+1].sup.+.
Step C.
N-[6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00900##
[0822] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (42 mg, 0.26 mmol) and diisopropylethylamine (0.09 mL, 0.52
mmol) in DMF (2 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (131 mg, 0.34 mmol) then the mixture was
stirred at 25.degree. C. for 15 min. To the mixture was added a
solution of
2-[4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]ethanol
(50 mg, 0.17 mmol) in DMF (2 mL) and the resulting mixture was
stirred at 25.degree. C. for 16 h. The mixture was purified by
preparative HPLC(Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile
10-70%; B: 10 mM ammonium bicarbonate in water) to afford
N-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-yl]p-
yrazolo[1,5-a]pyrimidine-3-carboxamide (45 mg, 60%) as a yellow
solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.42 (s, 1H),
9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.92 (dd, J=1.6, 4.4 Hz, 1H), 8.68
(s, 1H), 8.31 (s, 1H), 7.36 (dd, J=4.4, 7.2 Hz, 1H), 6.69 (s, 1H),
4.45 (t, J=5.2 Hz, 1H), 3.54 (q, J=5.6 Hz, 2H), 3.00 (s, 2H),
2.84-2.78 (m, 4H), 2.74-2.61 (m, 4H), 2.50 (t, J=5.6 Hz, 2H), 1.41
(s, 6H). MS (ESI): m/z=437.3 [M+1].sup.+.
Example 61.
6-Cyclopropyl-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,-
5-a]pyrimidine-3-carboxamide
##STR00901##
[0823] Step A. Ethyl
6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00902##
[0825] To a mixture of ethyl 3-amino-1H-pyrazole-4-carboxylate (3.0
g, 19.34 mmol) and 2-bromomalonaldehyde (3.21 g, 21.26 mmol) in
ethanol (10 mL) was added acetic acid (30 mL). The mixture was
stirred for 2 h at 70.degree. C. The reaction was concentrated to
dryness. The residue was dissolved in ethyl acetate and saturated
sodium bicarbonate solution was added. The organic phase was
extracted and dried over sodium sulfate before concentration to
dryness. The residue was then purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:3) as eluting solvents to
afford ethyl 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate (3.3 g,
63%) as a white solid. MS (ESI): m/z=270.0 [M+1].sup.+.
Step B. Ethyl
6-cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00903##
[0827] A mixture of ethyl
6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate (400 mg, 1.48 mmol),
cyclopropylboronic acid (200 mg, 2.33 mmol), palladium diacetate
(56 mg, 0.25 mmol), triphenylphosphine (168 mg, 0.60 mmol) and
potassium phosphate (1260 mg, 5.94 mmol) in toluene (6 mL) and
water (1 mL) in a sealed tube was stirred under N.sub.2 atmosphere
at 120.degree. C. for 2 h. The mixture was poured onto water (30
mL) and the aqueous phase was extracted with ethyl acetate (100
mL). The organic phase was washed with water and brine and dried
over sodium sulfate before concentration to dryness. The residue
was purified by preparative TLC using ethyl acetate:petroleum ether
(1:3) to afford ethyl
6-cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylate (205 mg, 60%)
as a yellow solid. MS(ESI): m/z=232.1 [M+1].sup.+.
Step C. 6-Cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00904##
[0829] The mixture of ethyl
6-cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylate (60 mg, 0.26
mmol) and lithium hydroxide (12 mg, 0.29 mmol) in THF (3 mL),
methanol (3 mL) and water (3 mL) was stirred at 100.degree. C. for
10 min. The mixture was neutralized with 1N hydrogen chloride
solution. The aqueous phase was extracted with EtOAc (20 mL). The
organic phase was separated, dried over sodium sulfate and
concentrated under reduced pressure to afford
6-cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (52 mg) as
a yellow solid, which was directly used in the next step without
further purification. MS (ESI): m/z=204.1 [M+1].sup.+.
Step E.
6-Cyclopropyl-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR00905##
[0831] To a mixture of
6-cyclopropylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (61 mg,
0.30 mmol) and diisopropylethylamine (0.11 mL, 0.66 mmol) in DMF (2
mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (154 mg, 0.41 mmol) and the mixture was stirred
at 25.degree. C. for 20 min. To the mixture was added a solution of
2,2-dimethyl-6-morpholino-3H-benzofuran-5-amine (50 mg, 0.20 mmol)
in DMF (2 mL) and the mixture was stirred at 25.degree. C. for 16
h. The product was crushed out. After filtration, the solid was
collected and washed with methanol to afford
6-cyclopropyl-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,-
5-a]pyrimidine-3-carboxamide (61 mg, 70%) as a yellow solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.41 (s, 1H), 8.70 (s,
1H), 8.65 (d, J=2.0 Hz, 1H), 8.50 (dd, J=0.8 Hz, 2.0 Hz, 1H), 8.43
(s, 1H), 6.65 (s, 1H), 3.97 (t, J=4.4 Hz, 4H), 3.04 (s, 2H), 2.92
(t, J=4.4 Hz, 4H), 2.09-2.00 (m, 1H), 1.49 (s, 6H), 1.20-1.13 (m,
2H), 0.86-0.79 (m, 2H). MS (ESI): m/z=434.1[M+1].sup.+.
Example 62.
N-[2,2-Dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide
##STR00906##
[0832] Step A. tert-Butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate
##STR00907##
[0834] A mixture of
N-Boc-1,2,5,6-tetrahydropyridine-4-boronicacidpinacolester (1350
mg, 4.37 mmol) 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 1) (345 mg, 1.52 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (99
mg, 0.14 mmol) and cesium carbonate (1120 mg, 3.44 mmol) in
1,4-dioxane (10 mL) and water (1 mL) in a sealed tube was stirred
at 90.degree. C. under microwave conditions for 2 h. The mixture
was poured into water (30 mL) and extracted with ethyl acetate (200
mL). The organic phase was washed with water and brine and dried
over sodium sulfate before concentration to dryness. The residue
was then purified by preparative TLC using ethyl acetate:petroleum
ether(1:5) to afford tert-butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate (550 mg, 87%) as a yellow oil. MS (ESI):
m/z=397.2[M+Na].sup.+.
Step B. tert-Butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
##STR00908##
[0836] A mixture of tert-butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate (100 mg, 0.27 mmol) and 10% palladium on carbon (50 mg) in
methanol (10 mL) was stirred under hydrogen atmosphere at
20.degree. C. for 2 h. After filtration through a plug of celite
and concentration under reduced pressure, it was afforded
tert-butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
(85 mg) as a brown oil, which was directly used in the next step
without further purification. MS (ESI): m/z=291.1[M-tBu].sup.+.
Step C. tert-Butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate
##STR00909##
[0838] To a mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(60 mg, 0.37 mmol) and diisopropylethylamine (0.12 mL, 0.74 mmol)
in DMF (2 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate and stirred for 20 min at 25.degree. C. To the
mixture was added a solution of tert-butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
(85 mg, 0.25 mmol) in DMF (2 mL) and stirred at 25.degree. C. for
16 h. The mixture was poured into water and the aqueous phase was
extracted with ethyl acetate (100 mL). The organic phase was washed
with water and brine and dried over sodium sulfate before
concentration to dryness. The residue was purified by preparative
TLC using ethyl acetate:petroleum ether (3:2) as eluting solvents
to afford tert-butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate (63 mg, 52%) as a yellow solid. MS
(ESI): m/z=492.2[M+1].sup.+.
Step D.
N-[2,2-Dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]-
pyrimidine-3-carboxamide
##STR00910##
[0840] To a solution of tert-butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate (63 mg, 0.13 mmol) in DCM (4 mL)
was added trifluoroacetic acid (0.29 mL, 3.95 mmol) and the mixture
was stirred at 25.degree. C. for 2 h. The mixture was neutralized
by triethylamine. After concentration, the residue was purified by
preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate in water) to afford
N-[2,2-dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (33 mg, 66%) as a yellow solid. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.64 (s, 1H), 9.40 (dd, J=1.6, 6.8 Hz,
1H), 8.87 (dd, J=1.6, 4.4 Hz, 1H), 8.69 (s, 1H), 7.74 (s, 1H), 7.34
(dd, J=4.4, 6.8 Hz, 1H), 6.63 (s, 1H), 3.02 (t, J=12.0 Hz, 2H),
3.00 (s, 2H), 2.97-2.87 (m, 1H), 2.59 (t, J=12.0 Hz, 2H), 1.69 (d,
J=11.2 Hz, 2H), 1.59-1.45 (m, 2H), 1.42 (s, 6H). MS (ESI):
m/z=392.2[M+1].sup.+.
Example 63.
N-[2,2-Dimethyl-6-(1-methyl-4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00911##
[0841] Step A.
N-[2,2-Dimethyl-6-(1-methyl-4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00912##
[0843] To a solution of
N-[2,2-dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (Example 62) (39 mg, 0.10 mmol) in methanol (4
mL) was added formaldehyde (200 mg, 2.46 mmol, 30 wt %) and the
mixture was stirred at 25.degree. C. for 30 min. To the mixture was
added sodium cyanoborohydride (30 mg, 0.5 mmol) the reaction was
stirred at 25.degree. C. for 1 h. Water was added and the mixture
was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um;
A: acetonitrile 25-55%; B: 10 mM ammonium bicarbonate in water) to
afford
N-[2,2-dimethyl-6-(1-methyl-4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5--
a]pyrimidine-3-carboxamide (23 mg, 57%) as a yellow solid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.61 (s, 1H), 9.40 (dd, J=1.6,
6.8 Hz, 1H), 8.87 (dd, J=1.6, 4.4 Hz, 1H), 8.69 (s, 1H), 7.73 (s,
1H), 7.35 (dd, J=4.4, 6.8 Hz, 1H), 6.65 (s, 1H), 3.00 (s, 2H), 2.88
(d, J=11.6 Hz, 2H), 2.83-2.73 (m, 1H), 2.18 (s, 3H), 1.96 (t, J=9.6
Hz, 2H), 1.77-1.59 (m, 4H), 1.42 (s, 6H). MS (ESI):
m/z=406.2[M+1].sup.+.
Examples 64 and 65.
Cis-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]pyrazolo[-
1,5-a]pyrimidine-3-carboxamide and
Trans-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR00913##
[0844] Step A.
tert-Butyl-[4-[(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexoxy]--
diphenyl-silane
##STR00914##
[0846] To a mixture of 4-[tert-butyl(diphenyl)silyl]oxycyclohexanol
(255 mg, 0.72 mmol), potassium tert-butanolate (130 mg, 1.16 mmol)
and 6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran (Example 3, Step F)
(265 mg, 1.25 mmol) in 1,4-dioxane (7 mL) was stirred at 40.degree.
C. for 36 h. The mixture was purified by reverse phase
chromatography (C18, 80 g, 40-60 um, 10 um; A: acetonitrile 0.1% to
100%; 10 mM in water) to afford
tert-butyl-[4-[(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexoxy]--
diphenyl-silane (110 mg, 28%) as a yellow oil. MS (ESI):
m/z=568.2[M+Na].sup.+.
Step B.
4-[(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexanol
##STR00915##
[0848] The mixture of
tert-butyl-[4-[(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexoxy]--
diphenyl-silane (100.0 mg, 0.18 mmol) in methanol (10 mL) was added
12N hydrogen chloride solution (0.3 mL, 3.6 mmol) and the mixture
was stirred at 25.degree. C. for 5 h. The mixture was neutralized
by triethylamine to pH=8.0 and concentrated under reduced pressure.
The residue was purified by preparative TLC using ethyl
acetate:petroleum ether (1:3) to afford
4-[(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexanol (53
mg, 94%) as a yellow oil. MS (ESI): m/z=330.1 [M+Na].sup.+.
Step C.
4-[(5-Amino-2,2-dimethyl-3H-benzofuran-6-yl)oxy]cyclohexanol
##STR00916##
[0850] A mixture of
4-[(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)oxy]cyclohexanol (53
mg, 0.17 mmol) and 10% palladium on carbon (25 mg) in methanol (6
mL) was stirred under a hydrogen atmosphere at 25.degree. C. for 1
h. After filtration through a plug of celite and concentration, it
was afforded
4-[(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)oxy]cyclohexanol (45
mg) as a brown oil which was directly used in the next step without
further purification. MS (ESI): m/z=278.1[M+1].sup.+.
Step D.
Cis-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide and
Trans-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR00917##
[0852] To the mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (40 mg, 0.25 mmol) and diisopropylethylamine (0.08 mL, 0.50
mmol) in DMF (2 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (123 mg, 0.32 mmol) then the mixture was
stirred at 25.degree. C. for 20 min. To the mixture was added the
solution of
4-[(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)oxy]cyclohexanol (45
mg, 0.16 mmol) in DMF (2 mL) and the mixture was stirred at
25.degree. C. for 16 h. The crude was purified by preparative HPLC
(Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10 mM
ammonium bicarbonate in water) to afford
Cis-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (26 mg, 38%) and
Trans-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]pyrazol-
o[1,5-a]pyrimidine-3-carboxamide (10 mg, 15%) as a yellow
solids.
[0853]
Cis-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]pyr-
azolo[1,5-a]pyrimidine-3-carboxamide: .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.18 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H),
8.83 (dd, J=1.6, 4.4 Hz, 1H), 8.66 (s, 1H), 8.28 (s, 1H), 7.31 (dd,
J=4.4, 7.2 Hz, 1H), 6.63 (s, 1H), 4.57 (d, J=4.4 Hz, 1H), 4.42-4.34
(m, 1H), 3.62-3.51 (m, 1H), 2.97 (s, 2H), 2.12-2.01 (m, 2H),
1.95-1.85 (m, 2H), 1.65-1.52 (m, 2H), 1.41 (s, 6H), 1.39-1.28 (m,
2H). MS (ESI): m/z=423.2[M+1].sup.+.
[0854]
Trans-N-[6-(4-hydroxycyclohexoxy)-2,2-dimethyl-3H-benzofuran-5-yl]p-
yrazolo[1,5-a]pyrimidine-3-carboxamide: .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.11 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H),
8.98 (dd, J=1.6, 4.4 Hz, 1H), 8.67 (s, 1H), 8.26 (s, 1H), 7.35 (dd,
J=4.4, 7.2 Hz, 1H), 6.60 (s, 1H), 4.61 (d, J=3.2 Hz, 1H), 4.54-4.47
(m, 1H), 3.69-3.61 (m, 1H), 2.97 (s, 2H), 2.04-1.94 (m, 2H),
1.82-1.72 (m, 2H), 1.72-1.65 (m, 2H), 1.64-1.55 (m, 2H), 1.41 (s,
6H). MS (ESI): m/z=423.2[M+1].sup.+.
Examples 66 and 67.
N-[(2R)-6-(3,3-Difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-(3,3-Difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00918##
[0855] Step A.
[6-(3,3-Difluoropyrrolidin-1-yl)-2-methyl-5-nitro-3H-benzofuran-2-yl]meth-
anol
##STR00919##
[0857] To a solution of
(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 3) (150.0 mg, 0.66 mmol) and potassium carbonate
(228.0 mg, 1.65 mmol) in acetonitrile (5 mL) was added
3,3-difluoropyrrolidine hydrochloride (114.0 mg, 0.79 mmol) and the
mixture was stirred for 16 h. Water (10 mL) was added to the
mixture. The aqueous phase was extracted with DCM (3.times.20 mL).
The organic phases were combined and washed with water, dried over
sodium sulfate and concentrated in vacuo to afford the
[6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-5-nitro-3H-benzofuran-2-yl]meth-
anol (208 mg) as a yellow solid, which was used directly to next
step without further purification. MS (ESI): m/z=315.1
[M+1].sup.+.
Step B.
[5-Amino-6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-3H-benzofuran-2--
yl]methanol
##STR00920##
[0859] A mixture of
[6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-5-nitro-3H-benzofuran-2-yl]meth-
anol (208.0 mg, 0.66 mmol) and 10% palladium on carbon (20.0 mg,
0.66 mmol) in methanol (5 mL) was stirred at room temperature under
hydrogen atmosphere for 1 h. The reaction was filtered through a
plug of celite and the filtrate was concentrated under reduced
pressure to afford
[5-amino-6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-3H-benzofuran-2-yl]meth-
anol (188 mg) as a colorless oil, which was used directly to next
step without further purification. MS (ESI): m/z=285.1
[M+1].sup.+.
Step C.
N-[(2R)-6-(3,3-Difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-
-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-(3,3-Difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00921##
[0861] A mixture of
[5-amino-6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-3H-benzofuran-2-yl]meth-
anol (181.0 mg, 0.64 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (104.0 mg, 0.64 mmol) and diisopropylethylamine (0.22 mL, 1.33
mmol) in DMF (5 mL) was added
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (364.0 mg, 0.90 mmol) at 25.degree. C. The
mixture was stirred at 25.degree. C. for 16 h. The mixture was
purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 25-55%; B: 10 mM ammonium bicarbonate in water) and
followed chiral resolution by SFC(SFC-80 (Thar, Waters), OD 20*250
mm, 5 um (Dacel), CO.sub.2/methanol {0.2% Ammonia (7 m
methanol)}=65/35) to afford
N-[(2R)-6-(3,3-difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-(3,3-difluoropyrrolidin-1-yl)-2-(hydroxymethyl)-2-methyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (32.3 mg, 12%)
(38.6 mg, 14%) as a yellow solids with absolute stereochemistry
assigned arbitrarily.
[0862] Example 66, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.: 10.25 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.79 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.21 (s, 1H), 7.33 (dd, J=4.0,
6.8 Hz, 1H), 6.72 (s, 1H), 5.05 (t, J=5.6 Hz, 1H), 3.52-3.39 (m,
4H), 3.24-3.15 (m, 3H), 2.83 (d, J=15.6 Hz, 1H), 1.34 (s, 3H). MS
(ESI): m/z=430.2 [M+1].sup.+.
[0863] Example 67, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.: 10.24 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.79 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s 1H), 8.21 (s, 1H), 7.34 (dd, J=4.0, 7.2
Hz, 1H), 6.72 (s, 1H), 5.05 (t, J=5.6 Hz, 1H), 3.53-3.39 (m, 4H),
3.24-3.15 (m, 3H), 2.83 (d, J=15.6 Hz, 1H), 1.34 (s, 3H). MS (ESI):
m/z=430.1 [M+1].sup.+.
Example 68.
N-(6-(3,3-Difluoro-4-hydroxypyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00922##
[0864] Step A. 4,4-Difluoropyrrolidin-3-ol trifluoroacetic acid
salt
##STR00923##
[0866] A mixture of tert-butyl
3,3-difluoro-4-hydroxypyrrolidine-1-carboxylate (100 mg, 0.45 mmol)
and trifluoroacetic acid (1 mL) in DCM (5 mL), was stirred at
20.degree. C. for 2 h. After removal of solvents under reduced
pressure, it was afforded 4,4-difluoropyrrolidin-3-ol
trifluoroacetic acid salt (46 mg) as a brown oil, which was used
directly to next step without further purification. MS (ESI):
m/z=124.1 [M+1].sup.+.
Step B.
1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4,4-difluoropy-
rrolidin-3-ol
##STR00924##
[0868] A mixture of 4,4-difluoropyrrolidin-3-ol trifluoroacetic
acid salt (46 mg, 0.35 mmol),
6-fluoro-2,2-dimethyl-5-nitro-3H-benzofuran (Example 3, Step F) (75
mg, 0.35 mmol) and potassium carbonate (145 mg, 1.05 mmol) in
acetonitrile (5 mL) was stirred at 90.degree. C. for 20 h. After
removal of the solvents under reduced pressure, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:4 to 1:1) to afford
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4,4-difluoropyrrolidi-
n-3-ol (62 mg, 53%) as a yellow solid. MS (ESI): m/z=315.1
[M+1].sup.+.
Step C.
1-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4,4-difluoropy-
rrolidin-3-ol
##STR00925##
[0870] A mixture of
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4,4-difluoropyrrolidi-
n-3-ol (62 mg, 0.20 mmol) and 10% palladium on carbon(15 mg) in
methanol (5 mL) was stirred at 20.degree. C. under hydrogen
atmosphere for 2 h. After filtration and careful concentration
(product is volatile), it was afforded
1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4,4-difluoro-
pyrrolidin-3-ol (52 mg, 80%) as a yellow solid. MS (ESI): m/z=285.0
[M+1].sup.+.
Step D.
N-(6-(3,3-Difluoro-4-hydroxypyrrolidin-1-yl)-2,2-dimethyl-2,3-dihy-
drobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00926##
[0872] A mixture of
1-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-4,4-difluoropyrrolidi-
n-3-ol (52 mg, 0.15 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (30 mg, 0.18 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(119 mg, 0.23 mmol) and diisopropylethylamine (59 mg, 0.46 mmol) in
DMF (3 mL) was stirred at 20.degree. C. for 16 h. The crude was
purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 15-40%; B: 10 mM ammonium bicarbonate in water) to
afford
N-(6-(3,3-difluoro-4-hydroxypyrrolidin-1-yl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (51.2 mg, 78%)
as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
10.07 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.77 (dd, J=2.0, 4.4
Hz, 1H), 8.68 (s, 1H), 8.10 (s, 1H), 7.35 (dd, J=4.0, 6.8 Hz, 1H),
6.65 (s, 1H), 5.92 (d, J=5.6 Hz, 1H), 4.37-4.32 (m, 1H), 3.60-3.45
(m, 3H), 2.99 (s, 2H), 2.91-2.87 (m, 1H), 1.42 (s, 3H), 1.41 (s,
3H). MS (ESI): m/z=430.1 [M+1].sup.+.
Example 69.
N-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-(trifluorometh-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00927##
[0873] Step A. Methylpyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00928##
[0875] To a solution of pyrrolo[1,2-a]pyrimidine-8-carboxylic acid
(4.97 g, 30.7 mmol) in methanol (120 mL) was added concentrated
sulfuric acid (5 mL). The reaction mixture was stirred for 18 h at
reflux. After concentration, saturated sodium bicarbonate solution
was added slowly. The aqueous phase was extracted with ethyl
acetate (3.times.50 mL). The combined organic phases were washed
with brine and dried over sodium sulfate. After filtration and
concentration, methyl pyrrolo[1,2-a]pyrimidine-8-carboxylate (4.50
g, 83%) was afforded as a yellow solid. MS (ESI): m/z=200.0
[M+Na].
Step B. Methyl 6-iodopyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00929##
[0877] To a mixture of methyl
pyrrolo[1,2-a]pyrimidine-8-carboxylate (3.43 g, 19.47 mmol) and
sodium acetate (15.97 g, 194.74 mmol) in acetic acid (80 mL) was
added iodine monochloride (3.79 g, 23.37 mmol). The reaction
mixture was stirred for 18 h at 25.degree. C. After concentration,
saturated sodium bicarbonate solution was added. The aqueous phase
was extracted with ethyl acetate (3.times.100 mL). The combined
organic phases were washed with brine and dried over sodium
sulfate. After concentration under reduced pressure, the residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:4) as eluting solvents to afford methyl
6-iodopyrazolo[1,5-a]pyrimidine-3-carboxylate (2.97 g, 51%) as a
yellow solid. MS (ESI): m/z=325.9 [M+Na].
Step C. Methyl
6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR00930##
[0879] A mixture of methyl
6-iodopyrazolo[1,5-a]pyrimidine-3-carboxylate (400.0 mg, 1.32 mmol)
and (1,10-phenanthroline)(trifluoromethyl)copper(I) (619.2 mg, 1.98
mmol) in DMF (0.5 mL) was heated to 50.degree. C. and stirred for
18 h in glove box. Water and ethyl acetate (50 mL) was added and
the organic phase was washed with water, brine and dried over
sodium sulfate. After concentration under reduced pressure, the
residue was purified by silica gel chromatographyt using ethyl
acetate:petroleum ether (1:4) as eluting solvents to afford methyl
6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (100 mg,
31%) as a yellow solid. MS (ESI): m/z=246.0 [M+1].sup.+.
Step D. 6-(Trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00931##
[0881] A mixture of methyl
6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (50.0
mg, 0.20 mmol) in concentrated hydrochloric acid (2 mL) was stirred
for 4 hat 100.degree. C. The reaction was concentrated to dryness
and the residue was purified by preparative HPLC (A: acetonitrile
25-37%; B: 0.05% formic acid in water) to afford
6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (25
mg, 53%) as a white solid. MS (ESI): m/z=232.0 [M+1].sup.+.
Step E.
N-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-(triflu-
oromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00932##
[0883] A mixture of 2,2-dimethyl-6-morpholino-3H-benzofuran-5-amine
(Example 33, step B) (34.0 mg, 0.14 mmol),
6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (25
mg, 0.11 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (78.09 mg, 0.21 mmol) and diisopropylethylamine
(52.99 mg, 0.41 mmol) in DMF (5 mL) was stirred for 18 h at
25.degree. C. The crude was purified by preparative HPLC (Xbridge
21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10 mmol/L
ammonium bicarbonate in water) to afford
N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-(triluoromet-
hyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (34 mg, 67%) as a
yellow solid.
[0884] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.26 (s, 1H),
10.12 (d, J=0.8 Hz, 1H), 9.23 (d, J=2.0 Hz, 1H), 8.88 (s, 1H), 8.27
(s, 1H), 6.72 (s, 1H), 3.83-8.10 (m, 4H), 3.01 (s, 2H), 2.83-2.79
(m, 4H), 1.42 (s, 6H). MS (ESI): m/z=462.1 [M+1].sup.+.
Example 70.
N-[2,2-Dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-yl]pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR00933##
[0885] Step A.
2,2-Dimethyl-5-nitro-6-(2,2,2-trifluoroethoxy)-3H-benzofuran
##STR00934##
[0887] The mixture of cesium carbonate (125.0 mg, 0.38 mmol),
palladium diacetate (5.0 mg, 0.02 mmol),
6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran (Intermediate 4) (52.0
mg, 0.19 mmol) and
racemic-2-(di-tert-butylphosphino)-1,1'-binaphthyl (77.0 mg, 0.19
mmol) in 2,2,2-trifluoroethanol (0.30 mL) and toluene (3.0 mL) was
heated in a sealed tube at 80.degree. C. under microwave condition
and the reaction was stirred for 3 h. The reaction was concentrated
to dryness under reduced pressure and then purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:10) as
eluting solvents to afford
2,2-dimethyl-5-nitro-6-(2,2,2-trifluoroethoxy)-3H-benzofuran (37
mg, 56%) as a colorless oil. MS (ESI): m/z=292.0 [M+1].sup.+.
Step B.
2,2-Dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-amine
##STR00935##
[0889] A mixture of 10% palladium on carbon (5.0 mg) and
2,2-dimethyl-5-nitro-6-(2,2,2-trifluoroethoxy)-3H-benzofuran (37.0
mg, 0.13 mmol) in methanol (2 mL) was stirred at 25.degree. C.
under hydrogen atmosphere for 2 h. After filtration and
concentration under reduced pressure, it was afforded
2,2-dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-amine (33
mg) as a colorless oil, which was used to next step without further
purification. MS (ESI): m/z=262.1 [M+1].sup.+.
Step C.
N-[2,2-Dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR00936##
[0891] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(21.0 mg, 0.13 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(99.0 mg, 0.19 mmol), N-ethyl-N-isopropylpropan-2-amine (0.04 mL,
0.25 mmol) and
2,2-dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-amine (33.0
mg, 0.13 mmol) in DMF (5 mL) was stirred at room temperature for 18
h. After filtration and concentration, the residue was purified by
preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate in water) to afford
N-[2,2-dimethyl-6-(2,2,2-trifluoroethoxy)-3H-benzofuran-5-yl]pyrazolo[1,5-
-a]pyrimidine-3-carboxamide (9.1 mg, 17%) as a yellow solid.
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 10.27 (s, 1H), 8.80 (dd,
J=1.6, 6.8 Hz, 1H), 8.74 (s, 1H), 8.68 (dd, J=1.6, 4.0 Hz, 1H),
8.46 (s, 1H), 7.03 (dd, J=4.0, 7.2 Hz, 1H), 6.35 (s, 1H), 4.41 (q,
J=8.0 Hz, 2H), 3.03 (s, 2H), 1.48 (s, 6H). MS (ESI): m/z=407.1
[M+1].sup.+.
Examples 71 and 72.
N-[(2R)-2-(Hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofuran-5-yl-
]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofuran-5-yl-
]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00937##
[0892] Step A. 4-(2-Methylallyloxy)-1-nitro-2-(trifluoromethyl)
benzene
##STR00938##
[0894] A mixture of 4-nitro-3-(trifluoromethyl)phenol (1000 mg,
4.83 mmol), 3-bromo-2-methylpropene (0.65 mL, 6.5 mmol), cesium
carbonate (3080 mg, 9.45 mmol) in DMF (12 mL) was stirred at
50.degree. C. for 2 h. The mixture was poured into water (50 mL)
and extracted by ethyl acetate (150 ml) and the organics washed
with water and brine. The organic phases were then separated and
dried over anhydrous sodium sulfate then was concentration to
dryness to afford
4-(2-methylallyloxy)-1-nitro-2-(trifluoromethyl)benzene (1.2 g) as
a yellow oil, which was directly used to the next step without
purification. MS (ESI): m/z=262.0 [M+1].sup.+.
Step B. 2-(2-Methylallyl)-4-nitro-5-(trifluoromethyl)phenol
##STR00939##
[0896] A mixture of
4-(2-methylallyloxy)-1-nitro-2-(trifluoromethyl)benzene (1200 mg,
4.59 mmol) in DMF (14 mL) was stirred at 200.degree. C. in a sealed
tube under microwave condition for 3 h. The mixture was purified by
reverse phase chromatography (C18, 120 g, acetonitrile 18-22%; B:
0.1% ammonium bicarbonate in water) to afford
2-(2-methylallyl)-4-nitro-5-(trifluoromethyl)phenol (222 mg, 19%)
as a yellow oil. MS (ESI): m/z=262.0 [M+1].sup.+
Step C.
[2-Methyl-5-nitro-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
##STR00940##
[0898] A mixture of
2-(2-methylallyl)-4-nitro-5-(trifluoromethyl)phenol (222 mg, 0.85
mmol) in DCM (15 mL) was added 3-chloroperbenzoic acid (222 mg,
1.13 mmol) at 0.degree. C. then was stirred at 25.degree. C. for 18
h. The reaction mixture was diluted with DCM (30 mL) then was
washed with sodium sulfite solution, sodium bicarbonate solution
and water, dried over anhydrous sodium sulfate, and concentrated in
vacuo. The residue was purified by reverse phase chromatography
(C18, 60 g, acetonitrile 25-27%; B: 0.1% ammonium bicarbonate in
water) to afford
[2-methyl-5-nitro-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
(66 mg, 28%) as a yellow oil. MS (ESI): m/z=278.0 [M+1].sup.+.
Step D.
[5-Amino-2-methyl-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
##STR00941##
[0900] The mixture of
[2-methyl-5-nitro-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
(66 mg, 0.24 mmol) and 10% palladium on carbon (20 mg) in methanol
(10 mL) was stirred at 25.degree. C. under hydrogen atmosphere for
1 h. After filtration and concentration under reduced pressure, it
was afforded
[5-amino-2-methyl-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
(55 mg, 93%) as a brown oil. MS (ESI): m/z=248.1 [M+1].sup.+.
Step E.
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofur-
an-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2R)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofuran-5-yl-
]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00942##
[0902] The mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(55 mg, 0.34 mmol) and
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (170 mg, 0.45 mmol), N,N-diisopropylethylamine
(0.11 mL, 0.68 mmol) and
[5-amino-2-methyl-6-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
(55 mg, 0.22 mmol) in DMF (4 mL) was stirred at 75.degree. C. for
24 h. After cooling room temperature, the mixture was purified by
preparative HPLC(Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate) in water) and then the
product was resolved by chiral-HPLC [SFC-80 (Thar, Waters), AD
20*250 mm, 5 um (Dacel), carbon dioxide/methanol {0.5% ammonia (7 m
methanol)}=65/35] to afford
N-[(2R)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofuran-5-yl-
]pyrazol[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)-3H-benzofuran-5-yl-
]pyrazol[1,5-a]pyrimidine-3-carboxamide (5.6 mg, 6%) (8.1 mg, 9%)
as a white solids with absolute stereochemistry assigned
arbitrarily.
[0903] Example 70, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.94 (s, 1H), 8.82 (dd, J=1.6, 7.2 Hz, 1H), 8.76 (s, 1H),
8.70 (dd, J=1.6, 4.0 Hz, 1H), 8.00 (s, 1H), 7.05 (dd, J=4.0, 7.2
Hz, 1H), 7.03 (s, 1H), 3.76-3.61 (m, 2H), 3.36 (d, J=16.4 Hz, 1H),
3.00 (d, J=16.4 Hz, 1H), 1.89 (t, J=6.0 Hz, 1H), 1.47 (s, 3H). MS
(ESI): m/z=393.1 [M+1].sup.+.
[0904] Example 71, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.94 (s, 1H), 8.82 (dd, J=1.6, 7.2 Hz, 1H), 8.76 (s, 1H),
8.70 (dd, J=1.6, 4.0 Hz, 1H), 8.00 (s, 1H), 7.05 (dd, J=4.0, 7.2
Hz, 1H), 7.03 (s, 1H), 3.76-3.61 (m, 2H), 3.36 (d, J=16.4 Hz, 1H),
3.00 (d, J=16.4 Hz, 1H), 1.89 (t, J=6.0 Hz, 1H), 1.47 (s, 3H). MS
(ESI): m/z=393.1 [M+1].sup.+.
Examples 73 and 74.
N-[(2S)-6-(Difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2R)-6-(difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00943##
[0905] Step A. 5-(2-Methylallyloxy)-2-nitro-benzaldehyde
##STR00944##
[0907] A mixture of 5-hydroxy-2-nitrobenzaldehyde (1000 mg, 5.98
mmol), 3-bromo-2-methylpropene (0.81 mL, 8.0 mmol), cesium
carbonate (4000 mg, 12.28 mmol) in DMF (10 mL) was stirred at
50.degree. C. for 2 h. The mixture was poured into water (50 mL).
The aqueous phase was extracted by ethyl acetate (150 mL) and the
organic phase was washed with water and brine and dried over
anhydrous sodium sulfate. The organic phase was concentration to
dryness to afford 5-(2-methylallyloxy)-2-nitro-benzaldehyde (1.25
g) as a yellow oil, which was directly used to the next step
without purification. MS (ESI): m/z=222.1 [M+1].sup.+.
Step B. 2-(Difluoromethyl)-4-(2-methylallyloxy)-1-nitro-benzene
##STR00945##
[0909] The mixture of 5-(2-methylallyloxy)-2-nitro-benzaldehyde
(1250 mg, 5.65 mmol) in DCM (25 mL) was added
diethylaminosulfurtrifluoride (1.88 mL, 14.13 mmol) at 0.degree. C.
then was stirred at 25.degree. C. for 8 h. The mixture was diluted
with DCM (200 mL) then was washed with water, dried over anhydrous
sodium sulfate and concentrated in vacuo. The residue was purified
by silicagel chromatography using ethyl acetate:petroleum ether
(1:20) as eluting solvents to afford
2-(difluoromethyl)-4-(2-methylallyloxy)-1-nitro-benzene (1310 mg,
95%) as a yellow oil. MS (ESI): m/z=244.1 [M+1].sup.+.
Step C. 5-(Difluoromethyl)-2-(2-methylallyl)-4-nitro-phenol
##STR00946##
[0911] The mixture of
2-(difluoromethyl)-4-(2-methylallyloxy)-1-nitro-benzene (1300 mg,
5.35 mmol) in DMF (16 mL) was stirred at 200.degree. C. in a sealed
tube under microwave condition for 3 h. The mixture was purified by
reverse phase chromatography (C18, 120 g, A: acetonitrile 22-25%;
B: 0.1% ammonium bicarbonate in water) to afford
5-(difluoromethyl)-2-(2-methylallyl)-4-nitro-phenol (310 mg, 24%)
as a yellow oil. MS (ESI): m/z=244.1 [M+1].sup.+.
Step D.
[6-(Difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methanol
##STR00947##
[0913] A mixture of
5-(difluoromethyl)-2-(2-methylallyl)-4-nitro-phenol (310 mg, 1.27
mmol) in DCM (15 mL) was added 3-chloroperbenzoic acid (375 mg,
1.91 mmol) at 0.degree. C. then was stirred at 25.degree. C. for 18
h. The reaction mixture was diluted with DCM (50 mL). The organic
phase was washed with sodium bicarbonate solution, water, dried
over anhydrous sodium sulfate and concentrated in vacuo. The
residue was purified by reverse phase chromatography (C18, 80 g, A:
acetonitrile 20-27%; B: 0.1% ammonium bicarbonate in water) to
afford
[6-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methanol
(156 mg, 47%) as a yellow oil. MS (ESI): m/z=260.1 [M+1].sup.-.
Step E.
[5-Amino-6-(difluoromethyl)-2-methyl-3H-benzofuran-2-yl]methanol
##STR00948##
[0915] The mixture of
[6-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-2-yl]methanol
(140 mg, 0.54 mmol) and 10% palladium on carbon (50 mg) in methanol
(15 mL) was stirred at 25.degree. C. under hydrogen atmosphere for
1 h. After filtration and concentration under reduced pressure, it
was afforded
[5-amino-6-(difluoromethyl)-2-methyl-3H-benzofuran-2-yl]methanol
(115 mg) as a brown oil, which was used directly to next step
without further purification. MS (ESI): m/z=230.1 [M+1].sup.+.
Step F.
N-[(2S)-6-(difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2R)-6-(difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00949##
[0917] The mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(120 mg, 0.74 mmol), N,N-diisopropylethylamine (0.26 mL, 1.56
mmol), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (395 mg, 1.04 mmol) and
[5-amino-6-(difluoromethyl)-2-methyl-3H-benzofuran-2-yl]methanol
(115 mg, 0.50 mmol) in DMF (6 mL) was stirred at 65.degree. C. for
16 h. After cooling room temperature, the mixture was purified by
preparative HPLC (Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 mM ammonium bicarbonate in water) and Chiral-HPLC
[SFC-80 (Thar, Waters), AY 20*250 mm, 5 um (Dacel), carbon
dioxide/methanol {0.5% ammonia (7 m methanol)}=60/40] to afford
N-[(2R)-6-(difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-(difluoromethyl)-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide (44.4 mg, 24%) (32.7 mg,
17%) as yellow solids with absolute stereochemistry assigned
arbitrarily.
[0918] Example 73, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.77 (s, 1H), 9.38 (dd, J=1.6, 7.2 Hz, 1H), 8.87 (dd,
J=1.6, 4.4 Hz, 1H), 8.70 (s, 1H), 7.67 (s, 1H), 7.33 (dd, J=4.4,
7.2 Hz, 1H), 7.042 (t, J=55.2 Hz, 1H), 6.90 (s, 1H), 5.11 (t, J=6.0
Hz, 1H), 3.53-3.40 (m, 2H), 3.29 (d, J=16.0 Hz, 1H), 2.92 (d,
J=16.0 Hz, 1H), 1.37 (s, 3H). MS (ESI): m/z=375.1 [M+1].sup.+.
[0919] Example 74, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.77 (s, 1H), 9.38 (dd, J=1.6, 7.2 Hz, 1H), 8.87 (dd,
J=1.6, 4.4 Hz, 1H), 8.70 (s, 1H), 7.67 (s, 1H), 7.33 (dd, J=4.4,
7.2 Hz, 1H), 7.042 (t, J=55.2 Hz, 1H), 6.90 (s, 1H), 5.11 (t, J=6.0
Hz, 1H), 3.53-3.40 (m, 2H), 3.29 (d, J=16.0 Hz, 1H), 2.92 (d,
J=16.0 Hz, 1H), 1.37 (s, 3H). MS (ESI): m/z=375.1 [M+1].sup.+.
Example 75.
6-(Difluoromethyl)-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofur-
an-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00950##
[0920] Step A. 6-Formylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00951##
[0922] The mixture of 5-amino-1H-pyrazole-4-carboxylic acid (270
mg, 2.12 mmol) and methanetricarbaldehyde (205 mg, 2.05 mmol) in
ethanol (1.5 mL) and acetic acid (0.50 mL) was stirred at
25.degree. C. for 1 h and at 70.degree. C. for 1 h. After cooling
to room temperature, the mixture was filtered, the solid was washed
with ethanol and dryness in vacuo to afford
6-formylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (135 mg, 33.2%)
as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
12.04 (brs, 1H), 10.06 (s, 1H), 9.93 (d, J=2.0 Hz, 1H), 9.11 (d,
J=2.0 Hz, 1H), 8.79 (s, 1H). MS (ESI): m/z=192.1 [M+1].sup.+.
Step B.
6-Formyl-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00952##
[0924] The mixture of
6-formylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (110 mg, 0.58
mmol), N,N-diisopropylethylamine (0.22 mL, 1.35 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (330 mg, 0.87 mmol) and
(5-amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)methanol (Example
6, Step B) (115 mg, 0.44 mmol) in DMF (6 mL) was stirred at
25.degree. C. for 3 h. Water and ethyl acetate (150 mL) was added.
The organic phase was washed with water, brine, dried over
anhydrous sodium sulfate and concentrated in vacuo. Methyl alcohol
(1 mL) was added then the solid was collected after filtration to
afford
6-formyl-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (115 mg) and as a yellow
solid, which was used directly to next step without further
purification. MS (ESI): m/z=438.1 [M+1].sup.+.
Step C.
6-(Difluoromethyl)-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-b-
enzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00953##
[0926] To the mixture of
6-formyl-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (70 mg, 0.16 mmol) in DCM (10
mL) was added diethylaminosulfurtrifluoride (0.21 mL, 1.55 mmol)
under at 0.degree. C. and the mixture was stirred for 2 h. The
reaction mixture was diluted with DCM (10 mL) and water. The
organic phase was dried over anhydrous sodium sulfate and
concentrated in vacuo. The residue was purified by preparative HPLC
(A: acetonitrile 25-45%; B: 0.05% formic acid in water) to afford
6-(difluoromethyl)-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofur-
an-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (10.9 mg, 15%) as a
yellow solid. .sup.1H NMR (400 MHz, MeOD-d.sub.4) .delta. 9.46 (d,
J=1.6 Hz, 1H), 9.07 (d, J=1.6 Hz, 1H), 8.78 (s, 1H), 8.26 (s, 1H),
7.15 (t, J=55.2 Hz, 1H), 6.73 (s, 1H), 4.01-3.90 (m, 4H), 3.65-3.56
(m, 2H), 3.27 (d, J=15.2 Hz, 1H), 2.99-2.90 (m, 5H), 1.44 (s, 3H).
MS (ESI): m/z=460.1 [M+1].sup.+.
Examples 76 and 77.
(R)--N-(2-Methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00954##
[0927] Step A.
6-Chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydrobenzofuran
##STR00955##
[0928] The mixture of 3-(4-chloro-2-fluorophenyl)-1,1,1
-trifluoro-2-methylpropan-2-ol (500 mg. 1.95 mmol) and
tert-butoxvpotassium (875 mg. 7.80 mmol) in THF (20 mL) was stirred
at 65.degree. C. for 18 h. After cooling to room temperature, water
was added. The organic phase was separated and dried over sodium
sulfate. After concentration under reduced pressure, the residue
was purified by silica gel chromatography using ethyl acetate
petroleum ether (from 1:4 to 1:3) as eluting solvents to afford
6-chloro-2-methyl-2-(trifluoromethl)-2,3-dihydrobenzofuran (200 mg,
22%) as a colorless oil. MS (ESI): m/z=237.1 [M+l].sup.+.
Step B.
6-Chloro-2-methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofura-
n
##STR00956##
[0930] To a solution of
6-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydrobenzofuran (250
mg, 1.06 mmol) in DCM (20 mL) at 25.degree. C. was slowly added
fuming nitric acid (0.5 mL) and stirred for 15 min. Water and ethyl
acetate (30 mL) was added. The organic phase was separated and
dried over sodium sulfate. After concentration under reduced
pressure, the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (from 1:6 to 1:4) as eluting
solvents to afford
6-chloro-2-methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran
(250 mg, 82%) as orange solid. MS (ESI): m/z=282.2 [M+1].sup.+.
Step C.
4-(2-Methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-6-yl-
)morpholine
##STR00957##
[0932] A mixture of
6-chloro-2-methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran
(250 mg, 0.89 mmol) in morpholine (1 mL) in a sealed vial was
stirred at 65.degree. C. for 18 h. The mixture was concentrated
under reduced pressure. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:3) as eluting
solvents to afford
4-(2-methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-6-yl)morpho-
line (150 mg, 84%) as a yellow solid. MS (ESI): m/z=333.1
[M+1].sup.+.
Step D.
2-Methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5--
amine
##STR00958##
[0934] A mixture of
4-(2-methyl-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-6-yl)morpho-
line (150 mg, 0.45 mmol) and 10% palladium on carbon (15 mg) in
methanol (6 mL) was stirred at room temperature for 1 h under an
atmosphere of hydrogen. The catalyst was filtered off. The filtrate
was concentrated under reduced pressure to afford
2-methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-amine
(100 mg) as a colorless oil, which was used directly in the next
step without purification. MS (ESI): m/z=303.1 [M+1].sup.+.
Step E.
(R)--N-(2-Methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and(S)--N-(2-Methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofura-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00959##
[0936] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (54
mg, 0.33 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(172 mg, 0.33 mmol) and N-ethyl-N-isopropylpropan-2-amine (85 mg,
0.66 mmol) in DMF (5 mL) was stirred at room temperature for 30
min.
2-Methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-amine
(100 mg, 0.33 mmol) was added. The resulting mixture was stirred at
room temperature for 18 h. Water and ethyl acetate (30 mL) was
added. The organic phase was separated and dried over sodium
sulfate. After concentration, the residue was purified by silica
gel chromatography using ethyl acetate:petroleum ether (10:1) as
eluting solvents to afford the desired product and then it was
resolved by chiral HPLC(Column: CE-4, Mobile Phase:
Hexane/ethanol/DEA=70/30/0.1) to afford
(R)--N-(2-methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-methyl-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (48 mg each, 33.3%
each) as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[0937] Example 76, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 10.48 (s, 1H), 9.38 (dd, J=1.6, 6.8 Hz, 1H), 8.96 (dd,
J=1.6, 4.4 Hz, 1H), 8.69 (s, 1H), 8.40 (s, 1H), 7.35 (dd, J=4.0,
6.8 Hz, 1H), 6.93 (s, 1H), 3.85-3.83 (m, 4H), 3.52 (d, J=16.8 Hz,
1H), 3.30 (d, J=16.8 Hz, 1H), 2.85-2.83 (m, 4H), 1.62 (s, 3H). MS
(ESI): m/z=448.2 [M+1].sup.+.
[0938] Example 77, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.48 (s, 1H), 9.38 (dd, J=1.6, 6.8 Hz, 1H), 8.95 (dd,
J=1.6, 4.0 Hz, 1H), 8.69 (s, 1H), 8.40 (s, 1H), 7.35 (dd, J=4.0,
6.8 Hz, 1H), 6.93 (s, 1H), 3.85-3.83 (m, 4H), 3.52 (d, J=16.8 Hz,
1H), 3.30 (d, J=16.8 Hz, 1H), 2.90-2.80 (m, 4H), 1.62 (s, 3H). MS
(ESI): m/z=448.2 [M+1].sup.+.
Examples 78 and 79.
N--((S)-2-(Hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide and
N--((R)-2-(hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00960##
[0939] Step A. (1S,4S)-tert-Butyl
5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
##STR00961##
[0941] The mixture of (1S,4S)-tert-butyl
2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (70 mg, 0.35 mmol),
2,2,2-trifluoroethyl trifluoromethanesulfonate (81 mg, 0.35 mmol)
and potassium carbonate (97 mg, 0.70 mmol) in acetonitrile (5 mL)
was stirred at room temperature for 18 h. After filtration, the
filtrate was concentrated in vacuo to afford (1S,4S)-tert-butyl
5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
(95 mg) as a colorless oil, which was used directly to the next
step without purification. MS (ESI): m z=281.1 [M+1].sup.+.
Step B.
(1S,4S)-2-(2,2,2-Trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane
##STR00962##
[0943] A mixture of (1S,4S)-tert-butyl
5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
(95 mg, 0.34 mmol) in 2,2,2-trifluoroacetic acid (1 mL) and DCM (2
mL) was stirred at room temperature for anh. The mixture was
concentrated in vacuo to afford
((1S,4S)-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane
2,2,2-trifluoroacetic acid salt (55 mg) as a colorless oil, which
was used directly to the next step without purification. MS (ESI):
m/z=181.1 [M+1].sup.+.
Step C.
(2-Methyl-5-nitro-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabic-
yclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol
##STR00963##
[0945] A mixture of
(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (70
mg, 0.31 mmol),
(1S,4S)-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptane (55
mg, 0.31 mmol) and cesium carbonate (303 mg, 0.93 mmol) in
acetonitrile (5 mL) was stirred at room temperature for 18 h. The
mixture was poured into water and the aqueous phase was extracted
with ethyl acetate (2.times.30 mL). The organic phases were
combined, washed with water and brine. After concentration under
reduced pressure, the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:3) as eluting
solvents to afford
(2-methyl-5-nitro-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.-
2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol (110 mg, 92%)
as a yellow solid. MS (ESI): m/z=388.1 [M+1].sup.+.
Step D.
(5-Amino-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabic-
yclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol
##STR00964##
[0947] A mixture of
(2-methyl-5-nitro-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.-
2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol (110 mg, 0.28
mmol) and 10% palladium on carbon (11 mg) in methanol (5 mL) was
stirred at room temperature for 1 h under an atmosphere of
hydrogen. After filtration and concentration under reduced
pressure, it was afforded
(5-amino-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.-
2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol (80 mg, 79%)
as a colorless oil, which was used directly to the next step
without purification. MS (ESI): m/z=358.1 [M+1].sup.+.
Step E.
N--((S)-2-(Hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroet-
hyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide and
N--((R)-2-(Hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR00965##
[0949] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (36
mg, 0.22 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(115 mg, 0.22 mmol) and N-ethyl-N-isopropylpropan-2-amine (85 mg,
0.66 mmol) in DMF (5 mL) was stirred at room temperature for 30
min.
(5-Amino-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.-
2.1]heptan-2-yl)-2,3-dihydrobenzofuran-2-yl)methanol (80 mg, 0.22
mmol) was added. The resulting mixture was stirred at room
temperature for 18 h. Water and ethyl acetate (30 mL) was added.
The organic phase was separated and dried over sodium sulfate.
After concentration under reduced pressure, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (10:1) as eluting solvents to afford the desired product and
then it was resolved by chiral pre-SFC (Column: OD 4.6*250 mm, 5 um
(Decial), Column temperature: 35.degree. C., Mobile phase:
CO2/Methanol(0.2% Methanol Ammonia)=70/30) to afford
N--((S)-2-(hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide and
N--((R)-2-(hydroxymethyl)-2-methyl-6-((1S,4S)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide (8 mg each, 7% each) as yellow solids
with absolute stereochemistry assigned arbitrarily.
[0950] Example 78, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.9.74 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.85 (dd, J=1.6,
4.0 Hz, 1H), 8.69 (s, 1H), 7.80 (s, 1H), 7.33 (dd, J=4.0, 6.8 Hz,
1H), 6.48 (s, 1H), 5.04 (t, J=6.0 Hz, 1H), 3.93 (s, 1H), 3.51 (s,
1H), 3.45-3.41 (m, 2H), 3.32-3.25 (m, 3H), 3.16 (d, J=16.0 Hz, 1H),
3.07-3.04 (m, 1H), 2.92-2.88 (m, 2H), 2.78 (d, J=15.6 Hz, 1H),
1.89-1.76 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z=503.3
[M+1].sup.+.
[0951] Example 79, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 9.72 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.85 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 7.78 (s, 1H), 7.33 (dd, J=4.0,
6.8 Hz, 1H), 6.47 (s, 1H), 5.04 (t, J=6.0 Hz, 1H), 3.93 (s, 1H),
3.50 (s, 1H), 3.45-3.41 (m, 2H), 3.32-3.25 (m, 3H), 3.16 (d, J=16.0
Hz, 1H), 3.07-3.04 (m, 1H), 2.92-2.88 (m, 2H), 2.78 (d, J=15.6 Hz,
1H), 1.89-1.76 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z=503.3
[M+1].sup.+.
Examples 80 and 81.
(R)--N-(7-Chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(7-chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00966##
[0952] Step A. 1,2-Dichloro-3-(2-methylallyloxy)benzene
##STR00967##
[0954] A mixture of 2,3-dichlorophenol (500 mg, 3.07 mmol),
3-bromo-2-methylpropene (497 mg, 3.68 mmol) and potassium carbonate
(848 mg, 6.14 mmol) in acetonitrile (10 mL) was stirred at
25.degree. C. for 18 h. The reaction was then filtered,
concentrated and purified by silica gel chromatography using
petroleum ether to afford 1,2-dichloro-3-(2-methylallyloxy)benzene
(659 mg, 99%) as a colorless oil. MS (ESI): m/z=218.1
[M+1].sup.+.
Step B. 2,3-Dichloro-6-(2-methylallyl)phenol
##STR00968##
[0956] A mixture of 1,2-dichloro-3-(2-methylallyloxy)benzene (600
mg, 2.76 mmol) in DMF (3 mL) was stirred at 220.degree. C. under
microwave for 2 h. Water was added and the mixture was extracted
with ethyl acetate (10 mL). The organic phase was washed with
brine, dried over sodium sulfate and concentrated to afford
2,3-dichloro-6-(2-methylallyl)phenol (400 mg) as light yellow oil,
which was used directly to next step without further
purification.
Step C.
(6,7-Dichloro-2-methyl-2,3-dihydrobenzofuran-2-yl)methanol
##STR00969##
[0958] A mixture of 3-chloro-2-methyl-6-(2-methylallyl)phenol (400
mg, 1.84 mmol) in DCM (10 mL) was added 3-chloroperoxybenzoic acid
(558 mg, 2.76 mmol) under ice-cooling. The mixture was stirred at
25.degree. C. for 18 h. The reaction was filtered and the filtrate
was concentrated to afford
(6,7-dichloro-2-methyl-2,3-dihydrobenzofuran-2-yl)methanol (300 mg,
70%) as a yellow oil, which was used directly to next step without
purification further. MS (ESI): m/z=233.1 [M+1].sup.+.
Step D.
(6,7-Dichloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00970##
[0960] To a mixture of
(6,7-dichloro-2-methyl-2,3-dihydrobenzofuran-2-yl)methanol (300 mg,
1.29 mmol) in DCM (10 mL) was added drop-wise fuming nitric acid
(0.5 mL) at 25.degree. C. The mixture was stirred at 25.degree. C.
for 30 min and poured into ice water. The aqueous phase was
extracted with ethyl acetate (30 mL). The organic phase was dried
over sodium sulfate. After concentration under reduced pressure,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:4) as eluting solvents to afford
(6,7-dichloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(220 mg, 61%) as light grey solid. MS (ESI): m/z=279.1
[M+1].sup.+.
Step E.
(7-Chloro-2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl-
)methanol
##STR00971##
[0962] A mixture of
(6,7-dichloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(220 mg, 0.79 mmol) in morpholine (2 mL) in a sealed tube was
stirred at 110.degree. C. for 18 h. The mixture was concentrated
and purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
(7-chloro-2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methan-
ol (200 mg, 77%) as a yellow oil. MS (ESI): m/z=329.1
[M+1].sup.+.
Step F.
(5-Amino-7-chloro-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl-
)methanol
##STR00972##
[0964] A mixture of
(7-chloro-2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methan-
ol (100 mg, 0.30 mmol) and 10% palladium on carbon (10 mg) in
methanol (10 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration and concentration under
reduced pressure, it was afforded
(5-amino-7-chloro-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methan-
ol (60 mg) as a green oil, which was used directly to next step
without further purification. MS (ESI): m/z=299.1[M+1].sup.+.
Step G.
(R)--N-(7-Chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihyd-
robenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(7-chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00973##
[0966] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (33
mg, 0.20 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(104 mg, 0.69 mmol), N-ethyl-N-isopropylpropan-2-amine (78 mg, 0.60
mmol) and
(5-amino-7-chloro-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)me-
thanol (60 mg, 0.20 mmol) in DMF (5 mL) was stirred at room
temperature for 18 h. Water was added and the mixture was extracted
with ethyl acetate (10 mL). The organic phase was washed with brine
and dried over sodium sulfate. After concentration under reduced
pressure and the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (10:1) as eluting solvents to
afford
N-(7-chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (40 mg, 45%) as a
yellow solid. Then the desired product was resolved by chiral
pre-SFC(Column: AD 20*250 mm, 5 um (Dacel), Column temperature:
35.degree. C., Mobile phase: CO.sub.2/Ethanol{0.5% Ammonia (7 m
methanol)}=70/30) to obtain
(R)--N-(7-chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(7-chloro-2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (15 mg each, 17%
each) as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[0967] Example 80, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 10.73 (s, 1H), 9.39 (dd, J=1.6, 7.2 Hz, 1H), 8.91 (dd,
J=1.6, 4.0 Hz, 1H), 8.70 (s, 1H), 8.44 (s, 1H), 7.37 (dd, J=4.0,
7.2 Hz, 1H), 5.13 (t, J=5.6 Hz, 1H), 4.02-3.93 (m, 2H), 3.89-3.83
(m, 2H), 3.70 (t, J=10.8 Hz, 2H), 3.54-3.41 (m, 2H), 3.38-3.34 (m,
1H), 2.96 (d, J=16.4 Hz, 1H), 2.69 (d, J=11.6 Hz, 2H), 1.38 (s,
3H).
[0968] MS (ESI): m/z=444.1 [M+1].sup.+.
[0969] Example 81, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.73 (s, 1H), 9.39 (dd, J=1.6, 7.2 Hz, 1H), 8.91 (dd,
J=1.6, 4.4 Hz, 1H), 8.70 (s, 1H), 8.44 (s, 1H), 7.37 (dd, J=4.4,
6.8 Hz, 1H), 5.13 (t, J=5.6 Hz, 1H), 4.02-3.93 (m, 2H), 3.89-3.82
(m, 2H), 3.70 (t, J=10.0 Hz, 2H), 3.55-3.41 (m, 2H), 3.38-3.34 (m,
1H), 2.96 (d, J=16.4 Hz, 1H), 2.69 (d, J=12.0 Hz, 2H), 1.38 (s,
3H). MS (ESI): m/z=444.1 [M+1].sup.+.
Example 82.
N-(3,3-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR00974##
[0970] Step A. 4-Fluoro-2-(2-methylallyloxy)-1-nitrobenzene
##STR00975##
[0972] A mixture of 5-fluoro-2-nitrophenol (2.0 g, 12.73 mmol),
3-bromo-2-methylpropene (1.54 mL, 15.3 mmol) and potassium
carbonate (3.5 g, 25.46 mmol) in acetonitrile (50 mL) was stirred
at 50.degree. C. for 18 h. The reaction was filtered and the
filtrate was concentrated and purified by silica gel chromatography
using petroleum ether to afford
4-fluoro-2-(2-methylallyloxy)-1-nitro-benzene (780 mg, 29%) as
light oil. MS (ESI): m z=230.2 [M+H.sub.2O].sup.+.
Step B. 4-Fluoro-2-(2-methylallyloxy)aniline
##STR00976##
[0974] A mixture of 4-fluoro-2-(2-methylallyloxy)-1-nitro-benzene
(780 mg, 3.69 mmol), iron powder (1.0 g, 18.47 mmol) and ammonium
chloride (978 mg, 18.47 mmol) in ethanol (30 mL) and water (4 mL)
was stirred at 70.degree. C. for 2 h. The reaction was filtered and
the filtrate was dried over sodium sulfate and concentrated. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:30) to afford
4-fluoro-2-(2-methylallyloxy)aniline (560 mg, 84%) as light oil. MS
(ESI): m/z=182.1 [M+1].sup.+.
Step C. 1-Azido-4-fluoro-2-(2-methylallyloxy)benzene
##STR00977##
[0976] To a mixture of 4-fluoro-2-(2-methylallyloxy)aniline (100
mg, 0.55 mmol) in acetonitrile (10 mL) was added tert-butyl nitrite
(85 mg, 0.83 mmol) followed by trimethylsilylazid (95 mg, 0.83
mmol) at 0.degree. C. The mixture was stirred at 25.degree. C. for
1 h. Water was added and the aqueous phase was extracted with ethyl
acetate (20 mL). The organic phase was separated, dried over sodium
sulfate. The filtrate was concentrated under reduced pressure to
afford 1-azido-4-fluoro-2-(2-methylallyloxy)benzene (99 mg) as a
yellow oil, which was used directly to next step without further
purification. MS (ESI): m/z=208.0 [M+1].sup.+.
Step D.
5-Fluoro-la-methyl-1a,2-dihydro-1H-azirino[1,2-d]benzo[b][1,4]oxaz-
ine
##STR00978##
[0978] A mixture of 1-azido-4-fluoro-2-(2-methylallyloxy)benzene
(99 mg, 0.48 mmol) in toluene (5 mL) was stirred at 110.degree. C.
for 18 h. The solvent was removed under reduced pressure. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:15) as eluting solvents to afford
5-fluoro-1a-methyl-1,2-dihydroazirino[2,1-c][1,4]benzoxazine (38
mg, 44%) as a colorless oil. .sup.1HNMR (400 MHz, CDCl.sub.3):
7.00-7.03 (m, 1H), 6.75-6.79 (m, 1H), 6.66-6.71 (m, 1H), 4.13 (d,
J=11.2 Hz, 1H), 3.95 (d, J=11.2 Hz, 1H), 2.30 (s, 2H), 1.37 (s,
3H).
Step E.
7-Fluoro-3,3-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00979##
[0980] A mixture of 10% palladium on carbon (60 mg) and
5-fluoro-la-methyl-1,2-dihydroazirino[2,1-c][1,4]benzoxazine (300
mg, 1.67 mmol) in ethanol (20 mL) was stirred at 25.degree. C.
under hydrogen atmosphere for 2 h. After filtration and
concentration under reduced pressure, it was afforded
7-fluoro-3,3-dimethyl-2,4-dihydro-1,4-benzoxazine (200 mg) as a
brown solid, which was used directly to next step without further
purification. MS (ESI): m/z=182.1 [M+1].sup.+.
Step F.
7-Fluoro-3,3-dimethyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine
##STR00980##
[0982] To a mixture of
7-fluoro-3,3-dimethyl-2,4-dihydro-1,4-benzoxazine (160 mg, 0.88
mmol) in sulfuric acid (4 mL) was added slowly guanidine nitrate
(108 mg, 0.88 mmol) at 0.degree. C. The mixture was stirred at
0.degree. C. for 3 h. The mixture was poured into ice water and
neutralized with sodium carbonate. The aqueous phase was extracted
with ethyl acetate (20 mL). The organic phase was dried over sodium
sulfate and concentrated. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:4) as eluting
solvents to afford
7-fluoro-3,3-dimethyl-6-nitro-2,4-dihydro-1,4-benzoxazine (70 mg,
35%) as a brown solid. MS (ESI): m/z=227.1 [M+1].sup.+.
Step G.
3,3-Dimethyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxaz-
ine
##STR00981##
[0984] A mixture of
7-fluoro-3,3-dimethyl-6-nitro-2,4-dihydro-1,4-benzoxazine (70 mg,
0.31 mmol), morpholine (40 mg, 0.46 mmol) and cesium carbonate (202
mg, 0.62 mmol) in acetonitrile (10 mL) was stirred at 85.degree. C.
for 18 h. The reaction was filtered and the filtrate was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:1) as eluting solvents to afford
3,3-dimethyl-7-morpholino-6-nitro-2,4-dihydro-1,4-benzoxazine (69
mg, 56%) as a yellow oil. MS (ESI): m/z=294.1 [M+1].sup.+.
Step H.
3,3-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ami-
ne
##STR00982##
[0986] A mixture of 10% palladium on carbon (15 mg) and
3-dimethyl-7-morpholino-6-nitro-2,4-dihydro-1,4-benzoxazine (69 mg,
0.24 mmol) in ethyl acetate (15 mL) was stirred at 40.degree. C.
under hydrogen atmosphere for 2 h. After filtration and
concentration under reduced pressure, it was afforded
3,3-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
(50 mg, 76%) as dark solid. MS (ESI): m/z=264.1 [M+1].sup.+.
Step I.
N-(3,3-Dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00983##
[0988] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (37
mg, 0.23 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(148 mg, 0.28 mmol), N-ethyl-N-isopropylpropan-2-amine (69 mg, 0.57
mmol) and
3,3-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine
(50 mg, 0.19 mmol) in DMF (10 mL) was stirred at room temperature
for 18 h. Water was added. The aqueous phase was extracted with
ethyl acetate (10 mL). The organic phase was washed with brine and
dried over sodium sulfate. After concentration under reduced
pressure, the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (9:1) as eluting solvents to
afford
N-(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3--
carboxamide (10 mg, 13%) as a yellow solid. .sup.1HNMR (400 MHz,
CDCl.sub.3): 10.48 (s, 1H), 8.82 (dd, J=1.6, 7.2 Hz, 1H), 8.79 (s,
1H), 8.75 (dd, J=1.6, 4.0 Hz, 1H), 8.18 (s, 1H), 7.05 (dd, J=4.0,
7.2 Hz, 1H), 6.47 (s, 1H), 5.36 (brs, 1H), 3.93-3.95 (m, 4H), 3.83
(s, 2H), 2.88-2.89 (m, 4H), 1.24 (s, 6H). MS (ESI): m/z=409.2
[M+1].sup.+.
Examples 83 and 84.
(R)--N-(2-(Hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00984##
[0989] Step A. 1-Chloro-2-methyl-3-(2-methylallyloxy)benzene
##STR00985##
[0991] A mixture of 3-chloro-2-methylphenol (2.0 g, 14.03 mmol),
3-bromo-2-methylpropene (1.7 mL, 16.86 mmol) and potassium
carbonate (3.87 g, 28.05 mmol) in acetonitrile (50 mL) was stirred
at 25.degree. C. for 18 h. The reaction was filtered and the
filtrate was concentrated under reduced pressure and the residue
was purified by silica gel chromatography using petroleum ether to
afford 1-chloro-2-methyl-3-(2-methylallyloxy)benzene (2.3 g, 83%)
as a colorless oil. .sup.1HNMR (400 MHz, CDCl.sub.3): 7.03-7.07 (m,
1H), 6.96-6.98 (m, 1H), 6.72 (d, J=8.0 Hz, 1H), 5.10 (s, 1H), 4.99
(s, 1H), 4.42 (s, 1H), 2.31 (s, 3H), 1.84 (s, 3H).
Step B. 3-Chloro-2-methyl-6-(2-methylallyl)phenol
##STR00986##
[0993] A mixture of 1-chloro-2-methyl-3-(2-methylallyloxy)benzene
(300 mg, 1.53 mmol) in DMF (4.5 mL) was stirred at 220.degree. C.
under microwave condition for 2 h. Water was added and the mixture
was extracted with ethyl acetate (10 mL). The organic phase was
washed with brine and dried over sodium sulfate. The reaction was
filtered and the filtrate was concentrated to afford
3-chloro-2-methyl-6-(2-methylallyl)phenol (322 mg, 86%) as a
colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 6.90 (d,
J=8.4 Hz, 1H), 6.85 (d, J=8.0 Hz, 1H), 5.42 (s, 1H), 4.96 (s, 1H),
4.91 (s, 1H), 3.34 (s, 1H), 2.28 (s, 3H), 1.57 (s, 3H).
Step C.
(6-Chloro-2,7-dimethyl-2,3-dihydrobenzofuran-2-yl)methanol
##STR00987##
[0995] A mixture of 3-chloro-2-methyl-6-(2-methylallyl)phenol (300
mg, 1.53 mmol) in DCM (10 mL) was added 3-chloroperoxybenzoic acid
(306 mg, 1.83 mmol) at 0.degree. C. The mixture was stirred at
25.degree. C. for 18 h. The reaction was filtered and the filtrate
was concentrated to afford
(6-chloro-2,7-dimethyl-3H-benzofuran-2-yl)methanol (500 mg) as a
yellow oil, which was used directly to next step without further
purification. MS (ESI): m/z=213.1 [M+1].sup.-.
Step D.
(6-Chloro-2,7-dimethyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR00988##
[0997] A mixture of
(6-chloro-2,7-dimethyl-3H-benzofuran-2-yl)methanol (500 mg, 2.35
mmol) in DCM (10 mL) was added drop wise fuming nitric acid (0.3
mL) at 25.degree. C. The mixture was stirred at 25.degree. C. for
30 min. The mixture was poured into ice water and extracted with
ethyl acetate (30 mL). The organic phase was dried over sodium
sulfate and concentrated. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:4) as eluting
solvents to afford
(6-chloro-2,7-dimethyl-5-nitro-3H-benzofuran-2-yl)methanol (182 mg,
50%) as light grey solid. MS (ESI): m/z=258.1 [M+1].sup.+.
Step E.
(2,7-Dimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)meth-
anol
##STR00989##
[0999] A mixture of
(6-chloro-2,7-dimethyl-5-nitro-3H-benzofuran-2-yl)methanol (182 mg,
0.71 mmol) in morpholine (4 mL) was stirred at 110.degree. C. for
18 h. After concentration under reduced pressure, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:1) as eluting solvents to afford
(2,7-dimethyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)methanol (200
mg, 79%) as a yellow oil. MS (ESI): m/z=309.1 [M+1].sup.+.
Step F.
(5-Amino-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)meth-
anol
##STR00990##
[1001] A mixture of 10% palladium on carbon (60 mg) and
(2,7-dimethyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)methanol (200
mg, 0.65 mmol) in methanol (20 mL) was stirred at 25.degree. C.
under hydrogen atmosphere for 1 h. After filtration and
concentration under reduced pressure, it was afforded
(5-amino-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol
(183 mg) as a green oil, which was used directly to next step
without further purification. MS (ESI): m/z=279.1 [M+1].sup.-.
Step G.
(R)--N-(2-(Hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(Hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00991##
[1003] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (90
mg, 0.55 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(360 mg, 0.69 mmol), N-ethyl-N-isopropylpropan-2-amine (167 mg,
1.38 mmol) and
(5-amino-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)m-
ethanol (183 mg, 0.46 mmol) in DMF (10 mL) was stirred at room
temperature for 18 h. Water was added and the mixture was extracted
with ethyl acetate (20 mL). The organic phase was washed with brine
and dried over sodium sulfate and concentration under reduced
pressure. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (9:1) as eluting solvents to
afford
N-(2-(hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (80 mg, 41%) as a yellow
solid. The product was resolved by chiral pre-SFC(Column: AD 20*250
mm, 5 um (Dacel), Mobile phase: CO.sub.2/methanol {0.5% Ammonia (7
m methanol)}=70/30) to obtain
(R)--N-(2-(hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (30 mg, 37%) (35 mg,
44%) as a yellow solids with absolute stereochemistry assigned
arbitrarily.
[1004] Example 83, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.62 (s, 1H), 8.83 (dd, J=1.8, 7.2 Hz, 1H), 8.79 (s, 1H),
8.77 (dd, J=1.8, 4.0 Hz, 1H), 8.36 (s, 1H), 7.07 (dd, J=4.4, 7.2
Hz, 1H), 4.08-4.12 (m, 2H), 3.89-3.91 (m, 2H), 3.64-3.67 (m, 2H),
3.52-3.57 (m, 2H), 3.26 (d, J=15.6 Hz, 1H), 2.94 (d, J=15.6 Hz,
1H), 2.84 (d, J=11.6 Hz, 2H), 2.30 (s, 3H), 2.06 (br, 1H), 1.45 (s,
3H). MS (ESI): m/z=424.1[M+1].sup.+.
[1005] Example 84, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.62 (s, 1H), 8.83 (dd, J=1.8, 7.2 Hz, 1H), 8.79 (s, 1H),
8.77 (dd, J=1.8, 4.0 Hz, 1H), 8.36 (s, 1H), 7.07 (dd, J=4.4, 7.2
Hz, 1H), 4.08-4.12 (m, 2H), 3.89-3.91 (m, 2H), 3.64-3.67 (m, 2H),
3.52-3.57 (m, 2H), 3.26 (d, J=15.6 Hz, 1H), 2.94 (d, J=15.6 Hz,
1H), 2.84 (d, J=11.6 Hz, 2H), 2.30 (s, 3H), 2.06 (br, 1H), 1.45 (s,
3H). MS (ESI): m/z=424.1[M+1].sup.+.
Examples 85 and 86.
(R)-6-Acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-Acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00992##
[1006] Step A. 6-Bromopyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR00993##
[1008] The mixture of 2-bromomalonaldehyde (754.8 mg, 5 mmol) and
5-amino-1H-pyrazole-4-carboxylic acid (635.5 mg, 5 mmol) was
stirred at 90.degree. C. in acetic acid (6 mL) and ethanol (2 mL)
for 4 h. After cooling to room temperature and concentration, the
residue was filtered and solid was washed with water and ethyl
acetate to afford 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (680 mg, 52.1%) as pale brown solid. MS (ESI):
m/z=244.0[M+1].sup.+.
Step B.
6-Bromo-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00994##
[1010] A mixture of 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (88 mg, 0.36 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(237 mg, 0.45 mmol), N-ethyl-N-isopropylpropan-2-amine (110 mg,
0.91 mmol) and
(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)metha-
nol (Example 6, Step B) (80 mg, 0.30 mmol) in DMF (10 mL) was
stirred at room temperature for 18 h. Water was added and the
mixture was extracted with ethyl acetate (20 mL). The organic phase
was washed with brine and dried over sodium sulfate and
concentration. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (9:1) as eluting
solvents to afford
6-bromo-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran--
5-yl)pyrazolo[1,5-a]pyrimidine-3-carb oxamide (66 mg, 45%) as a
yellow solid. MS (ESI): m/z=488.1[M+1].sup.+.
Step C.
(R)-6-Acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydr-
obenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-Acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00995##
[1012] A mixture of tributyl(1-ethoxyvinyl)stannane (98 mg, 0.27
mmol),
6-bromo-N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyr-
azolo[1,5-a]pyrimidine-3-carboxamide (66 mg, 0.14 mmol) and
tetrakis(triphenylphosphine)palladium (16 mg, 0.01 mmol) in toluene
(15 mL) was stirred at 100.degree. C. under nitrogen atmosphere for
18 h. After cooling down to room temperature, the mixture was added
hydrochloride solution (6 mL, 4 m in dioxane). The mixture was
stirred at room temperature for 1 hs. After concentration under
reduced pressure, the residue was purified by preparative HPLC
(Gilson 281, Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile,
25-55%; B: 10 mM ammonium bicarbonate in water) to afford
6-acetyl-N-[(2R)-2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5--
yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (40 mg, 65%) as a yellow
solid. The product was resolved by chiral pre-SFC(Column: OJ 30*250
mm, 5 um (Dacel), Mobile phase: CO.sub.2/methanol {0.2% Ammonia (7
m methanol)}=75/25) to afford
(R)-6-acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)-6-acetyl-N-(2-(hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (5.3 mg, 0.08%)
(2.8 mg, 0.04%) as a yellow solid.
[1013] Example 85, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.41 (s, 1H), 9.35 (d, J=2.0 Hz, 1H), 9.24 (d, J=2.0 Hz,
1H), 8.90 (s, 1H), 8.42 (s, 1H), 6.68 (s, 1H), 3.94-3.97 (m, 4H),
3.66 (s, 2H), 3.25 (d, J=16.4 Hz, 1H), 2.94 (d, J=16.4 Hz, 1H),
2.90-2.92 (m, 4H), 1.98-2.02 (m, 1H), 1.88-1.92 (m, 1H), 1.46 (s,
3H). MS (ESI): m/z=452.1[M+1].sup.+.
[1014] Example 86, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.41 (s, 1H), 9.35 (d, J=2.0 Hz, 1H), 9.24 (d, J=2.0 Hz,
1H), 8.90 (s, 1H), 8.42 (s, 1H), 6.68 (s, 1H), 3.94-3.97 (m, 4H),
3.66 (s, 2H), 3.25 (d, J=16.4 Hz, 1H), 2.94 (d, J=16.4 Hz, 1H),
2.90-2.92 (m, 4H), 1.98-2.02 (m, 1H), 1.88-1.92 (m, 1H), 1.46 (s,
3H). MS (ESI): m/z=452.1[M+1].sup.+.
Examples 87 and 88.
N-[(2R)-6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00996##
[1015] Step A.
2-[4-[2-(Hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]piperazin-1-y-
l]ethanol
##STR00997##
[1017] A mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 2) (150 mg, 0.62 mmol) and 1-piperazineethanol (320
mg, 2.46 mmol) in DMSO (2 mL) was stirred at 90.degree. C. for 3 h.
The mixture was purified by silica gel chromatography using
methanol: DCM (1:10) as eluting solvents to afford
2-[4-[2-(Hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]piperazin-1-y-
l]ethanol (110 mg, 49%) as a yellow oil. MS (ESI): m/z=338.2
[M+1].sup.+.
Step B.
2-[4-[5-Amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]pipera-
zin-1-yl]ethanol
##STR00998##
[1019] A mixture of
2-[4-[2-(hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]piperazin-1-y-
l]ethanol (110.0 mg, 0.33 mmol) and 10% palladium on carbon (11 mg)
in methanol (10 mL) was stirred at room temperature under hydrogen
atmosphere for 1 h. The solid was filtered off and the filtrate was
concentrated under reduced pressure to afford
2-[4-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]piperazin-1-y-
l]ethanol (102 mg) as a yellow oil, which was used directly to next
step without further purification. MS (ESI): m/z=308.2
[M+1].sup.+.
Step C.
N-[(2R)-6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-m-
ethyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-[(2S)-6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR00999##
[1021] A solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(110 mg, 0.67 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (320 mg, 0.84 mmol) and diisopropylethylamine
(0.22 mL, 1.34 mmol) was stirred in DMF (3 mL) at room temperature
for 10 min. To this mixture was added
2-[4-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]piperazin-1-y-
l]ethanol (102 mg, 0.33 mmol) in DMF (2 mL) and the mixture was
stirred for an additional 16 h. The crude reaction was purified by
preparative HPLC (Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile
25-70%; B: 10 mM ammonium bicarbonate in water) and then the
product was resolved by chiral separation (SFC (OD-H 20*250 mm, 5
um, CO.sub.2/methanol(0.2% Ammonia (7 m methanol))=75/25,
35.degree. C.) to afford
N-[(2R)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (10.1 mg
each, 7% each) as a yellow solids with absolute stereochemistry
assigned arbitrarily.
[1022] Example 87, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.40 (s, 1H), 8.83 (dd, J=1.6, 7.2 Hz, 1H), 8.79 (s, 1H),
8.72 (dd, J=1.6, 4.0 Hz, 1H), 8.42 (s, 1H), 7.06 (dd, J=4.0, 7.2
Hz, 1H), 6.67 (s, 1H), 3.73-3.62 (m, 4H), 3.25 (d, J=15.8 Hz, 1H),
2.99-2.89 (m, 5H), 2.71-2.83 (m, 4H), 2.68-2.61 (m, 2H), 1.46 (s,
3H). MS (ESI): m/z=453.3 [M+1].sup.+.
[1023] Example 88, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.40 (s, 1H), 8.83 (dd, J=1.6, 7.2 Hz, 1H), 8.79 (s, 1H),
8.72 (dd, J=1.6, 4.0 Hz, 1H), 8.42 (s, 1H), 7.05 (dd, J=4.0, 7.2
Hz, 1H), 6.67 (s, 1H), 3.71-3.64 (m, 4H), 3.25 (d, J=15.7 Hz, 1H),
2.98-2.90 (m, 5H), 2.71-2.83 (m, 4H), 2.68-2.61 (m, 2H), 1.46 (s,
3H). MS (ESI): m/z=453.3 [M+1].sup.+.
Example 89.
N-[6-[1-(2,2-Difluoroethyl)-4-piperidyl]-2,2-dimethyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01000##
[1024] Step A. tert-Butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate
##STR01001##
[1026] The mixture of tert-butyl
4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-5,6-dihydropyridine-1-
(2H)-carboxylate, 6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 4) (1.0 g, 3.68 mmol), [1,1'-bis
(diphenylphosphino)ferrocene]dichloropalladium (II) (135 mg, 0.18
mmol) and cesium carbonate (2.4 g, 7.37 mmol) in 1,4-dioxane (10
mL) and water (1 mL) in sealed tube was stirred at 90.degree. C.
under microwave condition for 2 h. The mixture was poured into
water (30 mL) and extracted with ethyl acetate (100 mL). The
organic phases were washed with water and brine and dried over
sodium sulfate before concentration to dryness. The residue was
purified by preparative TLC using ethyl acetate:petroleum ether
(1:4) as eluting solvents to afford tert-butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate (1.28 g, 93%) as a yellow solid. MS (ESI): m/z=397.1
[M+Na].sup.+.
Step B. tert-Butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
##STR01002##
[1028] A mixture of tert-butyl
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-3,6-dihydro-2H-pyridine-1-car-
boxylate (50 mg, 0.13 mmol) and 10% palladium on carbon (8 mg) in
methanol (10 mL) was stirred at room temperature under a hydrogen
atmosphere for 1 h. The solid was filtered off and the filtrate was
concentrated under reduced pressure to afford tert-butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
(960 mg) as a brown oil, which was used directly to next step
without further purification.
Step C. tert-Butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate
##STR01003##
[1030] A solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(860 mg, 5.27 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (2.0 g, 5.26 mmol) and diisopropylethylamine (2
mL, 8.13 mmol) was stirred in DMF (10 mL) at room temperature for
10 min. To this mixture [5-tert-butyl
4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperidine-1-carboxylate
(910 mg, 2.63 mmol) in DMF (4 mL) was added and stirred for
additional 16 h. The mixture was poured into water (50 mL) and
extracted with ethyl acetate (100 mL). The organics washed with
water, brine and dried over sodium sulfate before concentration to
dryness. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (1:1) as eluting solvents to
afford tert-butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate (1.2 g, 84%) as a yellow
solid.
[1031] MS (ESI): m/z=492.2[M+1].sup.+.
Step D.
N-[2,2-Dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]-
pyrimidine-3-carboxamide
##STR01004##
[1033] To a solution of tert-butyl
4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofur-
an-6-yl]piperidine-1-carboxylate (1.2 g, 2.20 mmol) in DCM (5 mL)
was added trifluoroacetic acid (2.9 mL, 39.5 mmol) and the mixture
was stirred at 25.degree. C. for 2 h. The mixture was neutralized
by triethylamine. After concentration, it was afforded
N-[2,2-dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (950 mg) as a yellow solid, which was used
directly to next step without further purification. MS (ESI):
m/z=392.2[M+1].sup.+.
Step E.
N-[6-[1-(2,2-Difluoroethyl)-4-piperidyl]-2,2-dimethyl-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01005##
[1035] A mixture of
N-[2,2-dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (160 mg, 0.41 mmol), 2,2-difluoroethyl
trifluoromethanesulfonate (262 mg, 1.22 mmol) and cesium carbonate
(400 mg, 1.23 mmol) was stirred in DMF (10 mL) at 25.degree. C. for
15 h. The mixture was purified by preparative HPLC(Xbridge 19*250
mm c18, 10 um; A: acetonitrile 30-60%; B: 10 mM ammonium
bicarbonate in water) to afford
N-[6-[1-(2,2-difluoroethyl)-4-piperidyl]-2,2-dimethyl-3H-benzofuran-5-yl]-
pyrazzolo[1,5-a]pyrimidine-3-carboxamide (25 mg, 14%) as a yellow
solid. H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.60 (s, 1H), 9.39
(dd, J=1.6, 6.8 Hz, 1H), 8.89 (dd, J=1.6, 4.0 Hz 1H), 8.68 (s, 1H),
7.74 (s, 1H), 7.34 (dd, J=4.0, 6.8 Hz, 1H), 6.66 (s, 1H), 6.15 (tt,
J=3.6, 56.0 Hz, 1H), 3.12-2.90 (m, 4H), 2.75 (m, 3H), 2.36-2.20 (m,
2H), 1.71 (m, 5H), 1.42 (s, 6H). MS (ESI): m/z=457.3 [M+1].
Example 90.
N-[2,2-Dimethyl-6-[1-(2,2,2-trifluoroethyl)-4-piperidyl]-3H-benzofuran-5--
yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01006##
[1037] A mixture of
N-[2,2-dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (184 mg, 0.47 mmol), 2,2,2-trifluoroethyl
trifluoromethanesulfonate (300 mg, 2.75 mmol) and potassium
carbonate (260 mg, 4.0 mmol) was stirred in DMF (10 mL) at
25.degree. C. for 15 h. The mixture was purified by preparative
HPLC(Xbridge 21.2*250 mm c18, 10 um, A: acetonitrile 25-55%; B: 10
mM ammonium bicarbonate in water) to afford
N-[2,2-dimethyl-6-[1-(2,2,2-trifluoroethyl)-4-piperidyl]-3H-benzof-
uran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (42 mg, 19%) as a
yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.60 (s,
1H), 9.39 (dd, J=1.6, 7.0 Hz, 1H), 8.88 (dd, J=1.6, 4.0 Hz, 1H),
8.69 (s, 1H), 7.74 (s, 1H), 7.35 (dd, J=4.0, 7.0 Hz, 1H), 6.67 (s,
1H), 3.19 (q, J=10.3 Hz, 2H), 3.06-2.99 (m, 4H), 2.86-2.78 (m, 1H),
2.50-2.39 (m, 2H), 1.77-1.65 (m, 4H), 1.42 (s, 6H). MS (ESI):
m/z=475.3 [M+1].
Example 91.
6-(Difluoromethyl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide
##STR01007##
[1038] Step A.
N-(2,2-Dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-formyl-pyrazolo[1,5-a]-
pyrimidine-3-carboxamide
##STR01008##
[1040] A solution of 6-formylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (Example 75, step A) (191 mg, 1.0 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (750 mg, 1.97 mmol) and diisopropylethylamine
(0.5 mL, 3.0 mmol) was stirred in DMF (2 mL) at room temperature
for 10 min. To this mixture was added
2,2-dimethyl-6-morpholino-3H-benzofuran-5-amine (245 mg, 0.98 mmol)
in DMF (1 mL) and the reaction was stirred for additional 16 h. The
mixture was poured into water (20 mL) and extracted with ethyl
acetate (50 mL). The organic phase was washed with water, brine and
dried over sodium sulfate before concentration to dryness. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:10) as eluting solvents to afford
N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-formyl-pyrazolo[1,5-a]-
pyrimidine-3-carboxamide (283 mg, 61%) as a yellow solid. MS (ESI):
m/z=422.2[M+1].sup.+.
Step B.
6-(Difluoromethyl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01009##
[1042] To a solution of
N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-formyl-pyrazolo[1,5-a]-
pyrimidine-3-carboxamide (120 mg, 0.28 mmol) in DCM (8 mL),
diethylaminosulfurtrifluoride (0.17 mL, 1.28 mmol) was added at
0.degree. C. The mixture was stirred at 25.degree. C. for 8 h. The
mixture was purified by preparative HPLC (Xbridge 21.2*250 mm c18,
10 um acetonitrile 30-70% (10 mM ammonium bicarbonate) in water) to
afford
6-(difluoromethyl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carb oxamide (10.1 mg, 7.4%) as a brown
solid. H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.36 (s, 1H), 9.75
(d, J=1.6 Hz, 1H), 9.12 (d, J=1.6 Hz, 1H), 8.80 (s, 1H), 8.30 (s,
1H), 7.32 (t, J=54.6 Hz, 2H), 6.73 (s, 1H), 3.90-3.78 (m, 4H), 3.01
(s, 2H), 2.87-2.73 (m, 4H), 1.42 (s, 6H). MS (ESI): m/z=444.2
[M+1].
Examples 92 and 93.
(S)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR01010##
[1044] Example 16 was chirally resolved using chiral SFC to provide
(S)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxam-
ide with absolute stereochemistry assigned arbitrarily.
[1045] Example 92, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 9.21 (dd, J=2.1, 1.2 Hz, 1H), 8.83 (d, J=2.0
Hz, 1H), 8.58 (s, 1H), 8.33-8.27 (m, 1H), 6.66 (s, 1H), 5.02 (t,
J=5.8 Hz, 1H), 4.58 (t, J=5.2 Hz, 1H), 3.49-3.33 (m, 4H), 3.18 (dd,
J=15.7, 1.2 Hz, 1H), 2.92 (d, J=11.2 Hz, 2H), 2.86-2.77 (m, 1H),
2.62 (td, J=11.3, 3.1 Hz, 2H), 2.41 (d, J=1.1 Hz, 3H), 1.73-1.57
(m, 4H), 1.50 (dq, J=10.4, 5.3 Hz, 1H), 1.34 (s, 3H). MS (ESI):
m/z=452.2 [M+1].
[1046] Example 93, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 9.21 (dq, J=1.9, 0.9 Hz, 1H), 8.83 (d, J=2.0
Hz, 1H), 8.58 (s, 1H), 8.30 (d, J=0.9 Hz, 1H), 6.66 (s, 1H), 5.02
(t, J=5.8 Hz, 1H), 4.58 (t, J=5.2 Hz, 1H), 3.49-3.32 (m, 4H),
3.32-3.14 (m, 1H), 2.92 (d, J=11.2 Hz, 2H), 2.81 (dd, J=15.5, 1.2
Hz, 1H), 2.62 (td, J=11.4, 3.2 Hz, 2H), 2.41 (d, J=1.1 Hz, 3H),
1.66 (qd, J=11.8, 10.6, 4.2 Hz, 4H), 1.50 (dq, J=10.6, 5.3 Hz, 1H),
1.34 (s, 3H). MS (ESI): m/z=452.2 [M+1].
Examples 94 and 95.
(S)--N-(6-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3-di-
hydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(6-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3-di-
hydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01011##
[1048] The enantiomers of Example 18 were resolved using chiral SFC
to provide
(S)--N-(6-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethy-
l-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(6-(3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)-2,2-dimethyl-2,3-di-
hydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide with
absolute stereochemistry assigned arbitrarily.
[1049] Example 94, Peak 1: .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 9.84 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.87 (dd,
J=4.2, 1.6 Hz, 1H), 8.69 (s, 1H), 8.03 (d, J=1.0 Hz, 1H), 7.34 (dd,
J=7.0, 4.2 Hz, 1H), 6.54 (s, 1H), 4.70 (t, J=5.3 Hz, 1H), 3.38 (s,
6H), 3.15-3.05 (m, 1H), 3.04-2.95 (m, 5H), 2.74 (d, J=9.0 Hz, 1H),
1.84 (ddd, J=12.1, 8.0, 6.3 Hz, 1H), 1.54 (ddd, J=12.1, 8.0, 5.6
Hz, 1H), 1.42 (s, 7H), 1.14 (s, 3H). MS (ESI): m/z=422.2 [M+1].
[1050] Example 95, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.83 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.86 (dd,
J=4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.02 (d, J=1.0 Hz, 1H), 7.33 (dd,
J=7.0, 4.2 Hz, 1H), 6.53 (s, 1H), 4.69 (t, J=5.4 Hz, 1H), 3.47-3.32
(m, 2H), 3.14-2.94 (m, 5H), 2.73 (d, J=9.0 Hz, 1H), 1.83 (ddd,
J=12.2, 7.9, 6.2 Hz, 1H), 1.53 (ddd, J=12.2, 8.0, 5.6 Hz, 1H), 1.41
(s, 6H), 1.13 (s, 3H). MS (ESI): m/z=422.2 [M+1].
Examples 96 and 97.
(S)--N-(2-ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide
##STR01012##
[1052] The enantiomers of Example 21 were resolved using chiral SFC
to provide
(S)--N-(2-ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-ethyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide with absolute stereochemistry
assigned arbitrarily.
[1053] Example 96, Peak 1: .sup.1HNMR (400 MHz, DMSO-d6) .delta.
10.43 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.94 (dd, J=4.2, 1.7
Hz, 1H), 8.68 (s, 1H), 8.30 (d, J=1.0 Hz, 1H), 7.34 (dd, J=7.0, 4.2
Hz, 1H), 6.72 (s, 1H), 3.88-3.80 (m, 4H), 3.13-3.01 (m, 1H),
2.96-2.86 (m, 1H), 2.86-2.77 (m, 4H), 1.71 (q, J=7.4 Hz, 2H), 1.35
(s, 3H), 0.92 (t, J=7.4 Hz, 3H). MS (ESI): m/z=408.2 [M+1].
[1054] Example 97, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.43 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.94 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.30 (d, J=1.0 Hz, 1H), 7.34 (dd, J=7.0, 4.2
Hz, 1H), 6.72 (s, 1H), 3.88-3.79 (m, 4H), 3.04 (d, J=1.2 Hz, 1H),
2.97-2.86 (m, 1H), 2.86-2.76 (m, 4H), 1.70 (t, J=7.4 Hz, 2H), 1.35
(s, 3H), 0.92 (t, J=7.4 Hz, 3H). MS (ESI): m/z=408.2 [M+1].
Examples 98 and 99.
N-[(2R)-6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01013##
[1055] Step A.
[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-
-yl]methanol
##STR01014##
[1057] A mixture of
(6-chloro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 2) (440 mg, 1.81 mmol),
1-(2,2-difluoroethyl)piperazine hydrochloride (3000 mg, 16.1 mmol)
and potassium carbonate (1480 mg, 10.72 mmol) in acetonitrile (15
mL) was stirred at 85.degree. C. for 4 d.
[1058] After filtration and concentration under reduced pressure,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
[6-[4-(2,
2-difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]metha-
nol (486 mg, 75%) as yellow oil. MS (ESI): m/z=358.2
[M+1].sup.+.
Step B.
[5-Amino-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzo-
furan-2-yl]methanol
##STR01015##
[1060] The mixture of
[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-
-yl]methanol (512 mg, 1.43 mmol) and palladium on carbon (150 mg)
in methanol (20 mL) was stirred under hydrogen atmosphere at
25.degree. C. for 1 h. After filtration and concentration under
reduced pressure, it was afforded
[5-amino-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzofuran-2-
-yl]methanol (430 mg, 92%) as a brown oil, which was used directly
in the next step without further purification. MS (ESI): m/z=328.1
[M+1].sup.+.
Step C.
N-[(2R)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)--
2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-[(2S)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01016##
[1062] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(344 mg, 2.11 mmol), N,N-diisopropylethylamine (0.66 mL, 3.99
mmol), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (1016 mg, 2.67 mmol) and
[5-amino-6-(difluoromethyl)-2-methyl-3H-benzofuran-2-yl]methanol
(430 mg, 1.31 mmol) in DMF (15 mL) was stirred at 25.degree. C. for
16 h. The mixture was purified by preparative HPLC (Xbridge
21.2*250 mm c18, 10 um; A: acetonitrile 25-75%; B: 10 mM ammonium
bicarbonate in water) and then the product was resolved by
Chiral-HPLC [Gilson-281, IA 20*250 mm, 5 um (Dacel), hexane (0.1%
n,n-diethylamine)/ethanol(0.1% n,n-diethylamine)=70/30] to afford
N-[(2R)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (121
mg, 20%) (118 mg, 19%) as yellow solids with absolute
stereochemistry assigned arbitrarily.
[1063] Example 98, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 10.41 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.95 (dd,
J=1.6, 4.4 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.35 (dd, J=4.4,
7.2 Hz, 1H), 6.70 (s, 1H), 6.20 (tt, J=4.0, 55.6 Hz, 1H), 5.04 (t,
J=6.0 Hz, 1H), 3.48-3.38 (m, 2H), 3.19 (d, J=16 Hz, 1H), 2.93-2.71
(m, 11H), 1.34 (s, 3H). MS (ESI): m/z=473.2 [M+1].sup.+.
[1064] Example 99, Peak 2: .sup.1HNMR (400 MHz, DMSO-d.sub.6)
.delta. 10.41 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.95 (dd,
J=1.6, 4.4 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.35 (dd, J=4.4,
7.2 Hz, 1H), 6.70 (s, 1H), 6.20 (tt, J=4.0, 55.6 Hz, 1H), 5.04 (t,
J=6.0 Hz, 1H), 3.48-3.38 (m, 2H), 3.19 (d, J=16 Hz, 1H), 2.93-2.71
(m, 11H), 1.34 (s, 3H). MS (ESI): m/z=473.2 [M+1].sup.+.
TABLE-US-00004 TABLE 4 The following examples were made in a manner
similar to that for Example 4: Ex. Name Structure NMR, MS 100
N-[6-(6,8-dihydro-5H- imidazo[1,5-a]pyrazin-7- yl)-2,2-dimethyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyridine-3- carboxamide
##STR01017## 1H NMR (400 MHz, DMSO-d6) .delta. 10.75 (s, 1H), 9.27
(dd, J = 7.0, 1.6 Hz, 1H), 8.64 (s, 1H), 8.41 (d, J = 1.0 Hz, 1H),
7.71 (s, 1H), 7.61 (dd, J = 4.2, 1.7 Hz, 1H), 7.17 (dd, J = 7.0,
4.2 Hz, 1H), 6.83 (s, 1H), 6.63 (s, 1H), 4.27-4.19 (m, 2H), 4.03
(s, 2H), 3.40-3.23 (m, 2H), 3.13-3.00 (m, 2H), 1.43 (s, 6H). MS
(ESI): m/z = 430.2 [M + 1].sup.+. 101 N-[2,2-dimethyl-6- (5,6,8,9-
tetrahydroimidazo[1,5- d][1,4]diazepin-7-yl)- 3H-benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01018## .sup.1H
NMR (400 MHz, DMSO- d6) .delta. 10.70 (s, 1H), 9.34 (dd, J = 7.0,
1.6 Hz, 1H), 8.73- 8.64 (m, 2H), 8.35 (d, J = 1.0 Hz, 1H), 7.53 (d,
J = 1.1 Hz, 1H), 7.26 (dd, J = 7.0, 4.2 Hz, 1H), 6.75-6.66 (m, 2H),
4.33 (dd, J = 6.1, 2.5 Hz, 2H), 3.12-3.01 (m, 4H), 2.94 (dd, J =
6.8, 3.2 Hz, 2H), 1.40 (s, 6H). MS (ESI): m/z = 444.2 [M +
1].sup.+. 102 N-[6-[4- (hydroxymethyl)imidazol-
1-yl]-2,2-dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01019## .sup.1H NMR (400 MHz,
DMSO- d6) .delta. 9.73 (s, 1H), 9.30 (dd, J = 7.0, 1.6 Hz, 1H),
8.65- 8.55 (m, 2H), 8.29 (t, J = 1.0 Hz, 1H), 7.76 (d, J = 1.4 Hz,
1H), 7.25 (dd, J = 7.0, 4.2 Hz, 1H), 7.18 (dt, J = 1.5, 0.8 Hz,
1H), 6.75 (s, 1H), 4.96 (t, J = 5.5 Hz, 1H), 4.43 (dd, J = 5.5, 0.9
Hz, 2H), 3.12 (d, J = 1.3 Hz, 2H), 1.46 (s, 6H). MS (ESI): m/z =
405.1 [M + 1].sup.+. 103 N-(6-imidazol-1-yl-2,2- dimethyl-3H-
benzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01020## .sup.1H NMR (400 MHz, DMSO- d6) .delta. 9.64 (s, 1H),
9.30 (dd, J = 7.0, 1.7 Hz, 1H), 8.63 (s, 1H), 8.50 (dd, J = 4.2,
1.7 Hz, 1H), 8.22 (d, J = 1.1 Hz, 1H), 7.85 (t, J = 1.1 Hz, 1H),
7.37 (t, J = 1.3 Hz, 1H), 7.26 (dd, J = 7.0, 4.2 Hz, 1H), 7.14 (t,
J = 1.1 Hz, 1H), 6.79 (s, 1H), 3.13 (d, J = 1.3 Hz, 2H), 1.47 (s,
6H). MS (ESI): m/z = 375.1 [M + 1].sup.+. 104 N-[2,2-dimethyl-6-(2-
methylpyrrolidin-1-yl)- 3H-benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- ##STR01021## .sup.1H NMR (400 MHz, DMSO- d6)
.delta. 10.67 (s, 1H), 9.34 (dd, J = 7.0, 1.6 Hz, 1H), 8.83 (dd, J
= 4.2, 1.6 Hz, 1H), 8.66 (s, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.29
(dd, J = 7.0, 4.1 Hz, 1H), 6.69 (s, 1H), 3.44-3.29 (m, 4H), 3.00
(s, 2H), 2.65 (q, J = 8.3 Hz, 1H), 2.20-2.10 (m, 1H), 1.95 (d, J =
7.3 Hz, 2H), 1.86 (td, J = 8.2, 4.1 Hz, 1H), 1.71-1.56 (m, 1H),
1.41 (d, J = 4.7 Hz, 6H), 0.93 (d, J = 6.0 Hz, 3H. MS (ESI): m/z =
392.2 [M + 1].sup.+. 105 N-[6-(3-hydroxy-3- methyl-azetidin-1-yl)-
2,2-dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01022## .sup.1H NMR (400 MHz, DMSO- d6) .delta.
9.37 (dd, J = 7.0, 1.6 Hz, 1H), 9.23 (s, 1H), 8.86 (dd, J = 4.2,
1.7 Hz, 1H), 8.67 (s, 1H), 7.51 (d, J = 0.9 Hz, 1H), 7.33 (dd, J =
7.0, 4.2 Hz, 1H), 6.13 (s, 1H), 5.31 (s, 1H), 3.77-3.70 (m, 2H),
3.55-3.49 (m, 2H), 3.41-3.26 (m, 4H), 2.93 (d, J = 1.3 Hz, 2H),
1.43 (d, J = 19.0 Hz, 10H). MS (ESI): m/z = 394.2 [M + 1].sup.+.
106 N-(2,2-dimethyl-6-(2- oxa-8- azaspiro[4.5]decan-8- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01023## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.44 (s,
1H), 8.82 (dd, J = 1.6, 6.8 Hz, 1H), 8.79 (s, 1H), 8.63 (dd, J =
2.0, 4.4 Hz, 1H), 8.40 (s, 1H), 7.05 (dd, J = 4.0, 7.2 Hz, 1H),
6.63 (s, 1H), 3.90 (t, J = 7.2 Hz, 2H), 3.64 (s, 2H), 3.03 (s, 2H),
2.86-2.84 (m, 4H), 1.89-1.84 (m, 6H), 1.49 (s, 6H). MS (ESI): m/z =
448.3 [M + 1].sup.+. 107 N-(2,2-dimethyl-6-(2- oxa-6-
azaspiro[3.4]octan-6-yl)- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01024## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.77 (s, 1H), 8.81 (dd, J = 1.6, 7.2 Hz, 1H),
8.78 (s, 1H), 8.60 (d, J = 2.8 Hz, 1H), 8.08 (s, 1H), 7.02 (dd, J =
4.0, 6.8 Hz, 1H), 6.52 (s, 1H), 4.68 (s, 4H), 3.39 (s, 2H), 3.11
(t, J = 6.8 Hz, 2H), 3.02 (s, 2H), 2.24 (t, J = 6.8 Hz, 2H), 1.48
(s, 6H). MS (ESI): m/z = 420.2[M + 1].sup.+. 108
N-(2,2-dimethyl-6-(2- oxa-7- azaspiro[4.4]nonan-7- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01025## .sup.1H NMR (400 MHz, DMSO- d6) .delta. 9.80 (s, 1H),
9.36 (d, J = 6.8 Hz, 1H), 8.83 (d, J = 4.0 Hz, 1H), 8.68 (s, 1H),
7.98 (s, 1H), 7.32 (dd, J = 4.0, 6.8 Hz, 1H), 6.56 (s, 1H),
3.82-3.64 (m, 3H), 3.59 (d, J = 8.4 Hz, 1H), 3.15- 3.07 (m, 2H),
3.05 (s, 2H), 2.97 (s, 2H), 2.01-1.91 (m, 4H), 1.41 (s, 6H). MS
(ESI): m/z = 434. [M + 1].sup.+. 109 N-(6-(1-hydroxy-8-
azaspiro[4.5]decan-8- yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01026## .sup.1H
NMR (400 MHz, DMSO- d6) .delta. 10.55 (s, 1H), 9.35 (dd, J = 1.6,
6.8 Hz, 1H), 9.03 (dd, J = 2.8, 4.4 Hz, 1H), 8.67 (s, 1H), 8.36 (s,
1H), 7.32 (dd, J = 4.4, 6.8 Hz, 1H), 6.70 (s, 1H), 4.63 (s, 1H),
3.67 (d, J = 5.2 Hz, 1H), 3.22 (d, J = 1.2 Hz, 2H), 2.99-2.68 (m,
4H), 2.04-1.99 (m, 1H), 1.89- 1.83 (m, 2H), 1.73-1.64 (m, 2H),
1.52-1.46 (m, 2H), 1.41 (s, 7H), 1.30-1.27 (m, 1H). MS (ESI): m/z =
462.3 [M + 1].sup.+. 110 N-(6-(2-hydroxy-7- azaspiro[3.5]nonan-7-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01027## .sup.1H NMR (400 MHz,
DMSO- d6): .delta. 10.46 (s, 1H), 9.36 (d, J = 6.8 Hz, 1H), 8.74
(d, J = 2.8 Hz, 1H), 8.67 (s, 1H), 8.30 (s, 1H), 7.35 (dd, J = 4.0,
6.8 Hz, 1H), 6.64 (s, 1H), 4.18-4.05 (m, 1H), 2.99 (s, 2H),
2.74-2.58 (m, 4H), 2.29-2.14 (m, 2H), 1.81-1.67 (m, 4H), 1.67-1.54
(m, 2H), 1.41 (s, 6H). MS (ESI): m/z = 448.3 [M + 1].sup.+. 111
N-[2,2-dimethyl-6-(3- oxo-2,7- diazaspiro[3.5]nonan-7-
yl)-3H-benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01028## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.68 (s,
1H), 9.15 (d, J = 2.4 Hz, 1H), 8.79 (dd, J = 1.6, 7.2 Hz, 1H), 8.77
(s, 1H), 8.54 (s, 1H), 7.11 (dd, J = 4.0, 7.2 Hz, 1H), 6.59 (s,
1H), 5.65 (s, 1H), 3.31 (s, 2H), 3.11-3.05 (m, 2H), 3.03 (s, 2H),
2.74-2.64 (m, 2H), 2.56-2.46 (m, 2H), 1.93-1.86 (m, 2H), 1.48 (s,
6H). MS (ESI): m/z = 447.3 [M + 1].sup.+. 112 N-(6-(6,6-difluoro-3-
azabicyclo[3.1.0]hexan- 3-yl)-2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01029## .sup.1H NMR (400 MHz, DMSO- d6): .delta. 9.70 (s, 1H),
9.36 (dd, J = 1.6, 7.2 Hz, 1H), 8.82 (dd, J = 1.6, 4.0 Hz, 1H),
8.67 (s, 1H), 7.85 (s, 1H), 7.32 (dd, J = 4, 6.8 Hz, 1H), 6.57 (s,
1H), 3.50-3.40 (m, 4H), 2.97 (s, 2H), 2.59-2.52 (m, 2H), 1.41 (s,
6H). MS (ESI): m/z = 426.2 [M + 1].sup.+. 113 N-[2,2-Dimethyl-6-(6-
oxo-1H-pyridin-3-yl)- 3H-benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01030## .sup.1H NMR (400 MHz,
DMSO- d6) .delta. 9.65 (s, 1H), 9.34 (dd, J = 1.6, 7.0 Hz, 1H),
8.64 (s, 1H), 8.52 (dd, J = 1.6, 4.0 Hz, 1H), 8.13 (s, 1H), 7.47-
7.40 (m, 2H), 7.32 (dd, J = 4.0, 7.0 Hz, 1H), 6.65 (s, 1H), 6.39
(d, J = 9.1 Hz, 1H), 3.07 (s, 2H), 1.44 (s, 6H). MS (ESI): m/z =
402.2 [M + 1] 114 N-(2,2-Dimethyl-6-(2- oxa-7-
azaspiro[3.5]nonan-7- yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01031## .sup.1H
NMR (400 MHz, DMSO- d6): .delta. 10.44 (s, 1H), 9.35 (d, J = 6.8
Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.67 (s, 1H), 8.31 (s, 1H),
7.32-7.30 (m, 1H), 6.63 (s, 1H), 4.51-4.29 (m, 4H), 3.08-2.91 (m,
2H), 2.81-2.57 (m, 4H), 2.14-1.89 (m, 4H), 1.40 (s, 6H). MS (ESI):
m/z = 434.2 [M + 1]+. 115 N-(6-(3-Fluoro-4- hydroxypiperidin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01032## .sup.1H NMR (400 MHz,
DMSO- d6): .delta. 10.39 (s, 1H), 9.36 (dd, J = 1.6, 7.2 Hz, 1H),
8.89 (dd, J = 1.6, 4.0 Hz, 1H), 8.67 (s, 1H), 8.31 (s, 1H), 7.32
(dd, J = 4.0, 7.2 Hz, 1H), 6.68 (s, 1H), 5.08-5.07 (d, J = 6.0 Hz,
1H), 4.86-4.72 (m, 1H), 3.95-3.90 (m, 1H), 3.17-3.11 (m, 1H),
3.03-2.89 (m, 4H), 2.58-2.51 (m, 1H), 2.02-2.00 (m, 1H), 1.99-1.78
(m, 1H), 1.41 (s, 1H). MS (ESI): m/z = 426.2 [M + 1].sup.+. 116
N-(6-(1,4-diazepan-1- yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01033## .sup.1H
NMR (400 MHz, DMSO- d.sub.6): .delta. 10.37 (s, 1H), 9.38 (d, J =
6.6 Hz, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.68 (s, 1H), 8.38 (s, 1H),
8.27 (s, 1H), 7.35 (dd, J = 4.4, 6.6 Hz, 1H), 6.72 (s, 1H),
3.20-3.22 (m, 4H), 3.14-3.15 (m, 2H), 2.99-3.02 (m, 4H), 1.98-1.99
(m, 2H), 1.41 (s, 6H). MS (ESI): m/z = 407.3[M + 1].sup.+. 117
N-(2,2-dimethyl-6-(1,4- oxazepan-4-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01034## .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 10.52 (s, 1H), 8.82 (dd, J = 6.8
Hz, 1H), 8.78 (s, 1H), 8.75 (dd, J = 4.4 Hz, 1H), 8.37 (s, 1H),
7.05 (dd, J = 4.4, 6.8 Hz, 1H), 6.65 (s, 1H), 3.99 (t, J = 7.0 Hz,
2H), 3.91-3.93 (m, 2H), 3.11-3.14 (m, 4H), 3.03 (s, 2H), 2.06-2.12
(m, 2H), 1.45 (s, 6H). MS (ESI): m/z = 408.2 [M + 1].sup.+.
##STR01035##
Example 118.
N-[2,2-Dimethyl-6-(morpholin-4-yl)-1,1-dioxo-2,3-dihydro-benzothiophen-5--
yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01036##
[1065] Step A. Methyl 4-chloro-2-fluoro-5-nitro-benzoate
##STR01037##
[1067] To a mixture of 4-chloro-2-fluoro-5-nitro-benzoic acid (5.06
g, 23.05 mmol) in methyl alcohol (15 mL) was added drop wise
sulfurous dichloride (10 mL). The mixture was stirred at 90.degree.
C. for 16 h. The mixture was concentrated to afford methyl
4-chloro-2-fluoro-5-nitro-benzoate (5.2 g, 92%) as a white solid,
which was used directly to next step without further purification.
MS (ESI): m/z=234.1[M+1].sup.+.
Step B. 4-Chloro-2-methylsulfanyl-5-nitro-benzoate
##STR01038##
[1069] A mixture of methyl 4-chloro-2-fluoro-5-nitro-benzoate
(800.0 mg, 3.43 mmol) in tetrahydrofuran (20 mL) was added sodium
methanethiolate (20% wt in water, 1.2 g, 3.43 mmol). The mixture
was stirred at 25.degree. C. for 4 h. Water and ethyl acetate (30
mL) was added. The organic layer was separated, dried over sodium
sulfate and concentrated to afford methyl
4-chloro-2-methylsulfanyl-5-nitro-benzoate (800 mg) as a yellow
solid, which was used directly to next step without further
purification. MS (ESI): m/z=262.0[M+1].sup.+.
Step C. Methyl 2-methylsulfanyl-4-morpholino-5-nitro-benzoate
[1070] A mixture of methyl
4-chloro-2-methylsulfanyl-5-nitro-benzoate (600.0 mg, 2.29 mmol) in
morpholine (3995.15 mg, 45.86 mmol) was stirred at 60.degree. C.
overnight. The mixture was concentrated and the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:4) as eluting solvents to afford methyl
2-methylsulfanyl-4-morpholino-5-nitro-benzoate (506 mg, 70%) as
yellow solid. MS (ESI): m/z=313.0[M+1].sup.+.
Step D. Methyl 2-methylsulfonyl-4-morpholino-5-nitro-benzoate
##STR01039##
[1072] To a mixture of methyl
2-methylsulfanyl-4-morpholino-5-nitro-benzoate (506.0 mg, 1.62
mmol) in methyl alcohol (10 mL) and water (10 mL) was added oxone
(1082.16 mg, 6.48 mmol). The mixture was stirred at 50.degree. C.
for 5 h. Ethyl acetate (30 mL) and water was added and the organic
layer was separated, dried over sodium sulfate and concentrated to
afford methyl 2-methylsulfonyl-4-morpholino-5-nitro-benzoate (478
mg) as a yellow solid, which was used directly to next step without
further purification. MS (ESI): m/z=345.0[M+1].sup.+.
Step E. 6-Morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one
##STR01040##
[1074] A mixture of methyl
2-methylsulfonyl-4-morpholino-5-nitro-benzoate (574.0 mg, 1.67
mmol) in N,N-Dimethylformamide (15 mL) was treated with sodium
hydride (60% wt with mineral oil, 100 mg, 2.5 mmol) at 0.degree. C.
The mixture was stirred at 25.degree. C. for 4 h. Water was added
slowly and the pH was adjusted to 3 using IN HCl. The aqueous layer
was extracted with ethyl acetate (70 mL). The organic layer was
concentrated to afford
6-morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one (560 mg) as a
yellow solid, which was used directly to next step without further
purification. MS (ESI): m/z=313.0[M+1].sup.+.
Step F.
2,2-Dimethyl-6-morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one
##STR01041##
[1076] A mixture of
6-morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one (560.0 mg, 1.79
mmol) iodomethane (1272.6 mg, 8.97 mmol) and
1,8-diazabicyclo[5.4.0]undec-7-ene (1362.79 mg, 8.97 mmol) in
N,N-dimethylformamide (10 mL) was stirred at 40.degree. C. in a
sealed tube for 16 h. Water was added and the aqueous layer was
extracted with ethyl acetate (70 mL). The organic layer was washed
with brine, dried over sodium sulfate and concentrated. The residue
was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:5) as eluting solvents to afford
2,2-dimethyl-6-morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one
(250 mg, 33%) as yellow solid. MS (ESI): m/z=341.1 [M+1].sup.+.
Step G.
2,2-Dimethyl-6-morpholino-5-nitro-1,1-dioxo-3H-benzothiophen-3-ol
##STR01042##
[1078] A mixture of
2,2-dimethyl-6-morpholino-5-nitro-1,1-dioxo-benzothiophen-3-one
(200.0 mg, 0.47 mmol) in methyl alcohol (30 mL) was treated with
sodium borohydride (53.59 mg, 1.41 mmol) The mixture was stirred at
25.degree. C. for 3 h. The mixture was quenched with water and
ethyl acetate (30 mL) was added. The organic layer was separated,
dried over sodium sulfate and concentrated to afford
2,2-dimethyl-6-morpholino-5-nitro-1,1-dioxo-3H-benzothiophen-3-ol
(150 mg) as a brown solid, which was used directly to next step
without further purification. MS (ESI): m/z=343.1 [M+1].sup.+.
[1079] Step H. 2,2-Dimethyl-6-morpholino-5-nitro-3H-benzothiophene
1,1-dioxide
##STR01043##
[1080] A mixture of
2,2-dimethyl-6-morpholino-5-nitro-1,1-dioxo-3H-benzothiophen-3-ol
(150.0 mg, 0.44 mmol) triethylsilane (2 mL, 12.52 mmol) in
trifluoroacetic acid (8 mL, 107.7 mmol) was stirred at 50.degree.
C. for 16 h. The mixture was concentrated and purified by silica
gel chromatography using ethyl acetate:petroleum ether (1:5 to 1:3)
as eluting solvents to afford
2,2-dimethyl-6-morpholino-5-nitro-3H-benzothiophene 1,1-dioxide (88
mg, 62%) as a yellow solid. MS (ESI): m/z=327.0 [M+1].sup.+.
Step I.
2,2-Dimethyl-6-morpholino-1,1-dioxo-3H-benzothiophen-5-amine
##STR01044##
[1082] A mixture of
2,2-dimethyl-6-morpholino-5-nitro-3H-benzothiophene 1,1-dioxide
(78.0 mg, 0.24 mmol) and 10 wt % palladium on carbon (20.0 mg, 0.24
mmol) in methyl alcohol (20 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 1 h. The reaction was filtered through
celite and concentrated under reduced pressure to afford
2,2-dimethyl-6-morpholino-1,1-dioxo-3H-benzothiophen-5-amine (60
mg) as a pink solid, which was used directly to next step without
further purification. MS (ESI): m/z=297.2 [M+1].sup.+.
Step J.
N-[2,2-Dimethyl-6-(morpholin-4-yl)-1,1-dioxo-2,3-dihydro-benzothio-
phen-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01045##
[1084] A mixture of
2,2-dimethyl-6-morpholino-1,1-dioxo-3H-benzothiophen-5-amine (50.0
mg, 0.17 mmol), pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(Example 3, Step B) (153.16 mg, 0.84 mmol), and potassium carbonate
(879.55 mg, 1.69 mmol) in toluene (10 mL) was stirred at
110.degree. C. for 14 h. Ethyl acetate (10 mL) and water were
added. The organic layer was separated, dried over sodium sulfate
and concentrated. The residue was purified by preparative HPLC
(Gilson 281, Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile
25-55%; B: 10 M ammonium bicarbonate in water) to afford
N-(2,2-dimethyl-6-morpholino-1,1-dioxo-3H-benzothiophen-5-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide (30 mg, 40%) as a white solid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.88 (s, 1H), 9.42 (dd, J=1.6,
7.2 Hz, 1H), 9.00 (dd, J=1.6, 4.4 Hz, 1H), 8.76 (s, 1H), 8.63 (s,
1H), 7.70 (s, 1H), 7.39 (dd, J=4.4, 7.2 Hz, 1H), 3.88-3.90 (m, 4H),
3.15 (s, 2H), 2.92-2.95 (m, 4H), 1.38 (s, 6H). MS (ESI): m/z=442.1
[M+1].sup.+.
Examples 119 and 120.
N--((S)-2-(hydroxymethyl)-2-methyl-6-((1R,4R)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide and
N--((R)-2-(hydroxymethyl)-2-methyl-6-((1R,4R)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR01046##
[1086]
N--((S)-2-(hydroxymethyl)-2-methyl-6-((1R,4R)-5-(2,2,2-trifluoroeth-
yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide and
N--((R)-2-(hydroxymethyl)-2-methyl-6-((1R,4R)-5-(2,2,2-trifluoroethyl)-2,-
5-diazabicyclo[2.2.1]heptan-2-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide (3.8 mg, 3%) (4.9 mg, 4%) were isolated
as yellow solids with absolute stereochemistry assigned arbitrarily
using a method similar to Examples 78 and 79.
[1087] Example 119, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.9.74 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.85 (dd, J=1.6,
4.0 Hz, 1H), 8.69 (s, 1H), 7.80 (s, 1H), 7.33 (dd, J=4.0, 6.8 Hz,
1H), 6.48 (s, 1H), 5.04 (t, J=6.0 Hz, 1H), 3.93 (s, 1H), 3.51 (s,
1H), 3.45-3.41 (m, 2H), 3.32-3.25 (m, 3H), 3.16 (d, J=16.0 Hz, 1H),
3.07-3.04 (m, 1H), 2.92-2.88 (m, 2H), 2.78 (d, J=15.6 Hz, 1H),
1.89-1.76 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z=503.3
[M+1].sup.+.
[1088] Example 120, Peak 2: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 9.72 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.85 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 7.78 (s, 1H), 7.33 (dd, J=4.0,
6.8 Hz, 1H), 6.47 (s, 1H), 5.04 (t, J=6.0 Hz, 1H), 3.93 (s, 1H),
3.50 (s, 1H), 3.45-3.41 (m, 2H), 3.32-3.25 (m, 3H), 3.16 (d, J=16.0
Hz, 1H), 3.07-3.04 (m, 1H), 2.92-2.88 (m, 2H), 2.78 (d, J=15.6 Hz,
1H), 1.89-1.76 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z=503.3
[M+1].sup.+.
Examples 121 and 122.
(S)--N-(6-(4,4-Difluoropiperidin-1-yl)-2-(hydroxymethyl)-2-methyl-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(6-(4,4-difluoropiperidin-1-yl)-2-(hydroxymethyl)-2-methyl-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01047##
[1090]
(S)--N-(6-(4,4-Difluoropiperidin-1-yl)-2-(hydroxymethyl)-2-methyl-2-
,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(6-(4,4-difluoropiperidin-1-yl)-2-(hydroxymethyl)-2-methyl-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide were
isolated as white solids with absolute stereochemistry assigned
arbitrarily using a method similar to Examples 78 and 79.
[1091] Example 121, Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.42 (s, 1H), 9.38 (dd, J=7.0, 1.6 Hz, 1H), 8.75 (dd, J=4.2, 1.7
Hz, 1H), 8.69 (s, 1H), 8.32 (d, J=1.0 Hz, 1H), 7.37 (dd, J=7.0, 4.2
Hz, 1H), 6.73 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.42 (h, J=5.8 Hz,
2H), 3.20 (dd, J=15.8, 1.2 Hz, 1H), 2.93 (t, J=5.5 Hz, 4H), 2.83
(dd, J=15.6, 1.2 Hz, 1H), 2.31-2.17 (m, 5H), 1.34 (s, 3H). MS
(ESI): m/z=444.2 [M+1].sup.+.
[1092] Example 122, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.42 (s, 1H), 9.38 (dd, J=7.0, 1.6 Hz, 1H), 8.75 (dd, J=4.2, 1.7
Hz, 1H), 8.69 (s, 1H), 8.32 (d, J=1.0 Hz, 1H), 7.37 (dd, J=7.0, 4.2
Hz, 1H), 6.73 (s, 1H), 5.07-5.00 (m, 1H), 3.44 (h, J=5.5 Hz, 7H),
3.39 (d, J=1.2 Hz, OH), 3.24-3.17 (m, 1H), 2.93 (t, J=5.6 Hz, 4H),
2.87-2.78 (m, 1H), 2.32-2.17 (m, 4H), 1.34 (s, 3H). MS (ESI):
m/z=444.2 [M+1].sup.+.
Examples 123 and 124.
N--((S)-6-((1R,4R)-5-(2,2-Difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2--
yl)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide and
N--((R)-6-((1R,4R)-5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2--
yl)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide
##STR01048##
[1094]
N--((S)-6-((1R,4R)-5-(2,2-Difluoroethyl)-2,5-diazabicyclo[2.2.1]hep-
tan-2-yl)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide and
N--((R)-6-((1R,4R)-5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2--
yl)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide were isolated as white solids with absolute
stereochemistry assigned arbitrarily using a method similar to
Examples 78 and 79.
[1095] Example 123, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.: 9.72 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.86 (dd,
J=2.0, 4.4 Hz, 1H), 8.68 (s, 1H), 7.78 (s, 1H), 7.33 (dd, J=4.4,
6.8 Hz, 1H), 6.45 (s, 1H), 5.99 (tt, J=4.4, 56.0 Hz, 1H), 5.04 (t,
J=6.0 Hz, 1H), 3.90 (s, 1H), 3.49-3.32 (m, 2H), 3.31-3.26 (m, 1H),
3.16 (d, J=15.6 Hz, 1H), 3.10-3.00 (m, 1H), 2.97-2.81 (m, 4H), 2.78
(d, J=15.6 Hz, 1H), 1.88-1.72 (m, 2H), 1.34 (s, 3H). MS (ESI):
m/z=485.2 [M+1].sup.+.
[1096] Example 124, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta.: 9.74 (s, 1H), 9.37 (dd, J=1.6, 7.2 Hz, 1H), 8.86 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 7.80 (s, 1H), 7.33 (dd, J=4.4,
6.8 Hz, 1H), 6.47 (s, 1H), 6.00 (tt, J=4.0, 56.0 Hz, 1H), 5.04 (t,
J=5.6 Hz, 1H), 3.90 (s, 1H), 3.48-3.38 (m, 3H), 3.15 (d, J=15.6 Hz,
1H), 3.06-2.99 (m, 1H), 2.97-2.82 (m, 4H), 2.78 (d, J=15.6 Hz, 1H),
1.88-1.72 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z=485.2
[M+1].sup.+.
Examples 125 and 126.
(R)--N-(2-(Hydroxymethyl)-2-methyl-6-(2-oxa-8-azaspiro[4.5]decan-8-yl)-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-(2-oxa-8-azaspiro[4.5]decan-8-yl)-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01049##
[1098]
(R)--N-(2-(Hydroxymethyl)-2-methyl-6-(2-oxa-8-azaspiro[4.5]decan-8--
yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-(2-oxa-8-azaspiro[4.5]decan-8-yl)-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
were isolated as white solids with absolute stereochemistry
assigned arbitrarily using a method similar to Examples 78 and
79.
[1099] Example 125, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.46 (s, 1H), 9.36 (dd, J=1.6, 7.0 Hz, 1H), 8.83 (dd,
J=1.6, 4.2 Hz, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 7.34 (dd, J=4.2,
7.0 Hz, 1H), 6.70 (s, 1H), 5.04 (t, J=5.8 Hz, 1H), 3.77 (t, J=7.1
Hz, 2H), 3.57 (s, 2H), 3.43 (t, J=5.6 Hz, 2H), 3.19 (d, J=15.8 Hz,
1H), 2.84-2.72 (m, 5H), 1.84-1.72 (m, 6H), 1.34 (s, 3H). MS (ESI):
m/z=464.2 [M+1].sup.+.
[1100] Example 126, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.46 (s, 1H), 9.36 (dd, J=1.6, 7.0 Hz, 1H), 8.83 (dd,
J=1.6, 4.2 Hz, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 7.34 (dd, J=4.2,
7.0 Hz, 1H), 6.70 (s, 1H), 5.04 (t, J=5.8 Hz, 1H), 3.77 (t, J=7.1
Hz, 2H), 3.57 (s, 2H), 3.43 (t, J=5.6 Hz, 2H), 3.19 (d, J=15.8 Hz,
1H), 2.84-2.72 (m, 5H), 1.84-1.72 (m, 6H), 1.34 (s, 3H). MS (ESI):
m/z=464.3 [M+1].sup.+.
Examples 127 and 128.
(R)--N-(2-(Hydroxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01050##
[1102]
(R)--N-(2-(Hydroxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)-2,3-d-
ihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide were
isolated as white solids with absolute stereochemistry assigned
arbitrarily using a method similar to Examples 78 and 79.
[1103] Example 127, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.41 (s, 1H), 8.83 (dd, J=1.2, 6.8 Hz, 1H), 8.80-8.75 (m,
2H), 8.44 (s, 1H), 7.07 (dd, J=4.0, 6.8 Hz, 1H), 6.69 (s, 1H),
3.71-3.61 (m, 2H), 3.25 (d, J=15.6 Hz, 1H), 3.06-2.88 (m, 5H),
2.8-2.63 (m, 4H), 2.44 (s, 3H), 1.46 (s, 3H).
[1104] MS (ESI): m/z=439.2 [M+1].sup.+.
[1105] Example 128, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.44 (s, 1H), 8.83 (d, J=6.8 Hz, 1H), 8.80-8.75 (m, 2H),
8.44 (s, 1H), 7.07 (dd, J=4.0, 7.2 Hz, 1H), 6.70 (s, 1H), 3.71-3.61
(m, 2H), 3.25 (d, J=15.6 Hz, 1H), 3.06-2.88 (m, 5H), 2.8-2.63 (m,
4H), 2.41 (s, 3H), 1.46 (s, 3H). MS (ESI): m/z=439.2
[M+1].sup.+.
Examples 129 and 130.
(R)--N-(2-(Hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01051##
[1107]
(R)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-met-
hyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
were isolated as white solids with absolute stereochemistry
assigned arbitrarily using a method similar to Examples 78 and
79.
[1108] Example 129, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.48 (s, 1H), 8.80 (d, J=7.2 Hz, 1H), 8.79-8.76 (m, 2H),
8.45 (s, 1H), 7.02 (dd, J=4.0, 7.2 Hz, 1H), 6.67 (s, 1H), 3.69-3.60
(m, 4H), 3.23 (d, J=15.6 Hz, 1H), 3.10 (d, J=11.6 Hz, 2H), 2.94 (d,
J=15.6 Hz, 1H), 2.68 (t, J=10.8 Hz, 2H), 1.91 (t, J=6.4 Hz, 1H),
1.83-1.65 (m, 5H) 1.46 (s, 3H). MS (ESI): m/z=438.2[M+1].sup.+.
[1109] Example 130, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.50 (s, 1H), 8.80 (d, J=7.2 Hz, 1H), 8.79-8.75 (m, 2H),
8.45 (s, 1H), 7.02 (dd, J=6.8 Hz, 1H), 6.67 (s, 1H), 3.70-3.66 (m,
4H), 3.23 (d, J=15.6 Hz, 1H), 3.10 (d, J=11.6 Hz, 2H), 2.94 (d,
J=15.6 Hz, 1H), 2.68 (t, J=10.8 Hz, 2H), 1.90 (t, J=6.4 Hz, 1H),
1.83-1.65 (m, 5H), 1.46 (s, 3H). MS (ESI): m/z=438.2
[M+1].sup.+.
Example 131. N-[6-[4-(2,2-Difluoroethyl)
piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-6-fluoro-p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01052##
[1111] The title compound was made in a manner analogous to
Examples 54 and 55 to give N-[6-[4-(2, 2-difluoroethyl)
piperazin-1-yl]-2-(hydroxymethyl)-2-methyl-3H-benzofuran-5-yl]-6-fluoro-p-
yrazolo[1,5-a]pyrimidine-3-carboxamide. .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.24 (s, 1H), 9.83 (dd, J=4.8,
2.4 Hz, 1H), 9.15 (d, J=2.4 Hz, 1H), 8.70 (s, 1H), 8.27 (s, 1H),
6.70 (s, 1H), 6.20 (tt, J=56, 4.0 Hz, 1H), 5.04 (t, J=5.6 Hz, 1H),
3.44-3.41 (m, 2H), 3.19 (d, J=15.2 Hz, 1H), 2.89-2.78 (m, 11H),
1.34 (s, 3H). LCMS (ESI): m/z=491.1 [M+H].sup.+.
Examples 132 and 133.
(S)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxam-
ide and
(R)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)-6-fluoropyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
##STR01053##
[1113]
(S)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)-2-
-methyl-2,3-dihydrobenzofuran-5-yl)-6-fluoropyrazolo[1,5-a]pyrimidine-3-ca-
rboxamide and
(R)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxam-
ide were resolved in a manner analogous to Examples 163 and 164
with absolute stereochemistry assigned arbitrarily.
[1114] Example 132. Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.24 (s, 1H), 9.83 (dd, J=4.4, 2.4 Hz, 1H), 9.16 (d, J=2.4 Hz,
1H), 8.71 (s, 1H), 8.27 (s, 1H), 6.70 (s, 1H), 6.35-6.05 (m, 1H),
5.06 (br s, 1H), 3.50-3.40 (m, 2H), 3.19 (d, J=15.6 Hz, 1H),
2.95-2.70 (m, 11H), 1.34 (s, 3H). MS (ESI): m/z=491.2
[M+1].sup.+.
[1115] Example 133. Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.24 (s, 1H), 9.83 (dd, J=4.4, 2.4 Hz, 1H), 9.16 (d, J=2.8 Hz,
1H), 8.71 (s, 1H), 8.27 (s, 1H), 6.70 (s, 1H), 6.34-6.06 (m, 1H),
5.05 (t, J=5.6 Hz, 1H), 3.50-3.40 (m, 2H), 3.25-3.10 (m, 1H),
3.00-2.70 (m, 11H), 1.34 (s, 3H).
[1116] MS (ESI): m/z=491.2 [M+1].sup.+.
Examples 134 and 135.
(R)--N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01054##
[1118]
N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyr-
azolo[1,5-a]pyrimidine-3-carboxamide (Example 150), 116.3 mg, 0.276
mmol) was resolved by chiral preparatory SFC to afford
(R)--N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (35.3 mg, 30%) and
(S)--N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (42.0 mg, 36%) as light yellow
solids with absolute stereochemistry assigned arbitrarily.
[1119] Example 134 Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.42 (s, 1H), 9.37 (dd, J=7.0, 1.7 Hz, 1H), 8.94 (dd,
J=4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 7.34 (dd, J=7.0,
4.2 Hz, 1H), 6.72 (s, 1H), 3.87-3.79 (m, 4H), 3.13 (dd, J=15.9, 1.3
Hz, 1H), 2.86-2.77 (m, 5H), 1.94 (h, J=6.8 Hz, 1H), 1.28 (s, 3H),
0.93 (dd, J=20.3, 6.8 Hz, 6H). MS (ESI): m/z=422.2 [M+1].sup.+.
[1120] Example 135 Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.42 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.94 (dd,
J=4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 7.34 (dd, J=7.0,
4.1 Hz, 1H), 6.72 (s, 1H), 3.87-3.80 (m, 4H), 3.13 (dd, J=15.7, 1.4
Hz, 1H), 2.86-2.77 (m, 5H), 1.94 (h, J=6.8 Hz, 1H), 1.28 (s, 3H),
0.93 (dd, J=20.3, 6.8 Hz, 6H). MS (ESI): m/z=422.2 [M+1].sup.+.
Example 136.
N-(6-Methyl-2-morpholino-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01055##
[1121] Step A. Ethyl
2-[4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzo-
furan-6-yl]piperazin-1-yl]acetate
##STR01056##
[1123] Ethyl
2-[4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]acetate
(Example 134 Step C; 200 mg, 0.60 mmol) in pyridine (10 ml) was
treated with pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (120 mg,
0.66 mmol) and stirred at 25.degree. C. for 4 h. The reaction was
concentrated and purified by silica gel chromatography (eluting
gradient 0-10% methanol: dichloromethane) to afford ethyl
2-[4-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzo-
furan-6-yl]piperazin-1-yl]acetate (280 mg, 98% yield) as a brown
solid. LCMS (ESI): m/z=479.0 [M+H].sup.+
Step B.
N-[2,2-Dimethyl-6-[4-[2-(methylamino)-2-oxo-ethyl]piperazin-1-yl]--
3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01057##
[1125] Ethyl
2-[4-[2,2-Dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzo-
furan-6-yl]piperazin-1-yl]acetate (280 mg, 0.59 mmol) was treated
with 2M methylamine in tetrahydrofuran (10 ml, 20 mmol) was stirred
at 100.degree. C. for 36 h under autoclave, concentrated and
purified by preparatory TLC (eluent: 10% methanol in
dichloromethane) to afford
N-[2,2-dimethyl-6-[4-[2-(methylamino)-2-oxo-ethyl]piperazin-1-yl]-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (93.6 mg, 33%
yield) as a brown solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.42
(s, 1H), 9.40-9.35 (m, 1H), 8.97-8.95 (m, 1H), 8.67 (s, 1H), 8.33
(s, 1H), 7.75-7.74 (m, 1H), 7.36 (dd, J=7.2, 4.4 Hz, 1H), 6.67 (s,
1H), 3.04 (s, 2H), 3.00 (s, 2H), 2.85-2.84 (m, 4H), 2.72-2.68 (m,
4H), 2.64 (d, J=4.8 Hz, 3H), 1.41 (s, 6H). LCMS (ESI) m/z: 464.1
[M+H].sup.+.
Example 137.
N-[6-[4-(2-Hydroxy-1,1-dimethyl-ethyl)piperazin-1-yl]-2,2-dimethyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01058##
[1126] Step A. tert-Butyl
4-(2-ethoxy-1,1-dimethyl-2-oxo-ethyl)piperazine-1-carboxylate
##STR01059##
[1128] A mixture of tert-butyl 1-piperazinecarboxylate (3.0 g,
20.08 mmol), ethyl 2-bromoisobutyrate (5.9 g, 30.12 mmol) and
potassium carbonate (5.6 g, 40.16 mmol) in acetonitrile (40 ml) was
stirred at 80.degree. C. for 15 h under nitrogen. The mixture was
filtered, the filtrate was concentrated and the residue was
purified by silica gel chromatography (eluent 15% ethyl acetate:
petroleum ether) to give tert-butyl
4-(2-ethoxy-1,1-dimethyl-2-oxo-ethyl)piperazine-1-carboxylate (2.8
g, 47% yield) as a colorless oil. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 4.20-4.16 (m, 2H), 3.43-3.41 (m, 4H),
2.55-2.53 (m, 4H), 1.46 (s, 9H), 1.45-1.26 (m, 9H).
Step B. Ethyl 2-methyl-2-piperazin-1-yl-propanoate
dihydrochloride
##STR01060##
[1130] tert-Butyl
4-(2-ethoxy-1,1-dimethyl-2-oxo-ethyl)piperazine-1-carboxylate (1.0
g, 3.33 mmol) in 1,4-dioxane (10 ml) was treated with hydrochloric
acid (0.83 ml, 3.32 mmol), stirred at 15.degree. C. for 15 h and
concentrated to afford ethyl 2-methyl-2-piperazin-1-yl-propanoate
dihydrochloride (700 mg, 77% yield) as a yellow oil which was use
directly without further purification. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.62 (s, 2H), 4.20 (q, J=7.2 Hz, 2H),
3.50-3.25 (m, 8H), 1.52 (s, 6H), 1.26 (t, J=7.2 Hz, 3H).
Step C. Ethyl
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-methyl-pr-
opanoate
##STR01061##
[1132] 6-Chloro-2,2-dimethyl-5-nitro-3H-benzofuran (100 mg, 0.44
mmol) in acetonitrile (10 ml) was treated with potassium carbonate
(182 mg, 1.32 mmol) and ethyl 2-methyl-2-piperazin-1-yl-propanoate
dihydrochloride (180 mg, 0.66 mmol) and stirred at 100.degree. C.
for 16 h. The mixture was filtered, concentrated and purified by
silica gel chromatography (eluting gradient 0-20% ethyl acetate:
petroleum ether) to afford ethyl
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-methyl-pr-
opanoate (150 mg, 87% yield) as a yellow oil. LCMS (ESI): m/z=392.1
[M+H].sup.+.
Step D.
2-[4-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-me-
thyl-propan-1-ol
##STR01062##
[1134] To a solution of ethyl
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-methyl-pr-
opanoate (150 mg, 0.38 mmol) in methyl alcohol (5 ml) and
tetrahydrofuran (10 ml) was added lithium borohydride (17 mg, 0.77
mmol). After being stirred at 40.degree. C. for 16 h, the reaction
was diluted with water (1 ml) and extracted with dichloromethane
(20 ml.times.3). The combined organic phases were washed with brine
(20 ml.times.2), dried over sodium sulfate, filtered and
concentrated. The residue was purified by silica gel chromatography
(eluting gradient 0-50% ethyl acetate: petroleum ether) to afford
2-[4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-methyl-pr-
opan-1-ol (80 mg, 60% yield) as a yellow oil. LCMS (ESI): m/z=350.3
[M+H].sup.+.
Step E.
2-[4-(5-Amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]-2-me-
thyl-propan-1-ol
##STR01063##
[1136]
2-[4-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)piperazin-1-yl]-2-met-
hyl-propan-1-ol (80 mg, 0.23 mmol) in methanol (10 ml) was treated
with 10% of palladium on carbon (24 mg, 0.02 mmol) and stirred at
25.degree. C. for 2 h under hydrogen (15 psi). The reaction was
filtered and the filtrate was concentrated to afford
2-[4-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)piperazin-1-yl]-2-methyl-pr-
opan-1-ol (53 mg, 73% yield) as a yellow oil, which was used
directly without further purification.
Step F.
N-[6-[4-(2-Hydroxy-1,1-dimethyl-ethyl)piperazin-1-yl]-2,2-dimethyl-
-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01064##
[1138]
N-[6-[4-(2-Hydroxy-1,1-dimethyl-ethyl)piperazin-1-yl]-2,2-dimethyl--
3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (30 mg,
39% yield) was made in a manner analogous to Example 136 and
isolated as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.32 (s, 1H), 8.84-8.80 (m, 2H), 8.69 (dd, J=4.0, 1.6 Hz,
1H), 8.36 (s, 1H), 7.05 (dd, J=6.8, 4.0 Hz, 1H), 6.64 (s, 1H), 3.38
(s, 2H), 3.04 (s, 2H), 3.00-2.90 (m, 4H), 2.85-2.75 (m, 4H), 1.49
(s, 6H), 1.10 (s, 6H). LCMS (ESI) m/z: 465.1 [M+H].sup.+.
Example 138.
N-(2-Isopropyl-6-morpholino-1-oxoisoindolin-5-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide
##STR01065##
[1139] Step A. 6-Chloro-2-isopropyl-5-nitroisoindolin-1-one
##STR01066##
[1141] To a solution of methyl
2-(bromomethyl)-5-chloro-4-nitrobenzoate (prepared following
protocol from WO 2013/079505) (130 mg, 0.42 mmol) in methanol (4.2
mL) was added trimethylamine (0.071 mL, 0.51 mmol) and
isopropylamine (0.043 mL, 0.51 mmol). The reaction mixture was
heated at 70.degree. C. for 6 h, cooled to ambient temperature, and
diluted with isopropyl acetate and 1N HCl. The layers were
separated and the aqueous layer was washed with isopropyl acetate
(2.times.). The combined organic layers were dried over sodium
sulfate and carried on without further purification.
Step B. 2-Isopropyl-6-morpholino-5-nitroisoindolin-1-one
##STR01067##
[1143] A solution of 6-chloro-2-isopropyl-5-nitroisoindolin-1-one
(88 mg, 0.35 mmol), morpholine (0.036 mL, 0.42 mmol),
diisopropylamine (0.12 mL, 0.69 mmol) in DMSO (1 mL) was heated at
90.degree. C. for 18 h. The reaction mixture was cooled to ambient
temperature, diluted with water and extracted with isopropyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate, filtered and absorbed onto celite to be
purified by silica gel chromatography (0% to 100% isopropyl acetate
in heptanes) to afford
2-isopropyl-6-morpholino-5-nitroisoindolin-1-one (17 mg, 16%) as an
orange oil. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 7.80 (s,
1H), 7.64 (s, 1H), 4.67 (p, J=6.8 Hz, 1H), 4.36 (s, 2H), 3.88-3.79
(m, 4H), 3.12-3.02 (m, 4H), 1.31 (d, J=6.8 Hz, 6H).
Step C. 5-Amino-2-isopropyl-6-morpholinoisoindolin-1-one
##STR01068##
[1145] 2-Isopropyl-6-morpholino-5-nitroisoindolin-1-one (17 mg,
0.056 mmol) was brought up in ethanol (0.35 mL) and water (0.035
mL) and treated with tin(II) chloride dehydrate (42 mg, 0.22 mmol)
and heated to 65.degree. C. for 5 h. DCM (0.75 mL) and 2M NaOH (aq)
(0.37 mL) were added and the mixture was passed through a
hydrophobic frit. The solvent was removed in vacuo to give the
desired product as a yellow solid. The crude material was carried
on without further purification. MS (ESI): m/z=276.1
[M+1].sup.+.
Step D.
N-(2-Isopropyl-6-morpholino-1-oxoisoindolin-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide
##STR01069##
[1147] A solution of
5-amino-2-isopropyl-6-morpholino-isoindolin-1-one (19 mg, 0.069
mmol), pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (19 mg, 0.10
mmol), 4-dimethylaminopyridine (2 mg, 0.014 mmol), and
diisopropylethylamine (0.036 mL, 0.21 mmol) in DCE (1 mL) was
stirred at ambient temperature for 18 h. The reaction was
concentrated under reduced pressure and purified by reverse phase
HPLC to afford
N-(2-isopropyl-6-morpholino-1-oxoisoindolin-5-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide (6.8 mg, 24%). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.90 (s, 1H), 9.41 (dd, J=7.0, 1.6 Hz, 1H), 9.00 (dd,
J=4.2, 1.6 Hz, 1H), 8.76 (d, J=3.8 Hz, 2H), 7.56 (s, 1H), 7.39 (dd,
J=7.0, 4.2 Hz, 1H), 4.42 (d, J=5.3 Hz, 3H), 3.94-3.83 (m, 4H),
2.96-2.85 (m, 4H), 1.23 (d, J=6.8 Hz, 6H). MS (ESI): m/z=421.2
[M+1].sup.+.
Example 139.
(R)--N-(2-(2-Fluoro-3-hydroxy-3-methylbutyl)-6-morpholino-1-oxoisoindolin-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01070##
[1149]
(R)--N-(2-(2-Fluoro-3-hydroxy-3-methylbutyl)-6-morpholino-1-oxoisoi-
ndolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (44 mg, 32%)
was prepared following the procedure described for Example 138
using (R)-4-amino-3-fluoro-2-methylbutan-2-ol (WO 2014/074675).
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.90 (s, 1H), 9.41 (dd,
J=7.0, 1.6 Hz, 1H), 9.00 (dd, J=4.2, 1.6 Hz, 1H), 8.76 (d, J=2.4
Hz, 2H), 7.59 (s, 1H), 7.39 (dd, J=7.0, 4.2 Hz, 1H), 4.90 (s, 1H),
4.55 (s, 3H), 4.05-3.85 (m, 5H), 3.70 (td, J=15.9, 9.3 Hz, 1H),
2.99-2.85 (m, 4H), 1.24-1.12 (m, 6H). MS (ESI): m/z=483.2
[M+1].sup.+.
Example 140.
N-(2-Methyl-6-morpholino-1-oxoisoindolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-
-carboxamide
##STR01071##
[1151]
N-(2-Methyl-6-morpholino-1-oxoisoindolin-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide (55 mg, 17%) was prepared following the
procedure described for Example 138. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.88 (s, 1H), 9.40 (dd, J=7.0, 1.6 Hz, 1H), 8.99 (dd,
J=4.2, 1.6 Hz, 1H), 8.74 (d, J=4.6 Hz, 2H), 7.56 (s, 1H), 7.38 (dd,
J=7.0, 4.2 Hz, 1H), 4.45 (s, 2H), 3.94-3.84 (m, 4H), 3.07 (s, 3H),
2.97-2.86 (m, 4H). MS (ESI): m/z=393.1 [M+1].sup.+.
Example 141.
N-(2-(Hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a]pyr-
imidine-3-carboxamide
##STR01072##
[1152] Step A.
2-((tert-Butyldimethylsilyloxy)methyl)-7-chloro-2-methylchroman-4-one
##STR01073##
[1154] A mixture of 1-(4-chloro-2-hydroxyphenyl)ethanone (513.0 mg,
3.01 mmol) pyrrolidine (0.5 mL, 6.01 mmol) and
1-(tert-butyldimethylsilyloxy)propan-2-one (849.56 mg, 4.51 mmol)
in methyl alcohol (10 mL) was stirred at reflux for 16 h. After
concentration, the residue was purified on silica gel
chromatography using ethyl acetate:petroleum ether (5:95) as
eluting solvents to afford
2-[[tert-butyl(dimethyl)silyl]oxymethyl]-7-chloro-2-methyl-chroman-4-one
(685 mg, 57%) as an orange oil. MS (ESI): m/z=341.1
[M+1].sup.+.
Step B.
2-((tert-Butyldimethylsilyloxy)methyl)-7-chloro-2-methylchroman-4--
ol
##STR01074##
[1156] To a solution of
2-[[tert-butyl(dimethyl)silyl]oxymethyl]-7-chloro-2-methyl-chroman-4-one
(102.0 mg, 0.30 mmol) in methyl alcohol (15 mL) was added sodium
borohydride (34.11 mg, 0.90 mmol). The mixture was stirred at
25.degree. C. for 3 h. Water and ethyl acetate (30 mL) was added.
The organic layer was separated, dried sodium sulfate and
concentrated to afford
2-[[tert-butyl(dimethyl)silyl]oxymethyl]-7-chloro-2-methyl-chroman-4-ol
(101 mg, crude) as a yellow oil, which was used directly to next
step without further purification. MS (ESI): m/z=365.2
[M+23].sup.+.
Step C. (7-Chloro-2-methylchroman-2-yl)methanol
##STR01075##
[1158] A mixture of
2-[[tert-butyl(dimethyl)silyl]oxymethyl]-7-chloro-2-methyl-chroman-4-ol
(513 mg, 1.5 mmol) and triethylsilane (6.85 mL, 42.75 mmol) in
trifluoroacetic acid (25 mL) was stirred at 50.degree. C.
overnight. Saturated sodium bicarbonate solution was added until
pH=7.0. The aqueous phase was extracted with ethyl acetate (20 mL).
The organic layer was dried over sodium sulfate and concentrated in
vacuo to afford (7-chloro-2-methyl-chroman-2-yl)methanol (115 mg,
crude) as a yellow oil, which was used directly to next step
without further purification. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 6.98 (d, J=8.0 Hz, 1H), 8.87-8.80 (m, 2H), 4.43-4.32 (m,
2H), 2.82-2.70 (m, 2H), 2.02-1.92 (m, 1H), 1.87-1.79 (m, 1H), 1.36
(s, 3H).
Step D. (7-Chloro-2-methylchroman-2-yl)methyl benzoate
##STR01076##
[1160] A mixture of (7-chloro-2-methyl-chroman-2-yl)methanol (115
mg, 0.54 mmol), benzoyl chloride (91 mg, 0.65 mmol) and
triethylamine (164 mg, 1.62 mmol) in dichloromethane (10 mL) was
stirred overnight. After concentration, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether (1:20
to 1:10) as eluting solvents to afford
(7-chloro-2-methylchroman-2-yl)methyl benzoate (130 mg, 76%) as a
yellow oil. MS (ESI): m/z=317.2 [M+1].sup.+.
Step E. (7-Chloro-2-methyl-6-nitrochroman-2-yl)methyl benzoate
##STR01077##
[1162] To a solution of (7-Chloro-2-methylchroman-2-yl)methyl
benzoate (130 mg, 0.41 mmol) in dichloromethane (5 mL) was added
fuming nitric acid (1 mL) drop wise. Water and ethyl acetate (20
mL) was added. The organic layer was dried over sodium sulfate and
concentrated under reduced pressure to afford
(7-Chloro-2-methyl-6-nitrochroman-2-yl)methyl benzoate (110 mg,
crude) as a yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=362.1 [M+1].sup.-.
Step F. (2-Methyl-7-morpholino-6-nitro-chroman-2-yl)methyl
benzoate
##STR01078##
[1164] A mixture of morpholine (5 mL, 57.16 mmol) and
(7-chloro-2-methyl-6-nitro-chroman-2-yl)methylbenzoate (110.0 mg,
0.3 mmol) was stirred at 100.degree. C. overnight. The reaction was
concentrated to dryness to afford
(2-methyl-7-morpholino-6-nitro-chroman-2-yl)methyl benzoate (115
mg, crude) as a yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=413.2 [M+1].sup.+.
Step G. (2-Methyl-7-morpholino-6-nitro-chroman-2-yl)methanol
##STR01079##
[1166] A solution of
(2-methyl-7-morpholino-6-nitro-chroman-2-yl)methyl benzoate (94.0
mg, 0.23 mmol) in methyl alcohol (10 mL) at 0.degree. C. was added
sodium methanolate (36.92 mg, 0.68 mmol). The mixture was stirred
for 1 h at room temperature. The solvent was removed under reduced
pressure. The residue was dissolved by dichloromethane (25 mL) and
saturated ammonium chloride solution was added. The organic layer
was washed with water, brine, dried over sodium sulfate and
concentrated to afford
(2-methyl-7-morpholino-6-nitro-chroman-2-yl)methanol (137 mg,
crude) as a yellow solid, which was used directly to next step
without further purification.
[1167] MS (ESI): m/z=309.1 [M+1].sup.-.
Step H. (6-Amino-2-methyl-7-morpholino-chroman-2-yl)methanol
##STR01080##
[1169] A mixture of palladium on carbon (20 mg) and
(2-methyl-7-morpholino-6-nitro-chroman-2-yl)methanol (131.19 mg,
0.43 mmol) in methyl alcohol (10 mL) was stirred at room
temperature under hydrogen atmosphere for 30 min. After filtration
and concentration, it was afforded
(6-amino-2-methyl-7-morpholino-chroman-2-yl)methanol (79 mg, 60%)
as a light yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=279.1 [M+1].sup.+.
Step I.
N-[2-(Hydroxymethyl)-2-methyl-7-morpholino-chroman-6-yl]pyrazolo[1-
,5-a]pyrimidine-3-carboxamide
##STR01081##
[1171] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(46.3 mg, 0.28 mmol), diisopropylethylamine (73.36 mg, 0.57 mmol)
and (7-azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium
hexafluorophosphate (162.77 mg, 0.31 mmol) in N,N-dimethylformamide
(2 mL) was stirred at 0.degree. C. Then
(6-amino-2-methyl-7-morpholino-chroman-2-yl)methanol (79.0 mg, 0.28
mmol) in N,N-dimethylformamide (1 mL) was added. The mixture was
stirred at room temperature for 2 h. The crude was purified by
reverse phase chromatography (Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile, 25-75%; B: 10 mM ammonium bicarbonate in water) to
afford
N-[2-(hydroxymethyl)-2-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a]py-
rimidine-3-carboxamide (55 mg, 46%) as an off-white solid. .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 10.41 (s, 1H), 8.83 (dd, J=1.6,
6.8 Hz, 1H), 8.79-8.76 (m, 2H), 8.37 (s, 1H), 7.06 (dd, J=4.0, 7.2
Hz, 1H), 6.68 (s, 1H), 3.98-3.92 (m, 4H), 3.69-3.60 (m, 2H),
2.96-2.89 (m, 4H), 2.89-2.76 (m, 2H), 2.08-1.98 (m, 1H), 1.89 (t,
J=6.4 Hz, 1H), 1.77-1.70 (m, 1H), 1.29 (s, 3H). MS (ESI): m/z=424.2
[M+1].sup.+.
Example 142.
N-(6-Morpholinospiro[3H-benzofuran-2,4'-piperidine]-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide
##STR01082##
[1172] Step A. tert-Butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate
##STR01083##
[1174] To a solution of magnesium (2400 mg, 100 mmol) and iodine
(180 mg, 0.71 mmol) in diethyl ether (25 mL) at reflux was added
1-(bromomethyl)-2,4-difluorobenzene (8200.0 mg, 39.61 mmol) slowly
and stirred for 30 min. To a solution of tert-butyl
4-oxopiperidine-1-carboxylate (6500.0 mg, 32.62 mmol) in diethyl
ether (200 mL) was added Grignard reagent at -78.degree. C. and the
reaction was stirred room temperature for 2 h. Water and EtOAc (200
mL) was added. The organic layer was separated and dried over
sodium sulfate. After concentration under reduced pressure, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:4 to 1:2) to afford tert-butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate
(9500 mg, 73%) as a white solid. MS (ESI): m/z=350.1
[M+23].sup.+.
Step B. tert-Butyl
6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01084##
[1176] A mixture of tert-butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate
(491.0 mg, 1.5 mmol) and potassium tert-butanolate (420.74 mg, 3.75
mmol) in tetrahydrofuran (30 mL) was stirred at 65.degree. C. for 3
h. Water was added. The aqueous layer was extracted with ethyl
acetate (60 mL). The organic layer was dried over sodium sulfate
and concentrated to afford tert-butyl
6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate (409
mg, crude) as a yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=252.2 [M-55].sup.+.
Step C. 6-Fluorospiro[3H-benzofuran-2,4'-piperidine]
##STR01085##
[1178] To a solution of tert-butyl
6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate (270.0
mg, 0.88 mmol) in dichloromethane (9 mL), was added trifluoroacetic
acid (1 mL). The reaction solution was stirred for 2 h at room
temperature. Saturated sodium bicarbonate solution was added until
pH=7.0. The aqueous layer was extracted twice with 20 mL of
dichloromethane. The combined organic layer was washed with
saturated brine and dried over anhydrous magnesium sulfate. After
removal of the solvent, it was afforded
6-fluorospiro[3H-benzofuran-2,4'-piperidine] (189 mg, crude) as a
yellow solid, which was used directly to next step without further
purification. MS (ESI): m/z=208.2 [M+1].sup.+.
Step D. 6-Fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]
##STR01086##
[1180] To a solution of
6-fluorospiro[3H-benzofuran-2,4'-piperidine] (171.0 mg, 0.8300
mmol) in dichloromethane (10 ml) was added concentrated nitric acid
(0.5 mL, 8 mmol). The reaction was stirred at 25.degree. C. for 1
h. Water was added. Then saturated sodium bicarbonate was added
until pH=7.0. The aqueous was extracted with dichloromethane (50
mL). The organic layer was dried over sodium sulfate and
concentrated in vacuo to afford
6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine] (135 mg,
crude) as a yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=253.2 [M+1].sup.+.
Step E. tert-Butyl
6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01087##
[1182] A mixture of
6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine] (135.0 mg,
0.54 mmol), triethylamine (108.31 mg, 1.07 mmol) and di-tert-butyl
dicarbonate (80.28 mg, 0.80 mmol) was stirred at room temperature
for 2 h. Then the reaction was concentrated in vacuo to obtained
tert-butyl
6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
(with 7a impurity) (270 mg, crude) as a yellow solid, which was
used directly to next step without further purification. MS (ESI):
m/z=297.1 [M-55].sup.+.
Step F. tert-Butyl
6-morpholino-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01088##
[1184] A mixture of tert-butyl
6-fluoro-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate
(270.0 mg, 0.38 mmol), morpholine (66.76 mg, 0.77 mmol) and
potassium carbonate (132.09 mg, 0.96 mmol) in acetonitrile (6 mL)
was stirred at room temperature overnight. Then to the reaction was
added water and the aqueous layer was extracted twice with 20 mL of
ethyl acetate. The combined organic layer was washed with saturated
brine and then dried over anhydrous magnesium sulfate. After
removal of solvents, the residue was purified on silica gel
chromatography using ethyl acetate:petroleum ether (1:1) as eluting
solvents to afford tert-butyl
6-morpholino-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate
(73 mg, 42%) as a yellow oil. MS (ESI): m/z=420.3 [M+1].sup.+.
Step G. tert-Butyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01089##
[1186] A mixture of palladium on carbon (20.0 mg, 10% wt) and
tert-butyl
6-morpholino-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
(73.0 mg, 0.17 mmol) in methylalcohol (10 mL) was stirred at room
temperature under hydrogen atmosphere for 2 h. After filtration and
concentration under reduced pressure, it was afforded tert-butyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
(61 mg, 79%) as a yellow solid. MS (ESI): m/z=390.2
[M+1].sup.+.
Step H. tert-Butyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01090##
[1188] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(25.55 mg, 0.16 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium
hexafluorophosphate (89.82 mg, 0.17 mmol) and
N-ethyl-N-isopropylpropan-2-amine (60.72 mg, 0.47 mmol) in
N,N-dimethylformanide (2 mL) was stirred at 0.degree. C. Then
tert-butyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate
(61.0 mg, 0.16 mmol) in N,N-dimethylformanide (1 mL) was added and
the reaction was stirred at room temperature for 2 h. The crude was
purified by reverse phase chromatography (Gilson 281-G, Phenomenex,
Gemini C18, 21.2.times.100 mm. 5 um, 110 A, A: acetonitrile 55-70%;
B: 0.05% formic acid in water) to afford tert-butyl
6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)spiro[3H-benzof-
uran-2,4'-piperidine]-1'-carboxylate (73 mg, 87%) as a yellow
solid. MS (ESI): m/z=535.3 [M+1].sup.+.
Step I.
N-(6-morpholinospiro[3H-benzofuran-2,4'-piperidine]-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide
##STR01091##
[1190] To a solution of tert-butyl
6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)spiro[3H-benzof-
uran-2,4'-piperidine]-1'-carboxylate (73.0 mg, 0.14 mmol) in
dichloromethane (5 mL) was added trifluoroacetic acid (0.5 mL). The
reaction solution was stirred for 2 h at room temperature. To the
reaction solution, an aqueous saturated sodium bicarbonate was
added until pH=7.0. The aqueous layer was extracted twice with 20
mL of dichloromethane. The combined organic layer was washed with
saturated brine and then dried over anhydrous magnesium sulfate.
After concentration, the residue was purified by reverse phase
chromatography (Gilson 281-G, Phenomenex, Gemini C18,
21.2.times.100 mm. 5 um, 110 A, A: acetonitrile, 55-70%; B: 0.05%
formic acid in water) to afford
N-(6-morpholinospiro[3H-benzofuran-2,4'-piperidine]-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide (29 mg, 49%) as a yellow solid. .sup.1H NMR
(400 MHz, MeOD-d.sub.4) .delta. 9.03 (dd, J=1.6, 7.2 Hz, 1H), 8.82
(dd, J=1.6, 4.0 Hz, 1H), 8.56 (s, 1H), 8.41 (s, 1H), 8.20 (s, 1H),
7.19 (dd, J=4.0, 7.2 Hz, 1H), 6.69 (s, 1H), 3.87-3.80 (m, 4H),
3.31-3.20 (m, 4H), 3.04 (s, 1H), 2.82-2.76 (m, 4H), 2.10-2.02 (m,
2H), 1.98-1.88 (m, 2H). MS (ESI): m/z=435.3 [M+1].sup.+.
Example 143.
N-(7-Cyano-2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide
##STR01092##
[1191] Step A. 2-Chloro-6-(2-methylallyloxy)benzonitrile
##STR01093##
[1193] A mixture of 2-chloro-6-hydroxy-benzonitrile (500.0 mg, 3.26
mmol), 3-bromo-2-methylpropene (0.39 mL, 3.91 mmol) and potassium
carbonate (898.6 mg, 6.51 mmol) in acetonitrile (10 mL) was stirred
at 25.degree. C. overnight. The solid was filtered off, the
filtrate was concentrated and purified by silica gel chromatography
using petroleum ether: ethyl acetate (100:1) to afford
2-chloro-6-(2-methylallyloxy)benzonitrile (699.0 mg, 98%) as a
light oil. MS (ESI): m/z=208.1 [M+1].sup.+.
Step B. 6-Chloro-2-hydroxy-3-(2-methylallyl)benzonitrile
##STR01094##
[1195] A mixture of 2-chloro-6-(2-methylallyloxy)benzonitrile
(100.0 mg, 0.48 mmol) in N,N-dimethylformamide (3 mL) was stirred
at 220.degree. C. under microwave condition for 2 h. Water was
added. The aqueous phase was extracted with ethyl acetate (20 mL).
The organic layer was washed with brine and dried over sodium
sulfate. The organic layer was concentrated to afford
6-chloro-2-hydroxy-3-(2-methylallyl)benzonitrile (70 mg, 70%) as a
light oil. (ESI): m/z=208.2 [M+1].sup.+.
Step C.
6-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-carbonitrile
##STR01095##
[1197] To a mixture of
6-chloro-2-hydroxy-3-(2-methylallyl)benzonitrile (200.0 mg, 0.96
mmol) in dichloromethane (10 mL) was added 3-chloroperoxybenzoic
acid (292.3 mg, 1.44 mmol) at 0.degree. C. The mixture was stirred
at 25.degree. C. overnight. Water and dichloromethane (20 mL) was
added. The organic layer was washed by saturated sodium
bicarbonate, brine and dried over sodium sulfate. After
concentration, it was afforded
6-chloro-2,2-dimethyl-3H-benzofuran-7-carbonitrile (200.0 mg,
crude) as a colorless oil, which was used to next step without
further purification. MS (ESI): m/z=208.1 [M+1].sup.-.
Step D.
6-Chloro-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-7-carbonitrile
##STR01096##
[1199] A mixture of
6-chloro-2,2-dimethyl-3H-benzofuran-7-carbonitrile (200.0 mg, 0.96
mmol) in dichloromethane (10 mL) was added fuming nitric acid (0.5
mL) drop wise at 25.degree. C. The mixture was stirred at
25.degree. C. for 30 min. The mixture was poured into ice water.
The aqueous layer was extracted with ethyl acetate (30 mL). The
organic layer was dried over sodium sulfate. After concentration,
the residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:9) to afford
6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran-7-carbonitrile (200.0
mg, 74%) as a light grey solid. MS (ESI): m/z=253.1
[M+1].sup.+.
Step E.
2,2-Dimethyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-7-carbonit-
rile
##STR01097##
[1201] A mixture of
6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran-7-carbonitrile (100.0
mg, 0.40 mmol) in morpholine (2 mL) in a sealed vial was stirred at
110.degree. C. overnight. The mixture was concentrated and the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:2) to afford
2,2-dimethyl-6-morpholino-5-nitro-3H-benzofuran-7-carbonitrile (100
mg, 79%) as a yellow oil. MS (ESI): m/z=304.2 [M+1].sup.+.
Step F.
5-Amino-2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-7-carbonit-
rile
##STR01098##
[1203] A mixture of
2,2-dimethyl-6-morpholino-5-nitro-3H-benzofuran-7-carbonitrile
(80.0 mg, 0.26 mmol) and palladium on carbon (8 mg, 10% wt) in
methanol (10 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration and concentration under
reduced pressure, it was afforded
5-amino-2,2-dimethyl-6-morpholino-3H-benzofuran-7-carbonitrile
(70.0 mg, crude) as a green oil, which was used directly to next
step without further purification. MS (ESI): m/z=274.1
[M+1].sup.+.
Step G.
N-(7-Cyano-2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)py-
razolo[1,5-a]pyrimidine-3-carboxamide
##STR01099##
[1205] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(41.8 mg, 0.26 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(133.4 mg, 0.26 mmol) and N-ethyl-N-isopropylpropan-2-amine (99.1
mg, 0.77 mmol) in N,N-dimethylformamide (5 mL) was stirred at room
temperature for 30 min.
5-Amino-2,2-dimethyl-6-morpholino-3H-benzofuran-7-carbonitrile
(70.0 mg, 0.26 mmol) was added. The resulting mixture was stirred
at room temperature overnight. Water and ethyl acetate (30 mL) was
added. The organic layer was separated the organic layer was washed
with brine and dried over sodium sulfate. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (10:1) and then further purified by
preparative HPLC(Column: Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile, 25-75%; B: 10 mM ammonium bicarbonatein water) to
afford
N-(7-cyano-2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (28 mg, 26%) as a yellow solid. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 10.65 (s, 1H), 8.85 (d, J=7.2 Hz,
1H), 8.82-8.77 (m, 2H), 8.73 (s, 1H), 7.13-7.08 (m, 1H), 4.05-3.95
(m, 4H), 3.73-2.70 (m, 6H), 1.54 (s, 6H). MS (ESI):
m/z=419.2[M+1].sup.+.
Example 144.
N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-
-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01100##
[1206] Step A. Methyl
2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carboxylate
##STR01101##
[1208] A mixture of
6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-carboxylate (Intermediate
3, step D) (300.0 mg, 1.18 mmol) in morpholine (2 mL) in a sealed
tube was stirred at 80.degree. C. overnight. The mixture was
concentrated and the residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:6) as eluting
solvents to afford methyl
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylate (329.0
mg, 83%) as yellow oil. MS (ESI): m/z=323.1 [M+1].sup.+.
Step B.
2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-carbaldehyde
##STR01102##
[1210] To a mixture of methyl
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carboxylate (315.0
mg, 0.89 mmol) in dichloromethane (10 mL) was added diisobutyl
aluminium hydride (1.33 mL, 1.33 mmol) drop wise at -78.degree. C.
over 5 min. Then the mixture was stirred at -78.degree. C. for 2 h.
The mixture was quenched with sodium sulfate decahydrate. The
reaction was filtered and the filtrate was concentrated and the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:6) as eluting solvents to afford
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carbaldehyde (163.0
mg, 56%) as a yellow solid. (ESI): m/z=293.1 [M+1].sup.+.
Step C.
4-(2-(Difluoromethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-
morpholine
##STR01103##
[1212] To a mixture of
2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-carbaldehyde (163.0
mg, 0.56 mmol) in dichloromethane (10 mL) was added drop wise
diethylaminosulfurtrifluoride (561.8 mg, 2.79 mmol) at -78.degree.
C. The mixture was stirred at -78.degree. C. overnight,
concentrated and purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:9) as eluting solvents to afford
4-[2-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(77.0 mg, 42%) as a yellow solid. (ESI): m/z=315.1 [M+1].sup.+.
Step D.
2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-a-
mine
##STR01104##
[1214] A mixture of
4-[2-(difluoromethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(77.0 mg, 0.25 mmol) and palladium on carbon (15 mg, 15% wt) in
methyl alcohol (5 mL) was stirred at 25.degree. C. under hydrogen
atmosphere for 1 h. After filtration, the filtrate was concentrated
under reduced pressure to afford
2-(difluoromethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine
(55.0 mg, crude) as a colorless oil, which was used to next step
without purification further.
[1215] (ESI): m/z=285.1 [M+1].sup.-.
Step E.
N-(2-(Difluoromethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran--
5-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01105##
[1217] A mixture of
2-(difluoromethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine
(55.0 mg, 0.19 mmol),
6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Example 7,
step A) (34.27 mg, 0.19 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(100.9 mg, 0.19 mmol) and N-ethyl-N-isopropylpropan-2-amine (75.0
mg, 0.58 mmol) in N,N-dimethylformamide (5 mL) was stirred at room
temperature overnight. Water and ethyl acetate (30 mL) were added
and the organic layer was separated. The organic layer was washed
with brine and dried over sodium sulfate. After concentration, the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (10:1) as eluting solvents to afford
N-[2-(difluoromethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]-6-methyl--
pyrazolo[1,5-a]pyrimidine-3-carboxamide (38.0 mg, 44%) as a yellow
solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.40 (s, 1H),
9.24 (s, 1H), 8.87 (s, 1H) 8.60 (s, 1H), 8.36 (s, 1H), 6.85 (s,
1H), 6.18 (t, J=54.8 Hz, 1H), 3.88-3.82 (m, 4H), 3.36 (d, J=17.2
Hz, 1H), 3.06 (d, J=16.4 Hz, 1H), 2.86-2.79 (m, 4H), 2.44 (s, 3H)
1.46 (s, 3H). MS (ESI): m/z=444.1[M+1].sup.+.
Example 145.
[1-[2,2-Dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofu-
ran-6-yl]-4-piperidyl]methyl diethyl phosphate
##STR01106##
[1218] Step A.
[1-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate
##STR01107##
[1220] To a solution of
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methanol
(Example 4, Step A) (270 mg, 0.85 mmol), iodine (22 mg, 0.09 mmol)
and diethyl phosphate (141 mg, 1.02 mmol) in dichloromethane (10
mL) was added hydrogen peroxide (0.31 mL, 4.26 mmol) then the
mixture was stirred at 20.degree. C. for 20 h. Water and
dichloromethane (50 mL) was added and the aqueous phase was
extracted with dichloromethane (2.times.50 mL). The combined
organic phases were washed with brine, dried over sodium sulfate
and concentrated under reduced pressure. The residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:1 to 2:1) as eluting solvents to afford
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate (113 mg, 23%) as a yellow solid. MS (ESI):
m/z=443.1 [M+1].sup.+.
Step B.
[1-(5-Amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate
##STR01108##
[1222] A mixture of
[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate (113 mg, 0.19 mmol), iron powder (54 mg, 0.96
mmol) and ammonium chloride (52 mg, 0.96 mmol) in ethanol (5 mL)
and water (0.5 mL), was heated at 60.degree. C. for 2 h. After
filtration, water and dichloromethane (50 mL) was added. The
aqueous phase was extracted with dichloromethane (2.times.50 mL).
The combined organic phases were washed with brine, dried over
sodium sulfate and concentrated under reduced pressure to afford
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate (79 mg, crude) as a brown solid, which was used
directly to next step without further purification. MS (ESI):
m/z=413.3 [M+1].sup.+.
Step C.
[1-[2,2-Dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H--
benzofuran-6-yl]-4-piperidyl]methyl diethyl phosphate
##STR01109##
[1224] A mixture of
[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-piperidyl]methyl
diethyl phosphate (79 mg, 0.14 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (27 mg, 0.17 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (78 mg, 0.21 mmol) and diisopropylethylamine
(53 mg, 0.41 mmol) in N,N-dimethylformamide (5 mL) was stirred at
20.degree. C. for 1 h. The mixture was purified by preparative HPLC
(Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10 mM
ammonium bicarbonate in water) to afford
[1-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benzofu-
ran-6-yl]-4-piperidyl]methyl diethyl phosphate (7 mg, 9%) as yellow
solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 10.51 (s, 1H),
8.85 (dd, J=1.6, 4.0 Hz, 1H), 8.79-8.76 (m, 2H), 8.44 (s, 1H), 7.10
(dd, J=1.6, 7.2 Hz, 1H), 6.63 (s, 1H), 4.14 (q, J=7.2 Hz, 4H),
4.01-4.00 (m, 2H), 3.11 (d, J=11.6 Hz, 2H), 3.03 (s, 2H), 2.69-2.64
(m, 2H), 1.87-1.77 (m, 5H), 1.48 (s, 6H), 1.35 (t, J=6.8 Hz, 6H).
MS (ESI): m/z=558.3 [M+1].sup.+.
Example 146.
N-(1-methyl-6'-morpholino-3'H-spiro[azetidine-3,2'-benzofuran]-5'-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01110##
[1225] Step A. tert-Butyl
3-[(2,4-Difluorophenyl)methyl]-3-hydroxy-azetidine-1-carboxylate
##STR01111##
[1227] To the mixture of magnesium powder (2.0 g, 81.51 mmol) and
iodine (6.1 g, 24.15 mmol) in diethyl ether (40 mL) at 40.degree.
C. was added 2,4-difluorobenzylbromide (5.0 g, 24.15 mmol)
dropwise. The reaction was stirred for 30 min. To a solution of
1-Boc-3-azetidinoe (4.1 g, 24.15 mmol) in diethyl ether (40 mL) was
added Grignard reagent at -78.degree. C. and the reaction was
stirred at room temperature for 2 h. Saturated ammonium chloride
solution was added. The aqueous layer was extracted with ethyl
acetate (40 mL) twice. The combined organic layer was dried over
anhydrous sodium sulfate, concentrated under reduced pressure to
afford tert-butyl
3-[(2,4-difluorophenyl)methyl]-3-hydroxy-azetidine-1-carboxylate (4
g, crude) as a colorless oil, which was used directly to next step
without further purification. MS (ESI): m/z=244.1 [M-56].sup.+.
Step B. tert-Butyl
6-fluorospiro[3H-benzofuran-2,3'-azetidine]-1'-carboxylate
##STR01112##
[1229] The mixture of potassium tert-butylate (3.7 g, 33.41 mmol)
and tert-butyl
3-[(2,4-difluorophenyl)methyl]-3-hydroxy-azetidine-1-carboxylate
(4.0 g, 13.36 mmol) in tetrahydrofuran (75 mL) was stirred at
65.degree. C. overnight. After cooling to room temperature, water
was added. The aqueous layer was extracted with ethyl acetate (100
mL). The organic layer was washed with water, brine, dried over
anhydrous sodium sulfate and concentrated. The residue was purified
by reverse phase Combiflash (A: acetonitrile 30%-50%; B: 0.1% wt
ammonium bicarbonate in water) to afford tert-butyl
6-fluorospiro[3H-benzofuran-2,3'-azetidine]-1'-carboxylate (350 mg,
19%) as an orange oil. MS (ESI): m/z=224.1 [M-56].sup.+.
Step C. 6-Fluorospiro[3H-benzofuran-2,3'-azetidine]
##STR01113##
[1231] A mixture of tert-butyl
6-fluorospiro[3H-benzofuran-2,3'-azetidine]-1'-carboxylate (350 mg,
1.25 mmol) and trifluoroacetic acid (2 mL) in dichloromethane (40
mL) at room temperature was stirred overnight. Ammonia (30% wt in
methanol, 10 mL) was slowly added. After concentration under
reduced pressure, it was afforded
6-fluorospiro[3H-benzofuran-2,3'-azetidine] (400.0 mg, crude) as a
yellow solid, which was used directly to next step without further
purification. MS (ESI): m/z=180.1 [M+1].sup.+.
Step D. 6-Fluoro-1'-methyl-spiro[3H-benzofuran-2,3'-azetidine]
##STR01114##
[1233] To a solution of 6-fluorospiro[3H-benzofuran-2,3'-azetidine]
(100.0 mg, 0.56 mmol) in methyl alcohol (4 mL) was added
formaldehyde (30% wt in water, 1.1 g, 13.8 mmol) then the mixture
was stirred at 25.degree. C. for 30 min. To the mixture was added
sodium cyanoborohydride (70.0 mg, 1.12 mmol). The reaction was
stirred at 25.degree. C. for 1 h. Water was added and the crude was
purified by reverse phase combiflash (A: acetonitrile 23%-30%; B:
0.1% wt ammonium bicarbonate in water) to afford
6-fluoro-1'-methyl-spiro[3H-benzofuran-2,3'-azetidine] (108 mg,
99%) as a yellow solid. MS (ESI): m/z=194.1 [M+1].sup.+.
Step E.
6-Fluoro-1'-methyl-5-nitro-spiro[3H-benzofuran-2,3'-azetidine]
##STR01115##
[1235] A mixture of
6-fluoro-1'-methyl-spiro[3H-benzofuran-2,3'-azetidine] (90.0 mg,
0.4700 mmol) in dichloromethane (10 mL) was added drop wise fuming
nitric acid (0.3 mL, 4.66 mmol) at 25.degree. C. The mixture was
stirred at 25.degree. C. for 30 min and poured into ice water. 5M
Sodium hydroxide was added until pH=10.0. The organic layer was
dried over anhydrous sodium sulfate and concentrated under reduced
pressure to afford
6-fluoro-1'-methyl-5-nitro-spiro[3H-benzofuran-2,3'-azetidine] (85
mg, 77%) as a yellow solid. .sup.1H NMR (400 MHz, MeOD-d.sub.4):
7.90-7.88 (d, J=8.0 Hz, 1H), 6.70-6.67 (d, J=11.6 Hz, 1H),
3.52-3.46 (m, 4H), 3.39 (s, 2H), 2.35 (s, 3H). MS (ESI): m/z=239.1
[M+1].sup.+.
Step F.
1'-Methyl-6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-azetidine]
##STR01116##
[1237] A solution of
6-fluoro-1'-methyl-5-nitro-spiro[3H-benzofuran-2,3'-azetidine]
(116.0 mg, 0.49 mmol) in morpholine (426.0 mg, 4.9 mmol), was
stirred at 110.degree. C. for 3 h, then removed the solvents under
reduced pressure to get the residue and used in next step directly
without further purification. MS (ESI): m/z=306.1 [M+1].sup.+.
Step G.
1'-Methyl-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-amine
##STR01117##
[1239] To a solution of
1'-methyl-6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-azetidine]
(90.0 mg, 0.29 mmol) in methyl alcohol (10 mL) was added palladium
on carbon (20.0 mg, 10% wt). The mixture was stirred at 25.degree.
C. for 2 h under hydrogen atmosphere. After filtration and
concentration, it was afforded
1'-methyl-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-amine
(65 mg, 82%) as a brown oil. MS (ESI): m/z=276.2 [M+1].sup.+.
Step H.
N-(1'-Methyl-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01118##
[1241] To a solution of
1'-methyl-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-amine
(30.0 mg, 0.11 mmol) in N,N-dimethylformamide (3 mL) was added
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (23.0 mg, 0.14 mmol),
N,N-diisopropylethylamine (42.0 mg, 0.33 mmol) and
o-(7-azabenzotriazol-1-yl)-N,N,N',N'-te-tramethyluronium
hexafluorophosphate (83.0 mg, 0.22 mmol). The mixture was stirred
at 25.degree. C. for 3 h. Water was added. The aqueous layer was
extracted with ethyl acetate (20 mL). The organic layer was washed
with water, brine, dried over sodium sulfate and concentrated. The
residue was purified by preparative HPLC (A: acetonitrile 25-55%;
B: 0.05% wt formic acid in water) to afford
N-(1'-methyl-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide (20 mg, 44%) as a yellow solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.46 (s, 1H), 9.37
(dd, J=1.6, 6.8 Hz, 1H), 8.95 (dd, J=1.6, 4.0 Hz, 1H), 8.68 (s,
1H), 8.34 (s, 1H), 7.35 (dd, J=4.0, 6.8 Hz, 1H), 6.80 (s, 1H), 3.84
(t, J=8.8 Hz, 4H), 3.46-3.42 (m, 4H), 3.27-3.25 (m, 2H), 2.86-2.76
(m, 4H), 2.31 (s, 3H). MS (ESI): m/z=421.3 [M+1].sup.+.
Example 147.
N-(1-(2,2-Difluoroethyl)-6'-morpholino-3'H-spiro[azetidine-3,2'-benzofura-
n]-5'-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01119##
[1242] Step A.
1'-(2,2-Difluoroethyl)-6-fluoro-spiro[3H-benzofuran-2,3'-azetidine]
##STR01120##
[1244] A mixture of 6-fluorospiro[3H-benzofuran-2,3'-azetidine]
(Example 146, Step C) (185.0 mg, 1.03 mmol), 2,2-difluoroethyl
trifluoromethanesulfonate (265.0 mg, 1.24 mmol) and potassium
carbonate (442.0 mg, 3.2 mmol) in acetonitrile (10 mL) was stirred
at 25.degree. C. overnight. After filtration and concentration, it
was afforded
1'-(2,2-difluoroethyl)-6-fluoro-spiro[3H-benzofuran-2,3'-azetidine]
(170 mg, crude) as white solid, which was used directly to next
step without further purification. MS (ESI): m/z=244.1
[M+1].sup.+.
Step B.
1'-(2,2-Difluoroethyl)-6-fluoro-5-nitro-spiro[3H-benzofuran-2,3'-a-
zetidine]
##STR01121##
[1246] A mixture of
1'-(2,2-difluoroethyl)-6-fluoro-spiro[3H-benzofuran-2,3'-azetidine]
(113.0 mg, 0.47 mmol) in dichloromethane (10 mL) was added drop
wise fuming nitric acid (0.3 mL, 4.66 mmol) at 25.degree. C. The
mixture was stirred at 25.degree. C. for 30 min. The mixture was
poured into ice water. 5N sodium hydroxide was added until pH=10.0.
The aqueous layer was extracted with dichloromethane (40 mL). The
organic layer was dried over anhydrous sodium sulfate and
concentrated under reduced pressure to afford
1'-(2,2-difluoroethyl)-6-fluoro-5-nitro-spiro[3H-benzofuran-2,3'-a-
zetidine] (165 mg crude) as a yellow solid, which was used directly
to next step without further purification. MS (ESI): m/z=289.1
[M+1].sup.+.
Step C.
1-(2,2-Difluoroethyl)-6'-morpholino-5'-nitro-3'H-spiro[azetidine-3-
,2'-benzofuran]
##STR01122##
[1248] A solution of
1'-(2,2-difluoroethyl)-6-fluoro-5-nitro-spiro[3H-benzofuran-2,3'-azetidin-
e] (120.0 mg, 0.42 mmol) in morpholine (426.0 mg, 4.9 mmol) was
stirred at 110.degree. C. for 3 h. After concentration, it was
afforded
1-(2,2-difluoroethyl)-6'-morpholino-5'-nitro-3'H-spiro[azetidine-3,2'-ben-
zofuran] (90 mg, crude) as a yellow oil, which was used to the next
step directly without further purification. MS (ESI): m/z=356.2
[M+1].sup.+.
Step D.
1'-(2,2-Difluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,3'-azeti-
dine]-5-amine
##STR01123##
[1250] To a solution of
1'-(2,2-difluoroethyl)-6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-azet-
idine](90.0 mg, 0.25 mmol) in methyl alcohol (10 mL) was added
palladium on carbon (20.0 mg, 10% wt). The mixture was stirred at
25.degree. C. for 2 h under hydrogen atmosphere. After filtration
and concentration, it was afforded
1'-(2,2-difluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,3'-aze-
tidine]-5-amine (50 mg, crude) as a brown oil, which was used to
the next step directly without further purification. MS (ESI):
m/z=326.2 [M+1].sup.+.
Step E.
N-[1'-(2,2-Difluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,3'-az-
etidine]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01124##
[1252] To a solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(26.0 mg, 0.16 mmol) in N,N-dimethylformamide (3 mL) was added
1'-(2,2-difluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine]-5-
-amine (40.0 mg, 0.1200 mmol), N,N-diisopropylethylamine (47.0 mg,
0.37 mmol) and
o-(7-azabenzotriazol-1-yl)-N,N,N',N-tetramethyluronium
hexafluorophosphate (93.0 mg, 0.25 mmol). The mixture was stirred
at 25.degree. C. for 3 h. Water and ethyl acetate (20 mL) was added
and the organic layer was washed with water, brine and
concentrated. The residue was purified by preparative HPLC (A:
acetonitrile 25-55%; B: 0.05% wt formic acid in water) to afford
N-[1'-(2,2-difluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,3'-azetidine-
]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (16.0 mg, 0.034
mmol, 28%) as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.45 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.95 (dd,
J=1.6, 4.4 Hz, 1H), 8.68 (s, 1H), 8.35 (s, 1H), 7.34 (dd, J=4.4,
6.8 Hz, 1H), 6.80 (s, 1H), 6.15-5.87 (m, 1H), 3.85-3.83 (m, 4H),
3.57-3.44 (m, 6H), 2.95-2.86 (m, 2H), 2.82-2.80 (m, 4H).
[1253] MS (ESI): m/z=471.1 [M+1].sup.+.
Example 148.
N-[6-Morpholino-1'-(2,2,2-trifluoroethyl)spiro[3H-benzofuran-2,3'-azetidi-
ne]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01125##
[1255] The title compound was made in a manner analogous to Example
147 to give
N-[6-Morpholino-1'-(2,2,2-trifluoroethyl)spiro[3H-benzofuran-2,3'-az-
etidine]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (72 mg, 25%)
as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
10.46 (s, 1H), 9.37 (dd, J=1.6, 6.8 Hz, 1H), 8.95 (dd, J=1.6, 4.4
Hz, 1H), 8.68 (s, 1H), 7.34 (dd, J=4.4, 6.8 Hz, 1H), 6.81 (s, 1H),
3.85-3.83 (m, 4H), 3.64-3.57 (m, 6H), 3.16 (s, 2H), 2.82-2.80 (m,
4H). MS (ESI): m/z=489.2 [M+1].sup.+.
Example 149.
N-(6-(4-(2,2-difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-dihydrobe-
nzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01126##
[1256] Step A. tert-Butyl
4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane-1-carbo-
xylate
##STR01127##
[1258] A mixture of
6-fluoro-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran (Example 3,
Step F) (210 mg, 0.99 mmol), tert-butyl 1,4-diazepane-1-carboxylate
(219 mg, 1.09 mmol) and potassium carbonate (412 mg, 2.98 mmol) in
acetonitrile (10 mL) was stirred at 80.degree. C. for 2 h. After
removal of the solvents under reduced pressure, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (from 1:9 to 1:1) as eluting solvents to afford tert-butyl
4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane-1-carbo-
xylate (260 mg, 63%) as a yellow solid. MS (ESI): m/z=392.2
[M+1].sup.+.
Step B.
1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane
##STR01128##
[1260] A mixture of tert-butyl
4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane-1-carbo-
xylate (260 mg, 0.66 mmol) and trifluoroacetic acid (1 mL) in
dichloromethane (3 mL), was stirred at 25.degree. C. for 2 h. After
removal of solvents under reduced pressure, it was afforded
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane
trifluoroacetic acid salt (180 mg, crude) as a yellow solid, which
was used directly to next step without further purification.
[1261] MS (ESI): m/z=291.2 [M+1].sup.+.
Step C.
1-(2,2-Difluoroethyl)-4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofura-
n-6-yl)-1,4-diazepane
##STR01129##
[1263] A mixture of
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1,4-diazepane
trifluoroacetic acid salt (180 mg, 0.61 mmol), 2,2-difluoroethyl
trifluoromethanesulfonate (132 mg, 0.61 mmol) and potassium
carbonate (257 mg, 1.85 mmol) in acetonitrile (10 mL) was stirred
at 80.degree. C. for 16 h. After filtration and removal of the
solvents under reduced pressure, the residue was purified by silica
gel chromatography using ethyl acetate:petroleum ether (from 1:9 to
1:1) as eluting solvents to afford
1-(2,2-difluoroethyl)-4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofura-
n-6-yl)-1,4-diazepane (150 mg, 64%) as a yellow solid. MS (ESI):
m/z=356.2 [M+1].sup.+.
Step D.
6-(4-(2,2-Difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-dihyd-
robenzofuran-5-amine
##STR01130##
[1265] A mixture of
1-(2,2-difluoroethyl)-4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-
-1,4-diazepane (150 mg, 0.42 mmol) and palladium on carbon (20 mg,
10% wt) in methanol (3 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 2 hours. After filtration and
concentration, it was afforded
6-(4-(2,2-difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-dihydrobenzo-
furan-5-amine (120 mg, crude) as a brown oil, which was used
directly to next step without further purification. MS (ESI):
m/z=326.3 [M+1].sup.+.
Step E.
N-(6-(4-(2,2-Difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-di-
hydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01131##
[1267] A mixture of
6-(4-(2,2-difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-dihydrobenzo-
furan-5-amine (120 mg, 0.36 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (60 mg, 0.36 mmol),
2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (210 mg, 0.55 mmol) and diisopropylethylamine
(95 mg, 0.73 mmol) in N,N-dimethylformamide (3 mL) was stirred at
60.degree. C. for 3 h. The crude was purified by preparative HPLC
(Xbridge 21.2*250 mm c18, 10 um; A: acetonitrile 25-55%; B: 10 mM
ammonium bicarbonate in water) to afford
N-(6-(4-(2,2-difluoroethyl)-1,4-diazepan-1-yl)-2,2-dimethyl-2,3-dihydrobe-
nzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (22 mg, 12%)
as a yellow solid. .sup.1H NMR (400 MHz, MeOD-d.sub.4): .delta.
9.17 (d, J=6.0 Hz, 1H), 8.95 (d, J=2.8 Hz, 1H), 8.70 (s, 1H), 8.06
(s, 1H), 7.31 (dd, J=6.0, 2.8 Hz, 1H), 6.73 (s, 1H), 6.27-6.54 (tt,
J=1.2, 53.2 Hz 1H), 3.77-3.89 (m, 6H), 3.45 (s, 2H), 3.23 (t, J=5.6
Hz 2H), 3.05 (s, 2H), 2.21-2.27 (m, 2H), 1.48 (s, 6H). MS (ESI):
m/z=471.3 [M+1].sup.+.
Example 150.
N-(2-Isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide
##STR01132##
[1268] Step A. 1-(2,4-Difluorophenyl)-2,3-dimethylbutan-2-ol
##STR01133##
[1270] A mixture of magnesium (2.2 g, 92.88 mmol) and iodine (59
mg, 0.23 mmol) in diethyl ether (80 mL) at 40.degree. C. under
nitrogen atmosphere was slowly added 2,4-difluorobenenzyl bromide
(4.2 g, 20.31 mmol) and stirred for 2 h. To a solution of
3-methyl-2-butanone (2 g, 23.22 mmol) in diethyl ether (100 mL) at
-78.degree. C. under nitrogen atmosphere was added Grignard reagent
and the reaction was stirred at room temperature for 2 h. Saturated
ammonium chloride solution and ethyl acetate (200 mL) was added.
The organic layer was separated, washed with water, brine and dried
over sodium sulfate. After concentration, the residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:10) as eluting solvents to afford
1-(2,4-difluorophenyl)-2,3-dimethyl-butan-2-ol (3.4 g, 65%) as a
yellow oil. MS (ESI): m/z=197.2 [M-17].sup.+.
Step B. 6-Fluoro-2-isopropyl-2-methyl-2,3-dihydrobenzofuran
##STR01134##
[1272] A mixture of 1-(2,4-difluorophenyl)-2,3-dimethyl-butan-2-ol
(428 mg, 2 mmol) and tetrahydrofuran (50 mL) at 0.degree. C. was
added potassium tert-butylate (1.12 g, 9.99 mmol). The reaction was
stirred for 16 h. The aqueous layer was extracted with ethyl
acetate (100 mL) and the organics were washed with saturated brine
solution. The organics were then separated and dried over sodium
sulfate before concentration to dryness. The residue was purified
by silica gel chromatography using ethyl acetate:petroleum ether
(1:20) as eluting solvents to afford
6-fluoro-2-isopropyl-2-methyl-3H-benzofuran (350 mg, 90%) as a
yellow oil. MS (ESI): m/z=217.1 [M+23].sup.+.
Step C.
6-Fluoro-2-isopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran
##STR01135##
[1274] To a solution of 6-fluoro-2-isopropyl-2-methyl-3H-benzofuran
(350 mg, 1.8 mmol) in dichloromethane (30 mL) at 0.degree. C. was
added fuming nitric acid (2 mL). Water and dichloromethane (30 mL)
were added and the organics were then separated and dried over
sodium sulfate before concentration to dryness. The residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:5) as eluting solvents to afford
6-fluoro-2-isopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran (220
mg, 51%) as a yellow oil. MS (ESI): m/z=240.1 [M+1].sup.+.
Step D.
4-(2-Isopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morphol-
ine
##STR01136##
[1276] A mixture of
6-fluoro-2-isopropyl-2-methyl-5-nitro-3H-benzofuran (220 mg, 0.92
mmol), morphline (88 mg, 1.01 mmol) and potassium carbonate (254
mg, 1.84 mmol) in acetonitrile (15 mL) was stirred at 25.degree. C.
for 16 h. Water was added and the aqueous layer was extracted with
ethyl acetate (30 mL). The organic layer was washed with brine and
dried over sodium sulfate before concentration to dryness. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (1:1) as eluting solvents to afford
4-(2-isopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(250 mg, 85%) as a yellow solid. MS (ESI): m/z=307.2
[M+1].sup.-.
Step E.
2-Isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
##STR01137##
[1278] A mixture of palladium on carbon (80.0 mg, 10% wt) and
4-(2-isopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine
(250 mg, 0.78 mmol) in methanol (15 mL) was stirred at 25.degree.
C. under hydrogen atmosphere for 2 h. After filtration and
concentration under reduced pressure, it was afforded
2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
(200 mg, 89%) as a white oil. MS (ESI): m/z=277.3 [M+1].sup.+.
Step F.
N-(2-Isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)py-
razolo[1,5-a]pyrimidine-3-carboxamide
##STR01138##
[1280] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(130 mg, 0.80 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (464 mg, 0.87 mmol), ethyldiisopropylamine (347
mg, 2.16 mmol)
2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-amine
(200 mg, 0.72 mmol) in N,N-dimethylformamide (10 mL) was stirred at
room temperature overnight. After concentration, the residue was
purified by preparative HPLC (A: acetonitrile 25-45%; 0.05% wt
formic acid in water) to afford
N-(2-isopropyl-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (125 mg, 41%) as a yellow
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.46 (s, 1H),
8.83 (dd, J=1.6, 7.2 Hz, 1H), 8.79 (s, 1H), 8.76 (dd, J=1.6, 4.0
Hz, 1H), 8.40 (s, 1H), 7.06 (dd, J=4.0, 7.2 Hz, 1H), 6.65 (s, 1H),
4.00-3.89 (m, 4H), 3.16 (d, J=11.6 Hz, 1H), 2.93-2.87 (m, 4H), 2.83
(d, J=11.6 Hz, 1H), 2.08-1.95 (m, 2H), 1.01 (d, J=6.8, 3H), 0.96
(d, J=6.8 Hz, 6H). MS (ESI): m/z=422.2 [M+1].sup.+.
Example 151.
N-(6-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)-2-(hydroxymethyl)-2-met-
hyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01139##
[1281] Step A. 2-Methyl-1-(piperazin-1-yl)propan-2-ol
##STR01140##
[1283] Piperazine (6.88 g, 80 mmol) was dissolved in ethanol (40
mL). 1-Chloro-2-methyl-2-propanol (2.18 g, 20 mmol) was added. The
mixture was stirred at 110.degree. C. for 6 h. After the mixture
was left to cool to room temperature, the solvent was evaporated.
Ethyl acetate (40 mL) was added and the precipitated solid was
removed by filtration. The filtrate was concentrated under reduced
pressure to afford 2-methyl-1-piperazin-1-yl-propan-2-ol (4.1 g,
crude) as a white solid, which was used directly to the next step
without purification. MS (ESI): m/z=159.3 [M+1].sup.+.
Step B.
1-(4-(2-(Hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-y-
l)piperazin-1-yl)-2-methylpropan-2-ol
##STR01141##
[1285] A mixture of
(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Intermediate 3) (300 mg, 1.32 mmol),
2-methyl-1-(piperazin-1-yl)propan-2-ol (1.44 g, 6.6 mmol) and
potassium carbonate (365 mg, 2.64 mmol) in acetonitrile (10 mL) was
stirred at 25.degree. C. for 16 h. Water was added and the aqueous
layer was extracted with ethyl acetate (20 mL) and the organic was
washed with brine and dried over sodium sulfate before
concentration to dryness. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:2) as eluting
solvents to afford
1-(4-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piper-
azin-1-yl)-2-methylpropan-2-ol (100 mg, 18%) as a yellow solid. MS
(ESI): m/z=366.3 [M+1].sup.-.
Step C.
1-(4-(5-Amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-y-
l)piperazin-1-yl)-2-methylpropan-2-ol
##STR01142##
[1287] A mixture of palladium on carbon (30 mg, 10% wt) and
1-(4-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piper-
azin-1-yl)-2-methylpropan-2-ol (100 mg, 0.27 mmol) in methanol (10
mL) was stirred at 25.degree. C. under hydrogen atmosphere for 2 h.
After filtration and concentration under reduced pressure, it was
afforded
1-(4-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piper-
azin-1-yl)-2-methylpropan-2-ol (60 mg, crude) as a white oil, which
was used directly to next step without further purification. MS
(ESI): m/z=336.1 [M+1].sup.+.
Step D.
N-(6-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)-2-(hydroxymethyl-
)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR01143##
[1289] A mixture of
1-(4-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piper-
azin-1-yl)-2-methylpropan-2-ol (60 mg, 0.18 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (113 mg, 0.21 mmol), ethyldiisopropylamine (68
mg, 0.54 mmol) and pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (32
mg, 0.21 mmol) in N,N-dimethylformamide (10 mL) was stirred at room
temperature overnight. After concentration, the residue was
purified by preparative HPLC (A: acetonitrile 25-45%; B: 0.05% wt
formic acid in water) to afford
N-(6-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)-2-(hydroxymethyl)-2-met-
hyl-2,3-dihydrobenzofuran-5-yl)pyrazzolo[1,5-a]pyrimidine-3-carboxamide
(50 mg, 58%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.39 (s, 1H), 8.86-8.75 (m, 3H), 8.43 (s, 1H), 8.17 (s,
1H), 7.08 (dd, J=4.0, 6.8 Hz, 1H), 6.68 (s, 1H), 5.33 (s, 1H),
3.69-3.61 (m, 2H), 3.25 (d, J=16.0 Hz, 1H), 3.08-2.90 (m, 8H),
2.58-2.50 (m, 2H), 1.46 (s, 3H), 1.26 (s, 6H). MS (ESI): m/z=481.2
[M+1].sup.+.
Example 152.
N-(1'-Methyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidine]-5-yl)pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR01144##
[1290] Step A. tert-Butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate
##STR01145##
[1292] To a solution of magnesium (2400 mg, 100 mmol) and iodine
(180 mg, 0.71 mmol) in diethyl ether (25 mL) at reflux was added
1-(bromomethyl)-2,4-difluorobenzene (8200.0 mg, 39.61 mmol) slowly
and stirred for 30 min. To a solution of tert-butyl
4-oxopiperidine-1-carboxylate (6500.0 mg, 32.62 mmol) in diethyl
ether (200 mL) was added Grignard reagent and stirred at
-78.degree. C. then room temperature for 2 h. Water and EtOAc (200
mL) was added. The organic layer was separated and dried over
sodium sulfate. After concentration, the residue was purified by
silica gel chromatography using petroleum ether: ethyl acetate (4:1
to 2:1) as eluting solvents to afford tert-butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-carboxylate
(9500 mg, 73%) as a white solid. MS (ESI):
m/z=350.1[M+23].sup.+.
Step B. tert-Butyl
6-fluoro-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate
##STR01146##
[1294] A mixture of tert-butyl
4-[(2,4-difluorophenyl)methyl]-4-hydroxy-piperidine-1-(818.0 mg,
2.5 mmol) and potassium tert-butanolate (700.95 mg, 6.25 mmol) in
tetrahydrofuran (50 mL) was stirred at 65.degree. C. for 3 h. To
the reaction mixture was added water and the aqueous layer was
extracted with ethyl acetate (100 mL). The organic layer was dried
over sodium sulfate and concentrated to dryness to afford
tert-butyl
6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate (644
mg, crude) as a yellow solid, which was used directly to next step
without further purification. MS (ESI): m/z=252.2 [M-55].sup.+.
Step C. 6-Fluorospiro[3H-benzofuran-2,4'-piperidine]
##STR01147##
[1296] To a solution of tert-butyl
6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-carboxylate (644.0
mg, 2.1 mmol) in dichloromethane (20 mL), was added trifluoroacetic
acid (2 mL). The reaction solution was stirred for 2 h at room
temperature. To the reaction was added saturated sodium hydrogen
carbonate (20 mL). The aqueous layer was extracted twice with 20 mL
of dichloromethane. The combined organic layer was washed with
brine and dried over anhydrous magnesium sulfate. After removal of
the solvent, it was afforded
6-fluorospiro[3H-benzofuran-2,4'-piperidine] (429 mg, crude) as a
yellow solid, which was used directly to next step without further
purification. MS (ESI): m/z=208.2 [M+1].sup.+.
Step D. 6-Fluoro-1'-methyl-3H-spiro[benzofuran-2,4'-piperidine]
##STR01148##
[1298] To a solution of
6-fluorospiro[3H-benzofuran-2,4'-piperidine] (429.0 mg, 1.51 mmol)
in methyl alcohol (40 mL) was added formaldehyde (28% wt in water,
1.5 mL) at room temperature. The reaction solution was stirred for
30 min at room temperature. Sodium borohydride (574.22 mg, 15.11
mmol) was added slowly and the reaction was stirred for 2 h at room
temperature. To the reaction solution saturated ammonium chloride
(200 mL) was added and the aqueous layer was extracted twice with
200 mL of ethyl acetate. The combined organic layers were washed
with brine and dried over anhydrous magnesium sulfate. After
concentration, it was afforded
6-fluoro-1'-methyl-spiro[3H-benzofuran-2,4'-piperidine] (402 mg,
crude) as a yellow oil, which was used directly to next step
without further purification. MS (ESI): m/z=222.2 [M+1].sup.+.
Step E.
6-Fluoro-1'-methyl-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]
##STR01149##
[1300] To a solution of
6-fluoro-1'-methyl-spiro[3H-benzofuran-2,4'-piperidine] (402.0 mg,
1.82 mmol) in dichloromethane (30 mL) was added fuming nitric acid
(1.7 mL, 27.25 mmol) slowly. The mixture was stirred at room
temperature for 30 min. Water (50 mL) was added. Sodium bicarbonate
was added until pH=7 was reached and the aqueous layer was
extracted with dichloromethane (50 mL). The organic layer was dried
over sodium sulfate and concentrated to afford
6-fluoro-1'-methyl-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]
(399 mg, crude) as a yellow solid, which was used directly to next
step without further purification. MS (ESI): m/z=267.1
[M-55].sup.+.
Step F.
1'-Methyl-6-morpholino-5-nitro-3H-spiro[benzofuran-2,4'-piperidine-
]
##STR01150##
[1302] A mixture of
6-fluoro-1'-methyl-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]
(399.0 mg, 1.5 mmol), morpholine (195.82 mg, 2.25 mmol) and
potassium carbonate (516.64 mg, 3.75 mmol) in acetonitrile (10 mL)
was stirred at 25.degree. C. overnight. Water was added and the
aqueous layer was extracted twice with 20 mL of ethyl acetate. The
combined organic layer was washed with saturated brine and dried
over anhydrous magnesium sulfate. After concentration, it was
afforded
1'-methyl-6-morpholino-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]
(467 mg, crude) as a yellow solid, which was used directly to next
step without further purification. MS (ESI): m/z=334.2
[M+1].sup.+.
Step G.
1'-Methyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidin]-5-amine
##STR01151##
[1304] A mixture of 10 wt % palladium on carbon (70.0 mg) and
1'-methyl-6-morpholino-5-nitro-3H-spiro[benzofuran-2,4'-piperidine]
(467.0 mg, 1.4 mmol) in methyl alcohol (40 mL) was stirred at room
temperature under a hydrogen atmosphere for 2 h. After filtration
and concentration under reduced pressure, it was afforded
1'-methyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidin]-5-amine
(419 mg, crude) as a brown solid, which was used directly to next
step without further purification. MS (ESI): m/z=304.3
[M+1].sup.+.
Step H.
N-(1'-Methyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidine]-5-y-
l)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01152##
[1306] To a mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(109.69 mg, 0.6700 mmol),
(3-hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinylphospho-
nium hexafluorophosphate (385.62 mg, 0.74 mmol) and
N-ethyl-N-isopropylpropan-2-amine (260.7 mg, 2.02 mmol) in
N,N-dimethylformanide (5 mL) at 0.degree. C. was added
1'-methyl-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-5-amine
(204.0 mg, 0.6700 mmol) in N,N-dimethylformanide (2 mL) and the
reaction was stirred at room temperature overnight. The crude was
purified by reverse phase chromatography (Xbridge Prep C18 10 um
OBD, 19*250 mm, A: acetonitrile 30-60%; B: 0.01% wt ammonium
hydroxide and 10 mM ammonium carbonate in water) to afford
N-(1'-methyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidine]-5-yl)pyraz-
olo[1,5-a]pyrimidine-3-carboxamide (121 mg, 40%) as a yellow solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.46 (s, 1H), 8.83 (dd,
J=1.6, 6.8 Hz, 1H), 8.78 (s, 1H), 8.77 (dd, J=1.6, 4.4 Hz, 1H),
8.43 (s, 1H), 7.06 (dd, J=4.4, 7.2 Hz, 1H), 6.69 (s, 1H), 3.99-3.91
(m, 4H), 3.02 (s, 2H), 2.94-2.88 (m, 4H), 2.66-2.44 (m, 4H), 2.35
(s, 3H), 2.05-1.95 (m, 2H), 1.89-1.79 (m, 2H).
[1307] MS (ESI): m/z=449.3 [M+1].sup.+.
Example 153 and 154.
(R)--N-(2-(hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01153##
[1308] Step A. Methyl
2-(2,4-difluorobenzyl)-3,3,3-trifluoro-2-hydroxypropanoate
##STR01154##
[1310] To a solution of magnesium powder (3290.81 mg, 137.12 mmol)
and iodine (243.76 mg, 0.96 mmol) in diethyl ether (50 mL) at
reflux was added 2,4-difluorobenzyl bromide (11291.0 mg, 54.54
mmol) drop wise and stirred for 30 min. This Grignard solution was
then added to a solution of methyl 3,3,3-trifluoro-2-oxopropanoate
(8567.5 mg, 54.92 mmol) in diethyl ether (200 mL) at -78.degree. C.
and stirred for 30 min followed by room temperature for 2 h.
Saturated ammonium chloride solution and ethyl acetate (200 mL) was
added. The organic phase was separated and dried over sodium
sulfate. After concentration, the residue was purified by silica
gel chromatography using ethyl acetate:petroleum ether (from 1:20
to 1:10) as eluting solvents to afford methyl
3-(2,4-difluorophenyl)-2-hydroxy-2-methyl-propanoate (9.7 g, 63%)
as a yellow oil. MS (ESI): m/z=307.1 [M+23].sup.+.
Step B. 2-(2,4-Difluorobenzyl)-3,3,3-trifluoro-2-hydroxypropanoic
acid
##STR01155##
[1312] A mixture of methyl
2-(2,4-difluorobenzyl)-3,3,3-trifluoro-2-hydroxypropanoate (9.7 g,
34.13 mmol) and potassium hydroxide (5.73 g, 102.4 mmol) in methyl
alcohol (100 mL) and water (50 mL) was stirred at 50.degree. C. for
2 h. After cooling to room temperature, IN hydrochloric acid was
added until pH=3.0. The aqueous phase was extracted with ethyl
acetate (200 mL). The organic layer was separated, dried over
sodium sulfate and concentrated to afford
2-(2,4-difluorobenzyl)-3,3,3-trifluoro-2-hydroxypropanoic acid (9.2
g, crude) as a white solid, which was used directly to next step
without further purification. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.35-7.29 (m, 1H), 6.85-6.77 (m, 2H), 3.45 (d, J=16.0 Hz,
1H), 3.20 (d, J=16.0 Hz, 1H).
Step C.
6-Fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylic
acid
##STR01156##
[1314] To a mixture of
2-(2,4-difluorobenzyl)-3,3,3-trifluoro-2-hydroxypropanoic acid (3.6
g, 13.33 mmol) in N,N-dimethylformamide (5 mL) and toluene (20 mL)
was added sodium hydride (1.06 g, 26.65 mmol) at room temperature.
The mixture was stirred at 110.degree. C. overnight. After cooling
to room temperature, IN hydrochloric acid was added until pH=3.0.
The aqueous phase was extracted with ethyl acetate (50 mL). The
organic layer was separated, dried over sodium sulfate and
concentrated to afford
6-fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylic
acid (3.3 g, crude) as a brown solid, which was used directly to
next step without further purification.
[1315] MS (ESI): m/z=273.1 [M+23].sup.+.
Step D. Methyl
6-fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
##STR01157##
[1317] To a mixture of
6-fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylic
acid (500 mg, 2.0 mmol) and cesium carbonate (1.3 g, 4.0 mmol) in
N,N-dimethylformamide (10 mL) was added methyl iodide (570 mg, 4.0
mmol). The mixture was stirred at room temperature overnight. Water
was added and the aqueous phase was extracted with ethyl acetate
(50 mL). The organic layer was washed with brine, dried over sodium
sulfate and concentrated to afford methyl
6-fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
(500 mg, crude), which was used directly to next step without
further purification. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.12-7.09 (m, 1H), 6.70-6.66 (m, 2H), 3.89 (s, 3H), 3.68 (d, J=16.0
Hz, 1H), 3.62 (d, J=16.0 Hz, 1H).
Step E. Methyl
6-fluoro-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
##STR01158##
[1319] To a mixture of methyl methyl
6-fluoro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
(3.8 g, 8.77 mmol) in dichloromethane (20 mL) was added fuming
nitric acid (4.0 mL). The mixture was stirred at room temperature
for 1 h. The mixture was poured into ice water and the aqueous
phase was extracted with ethyl acetate (50 mL). The organic phase
was separated, dried over sodium sulfate and concentrated. The
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether from 1:20 to 1:5 as eluting solvents to
afford methyl
6-fluoro-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
(2.6 g, 96%) as a light yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.00 (d, J=7.2 Hz, 1H), 6.86 (d, J=10.4 Hz,
1H), 3.93 (s, 3H), 3.76 (d, J=15.6 Hz, 1H), 3.70 (d, J=15.6 Hz,
1H). MS (ESI): m/z=310.0 [M+1].sup.+.
Step F. Methyl
6-morpholino-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxyl-
ate
##STR01159##
[1321] A mixture of morpholine (108 mg, 1.25 mmol),
6-fluoro-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxylate
(350 mg, 1.13 mmol) and cesium carbonate (738 mg, 2.26 mmol) in
acetonitrile (20 mL) was stirred at room temperature for 3 h. Water
was added and the aqueous phase was extracted with ethyl acetate
(40 mL). The organic layer was separated, dried over sodium sulfate
and concentrated to afford methyl
6-morpholino-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxyl-
ate (400 mg, 84%) as a yellow oil. MS (ESI): m/z=377.1
[M+1].sup.+.
Step G.
(6-Morpholino-5-nitro-2-(trifluoromethyl)-2,3-Dihydrobenzofuran-2--
yl)methanol
##STR01160##
[1323] To a mixture of methyl
6-morpholino-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-carboxyl-
ate (400 mg, 1.06 mmol) in tetrahydrofuran (20 mL) and ethanol (5
mL) was added sodium borohydride (121.19 mg, 3.19 mmol) and lithium
chloride (134 mg, 3.19 mmol) at 0.degree. C. The mixture was
stirred at room temperature for 2 h. Saturated ammonium chloride
solution and ethyl acetate (50 mL) was added. The organic layer was
separated, dried over sodium sulfate and concentrated to afford
(6-morpholino-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)meth-
anol (370 mg, crude) as a yellow solid, which was used directly to
next step without further purification. MS (ESI): m/z=349.1
[M+1].sup.+.
Step H.
(5-Amino-6-morpholino-2-(trifluoromethyl)-2,3-Dihydrobenzofuran-2--
yl)methanol
##STR01161##
[1325] A mixture of palladium on carbon (60 mg, 10% wt) and
(6-morpholino-5-nitro-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)meth-
anol (370 mg, 1.06 mmol) in methyl alcohol (30 mL) was stirred at
room temperature under hydrogen atmosphere for 2 h. After
filtration and concentration under reduced pressure, it was
afforded
(5-amino-6-morpholino-2-(trifluoromethyl)-2,3-dihydrobenzofuran-2-yl)meth-
anol (50 mg, crude) as a dark solid, which was used directly to
next step without further purification. MS (ESI): m/z=319.1
[M+1].sup.+.
Step I.
(R)--N-(2-(hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01162##
[1327] A mixture of
[5-amino-6-morpholino-2-(trifluoromethyl)-3H-benzofuran-2-yl]methanol
(310 mg, 0.97 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(167 mg, 1.02 mmol), (7-azabenzotriazol-1-yl
oxy)tripyrrolidinophosphoniumhexafluorophosphate (558 mg, 1.07
mmol) and N-ethyl-N-isopropylpropan-2-amine (354 mg, 2.92 mmol) in
N,N-dimethylformamide (10 mL) was stirred at room temperature for 2
h. Water was added and the aqueous phase was extracted with ethyl
acetate (20 mL). The organic layer was separated, washed with
brine, dried over sodium sulfate and concentrated under reduced
pressure. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (9:1) to afford 250 mg racemic
product as a yellow solid. The product was resolved by chiral
preparatory SFC (Column: OJ 4.6*250 mm, 5 um (Decial), Mobile
phase: CO.sub.2/MeOH (0.2% Methanol Ammonia)=65/35) to afford
N-[(2R)-2-(hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-3H-benzofuran--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-[(2
S)-2-(Hydroxymethyl)-6-morpholino-2-(trifluoromethyl)-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide (105 mg, 22%) (100 mg, 21%)
as light yellow solids with absolute stereochemistry assigned
arbitrarily.
[1328] Example 153, Peak1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.49 (s, 1H), 8.84 (dd, J=1.6, 7.2 Hz, 1H), 8.78 (s, 1H),
8.76 (dd, J=4.0, 6.4 Hz, 1H), 8.49 (s, 1H), 7.08 (dd, J=1.6, 4.0
Hz, 1H), 6.77 (s, 1H), 4.07 (d, J=12.4 Hz, 1H), 3.96-3.93 (m, 4H),
3.86 (d, J=12.4 Hz, 1H), 3.53 (d, J=16.4 Hz, 1H), 3.42 (d, J=16.4
Hz, 1H), 2.92-2.89 (m, 4H). MS (ESI): m/z=464.2 [M+1].sup.+.
[1329] Example 154, Peak2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.49 (s, 1H), 8.84 (dd, J=1.6, 7.2 Hz, 1H), 8.78 (s, 1H),
8.76 (dd, J=4.0, 6.4 Hz, 1H), 8.49 (s, 1H), 7.08 (dd, J=1.6, 4.0
Hz, 1H), 6.77 (s, 1H), 4.07 (d, J=12.4 Hz, 1H), 3.96-3.93 (m, 4H),
3.86 (d, J=12.4 Hz, 1H), 3.53 (d, J=16.4 Hz, 1H), 3.42 (d, J=16.4
Hz, 1H), 2.92-2.89 (m, 4H). MS (ESI): m/z=464.2 [M+1].sup.+.
Examples 155 and 156.
(R)--N-(2-((difluoromethoxy)methyl)-2-Methyl-6-morpholino-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-((difluoromethoxy)methyl)-2-Methyl-6-morpholino-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01163##
[1331]
(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
##STR01164##
A mixture of morpholine (230 mg, 2.64 mmol),
(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl) methanol
(Intermediate 3)(300 mg. 1.32 mmol) and potassium carbonate (364
mg. 2.64 mmol) in acetonitrile (20 mL.) was stirred at room
temperature for 3h. Water was added and the mixture was extracted
with ethyl acetate (40 mL). The organic layer was concentrated to
afford
(2-methyl-6-morpholino-5-nitro-2.3-dihydrobenzofuran-2-yl)methanol
(420 mg. crude) as a yellow oil, which was used directly to next
step without further purification. MS (ESI): m/z=295.1
[M+1].sup.+.
Step B.
4-(2-((Difluoromethoxy)methyl)-2-Methyl-5-nitro-2,3-dihydrobenzofu-
ran-6-yl)morpholine
##STR01165##
[1333] To a mixture of
(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(180 mg, 0.61 mmol) and copper iodide (34 mg, 0.24 mmol) in
acetonitrile (20 mL) was added difluoro(fluorosulfonyl)acetic acid
(218 mg, 1.22 mmol) at 50.degree. C. The mixture was stirred
50.degree. C. for 1 h. The mixture was concentrated and purified by
silica gel chromatography using ethyl acetate:petroleum ether
(3:20) to afford
4-(2-((difluoromethoxy)methyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-y-
l)morpholine (70 mg, 31%) as a yellow oil. MS (ESI): m/z=345.1
[M+1].sup.+.
Step C.
2-((Difluoromethoxy)methyl)-2-methyl-6-morpholino-2,3-dihydrobenzo-
furan-5-amine
##STR01166##
[1335] A mixture of palladium on carbon (20 mg, 10% wt) and
4-(2-((difluoromethoxy)methyl)-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-y-
l)morpholine (70 mg, 0.2 mmol) in methanol (15 mL) was stirred at
room temperature under hydrogen atmosphere for 1 h. After
filtration and concentration under reduced pressure, it was
afforded
2-((difluoromethoxy)methyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-
-amine (60 mg, crude) as a green oil, which was used directly to
next step without further purification. MS (ESI):
m/z=315.1[M+1].sup.+.
Step D.
(R)--N-(2-((difluoromethoxy)methyl)-2-Methyl-6-morpholino-2,3-dihy-
drobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-((difluoromethoxy)methyl)-2-Methyl-6-morpholino-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01167##
[1337] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (80
mg, 0.5 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(324 mg, 0.62 mmol), N-ethyl-N-isopropylpropan-2-amine (150 mg,
1.24 mmol) and
2-((difluoromethoxy)methyl)-2-methyl-6-morpholino-2,3-dihydrobe-
nzofuran-5-amine (140 mg, 0.42 mmol) in N,N-dimethylformamide (10
mL) was stirred at room temperature for 2 h. Water was added and
the aqueous phase was extracted with ethyl acetate (20 mL). The
organic layer was washed with brine, dried over sodium sulfate and
concentrated. The residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (3:1) as eluting solvents to
afford
N-(2-(hydroxymethyl)-2,7-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (140 mg, 73%) as a yellow
solid. The product was resolved by chiral preparatory SFC (Column:
AD 20*250 mm, 5 um (Dacel), Mobile phase: CO2/MEOH {0.5% Ammonia
(7M methanol))=70/30) to afford
N-[(2R)-2-(difluoromethoxymethyl)-2-methyl-6-morpholino-3H-benz-
ofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(difluoromethoxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-y-
l]pyrazolo[1,5-a]pyrimidine-3-carboxamide (50 mg, 53%) (45 mg, 47%)
as yellow solids with absolute stereochemistry assigned
arbitrarily.
[1338] Example 155, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 9.36 (dd, J=1.5, 6.8 Hz, 1H), 8.94 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.35 (dd, J=4.0,
7.2 Hz, 1H), 6.73 (t, J=75.2 Hz, 1H), 6.77 (s, 1H), 3.94 (s, 2H),
3.85-3.83 (m, 4H), 3.18 (d, J=15.6 Hz, 1H), 2.97 (d, J=15.6 Hz,
1H), 2.83-2.81 (m, 4H), 1.42 (s, 3H). MS (ESI):
m/z=460.2[M+1].sup.+.
[1339] Example 156, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 9.36 (dd, J=1.5, 6.8 Hz, 1H), 8.94 (dd,
J=1.6, 4.0 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.35 (dd, J=4.0,
7.2 Hz, 1H), 6.73 (t, J=75.2 Hz, 1H), 6.77 (s, 1H), 3.94 (s, 2H),
3.85-3.83 (m, 4H), 3.18 (d, J=15.6 Hz, 1H), 2.97 (d, J=15.6 Hz,
1H), 2.83-2.81 (m, 4H), 1.42 (s, 3H). MS (ESI):
m/z=460.2[M+1].sup.+.
Examples 157 and 158.
(R)--N-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofu-
ran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofu-
ran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01168##
[1340] Step A.
2-(6-Fluoro-2-methyl-2,3-dihydrobenzofuran-2-yl)propan-2-ol
##STR01169##
[1342] To a solution of methyl
6-fluoro-2-methyl-3H-benzofuran-2-carboxylate (877 mg, 4.17 mmol)
in anhydrous tetrahydrofuran (20 mL) was added drop-wise
methylmagnesium bromide (3 M in ditheyl ether, 4.17 mL, 12.52 mmol)
under N.sub.2 atmosphere at -78.degree. C. The mixture was stirred
at -78.degree. C. for 1 h. The mixture was quenched with saturated
ammonium chloride solution. Ethyl acetate (50 mL) was added. The
organic layer was separated, dried over sodium sulfate and
concentrated to afford
2-(6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-yl)propan-2-ol (800
mg, crude) as a colorless oil, which was used directly to next step
without further purification. MS (ESI): m/z=193.1 [M-17].sup.+.
Step B.
2-(6-Fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-o-
l
##STR01170##
[1344] A mixture of
2-(6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-yl)propan-2-ol (400
mg, 1.9 mmol) in dichloromethane (15 mL) was added concentrated
nitric acid (60-70% wt, 0.5 mL). The mixture was stirred at room
temperature for 1 h. The mixture was poured into ice water and
extracted with dichloromethane (30 mL). The organic layer was
separated, dried over sodium sulfate and concentrated. The residue
was purified by silica gel chromatography ethyl acetate:petroleum
ether (1:4) as eluting solvents to afford
2-(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol
(320 mg, 59%) as a brown oil. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.94 (d, J=7.8 Hz, 1H), 6.61 (d, J=12.8 Hz, 1H), 3.54 (d,
J=15.6 Hz, 1H), 2.82 (d, J=15.6 Hz, 1H), 1.38 (s, 3H), 1.24 (s,
6H).
Step C.
2-(2-Methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-
-2-ol
##STR01171##
[1346] A mixture of morpholine (218 mg, 2.51 mmol),
2-(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol
(320 mg, 1.25 mmol) and potassium carbonate (346 mg, 2.51 mmol) in
acetonitrile (20 mL) was stirred at room temperature for 3 h. Water
was added and the aqueous phase was extracted with ethyl acetate
(50 mL). The organic layer was dried over sodium sulfate and
concentrated to afford
2-(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol
(318 mg, crude) as a yellow oil, which was used directly to next
step without further purification. MS (ESI): m/z=323.2
[M+1].sup.+.
Step D.
2-(5-Amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)propan-
-2-ol
##STR01172##
[1348] A mixture of palladium on carbon (100 mg, 10% wt) and
2-(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol
(300 mg, 0.93 mmol) in methanol (30 mL) was stirred at room
temperature under hydrogen atmosphere for 1 h. After filtration and
concentration under reduced pressure, it was afforded
2-(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)propan-2-ol
(280 mg, crude) as a green oil, which was used directly to next
step without further purification. MS (ESI):
m/z=293.2[M+1].sup.+.
Step E.
(R)--N-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofu-
ran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01173##
[1350] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(174 mg, 1.07 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(695 mg, 1.33 mmol), N-ethyl-N-isopropylpropan-2-amine (323 mg,
2.67 mmol) and
2-(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)pro-
pan-2-ol (260 mg, 0.89 mmol) in N,N-dimethylformamide (10 mL) was
stirred at room temperature for 2 h. The crude reaction was
purified by preparative HPLC (Gilson 281, Xbridge 21.2*250 mm c18,
10 um; A: acetonitrile, 25-55%, B: 10 M ammonium bicarbonatein
water) to afford
N-(2-(2-hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-
-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (100 mg) as a yellow
solid. The product was resolved by chiral preparatory SFC (Column:
AD 20*250 mm, 5 um (Dacel), Mobile phase: CO2/MEOH{0.5% Ammonia (7M
methanol)}=70/30) to afford
N-[(2R)-2-(1-hydroxy-1-methyl-ethyl)-2-methyl-6-morpholino-3H-b-
enzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(1-hydroxy-1-methyl-ethyl)-2-methyl-6-morpholino-3H-benzofuran--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (45 mg, 45%) (50 mg,
50%) as yellow solids with absolute stereochemistry assigned
arbitrarily.
[1351] Example 157, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.43 (s, 1H), 9.37 (dd, J=7.2, 1.6 Hz, 1H), 8.94 (dd,
J=4.0, 1.6 Hz, 1H), 8.68 (s. 1H), 8.29 (s, 1H), 7.34 (dd, J=7.2,
4.0 Hz, 1H), 6.71 (s, 1H), 4.53 (s, 1H), 3.85-3.83 (m, 4H), 3.46
(d, J=16.0 Hz, 1H), 2.83-2.81 (m, 4H), 2.73 (d, J=16.0 Hz, 1H),
1.32 (s, 3H), 1.17 (d, J=5.2 Hz, 6H). MS (ESI):
m/z=438.3[M+1].sup.+.
[1352] Example 158, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.43 (s, 1H), 9.37 (dd, J=7.2, 1.6 Hz, 1H), 8.94 (dd,
J=4.0, 1.6 Hz, 1H), 8.68 (s. 1H), 8.29 (s, 1H), 7.34 (dd, J=7.2,
4.0 Hz, 1H), 6.71 (s, 1H), 4.53 (s, 1H), 3.85-3.83 (m, 4H), 3.46
(d, J=16.0 Hz, 1H), 2.83-2.81 (m, 4H), 2.73 (d, J=16.0 Hz, 1H),
1.32 (s, 3H), 1.17 (d, J=5.2 Hz, 6H). MS (ESI):
m/z=438.3[M+1].sup.+.
[1353] Examples 159 and 160.
(R)--N-(2-Cyclopropyl-6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-Cyclopropyl-6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01174##
Step A. 2-Cyclopropyl-1-(2,4-difluorophenyl)propan-2-ol
##STR01175##
[1355] To a mixture of 1-(2,4-difluorophenyl)propan-2-one (prepared
by similar method as Example 14, step B) (900.0 mg, 5.29 mmol) in
tetrahydrofuran (20 mL) was added drop-wise cyclopropylmagnesium
bromide (0.5 M in tetrahydrofuran, 10.58 mL, 5.29 mmol) at
-78.degree. C. under nitrogen atmosphere. The mixture was stirred
at room temperature for 1 h. The reaction was quenched by addition
of saturated ammonium chloride (20 mL). The mixture was extracted
with ethyl acetate (50 mL) twice. The combined organic layers were
washed with water, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The residue was purified on
silica gel chromatography using ethyl acetate:petroleum ether
(1:10) as eluting solvents to afford
2-cyclopropyl-1-(2,4-difluorophenyl)propan-2-ol (800.0 mg, 68%) as
a light yellow foam. MS (ESI): m/z=195.1 [M-17].sup.+.
Step B. 2-Cyclopropyl-6-fluoro-2-methyl-2,3-dihydrobenzofuran
##STR01176##
[1357] A mixture of 2-cyclopropyl-1-(2,4-difluorophenyl)propan-2-ol
(600.0 mg, 2.83 mmol) and tert-butoxypotassium (1268.9 mg, 11.31
mmol) in tetrahydrofuran (10 mL) was stirred at 65.degree. C. for 3
h. After cooling to room temperature, water and ethyl acetate (20
mL) was added. The organic layer was separated and dried over
sodium sulfate. After concentration, the residue was purified by
silica gel chromatography using ethyl acetate:petroleum ether
(1:10) as eluting solvents to afford
2-cyclopropyl-6-fluoro-2-methyl-3H-benzofuran (460.0 mg, 80%) as a
colorless oil. MS (ESI): m/z=193.1 [M+H].sup.+.
Step C.
2-Cyclopropyl-6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran
##STR01177##
[1359] To a solution of
2-cyclopropyl-6-fluoro-2-methyl-3H-benzofuran (460.0 mg, 2.39 mmol)
in dichloromethane (20 mL) at 0.degree. C. was slowly added fuming
nitric acid (0.5 mL) and stirred for 15 min. The mixture was poured
into ice water and the organic layer was separated and dried over
hydrous sodium sulfate. After concentration, the residue was
purified by silica gel chromatography using ethyl acetate:petroleum
ether (1:15) as eluting solvents to afford
2-cyclopropyl-6-fluoro-2-methyl-5-nitro-3H-benzofuran (450.0 mg,
75%) as an orange solid. MS (ESI): m/z=238.1 [M+1].sup.+.
Step D.
1-(2-Cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-(2-
,2-difluoroethyl)piperazine
##STR01178##
[1361] A mixture of
2-cyclopropyl-6-fluoro-2-methyl-5-nitro-3H-benzofuran (220.0 mg,
0.93 mmol), 1-(2,2-difluoroethyl)piperazine dihydrochloride (310.3
mg, 1.39 mmol) and cesium carbonate (906.5 mg, 2.78 mmol) in
acetonitrile (5 mL) was stirred at 60.degree. C. overnight. The
reaction mixture was filtered and the filtrate was concentrated
under reduced pressure. The residue was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:2) to afford
1-(2-cyclopropyl-2-methyl-5-nitro-3H-benzofuran-6-yl)-4-(2,2-difluoroethy-
l)piperazine (300.0 mg, 84%) as a yellow solid. MS (ESI): m/z=368.2
[M+1].sup.+.
Step E.
2-Cyclopropyl-6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-methyl-2,3-
-dihydrobenzofuran-5-amine
##STR01179##
[1363] A mixture of
1-(2-cyclopropyl-2-methyl-5-nitro-3H-benzofuran-6-yl)-4-(2,2-difluoroethy-
l)piperazine (150.0 mg, 0.41 mmol) and palladium on carbon (15.0
mg, 10% wt) in methanol (5 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 2 h. After filtration, the filtrate was
concentrated under reduced pressure to afford
2-cyclopropyl-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzofu-
ran-5-amine (100.0 mg, crude) as a colorless oil, which was used
directly to next step without further purification. MS (ESI):
m/z=338.3 [M+1].sup.+.
Step F.
(R)--N-(2-Cyclopropyl-6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-Cyclopropyl-6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01180##
[1365] A mixture of
2-cyclopropyl-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-benzofu-
ran-5-amine (240.0 mg, 0.71 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(370.9 mg, 0.71 mmol) and N-ethyl-N-isopropylpropan-2-amine (275.8
mg, 2.13 mmol) in N,N-dimethylformamide (5 mL) was stirred at room
temperature for 30 min. Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(116.0 mg, 0.71 mmol) was then added. The resulting mixture was
stirred at room temperature overnight. Water and ethyl acetate (30
mL) was added and the organic layer was separated and dried over
sodium sulfate. After filtration and concentration under reduced
pressure, the residue was purified by silica gel chromatography
using ethyl acetate:petroleum ether (10:1) and then resolved by
chiral pre-HPLC(Column: AS-H 20*250 mm, 5 um (Dacel), Mobile phase:
Hexane (0.1% DEA)/Ethanol(0.1% DEA)=80/20) to afford
N-[(2R)-2-cyclopropyl-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-me-
thyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-cyclopropyl-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-methyl-3H-
-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (40 mg,
12%) (55 mg, 16%) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[1366] Example 159, Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 10.38 (s, 1H), 9.35 (d, J=6.8 Hz, 1H), 8.94 (d, J=2.8 Hz,
1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.35 (dd, J=4.0, 6.8 Hz, 1H), 6.68
(s, 1H), 6.19 (tt, J=4.0, 56.0 Hz, 1H), 2.98 (q, J=15.6, 32.0 Hz,
2H), 2.91-2.73 (m, 10H), 1.36 (s, 3H), 1.25-1.16 (m, 1H), 0.46-0.40
(m, 3H) 0.31-0.27 (m, 1H). MS (ESI): m/z=483.3[M+1].sup.+.
[1367] Example 160, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.38 (s, 1H), 9.35 (d, J=6.8 Hz, 1H), 8.94 (d, J=2.8 Hz,
1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.35 (dd, J=4.0, 6.8 Hz, 1H), 6.68
(s, 1H), 6.19 (tt, J=4.0, 56.0 Hz, 1H), 2.98 (q, J=15.6, 32.0 Hz,
2H), 2.91-2.73 (m, 10H), 1.36 (s, 3H), 1.25-1.16 (m, 1H), 0.46-0.40
(m, 3H) 0.31-0.27 (m, 1H). MS (ESI): m/z=483.3[M+1].sup.+.
Examples 161 and 162.
(R)--N-(2-Cyclopropyl-6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-meth-
yl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(2-Cyclopropyl-6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-2-meth-
yl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01181##
[1368] Step A.
(1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-fluoropiperidin-4--
yl)methanol 2,2,2-trifluoroacetic acid salt
##STR01182##
[1370] A mixture of tert-butyl
4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (300 mg, 1.29
mmol in trifluoroacetic acid (1 mL) and dichloromethane (2 mL) was
stirred 20.degree. C. for 1 h. The mixture was concentration under
reduced pressure to afford (4-fluoropiperidin-4-yl)methanol
2,2,2-trifluoroacetic acid salt (300 mg, 1.21 mmol, crude) as a
colorless oil, which was used directly to the next step without
purification. MS (ESI): m/z=134.1 [M+1].sup.+.
Step B.
(1-(2-Cyclopropyl-2-methyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-4-f-
luoropiperidin-4-yl)methanol
##STR01183##
[1372] A mixture of
2-cyclopropyl-6-fluoro-2-methyl-5-nitro-3H-benzofuran (Examples 159
and 160, step C) (110.0 mg, 0.46 mmol),
(4-fluoro-4-piperidyl)methanol and potassium carbonate (192.3 mg,
1.39 mmol) in acetonitrile (5 mL) was stirred at room temperature
overnight. The reaction mixture was filtered and the filtrate was
concentrated under vacuum and the residue was purified on silica
gel chromatography using ethyl acetate:petroleum ether (1:5) as
eluting solvents to afford
[1-(2-cyclopropyl-2-methyl-5-nitro-3H-benzofuran-6-yl)-4-fluoro-4-piperid-
yl]methanol (130.0 mg, 76%) as a yellow solid. MS (ESI): m/z=351.2
[M+1].sup.+.
Step F.
(1-(5-Amino-2-cyclopropyl-2-methyl-2,3-dihydrobenzofuran-6-yl)-4-f-
luoropiperidin-4-yl)methanol
##STR01184##
[1374] A mixture of
[1-(2-cyclopropyl-2-methyl-5-nitro-3H-benzofuran-6-yl)-4-fluoro-4-piperid-
yl]methanol (130.0 mg, 0.37 mmol) and palladium on carbon (13 mg,
10% wt) in methyl alcohol (5 mL) was stirred at 25.degree. C. under
hydrogen atmosphere for 1 h. After filtration, the filtrate was
concentrated under reduced pressure to afford
[1-(5-amino-2-cyclopropyl-2-methyl-3H-benzofuran-6-yl)-4-fluoro-4-piperid-
yl]methanol (100.0 mg, crude) as a colorless oil, which was used in
the next step without further purification. MS (ESI): m/z=321.2
[M+1].sup.+.
Step G.
(R)--N-(2-Cyclopropyl-6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)-
-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxami-
de and
(S)--N-(2-Cyclopropyl-6-(4-fluoro-4-(hydroxymethyl)piperidin-1-yl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e
##STR01185##
[1376] A mixture of
[1-(5-amino-2-cyclopropyl-2-methyl-3H-benzofuran-6-yl)-4-fluoro-4-piperid-
yl]methanol (100.0 mg, 0.3100 mmol),
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (56.7 mg, 0.31 mmol),
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(162.7 mg, 0.31 mmol) and N-ethyl-N-isopropylpropan-2-amine (121.0
mg, 0.94 mmol) in N,N-dimethylformamide (5 mL) was stirred at room
temperature overnight. Water and ethyl acetate (30 mL) were added
and the organic layer was separated. The organic layer was washed
with brine and dried over sodium sulfate. After filtration, the
mixture was concentrated and purified by silica gel chromatography
using ethyl acetate:petroleum ether (10:1) and resolved by chiral
preparative HPLC(Column CE-4, Mobile Phase: n-Hexane (0.1% DEA):
EtOH (0.1% DEA)=70:30, Flow rate: 50 mL/min) to afford
N-[(2S)-2-cyclopropyl-6-[4-fluoro-4-(hydroxymethyl)-1-piperidyl-
]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-[(2R)-2-cyclopropyl-6-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]-2-methyl-
-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (36.0
mg, 25%; 25.0 mg, 17%) as yellow solids with absolute
stereochemistry assigned arbitrarily.
[1377] Example 161, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.41 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.88 (dd,
J=1.2, 4.0 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.33 (dd, J=4.0,
7.2 Hz, 1H), 6.68 (s, 1H), 5.15 (t, J=6.0 Hz, 1H), 3.53 (dd, J=6.0,
18.0 Hz, 2H), 2.99 (q, J=16.0, 31.6 Hz, 2H), 2.92-2.78 (m, 4H),
2.15-1.95 (m, 2H), 1.91-1.75 (m, 2H), 1.37 (s, 3H), 1.27-1.16 (m,
1H), 0.46-0.36 (m, 3H) 0.33-0.26 (m, 1H). MS (ESI):
m/z=466.2[M+1].sup.+.
[1378] Example 162, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.41 (s, 1H), 9.36 (dd, J=1.6, 7.2 Hz, 1H), 8.88 (dd,
J=1.2, 4.0 Hz, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.33 (dd, J=4.4,
7.2 Hz, 1H), 6.68 (s, 1H), 5.15 (t, J=6.0 Hz, 1H), 3.52 (dd, J=6.0,
18.0 Hz, 2H), 2.99 (q, J=16.0, 31.6 Hz, 2H), 2.92-2.78 (m, 4H),
2.14-1.94 (m, 2H), 1.91-1.79 (m, 2H), 1.36 (s, 3H), 1.27-1.17 (m,
1H), 0.46-0.36 (m, 3H) 0.33-0.26 (m, 1H). MS (ESI):
m/z=466.2[M+1].sup.+.
Examples 163 and 164.
(R)-6-Chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-m-
ethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)-6-Chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-
-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxami-
de
##STR01186##
[1379] Step A. 6-Chloropyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR01187##
[1381] A mixture of 5-amino-1H-pyrazole-4-carboxylic acid (100.0
mg, 0.79 mmol) and 2-chloromalonaldehyde (84.0 mg, 0.79 mmol) in
acetic acid (1 mL) and 0.3 mL ethanol was stirred for 2 h at
60.degree. C. After filtration, the wet cake was washed with
methanol and dried in vacuo to afford
6-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid (80 mg, crude)
as a white solid, which was used directly to next step without
further purification. MS (ESI): m/z=179.9 [M-17].sup.+.
Step B.
[1-[2-(Hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]-4-piper-
idyl]methanol
##STR01188##
[1383] A mixture of
(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol
(Intermediate 3) (285 mg, 1.22 mmol) and 4-piperidinylmethanol (211
mg, 1.83 mmol) in acetonitrile (5 mL), was stirred at 20.degree. C.
for 2 h. The solvent was removed under reduced pressure and the
residue was purified by silica gel chromatography using ethyl
acetate:petroleum ether (from 1:1 to 2:1) as eluting solvents to
afford
[1-[2-(hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]-4-piperidyl]me-
thanol (360 mg, 91%) as a yellow oil. MS (ESI): m/z=323.1
[M+1].sup.-.
Step C.
[1-[5-Amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]-4-piper-
idyl]methanol
##STR01189##
[1385] A mixture of
[1-[2-(hydroxymethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]-4-piperidyl]me-
thanol (120 mg, 0.37 mmol) and palladium on carbon (20 mg, 10% wt)
in methanol (10 mL) was stirred at 20.degree. C. under hydrogen
atmosphere for 2 hours. After filtration and concentration under
reduced pressure,
[1-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]-4-piperidyl]me-
thanol (87 mg) was afforded as a brown solid, which was used
directly to next step without further purification. MS (ESI):
m/z=293.2 [M+1].sup.+.
Step D.
(R)-6-Chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1--
yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbox-
amide and
(S)-6-Chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin--
1-yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carb-
oxamide
##STR01190##
[1387] A mixture of
[1-[5-amino-2-(hydroxymethyl)-2-methyl-3H-benzofuran-6-yl]-4-piperidyl]me-
thanol (87 mg, 0.30 mmol),
6-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid (70 mg, 0.36
mmol), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (170 mg, 0.45 mmol) and diisopropylethylamine
(115 mg, 0.89 mmol) in N,N-dimethylformamide (5 mL) was stirred at
20.degree. C. for 2 h. The mixture was purified by silica gel
chromatography using ethyl acetate:petroleum ether (1:1 to 2:1) as
eluting solvents to afford
6-chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-methy-
l-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
(120 mg, 81%) as a yellow solid. The product was resolved by chiral
SFC (SFC-80 (Thar, Waters), AD 20*250 mm, 5 um (Dacel), mobile
phase: CO2/MEOH{0.5% Ammonia (7M methanol)}=60/40) to afford
(S)-6-chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-2-m-
ethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)-6-chloro-N-(2-(hydroxymethyl)-6-(4-(hydroxymethyl)piperidin-1-yl)-
-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxami-
de (43.1 mg, 72%) (28.9 mg, 48%) as yellow solids with absolute
stereochemistry assigned arbitrarily.
[1388] Example 163, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.39 (s, 1H), 9.81-9.80 (m, 1H), 8.98-8.97 (m, 1H), 8.69
(s, 1H), 8.31 (s, 1H), 6.67 (s, 1H), 5.02 (t, J=5.6 Hz, 1H), 4.64
(t, J=4.8 Hz, 1H), 3.45-3.39 (m, 4H), 3.20-3.17 (m, 1H), 2.91-2.89
(m, 2H), 2.83-2.79 (m, 1H), 2.66-2.60 (m, 2H), 1.67-1.63 (m, 4H),
1.51-1.48 (m, 1H), 1.33 (s, 3H). MS (ESI): m/z=472.2
[M+1].sup.+.
[1389] Example 164, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 10.39 (s, 1H), 9.81 (d, J=2.0 Hz, 1H), 8.98 (d, J=2.0 Hz,
1H), 8.69 (s, 1H), 8.31 (s, 1H), 6.67 (s, 1H), 5.02 (t, J=5.6 Hz,
1H), 4.64 (t, J=4.8 Hz, 1H), 3.45-3.39 (m, 4H), 3.20-3.17 (m, 1H),
2.91-2.89 (m, 2H), 2.83-2.79 (m, 1H), 2.66-2.60 (m, 2H), 1.67-1.63
(m, 4H), 1.51-1.48 (m, 1H), 1.33 (s, 3H). MS (ESI): m/z=472.2
[M+1].sup.+.
TABLE-US-00005 TABLE 5 The following examples were made in a manner
similar to that for Examples 163 and 164. Ex. Name Structure NMR,
MS 165, 166 (S)-6-Chloro-N-(2- (hydroxymethyl)-2-
methyl-6-morpholino- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide and (R)-6- Chloro-N-(2-
(hydroxymethyl)-2- methyl-6-morpholino- 2,3-dihydrobenzofuran-
5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01191## Example 165,
Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.33 (s, 1H),
8.87 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H),
8.43 (s, 1H), 6.68 (s, 1H), 3.97-3.94 (m, 4H), 3.67 (s, 2H), 3.25
(d, J = 16.0 Hz, 1H), 2.94 (d, J = 15.6 Hz, 1H), 2.92-2.89 (m, 4H),
1.46 (s, 3H). MS (ESI): m/z = 444.1 [M + 1].sup.+. Example 166,
Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.33 (s, 1H),
8.87 (d, J = 2.4 Hz, 1H), 8.77 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H),
8.43 (s, 1H), 6.68 (s, 1H), 3.95-3.93 (m, 4H), 3.67 (s, 2H), 3.25
(d, J = 16.0 Hz, 1H), 2.94 (d, J = 15.2 Hz, 1H), 2.92-2.89 (m, 4H),
1.46 (s, 3H). MS (ESI): m/z = 444.1 [M + 1].sup.+. 167
6-Chloro-N-(2,2- dimethyl-6-(2-oxa-8- azaspiro[4.5]decan-8-
yi)-2,3- dihydrobenzofiiran-5- yl)pyrazolo[l,5- a]pyrimidine-3-
carboxamide ##STR01192## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.30 (s, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.54 (d, J =
2.4 Hz, 1H), 8.38 (s, 1H), 6.64 (s, 1H), 3.91 (t, J = 7.2 Hz, 2H),
3.65 (s, 2H), 3.03 (s, 2H), 2.86- 2.84 (m, 4H), 1.85 (t, J = 7.2
Hz, 2H), 1.85-1.81 (m, 4H), 1.48 (s, 6H). MS (ESI): m/z = 482.1 [M
+ 1].sup.+. 168 N-(6-(4-(2,2- Difluoroethyl)piperazin- 1-yl)-2-
(hydroxymethyl)-2- methyl-2,3- dihydrobenzofuran-5- yi)-6-
methylpyrazolo[l,5- a]pyrimidine-3- carboxamide ##STR01193##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.18 (s,
1H), 9.82 (d, J = 2.0 Hz, 1H), 8.96 (d, J = 2.0 Hz, 1H), 8.70 (s,
1H), 8.26 (s, 1H), 6.70 (s, 1H), 6.20 (tt, J = 56.0, 4.4 Hz, 1H) ,
5.05 (t, J = 5.6 Hz, 1H), 3.45- 3.41 (m, 2H), 3.20 (d, J = 16.4 Hz,
1H), 2.88-2.78 (m, 11H), 1.33 (s, 3H). LCMS (ESI): m/z = 507.0 [M +
H].sup.+. 169 and 170 (S)-6-Chloro-N-(6-(4- (2,2-
difluoroethyl)piperazin- 1-yl)-2- (hydroxymethyl)-2- methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
and (R)-6- Chloro-N-(6-(4-(2,2- difluoroethyl)piperazin- 1-yl)-2-
(hydroxymethyl)-2- methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01194## Example 169 Peak
1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.22 (s, 1H), 8.88
(d, J = 2.0 Hz, 1H), 8.78 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.40
(s, 1H), 6.68 (s, 1H), 6.15-5.80 (m, 1H), 3.68-3.67 (m, 2H),
3.25-3.23 (m, 1H), 2.95-2.84 (m, 11H), 1.92 (t, J = 6.4 Hz, 1H),
1.47 (s, 3H). LCMS (ESI): m/z = 507.2 [M + H].sup.+. Example 170
Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.22 (s, 1H),
8.88 (d, J= 2.0 Hz, 1H), 8.78 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H),
8.40 (s, 1H), 6.68 (s, 1H), 6.15-5.80 (m, 1H), 3.69- 3.66 (m, 2H),
3.25-3.23 (m, 1H), 2.95-2.84 (m, 11H), 2.00 (t, J = 6.4 Hz, 1H),
1.47 (s, 3H). LCMS (ESI): m/z = 507.2 [M + H].sup.+.
Examples 171 and 172.
(R)--N-(2-(Hydroxymethyl)-2-methyl-6-(trifluoromethoxy)-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-6-(trifluoromethoxy)-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01195##
[1391] The title compounds were made in a manner analogous to
Example 70 to give
N-(2-(hydroxymethyl)-2-methyl-6-(trifluoromethoxy)-2,3-dihydroben-
zofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide which was
resolved via Chiral SFC to afford
N-[(2R)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethoxy)-3H-benzofuran-5-y-
l]pyrazolo[1,5-a]pyrimidine-3-carboxamide (73.9 mg, 38.1% yield)
and
N-[(2S)-2-(hydroxymethyl)-2-methyl-6-(trifluoromethoxy)-3H-benzofuran-5-y-
l]pyrazolo[1,5-a]pyrimidine-3-carboxamide (73.4 mg, 37.9% yield) as
light yellow solids. Stereochemistry was arbitrarily assigned based
on peak elution.
[1392] Example 171 peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6): .delta. 10.23 (s, 1H), 9.40 (dd, J=1.6, 7.2 Hz,
1H), 8.83 (dd, J=1.6, 4.4 Hz, 1H), 8.72 (s, 1H), 8.28 (s, 1H), 7.34
(dd, J=4.4, 7.2 Hz, 1H), 6.86 (s, 1H), 5.11 (t, J=5.6 Hz, 1H),
3.53-3.40 (m, 2H), 3.28 (d, J=16.4 Hz, 1H), 2.92 (d, J=16.4 Hz,
1H), 1.37 (s, 3H). .sup.19F NMR (400 MHz, DMSO-d6) .delta.-57.24
(s, 3F). MS (ESI): m/z=409.1 [M+1].sup.+.
[1393] Example 172 peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6): .delta. 10.23 (s, 1H), 9.40 (dd, J=1.6, 6.8 Hz,
1H), 8.83 (dd, J=1.6, 4.0 Hz, 1H), 8.72 (s, 1H), 8.28 (s, 1H), 7.34
(dd, J=4.0, 6.8 Hz, 1H), 6.85 (s, 1H), 5.11 (t, J=5.6 Hz, 1H),
3.53-3.40 (m, 2H), 3.28 (d, J=16.4 Hz, 1H), 2.92 (d, J=16.4 Hz,
1H), 1.37 (s, 3H). 19F NMR (400 MHz, DMSO-d.sub.6) .delta.-57.24
(s, 3F). MS (ESI): m/z=409.1 [M+1].sup.+.
Example 173.
N-[6-Morpholino-1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl]pyrazolo[1,-
5-a]pyrimidine-3-carboxamide
##STR01196##
[1394] Step A.
6-Chloro-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one
##STR01197##
[1396] To methyl 2-(bromomethyl)-5-chloro-4-nitro-benzoate
(preparation 5, WO 2013079505 (150 mg, 0.49 mmol) in methanol (5
ml) was added triethylamine (0.081 ml, 0.58 mmol) and
2,2,2-trifluoroethylamine (0.047 ml, 0.58 mmol). The reaction was
heated to 70.degree. C. for 18 h, concentrated and purified by
silica gel chromatography (eluting gradient 0-20% methanol:
dichloromethane) to afford
6-chloro-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one (90 mg,
63%). LCMS (ESI) m/z: 295.0 [M+H]+.
Step B.
6-Morpholino-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one
##STR01198##
[1398] A solution of
6-chloro-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one (90 mg,
0.31 mmol), morpholine (0.032 ml, 0.37 mmol),
N,N-diisopropylethylamine (0.100 ml, 0.61 mmol) in dimethyl
sulfoxide (1.5 ml) was heated at 80.degree. C. for 18 h. The
reaction was cooled to rt then diluted with water and extracted
with isopropyl acetate (3.times.). The combined organic layers were
washed with brine, dried over sodium sulfate, filtered and
concentrated. The crude product purified by silica gel
chromatography (eluting gradient 0-20% methanol: dichloromethane)
to afford
6-morpholino-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one (87
mg, 82%). LCMS (ESI) m/z: 346.0 [M+H]+.
Step C.
5-Amino-6-morpholino-2-(2,2,2-trifluoroethyl)isoindolin-1-one
##STR01199##
[1400] To solution of
6-morpholino-5-nitro-2-(2,2,2-trifluoroethyl)isoindolin-1-one (60
mg, 0.17 mmol) in ethanol (3.5 ml) and water (1.0 ml) was added
iron (48 mg, 0.87 mmol) and ammonium chloride (37 mg, 0.69 mmol).
The reaction mixture was heated to 50.degree. C. for 6 h. The
reaction mixture was cooled to rt then filtered through celite and
concentrated. The crude product was purified by silica gel
chromatography (eluting gradient 0-20% methanol. dichloromethane)
to afford
5-amino-6-morpholino-2-(2,2,2-trifluoroethyl)isoindolin-1-one (40
mg, 73%). LCMS (ESI) m/z: 316.0 [M+H]+.
Step D.
N-[6-morpholino-1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl]pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01200##
[1402] To a solution of
5-amino-6-morpholino-2-(2,2,2-trifluoroethyl)isoindolin-1-one (50
mg, 0.16 mmol) and pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(60 mg, 0.32 mmol) in 1,2-dichloroethane (2.00 ml) was added
triethylamine (0.090 ml, 0.63 mmol). The reaction mixture was
stirred at 70.degree. C. for 18 h. The reaction was quenched with
water and extracted with ethyl acetate. The organic phase was dried
with sodium sulfate, filtered, and concentrated. The crude product
was purified by silica gel chromatography (eluting gradient 0-20%
methanol:dichloromethane) followed by reverse-phase HPLC to afford
N-[6-morpholino-1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl]pyrazolo[1,-
5-a]pyrimidine-3-carboxamide (14 mg, 19%). .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.94 (s, 1H), 9.43 (dd, J=7.0,
1.5 Hz, 1H), 9.01 (dd, J=4.3, 1.6 Hz, 1H), 8.80 (s, 1H), 8.77 (s,
1H), 7.66 (s, 1H), 7.40 (dd, J=7.0, 4.2 Hz, 1H), 4.62 (s, 2H), 4.38
(q, J=9.7 Hz, 2H), 3.90 (t, J=4.4 Hz, 4H), 2.93 (t, J=4.5 Hz, 4H).
LCMS (ESI) m/z: 461.1 [M+H]+.
TABLE-US-00006 TABLE 6 The following examples were made in a manner
similar to that for Example 173: Ex. Name Structure NMR, MS 174
N-[2-(2,2- difluoroethyl)-6- morpholino-1- oxo-isoindolin- 5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01201## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.93 (s, 1H),
9.43 (dd, J = 7.0, 1.6 Hz, 1H), 9.01 (dd, J = 4.2, 1.6 Hz, 1H),
8.77 (d, J = 2.9 Hz, 2H), 7.63 (s, 1H), 7.40 (dd, J = 7.0, 4.2 Hz,
1H), 6.29 (tt, J = 55.2, 3.6 Hz, 1H), 4.58 (s, 2H), 4.09- 3.76 (m,
6H), 3.01-2.84 (m, 4H). LCMS (ESI) m/z: 443.1 [M + H]+. 175
N-[2-(3- hydroxy-3- methyl-butyl)-6- morpholino-1- oxo-isoindolin-
5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01202##
.sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.89
(s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.2, 1.6 Hz,
1H), 8.75 (d, J = 2.4 Hz, 2H), 7.56 (s, 1H), 7.39 (dd, J = 7.0, 4.2
Hz, 1H), 4.46 (s, 2H), 4.34 (s, 1H), 3.94-3.86 (m, 4H), 3.64-3.54
(m, 2H), 2.96- 2.87 (m, 4H), 1.73-1.63 (m, 2H), 1.15 (s, 6H). LCMS
(ESI) m/z: 465.2 [M + H]+. 176 N-[2-(2- hydroxy-2- methyl-propyl)-
6-morpholino-1- oxo-isoindolin- 5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01203## .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 10.90 (s, 1H), 9.42 (dd, J = 7.0, 1.6 Hz, 1H),
9.01 (dd, J = 4.2, 1.6 Hz, 1H), 8.77 (s, 1H), 8.74 (s, 1H), 7.59
(s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H), 4.69 (s, 1H), 4.64 (s,
2H), 3.94-3.85 (m, 4H), 3.47-3.41 (m, 2H), 2.96- 2.86 (m, 4H), 1.11
(s, 6H). LCMS (ESI) m/z: 451.2 [M + H]+ 177 N-[6-[4-(2-
amino-2-oxo- ethyl)piperazin- 1-yl]-1-oxo-2- tetrahydropyran-
4-yl-isoindolin- 5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01204## .sup.1H NMR (400 MHz, DMSO- d6) .delta. 10.89 (s, 1H),
9.40 (dd, J = 7.0, 1.6 Hz, 1H), 9.03 (dd, J = 4.2, 1.6 Hz, 1H),
8.78 (s, 1H), 8.75 (s, 1H), 7.58 (s, 1H), 7.39 (dd, J = 7.0, 4.2
Hz, 1H), 7.29 (s, 1H), 7.19 (s, 1H), 4.47 (s, 2H), 4.32-4.19 (m,
1H), 4.01-3.91 (m, 2H), 3.50- 3.41 (m, 2H), 3.06 (s, 2H), 2.95 (dd,
J = 5.5, 3.5 Hz, 4H), 2.83-2.75 (m, 4H), 1.83 (qd, J = 12.3, 4.5
Hz, 2H), 1.71-1.61 (m, 2H). LCMS (ESI) m/z: 519.2 [M + H]+ 178
N-[2-(2- methoxyethyl)- 6-morpholino-1- oxo-isoindolin- 5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01205## .sup.1H
NMR (400 MHz, DMSO- d6) .delta. 10.89 (s, 1H), 9.41 (dd, J = 7.0,
1.6 Hz, 1H), 9.00 (dd, J = 4.2, 1.6 Hz, 1H), 8.75 (d, J = 3.3 Hz,
2H), 7.58 (d, J = 0.5 Hz, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H),
4.53-4.47 (m, 2H), 3.93-3.87 (m, 4H), 3.70- 3.64 (m, 2H), 3.56 (td,
J = 5.4, 0.7 Hz, 2H), 3.27 (s, 3H), 2.95-2.88 (m, 4H). LCMS (ESI)
m/z: 437.2 [M + H]+ 179 N-[2-(2- hydroxyethyl)-6- morpholino-1-
oxo-isoindolin- 5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01206## LCMS (ESI) m/z: 423.1 [M + H]+ 180 N-[2-(1-methyl-
4-piperidyl)-6- morpholino-1- oxo-isoindolin- 5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01207## .sup.1H NMR (400 MHz,
DMSO- d6) .delta. 10.90 (s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H),
9.00 (dd, J = 4.2, 1.6 Hz, 1H), 8.76 (d, J = 2.8 Hz, 2H), 7.57 (s,
1H), 7.39 (dd, J = 7.0, 4.3 Hz, 1H), 4.45 (s, 2H), 4.03-3.86 (m,
5H), 2.96-2.82 (m, 6H), 2.19 (s, 3H), 2.00 (td, J = 11.9, 2.3 Hz,
2H), 1.81 (qd, J = 12.2, 3.8 Hz, 2H), 1.72-1.60 (m, 2H). LCMS (ESI)
m/z: 476.2 [M + H]+ 181 N-[2-(4- hydroxycyclo- hexyl)-6-
morpholino-1- oxo-isoindolin- 5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01208## .sup.1H NMR (400 MHz, DMSO- d6) .delta.
10.89 (s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 8.99 (dd, J = 4.3,
1.7 Hz, 1H), 8.75 (d, J = 1.3 Hz, 2H), 7.56 (s, 1H), 7.38 (dd, J =
7.0, 4.2 Hz, 1H), 4.62 (d, J = 4.4 Hz, 1H), 4.41 (s, 2H), 4.03-3.85
(m, 5H), 3.42 (dd, J = 10.5, 4.7 Hz, 1H), 2.94-2.86 (m, 4H), 1.91
(d, J = 13.5 Hz, 2H), 1.77-1.55 (m, 4H), 1.39-1.25 (m, 2H). LCMS
(ESI) m/z: 477.2 [M + H]+
TABLE-US-00007 TABLE 7 The following examples were made in a manner
similar to that for Example 4: Ex. Name Structure NMR, MS 182
N-[2,2-dimethyl- 6-[(1S,5R)-6- (methyl- carbamoyl)-3-
azabicyclo[3.1.0] hexan-3-yl]-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01209## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 9.58 (s, 1H), 9.36 (dd, J =
7.0, 1.7 Hz, 1H), 8.90 (dd, J = 4.3, 1.7 Hz, 1H), 8.67 (s, 1H),
8.01 (d, J = 0.9 Hz, 1H), 7.73 (d, J = 4.7 Hz, 1H), 7.34 (dd, J =
7.0, 4.3 Hz, 1H), 6.60 (s, 1H), 3.43- 3.38 (m, 2H), 3.12-3.05 (m,
2H), 3.00-2.93 (m, 2H), 2.58 (d, J = 4.6 Hz, 3H), 2.17 (t, J = 3.0
Hz, 1H), 1.94-1.87 (m, 2H), 1.40 (s, 6H). LCMS (ESI) m/z: 447.2 [M
+ H]+. 183 N-[2,2-dimethyl- 6-[4-[2- (methylamino)- 2-oxo-ethyl]-1-
piperidyl]-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01210## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.44 (s, 1H), 9.37 (dd, J = 7.0, 1.6
Hz, 1H), 8.88 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.32 (d, J =
1.0 Hz, 1H), 7.78 (d, J = 4.8 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz,
1H), 6.68 (s, 1H), 3.02- 2.96 (m, 2H), 2.94-2.84 (m, 2H), 2.69-2.56
(m, 5H), 2.11 (d, J = 6.9 Hz, 2H), 1.81 (s, 1H), 1.69 (d, J = 12.1
Hz, 2H), 1.62-1.48 (m, 2H), 1.41 (s, 6H). LCMS (ESI) m/z: 463.3 [M
+ H]+. 184 N-[6-(4- carbamoyl-4- methyl-1- piperidyl)-2,2-
dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01211## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.43 (s, 1H), 9.36 (dd, J = 7.0, 1.7
Hz, 1H), 8.90 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.32 (d, J =
1.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 7.18 (s, 1H), 6.90 (s,
1H), 6.63 (s, 1H), 3.02- 2.96 (m, 2H), 2.87-2.76 (m, 2H), 2.73-2.62
(m, 2H), 2.21 (m, 2H), 1.67- 1.56 (m, 2H), 1.41 (s, 6H), 1.21 (s,
3H). LCMS (ESI) m/z: 449.2 [M + H]+. 185 N-[6-(4- hydroxyazepan-
1-yl)-2,2- dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01212## .sup.1H NMR 400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.45 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.93 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.26 (d, J = 1.0 Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.64 (s,
1H), 4.54 (d, J = 3.7 Hz, 1H), 3.98- 3.87 (m, 1H), 3.03-2.80 (m,
6H), 2.04 (m, 1H), 1.99- 1.80 (m, 3H), 1.80-1.57 (m, 2H), 1.40 (s,
6H). LCMS (ESI) m/z: 422.2 [M + H]+. 186 N[6-[(1S,5R)-6-
carbamoyl-3- azabicyclo[3.1.0] hexan-3-yl]-2,2- dimethyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01213## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 9.58 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.98 (dd, J =
4.3, 1.7 Hz, 1H), 8.68 (s, 1H), 8.01 (d, J = 1.0 Hz, 1H), 7.39-7.29
(m, 2H), 6.78 (s, 1H), 6.60 (s, 1H), 3.44-3.38 (m, 2H), 3.11- 3.03
(m, 2H), 2.97 (d, J = 1.1 Hz, 2H), 2.20 (t, J = 3.0 Hz, 1H), 1.90
m, 2H), 1.41 (s, 6H). LCMS (ESI) m/z: 433.2 [M + H]+. 187
N-[6-[4-(2- amino-2-oxo- ethyl)piperazin- 1-yl]-2,2- dimethyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01214## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.42 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.97 (dd, J
= 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.35 (dd, J = 7.0,
4.2 Hz, 1H), 7.19 (d, J = 29.3 Hz, 2H), 6.68 (s, 1H), 3.01 (m, 4H),
2.85 (m, 4H), 2.73 (m, 4H), 1.41 (s, 6H). LCMS (ESI) m/z: 450.2 [M
+ H]+. 188 N-[2,2-dimethyl- 6-[3-(3- methylimidazol-
4-yl)pyrrolidin- 1-yl]-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01215## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.00 (s, 1H), 9.35 (dd, J =
7.0, 1.6 Hz, 1H), 8.82 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.00 (d, J = 1.0 Hz, 1H), 7.48 (dd, J = 1.1, 0.5 Hz, 1H), 7.30 (dd,
J = 7.0, 4.2 Hz, 1H), 6.74 (t, J = 0.9 Hz, 1H), 6.63 (s, 1H), 3.55
(s, 3H), 3.53-3.43 (m, 2H), 3.16-3.05 (m, 2H), 3.03- 2.94 (m, 2H),
2.39 (m, 1H), 2.02-1.89 (m, 1H), 1.41 (s, 6H). LCMS (ESI) m/z:
458.2 [M + H]+. 189 N-[6-(5,7- dihydropyrrolo [3,4-b]pyridin-6-
yl)-2,2-dimethyl- 3H-benzofuran- 5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01216## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.38 (s, 1H), 9.29 (dd, J =
7.0, 1.6 Hz, 1H), 8.67 (s, 1H), 8.45 (ddt, J = 5.0, 1.4, 0.7 Hz,
1H), 8.14 (d, J = 1.0 Hz, 1H), 7.83 (dd, J = 4.2, 1.7 Hz, 1H),
7.76-7.72 (m, 1H), 7.36-7.27 (m, 1H), 7.16 (dd, J = 7.0, 4.2 Hz,
1H), 6.91 (s, 1H), 4.52 (s, 2H), 4.48 (s, 2H), 3.02 (s, 2H), 1.43
(s, 6H). LCMS (ESI) m/z: 427.2 [M + H]+. 190 N-[2,2-dimethyl-
6-[3-(1H- pyrazol-5-yl)-1- piperidyl]-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01217##
.sup.1HNMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 12.40 (s,
1H), 10.53 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.89 (dd, J =
4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.33 (s, 1H), 7.33 (dd, J = 7.0,
4.2 Hz, 1H), 6.70 (s, 1H), 6.04 (s, 1H), 3.12 (m, 1H), 3.00 (s,
2H), 2.93 (m, 1H), 2.67 (s, 2H), 2.16 (m, 1H), 2.05- 1.89 (m, 1H),
1.87-1.76 (m, 1H), 1.52 (m, 1H), 1.41 (d, J = 3.2 Hz, 6H). LCMS
(ESI) m/z: 458.2 [M + H]+. 191 N-[6- (1,3,3a,4,6,6a-
hexahydrofuro[3, 4-c]pyrrol-5-yl)- 2,2-dimethyl- 3H-benzofuran- 5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01218## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.02 (s, 1H),
9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.85 (dd, J = 4.2, 1.6 Hz, 1H),
8.69 (s, 1H), 8.15 (d, J = 1.0 Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz,
1H), 6.67 (s, 1H), 3.83- 3.76 (m, 2H), 3.60-3.53 (m, 2H), 3.15-3.08
(m, 2H), 3.02-2.98 (m, 2H), 2.96-2.87 (m, 2H), 2.73 (dd, J = 9.2,
3.1 Hz, 2H), 1.42 (s, 6H). LCMS (ESI) m/z: 420.2 [M + H]+. 192
N-[2,2-dimethyl- 6-[3-(1H- pyrazol-3- yl)pyirolidin-1- yl]-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01219## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 12.52 (d, J = 70.2 Hz, 1H), 10.04 (s, 1H), 9.35 (dd, J =
7.0, 1.6 Hz, 1H), 8.77 (s, 1H), 8.67 (s, 1H), 8.01 (s, 1H), 7.58
(s, 1H), 7.30 (dd, J = 7.0, 4.2 Hz, 1H), 6.60 (s, 1H), 6.13 (s,
1H), 3.68- 3.51 (m, 1H), 3.48-3.40 (m, 1H), 3.30-3.22 (m, 1H),
3.20-3.07 (m, 2H), 2.98 (s, 2H), 2.35 (m, 1H), 2.07 (m, 1H), 1.41
(s, 6H). LCMS (ESI) m/z: 444.2 [M + H]+. 193 N-[6-(5,5- difluoro-2-
azabicyclo[2.2.1] heptan-2-yl)-2,2- dimethyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01220## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 9.82 (s, 1H),
9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H),
8.67 (s, 1H), 7.91 (d, J = 1.1 Hz, 1H), 7.32 (dd, J = 7.0, 4.2 Hz,
1H), 6.48 (s, 1H), 3.93 (s, 1H), 3.39-3.34 (m, 1H), 3.17-3.08 (m,
1H), 2.97 (d, J = 1.1 Hz, 2H), 2.81 (s, 1H), 2.35-2.19 (m, 1H),
2.06 (d, J = 11.4 Hz, 2H), 1.88 (d, J = 10.5 Hz, 1H), 1 41 (s, 6H).
LCMS (ESI) m/z: 440.2 [M + H]+. 194 N-[2,2-dimethyl- 6-(6-oxa-2-
azaspiro[3.5] nonan-2-yl)-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01221## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 9.37 (dd, J = 7.0, 1.6 Hz, 1H),
9.25 (s, 1H), 8.87 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 7.58
(d, J = 1.0 Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.15 (s, 1H),
3.67 (s, 2H), 3.60 (d, J = 7.1 Hz, 2H), 3.49-3.40 (m, 4H), 2.93 (d,
J = 1.0 Hz, 2H), 1.74 (t, J = 6.0 Hz, 2H), 1.40 (s, 8H). LCMS (ESI)
m/z: 434.2 [M + H]+. 195 N-[2,2-dimethyl- 6-[3- (trifluoromethyl)
pyrrolidin-1-yl]- 3H-benzofuran- 5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01222## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.03 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.83 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H),
8.12 (d, J = 1.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.66 (s,
1H), 3.42- 3.34 (m, 1H), 3.14-3.01 (m, 3H), 2.99 (d, J = 1.1 Hz,
2H), 2.24 (m, 1H), 2.02 (m, 1H), 1.41 (d, J = 1.0 Hz, 6H). LCMS
(ESI) m/z: 446.2 [M + H]+. 196 N-(6-(3,3- difluoropiperidin-
1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01223## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.35 (s, 1H), 9.35 (dd, J =
7.0, 1.6 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.39-8.18 (m, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H), 6.73 (s, 1H),
3.23- 3.09 (m, 2H), 3.06-2.88 (m, 2H), 2.80-2.66 (m, 2H), 2.17-1.95
(m, 2H), 1.95-1.79 (m, 2H), 1.41 (s, 6H). (ESI): m/z = 428.2 [M +
1].sup.+. 197 N-(6-((3aR,6aS)- 5,5- difluorohexa- hydrocyclopenta
[c]pyrrol-2(1H)- yl)-2.2-dimethyl- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01224## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.83 (s, 1H),
9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.78 (dd, J = 4.2, 1.5 Hz, 1H),
8.69 (s, 1H), 7.95 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.62
(s, 1H), 3.12-3.01 (m, 2H), 2.99 (s, 2H), 2.84 (d, J =7.8 Hz, 4H),
2.32-2.14 (m, 2H), 2.10-1.83 (m, 2H), 1.42 (s, 6H). (ESI): m/z =
454.2 [M + 1].sup.+. 198 N-(6-(2- (methoxymethyl) morpholino)-2,2-
dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01225## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.41 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.89 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.30 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H),
4.02-3.77 (m, 3H), 3.45-3.27 (m, 2H), 3.17 (s, 3H), 3.00 (s, 2H),
2.91- 2.70 (m, 3H), 2.60-2.51 (m, 1H), 1.41 (s, 6H). (ESI): m/z =
438.2 [M + 1].sup.+. 199 N-(6-(6,6- difluoro-3- azabicyclo[3.2.0]
heptan-3-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01226## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.58 (s, 1H),
9.35 (dd, J = 7.0, 1.7 Hz, 1H), 8.75 (dd, J = 4.2, 1.6 Hz, 1H),
8.68 (s, 1H), 7.83 (s, 1H), 7.31 (dd, J = 7.0, 4.2 Hz, 1H), 6.67
(s, 1H), 3.44-3.20 (m, 3H), 3.17 (d, J = 9.0 Hz, 1H), 2.99 (s, 2H),
2.84 (dd, J = 10.4, 7.6 Hz, 1H), 2.79- 2.53 (m, 3H), 1.42 (s, 6H).
(ESI): m/z = 440.2 [M + 1].sup.+. 200 N-(6-((3aR,6aS)- 4,4-
difluorohexa- hydrocyclopenta [c]pyrrol-2(1H)-yl)- 2,2-dimethyl-
2,3- dihydrobenzo furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01227## .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 9.78 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.83
(dd, J = 4.3, 1.6 Hz, 1H), 8.68 (s, 1H), 7.93 (s, 1H), 7.31 (dd, J
= 7.0, 4.2 Hz, 1H), 6.64 (s, 1H), 3.14 (t, J = 8.0 Hz, 1H),
3.10-3.01 (m, 2H), 2.99 (s, 2H), 2.95-2.77 (m, 4H), 2.47-2.20 (m,
1H), 2.10- 1.91 (m, 1H), 1.91-1.75 (m, 1H), 1.68-1.50 (m, 1H), 1.41
(s, 6H). (ESI): m/z = 454.2 [M + 1].sup.+. 201 N-(6-(2-
(hydroxymethyl) pyrrolidin-1-yl)- 2,2-dimethyl- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01228##
.sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.54
(s, 1H), 9.35 (dd, J = 7.0, 1.6 Hz, 1H), 8.82 (dd, J = 4.2, 1.7 Hz,
1H), 8.66 (s, 1H), 8.27 (d, J = 1.0 Hz, 1H), 7.30 (dd, J = 7.0, 4.2
Hz, 1H), 6.76 (s, 1H), 4.33 (t, J = 5.5 Hz, 1H), 3.55- 3.39 (m,
1H), 3.39-3.10 (m, 3H), 3.00 (s, 2H), 2.77- 2.60 (m, 1H), 2.26-2.05
(m, 1H), 2.05-1.74 (m, 2H), 1.41 (s, 6H). (ESI): m/z = 408.2 [M +
1].sup.+. 202 N-(6-(3-(1H- imidazol-2- yl)piperidin-1-
yl)-2,2-dimethyl- 2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01229## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 11.67 (s, 1H), 10.56 (s, 1H),
9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.90 (dd, J = 4.2, 1.7 Hz, 1H),
8.68 (s, 1H), 8.36 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.92
(s, 1H), 6.70 (s, 1H), 3.36-3.23 (m, 1H), 3.16 (d, J = 11.7 Hz,
1H), 3.00 (s, 2H), 2.92 (d, J = 11.3 Hz, 1H), 2.78 (t, J = 11.0 Hz,
1H), 2.65 (td, J = 11.4, 2.6 Hz, 1H), 2.18 (d, J = 11.9 Hz, 1H),
1.96 (d, J = 11.9 Hz, 1H), 1.83 (s, 1H), 1.72-1.57 (m, 1H), 1.41
(d, J = 3.7 Hz, 6H). (ESI): m/z = 458.2 [M + 1].sup.+. 203
N-(6-((3R,4S)- 3,4- difluoropyrrolidin- 1-yl)-2,2- dimethyl-2,3-
dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01230## .sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6)
.delta. 9.92 (s, 1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.84 (dd, J =
4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 7.95 (s, 1H), 7.32 (dd, J = 7.0,
4.2 Hz, 1H), 6.59 (s, 1H), 5.52-5.36 (m, 1H), 5.36-5.18 (m, 1H),
3.67- 3.46 (m, 2H), 3.31 (s, 2H), 2.98 (s, 2H), 1.41 (s, 6H).
(ESI): m z = 414.2 [M + 1].sup.+. 204 N-(6-(5,5- difluoro-2-
azaspiro[3.3] heptan- 2-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-
5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01231## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.37 (dd, J =
7.0, 1.6 Hz, 1H), 9.22 (s, 1H), 8.83 (dd, J = 4.2, 1.6 Hz, 1H),
8.68 (s, 1H), 7.46 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.15
(s, 1H), 4.07 (d, J = 8.1 Hz, 2H), 3.68 (d, J = 8.0 Hz, 2H), 2.93
(s, 2H), 2.48- 2.31 (m, 2H), 1.93 (t, J = 8.5 Hz, 2H). (ESI): m/z =
440.2 [M + 1].sup.+. 205 N-(6-((4- cyanobenzyl) (methyl)amino)-
2,2- dimethyl-2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01232## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.47 (s, 1H), 9.37 (dd, J =
7.0, 1.7 Hz, 1H), 8.77 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.30-8.14 (m, 1H), 7.87-7.70 (m, 2H), 7.67 (d, J = 8.3 Hz, 2H),
7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.77 (s, 1H), 4.23 (s, 2H), 2.98
(s, 2H), 2.56 (s, 3H), 1.40 (s, 6H). (ESI): m/z = 453.2 [M +
1].sup.+. 206 N-(6-(4-(1H- imidazol-1- yl)piperidin-1-
yl)-2,2-dimethyl- 2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01233## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.30 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H),
8.24 (s, 1H), 7.85- 7.66 (m, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H),
7.28 (t, J = 1.3 Hz, 1H), 6.95 (t, J = 1.1 Hz, 1H), 6.71 (s, 1H),
4.33- 4.11 (m, 1H), 3.07 (d, J = 11.8 Hz, 2H), 3.01 (s, 2H),
2.93-2.74 (m, 2H), 2.25- 2.04 (m, 4H), 1.42 (s, 6H). (ESI): m/z =
458.2 [M + 1].sup.+. 207 N-(6-(4,4- difluoroazepan- 1-yl)-2,2-
dimethyl-2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01234## .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 10.42 (s, 1H), 9.38 (dd, J = 7.0, 1.6 Hz, 1H),
8.75 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.29 (s, 1H), 7.37
(dd, J = 7.0, 4.2 Hz, 1H), 6.73 (s, 1H), 3.11-3.02 (m, 2H), 2.99
(s, 2H), 2.97-2.90 (m, 2H), 2.55-2.40 (m, 2H), 2.39-2.20 (m, 2H),
1.90- 1.78 (m, 2H), 1.41 (s, 6H). (ESI): m/z = 442.2 [M + 1].sup.+.
208 N-(6- ((1R,5S,6r)-6- carbamoyl-3- azabicyclo[3.1.0]
hexan-3-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01235## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.58 (s, 1H),
9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.98 (dd, J = 4.2, 1.7 Hz, 1H),
8.68 (s, 1H), 8.01 (s, 1H), 7.37- 7.29 (m, 2H), 6.78 (s, 1H), 6.60
(s, 1H), 3.41 (d, J = 9.3 Hz, 2H), 3.08 (d, J = 9.3 Hz, 1H), 2.97
(s, 2H), 2.20 (t, J = 3.0 Hz, 1H), 1.92-1.87 (m, 2H), 1.41
(s, 6H). (ESI): m/z = 433.2 [M + 1].sup.+. 209 N-(6-(4-
hydroxyazepan- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01236## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.45 (s, 1H),
9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.93 (dd, J = 4.2, 1.7 Hz, 1H),
8.67 (s, 1H), 8.26 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.64
(s, 1H), 4.54 (d, J = 3.7 Hz, 1H), 3.98-3.86 (m, 1H), 3.05-2.89 (m,
4H), 2.89- 2.78 (m, 1H), 2.10-1.99 (m, 1H), 1.98-1.81 (m, 2H),
1.81-1.65 (m, 1H), 1.64 (s, 1H), 1.40 (d, J = 1.5 Hz, 6H). (ESI):
m/z = 422.2 [M + 1].sup.+. 210 N-(6-(4- carbamoyl-4-
methylpiperidin- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01237## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d6) .delta. 10.43 (s, 1H), 9.36
(dd, J = 7.0, 1.7 Hz, 1H), 8.89 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s,
1H), 8.32 (s, 1H), 7.33 (dd, J = 7.0, 4.1 Hz, 1H), 7.18 (s, 1H),
6.89 (s, 1H), 6.63 (s, 1H), 2.99 (s, 2H), 2.87- 2.76 (m, 2H),
2.72-2.62 (m, 2H), 2.26-2.16 (m, 2H), 1.67-1.56 (m, 2H), 1.41 (s,
6H), 1.21 (s, 3H). (ESI): m/z = 449.2 [M + 1].sup.+. 211
N-(2,2-dimethyl- 6-(4-(2- (methylamino)- 2- oxoethyl)piperidin-
1-yl)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01238## .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 10.43 (s, 1H), 9.37 (dd, J = 7.0, 1.7 Hz, 1H),
8.88 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.38-8.26 (m, 1H),
7.78 (q, J = 5.5, 5.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.68
(s, 1H), 2.99 (s, 2H), 2.93-2.84 (m, 2H), 2.69-2.60 (m, 2H), 2.58
(d, J = 4.6 Hz, 3H), 2.11 (d, J = 7.0 Hz, 2H), 1.88-1.73 (m, 1H),
1.69 (d, J = 12.6 Hz, 2H), 1.62-1.48 (m, 2H), 1.40 (s, 6H). (ESI):
m/z = 463.3 [M + 1].sup.+. 212 N-(2,2-dimethyl- 6-((1R,5S,6r)-6-
(methylcarbamoyl)- 3-azabicyclo[3.1.0] hexan-3-yl)-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01239## .sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6)
.delta. 9.58 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.90 (dd, J =
4.3, 1.7 Hz, 1H), 8.67 (s, 1H), 8.08-7.90 (m, 1H), 7.73 (q, J = 4.5
Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.60 (s, 1H), 3.40 (d, J =
9.2 Hz, 2H), 3.08 (d, J = 9.1 Hz, 2H), 2.97 (s, 2H), 2.58 (d, J =
4.6 Hz, 3H), 2.17 (t, J = 3.0 Hz, 1H), 1.97- 1.84 (m, 2H), 1.40 (s,
6H). (ESI): m/z = 447.2 [M + 1].sup.+. 213 N-(2,2-dimethyl-
6-(3-oxo-2,8- diazaspiro[4.5] decan-8-yl)-2,3- dihydrobenzofuran-
5-yl)pyrazolo[1,5- a]pyrimidine-3- ##STR01240## .sup.1H NMR (400
MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.46 (s, 1H), 9.35 (dd,
J = 7.0, 1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.34-8.28 (m, 1H), 7.58 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H),
6.73 (s, 1H), 3.21-3.12 (m, 2H), 3.04-2.95 (m, 2H), 2.84- 2.70 (m,
4H), 2.17 (s, 2H), 1.80 (d, J = 6.4 Hz, 4H), 1.41 (s, 6H). (ESI):
m/z = 461.2 [M + 1].sub.+. 214 N-(2,2-dimethyl- 6-(pyrrolidin-1-
yl)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01241## .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 10.13 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H),
8.85 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.08 (s, 1H), 7.31
(dd, J = 7.0, 4.2 Hz, 1H), 6.59 (s, 1H), 3.00 (m, 4H), 2.98 (s,
2H), 1.98- 1.86 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 378.2 [M +
1].sup.+. 215 N-(6-(6- (hydroxymethyl)- 3-azabicyclo[3.1.0]
hexan-3-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01242## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.69 (s, 1H),
9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.98 (dd, J = 4.2, 1.7 Hz, 1H),
8.68 (s, 1H), 8.12 (d, J = 1.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz,
1H), 6.63 (s, 1H), 4.54 (s, 1H), 3.33 (m, 2H), 3.26 (d, J = 8.7 Hz,
2H), 2.99- 2.95 (m, 2H), 2.97 (s, 2H), 1.92 (m, 1H), 1.42 (m, 2H),
1.40 (s, 6H). MS (ESI): m/z = 420.2 [M + 1].sup.+. 216 N-(6-(4-
cyanopiperidin- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01243## .sup.1H
NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.37 (s, 1H),
9.38 (dd, J = 7.0, 1.6 Hz, 1H), 8.86 (dd, J = 4.2, 1.6 Hz, 1H),
8.69 (s, 1H), 8.32 (d, J = 1.2 Hz, 1H), 7.38 (dd, J = 7.0, 4.2 Hz,
1H), 6.66 (s, 1H), 3.09 (m, 1H), 3.00 (s, 2H), 2.90 (m, 2H), 2.77
(m, 2H), 2.12 (m, 2H), 1.99 (m, 2H), 1.41 (s, 6H). MS (ESI): m/z =
417.2 [M + 1].sup.+. 217 N-(6-(3,3- difluoropyrrolidin- 1-yl)-2,2-
dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01244## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.24 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H),
8.22 (d, J = 1.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.73 (s,
1H), 3.48 (t, J = 13.1 Hz, 2H), 3.25- 3.14 (m, 2H), 3.00 (s, 2H),
2.49 (m, 2H), 1.41 (s, 6H). MS (ESI): m/z = 414.1 [M + 1].sup.+.
218 N-(2,2-dimethyl- 6-(4- (trifluoromethyl) piperidin-1-yl)- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01245## .sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6)
.delta. 10.34 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.72 (dd, J
= 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.38
(dd, J = 7.0, 4.2 Hz, 1H), 6.66 (s, 1H), 3.05- 2.95 (m, 5H), 2.72
(m, 2H), 1.98-1.77 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 460.2 [M
+ 1].sup.+. 219 N-(6-(4- isobutyrylpiperazin- 1-yl)-2,2-
dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01246## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.48 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.87 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H),
8.32 (d, J = 1.0 Hz, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H), 6.70 (s,
1H), 3.73 (s, 4H), 3.00 (s, 2H), 2.91 (p, J = 6.7 Hz, 1H), 2.78 (m,
4H), 1.41 (s, 6H), 1.03 (d, J = 6.7 Hz, 6H). MS (ESI): m/z = 463.2
[M + 1].sup.+. 220 N-(6-(4-acetyl- 1,4-diazepan-1-
yl)-2,2-dimethyl- 2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01247## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.39 (s, 1H), 9.36 (dt, J =
7.0, 1.5 Hz, 1H), 8.87 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (d, J = 1.5
Hz, 1H), 8.33-8.19 (m, 1H), 7.32 (ddd, J = 7.0, 4.2, 1.1 Hz, 1H),
6.67 (d, J = 20.9 Hz, 1H), 3.76-3.59 (m, 4H), 3.06-2.98 (m, 3H),
2.94 (m, 3H), 1.99 (m, 5H), 1.41 (s, 6H). MS (ESI): m/z = 449.2 [M
+ 1].sup.+. 221 N-(2,2-dimethyl- 6-(3-oxo-2,8- diazaspiro[4.5]
decan-8-yl)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01248## .sup.1H NMR (400 MHz,
dimethyl sulfoxide- d.sub.6) .delta. 10.46 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.32 (s, 1H), 7.67-7.51 (m, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H),
6.73 (s, 1H), 3.17 (s, 2H), 3.05-2.95 (s, 2H), 2.84-2.70 (m, 4H),
2.18 (s, 2H), 1.80 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 461.2 [M
+ 1].sup.+. 222 and 223 (R)-N-(2,2- dimethyl-6-(2- oxa-7-
azaspiro[4.4] nonan-7-yl)-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and (S)-N-(2,2-
dimethyl-6-(2- oxa-7- azaspiro[4.4] nonan-7-yl)-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(stereochemistry assigned arbitrarily) ##STR01249## Example 222
Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta.
9.80 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.83 (dd, J = 4.2,
1.7 Hz, 1H), 8.68 (s, 1H), 7.98 (d, J = 1.1 Hz, 1H), 7.32 (dd, J =
7.0, 4.2 Hz, 1H), 6.56 (s, 1H), 3.82-3.70 (m, 2H), 3.70-3.57 (m,
2H), 3.19- 3.06 (m, 2H), 3.05 (s, 2H), 2.97 (d, J = 1.3 Hz, 2H),
2.05-1.87 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 434 [M + 1].sup.+.
Example 223, Peak 2: .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 9.80 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.83
(dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 7.98 (t, J = 0.9 Hz, 1H),
7.32 (dd, J = 7.0, 4.2 Hz, 1H), 6.56 (s, 1H), 3.82-3.70 (m, 2H),
3.70-3.57 (m, 2H), 3.19- 3.06 (m, 2H), 3.05 (s, 2H), 2.97 (d, J =
1.1 Hz, 2H), 2.03-1.87 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 434
[M + 1].sup.+. 224 N-[6-(6- hydroxy-4- methyl-1,4- diazepan-1-yl)-
2,2-dimethyl- 3H-benzofuran- 5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01250## .sup.1H NMR (400 MHz, Methanol-d.sub.4)
.delta. 9.05 (d, J = 6.6 Hz, 1H), 8.83 (d, J = 3.7 Hz, 1H), 8.57
(s, 1H), 8.43 (d, J = 30.3 Hz, 1H), 7.86 (s, 1H), 7.23-7.15 (m,
1H), 6.61 (s, 1H), 4.22-4.15 (m, 1H), 3.63 (d, J = 12.7 Hz, 1H),
3.41 (td, J = 14.8, 14.4, 6.1 Hz, 3H), 3.29 (dd, J = 13.3, 3.9 Hz,
1H), 3.18 (m, 2H), 3.11 (dd, J = 13.4, 3.5 Hz, 1H), 2.93 (s, 2H),
2.77 (s, 3H), 1.35 (s, 6H). MS (ESI): m/z = 437.3 [M + 1].sup.+.
225 N-(6-(4-(2- (Isopropylamino)- 2-oxoethyl) piperazin-1-yl)- 2,2-
dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01251## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.41 (s, 1H), 9.36 (dd, J = 7.0,
1.6 Hz, 1H), 8.98 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.33 (d,
J = 0.9 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 7.0, 4.2
Hz, 1H), 6.71 (s, 1H), 3.99- 3.81 (m, 1H), 3.05-2.95 (m, 4H),
2.90-2.81 (m, 4H), 2.72 (d, J = 5.1 Hz, 4H), 1.41 (s, 6H), 1.08 (d,
J = 6.6 Hz, 6H). (ESI): m/z = 492.2 [M + 1].sup.+. 226 N-(6-(4-(1-
Amino-2- methyl-1- oxopropan-2- yl)piperazin-1- yl)-2,2-dimethyl-
2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01252## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d6) .delta. 10.34 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.86 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.26 (s, 1H),
7.37 (dd, J = 7.1, 4.2 Hz, 1H), 7.16 (d, J = 3.4 Hz, 1H), 7.02 (d,
J = 3.0 Hz, 1H), 6.66 (s, 1H), 3.00 (s, 2H), 2.86 (t, J = 4.6 Hz,
4H), 2.67 (d, J = 4.7 Hz, 4H), 1.41 (s, 6H), 1.15 (s, 6H). (ESI):
m/z = 478.2 [M + 1].sup.+. 227 N-(6-((3R,5S)-4- (2-Amino-2-
oxoethyl)-3,5- dimethylpiperazin- 1-yl)-2,2- dimethyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01253## (ESI): m/z = 478.2 [M + 1].sup.+. 228 N-(2,2-
Dimethyl-6-(4- (2-morpholino- 2- oxoethyl)piperazin- 1-yl)-2,3-
dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01254## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.38 (s, 1H), 9.37 (dd, J = 6.9, 1.6 Hz, 1H), 8.97 (dd, J
= 4.3, 1.7 Hz, 1H), 8.67 (s, 1H), 8.31 (s, 1H), 7.37 (dd, J = 7.0,
4.2 Hz, 1H), 6.69 (s, 1H), 3.57 (d, J = 22.3 Hz, 7H), 3.45 (t, J =
4.7 Hz, 2H), 3.29 (s, 2H), 3.00 (s, 2H), 2.82 (t, J = 4.7 Hz, 4H),
2.70 (d, J = 4.9 Hz, 5H), 2.54 (dd, J = 8.1, 4 2 Hz, 1H), 1.41 (s,
6H). (ESI): m/z = 520.2 [M + 1].sup.+. 229 N-(2,2- Dimethyl-6-(3-
(2- methylpyrimidin- 4-yl)pyrrolidin- 1-yl)-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01255##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.05 (s,
1H), 9.35 (dd, J = 7.0, 1.5 Hz, 1H), 8.73 (dd, J = 4.2, 1.6 Hz,
1H), 8.67 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.03 (s, 1H), 7.34-
7.24 (m, 2H), 6.64 (s, 1H), 3.64 (p, J = 7.9 Hz, 1H), 3.47-3.32 (m,
2H), 3.36- 3.13 (m, 3H), 2.99 (s, 2H), 2.47-2.34 (m, 1H), 2.27-
2.13 (m, 1H), 1.42 (s, 6H). (ESI): m/z = 470.2 [M + 1].sup.+. 230
N-(2,2- Dimethyl-6-(4- ((tetrahydrofuran- 2-yl)methyl)
piperazin-1-yl)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01256## .sup.1HNMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.41 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.91 (dd, J = 4.1, 1.6 Hz, 1H), 8.67 (s, 1H),
8.31 (s, 1H), 7.37 (dd, J = 7.0, 4.1 Hz, 1H), 6.69 (s, 1H),
4.02-3.91 (m, 1H), 3.81-3.70 (m, 1H), 3.61 (td, J = 7.8, 6.3 Hz,
1H), 2.99 (s, 2H), 2.84-2.73 (m, 6H), 2.66 (s, 2H), 2.01- 1.79 (m,
2H), 1.84-1.70 (m, 2H), 1.57-1.43 (m, 1H), 1.41 (s, 6H). MS (ESI):
m/z = 477.2 [M + 1].sup.+. 231 N-(6-(4-(2-(1H- Imidazol-1-
yl)ethyl)piperazin- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01257## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.39 (s, 1H),
9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.92 (dd, J = 4.3, 1.7 Hz, 1H),
8.68 (s, 1H), 8.30 (s, 1H), 7.65 (s, 1H), 7.35 (dd, J = 7.0, 4.2
Hz, 1H), 7.21 (d, J = 1.2 Hz, 1H), 6.87 (d, J = 1.0 Hz, 1H), 6.70
(s, 1H), 4.11 (t, J = 6.6 Hz, 2H), 3.00 (s, 2H), 2.82 (t, J = 4.7
Hz, 4H), 2.74 (t, J = 6.6 Hz, 2H), 2.70 (s, 5H), 1.41 (s, 6H). MS
(ESI): m/z = 487.2 [M + 1].sup.+. 232 N-(6-(4-(2- (Dimethylamino)-
2- oxoethyl)piperazin- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01258##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.39 (s,
1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.99 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.32 (s, 1H), 7.37 (dd, J = 7.0, 4.2 Hz, 1H),
6.69 (s, 1H), 5.75 (s, 2H), 3.28 (d, J = 9.9 Hz, 3H), 3.06 (s, 3H),
3.00 (s, 2H), 2.82 (d, J = 4.9 Hz, 7H), 2.72 (d, J = 4.5 Hz, 4H),
1.41 (s, 6H). MS (ESI): m/z = 478.2 [M + 1].sup.+. 233 N-(6-(5,6-
Dihydroimidazo [1,2-a]pyrazin- 7(8H)-yl)-2,2- dimethyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01259## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.73 (s, 1H), 9.28 (dd, J = 7.0, 1.6 Hz, 1H), 8.65 (s,
1H), 8.40 (s, 1H), 7.70 (dd, J = 4.1, 1.6 Hz, 1H), 7.25 (d, J = 1.2
Hz, 1H), 7.17 (dd, J = 7.0, 4.1 Hz, 1H), 6.92 (d, J = 1.2 Hz, 1H),
6.84 (s, 1H), 4.19 (t, J = 5.3 Hz, 2H), 4.00 (s, 2H), 3.43-3.35 (m,
2H), 3.04 (s, 2H), 1.43 (s, 6H). MS (ESI): m/z = 430.2 [M +
1].sup.+. 234 N-(6- (Hexahydro-5H- furo[2,3- c]pyrrol-5-yl)-
2,2-dimethyl- 2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01260## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 9.80 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.85 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H),
7.95 (s, 1H), 7.31 (dd, J = 7.0, 4.2 Hz, 1H), 6.58 (s, 1H), 4.57
(ddd, J = 8.0, 5.9, 2.9 Hz, 1H), 3.87 (q, J = 7.5 Hz, 1H),
3.72-3.57 (m, 1H), 3.13-3.02 (m, 2H), 3.00-2.81 (m, 3H), 2.07 (s,
2H), 1.90 (dq, J = 12.2, 7.6 Hz, 1H), 1.74-1.62 (m, 1H), 1.41 (s,
6H). MS (ESI): m/z = 420.2 [M + 1].sup.+. 235 N-(6-(4-(1,3,4-
Oxadiazol-2- yl)piperidin-1- yl)-2,2-dimethyl- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01261##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.49 (s,
1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 9.20 (s, 1H), 8.85 (dd, J =
4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.36 (s, 1H), 7.34 (dd, J = 7.0,
4.2 Hz, 1H), 6.70 (s, 1H), 3.27- 3.15 (m, 1H), 3.01 (s, 3H),
3.01-2.95 (m, 1H), 2.84 (td, J = 11.2, 3.1 Hz, 2H), 2.25-2.05 (m,
4H), 1.42 (s, 6H). MS (ESI): m/z = 460.2 [M + 1].sup.+. 236
N-(6-(3- Carbamoyl- pyrrolidin- 1-yl)-2,2- dimethyl-2,3-
dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01262##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.16 (s,
1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.90 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.11 (s, 1H), 7.37- 7.28 (m, 2H), 6.85 (s, 1H),
6.59 (s, 1H), 3.28 (d, J = 7.7 Hz, 1H), 3.16-2.93 (m, 3H), 2.98 (s,
2H), 2.11 (q, J = 7.1 Hz, 2H), 1.41 (s, 6H). MS (ESI): m/z = 421.2
[M + 1].sup.+. 237 N-(6-(9- Hydroxy-3-oxa- 7- azabicyclo[3.3.1]
nonan-7-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01263## 1:0.38
diastereomeric ratio. Resonances from the minor diastereomer are
indicated with partial integrals. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 9.52 (s, 1H), 9.43 (s, 0.35 H),
9.31-9.23 (m, 1.47 H), 8.80-8.71 (m, 1.45 H), 8.68 (m, J = 2.7 Hz,
1.38 H), 7.92 (s, 1H), 7.83 (s, 0.33 H), 7.30-7.21 (m, 1.46 H),
6.64 (s, 1H), 6.59 (s, 0.36 H), 5.07-4.99 (m, 1.44 H), 3.95-3.88
(m, 3H), 3.81-3.73 (m, 1H), 3.52 (d, J = 11.3 Hz, 1H), 3.44 (s,
1H), 3.42 (s, 1H), 3.15-3.01 (m, 5H), 2.98 (s, 3H), 2.78 (d, J =
10.5 Hz, 1H), 1.65-1.55 (m, 3H), 1.41 (s, 8H). MS (ESI): mz = 450.2
[M + 1].sup.+. 238 N-(2,2- Dimethyl-6- (1,4,6,7- tetrahydro-5H-
imidazo[4,5- c]pyridin-5-yl)- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01264## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 11.99-11.57 (m,
1H), 11.00- 10.63 (m, 1H), 9.27 (d, J = 7.0 Hz, 1H), 8.64 (s, 1H),
8.44-8.33 (m, 1H), 7.84- 7.61 (m, 1H), 7.50 (s, 1H), 7.17 (dd, J =
7.0, 4.2 Hz, 1H), 6.88-6.62 (m, 1H), 3.83 (d, J = 24.2 Hz, 2H),
3.27-3.13 (m, 2H), 3.02 (s, 2H), 2.86-2.68 (m, 2H), 1.42 (s, 6H).
MS (ESI): m/z = 430.2 [M + 1].sup.+. 239 N-(6-(1- Methoxy-2-
azabicyclo[2.2.1] heptan-2-yl)-2,2- dimethyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01265##
1:0.39 diastereomeric ratio. Resonances from the minor diastereomer
are indicated with partial integrals. .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.06 (s, 0.39 H), 9.73 (s,
1H), 9.37 (m, 1.38 H), 8.94-8.87 (m, 1.43 H), 8.71 (s, 0.30 H),
8.67 (s, 1H), 8.18 (s, 0.4 H), 7.82 (s, 1H), 7.38-7.29 (m, 1.39 H),
6.94 (s, 0.33 H), 6.48 (s, 1H), 3.99 (s, 1H), 3.74- 3.68 (m, 1H),
3.23 (s, 5H), 3.05 (s, 1H), 3.03 (s, 1H), 2.95 (s, 2H), 2.34 (s,
1H), 1.81-1.62 (m, 3H), 1.48- 1.38 (m, 10H). MS (ESI): m/z = 434.2
[M + 1].sup.+. 240 N-(6-(2- Azabicyclo[3.1.0] hexan-2-yl)-2,2-
dimethyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01266## 1:0.12 diastereomeric
ratio. Resonances from the minor diastereomer are indicated with
partial integrals. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.06 (s, 0.12 H), 10.01 (s, 1H), 9.39
(dd, J = 6.9, 1.5 Hz, 0.12 H), 9.35 (dd, J = 7.0, 1.7 Hz, 1H), 8.91
(dd, J = 4.3, 1.6 Hz, 0.12 H), 8.87 (dd, J = 4.3, 1.6 Hz, 1H), 8.71
(s, 0.12 H), 8.67 (s, 1H), 8.18 (s, 0.12 H), 8.13 (s, 1H), 7.34
(dd, J = 7.0, 4.2 Hz, 0.12 H), 7.30 (dd, J = 7.0, 4.2 Hz, 1H), 6.94
(s, 0.12 H), 6.87 (s, 1H), 3 .45 (t, J = 8.9 Hz, 1H), 3.30 (t, J =
13.1 Hz, 1H), 3.05 (s, 0H), 2.99 (s, 2H), 2.93 (td, J = 5.8, 2.6
Hz, 1H), 2.34-2.24 (m, 1H), 2.19-2.05 (m, 1H), 1.94 (dd, J = 11.8,
6.8 Hz, 1H), 1.60-1.50 (m, 1H), 1.41 (d, J = 4.7 Hz, 7H), 1.01-0.92
(m, 1H), 0.48 (dt, 8.3, 5.6 Hz, 1H). MS (ESI): m/z = 390.2 [M +
1].sup.+. 241 N-(2,2- Dimethyl-6-(3- sulfamoyl pyrrolidin-1-
yl)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01267## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.17 (s, 1H), 9.36 (dd, J = 7.0, 1.7
Hz, 1H), 8.90 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.18 (s,
1H), 7.33 (dd, J = 7.0, 4.3 Hz, 1H), 6.94 (s, 2H), 6.69 (s, 1H),
3.92- 3.80 (m, 1H), 3.52 (dd, J = 10.1, 8.4 Hz, 1H), 3.33- 3.03 (m,
4H), 3.00 (s, 2H), 2.37-2.27 (m, 2H), 1.42 (s, 6H). MS (ESI): m/z =
457.1 [M + 1].sup.+. 242 N-(6-(4-(2- (Cyclopropyl- amino)-2-
oxoethyl)piperazin- 1-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01268## MS (ESI):
m/z = 490.2 [M + 1].sup.+. 243 N-(2,2- Dimethyl-6-(4- (2-oxo-2-
(pyrrolidin-1- yl)ethyl)piperazin- 1-yl)-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01269##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.41 (s,
1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 9.02 (dd, J = 4.3, 1.7 Hz,
1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H),
6.70 (s, 1H), 3.52 (t, J = 6.7 Hz, 2H), 3.44-3.26 (m, 2H, buried
under H.sub.2O peak), 3.23 (s, 2H), 3.00 (s, 2H), 2.86- 2.72 (m,
8H), 1.94-1.82 (m, 2H), 1.83-1.71 (m, 2H), 1.42 (s, 6H). MS (ESI):
m/z = 504.2 [M + 1].sup.+. 244 N-(6-(4-(1- (Cyclopropyl- amino)-1-
oxopropan-2- yl)piperazin-1- yl)-2,2-dimethyl- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01270##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.41 (s,
1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 9.00 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.85 (d, J = 4.6 Hz, 1H), 7.37
(dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H), 3.08 (q, J = 6.8 Hz, 1H),
2.99 (s, 2H), 2.84- 2.66 (m, 9H), 1.41 (s, 6H), 1.14 (d, J = 6.9
Hz, 3H), 0.69-0.58 (m, 2H), 0.49- 0.34 (m, 2H). MS (ESI): m/z =
504.2 [M + 1].sup.+. 245 N-(2,2- Dimethyl-6-(4- (2,2,2-trifluoro-
1- hydroxyethyl) piperidin-1-yl)-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01271## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.51 (s, 1H), 9.35
(dd, J = 7.0, 1.7 Hz, 1H), 8.99 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s,
1H), 8.37 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H),
6.38 (d, J = 2.6 Hz, 1H), 3.94 (s, 1H), 2.99 (s, 2H), 2.95 (d, J =
11.4 Hz, 2H), 2.74-2.59 (m, 2H), 1.98-1.83 (m, 2H), 1.80- 1.72 (m,
2H), 1.66 (d, J = 12.3 Hz, 1H), 1.41 (s, 6H). MS (ESI): m/z = 490.2
[M + 1].sup.+. 246 N-(6-(4,6- dihydropyrrolo [3,4-c]pyrazol-
5(1H)-yl)-2,2- dimethyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01272## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 12.54 (s, 1H), 10.45
(s, 1H), 9.31 (dd, J = 7.0, 1.7 Hz, 1H), 8.66 (s, 1H), 8.10 (dd, J
= 4.1, 1.5 Hz, 1H), 8.06 (s, 1H), 7.51 (s, 1H), 7.21 (dd, J = 7.0,
4.2 Hz, 1H), 6.85 (s, 1H), 4.27 (s, 4H), 3.00 (s, 2H), 1.43 (s,
6H). MS (ESI): m/z = 416.2 [M + 1].sup.+. 247 N-(2,2-dimethyl-
6-(3-methyl-4,6- dihydropyrrolo [3,4-c]pyrazol- 5(1H)-yl)-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01273## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
12.19 (s, 1H), 10.43 (s, 1H), 9.31 (dd, J = 7.0, 1.7 Hz, 1H), 8.66
(s, 1H), 8.13 (dd, J = 4.2, 1.7 Hz, 1H), 8.08 (s, 1H), 7.23 (dd, J
= 7.0, 4.2 Hz, 1H), 6.82 (s, 1H), 4.20 (d, J = 12.3 Hz, 4H), 3.00
(s, 2H), 2.19 (s, 3H), 1.42 (s, 6H). MS (ESI): m/z = 430.2 [M +
1].sup.+.
Example 248.
N-(6-(2-(2,2-Difluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2,2-dimethyl-2-
,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01274##
[1403] Step A. tert-Butyl
7-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-2,7-diazaspiro[3.5]no-
nane-2-carboxylate
##STR01275##
[1405] To a mixture of 6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 4; 200 mg, 0.74 mmol), and cesium carbonate (790 mg,
2.43 mmol) in acetonitrile (2.23 ml) was added tert-butyl
2,7-diazaspiro[3.5]nonane-2-carboxylate and oxalic acid (256 mg,
0.809 mmol). The mixture was heated at 60.degree. C. for 16 h,
cooled to room temperature, and diluted with water and isopropyl
acetate. The aqueous phase was isolated and extracted with
isopropyl acetate (3.times.). The combined organic phases were
dried over anhydrous sodium sulfate, filtered and purified by flash
column chromatography (eluting gradient 0-100% isopropyl acetate:
heptanes) to afford the title compound (177 mg, 0.424 mmol, 58%
yield) as a bright yellow solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d6) .delta. 7.82 (s, 1H), 6.54 (s, 1H), 3.58 (s, 5H),
2.99 (s, 2H), 2.90-2.82 (m, 4H), 1.82-1.73 (m, 4H), 1.43 (s, 6H),
1.38 (s, 9H).
Step B.
7-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-2,7-diazaspiro-
[3.5]nonane
##STR01276##
[1407] tert-butyl
7-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-2,7-diazaspiro[3.5]no-
nane-2-carboxylate (176 mg, 0.422 mmol) was dissolved in
dichloromethane (3.3 ml) and treated with trifluoroacetic acid (1.3
ml). After 10 min, the solvent was removed under reduced pressure.
The product was taken on without further purification.
Step C.
2-(2,2-Difluoroethyl)-7-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofura-
n-6-yl)-2,7-diazaspiro[3.5]nonane
##STR01277##
[1409]
7-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-2,7-diazaspiro[-
3.5]nonane (67 mg, 0.21 mmol) was dissolved in dichloromethane (8
ml) and slowly treated with collidine (0.61 ml, 4.6 mmol) followed
by 2,2-difluoroethyl trifluoromethanesulfonate (0.044 ml, 0.32
mmol). After 18 h, methanol (5 ml) and potassium carbonate were
added. The reaction mixture stirred vigorously for 4 h at ambient
temperature and then was diluted with water and isopropyl acetate.
The aqueous phase was isolated and extracted with isopropyl acetate
(3.times.). The combined organic phases were dried over anhydrous
sodium sulfate, filtered and purified by column chromatography
(eluting gradient 0-100% isopropyl acetate: heptanes) to afford
2-(2,2-difluoroethyl)-7-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-
-2,7-diazaspiro[3.5]nonane (61 mg, 0.16 mmol) as a yellow solid.
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 7.81 (s,
1H), 6.54 (s, 1H), 5.93 (tt, J=55.9, 4.3 Hz, 1H), 3.08 (s, 4H),
2.98 (s, 2H), 2.85 (m, 4H), 2.82 (d, J=4.3 Hz, 2H), 1.82-1.72 (m,
4H), 1.43 (s, 6H).
Step D.
6-(2-(2,2-Difluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2,2-dimeth-
yl-2,3-dihydrobenzofuran-5-amine
##STR01278##
[1411] A mixture of
2-(2,2-difluoroethyl)-7-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-
-2,7-diazaspiro[3.5]nonane (61 mg, 0.16 mmol), iron (77 mg, 1.4
mmol), and ammonium chloride (74 mg, 1.4 mmol) in ethanol (6 ml)
and water (2 ml) was stirred at 80.degree. C. for 30 min. The
mixture was filtered through celite and a small plug of silica to
afford
6-(2-(2,2-difluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2,2-dimethyl-2,3--
dihydrobenzofuran-5-amine (0.16 mmol) which was used without
further purification. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 6.50 (s, 1H), 6.28 (s, 1H), 4.16 (s,
2H), 3.32-3.15 (m, 254H), 3.08 (s, 4H), 2.82 (s, 5H), 2.69-2.65 (m,
1H), 2.61 (s, 4H), 1.78 (t, J=5.3 Hz, 4H), 1.33 (s, 6H).
Step E.
N-(6-(2-(2,2-Difluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2,2-dim-
ethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01279##
[1413] To a solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(20.3 mg, 0.124 mmol) in dimethylformamide (2 ml) at 0.degree. C.
under a nitrogen atmosphere was added
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (62 mg, 0.119 mmol) followed by
2,4,6-trimethylpyridine (0.119 mmol).
6-[2-(2,2-Difluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl]-2,2-dimethyl-3-be-
nzofuran-5-amine (38 mg, 0.11 mmol) was then introduced and the
reaction mixture was warmed to room temperature. After 16 h, the
mixture was filtered through a plug of silica and concentrated in
vacuo. The residue was purified by reverse phase HPLC to afford the
title compound (23 mg, 0.047 mmol, 44% yield). .sup.1H NMR (400
MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.46 (s, 1H), 9.35 (dd,
J=7.0, 1.6 Hz, 1H), 8.74 (dd, J=4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.32 (d, J=1.0 Hz, 1H), 7.32 (dd, J=7.0, 4.2 Hz, 1H), 6.65 (s, 1H),
5.95 (tt, J=55.9, 4.2 Hz, 1H), 3.15 (s, 4H), 2.99 (s, 2H), 2.84
(td, J=16.1, 4.3 Hz, 2H), 2.75-2.63 (m, 4H), 1.92 (m, 4H), 1.40 (s,
6H). MS (ESI): m/z=497.2 [M+1].sup.+.
Example 249.
N-(2,2-dimethyl-6-(2-(2,2,2-trifluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl-
)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01280##
[1415] The title compound was made in a manner analogous to Example
248, replacing 2,2-difluoroethyl trifluoromethanesulfonate with
2,2,2-trifluoroethyl trifluoromethanesulfonate (Step C), to give
N-(2,2-dimethyl-6-(2-(2,2,2-trifluoroethyl)-2,7-diazaspiro[3.5]nonan-7-yl-
)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
(26 mg, 62% yield) as an orange crystalline solid. .sup.1H NMR (400
MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.46 (s, 1H), 9.35 (dd,
J=7.0, 1.6 Hz, 1H), 8.75 (dd, J=4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.32 (d, J=0.9 Hz, 1H), 7.32 (dd, J=7.0, 4.2 Hz, 1H), 6.65 (s, 1H),
3.26-3.16 (m, 6H), 2.99 (s, 2H), 2.77-2.63 (m, 4H), 1.98-1.88 (m,
4H), 1.40 (s, 6H). MS (ESI): m/z=515.2 [M+1].sup.+.
Example 250.
N-[2-(2-Hydroxy-1,1-dimethyl-ethyl)-6-morpholino-1-oxo-isoindolin-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide
##STR01281##
[1416] Step 1: Ethyl 5-fluoro-2-methyl-4-nitro-benzoate
##STR01282##
[1418] To a solution of 1-bromo-5-fluoro-2-methyl-4-nitrobenzene
(5.0 g, 21.36 mmol) and triethylamine (50 ml, 360.71 mmol) in
ethanol (100 ml) was added bis(triphenylphosphine) palladium(II)
dichloride (1.5 g, 2.14 mmol). The reaction was stirred at
70.degree. C. for 16 h under carbon monoxide (50 psi). The reaction
was filtered through celite and the filtrate was concentrated to
dryness. The residue was purified by flash column chromatography
(eluent 10% ethyl acetate: petroleum ether) to give ethyl
5-fluoro-2-methyl-4-nitro-benzoate (2.0 g, 41% yield) as a yellow
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.92 (d, J=7.2 Hz,
1H), 7.82 (d, J=11.6 Hz, 1H), 4.42 (q, J=7.2 Hz, 2H), 2.63 (s, 3H),
1.42 (t, J=7.2 Hz, 3H).
Step 2: Ethyl 2-(bromomethyl)-5-fluoro-4-nitro-benzoate
##STR01283##
[1420] To a solution of ethyl 5-fluoro-2-methyl-4-nitro-benzoate
(200 mg, 0.88 mmol) in carbon tetrachloride (5 ml) was added
benzoyl peroxide (43 mg, 0.18 mmol) and N-bromosuccinimide (313 mg,
1.76 mmol). The mixture was stirred at 100.degree. C. for 16 h
under nitrogen. The reaction was concentrated to dryness and the
crude reaction was purified by flash column chromatography (eluent
20% ethyl acetate: petroleum ether) to afford ethyl
2-(bromomethyl)-5-fluoro-4-nitro-benzoate (110 mg, 41% yield) as a
yellow oil. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.18 (d, J=6.4
Hz, 1H), 7.90 (d, J=10.8 Hz, 1H), 4.92 (s, 2H), 4.50 (q, J=7.2 Hz,
2H), 1.49 (t, J=7.2 Hz, 3H).
Step 3:
6-Fluoro-2-(2-hydroxy-1,1-dimethyl-ethyl)-5-nitro-isoindolin-1-one
##STR01284##
[1422] To a solution of ethyl
2-(bromomethyl)-5-fluoro-4-nitro-benzoate (110 mg, 0.36 mmol) in
methanol (3 ml) was added 2-amino-2-methyl-1-propanol (64 mg, 0.72
mmol) and triethylamine (73 mg, 0.72 mmol). The mixture was stirred
at 70.degree. C. for 6 h. The mixture was concentrated and purified
by preparatory TLC (50% ethyl acetate in petroleum ether) to afford
6-fluoro-2-(2-hydroxy-1,1-dimethyl-ethyl)-5-nitro-isoindolin-1-one
(60 mg, 62% yield) as a yellow solid. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 8.12 (d, J=6.4 Hz, 1H), 7.70 (d, J=9.2 Hz, 1H),
4.58 (s, 2H), 4.17 (t, J=6.8 Hz, 1H), 3.94 (d, J=6.8 Hz, 2H), 1.49
(s, 6H).
Step 4:
2-(2-Hydroxy-1,1-dimethyl-ethyl)-6-morpholino-5-nitro-isoindolin-1-
-one
##STR01285##
[1424] To a solution of
6-fluoro-2-(2-hydroxy-1,1-dimethyl-ethyl)-5-nitro-isoindolin-1-one
(240 mg, 0.89 mmol) in dimethyl sulfoxide (4 ml) was added
morpholine (156 mg, 1.79 mmol) and N,N-diisopropylethylamine (231
mg, 1.79 mmol). The mixture was stirred at 90.degree. C. for 3 h.
The mixture was concentrated and purified by preparatory TLC (50%
ethyl acetate in petroleum ether) to afford
2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-5-nitro-isoindolin-1-
-one (245 mg, 82% yield) as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.77 (s, 1H), 7.60 (s, 1H), 4.59 (t, J=6.8 Hz,
1H), 4.51 (s, 2H), 3.91 (d, J=6.8 Hz, 2H), 3.87 (t, J=4.4 Hz, 4H),
3.10 (t, J=4.4 Hz, 4H), 1.47 (s, 6H). LCMS (ESI): m/z=336.1
[M+H].sup.+.
Step 5:
5-Amino-2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-isoindolin-1-
-one
##STR01286##
[1426] To a solution of
2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-5-nitro-isoindolin-1-one
(245 mg, 0.73 mmol) in ethanol (5 ml) and water (1 ml) was added
iron (204 mg, 3.65 mmol) and ammonium chloride (195 mg, 3.65 mmol).
The reaction was stirred at 80.degree. C. for 2 h. The reaction was
filtered and the filtrate was concentrated. The crude material was
diluted with water (10 ml) and extracted with ethyl acetate (20
ml.times.3). The combined organic phases were washed with brine (20
ml), dried over sodium sulfate and concentrated to give
5-amino-2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-isoindolin-1-one
(210 mg, 94% yield) as a pale yellow solid.
[1427] LCMS (ESI): m/z=305.9 [M+H].sup.+.
Step 6:
N-[2-(2-Hydroxy-1,1-dimethyl-ethyl)-6-morpholino-1-oxo-isoindolin--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01287##
[1429] To a solution of
5-amino-2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-isoindolin-1-one
(210 mg, 0.69 mmol), N,N-diisopropylethylamine (267 mg, 2.06 mmol)
and 4-dimethyl aminopyridine (17 mg, 0.14 mmol) in
1,2-dichloroethane (8 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (200 mg, 1.10 mmol).
The reaction mixture was stirred at 35.degree. C. for 16 h. The
reaction was concentrated and purified by reverse phase HPLC
(20-50% acetonitrile in water with 0.05% ammonia hydroxide) to give
N-[2-(2-hydroxy-1,1-dimethyl-ethyl)-6-morpholino-1-oxo-isoindolin-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (60.8 mg, 19% yield) as pale
yellow solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.89 (s, 1H), 9.41 (d, J=5.6 Hz, 1H), 9.00 (d, J=2.8 Hz,
1H), 8.76 (s, 1H), 8.70 (s, 1H), 7.50 (s, 1H), 7.40 (dd, J=7.2, 4.0
Hz, 1H), 4.95 (t, J=5.6 Hz, 1H), 4.57 (s, 2H), 3.92-3.86 (m, 4H),
3.69 (d, J=6.0 Hz, 2H), 2.92-2.85 (m, 4H), 1.43 (s, 6H). LCMS
(ESI): m/z=451.1 [M+H].sup.+.
TABLE-US-00008 TABLE 8 The following examples were made in a manner
similar to that for Example 250. Ex. Name Structure NMR, MS 251
N-[6-Morpholino-2-(oxetan- 3-yl)-1-oxo-isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01288## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.92 (s, 1H), 9.41
(d, J = 6.4 Hz, 1H), 8.99 (s, 1H), 8.81-8.72 (m, 2H), 7.59 (s, 1H),
7.39 (m, 1H), 5.41 (t, J = 6.8 Hz, 1H), 4.92-4.84 (m, 2H),
4.83-4.73 (m, 4H), 3.95-3.85 (m, 4H), 2.96-2.86 (m, 4H). LCMS
(ESI): m/z = 435.2 [M + H].sup.+. 252 N-[6-Morpholino-2-[2-
(oxetan-3-yl)ethyl]-1-oxo- isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01289## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.93 (s, 1H), 8.81-8.82 (m, 4H), 7.72 (s, 1H),
7.17-7.09 (m, 1H), 4.82 (t, J = 6.8 Hz, 2H), 4.43 (t, J = 6.4 Hz,
2H), 4.37 (s, 2H), 4.08-4.96 (m, 4H), 3.58 (t, J = 7.2 Hz, 2H),
3.18-2.91 (m, 5H), 2.13-2.03 (m, 2H). LCMS (ESI): m/z = 463.1 [M +
H].sup.+. 253 N-(2-(Cyanomethyl)-6- morpholino-1- oxoisoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01290## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6):.delta. 10.92 (s, 1H),
9.42-9.40 (m, 1H), 9.00-8.99 (m, 1H), 8.80 (s, 1H), 8.76 (s, 1H),
7.64 (s, 1H), 7.40-7.38 (m, 1H), 4.71 (s, 2H), 4.57 (s, 2H), 3.90
(t, J = 4.4 Hz, 4H), 2.92 (t, J = 4.4 Hz, 4H). LCMS (ESI): m/z =
417.9 [M + H].sup.+. 254 N-(6-Morpholino-1-oxo-2-
tetrahydrofuran-3-yl- isoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01291## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.92 (s, 1H), 8.87-8.81 (m, 4H), 7.72 (s, 1H),
7.11 (dd, J = 6.8, 4.0 Hz, 1H), 5.15 (d, J = 4.0 Hz, 1H), 4.49-4.37
(m, 2H), 4.16-4.12 (m, 1H), 4.00 (s, 4H), 3.89-3.83 (m, 3H), 2.99
(s, 4H), 2.43-2.34 (m, 1H), 2.04-2.02 (m, 1H). LCMS (ESI): m/z =
448.9 [M + H].sup.+. 255 N-(6-Morpholino-1-oxo-2-
tetrahydropyran-4-yl- isoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01292## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.93 (s, 1H), 8.88-8.83 (m, 4H), 7.74 (s, 1H),
7.13 (dd, J = 6.4, 4.0 Hz, 1H), 4.55-4.46 (m, 1H), 4.38 (s, 2H),
4.15-4.05 (m, 2H), 4.06-3.96 (m, 4H), 3.59 (t, J = 11.2 Hz, 2H),
3.05-2.95 (m, 4H), 1.94-1.77 (m, 4H). LCMS (ESI): m/z = 463.0 [M +
H].sup.+. 256 N-(6-Methyl-2-morpholino- 7-oxo-6,7-dihydro-5H-
pyrrolo[3,4-b]pyridin-3- yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01293## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.92 (s, 1H), 8.88-8.82 (m, 4H), 7.72 (s, 1H),
7.12 (dd, J = 6.8, 4.0 Hz, 1H), 4.40 (s, 2H), 4.02 (t, J = 4.4 Hz,
4H), 3.71-3.67 (m, 2H), 3.25 (s, 3H), 3.01 (t, J = 4.4 Hz, 4H),
1.87-1.83 (m, 4H), 1.25 (s, 6H). LCMS (ESI): m/z = 479.2 [M +
H].sup.+. 257 N-[6-Morpholino-1-oxo-2- (tetrahydropyran-2-
ylmethyl)isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR01294## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.92 (s,
1H), 8.88-8.82 (m, 4H), 7.74 (s, 1H), 7.14 (dd, J = 6.8, 4.0 Hz,
1H), 4.66-4.47 (m, 2H), 4.01-3.97 (m, 5H), 3.81-3.39 (m, 4H),
3.00-2.99 (m, 4H), 1.86-1.67 (m, 2H), 1.55-1.49 (m, 3H), 1.37-1.31
(m, 1H). LCMS (ESI): m/z = 477.3 [M + H].sup.+. 258 N-[6-[4-(2,2-
Difluoroethyl)piperazin-1- yl]-2-[(2R)-2-fluoro-3-
hydroxy-3-methyl-butyl]-1- oxo-isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01295## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.82 (s, 1H), 8.90-8.75 (m, 4H), 7.73 (s, 1H),
7.14 (s, 1H), 6.14-5.83 (m, 1H), 4.65-4.42 (m, 3H), 4.28-4.10 (m,
1H), 3.75-3.60 (m, 1H), 3.12-2.84 (m, 9H), 2.48-2.40 (m, 1H), 1.34
(s, 6H). LCMS (ESI): m/z = 546.2 [M + H]+. 259 and 260
N-[2-[(2R)-2-Fluoro-3- hydroxy-3-methyl-butyl]-1-
oxo-6-[4-[(1S)-2,2,2- trifluoro-1-hydroxy-ethyl]-
1-piperidyl]isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide and ##STR01296## Example 259, Peak 1:
.sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.95
(s, 1H), 9.39 (d, J = 6.8 Hz, 1H), 9.06 (d, J = 3.6 Hz, 1H), 8.79
(s, 1H), 8.74 (s, 1H), 7.58 (s, 1H), 7.37 (dd, J = 6.8, 4.0 Hz,
1H), 6.43 (s, 1H), 4.89 (s, 1H), 4.59-4.35 (m, 3H), 4.05-3.85 (m,
2H), 3.73-3.65 (m, 1H), 3.08-2.96 (m, 2H), 2.88-2.73 (m, 2H),
2.03-1.69 (m, 5H), 1.25-1.10 (m, 6H). LCMS (ESI): m/z = 579.1 [M +
H].sup.+. N-[2-[(2R)-2-fluoro-3- hydroxy-3-methyl-butyl]-1-
oxo-6-[4-[(1R)-2,2,2- trifluoro-1-hydroxy-ethyl]-
1-piperidyl]isoindolin-5- yl]pyrazolo[1,5-
c]pyrimidine-3-carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01297## Example 260, Peak 2: .sup.1H NMR (400
MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.95 (s, 1H), 9.39 (d, J
= 6.8 Hz, 1H), 9.06 (d, J = 3.6 Hz, 1H), 8.79 (s, 1H), 8.74 (s,
1H), 7.59 (s, 1H), 7.37 (dd, J = 6.8, 4.4 Hz, 1H), 6.43 (s, 1H),
4.89 (s, 1H), 4.61-4.31 (m, 3H), 4.05-3.83 (m, 2H), 3.73-3.65 (m,
1H), 3.08-2.96 (m, 2H), 2.88-2.73 (m, 2H), 2.03-1.69 (m, 5H),
1.25-1.10 (m, 6H). LCMS (ESI): m/z = 579.1 [M + H].sup.+. 261
N-[6-(3,3- Difluoropyrrolidin-1-yl)-2- [(2R)-2-fluoro-3-hydroxy-3-
methyl-butyl]-1-oxo- isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01298## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.77 (s, 1H), 9.40 (dd, J = 7.0,
1.6 Hz, 1H), 8.84 (dd, J = 4.3, 1.6 Hz, 1H), 8.75 (s, 1H), 8.74 (s,
1H), 7.65 (s, 1H), 7.38 (dd, J = 7.0, 4.2 Hz, 1H), 4.90 (s, 1H),
4.61-4.34 (m, 3H), 3.94 (ddd, J = 38.5, 15.0, 1.9 Hz, 1H),
3.78-3.66 (m, 1H), 3.61 (t, J = 12.9 Hz, 2H), 2.59 (dq, J = 15.3,
8.0, 7.4 Hz, 2H), 1.18 (dd, J = 4.4, 1.6 Hz, 6H). LCMS (ESI): m/z =
503.2 [M + H]+. 262 N-[2-[(3- Hydroxycyclobutyl)methyl]-
6-morpholino-1-oxo- isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01299## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.89 (s, 1H), 9.41 (dd, J = 7.0,
1.6 Hz, 1H), 9.00 (dd, J = 4.3, 1.6 Hz, 1H), 8.75 (d, J = 4.6 Hz,
2H), 7.57 (s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H), 4.99 (d, J = 6.1
Hz, 1H), 4.44 (s, 2H), 4.33-4.21 (m, 1H), 3.95-3.85 (m, 4H), 3.55
(d, J = 8.0 Hz, 2H), 2.95-2.87 (m, 4H), 2.08-1.87 (m, 4H). LCMS
(ESI): m/z = 463.2 [M + H]+. 263 N-[6-[4-(Hydroxymethyl)-1-
piperidyl]-1-oxo-2-(2,2,2- trifluoroethyl)isoindolin-5-
yl]pyrazolo[1,5-a]pyrazine- 3-carboxamide ##STR01300## .sup.1H NMR
(400 MHz, dimethyl sulfoxide-d6) .delta. 10.98 (s, 1H), 9.40 (dd, J
= 7.0, 1.6 Hz, 1H), 8.96 (dd, J = 4.2, 1.6 Hz, 1H), 8.81 (s, 1H),
8.76 (s, 1H), 7.64 (s, 1H), 7.38 (dd, J = 7.0, 4.2 Hz, 1H), 4.60
(s, 3H), 4.36 (q, J = 9.7 Hz, 2H), 3.44 (t, J = 5.3 Hz, 2H), 3.01
(d, J = 11.3 Hz, 2H), 2.77 (dd, J = 12.1, 9.9 Hz, 2H), 1.83-1.73
(m, 2H), 1.66 (m, 3H). LCMS (ESI): m/z = 489.1 [M + H]+. 264
N-[2-[(2R)-2-Fluoro-3- hydroxy-3-methyl-butyl]-6- morpholino-1-oxo-
isoindolin-5-yl]-6-methyl- pyrazolo[1,5-a]pyrimidine- 3-carboxamide
##STR01301## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
10.84 (s, 1H), 9.27 (dd, J = 2.1, 1.1 Hz, 1H), 8.92 (d, J = 2.0 Hz,
1H), 8.76 (s, 1H), 8.67 (s, 1H), 7.58 (s, 1H), 4.90 (s, 1H),
4.63-4.35 (m, 3H), 3.91 (dd, J = 5.8, 3.2 Hz, 5H), 3.70 (td, J =
15.6, 9.4 Hz, 1H), 2.97-2.85 (m, 4H), 2.46 (d, J = 1.1 Hz, 3H),
1.22-1.13. LCMS (ESI): m/z = 497.2 [M + H]+. (m, 6H). 265
N-[6-[4-(2-Amino-2-oxo- ethyl)piperazin-1-yl]-1-oxo- 2-(2,2,2-
trifluoroethyl)isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01302## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.92 (s, 1H), 9.44-9.33 (m, 1H),
9.04 (dd, J = 4.3, 1.6 Hz, 1H), 8.82 (s, 1H), 8.76 (s, 1H), 7.64
(s, 1H), 7.40 (dd, J = 7.0, 4.2 Hz, 1H), 7.24 (d, J = 43.2 Hz, 2H),
4.61 (s, 2H), 4.37 (q, J = 9.6 Hz, 2H), 3.06 (s, 2H), 2.96 (t, J =
4.7 Hz, 4H), 2.80 (t, J = 4.4 Hz, 4H). LCMS (ESI): m/z = 517.1 [M +
H]+. 266 N-[6-[4-(2,2- Difluoroethyl)piperazin-1-
yl]-1-oxo-2-(2,2,2- trifluoroethyl)isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01303## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.86 (s, 1H), 9.41 (dd, J = 7.0,
1.6 Hz, 1H), 9.01 (dd, J = 4.2, 1.6 Hz, 1H), 8.80 (s, 1H), 8.76 (s,
1H), 7.62 (s, 1H), 7.40 (dd, J = 7.0, 4.2 Hz, 1H), 6.22 (t, J = 4.4
Hz, 1H), 4.60 (s, 2H), 4.37 (q, J = 9.6 Hz, 2H), 2.99-2.81 (m,
10H). LCMS (ESI): m/z = 524.1 [M + H]+. 267 N-[2-(3-hydroxy-2,2-
Dimethyl-propyl)-6- morpholino-1-oxo- isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01304## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.90 (s, 1H), 9.41
(ddd, J = 7.0, 1.7, 0.8 Hz, 1H), 9.00 (dt, J = 4.2, 1.1 Hz, 1H),
8.79-8.71 (m, 2H), 7.59 (s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H),
4.75 (t, J = 5.8 Hz, 1H), 4.57 (s, 2H), 3.90 (t, J = 4.4 Hz, 4H),
3.36 (tdd, J = 2.5, 1.6, 0.9 Hz, 2H), 3.16 (d, J = 5.8 Hz, 2H),
2.96-2.87 (m, 4H). LCMS (ESI): m/z = 465.2 [M + H]+. 268 N-[2-[[3-
(Hydroxymethyl)oxetan-3- yl]methyl]-6-morpholino-1-
oxo-isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR01305## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
10.91 (s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.3,
1.6 Hz, 1H), 8.75 (d, J = 5.8 Hz, 2H), 7.59 (s, 1H), 7.39 (dd, J =
7.0, 4.2 Hz, 1H), 4.94 (t, J = 5.3 Hz, 1H), 4.52 (s, 2H), 4.49 (d,
J = 6.0 Hz, 2H), 4.35 (d, J = 6.0 Hz, 2H), 3.90 (t, J = 4.5 Hz,
4H), 3.80 (s, 2H), 3.57 (d, J = 5.3 Hz, 2H), 2.95-2.88 (m, 4H).
LCMS (ESI): m/z = 479.2 [M + H]+. 269 6-Bromo-N-[2-[(2R)-2-
fluoro-3-hydroxy-3-methyl- butyl]-6-morpholino-1-oxo- isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01306## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.69 (s, 1H), 9.91
(d, J = 2.0 Hz, 1H), 9.06 (d, J = 2.1 Hz, 1H), 8.75 (s, 1H), 8.73
(s, 1H), 7.59 (s, 1H), 4.90 (s, 1H), 4.62-4.51 (m, 2H), 4.51-4.34
(m, 1H), 3.88 (m, 5H), 3.70 (m, 1H), 2.91 (m, 4H), 1.18 (dd, J =
4.6, 1.6 Hz, 6H). LCMS (ESI): m/z = 561.1 [M + H]+. 270
N-[2-(2,2-Difluoro-3- hydroxy-3-methyl-butyl)-6- morpholino-1-oxo-
isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR01307## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
10.91 (s, 1H), 9.41 (dt, J = 7.0, 1.2 Hz, 1H), 9.00 (dd, J = 4.3,
1.6 Hz, 1H), 8.77 (d, J = 6.8 Hz, 2H), 7.62 (s, 1H), 7.39 (dd, J =
7.0, 4.2 Hz, 1H), 5.43 (s, 1H), 4.59 (s, 2H), 4.12 (t, J = 17.0 Hz,
2H), 3.95-3.85 (m, 4H), 2.93 (m, 4H), 1.25 (s, 6H). LCMS (ESI): m/z
= 501.2 [M + H]+. 271 6-Chloro-N-[2-[(2R)-2-
fluoro-3-hydroxy-3-methyl- butyl]-6-morpholino-1-oxo- isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01308## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.70 (s, 1H), 9.86
(d, J = 2.3 Hz, 1H), 9.05 (d, J = 2.2 Hz, 1H), 8.78 (s, 1H), 8.73
(s, 1H), 7.59 (s, 1H), 4.90 (s, 1H), 4.58-4.35 (m, 3H), 3.93-3.84
(m, 5H), 3.70 (m, 1H), 2.95-2.88 (m, 4H), 1.18 (dd, J = 4.4, 1.6
Hz, 6H). LCMS (ESI): m/z = 517.1 [M + H]+. 272
N-[6-[4-(2-Amino-2-oxo- ethyl)piperazin-1-yl]-2-
isopropyl-1-oxo-isoindolin- 5-yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01309## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.89 (s, 1H), 9.43-9.35 (m, 1H),
9.03 (dd, J = 4.3, 1.6 Hz, 1H), 8.78 (s, 1H), 8.75 (s, 1H), 7.56
(s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H), 7.30 (s, 1H), 7.18 (s,
1H), 4.48-4.35 (m, 3H), 3.06 (s, 2H), 2.98-2.90 (m, 4H), 2.85-2.80
(m, 4H), 1.23 (d, J = 6.7 Hz, 6H). LCMS (ESI): m/z = 477.2 [M +
H]+. 273 N-[2-(2,2-Difluoro-3- hydroxy-propyl)-6- morpholino-1-oxo-
isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR01310## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
10.92 (s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.2,
1.6 Hz, 1H), 8.77 (d, J = 6.5 Hz, 2H), 7.63 (s, 1H), 7.39 (dd, J =
7.0, 4.2 Hz, 1H), 5.61 (t, J = 6.2 Hz, 1H), 4.59 (s, 2H), 4.02 (t,
J = 15.5 Hz, 2H), 3.92-3.88 (m, 4H), 3.68 (td, J = 13.6, 6.3 Hz,
2H), 2.97-2.88 (m, 4H). LCMS (ESI): m/z = 473.1 [M + H]+. 274
(R)-N-(6-(4-cyanopiperidin- 1-yl)-2-(2-fluoro-3-hydroxy-
3-methylbutyl)-1- oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01311## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.86 (s, 1H), 9.43 (dd, J = 7.0,
1.6 Hz, 1H), 8.91 (dd, J = 4.2, 1.6 Hz, 1H), 8.77 (d, J = 1.7 Hz,
2H), 7.56 (s, 1H), 7.44 (dd, J = 7.0, 4.2 Hz, 1H), 4.90 (s, 1H),
4.63-4.46 (m, 2H), 4.50-4.39 (m, 2H), 3.99 (m, 1H), 3.70 (m, 1H),
3.16 (s, 1H), 3.04-2.94 (m, 2H), 2.90 (m, 2H), 2.17 (m, 2H), 2.07
(m, 2H), 1.22-1.13 (m, 6H). LCMS (ESI) m/z:506.2 [M + H]+. 275 and
276 N-(6-morpholino-1-oxo-2- (tetrahydrofuran-3- yl)isoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01312## Example 276,
Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide- d6) .delta. 10.90
(s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.2, 1.6 Hz,
1H), 8.76 (s, 2H), 7.58 (s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H),
4.90 (m, 1H), 4.50 (s, 2H), 3.99 (m, 1H), 3.94-3.85 (m, 4H),
3.87-3.66 (m, 3H), 2.96-2.87 (m, 4H), 2.24 (m, 1H), 2.14-1.92 (m,
1H).MS (ESI): m/z = 449.2 [M + 1].sup.+. ##STR01313## Example 275,
Peak 2: .sup.1H NMR (400 MHz, dimethyl sulfoxide- d6) .delta. 10.90
(s, 1H), 9.41 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.2, 1.6 Hz,
1H), 8.76 (s, 2H), 7.58 (s, 1H), 7.39 (dd, J = 7.0, 4.2 Hz, 1H),
4.90 (m, 1H), 4.50 (s, 2H), 3.99 (m, 1H), 3.94-3.86 (m, 4H),
3.84-3.67 (m, 3H), 2.96-2.85 (m, 4H), 2.30-2.17 (m, 1H), 2.11-1.95
(m, 1H). MS (ESI): m/z = 449.2 [M + 1].sup.+. 277 and 278
N-(6-morpholino-1-oxo-2- ((tetrahydro-2H-pyran-2-
yl)methyl)isoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3-carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01314##
Example 278, Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide-
d.sub.6) .delta. 10.88 (s, 1H), 9.40 (dd, J = 7.0, 1.6 Hz, 1H),
8.99 (dd, J = 4.2, 1.6 Hz, 1H), 8.75 (s, 1H), 8.73 (s, 1H), 7.57
(s, 1H), 7.38 (dd, J = 7.0, 4.2 Hz, 1H), 4.52 (s, 2H), 3.97-3.80
(m, 5H), 3.61-3.45 (m, 3H), 3.35 (m, 1H), 2.97-2.84 (m, 4H),
1.84-1.71 (m, 1H), 1.57 (m, 1H), 1.45 (m, 3H), 1.20 (m, 1H). MS
(ESI): m/z = 477.2 [M + l].sup.+. ##STR01315## Example 277, Peak 2:
.sup.1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.89
(s, 1H), 9.40 (dd, J = 7.0, 1.6 Hz, 1H), 9.00 (dd, J = 4.2, 1.6 Hz,
1H), 8.75 (s, 1H), 8.73 (s, 1H), 7.57 (s, 1H), 7.39 (dd, J = 7.0,
4.2 Hz, 1H), 4.52 (s, 2H), 3.97-3.81 (m, 5H), 3.62-3.47 (m, 3H),
3.35 (m, 1H), 2.97-2.82 (m, 4H), 1.77 (m, 1H), 1.63-1.52 (m, 1H),
1.52-1.38 (m, 3H), 1.28-1.10 (m, 1H). MS (ESI): m/z = 477.2 [M +
1].sup.+.
279 N-[6-[4-(2,2- Difluoroethyl)piperazin-1-
yl]-2-(3-hydroxy-3-methyl- butyl)-1-oxo-isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01316## .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 10.82 (s, 1H), 8.88-8.86 (m, 1H),
8.83-8.82 (m, 2H), 8.80-8.78 (m, 1H), 7.71 (s, 1H), 7.13 (dd, J =
6.8, 4.0 Hz, 1H), 6.12-5.83 (m, 1H), 4.41 (s, 2H), 3.78 (t, J = 7.2
Hz, 2H), 3.03-3.01 (m, 4H), 2.93-2.87 (m, 6H), 1.84 (t, J = 7.2 Hz,
2H), 1.30 (s, 6H). LCMS (ESI): m/z = 528.3 [M + H].sup.+. 280
N-[6-[4-(2-Amino-2-oxo- ethyl)piperazin-1-yl]-2-(3-
hydroxy-3-methyl-butyl)-1- oxo-isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01317## .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.87 (s, 1H), 9.39 (dd, J = 7.2, 2.0 Hz, 1H),
9.03-9.01 (m, 1H), 8.75 (s, 1H), 8.74 (s, 1H), 7.54 (s, 1H), 7.39
(dd, J = 7.2, 4.4 Hz, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 4.45 (s,
2H), 4.35 (s, 1H), 3.58 (t, J = 8.0 Hz, 2H), 3.05 (s, 2H),
2.99-2.89 (m, 4H), 2.84-2.74 (m, 4H), 1.68 (t, J = 8.0 Hz, 2H),
1.15 (s, 6H). LCMS (ESI): m/z = 521.3 [M + H].sup.+. 281
N-[6-[4-(2-Amino-2-oxo- ethyl)piperazin-1-yl]-2-(1-
methyl-4-piperidyl)-1-oxo- isoindolin-5- yl]pyrazolo[1,5-
a]pyrimidine-3-carboxamide ##STR01318## .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 10.89 (s, 1H), 9.40 (d, J = 7.2 Hz, 1H), 9.05-9.00
(m, 1H), 8.78 (s, 1H), 8.75 (s, 1H), 7.56 (s, 1H), 7.39 (dd, J =
7.2, 4.0 Hz, 1H), 7.31 (s, 1H), 7.21 (s, 1H), 4.44 (s, 2H),
3.99-3.90 (m, 1H), 3.06 (s, 2H), 2.96-2.92 (m, 2H), 2.90-2.82 (m,
2H), 2.81-2.75 (m, 2H), 2.69-2.65 (m, 2H), 2.34-2.31 (m, 2H), 2.19
(s, 3H), 2.02-1.95 (m, 2H), 1.85-1.75 (m, 2H), 1.70-1.65 (m, 2H).
LCMS (ESI): m/z = 532.3 [M + H].sup.+. 282 and 283
N-[6-[4-[(1S)-2,2-Difluoro- 1-hydroxy-ethyl]-1-
piperidyl]-2-[(2R)-2-fluoro- 3-hydroxy-3-methyl-butyl]-
1-oxo-isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide and
##STR01319## Example 282, Peak 1: .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.97 (s, 1H), 9.40-9.35 (m, 1H), 9.10-9.05
(m, 1H), 8.78 (s, 1H), 8.74 (s, 1H), 7.58 (s, 1H), 7.36 (dd, J =
6.8, 4.4 Hz, 1H), 6.00 (td, J = 55.6, 4.4 Hz, 1H), 4.91 (br s, 1H),
4.65-4.29 (m, 3H), 4.04-3.55 (m, 3H), 3.07-2.95 (m, 2H), 2.86-2.70
(m, 2H), 2.04-1.86 (m, 2H), 1.84-1.63 (m, 3H), 1.18 (s, 3H), 1.17
(s, 3H). LCMS (ESI): m/z = 561.1 [M + H].sup.+.
N-[6-[4-[(1R)-2,2-difluoro- 1-hydroxy-ethyl]-1-
piperidyl]-2-[(2R)-2-fluoro- 3-hydroxy-3-methyl-butyl]-
1-oxo-isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01320##
Example 283, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.97 (s, 1H), 9.40-9.35 (m, 1H), 9.10-9.05 (m, 1H), 8.78 (s, 1H),
8.74 (s, 1H), 7.58 (s, 1H), 7.36 (dd, J = 6.8, 4.4 Hz, 1H), 6.00
(td, J = 55.6, 4.4 Hz, 1H), 4.93 (br s, 1H), 4.65-4.29 (m, 3H),
4.04-3.55 (m, 3H), 3.07-2.95 (m, 2H), 2.86-2.70 (m, 2H), 2.04-1.86
(m, 2H), 1.84-1.63 (m, 3H), 1.18 (s, 3H), 1.17 (s, 3H). LCMS (ESI):
m/z = 561.1 [M + H].sup.+. 284 N-[6-[4-(2,2-
Difluoroethyl)piperazin-1- yl]-2-[(2R)-2-fluoro-3-
hydroxy-3-methyl-butyl]-1- oxo-isoindolin-5-yl]-6-
methyl-pyrazolo[1,5- a]pyrimidine-3-carboxamide ##STR01321##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.75 (s, 1H), 9.27 (s,
1H), 8.88 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 8.66 (s, 1H), 7.55 (s,
1H), 6.38-6.08 (m, 1H), 4.91 (s, 1H), 4.54-4.37 (m, 3H), 4.00-3.87
(m, 1H), 3.74-3.64 (m, 1H), 2.98-2.86 (m, 10H), 2.46 (s, 3H), 1.18
(s, 3H), 1.17 (s, 3H). LCMS (ESI): m/z = 560.1 [M + H].sup.+. 285
6-Chloro-N-[6-[4-(2,2- difluoroethyl)piperazin-1-
yl]-2-[(2R)-2-fluoro-3- hydroxy-3-methyl-butyl]-1-
oxo-isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide
##STR01322## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.61 (s,
1H), 9.87 (d, J = 2.0 Hz, 1H), 9.01 (d, J = 2.4 Hz, 1H), 8.78 (s,
1H), 8.71 (s, 1H), 7.56 (s, 1H), 6.37-6.09 (m, 1H), 4.91 (s, 1H),
4.54-4.52 (m, 2H), 4.39-4.32 (m, 1H), 4.00-3.86 (m, 1H), 3.75-3.65
(m, 1H), 2.94-2.85 (m, 10H), 1.18 (s, 3H), 1.17 (s, 3H). LCMS
(ESI): m/z = 580.1 [M + H].sup.+.
Example 286.
N3-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide
##STR01323##
[1431] A solution of
6-bromo-N-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo--
isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example
269; 80 mg, 0.14 mmol), tris(dibenzylideneacetone)dipalladium(0)
(13.5 mg, 0.014 mmol), 1,1'-bis(diphenylphosphino)ferrocene (16.0
mg, 0.029 mmol) and zinc cyanide (37 mg, 0.31 mmol) in
N,N-dimethylformamide (1.5 ml) was purged with nitrogen and stirred
at 120.degree. C. for 30 min. The reaction was quenched with water
and extracted with ethyl acetate. The organic phase was isolated,
dried with sodium sulfate, filtered, concentrated and purified by
silica gel chromatography (eluting gradient 0%-20%
methanol:dichloromethane) followed by reverse-phase HPLC to afford
N3-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide (2.6 mg, 4%).
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 11.00 (s, 1H),
10.09 (s 1H), 8.96 (1H), 8.76 (s, 1H), 8.71 (s, 1H), 4.90 (s, 1H),
4.61-4.46 (m, 3H), 4.34-4.40 (m, 1H), 4.04-3.86 (m, 5H), 2.96-2.89
(m, 4H), 1.39-1.18 (m, 6H). LCMS (ESI) m/z: 526.2 [M+H]+.
Example 287.
N-(2-Isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide
##STR01324##
[1432] Step A. 5-Chloro-2-methyl-4-nitro-benzenesulfonyl
chloride
##STR01325##
[1434] To a chilled and well-stirred solution of acetic acid (1.84
ml, 32.15 mmol) and hydrochloric acid (10 ml, 120 mmol) was added
5-chloro-2-methyl-4-nitrophenylamine (6.0 g, 32.15 mmol) in small
portions at -5.degree. C., then sodium nitrite (2.9 g, 41.80 mmol)
in water (6 ml) was added drop-wise to the mixture and stirred for
3 h at -5.degree. C. to afford the solution of diazonium salt. In a
separate vessel, concentrated hydrochloric acid (10 ml) was added
drop-wise to sodium sulfite (18.7 g, 180.06 mmol) to afford sulfur
dioxide which was bubbled into acetic acid (10 ml) to afford the
solution of sulfur dioxide in acetic acid. Cuprous chloride (637
mg, 6.43 mmol) was added to the resulting solution. The solution of
diazonium salt was added drop-wise to the solution of sulfur
dioxide in acetic acid at -5.degree. C. After the addition, the
mixture was stirred at -5.degree. C. for further 3 h. Water (50 ml)
was added to the mixture which was extracted with dichloromethane
(150 ml.times.3). The combined organic phases were washed with
brine (150 ml.times.3), dried over anhydrous sodium sulfate,
filtered and concentrated. The crude material was purified by flash
column (eluent 0-10% ethyl acetate: petroleum ether) to afford
5-chloro-2-methyl-4-nitro-benzenesulfonyl chloride (4.5 g, 52%
yield) as yellow solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 7.92 (s, 1H), 7.90 (s, 1H), 2.57 (s,
3H).
Step B.
5-Chloro-N-isopropyl-2-methyl-4-nitro-benzenesulfonamide
##STR01326##
[1436] To a solution of 5-chloro-2-methyl-4-nitro-benzenesulfonyl
chloride (2.0 g, 7.4 mmol) and N,N-diisopropylethylamine (1.9 g,
14.8 mmol) in N,N-dimethylformamide (10 ml) was added
isopropylamine (525 mg, 8.88 mmol). The mixture was stirred at
20.degree. C. for 30 min, poured into water (50 ml) and extracted
with ethyl acetate (150 ml.times.3). The combined organic phases
were washed with brine (150 ml.times.3), dried over anhydrous
sodium sulfate and concentrated to dryness. The residual was
purified by flash column (eluting gradient 0-20% ethyl acetate:
petroleum ether) to afford
5-chloro-N-isopropyl-2-methyl-4-nitro-benzenesulfonamide (1.8 g,
83% yield) as yellow solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 8.18-8.15 (m, 2H), 8.06 (s, 1H),
3.34-3.31 (m, 1H), 2.67 (s, 3H), 0.99-0.98 (d, J=6.0 Hz, 6H).
Step C.
2-(Bromomethyl)-5-chloro-N-isopropyl-4-nitro-benzenesulfonamide
##STR01327##
[1438] To a solution of
5-chloro-N-isopropyl-2-methyl-4-nitro-benzenesulfonamide (350 mg,
1.20 mmol) in acetonitrile (10 ml) was added azobisisobutyronitrile
(20 mg, 0.12 mmol) and N-bromosuccinimide (234 mg, 1.32 mmol) under
nitrogen atmosphere. The mixture was stirred at 70.degree. C. for
16 h and then concentrated. The crude product was purified by flash
column (eluting gradient 0-20% ethyl acetate: petroleum ether) to
afford
2-(bromomethyl)-5-chloro-N-isopropyl-4-nitro-benzenesulfonamide (80
mg, 18% yield) as white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.23 (s, 1H), 8.05 (s, 1H), 4.97 (s, 2H), 3.63-3.50 (m,
1H), 1.18 (d, J=6.4 Hz, 6H).
Step D. 6-Chloro-2-isopropyl-5-nitro-3H-1,2-benzothiazole
1,1-dioxide
##STR01328##
[1440] To a solution of
2-(bromomethyl)-5-chloro-N-isopropyl-4-nitro-benzenesulfonamide
(240 mg, 0.64 mmol) in N,N-dimethylformamide (10 ml) were added
cesium carbonate (420 mg, 1.30 mmol) at 0.degree. C. The reaction
mixture was stirred at 25.degree. C. for 30 min. The reaction
mixture was poured into ice water (20 ml) and extracted with
dichloromethane (20 ml.times.3). The combined organic phases were
dried over anhydrous sodium sulfate, filtered and concentrated. The
crude material was purified by flash column (eluting gradient 0-10%
methanol: dichloromethane) to afford
6-chloro-2-isopropyl-5-nitro-3H-1,2-benzothiazole 1,1-dioxide (160
mg, 85% yield) as white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.97 (s, 1H), 7.88 (s, 1H), 4.43 (s, 2H), 4.18-4.09 (m,
1H), 1.41 (d, J=6.4 Hz, 6H).
Step E. 2-Isopropyl-6-morpholino-5-nitro-3H-1,2-benzothiazole
1,1-dioxide
##STR01329##
[1442] To a solution of
6-chloro-2-isopropyl-5-nitro-3H-1,2-benzothiazole 1,1-dioxide (160
mg, 0.56 mmol) in dimethyl sulfoxide (4 ml) was added
N,N-diisopropylethylamine (72 mg, 0.56 mmol) was added morpholine
(72 mg, 0.82 mmol). The mixture was stirred at 90.degree. C. for 1
h. The reaction mixture was concentrated and purified by
preparatory TLC (eluent: 20% ethyl acetate: petroleum ether) to
afford 2-isopropyl-6-morpholino-5-nitro-3H-1,2-benzothiazole
1,1-dioxide (160 mg, 85% yield) as white solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.75 (s, 1H), 7.53 (s, 1H), 4.36 (s, 2H),
4.10-4.07 (m, 1H), 3.86 (t, J=4.4 Hz, 4H), 3.10-3.08 (t, J=4.4 Hz,
4H), 1.40 (d, J=6.4 Hz, 6H).
Step F.
2-Isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine
##STR01330##
[1444] To a solution of
2-isopropyl-6-morpholino-5-nitro-3H-1,2-benzothiazole 1,1-dioxide
(160 mg, 0.46 mmol) in ethanol (5 ml) and water (1 ml) was added
iron (130 mg, 2.34 mmol) and ammonium chloride (63 mg, 1.17 mmol).
The mixture was stirred at 80.degree. C. for 2 h. The mixture was
filtered and the filtrate was concentrated. The residue was diluted
with water (20 ml) and extracted with ethyl acetate (20
ml.times.3). The combined organic phases were dried over anhydrous
sodium sulfate, filtered and concentrated to afford
2-isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine (140
mg) as a yellow solid, which was used without further purification.
LCMS (ESI): m/z=312.1 [M+H].sup.+.
Step G.
N-(2-Isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyr-
azolo[1,5-a]pyrimidine-3-carboxamide
##STR01331##
[1446] To a solution of
2-isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine (124
mg, 0.40 mmol) and pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (65
mg, 0.40 mmol) in pyridine (4 ml) was added phosphorus oxychloride
(0.18 ml, 1.99 mmol). The reaction was stirred at 25.degree. C. for
5 min. The reaction mixture was quenched with saturated sodium
bicarbonate solution (10 ml) at 0.degree. C. and extracted with
ethyl acetate (20 ml.times.3). The combined organic phases were
dried over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by reverse phase HPLC (23-53% acetonitrile in
water with 0.225% formic acid) to give
N-(2-isopropyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide (71.3 mg, 39% yield) as white solid.
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.91 (s,
1H), 9.42-9.40 (m, 1H), 9.01-9.00 (m, 1H), 8.76-8.74 (m, 2H), 7.78
(s, 1H), 7.41-7.38 (dd, J=7.2, 4.4 Hz, 1H), 4.45 (s, 2H), 3.90 (t,
J=6.4 Hz, 4H), 3.60-3.30 (m, 1H), 2.94-2.92 (m, 4H), 1.29 (d, J=6.8
Hz, 6H). LCMS (ESI): m/z=457.0 [M+H].sup.+.
Example 288.
N-[2-(2-Hydroxy-2-methyl-propyl)-6-morpholino-1,1-dioxo-3H-1,2-benzothiaz-
ol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01332##
[1448] The title compound was made in a manner analogous to Example
287 to give
N-[2-(2-hydroxy-2-methyl-propyl)-6-morpholino-1,1-dioxo-3H-1,2-benzo-
thiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (67 mg, 19%
yield) as a white solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.90 (s, 1H), 9.43-9.41 (m, 1H),
9.01-8.99 (m, 1H), 8.77-8.75 (m, 1H), 8.70-8.69 (m, 1H), 7.83 (s,
1H), 7.41-7.38 (m, 1H), 4.65 (s, 1H), 4.58 (s, 2H), 3.95-3.85 (m,
4H), 3.07 (s, 2H), 2.95-2.90 (m, 4H), 1.19 (s, 6H). LCMS (ESI):
m/z=487.1 [M+H].sup.+.
Example 289.
N-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1,1-dioxo-3H-1-
,2-benzothiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01333##
[1450] The title compound was made in a manner analogous to Example
287 to give
N-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1,1-dioxo-
-3H-1,2-benzothiazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.88
(s, 1H), 8.89-8.81 (m, 4H), 7.66 (s, 1H), 7.15 (dd, J=7.2, 4.4 Hz,
1H), 4.72-4.58 (m, 2H), 4.44-4.40 (m, 1H), 4.03 (t, J=4.4 Hz, 4H),
3.92-3.80 (m, 1H), 3.48-3.42 (m, 1H), 3.01 (t, J=4.4 Hz, 4H), 1.35
(s, 6H). LCMS (ESI): m/z=519.2 [M+H].sup.+.
Example 290. Diethyl
((2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-d-
ihydrobenzofuran-2-yl)methyl) phosphate
##STR01334##
[1452]
N-[2-(hydroxymethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide (142 mg, 0.35 mmol) was
dissolved in tetrahydrofuran (2.6 ml) and treated with
trimethylamine (0.07 ml, 0.52 mmol), diethyl chlorophosphate (0.06
ml, 0.38 mmol), and 4-dimethylaminopyridine (47 mg, 0.38 mmol).
Dichloromethane (2 ml) was added and the reaction mixture was
heated at 50.degree. C. Additional diethyl chlorophosphate (0.55
ml, 3.82 mmol) and trimethylamine (0.73 ml, 5.22 mmol) were added
and the reaction was allowed to stir at 50.degree. C. for 2 wk. The
reaction mixture was cooled to ambient temperature and diluted with
dichloromethane, water, and brine. The aqueous phase was isolated
and extracted into dichloromethane (3.times.). The combined organic
phases were dried over anhydrous sodium sulfate, filtered and
concentrated. The crude residue was purified via HPLC to afford the
title compound (29 mg, 0.053 mmol). .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.44 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz,
1H), 8.95 (dd, J=4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.33 (d, J=1.0 Hz,
1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.76 (s, 1H), 4.03 (d, J=5.7 Hz,
2H), 4.01-3.93 (m, 4H), 3.84 (m, 4H), 3.26-3.16 (m, 1H), 3.05-2.92
(m, 1H), 2.86-2.75 (m, 4H), 1.42 (s, 3H), 1.20 (tdd, J=7.1, 2.8,
0.9 Hz, 6H). MS (ESI): m/z=546.2 [M+1].sup.+.
Example 291.
(R)--N-(2,2-Dimethyl-6-(pyrrolidin-2-ylmethoxy)-2,3-dihydrobenzofuran-5-y-
l)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01335##
[1453] Step A. tert-Butyl
2-(((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)methyl)pyrrolidi-
ne-1-carboxylate
##STR01336##
[1455] A mixture of tert-butyl
(2R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (395 mg, 1.92
mmol), potassium tert-butoxide (249 mg, 2.20 mmol), and
6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran (250 mg, 1.10 mmol) in
dioxane (6.1 ml) was stirred at 40.degree. C. for 36 h. The
reaction mixture was diluted with water and isopropyl acetate. The
aqueous phase was isolated and extracted with isopropyl acetate
(3.times.). The combined organic phases were dried over anhydrous
sodium sulfate, filtered and purified by flash column
chromatography (eluting gradient 0-50% isopropyl acetate: heptanes)
to afford the title compound (196 mg, 0.498 mmol, 45% yield) as an
orange-yellow viscous oil. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 7.84 (s, 1H), 6.75 (s, 1H), 4.13 (d,
J=4.0 Hz, 2H), 4.08-3.94 (m, 2H), 3.27 (m, 2H), 3.00 (d, J=0.9 Hz,
2H), 2.02-1.85 (m, 2H), 1.76 (s, 1H), 1.45 (s, 6H), 1.39 (s,
9H).
Step B. tert-Butyl
(R)-2-(((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)methyl)pyrro-
lidine-1-carboxylate
##STR01337##
[1457] A mixture of tert-butyl
(R)-2-(((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)methyl)pyrro-
lidine-1-carboxylate (180 mg, 0.456 mmol), iron (535 mg, 9.58
mmol), and ammonium chloride (512 mg, 9.58 mmol) in ethanol (13 ml)
and water (2.5 ml) was stirred at 80.degree. C. for 30 min. The
mixture was filtered through celite and a small plug of silica to
afford tert-butyl
(R)-2-(((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)methyl)pyrro-
lidine-1-carboxylate (139 mg, 0.385 mmol) which was carried on
without further purification.
Step C. tert-Butyl
2-(((2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dihydro-
benzofuran-6-yl)oxy)methyl)pyrrolidine-1-carboxylate
##STR01338##
[1459] tert-Butyl
(R)-2-(((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)methyl)pyrro-
lidine-1-carboxylate (139 mg, 0.385 mmol),
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (105 mg, 0.578 mmol),
and dimethylaminopyridine (9.5 mg, 0.077 mmol) were dissolved in
dichloroethane (3 ml) and treated with N,N-diisopropylethylamine
(0.20 ml, 1.16 mmol) and stirred for 16 h at room temperature. The
reaction mixture was absorbed onto celite and purified via flash
column chromatography (eluting gradient 0-100% isopropyl acetate:
heptanes) to provide tert-butyl
(R)-2-(((2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-6-yl)oxy)methyl)pyrrolidine-1-carboxylate (130 mg,
0.257 mmol, 67% yield).
Step D.
(R)--N-(2,2-Dimethyl-6-(pyrrolidin-2-ylmethoxy)-2,3-dihydrobenzofu-
ran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01339##
[1461] tert-Butyl
(R)-2-(((2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-dih-
ydrobenzofuran-6-yl)oxy)methyl)pyrrolidine-1-carboxylate (130 mg,
0.256 mmol) was dissolved in dichloromethane (2 ml) and treated
with trifluoroacetic acid (0.25 ml). After 90 min, the solvent was
removed and the material was purified by reverse phase HPLC to
afford
(R)--N-(2,2-dimethyl-6-(pyrrolidin-2-ylmethoxy)-2,3-dihydrobenzofuran-5-y-
l)pyrazolo[1,5-a]pyrimidine-3-carboxamide (45 mg, 0.11 mmol).
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.12 (s,
1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.81 (dd, J=4.2, 1.7 Hz, 1H),
8.67 (s, 1H), 8.25 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.54 (s,
1H), 3.88 (d, J=6.4 Hz, 2H), 3.65-3.51 (m, 1H), 2.97 (s, 2H), 2.85
(t, J=6.7 Hz, 2H), 2.03-1.86 (m, 1H), 1.79-1.61 (m, 2H), 1.61-1.46
(m, 1H), 1.41 (s, 6H). MS (ESI): m/z=408.2 [M+1].sup.+
Example 292.
(R)--N-(6-((1-(2,2-Difluoroethyl)pyrrolidin-2-yl)methoxy)-2,2-dimethyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01340##
[1463]
(R)--N-(2,2-Dimethyl-6-(pyrrolidin-2-ylmethoxy)-2,3-dihydrobenzofur-
an-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 291, 52
mg, 0.128 mmol) was dissolved in dimethylformamide (2 ml) and
treated with triethylamine (0.45 ml, 3.20 mmol) followed by
2,2-difluoroethyl trifluoromethanesulfonate (0.021 ml, 0.154 mmol)
and heated at 60.degree. C. for 16 h. Additional triethylamine
(0.45 ml, 3.20 mmol) and 2,2-difluoroethyl
trifluoromethanesulfonate (0.021 ml, 0.154 mmol) were added and
continued to stir at 60.degree. C. for 4 h. The reaction mixture
was concentrated in vacuo and purified by reverse phase HPLC to
afford the title compound (24 mg, 0.05 mmol, 60% yield) as a solid.
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.02 (s,
1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.85 (dd, J=4.3, 1.6 Hz, 1H),
8.67 (s, 1H), 8.23 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.58 (s,
1H), 5.99 (tt, J=56.2, 4.4 Hz, 1H), 4.08 (dd, J=9.4, 5.1 Hz, 1H),
3.81 (dd, J=9.3, 7.2 Hz, 1H), 3.18 (m, 1H), 3.11 (m, 1H), 2.98 (s,
2H), 2.82 (qd, J=14.3, 4.8 Hz, 1H), 2.47 (m, 1H), 2.11-2.00 (m,
1H), 1.74 (m, 3H), 1.42 (s, 6H), 1.24 (s, 1H). MS (ESI): m/z=472.2
[M+1].sup.+.
TABLE-US-00009 TABLE 9 The following examples were made in a manner
similar to that for Example 64: Ex. Name Structure NMR, MS 293
N-(6- (((1S,3S,5S)-2- (2,2- difluoroethyl)-2- azabicyclo[3.1.0]
hexan-3- yl)methoxy)- 2,2-dimethyl- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01341## 1H NMR
(400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 9.98 (s, 1H), 9.37
(dd, J = 7.0, 1.6 Hz, 1H), 8.86 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s,
1H), 8.19 (d, J = 1.1 Hz, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.57
(s, 1H), 5.97 (tt, J = 56.2, 4.3 Hz, 1H), 4.00 (dd, J = 9.3, 5.9
Hz, 1H), 3.89-3.80 (m, 1H), 3.70 (dd, J = 9.4, 6.6 Hz, 1H),
3.23-3.11 (m, 2H), 2.97 (s, 2H), 2.67 (td, J = 6.3, 2.4 Hz, 1H),
2.42 (m, 1H), 1.66-1.60 (m, 1H), 1.51-1.43 (m, 1H), 1.41 (s, 6H),
0.57 (m, 1H), 0.32 (m, 1H). MS (ESI): m/z = 484.2 [M + 1]+. 294
N-(6- (((1R,5S,6R)-3- (2,2- difluoroethyl)-3- azabicyclo[3.1.0]
hexan-6- yl)methoxy)- 2,2-dimethyl- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01342## 1H NMR
(400 MHz, dimethyl sulfoxide- d.sub.6) .delta. 10.27 (s, 1H), 9.36
(dd, J = 7.0, 1.6 Hz, 1H), 8.75 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s,
1H), 8.27 (d, J = 1.1 Hz, 1H), 7.26 (dd, J = 7.0, 4.1 Hz, 1H), 6.50
(s, 1H), 6.12 (tt, J = 55.8, 4.2 Hz, 1H), 3.90 (d, J = 6.9 Hz, 2H),
3.05 (d, J = 8.7 Hz, 2H), 2.97 (s, 2H), 2.86 (td, J = 16.2, 4.2 Hz,
2H), 2.49- 2.45 (m, 2H), 1.71 (m, 1H), 1.52 (m, 2H), 1.41 (s, 6H).
MS (ESI): m/z = 484.2 [M + 1]+. 295 N-(6- (((1R,5S,6R)-3-
azabicyclo[3.1.0] hexan-6- yl)methoxy)- 2,2-dimethyl- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01343## 1H NMR (400 MHz, dimethyl sulfoxide- d.sub.6) .delta.
10.13 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.88 (dd, J = 4.2,
1.6 Hz, 1H), 8.67 (s, 1H), 8.23 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz,
1H), 6.52 (s, 1H), 3.96 (d, J = 6.9 Hz, 2H), 2.97 (s, 2H), 2.85 (d,
J = 11.1 Hz, 2H), 2.78-2.66 (m, 2H), 1.49 (m, 2H), 1.41 (s, 6H),
1.29 (m, 1H). MS (ESI): m/z = 420.2 [M + 1]+. 296 N-(2,2-
Dimethyl-6- ((tetrahydrofuran- 3- yl)methoxy)- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01344##
MS (ESI): m/z = 409.2 [M + 1].sup.+. 297 N-(2,2- Dimethyl-6-
(pyridin-3- ylmethoxy)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01345## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.09 (s, 1H), 9.35 (dd, J =
7.0, 1.6 Hz, 1H), 8.91 (d, J = 2.5 Hz, 1H), 8.66 (s, 1H), 8.62 (dd,
J = 4.9, 1.6 Hz, 1H), 8.40 (dd, J = 4.3, 1.6 Hz, 1H), 8.31 (s, 1H),
7.99 (dt, J = 8.0, 2.1 Hz, 1H), 7.49 (dd, J = 7.7, 4.8 Hz, 1H),
7.30 (dd, J = 7.0, 4.3 Hz, 1H), 6.77 (s, 1H), 5.25 (s, 2H), 3.00
(s, 2H), 1.43 (s, 6H). MS (ESI): m/z = 416.1 [M + 1].sup.+. 298
N-(6- (Cyclopropyl- methoxy)-2,2- dimethyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01346##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.31 (s,
1H), 9.37 (dd, J = 7.1, 1.6 Hz, 1H), 8.85 (dd, J = 4.2, 1.6 Hz,
1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.31 (dd, J = 7.0, 4.2 Hz, 1H),
6.52 (s, 1H), 3.91 (d, J = 6.8 Hz, 2H), 2.97 (s, 2H), 1.41 (s, 6H),
1.37 (dd, J = 8.2, 4.3 Hz, 1H), 0.64 (dt, J = 8.0, 2.9 Hz, 2H),
0.47-0.35 (m, 2H). MS (ESI): m/z = 379.1 [M + 1].sup.+. 299 N-(2,2-
Dimethyl-6-((3- methyloxetan-3- yl)methoxy)- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01347##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 9.89 (s,
1H), 9.37 (dd, J = 7.0, 1.5 Hz, 1H), 8.83 (dd, J = 4.3, 1.7 Hz,
1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H),
6.63 (s, 1H), 4.56 (d, J = 5.8 Hz, 2H), 4.39 (d, J = 5.8 Hz, 2H),
4.17 (s, 2H), 2.98 (s, 2H), 1.53 (s, 3H), 1.42 (s, 6H). MS (ESI):
m/z = 409.1 [M + 1].sup.+. 300 N-(2,2- Dimethyl-6-((1- methyl-1H-
pyrazol-4- yl)methoxy)- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01348## .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.16 (s, 1H),
9.35 (dd, J = 7.0, 1.7 Hz, 1H), 8.65 (s, 1H), 8.32-8.25 (m, 2H),
7.85 (s, 1H), 7.64 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.71
(s, 1H), 5.02 (s, 2H), 3.87 (s, 3H), 2.98 (s, 2H), 1.42 (s, 6H). MS
(ESI): m/z = 419.1 [M + 1].sup.+. 301 N-(2,2- Dimethyl-6-
(pyridin-4- ylmethoxy)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01349## MS (ESI): m/z = 416.1 [M +
1].sup.+. 302 N-(6-(2,2- Difluoroethoxy)- 2,2-dimethyl- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01350## .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.30 (s, 1H), 9.38 (dd, J = 7.0, 1.7 Hz, 1H), 8.83 (dd, J
= 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.34 (dd, J = 7.0,
4.2 Hz, 1H), 6.66 (s, 1H), 6.54 (t, J = 3.7 Hz, 1H), 4.41 (td, J =
14.2, 3.7 Hz, 2H), 2.99 (s, 2H), 1.42 (s, 6H). MS (ESI): m/z =
389.1 [M + 1].sup.+. 303 2,2-Dimethyl-6- [1-(1- methylpyrazol-
4-yl)ethoxy]- 3H-benzofuran- 5-amine ##STR01351## .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 10.22 (s, 1H), 8.80 (dd, J = 6.8, 1.6 Hz,
1H), 8.75 (s, 1H), 8.54 (dd, J = 4.4, 1.6 Hz, 1H), 8.40 (s, 1H),
7.57 (s, 1H), 7.34 (s, 1H), 7.01 (dd, J = 6.8, 4.0 Hz, 1H), 6.45
(s, 1H), 5.41 (q, J = 6.4 Hz, 1H), 3.84 (s, 3H), 3.01 (s, 2H), 1.75
(d, J = 6.4 Hz, 3H), 1.47 (s, 6H). LCMS (ESI): m/z = 455.0 [M +
H].sup.+. 304 N-(2,2- Dimethyl-6-((1- methylpiperidin-
3-yl)oxy)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01352## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.17 (s., 1H), 8.82 (d, J = 7.2 Hz, 1H), 8.76
(s, 1H), 8.68 (s., 1H), 8.41 (s, 1H), 7.04 (dd, J = 6.8, 4.0 Hz,
1H), 6.49 (s, 1H), 4.38 (m, 1H), 3.16-3.14 (m 1H), 3.02 (s, 2H),
2.74-2.72 (m, 1H), 2.32 (s, 3H), 2.28-2.23 (m, 2H), 2.05-2.01 (m,
1H), 1.87-1.85 (m, 1H), 1.78- 1.55 (m, 2H), 1.49 (s, 6H). LCMS
(ESI): m/z = 422.1 [M + H].sup.+. 305 and 306 R)-N-(2,2-
Dimethyl-6-((2- oxo piperidin-4- yl)methoxy)- 2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and
##STR01353## Example 305, Peak 1: .sup.1HNMR(400 MHz, CDCl.sub.3)
.delta. 9.85 (s, 1H), 8.86-8.77 (m, 3H), 8.36 (s, 1H), 7.04 (dd, J
= 6.4, 4.0 Hz, 1H), 6.40 (s, 1H), 5.76 (s, 1H), 4.07-4.04 (m, 1H),
3.92 (dd, J = 8.8, 6.4 Hz, 1H), 3.44-3.40 (m, 2H), 3.03 (s, 2H),
2.95- 2.91(m, 1H), 2.61-2.50 (m, 2 H), 2.06-1.94 (m, 1H), 1.91-1.80
(m, 1H), 1.49 (s, 6H). LCMS (ESI): m/z = 436.2 [M + H].sup.+.
(S)-N-(2,2- Dimethyl-6-((2- oxo piperidin-4- yl)methoxy)- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01354##
Example 306, Peak 1: .sup.1HNMR(400 MHz, CDCl.sub.3) .delta. 9.84
(s, 1H), 8.85-8.77 (m, 3H), 8.36 (s, 1H), 7.04 (dd, J = 6.8, 4.0
Hz, 1H), 6.40 (s, 1H), 5.76 (s, 1H), 4.07-4.04 (m, 1H), 3.92 (dd, J
= 8.8, 6.4 Hz, 1H), 3.44-3.40 (m, 2H), 3.03 (s, 2H), 2.95- 2.91(m,
1H), 2.61-2.50 (m, 2 H), 2.06-1.94 (m, 1H), 1.91-1.80 (m, 1H), 1.49
(s, 6H). LCMS (ESI): m/z = 436.2 [M + H].sup.+. 307 and 308 N-[2,2-
Dimethyl-6- [[(3R)-5- oxopyrrolidin-3- yl]methoxy]-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and
##STR01355## Example 308, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.85 (s, 1H), 8.82-8.71 (m, 3H), 8.32 (s, 1H), 7.05 (dd, J
= 7.2, 4.8 Hz, 1H), 6.41 (s, 1H), 5.53 (s, 1H), 4.11-4.06 (m, 2H),
3.64-3.59 (m, 1H), 3.43-3.39 (m, 1H), 3.06- 3.04 (m, 1H), 3.03 (s,
2H), 2.58 (d, J = 8.8 Hz, 2H), 1.49 (s,6 H). LCMS (ESI): m/z =
422.2 [M + H].sup.+. N-[2,2- Dimethyl-6- [[(3S)-5-oxo pyrrolidin-3-
yl]methoxy]-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide (absolute stereochemistry assigned arbitrarily)
##STR01356## Example 307, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.85 (s, 1H), 8.82-8.71 (m, 3H), 8.31 (s, 1H), 7.05 (dd, J
= 6.8, 4.4 Hz, 1H), 6.41 (s, 1H), 5.54 (s, 1H), 4.10-4.05 (m, 2H),
3.64-3.59 (m, 1H), 3.43-3.39 (m, 1H), 3.06- 3.04 (m, 1H), 3.03 (s,
2H), 2.58 (d, J = 8.8 Hz, 2H), 1.49 (s, 6H). LCMS (ESI): m/z =
422.2 [M + H].sup.+. 309 N-(2,2- Dimethyl-6- (piperidin-4-
ylmethoxy)-2,3- dihydrobenzo- furan-5-yl) pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01357## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.03 (s, 1 H), 9.40 (d, J =
6.0 Hz, 1 H), 8.85-8.75 (m, 2 H), 8.65 (s, 1 H), 8.23 (s, 1 H),
7.40 (dd, J = 7.2, 4.0 Hz, 1H), 6.60 (s, 1H), 3.96 (d, J = 6.8 Hz,
2 H), 3.30-3.25 (m, 2 H), 2.97-2.92 (m, 4 H), 2.30-2.15 (m, 2H),
2.10- 2.00 (m, 2 H), 1.55-1.45 (m, 2 H), 1.41 (s, 6 H). LCMS (ESI):
m/z = 422.3 [M + H].sup.+. 310 and 311 (S)-N-(6-(2,2-
difluoroethoxy)- 2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and
##STR01358## Example 310, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d6) .delta. 10.27 (s, 1H), 9.36 (dd, J = 7.0, 1.5 Hz,
1H), 8.83 (dd, J = 4.2, 1.5 Hz, 1H), 8.67 (s, 1H), 8.28 (s, 1H),
7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.70-6.33 (m, 2H), 5.04 (t, J = 5.8
Hz, 1H), 4.40 (td, J = 14.5, 3.2 Hz, 2H), 3.43 (m, 2H), 3.19 (d, J
= 15.6 Hz, 1H), 2.82 (d, J = 15.5 Hz, 1H), 1.35 (s, 3H). MS (ESI):
m/z = 405.1 [M + 1].sup.+. (R)-N-(6- (2,2- difluoroethoxy)- 2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01359## Example 311,
Peak 2: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.27
(s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.83 (dd, J = 4.2, 1.6 Hz,
1H), 8.67 (s, 1H), 8.28 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H),
6.70-6.31 (m, 2H), 5.04 (t, J = 5.7 Hz, 1H), 4.40 (td, J = 14.2,
3.0 Hz, 2H), 3.44 (m, 2H), 3.19 (d, J = 15.7 Hz, 1H), 2.82 (d, J =
15.6 Hz, 1H), 1.35 (s, 3H). MS (ESI): m/z = 405.1 [M + 1].sup.+.
312 and 313 N-[(2S)-6-(cis-4- Hydroxycyclo- hexoxy)-2-(1-
hydroxy-1- methyl-ethyl)-2- methyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01360##
Example 312, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.10 (s, 1H), 9.40-9.35 (m, 1H), 9.00-8.95 (m, 1H), 8.67 (s, 1H),
8.14 (s, 1H), 7.35-7.32 (m, 1H), 6.50 (s, 1H), 4.67 (s, 1H), 4.63
(d, J = 3.2 Hz, 1H), 4.55-4.50 (m, 1H), 3.65-3.60 (m, 1H), 2.67-
2.66 (m, 1H), 2.52-2.51 (m, 1H), 1.99-1.96 (m, 2H), 1.81-1.73 (m,
2H), 1.69- 1.59 (m, 4H), 1.24 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H).
LCMS (ESI): m/z = 467.0 [M + H].sup.+. N-[(2R)-6- (cis-4-
Hydroxycyclo- hexoxy)-2-(1- hydroxy-1- methyl-ethyl)-2- methyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01361##
Example 313, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.10 (s, 1H), 9.40-9.35 (m, 1H), 9.00-8.95 (m, 1H), 8.67 (s, 1H),
8.14 (s, 1H), 7.35-7.32 (m, 1H), 6.50 (s, 1H), 4.67 (s, 1H), 4.63
(d, J = 3.2 Hz, 1H), 4.55-4.50 (m, 1H), 3.65-3.60 (m, 1H), 2.67-
2.66 (m, 1H), 2.52-2.51 (m, 1H), 1.99-1.96 (m, 2H), 1.78-1.64 (m,
6H), 1.24 (s, 3H), 1.23 (s. 3H), 1.16 (s, 3H). LCMS (ESI): m/z =
467.0 [M + H].sup.+. 314 and 315 N-[(2S)-6- (trans-4- Hydroxycyclo-
hexoxy)-2-(1- hydroxy-1- methyl-ethyl)-2- methyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01362##
Example 314, Peak 1: .sup.1H NMR (400 MHz, DMSO- d.sub.6).delta.
10.18 (s, 1H), 9.36 (d, J = 6.8 Hz, 1H), 8.82 (dd, J = 4.0, 1.6 Hz,
1H), 8.65 (s, 1H), 8.14 (s, 1H), 7.33-7.30 (m, 1H), 6.52 (s, 1H),
4.67 (s, 1H), 4.58 (d, J = 4.0 Hz, 1H), 4.39-4.36 (m, 1H),
3.60-3.58 (m, 1H), 2.67- 2.66 (m, 1H), 2.52-2.51 (m, 1H), 2.07-2.04
(m, 2H), 1.93-1.86 (m, 2H), 1.58- 1.53 (m, 2H), 1.41-1.35 (m, 2H),
1.24 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H). LCMS (ESI): m/z = 467.0
[M + H].sup.+. N-[(2R)-6- (trans-4- Hydroxycyclo- hexoxy)-2-(1-
hydroxy-1- methyl-ethyl)-2- methyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01363## Example 315,
Peak 2: .sup.1H NMR (400 MHz, DMSO- d6) .delta. 10.18 (s, 1H),
9.40- 9.35 (m, 1H), 8.82 (dd, J = 4.4, 2.0 Hz, 1H), 8.65 (s, 1H),
8.14 (s, 1H), 7.33-7.30 (m, 1H), 6.52 (s, 1H), 4.67 (s, 1H), 4.58
(s, 1H), 4.39- 4.36 (m, 1H), 3.60-3.50 (m, 1H), 2.67-2.66 (m, 1H),
2.52-2.51 (m, 1H), 2.07- 2.04 (m, 2H), 1.92-1.88 (m, 2H), 1.57-1.56
(m, 2H), 1.38-1.35 (m, 2H), 1.24 (s, 3H), 1.23 (s, 3H), 1.16 (s,
3H). LCMS (ESI): m/z = 467.2 [M + H].sup.+. ##STR01364##
TABLE-US-00010 TABLE 10 The following examples were made in a
manner similar to that for Example 6: Ex. Name Structure NMR, MS
316 and 317 (R)-N-(2- (hydroxymethyl)- 6-(4- (hydroxymethyl)
piperidin-1-yl)- 2- (trifluoromethyl)- 2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01365##
Example 316, Peak 1: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
10.44 (s, 1H), 8.77-8.66 (m, 3H), 8.41 (s, 1H), 6.96 (dd, J = 7.0,
4.1 Hz, 1H), 6.69 (s, 1H), 3.99 (d, J = 12.3 Hz, 1H), 3.79 (d, J =
12.4 Hz, 1H), 3.56 (d, J = 4.9 Hz, 2H), 3.38 (q, J = 16.2 Hz, 2H),
3.02 (t, J = 10.6 Hz, 2H), 2.60 (dd, J = 11.7, 9.2 Hz, 2H),
2.34-1.90 (m, 1H), 1.79-1.62 (m, 4H), 1.30-1.11 (m, 2H). (ESI): m/z
= 492.2 [M + 1].sup.+. (S)-N-(2- (hydroxymethyl)- 6-(4-
(hydroxymethyl) piperidin-1-yl)- 2- (trifluoromethyl)- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute ##STR01366## Example 317, Peak 2: .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 10.52 (s, 1H), 8.86-8.75 (m, 3H), 8.50 (s,
1H), 7.03 (dd, J = 7.0, 4.2 Hz, 1H), 6.77 (s, 1H), 4.07 (d, J =
12.4 Hz, 1H), 3.85 (d, J = 12.4 Hz, 1H), 3.64 (d, J = 4.9 Hz, 2H),
3.55-3.37 (m, 2H), 3.21-2.97 (m, 2H), 2.67 (q, J = 10.0 Hz, 2H),
2.29- 1.87 (m, 2H), 1.75 (d, J = 29.5 Hz, 3H), 1.37-1.20
stereochemistry (m, 2H). (ESI): m/z = 492.2 assigned [M + 1].sup.+.
arbitrarily) 318 and 319 (R)-N-(6-(4- fluoro-4- (hydroxymethyl)
piperidin-1-yl)- 2- (hydroxymethyl)- 2- (trifluoromethyl)- 2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01367## Example 318, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.46 (s, 1H), 9.37 (dt, J = 7.0, 1.0
Hz, 1H), 8.89 (dd, J = 4.3, 1.5 Hz, 1H), 8.70 (s, 1H), 8.42 (s,
1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.92 (s, 1H), 5.57 (t, J = 6.1
Hz, 1H), 5.16 (t, J = 5.9 Hz, 1H), 3.76 (qd, J = 12.1, 6.1 Hz, 2H),
3.60-3.45 (m, 3H), 3.37 (s, 1H), 2.87 (q, J = 9.4, 8.8 Hz, 4H),
2.06 (dt, J = 35.2, 11.3 and Hz, 2H), 1.86 (t, J = 12.3 Hz, 2H).
(ESI): m/z = 510.2 [M + 1].sup.+. (S)-N-(6-(4- fluoro-4-
(hydroxymethyl) piperidin-1-yl)- 2- (hydroxymethyl)- 2-
(trifluoromethyl)- 2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01368## Example 319, Peak 2:
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.44 (s,
1H), 9.34 (d, J = 7.0 Hz, 1H), 8.88 (dd, J = 4.2, 1.5 Hz, 1H), 8.68
(s, 1H), 8.40 (s, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H), 6.90 (s,
1H), 5.66- 5.56 (m, 1H), 5.22-5.10 (m, 1H), 3.76 (qd, J = 12.1, 6.1
Hz, 2H), 3.53 (dd, J = 17.6, 6.2 Hz, 3H), 3.34 (d, J = 16.6 Hz,
1H), 2.94-2.79 (m, 4H), 2.15-1.95 (m, (absolute 2H), 1.90-1.81 (m,
2H). stereochemistry (ESI): m/z = 510.2 [M + 1].sup.+. assigned
arbitrarily) 320 and 321 (R)-N-(2- (hydroxymethyl)- 2-methyl-6-(1-
oxo-2,7- diazaspiro[3.5] nonan-7-yl)-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01369##
Example 320, Peak 1: .sup.1H NMR (400 MHz, Chloroform-d) .delta.
10.69 (s, 1H), 9.15 (s, 1H), 8.80 (dd, J = 7.1, 1.7 Hz, 1H), 8.77
(s, 1H), 8.56 (s, 1H), 7.11 (dd, J = 7.0, 4.1 Hz, 1H), 6.62 (s,
1H), 5.68 (s, 1H), 3.66 (d, J = 6.3 Hz, 2H), 3.33 (s, 2H), 3.24 (d,
J = 15.6 Hz, 1H), 3.13-3.04 (m, 2H), 2.94 (d, J = 15.5 Hz, 1H),
2.69 (t, J = 11.6 Hz, 2H), 2.52 (td, J = 12.6, 4.1 Hz, 2H), 1.92
(dd, J = 9.5, 5.0 Hz, 3H), 1.46 (s, 3H). (ESI): m/z = 463.2 [M +
1].sup.+. (S)-N-(2- (hydroxymethyl)- 2-methyl-6-(1- oxo-2,7-
diazaspiro[3.5] nonan-7-yl)-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01370## Example 321,
Peak 2: .sup.1H NMR (400 MHz, Chloroform-d) .delta. 10.69 (s, 1H),
9.14 (s, 1H), 8.84- 8.73 (m, 2H), 8.56 (s, 1H), 7.11 (dd, J = 7.0,
4.1 Hz, 1H), 6.62 (s, 1H), 5.68 (s, 1H), 3.66 (d, J = 6.0 Hz, 2H),
3.34 (s, 2H), 3.24 (d, J = 15.6 Hz, 1H), 3.08 (d, J = 11.8 Hz, 2H),
2.94 (d, J = 15.6 Hz, 1H), 2.70 (dd, J = 12.8, 10.5 Hz, 2H), 2.57-
2.45 (m, 2H), 1.91 (d, J = 13.5 Hz, 3H), 1.46 (s, 3H). (ESI): m/z =
463.2 [M + 1].sup.+. 322 N-{2- (hydroxymethyl)- 6-(6-
(hydroxymethyl)- 3- azabicyclo[3.1.0] hexan-3-yl)-2- methyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01371## .sup.1H NMR (400 MHz, Chloroform-d) .delta. 9.67 (s,
1H), 8.85 (d, J = 4.1 Hz, 1H), 8.76-8.68 (m, 2H), 8.17 (s, 1H),
6.99 (dd, J = 7.0, 4.2 Hz, 1H), 6.55 (s, 1H), 3.59 (s, 2H), 3.46
(d, J = 7.3 Hz, 2H), 3.34 (t, J = 8.1 Hz, 2H), 3.15 (d, J = 15.5
Hz, 1H), 2.96 (t, J = 8.9 Hz, 2H), 2.85 (d, J = 15.4 Hz, 1H), 1.38
(s, 5H), 1.31- 1.15 (m, 3H). (ESI): m/z = 436.2 [M + 1].sup.+. 323
and 324 N-[(2S)-2- (Hydroxymethyl)- 6-[4-(1- hydroxy-1-
methyl-ethyl)-1- piperidyl]-2- methyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01372##
Example 323, Peak 1: .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 10.45
(s, 1H), 8.85-8.75 (m, 3H), 8.43 (s, 1H), 7.00 (dd, J = 7.2, 4.0
Hz, 1H), 6.66 (s, 1H), 3.75-3.65 (m, 2H), 3.24 (d, J = 16.0 Hz,
1H), 3.20-3.10 (m, 1H), 2.94 (d, J = 16.0 Hz, 1 H), 2.66-2.60 (m, 2
H), 1.90- 1.70 (m,5H), 1.47 (s, 3 H), 1.27 (s, 6H). LCMS (ESI): m/z
= 466.2 [M + H].sup.+. N-[(2R)-2- (Hydroxymethyl)- 6-[4-(1-
hydroxy-1- methyl-ethyl)-1- piperidyl]-2- methyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a] pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01373## Example 324,
Peak 2: .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 10.44 (s, 1H),
8.84- 8.77(m, 3H), 8.42 (s, 1H), 7.00 (dd, J = 7.2, 4.0 Hz, 1H),
6.66 (s, 1H), 3.67 (s, 2H), 3.24 (d, J = 16.0 Hz, 1H), 3.20-3.10
(m, 1H), 2.94 (d, J = 16.0 Hz, 1 H), 2.65-2.62 (m, 2 H), 1.90- 1.70
(m, 5 H), 1.47 (s, 3 H), 1.26 (s, 6H). LCMS (ESI): m/z = 466.2 [M +
H].sup.+. 325 N-(6-(4-(2,2- Difluoroethyl) piperazin-1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-yl)-6-
methylpyrazolo [1,5-a] pyrimidine-3- carboxamide ##STR01374##
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.31 (s,
1H), 9.22 (s, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.59 (s, 1H), 8.27 (s,
1H), 6.69 (s, 1H), 6.33-6.04 (m, 1H), 5.04 (t, J = 6.0 Hz, 1H),
3.42 (t, J = 5.2 Hz, 1H), 3.32-3.17 (m, 2H), 2.88-2.84 (m, 2H),
2.84-2.79 (m, 8H), 2.44 (s, 3H), 1.33 (s, 3H). LCMS (ESI): m/z =
487.5 [M + H].sup.+ 326 and 327 (S)-N-(6-(4-(2,2- Difluoroethyl)
piperazin-1-yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo-
furan-5-yl)-6- methylpyrazolo [1,5-a] pyrimidine-3- carboxamide and
##STR01375## Example 326, Peak 1: .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.93 (s, 1H), 8.79 (d, J = 1.6 Hz, 1H), 8.57 (s, 1H), 8.18
(s, 1H), 6.69 (s, 1H), 6.18- 5.88 (m, 1H), 3.62-3.57 (m, 2H), 3.24
(d, J = 16.0 Hz, 1H), 2.93-2.85 (m, 11H), 2.50 (s, 3H), 1.42 (s,
3H). MS (ESI): m/z = 487.1 [M + 1].sup.+. (R)-N-(6-(4- (2,2-
Difluoroethyl) piperazin-1-yl)-2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzo- furan-5-yl)-6- methylpyrazolo [1,5-a] pyrimidine-3-
carboxamide (absolute stereochemistry ##STR01376## Example 327,
Peak 2: .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.92 (s, 1H),
8.78 (s, 1H), 8.56 (s, 1H), 8.18 (s, 1H), 6.68 (s, 1H), 6.17-5.87
(m, 1H), 3.62-3.57 (m, 2H), 3.24 (d, J = 16.0 Hz, 1H), 2.93- 2.85
(m, 11H), 2.50 (s, 3H), 1.42 (s, 3H). MS (ESI): m/z = 487.1 [M +
1].sup.+. assigned arbitrarily) 328 N-(6-(4-Fluoro- 4-
(hydroxymethyl) piperidin-1-yl)- 2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzo- furan-5-yl)-6- methylpyrazolo [1,5-a] pyrimidine-3-
carboxamide ##STR01377## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) 10.41 (s, 1H), 9.22 (s, 1H), 8.81 (d, J = 2.0
Hz, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 6.68 (s, 1H), 5.22 (t, J = 6.4
Hz, 1H), 5.04 (t, J = 6.4 Hz, 1H), 3.55-3.50 (m, 2H), 3.44-3.41 (m,
2H), 3.19 (d, J = 16.0 Hz, 1H), 2.87-2.80 (m, 5H), 2.40 (s, 3H),
2.17-2.02 (m, 2H), 1.82 (t, J = 5.2 Hz, 2H), 1.34 (s, 3H). LCMS
(ESI): m/z = 470.1 [M + H].sup.+. 329, 330, 331, and 332
N-((R)-6-((R)-4- hydroxy-4- methylazepan-1- yl)-2- (hydroxymethyl)-
2-methyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide, ##STR01378## Example 329, Peak 4:
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.50 (s, 1H),
9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.95 (dd, J = 4.2, 1.7 Hz, 1H),
8.67 (s, 1H), 8.24 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.64
(s, 1H), 5.02 (t, J = 5.8 Hz, 1H), 4.29 (s, 1H), 3.42 (m, 2H),
3.22-3.14 (m, 1H), 3.13- 3.03 (m, 1H), 2.94-2.75 (m, 4H), 2.07-1.86
(m, 3H), 1.85-1.69 (m, 2H), 1.62-1.49 (m, 1H), 1.33 (s, 3H), 1.18
(s, 3H). MS (ESI): m/z = 452.2 [M + 1].sup.+. N- ((R)-6-((S)-4-
hydroxy-4- methylazepan-1- yl)-2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide, ##STR01379## Example 330, Peak 3: .sup.1H NMR (400
MHz, dimethyl sulfoxide-d6) .delta. 10.50 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.95 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.24 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.64 (s, 1H), 5.02
(t, J = 5.8 Hz, 1H), 4.29 (s, 1H), 3.42 (m, 2H), 3.18 (d, J = 15.9
Hz, 1H), 3.07 (m, 1H), 2.95-2.73 (m, 4H), 2.09-1.86 (m, 3H),
1.85-1.70 (m, 2H), 1.63-1.47 (m, 1H), 1.34 (s, 3H), 1.18 (s, 3H).
MS (ESI): m/z = 452.2 [M + 1].sup.+. N- ((S)-6-((R)-4- hydroxy-4-
methylazepan-1- yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and
##STR01380## Example 331, Peak 2: 1H NMR (400 MHz, dimethyl
sulfoxide-d6) .delta. 10.50 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.95 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.24 (s, 1H),
7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.64 (s, 1H), 5.02 (t, J = 5.8 Hz,
1H), 4.29 (s, 1H), 3.49-3.35 (m, 2H), 3.18 (d, J = 16.1 Hz, 1H),
3.07 (m, 1H), 2.95- 2.73 (m, 4H), 2.06-1.87 (m, 3H), 1.85-1.70 (m,
2H), 1.60-1.48 (m, 1H), 1.34 (s, 3H), 1.18 (s, 3H). MS (ESI): m/z =
452.2 [M + 1].sup.+. N-((S)-6- ((S)-4-hydroxy- 4-methylazepan-
1-yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute and relative
stereochemistry ##STR01381## Example 332, Peak 1: .sup.1H NMR (400
MHz, dimethyl sulfoxide-d6) .delta. 10.50 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.95 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.24 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.64 (s, 1H), 5.02
(t, J = 5.8 Hz, 1H), 4.29 (s, 1H), 3.42 (m, 2H), 3.18 (d, J = 16.2
Hz, 1H), 3.14-2.98 (m, 1H), 2.95- 2.73 (m, 4H), 2.10-1.85 (m, 3H),
1.85-1.68 (m, assigned 2H), 1.62-1.47 (m, 1H), arbitrarily) 1.33
(s, 3H), 1.18 (s, 3H). MS (ESI): m/z = 452.2 [M + 1].sup.+. 333 and
334 (R)-N-(6-(4-(2- amino-2- oxoethyl) piperidin-1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01382##
Example 333, Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6)
.delta. 10.43 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.88 (dd, J
= 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.33 (m, 2H), 6.79
(s, 1H), 6.67 (s, 1H), 5.02 (t, J = 5.8 Hz, 1H), 3.42 (m, 2H), 3.19
(d, J = 16.0 Hz, 1H), 2.90 (d, J = 11.1 Hz, 2H), 2.82 (d, J = 15.9
Hz, 1H), 2.64 (t, J = 11.3 Hz, 2H), 2.14-2.04 (m, 2H), 1.89-1.77
(m, 1H), 1.73 (m, 2H), 1.64-1.49 (m, 2H), 1.34 (s, 3H). MS (ESI):
m/z = 465.2 [M + 1].sup.+. (S)-N-(6-(4- (2-amino-2- oxoethyl)
piperidin-1-yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned ##STR01383## Example 334, Peak 2: .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.43 (s, 1H), 9.36
(dd, J = 7.0, 1.6 Hz, 1H), 8.88 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s,
1H), 8.31 (s, 1H), 7.33 (m, 2H), 6.79 (s, 1H), 6.67 (s, 1H), 5.02
(t, J = 5.8 Hz, 1H), 3.42 (m, 2H), 3.19 (d, J = 16.0 Hz, 1H), 2.90
(d, J = 11.1 Hz, 2H), 2.82 (d, J = 15.9 Hz, 1H), 2.64 (t, J = 11.3
Hz, 2H), 2.10 (m, 2H), 1.87- arbitrarily) 1.77 (m, 1H), 1.73 (m,
2H), 1.67-1.46 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z = 465.2 [M +
1].sup.+. 335 and 336 (R)-N-(6-(4- cyanopiperidin- 1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01384##
Example 336, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.37 (s, 1H), 9.38 (dd, J = 7.0, 1.6
Hz, 1H), 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.69 (s, 1H), 8.30 (d, J =
1.0 Hz, 1H), 7.38 (dd, J = 7.0, 4.2 Hz, 1H), 6.65 (s, 1H), 5.09-
4.96 (m, 1H), 3.49-3.36 (m, 2H), 3.20 (d, J = 16.8 Hz, 1H), 3.09
(m, 1H), 2.96- 2.86 (m, 2H), 2.86-2.79 (m, 1H), 2.76 (m, 2H), 2.17-
2.07 (m, 2H), 2.00 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z = 433.2 [M
+ 1].sup.+. (S)-N-(6-(4- cyanopiperidin- 1-yl)-2- (hydroxymethyl)-
2-methyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01385## Example 335, Peak 2: .sup.1H NMR (400
MHz, dimethyl sulfoxide-d6) .delta. 10.37 (s, 1H), 9.38 (dd, J =
7.0, 1.7 Hz, 1H), 8.86 (dd, J = 4.2, 1.6 Hz, 1H), 8.69 (s, 1H),
8.30 (s, 1H), 7.38 (dd, J = 7.0, 4.2 Hz, 1H), 6.65 (s, 1H),
5.07-4.98 (m, 1H), 3.42 (m, 2H), 3.20 (d, J = 16.8 Hz, 1H), 3.09
(m, 1H), 2.97-2.87 (m, 2H), 2.87- 2.71 (m, 3H), 2.18-2.06 (m, 2H),
2.00 (m, 2H), 1.34 (s, 3H). MS (ESI): m/z = 433.2 [M + 1].sup.+.
337, 338, 339 and 340 N-((R)-6-((R)-4- hydroxyazepan- 1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide, ##STR01386## Example
337, Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta.
10.45 (s, 1H), 9.36 (dd, J =
7.0, 1.7 Hz, 1H), 8.93 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.24 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.63 (s, 1H),
5.06-4.97 (m, 1H), 4.54 (d, J = 3.7 Hz, 1H), 3.92 (m, 1H),
3.52-3.37 (m, 2H), 3.18 (d, J = 16.5 Hz, 1H), 3.03-2.75 (m, 5H),
2.10-2.00 (m, 1H), 1.99-1.79 (m, 3H), 1.81- 1.70 (m, 1H), 1.69-1.58
(m, 1H), 1.34 (s, 3H). MS (ESI): m/z = 438.2 [M + 1].sup.+. N-
((R)-6-((S)-4- hydroxyazepan- 1-yl)-2- (hydroxymethyl)-
2-methyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide, ##STR01387## Example 338, Peak 2:
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d6) .delta. 10.45 (s, 1H),
9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.93 (dd, J = 4.2, 1.7 Hz, 1H),
8.67 (s, 1H), 8.24 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.63
(s, 1H), 5.06-4.96 (m, 1H), 4.54 (d, J = 3.7 Hz, 1H), 4.00-3.85 (m,
1H), 3.48- 3.36 (m, 2H), 3.23-3.13 (m, 1H), 3.04-2.77 (m, 5H), 2.05
(m, 1H), 1.98- 1.81 (m, 3H), 1.81-1.71 (m, 1H), 1.72-1.58 (m, 1H),
1.33 (s, 3H). MS (ESI): m/z = 433.2 [M + 1].sup.+. N-
((S)-6-((R)-4- hydroxyazepan- 1-yl)-2- (hydroxymethyl)-
2-methyl-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01388## Example 339, Peak 3:
.sup.1H NMR (400 MHz, DMSO- d6) .delta. 10.45 (s, 1H), 9.36 (dd, J
= 7.0, 1.7 Hz, 1H), 8.93 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.24 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.63 (s, 1H), 5.02
(t, J = 5.8 Hz, 1H), 4.54 (d, J = 3.7 Hz, 1H), 3.92 (m, 1H), 3.51-
3.37 (m, 2H), 3.18 (d, J = 16.2 Hz, 1H), 3.06-2.90 (m, 3H), 2.87
(m, 1H), 2.85- 2.75 (m, 1H), 2.12-1.99 (m, 1H), 1.99-1.81 (m, 3H),
1.81-1.69 (m, 1H), 1.69-1.57 (m, 1H), 1.34 (s, 3H). MS (ESI): m/z =
438.2 [M + 1].sup.+. N-((S)-6- ((S)-4- hydroxyazepan- 1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute and relative
stereochemistry ##STR01389## Example 340, Peak 4: .sup.1H NMR (400
MHz, DMSO- d6) .delta. 10.45 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.93 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.24 (s, 1H),
7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.63 (s, 1H), 5.02 (t, J = 5.8 Hz,
1H), 4.54 (d, J = 3.6 Hz, 1H), 3.92 (m, 1H), 3.42 (m, 2H), 3.18 (d,
J = 16.1 Hz, 1H), 3.05-2.85 (m, 3H), 2.85-2.75 (m, 1H), 2.11-1.99
(m, 1H), 1.99- assigned 1.81 (m, 3H), 1.81-1.55 arbitrarily) (m,
2H), 1.33 (s, 3H). MS (ESI): m/z = 438.2 [M + 1].sup.+. 341 and 342
N-[(2R)-6-[4-(1- hydroxycyclo- propyl)-1- piperidyl]-2-
(hydroxymethyl)- 2-methyl-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01390## Example 341, Peak 1:
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.57 (s, 1H), 8.95-8.90
(m, 1H), 8.78-8.77 (m, 2H), 8.48 (s, 1H), 6.99 (dd, J = 6.8, 4.0
Hz, 1H), 6.65 (s, 1H), 3.66 (d, J = 6.0 Hz, 2H), 3.22 (d, J = 16.0
Hz, 1H), 3.15-3.12 (m, 2H), 2.93 (d, J = 16.0 Hz, 1H), 2.66-2.60
(m, 2H), 2.08-2.06 (m, 2H), 1.88 (t, J = 6.0Hz, 1H), 1.80- 1.78 (m,
3H), 1.46 (s, 3H), 1.02-0.99 (m, 1H), 0.79 (t, J = 6.0 Hz, 2H),
0.53 (t, J = 5.6 Hz, 2H). LCMS (ESI): m/z = 464.0 [M + H].sup.+.
N-[(2S)-6- [4-(1- hydroxycyclo- propyl)-1- piperidyl]-2-
(hydroxymethyl)- 2-methyl-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01391## Example 342, Peak 2: .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 10.50 (s, 1H), 8.90-8.85 (m, 1H), 8.75-8.65 (m,
2H), 8.41 (s, 1H), 6.92 (dd, J = 6.8, 4.0 Hz, 1H), 6.58 (s, 1H),
3.60-3.55 (m, 2H), 3.16 (d, J = 15.6 Hz, 1H), 3.10-3.00 (m, 2H),
2.86 (d, J = 15.6 Hz, 1H), 2.60-2.54 (m, 2H), 2.02-1.98 (m, 2H),
1.90-1.70 (m, 4H), 1.39 (s, 3H), 0.95-0.85 (m, 1H), 0.73 (t, J =
6.0 Hz, 2H), 0.46 (t, J = 5.6 Hz, 2H). LCMS (ESI): m/z = 464.1 [M +
H].sup.+. 343 N-[2- (Hydroxymethyl)- 2-methyl-6-(4- propanoyl-1-
piperidyl)-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01392## .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
10.62 (s, 1H), 9.05-9.00 (m, 1H), 8.80-8.75 (m, 2H), 8.53 (s, 1H),
7.10 (dd, J = 7.2, 4.0 Hz, 1H), 6.64 (s, 1H), 3.66 (s, 2H), 3.23
(d, J = 15.2 Hz, 1H), 3.12-3.09 (m, 2H), 2.93 (d, J = 15.6 Hz, 1H),
2.69-2.61 (m, 2H), 2.56 (q, J = 7.2 Hz, 2H), 2.12-2.09 (m, 2H),
1.87-1.83 (m, 2H), 1.46 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H). LCMS
(ESI): m/z = 486.2 [M + Na].sup.+. 344 and 345 N-(6-(4-(1H-
imidazol-1- yl)piperidin-1- yl)-2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01393##
Example 344, Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6)
.delta. 10.30 (s, 1H), 9.36 (dd, J = 7.0, 1.7 Hz, 1H), 8.82 (dd, J
= 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.23 (s, 1H), 7.77 (s, 1H), 7.35
(dd, J = 7.0, 4.2 Hz, 1H), 7.28 (t, J = 1.2 Hz, 1H), 6.95 (s, 1H),
6.70 (s, 1H), 5.11-4.94 (m, 1H), 4.22 (m, 1H), 3.51-3.39 (m, 2H),
3.25-3.16 (m, 1H), 3.11-3.00 (m, 2H), 2.93-2.77 (m, 3H), 2.21- 2.10
(m, 4H), 1.35 (s, 3H). MS (ESI): m/z = 474.2 [M + 1].sup.+.
##STR01394## Example 345, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d6) .delta. 10.30 (s, 1H), 9.36 (dd, J = 7.0, 1.7 Hz,
1H), 8.82 (dt, J = 4.2, 1.4 Hz, 1H), 8.68 (s, 1H), 8.23 (s, 1H),
7.77 (s, 1H), 7.39-7.31 (m, 1H), 7.28 (q, J = 1.4 Hz, 1H), 6.95 (t,
J = 1.0 Hz, 1H), 6.70 (s, 1H), 5.09-4.95 (m, 1H), 4.30-4.17 (m,
1H), 3.52- 3.39 (m, 2H), 3.25-3.17 (m, 1H), 3.14-3.00 (m, 2H),
2.92-2.77 (m, 3H), 2.23-2.07 (m, 4H), 1.35 (s, 3H). MS (ESI): m/z =
474.1 [M + 1].sup.+. 346 and 347 (S)-N-(6-(4- fluoro-4-
(hydroxymethyl) piperidin-1-yl)- 2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzo- furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
and ##STR01395## Example 346, Peak 1: .sup.1H NMR (400 MHz, DMSO-
d.sub.6) .delta. 10.41 (s, 1H), 9.22 (dd, J = 2.1, 1.2 Hz, 1H),
8.82 (d, J = 2.0 Hz, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 6.68 (s, 1H),
5.20 (t, J = 5.8 Hz, 1H), 5.09-4.96 (m, 1H), 3.53 (dd, J = 15.8,
5.8 Hz, 2H), 3.42 (m, 2H), 3.24-3.15 (m, 1H), 2.95- 2.76 (m, 5H),
2.40 (d, J = 1.1 Hz, 3H), 2.20-1.99 (m, 2H), 1.82 (t, J = 12.1 Hz,
2H), 1.34 (s, 3H). LCMS (ESI): m/z = 470.2 [M + H].sup.+.
(R)-N-(6-(4- fluoro-4- (hydroxymethyl) piperidin-1-yl)- 2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry ##STR01396## Example 347, Peak 2: .sup.1H NMR (400
MHz, DMSO- d.sub.6) .delta. 10.41 (s, 1H),9.22 (dt, J = 2.1, 1.1
Hz, 1H), 8.82 (dd, J = 2.1, 0.5 Hz, 1H), 8.59 (s, 1H), 8.31 (d, J =
0.9 Hz, 1H), 6.68 (s, 1H), 5.20 (t, J = 5.8 Hz, 1H), 5.07-4.98 (m,
1H), 3.53 (dd, J = 15.8, 5.9 Hz, 2H), 3.48-3.36 (m, 2H), 3.24-3.14
(m, 1H), 2.94- 2.76 (m, 5H), 2.44-2.36 (m, 3H), 2.09 (m, 2H),
assigned 1.82 (t, J = 12.1 Hz, 2H), arbitrarily) 1.34 (s, 3H). LCMS
(ESI): m/z = 470.2 [M + H].sup.+. 348 and 349 N-((R)-6-
((1R,5S,6S)-6- carbamoyl-3- azabicyclo[3.1.0] hexan-3-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzo- furan-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01397##
Example 348, Peak 1: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d6)
.delta. 9.32-9.28 (m, 2H), 8.84-8.80 (m, 1H), 8.77 (s, 1H), 7.44
(s, 1H), 7.32 (s, 1H), 7.26 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s,
1H), 6.41 (s, 1H), 5.04- 4.98 (m, 1H), 3.57 (d, J = 8.6 Hz, 2H),
3.46-3.38 (m, 2H), 3.20 (d, J = 8.6 Hz, 2H), 3.12 (d, J = 16.2 Hz,
1H), 2.74 (d, J = 16.0 Hz, 1H), 1.85-1.78 (m, 2H), 1.58 (t, J = 8.0
Hz, 1H), 1.33 (s, 3H). MS (ESI): m/z = 449.1 [M + 1].sup.+.
N-((S)-6- ((1R,5S,6R)-6- carbamoyl-3- azabicyclo[3.1.0]
hexan-3-yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzo-
furan-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01398## Example 349,
Peak 2: .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
9.32-9.28 (m, 2H), 8.83 (d, J = 1.7 Hz, 1H), 8.77 (s, 1H), 7.44 (s,
1H), 7.32 (s, 1H), 7.26 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H),
6.41 (s, 1H), 5.04-4.98 (m, 1H), 3.57 (d, J = 9.1 Hz, 2H), 3.47-
3.37 (m, 2H), 3.24-3.16 (m, 3H), 3.12 (d, J = 16.2 Hz, 1H), 2.74
(d, J = 16.1 Hz, 1H), 1.85-1.78 (m, 2H), 1.58 (t, J = 8.0 Hz, 1H),
1.33 (s, 3H).MS (ESI): m/z = 449.1 [M + 1].sup.+. 350 and 351 N-(2-
(hydroxymethyl)- 2-methyl-6-((1- methyl-1H- pyrazol-4-
yl)methoxy)-2,3- dihydrobenzo- furan-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01399## Example 350, Peak 2:
.sup.1H NMR (400 MHz, DMSO- d6) .delta. 10.13 (s, 1H), 9.33 (dd, J
= 7.0, 1.7 Hz, 1H), 8.64 (s, 1H), 8.32 (dd, J = 4.2, 1.7 Hz, 1H),
8.25 (s, 1H), 7.84 (s, 1H), 7.62 (d, J = 0.6 Hz, 1H), 7.32 (dd, J =
7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 5.06-5.00 (m, 3H), 3.86 (s, 3H),
3.50-3.39 (m, 2H), 3.17 (d, J = 15.7 Hz, 1H), 2.80 (d, J = 15.8 Hz,
1H), 1.35 (s, 3H). MS (ESI): m/z = 435.1 [M + 1].sup.+.
N-(3-hydroxy-3- methyl-7-((1- methyl-1H- pyrazol-4- yl)methoxy)
chroman-6- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01400## Example 351,
Peak 1: .sup.1H NMR (400 MHz, DMSO- d6) .delta. 10.13 (s, 1H), 9.33
(dd, J = 7.0, 1.7 Hz, 1H), 8.64 (s, 1H), 8.32 (dd, J = 4.2, 1.7 Hz,
1H), 8.25 (s, 1H), 7.84 (s, 1H), 7.68- 7.52 (m, 1H), 7.32 (dd, J =
7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 5.03 (m, 3H), 3.86 (s, 3H),
3.52-3.39 (m, 2H), 3.17 (d, J = 16.0 Hz, 1H), 2.80 (d, J = 15.9 Hz,
1H), 1.35 (s, 3H). MS (ESI): m/z = 435.1 [M + 1].sup.+.
Example 352.
N-(6-(4-(2,2-Difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(hydroxymethyl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01401##
[1464] Step A. tert-Butyl
4-(2,2-difluoro-1-hydroxyethyl)piperidine-1-carboxylate
##STR01402##
[1466] To a solution of tert-butyl 4-formyl-1-piperidinecarboxylate
(1 g, 4.69 mmol) in tetrahydrofuran (20 ml) was added
difluoromethyl trimethylsilane (0.82 g, 6.56 mmol) and 1M
tetrabutyl ammoniumfluoride (0.47 ml, 0.47 mmol) in
tetrahydrofuran. The mixture was stirred at 17.degree. C. for 15 h
under nitrogen atmosphere. The reaction was concentrated under
reduced pressure to give tert-butyl
4-(2,2-difluoro-1-hydroxy-ethyl)piperidine-1-carboxylate (1.4 g,
100% yield) as a light yellow oil, which was used directly without
further purification. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
5.76 (td, J=50.8, 4.4 Hz, 1H), 4.25-4.10 (m, 2H), 3.61-3.52 (m,
1H), 2.75-2.60 (m, 2H), 1.81-1.74 (m, 2H), 1.65-1.62 (m, 2H), 1.46
(s, 9H), 1.41-1.37 (m, 1H),
Step B. 2,2-Difluoro-1-(piperidin-4-yl)ethanol hydrochloride
##STR01403##
[1468] To a solution of tert-butyl
4-(2,2-difluoro-1-hydroxy-ethyl)piperidine-1-carboxylate (1.19 g,
4.49 mmol) in ethyl acetate (10 ml) was added hydrochloric acid (11
ml, 4 M, 45.33 mmol) in ethyl acetate. The mixture was stirred at
17.degree. C. for 40 min and concentrated under reduced pressure to
give 2,2-difluoro-1-(4-piperidyl)ethanol hydrochloride (900 mg, 99%
yield) as a colorless oil, which used directly without further
purification.
Step C.
N-(6-(4-(2,2-Difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(hydroxymet-
hyl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbo-
xamide
##STR01404##
[1470] The title compound was made in a manner analogous to Example
6, Steps A through C to afford
N-(6-(4-(2,2-Difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(hydroxymethyl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
(0.12 g, 53% yield over 3 steps). .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 9.08-9.04 (m, 2H), 8.63 (s, 1H), 8.27 (s, 1H),
7.22-7.20 (dd, J=7.6, 4.4 Hz, 1H), 6.68 (s, 1H), 5.95 (td, J=41.6,
4.8 Hz, 1H), 3.62-3.58 (m, 3H), 3.23 (d, J=16.0 Hz, 1H), 3.04-3.01
(m, 2H), 2.90 (d, J=16.0 Hz, 1H), 2.71-2.67 (m, 2H), 2.10-1.95 (m,
2H), 1.78-1.63 (m, 3H), 1.42 (s, 3H). LCMS (ESI): m/z=488.1
[M+H].sup.+.
Example 353.
N-[6-[4-Fluoro-4-(hydroxymethyl)-1-piperidyl]-2-(1-hydroxy-1-methyl-ethyl-
)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
(308303452)
##STR01405##
[1472] The title compound was made in a manner analogous to
Examples 157 and 158 to afford
N-[6-[4-fluoro-4-(hydroxymethyl)-1-piperidyl]-2-(1-hydroxy-1-methyl-ethyl-
)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
(63 mg, 29% yield) as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.43 (s, 1H), 8.87-8.74 (m, 2H), 8.68 (m, 1H),
8.44 (s, 1H), 7.03 (m, 1H), 6.71 (s, 1H), 3.73 (d, J=18.8 Hz, 2H),
3.51 (d, J=15.6 Hz, 1H), 3.07-2.90 (m, 4H), 2.80 (d, J=15.2 Hz,
1H), 2.17-1.97 (m, 4H), 1.42 (s, 3H), 1.37 (s, 3H), 1.26 (s,
3H).
[1473] LCMS (ESI): m/z=484.0 [M+H].sup.+.
Example 354 and 355.
(S)--N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e
##STR01406##
[1475] The title compounds were made in a manner analogous to
Examples 157 and 158 to afford
(S)--N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)-2-me-
thyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e (absolute stereochemistry assigned arbitrarily).
[1476] Example 354, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.47 (s, 1H), 9.36-9.35 (d, J=5.2 Hz,
1H), 8.90-8.88 (m, 1H), 8.67 (s, 1H), 8.30 (s, 1H), 7.34-7.31 (dd
J=4.4, 7.2 Hz, 1H), 6.68 (s, 1H), 4.55 (t, J=5.6 Hz, 1H), 4.50 (s,
1H), 3.44 (d, J=16.0 Hz, 1H), 3.40-3.38 (m, 2H), 2.94-2.91 (m, 2H),
2.71 (d, J=16.0 Hz, 1H), 2.66-2.60 (m, 2H), 1.72-1.70 (m, 2H),
1.59-1.56 (m, 3H), 1.31 (s, 3H), 1.16 (d, J=4.0 Hz, 6H). LCMS
(ESI): m/z=466.1 [M+H].sup.+.
[1477] Example 355, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.48 (s, 1H), 9.37-9.35 (d, J=6.8 Hz,
1H), 8.90-8.89 (m, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.35-7.32 (m,
1H), 6.69 (s, 1H), 4.56 (t, J=5.6 Hz, 1H), 4.51 (s, 1H), 3.45 (d,
J=16.0 Hz, 1H), 3.40-3.38 (m, 2H), 2.94-2.92 (m, 2H), 2.71 (d,
J=16.0 Hz, 1H), 2.66-2.61 (m, 2H), 1.73-1.70 (m, 2H), 1.59-1.53 (m,
3H), 1.32 (s, 3H), 1.16 (d, J=3.2 Hz, 6H). LCMS (ESI): m/z=466.1
[M+H].sup.+.
Example 356.
N-(6-Methyl-2-morpholino-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01407##
[1479] The title compound was made in a manner analogous to
Examples 157 and 158 to afford N-[6-4-(2-amino-2-oxo-ethyl)
piperazin-1-yl]-2-(1-hydroxy-1-methyl-ethyl)-2-methyl-3H-benzofuran-5-yl]-
pyrazolo[1,5-a]pyrimidine-3-carboxamide (64.5 mg, 27% yield) as a
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): 10.37 (s, 1H),
8.85 (dd, J=7.2, 2.0 Hz, 1H), 8.79 (s, 1H), 8.73-8.71 (m, 1H), 8.42
(s, 1H), 7.09-7.07 (m, 2H), 6.67 (s, 1H), 5.48 (s, 1H), 3.51 (d,
J=15.6 Hz, 1H), 3.13 (s, 2H), 2.97-2.96 (m, 4H), 2.83-2.79 (m, 5H),
1.43 (s, 3H), 1.37 (s, 3H), 1.26 (s, 3H). LCMS (ESI): m/z=494.0
[M+H].sup.+.
Example 357.
N-(6-(1-(2-Hydroxyethyl)piperidin-4-yl)-2,2-dimethyl-2,3-dihydrobenzofura-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01408##
[1481]
N-[2,2-Dimethyl-6-(4-piperidyl)-3H-benzofuran-5-yl]pyrazolo[1,5-a]p-
yrimidine-3-carboxamide (Example 62, Step D, 50.8 mg, 0.13 mmol)
was brought up in acetonitrile (1.3 ml, 24.7 mmol) and treated with
trimethylamine (0.45 ml, 3.24 mmol) followed by iodoethanol (29 mg,
0.169 mmol) and heated at 60.degree. C. for 72 h. The reaction
mixture was then concentrated and purified by reverse phase HPLC to
give
N-[6-[1-(2-hydroxyethyl)-4-piperidyl]-2,2-dimethyl-3H-benzofuran-5-yl]pyr-
azolo[1,5-a]pyrimidine-3-carboxamide (13.8 mg, 24% yield) as a
solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
9.61 (s, 1H), 9.39 (dd, J=7.0, 1.6 Hz, 1H), 8.87 (dd, J=4.3, 1.6
Hz, 1H), 8.68 (s, 1H), 7.74 (s, 1H), 6.65 (s, 1H), 4.36 (s, 1H),
3.51 (t, J=6.4 Hz, 2H), 3.00 (s, 2H), 2.98 (m, 2H), 2.88-2.75 (m,
1H), 2.40 (t, J=6.4 Hz, 2H), 2.15-2.00 (m, 2H), 1.82-1.57 (m, 4H),
1.42 (s, 6H). MS (ESI): m/z=436.2 [M+1].sup.+.
Example 358.
N-(3-Hydroxy-2,2-dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01409##
[1482] Step A. 1-Chloro-4-((2-methylallyl)oxy)-2-nitrobenzene
##STR01410##
[1484] Cesium carbonate (3.58 g, 11.0 mmol) was added portion-wise
to a solution of 4-chloro-3-nitrophenol (1.74 g, 10.0 mmol) in
N,N-dimethylformamide (25 ml) followed by addition of
3-bromo-2-methyl-prop-1-ene (1.62 g, 12.0 mmol). The mixture was
stirred for 3 h and filtered. The filtrate was concentrated in
vacuo and the residue partitioned between water and ethyl acetate.
The organic phase was isolated, washed with water and brine, dried
over magnesium sulfate and concentrated. The residue was purified
by silica gel chromatography (eluting gradient 0-20% isopropyl
acetate: heptane) to afford
1-chloro-4-((2-methylallyl)oxy)-2-nitrobenzene (2.00 g, 88% yield)
as a light yellow oil. MS (ESI): m/z=226[M-1].sup.-.
Step B. 4-(4-((2-Methylallyl)oxy)-2-nitrophenyl)morpholine
##STR01411##
[1486] A mixture of 1-chloro-4-(2-methylallyloxy)-2-nitro-benzene
(2.00 g, 8.8 mmol) and morpholine (23 ml, 263 mmol) was heated in a
sealed vial at 100.degree. C. for 36 h. The mixture was
concentrated in vacuo and the residue was partitioned between ethyl
ether and 5% aqueous citric acid. The organic phase was isolated,
washed with water and brine, dried over magnesium sulfate and
concentrated. The residue was purified by silica gel chromatography
(eluting gradient 0-20% isopropyl acetate: heptane) to afford
4-(4-((2-methylallyl)oxy)-2-nitrophenyl)morpholine (2.11 g, 78%
yield) as a yellow oil. MS (ESI): m/z=279[M+1].sup.+.
Step C. 5-((2-Methylallyl)oxy)-2-morpholinoaniline
##STR01412##
[1488] Iron (7.62 g, 136.5 mmol) was added portion-wise over a
period of 1 h to a mixture of
4-[4-(2-methylallyloxy)-2-nitro-phenyl]morpholine (2.11 g, 6.82
mmol) and saturated aqueous ammonium chloride (12 ml) in methanol
(40 ml) at 65.degree. C. After 30 min, the reaction was cooled to
room temperature, filtered through Celite and the precipitate was
washed with methanol. The filtrate was concentrated and the residue
partitioned between water and ethyl acetate. The organic phase was
isolated, washed with water and brine, dried over magnesium sulfate
and concentrated. The residue was purified by silica gel
chromatography (eluting gradient 0-4% methanol: dichloromethane) to
afford 5-((2-methylallyl)oxy)-2-morpholinoaniline (1.06 g, 62%
yield) as a light red oil. MS (ESI): m/z=249[M+1].sup.+.
Step D. 5-Amino-2-(2-methylallyl)-4-morpholinophenol
##STR01413##
[1490] A mixture of 5-(2-methylallyloxy)-2-morpholino-aniline (500
mg, 2.01 mmol) in dimethylformamide (6 ml) was subjected to a
microwave heating at 180.degree. C. for 12 h. The mixture was
concentrated in vacuo and the residue partitioned between ethyl
ether and water. The organic phase was isolated, washed with water
(3*20 ml) and brine, dried over magnesium sulfate and concentrated
to afford 5-amino-2-(2-methylallyl)-4-morpholinophenol (498 mg,
100% yield) MS (ESI): m/z=249[M+1].sup.+.
Step E. 2,2-Dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-amine
##STR01414##
[1492] Potassium tert-butoxide (450 mg, 4.0 mmol) was added
portion-wise to a solution of
5-amino-2-(2-methylallyl)-4-morpholino-phenol in tetrahydrofuran
(25 ml) at 5.degree. C. The mixture was then heated in a sealed
vial at 60.degree. C. for 2 h. The mixture was concentrated in
vacuo and the residue partitioned between ethyl acetate and 1%
aqueous citric acid. The organic phase was isolated, washed with
water and brine, dried over magnesium sulfate and concentrated. The
residue was purified by silica gel chromatography (eluting gradient
0-4% methanol: dichloromethane) to afford
2,2-dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-amine (234 mg,
45%) as a colorless solid. .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 6.83 (t, J=1.0 Hz, 1H), 6.17 (s, 1H), 4.02 (s, 2H), 3.82
(dd, J=5.7, 3.4 Hz, 4H), 2.92-2.88 (m, 2H), 2.86-2.80 (m, 4H), 1.44
(s, 6H). MS (ESI): m/z=249[M+1].sup.+.
Step F.
N-(2,2-Dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-yl)pyrazolo[1-
,5-a]pyrimidine-3-carboxamide
##STR01415##
[1494] A mixture of 2,2-dimethyl-5-morpholino-3H-benzofuran-6-amine
(234 mg, 0.90 mmol), pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
hydrochloride (254 mg, 1.17 mmol), N,N-diisopropylethylamine (0.47
ml, 2.68 mmol) and 4-dimethylaminopyridine (22 mg, 0.18 mmol) in
pyridine (6 ml) was subjected to a microwave heating at 110.degree.
C. for 30 min. The mixture was concentrated in vacuo and the
residue partitioned between ethyl acetate and water. The organic
phase was isolated, washed with aqueous saturated citric acid,
aqueous saturated sodium bicarbonate and brine, dried over
magnesium sulfate and concentrated. The residue was purified by
silica gel chromatography (eluting gradient 0-100% isopropyl
acetate: heptane) to afford
N-(2,2-dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-yl)pyrazzolo[1,5-a]p-
yrimidine-3-carboxamide (309 mg, 88%) as a light yellow solid. MS
(ESI): m/z=394[M+1].sup.+.
Step G.
2,2-Dimethyl-5-morpholino-6-(pyrazolo[1,5-a]pyrimidine-3-carboxami-
do)-2,3-dihydrobenzofuran-3-yl acetate
##STR01416##
[1496] 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (196 mg, 0.86
mmol) was added portion-wise to a solution of
N-(2,2-dimethyl-5-morpholino-3H-benzofuran-6-yl)pyrazolo[1,5-a]pyrimidine-
-3-carboxamide (309 mg, 0.786 mmol) in acetic acid (12 ml). The
mixture was stirred for 3 h, concentrated in vacuo and the residue
partitioned between ethyl acetate and 1 M aqueous sodium carbonate.
The organic phase was isolated, washed with aqueous sodium
carbonate, water and brine, dried over magnesium sulfate and
concentrated. The residue was purified by silica gel chromatography
(eluting gradient 0-60% isopropyl acetate: heptane) to afford
2,2-dimethyl-5-morpholino-6-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-2,3-
-dihydrobenzofuran-3-yl acetate (290 mg, 82%). MS (ESI):
m/z=452[M+1].sup.+.
Step H.
N-(3-Hydroxy-2,2-dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01417##
[1498] A mixture of
[2,2-dimethyl-5-morpholino-6-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)--
3H-benzofuran-3-yl]acetate (280 mg, 0.62 mmol) and lithium
hydroxide (1M in water, 1.55 mmol) was stirred in a mixture of
methanol and tetrahydrofuran (4:1) for 4 h. The mixture was
concentrated and the residue partitioned between ethyl acetate and
1% aqueous citric acid. The organic phase was isolated and
concentrated to afford
N-(3-hydroxy-2,2-dimethyl-5-morpholino-2,3-dihydrobenzofuran-6-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide (162 mg, 62%) as a colorless
solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
10.83 (s, 1H), 9.38 (dd, J=7.0, 1.6 Hz, 1H), 8.96 (dd, J=4.3, 1.6
Hz, 1H), 8.72 (s, 1H), 7.98 (s, 1H), 7.38-7.35 (m, 1H), 7.34 (s,
1H), 5.41 (d, J=6.7 Hz, 1H), 4.66 (d, J=6.7 Hz, 1H), 3.88 (t, J=4.7
Hz, 4H), 2.90-2.77 (m, 4H), 1.35 (s, 3H), 1.28 (s, 3H). MS (ESI):
m/z=410[M+1].sup.+.
Example 359.
N-(2,2-dimethyl-5-morpholino-3-oxo-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,-
5-a]pyrimidine-3-carboxamide
##STR01418##
[1500] Dess-Martin periodinane (179 mg, 0.42 mmol) was added
portion-wise to a solution of
N-(3-hydroxy-2,2-dimethyl-5-morpholino-3H-benzofuran-6-yl)pyrazolo[1,5-a]-
pyrimidine-3-carboxamide (115 mg, 0.28 mmol) in dichloromethane (30
ml). The mixture was stirred for 3 h. The mixture was filtered
through celite, the filtrate concentrated and the residue
partitioned between ethyl acetate and saturated aqueous sodium
bicarbonate. The organic phase was isolated, washed with water and
brine, dried over magnesium sulfate and concentrated. The residue
was purified by silica gel chromatography (eluent 100% isopropyl
acetate) followed by recrystallisation from acetonitrile to afford
N-(2,2-dimethyl-5-morpholino-3-oxo-2,3-dihydrobenzofuran-6-yl)pyrazolo[1,-
5-a]pyrimidine-3-carboxamide (26 mg, 22%) as a colorless solid.
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 11.17 (s,
1H), 9.42 (dd, J=7.0, 1.6 Hz, 1H), 9.00 (dd, J=4.2, 1.6 Hz, 1H),
8.79 (s, 1H), 8.38 (s, 1H), 7.59 (s, 1H), 7.40 (dd, J=7.0, 4.2 Hz,
1H), 3.90 (t, J=4.5 Hz, 4H), 2.95-2.83 (m, 4H), 1.40 (s, 6H). MS
(ESI): m/z=408[M+1].sup.+.
Examples 360 and 361.
(R)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(2-hydroxypropan-2-yl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e and
(S)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(2-hydroxypropan-2-
-yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbo-
xamide
##STR01419##
[1502] The title compounds were made in a manner analogous to
Example 157 and 158 to give
(R)--N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-(2-hydroxypropan-2-yl)--
2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid-
e and
(S)--N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-(2-hydroxypropan-2-
-yl)-2-methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbo-
xamide with absolute stereochemistry assigned arbitrarily.
[1503] Example 360, Peak 1: .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 10.37 (s, 1H), 8.87-8.81 (m, 1H), 8.79 (s, 1H), 8.74-8.69
(m, 1H), 8.40 (s, 1H), 7.08 (dd, J=7.0, 4.2 Hz, 1H), 6.67 (s, 1H),
5.96 (tt, J=55.9, 4.3 Hz, 1H), 3.50 (d, J=15.5 Hz, 1H), 3.01-2.78
(m, 11H), 2.01 (s, 1H), 1.41 (s, 3H), 1.37 (s, 3H), 1.25 (s, 3H).
(ESI): m/z=501.2 [M+1].sup.+.
[1504] Example 361, Peak 2: .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 10.37 (s, 1H), 8.87-8.81 (m, 1H), 8.79 (s, 1H), 8.75-8.70
(m, 1H), 8.40 (s, 1H), 7.08 (dd, J=7.0, 4.2 Hz, 1H), 6.67 (s, 1H),
5.96 (tt, J=55.9, 4.3 Hz, 1H), 3.50 (d, J=15.5 Hz, 1H), 2.99-2.76
(m, 12H), 1.41 (s, 3H), 1.37 (s, 3H), 1.25 (s, 3H). (ESI):
m/z=501.2 [M+1].sup.+.
Example 362.
N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-((difluoromethoxy)methyl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01420##
[1506] The title compound was made in a manner analogous to Example
155 and 156 to give
N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-((difluoromethoxy)methyl)-2--
methyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
.sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. 9.15 (d, J=7.0 Hz,
1H), 8.95 (d, J=4.1 Hz, 1H), 8.67 (s, 1H), 8.24 (s, 1H), 8.10 (s,
1H), 7.31 (dd, J=7.0, 4.2 Hz, 1H), 6.74 (s, 1H), 3.94 (s, 2H),
3.34-3.19 (m, 2H), 3.18 (d, J=3.5 Hz, 1H), 3.12 (s, 5H), 3.07-2.97
(m, 5H), 1.50 (s, 3H), 1.31 (s, 1H). (ESI): m/z=523.2
[M+1].sup.+.
Example 363.
N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)-2-methyl--
2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01421##
[1508] The title compound was made in a manner analogous to Example
157 and 158 to give
N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-(2-hydroxypropan-2-yl)-2-methyl--
2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 10.50 (s, 1H),
8.84-8.73 (m, 3H), 8.44 (s, 1H), 7.02 (dd, J=7.0, 4.1 Hz, 1H), 6.67
(s, 1H), 3.63 (t, J=4.9 Hz, 2H), 3.50 (d, J=15.4 Hz, 1H), 3.11 (d,
J=11.4 Hz, 2H), 2.79 (d, J=15.4 Hz, 1H), 2.68 (dt, J=11.4, 8.4 Hz,
2H), 2.06 (s, 1H), 1.79 (s, 3H), 1.51 (t, J=5.4 Hz, 1H), 1.41 (s,
3H), 1.36 (s, 3H), 1.25 (s, 3H). (ESI): m/z=466.2 [M+1].sup.+.
Example 364.
N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(difluoromethyl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01422##
[1510] The title compound was made in a manner analogous to
Examples 50 and 51 to give
N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-(difluoromethyl)-2-methyl-2,-
3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
.sup.1H NMR (400 MHz, Chloroform-d) .delta. 10.38 (s, 1H), 8.84 (d,
J=7.0 Hz, 1H), 8.79 (s, 1H), 8.73 (d, J=4.1 Hz, 1H), 8.43 (s, 1H),
7.08 (dd, J=7.0, 4.1 Hz, 1H), 6.71 (s, 1H), 5.85 (dt, J=82.7, 55.8
Hz, 2H), 3.43 (d, J=16.2 Hz, 1H), 3.08-2.80 (m, 11H), 1.54 (s, 3H).
(ESI): m/z=493.2 [M+1].sup.+.
Examples 365 and 366.
(R)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)-2-(trif-
luoromethyl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbox-
amide and
(S)--N-(6-(4-(2,2-Difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl-
)-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-
-3-carboxamide
##STR01423##
[1512] The title compounds were made in a manner analogous to
Example 153 and 154 to give
(R)--N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl)-2-(trif-
luoromethyl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carbox-
amide and
(S)--N-(6-(4-(2,2-difluoroethyl)piperazin-1-yl)-2-(hydroxymethyl-
)-2-(trifluoromethyl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-
-3-carboxamide with absolute stereochemistry assigned
arbitrarily.
[1513] Example 365, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.43 (s, 1H), 9.36 (d, J=7.0 Hz, 1H),
8.94 (d, J=4.1 Hz, 1H), 8.68 (s, 1H), 8.39 (s, 1H), 7.35 (dd,
J=7.0, 4.2 Hz, 1H), 6.92 (s, 1H), 6.19 (tt, J=55.7, 4.4 Hz, 1H),
5.59 (t, J=6.0 Hz, 1H), 3.76 (qd, J=12.1, 6.0 Hz, 2H), 3.49 (d,
J=16.6 Hz, 1H), 3.32 (s, 1H), 2.89-2.72 (m, 10H). (ESI): m/z=527.2
[M+1].sup.+.
[1514] Example 366, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.43 (s, 1H), 9.35 (d, J=7.0 Hz, 1H),
8.94 (d, J=4.1 Hz, 1H), 8.67 (s, 1H), 8.39 (s, 1H), 7.34 (dd,
J=7.0, 4.1 Hz, 1H), 6.91 (s, 1H), 6.19 (tt, J=55.6, 4.2 Hz, 1H),
5.59 (t, J=6.1 Hz, 1H), 3.75 (qd, J=12.1, 5.8 Hz, 2H), 3.49 (d,
J=16.6 Hz, 1H), 3.32 (s, 1H), 2.94-2.72 (m, 10H). (ESI): m/z=527.2
[M+1].sup.+.
Example 367 and 368.
N-[(2R)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide
##STR01424##
[1515] Step A. 2-Fluoro-4-(2-methylallyloxy)-1-nitro-benzene
##STR01425##
[1517] To a solution of 3-fluoro-4-nitrophenol (20.6 g, 131.2 mmol)
in acetonitrile was added 3-bromo-2-methylpropene (15.6 ml, 183.7
mmol) and potassium carbonate (25.4 g, 183.7 mmol). The reaction
mixture was stirred at 55.degree. C. for 13 h and then cooled to
room temperature and maintained there with stirring overnight. The
mixture was diluted with isopropyl acetate and washed with water.
The aqueous phase was isolated and extracted with isopropyl
acetate. The combined organic phases were dried over sodium
sulfate, filtered and purified by column chromatography (eluting
gradient 0-25% isopropyl acetate: heptanes) to give the title
compound as a white crystalline solid (26.0 g, 94% yield). .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 8.15 (t, J=9.2
Hz, 1H), 7.20 (dd, J=13.7, 2.7 Hz, 1H), 7.00 (ddd, J=9.3, 2.7, 1.1
Hz, 1H), 5.11-5.04 (m, 1H), 5.01 (d, J=1.5 Hz, 1H), 4.66 (s, 2H),
1.81-1.73 (m, 3H).
Step B. 4-[5-(2-Methylallyloxy)-2-nitro-phenyl]morpholine
##STR01426##
[1519] To a mixture of
2-fluoro-4-(2-methylallyloxy)-1-nitro-benzene (26.0 g, 123.2 mmol),
and potassium carbonate (56.2 g, 406.6 mmol) in dimethyl sulfoxide
(186.7 ml, 2600 mmol) was added morpholine (10.7 ml, 123.20 mmol)
and the mixture was heated to 100.degree. C. After 40 min, the
reaction was cooled to room temperature and diluted with water and
ethyl acetate. The organic phase was isolated and washed with
saturated aqueous sodium bicarbonate. The aqueous phase was then
extracted with ethyl acetate (3.times.). The combined organic
phases were washed brine, dried over sodium sulfate, filtered,
concentrated and purified by column chromatography (eluting
gradient 0-50% isopropyl acetate: heptanes) to give the title
product as a bright yellow-orange crystalline solid (32.3 g, 94%
yield). .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
7.92 (d, J=9.0 Hz, 1H), 6.72-6.66 (m, 2H), 5.13-5.04 (m, 1H), 5.00
(s, 1H), 4.60 (s, 2H), 3.77-3.64 (m, 4H), 3.07-2.91 (m, 4H), 1.78
(s, 3H).
Step C. 2-(2-Methylallyl)-5-morpholino-4-nitro-phenol
##STR01427##
[1521] A solution of
4-[5-(2-methylallyloxy)-2-nitro-phenyl]morpholine (375 mg, 1.35
mmol) was heated in dimethylformamide (2 ml) at 220.degree. C. for
60 min. The reaction was cooled to room temperature and diluted
with isopropyl acetate and brine. The aqueous phase was isolated
and extracted with isopropyl acetate (3.times.). The combined
organic phases were dried over sodium sulfate, filtered and
purified by column chromatography (eluting gradient 0-50% isopropyl
acetate: heptanes) to give the desired product (44.1 mg, 11.8%
yield) along with recovered starting material and undesired
regioisomers. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.73 (s, 1H), 7.74 (s, 1H), 6.59 (s, 1H), 4.84-4.73 (m,
1H), 4.64 (dd, J=2.2, 0.9 Hz, 1H), 3.79-3.64 (m, 5H), 3.20 (s, 2H),
2.97-2.88 (m, 5H), 1.66 (s, 3H).
Step D. 1-(2-Hydroxy-4-morpholino-5-nitro-phenyl)propan-2-one
##STR01428##
[1523] To a solution of
2-(2-Methylallyl)-5-morpholino-4-nitro-phenol (283.5 mg, 1.02 mmol)
in water (0.08 M) and dioxane (0.03 M) was added osmium tetroxide
(0.08 M in tert-butyl alcohol, 0.6 ml, 0.05 mmol) followed by
sodium periodate (435.8 mg, 2.04 mmol). The suspension was stirred
overnight at room temperature, poured into water and extracted with
dichloromethane. The organic phase was isolated, dried over sodium
sulfate, concentrated and purified by column chromatography
(eluting gradient 0-100% isopropyl acetate: heptanes) to give the
desired product (135.2 mg, 47% yield). .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 8.26 (s, 1H), 7.78 (s, 1H), 6.60 (s, 1H),
3.88-3.81 (m, 4H), 3.73 (s, 2H), 3.08-2.97 (m, 4H), 2.35 (s,
3H).
Step E. Methyl
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetate
##STR01429##
[1525] A mixture of
1-(2-hydroxy-4-morpholino-5-nitro-phenyl)propan-2-one (1.7 g, 6.07
mmol) methyl(triphenylphosphoranylidine)acetate (2.13 g, 6.37 mmol)
in chloroform (100 ml) was stirred at 60.degree. C. for 2 h.
Triethylamine (6 ml) was added and the mixture was stirred at
60.degree. C. for 12 h. The reaction was then concentrated and
purified by column chromatography (eluent 3% ethyl acetate:
petroleum ether) to afford methyl
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetate (1.6 g,
78% yield) as a yellow solid. (ESI): m/z=337.1 [M+1].sup.+.
Step F.
2-(2-Methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetaldehyde
##STR01430##
[1527] To a mixture of diisobutylaluminium hydride (2.01 ml, 2.01
mmol) in dichloromethane (10 ml) was added methyl
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetate (450.0
mg, 1.34 mmol) drop-wise at -78.degree. C. over 5 min and the
reaction was maintained there for 2 h. The mixture was quenched
with sodium sulfate decahydrate, filtered, concentrated and
purified by column chromatography (eluent 15% ethyl acetate:
petroleum ether) to afford
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetaldehyde
(450 mg, 99% yield) as a yellow solid. (ESI): m/z=307.1
[M+1].sup.+.
Step G.
4-[2-(2,2-Difluoroethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morph-
oline
##STR01431##
[1529] A mixture of diethylaminosulfur trifluoride (1.48 g, 7.35
mmol) in dichloromethane (30 ml) was added drop-wise to
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetaldehyde
(450.0 mg, 1.47 mmol) at -78.degree. C. and the reaction was
maintained there for 30 min followed by room temperature for 12 h.
The mixture was concentrated and purified by column chromatography
(eluent 15% ethyl acetate: petroleum ether) to afford
4-[2-(2,2-difluoroethyl)-2-methyl-5-nitro-3H-benzofuran-6-yl]morpholine
(320 mg, 63% yield) as a yellow solid. (ESI): m/z=329.1
[M+1].sup.+.
Step H.
2-(2,2-Difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine
##STR01432##
[1531] The title compound was made in a manner analogous to Example
2, Step B to afford
2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-amine
(245 mg, 84% yield) as a colorless oil. (ESI): m/z=299.1
[M+1].sup.+.
Examples 367 and 368.
N-[(2R)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide and
N-[(2S)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide
##STR01433##
[1533] The title compounds were made in a manner analogous to
Examples 29 and 30 to give
N-[(2R)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (130 mg, 36% yield) and
N-[(2S)-2-(2,2-difluoroethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]py-
razolo[1,5-a]pyrimidine-3-carboxamide (120 mg, 33% yield) as yellow
solids.
[1534] Example 367, Peak 1: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.44 (s, 1H), 9.36 (d, J=7.0 Hz, 1H),
8.93 (d, J=4.1 Hz, 1H), 8.67 (s, 1H), 8.32 (s, 1H), 7.34 (dd,
J=7.0, 4.2 Hz, 1H), 6.76 (s, 1H), 3.83 (t, J=4.2 Hz, 4H), 3.20 (d,
J=15.8 Hz, 1H), 3.00 (d, J=15.8 Hz, 1H), 2.81 (t, J=4.3 Hz, 4H),
2.50 (s, 1H), 2.35 (td, J=17.4, 4.6 Hz, 2H), 1.44 (s, 3H). MS
(ESI): m/z=444.2 [M+1].sup.+. MS (ESI): m/z=299.1 [M+1].sup.+.
[1535] Example 368, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.45 (s, 1H), 9.38 (dd, J=7.0, 1.4 Hz,
1H), 8.95 (dd, J=4.2, 1.4 Hz, 1H), 8.69 (s, 1H), 8.33 (s, 1H), 7.35
(dd, J=7.0, 4.2 Hz, 1H), 6.77 (s, 1H), 3.83 (t, J=4.2 Hz, 4H), 3.34
(s, 2H), 3.21 (d, J=15.8 Hz, 1H), 3.01 (d, J=15.8 Hz, 1H), 2.82 (t,
J=4.5 Hz, 4H), 2.36 (td, J=17.4, 4.7 Hz, 1H), 1.45 (s, 3H). MS
(ESI): m/z=299.1 [M+1].sup.+.
Example 369.
N-[1'-(2-Hydroxyethyl)-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01434##
[1536] Step A.
2-(6-Fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol
##STR01435##
[1538] To a solution of 6-fluorospiro[3H-benzofuran-2,4'-piperidine
(Example 142, Step C; 414.0 mg, 2 mmol) in acetonitrile (15 ml) was
added potassium carbonate (689.2 mg, 4.99 mmol) and 2-bromoethanol
(374.5 mg, 3 mmol). The reaction was stirred at 45.degree. C. for
12 h, cooled to room temperature, filtered and concentrated to give
2-(6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol (561
mg, quant.) as a yellow solid. MS (ESI): m/z=252.1 [M+1].sup.+.
Step B.
2-(6-Fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl)eth-
anol
##STR01436##
[1540] To a solution of
2-(6-fluorospiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol
(510.0 mg, 2 mmol) in dichloromethane (9 ml) was added fuming
nitric acid (1 ml, 16 mmol) and the reaction was stirred for 2 h.
The reaction was quenched with saturated aqueous sodium bicarbonate
and extracted with dichloromethane (2.times.). The combined organic
phases were isolated, washed with brine, dried over magnesium
sulfate and concentrated to give
2-(6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol
(374 mg, 35% yield) as a yellow oil. MS (ESI): m/z=297.1
[M+1].sup.+.
Step C.
2-(6-Morpholino-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-
)ethanol
##STR01437##
[1542] A mixture of potassium carbonate (435.2 mg, 3.16 mmol),
morpholine (0.33 ml, 3.79 mmol) and
2-(6-fluoro-5-nitro-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol
(374.0 mg, 1.26 mmol) in acetonitrile (10 ml) was stirred for 2 h.
The reaction was diluted with water and extracted with ethyl
acetate (2.times.). The combined organic phases were isolated,
washed with saturated brine, dried over anhydrous magnesium sulfate
and concentrated. The residue was purified by column chromatography
(eluent 1:10 methanol: dichloromethane) to afford
2-(6-morpholino-5-nitro-spiro
3H-benzofuran-2,4'-piperidine]-1'-yl)ethanol (214 mg, 47% yield) as
an orange solid. MS (ESI): m/z=364.2 [M+1].sup.+.
Step D.
2-(5-Amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-
)ethanol
##STR01438##
[1544] The title compound was made in a manner analogous to Example
2, Step B to afford
2-(5-amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl)ethano-
l (160 mg, 64% yield) as a yellow oil. (ESI): m/z=334.2
[M+1].sup.+.
Step E.
2-(5-Amino-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-1'-yl-
)ethanol
##STR01439##
[1546] The title compound was made in a manner analogous to Example
1, Step C to afford 2
N-[1'-(2-hydroxyethyl)-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (91 mg, 40% yield) as
a yellow solid. .sup.1H NMR (400 MHz, Chloroform-d) .delta. 10.47
(s, 1H), 8.87-8.74 (m, 3H), 8.43 (s, 1H), 7.07 (dd, J=7.0, 4.1 Hz,
1H), 6.69 (s, 1H), 3.95 (t, J=4.5 Hz, 4H), 3.64 (t, J=5.4 Hz, 2H),
3.02 (s, 2H), 2.92 (t, J=4.6 Hz, 4H), 2.74-2.57 (m, 4H), 2.00 (dt,
J=13.3, 4.3 Hz, 2H), 1.83 (ddd, J=13.2, 8.8, 4.7 Hz, 2H), 1.61 (s,
2H). (ESI): m/z=479.2 [M+1].sup.+.
TABLE-US-00011 TABLE 11 The following examples were made in a
manner similar to that for Example 152: Ex. Name Structure NMR, MS
370 N-[1'-(2,2- difluoroethyl)-6- morpholino- spiro[3H-
benzofuran-2,4'- piperidine]-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01440## .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 10.47 (s, 1H), 8.87-8.74 (m, 3H), 8.43 (s, 1H), 7.07 (dd, J
= 7.0, 4.1 Hz, 1H), 6.68 (s, 1H), 5.91 (tt, J = 56.1, 4.3 Hz, 1H),
3.95 (t, J = 4.5 Hz, 4H), 3.01 (s, 2H), 2.92 (t, J = 4.5 Hz, 4H),
2.88-2.65 (m, 6H), 1.99 (dt, J = 13.1, 3.7 Hz, 2H), 1.84 (ddd, J =
13.5, 9.3, 4.2 Hz, 2H). MS (ESI): m/z = 499.2 [M + l].sup.+. 371
N-(6-(4- (Hydroxymethyl) piperidin-1-yl)- 1'-methyl-3H-
spiro[benzofuran- 2,4'-piperidin]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01441## .sup.1H NMR (400 MHz,
Chloroform-d) .delta. 10.51 (s, 1H), 8.88-8.73 (m, 3H), 8.43 (s,
1H), 7.02 (dd, J = 7.0, 4.3 Hz, 1H), 6.69 (s, 1H), 3.71-3.56 (m,
2H), 3.10 (d, J = 11.4 Hz, 2H), 3.01 (s, 2H), 2.76-2.42 (m, 6H),
2.34 (s, 3H), 2.00 (d, J = 13.2 Hz, 3H), 1.90-1.67 (m, 6H). (ESI):
m/z = 477.2 [M + 1].sup.+. 372 N-(1'-isopropyl- 6-morpholino-
spiro[3H- benzofuran-2,4'- piperidine]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01442## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.47 (d, J = 4.8 Hz, 1H), 9.39
(dd, J = 7.0, 1.6 Hz, 1H), 8.95 (dd, J = 4.1, 1.7 Hz, 1H), 8.69 (d,
J = 2.1 Hz, 1H), 8.37 (s, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.81
(d, J = 2.6 Hz, 1H), 3.84 (t, J = 4.4 Hz, 4H), 3.50-3.36 (m, 4H),
3.21-3.06 (m, 3H), 2.82 (t, J = 4.5 Hz, 4H), 2.08 (dt, J = 50.5,
14.3 Hz, 4H), 1.30 (dd, J = 6.6, 3.6 Hz, 6H). (ESI): m/z = 477.3 [M
+ 1].sup.+. 373 N-(6-(4-(2- Amino-2- oxoethyl)piperazin- 1-yl)-1'-
methyl-3H- spiro[benzofuran- 2,4'-piperidin]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01443## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.42 (s, 1H), 9.40- 9.35 (m, 1H), 9.00-8.95
(m, 1H), 8.67 (s, 1H), 8.34 (s, 1H), 7.35 (dd, J = 6.8, 4.0 Hz,
1H), 7.23 (s, 1H), 7.17 (s, 1H), 6.72 (s, 1H), 3.03- 3.00 (m, 4H),
2.84-2.83 (m, 4H), 2.74-2.72 (m, 4H), 2.69-2.60 (m, 4H), 2.32 (s,
3H), 1.86-1.78 (m, 4H). LCMS (ESI) m/z: 505.2 [M + H].sup.+. 374
N-(1'-Acetyl-6- (4-(2-amino-2- oxoethyl)piperazin- 1-yl)-3H-
spiro[benzofuran- 2,4'-piperidin]-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01444## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.43 (s, 1H), 9.40- 9.35 (m, 1H), 9.00-8.95
(m, 1H), 8.68 (s, 1H), 8.36 (s, 1H), 7.35 (dd, J = 6.8, 4.0 Hz,
1H), 7.22 (s, 1H), 7.17 (s, 1H), 6.75 (s, 1H), 3.78- 3.73 (m, 1H),
3.54-3.41 (m, 2H), 3.38-3.32 (m, 1H), 3.04-3.01 (m, 4H), 2.85 (s,
4H), 2.74-2.72 (m, 4H), 2.03 (s, 3H), 1.86-1.66 (m, 4H). LCMS
(ESI): m/z = 533.2 [M + H].sup.+. 375 N-(6-(4-(2-
(Cyclopropylamino)- 2-oxoethyl)piperazin- 1-yl)-3H-
spiro[benzofuran- 2,4'-piperidin]- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01445## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.36 (s, 1H), 8.90-8.85 (m, 1H), 8.78 (s, 1H),
8.75- 8.70 (m, 1H), 8.41 (s, 1H), 7.17 (s, 1H), 7.07 (dd, J = 6.8,
4.0 Hz, 1H), 6.68 (s, 1H), 3.17-3.12 (m, 4H), 3.08 (s, 2H),
3.03-2.94 (m, 6H), 2.78-2.74 (m, 5H), 1.93-1.92 (m, 2H), 1.83- 1.80
(m, 2H), 0.84-0.81 (m, 2H), 0.55-0.50 (m, 2H). LCMS (ESI): m/z =
531.3 [M + H].sup.+. 376 N-(6-(4-(2- (Cyclopropylamino)-
2-oxoethyl)piperazin- 1-yl)-1'- methyl-3H- spiro[benzofuran-
2,4'-piperidin]- 5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01446## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.36 (s,
1H), 8.84-8.82 (m, 1H), 8.78 (s, 1H), 8.72- 8.70 (m, 1H), 8.41 (s,
1H), 7.17 (s, 1H), 7.01 (dd, J = 6.4, 4.0 Hz, 1H), 6.68 (s, 1H),
3.08 (s, 2H), 3.02 (s, 2H), 2.94-2.92 (m, 4H), 2.76-2.74 (m, 5H),
2.65- 2.61 (m, 3H), 2.37 (s, 3H), 2.04-2.02 (m, 2H), 2.00- 1.98 (m,
2H), 0.84-0.82 (m, 2H), 0.55-0.50 (m, 2H). LCMS (ESI): m/z = 545.3
[M + H].sup.+. 377 N-(6-(2,2- Difluoroethoxy)- 3H-
spiro[benzofuran- 2,4'-piperidin]- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01447## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.32 (s, 1H), 9.40- 9.35 (m, 1H), 8.85-8.75
(m, 2H), 8.67 (s, 1H), 8.35 (s, 1H), 7.34 (dd, J = 7.2, 4.0 Hz,
1H), 6.75 (s, 1H), 6.67- 6.40 (m, 1H), 4.46-4.37 (m, 2H), 3.32-3.15
(m, 4H), 3.11 (s, 2H), 2.05-1.95 (m, 4H). LCMS (ESI): m/z = 430.1
[M + H].sup.+. 378 N-(6-(2,2- difluoroethoxy)- 1'-methyl-3H-
spiro[benzofuran- 2,4'-piperidin]- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01448## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.24 (s, 1H), 8.84-8.80 (m, 1H), 8.75 (s, 1H),
8.70 (dd, J = 4.0, 1.6 Hz, 1H), 8.42 (s, 1H), 7.04 (dd, J = 6.8,
4.0 Hz, 1H), 6.42 (s, 1H), 6.40-6.10 (m, 1H), 4.30-4.22 (m, 2H),
3.01 (s, 2H), 2.58-2.53 (m, 4H), 2.35 (s, 3H), 2.02-2.00 (m, 2H),
1.99-1.68 (m, 2H). LCMS (ESI): m/z = 444.2 [M + H].sup.+.
Example 379.
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-y-
l]-6-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01449##
[1547] Step A. Ethyl
6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-carbo-
xylate
##STR01450##
[1549] A mixture of ethyl
6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate (1.5 g, 5.55 mmol),
N-(4-methoxybenzyl)-N-methylamine (1.67 g, 11.04 mmol) and
N,N-diisopropylethylamine (2.75 ml, 16.63 mmol) in ethanol (25 ml)
was stirred at 85.degree. C. for 96 h. The mixture was concentrated
to dryness and the residue was purified by column chromatography
(eluent 50% ethyl acetate: petroleum ether) to afford ethyl
6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-carbo-
xylate (1120 mg, 57.5% yield) as a yellow solid. (ESI): m/z=341.2
[M+1].sup.+.
Step B.
6-[(4-Methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine--
3-carboxylic acid
##STR01451##
[1551] A mixture of ethyl
6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-carbo-
xylate (50 mg, 0.15 mmol) and lithium hydroxide hydrate (7.0 mg,
0.17 mmol) in tetrahydrofuran (1 ml), methanol (1 ml) and water (1
ml) was stirred in a sealed tube at 100.degree. C. under microwave
irradiation for 45 min. The mixture will neutralized with 2N HCl
and concentrated to dryness to afford
6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-carbo-
xylic acid (50 mg, 98% yield) as a yellow solid. (ESI): m/z=313.1
[M+1].sup.+.
Step C.
N-[6-[4-(2,2-Difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofu-
ran-5-yl]-6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide
##STR01452##
[1553] A mixture of
6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-amin-
e (120.0 mg, 0.39 mmol),
6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-carbo-
xylic acid (150.0 mg, 0.48 mmol), HATU (300.0 mg, 0.79 mmol) and
N,N-diisopropylethylamine (0.3 ml, 1.72 mmol) in
N,N-dimethylformamide (2 ml) was stirred for 12 h. The reaction was
then purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10 um
acetonitrile 50-70% (10 mM ammonium bicarbonate) in water) to
afford
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-y-
l]-6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-3-car-
boxamide (96 mg, 41% yield).
Step D.
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofu-
ran-5-yl]-6-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01453##
[1555]
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofur-
an-5-yl]-6-[(4-methoxyphenyl)methyl-methyl-amino]pyrazolo[1,5-a]pyrimidine-
-3-carboxamide (120 mg, 0.2 mmol) and trifluoroacetic acid (2 ml,
0.2000 mmol) in dichloromethane (6 ml) was stirred for 3 h.
[1556] The reaction was then purified by preparative HPLC (Xbridge
21.2*250 mm c18, 10 um acetonitrile 50-70% (10 mM ammonium
bicarbonate) in water) to afford
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-y-
l]-6-(methyl amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide (60 mg,
62% yield). .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.30 (s, 1H), 8.61 (d, J=2.6 Hz, 1H), 8.38-8.27 (m, 3H),
6.70 (s, 1H), 2.99 (s, 2H), 2.93-2.73 (m, 14H), 1.41 (s, 6H).
(ESI): m/z=502.2 [M+1].sup.+.
TABLE-US-00012 TABLE 12 The following examples were made in a
manner similar to that for Example 64: Ex. Name Structure NMR, MS
380 N-(1'-methyl-6- morpholino-3H- spiro[benzofuran-
2,4'-piperidin]- 5-yl)-6- (methylamino) pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01454## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.33 (s, 1H), 8.64 (d, J = 2.6
Hz, 1H), 8.38-8.29 (m, 3H), 6.75 (s, 1H), 6.31 (q, J = 4.9 Hz, 1H),
3.83 (t, J = 4.5 Hz, 4H), 2.98 (s, 2H), 2.84-2.73 (m, 8H), 2.45 (s,
3H), 2.20 (s, 3H), 1.87- 1.70 (m, 4H). (ESI): m/z = 478.3 [M +
1].sup.+. 381 and 382 (S)-N-(6-(4-(2,2- difluoroethyl)
piperazin-1-yl)-2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzofuran- 5-yl)-6- (methylamino) pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01455## Example 381, Peak 1:
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.30 (s,
1H), 8.61 (d, J = 2.5 Hz, 1H), 8.35 (s, 1H), 8.33- 8.26 (m, 2H),
6.69 (s, 1H), 6.44-6.32 (m, 1H), 6.26- 6.01 (m, 1H), 5.05 (t, J =
5.8 Hz, 1H), 3.42 (t, J = 5.5 Hz, 2H), 3.18 (d, J = 15.7 Hz, 1H),
2.93-2.66 (m, 14H), 1.33 (s, 3H). (ESI): m/z = 502.2 [M + 1].sup.+.
(R)-N-(6-(4- (2,2- difluoroethyl) piperazin-1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran- 5-yl)-6-
(methylamino) pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
##STR01456## Example 382, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.30 (s, 1H), 8.61 (d, J = 2.4 Hz, 1H),
8.35 (s, 1H), 8.33- 8.28 (m, 2H), 6.69 (s, 1H), 6.48-6.30 (m, 1H),
5.05 (t, J = 5.8 Hz, 1H), 3.42 (t, J = 5.4 Hz, 2H), 3.18 (d, J =
15.7 Hz, 1H), 2.88 (dd, J = 15.6, 4.3 Hz, 1H), 2.84- 2.74 (m, 14H),
1.33 (s, 3H). (ESI): m/z = 502.2 [M + 1].sup.+. stereochemistry
assigned arbitrarily) 383 N-(6-(4-(2,2- difluoroethyl)
piperazin-1-yl)- 2',3',5',6'- tetrahydro-3H- spiro[benzofuran-
2,4'-pyran]-5- yl)-6- (methylamino) pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01457## .sup.1H NNMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.29 (s, 1H), 8.61 (d, J = 2.6 Hz, 1H),
8.33 (dd, J = 20.7, 3.1 Hz, 3H), 6.76 (s, 1H), 6.44-6.31 (m, 1H),
3.77 (dt, J = 11.6, 5.5 Hz, 2H), 3.63 (dt, J = 10.9, 4.9 Hz, 2H),
3.33 (s, 2H), 3.05 (s, 2H), 2.92-2.73 (m, 12H), 1.79 (t, J = 5.6
Hz, 4H). .sup.19F NMR (376 MHz, dimethyl sulfoxide-d.sub.6)
.delta.- 118.43. (ESI): m/z = 528.3 [M + 1].sup.+.
Example 384.
N-(6-Cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide
##STR01458##
[1557] Step A. 6-Cyclopropyl-2,2-dimethyl-5-nitro-3H-benzofuran
##STR01459##
[1559] A mixture of 6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran
(300.0 mg, 1.1 mmol), cyclopropylboronic acid (142.1 mg, 1.65
mmol), tricyclohexylphosphine (61.84 mg, 0.22 mmol), palladium
acetate (24.75 mg, 0.11 mmol) and potassium phosphate tribasic
(819.12 mg, 3.86 mmol) in toluene (8 ml) and water (1 ml) was
stirred under nitrogen at 110.degree. C. for 2 h under microwave
conditions. The reaction was concentrated to dryness and the
residue was taken up in ethyl acetate (20 ml) and the resulting
organic phase was washed with water (2.times.) and brine, dried
over magnesium sulfate, concentrated to dryness and purified by
column chromatography (eluent 25% ethyl acetate: isohexane) to
afford 6-cyclopropyl-2,2-dimethyl-5-nitro-3H-benzofuran (220 mg,
86% yield) as a yellow oil. MS (ESI): m/z=234.2 [M+1].sup.+.
Step B. 6-Cyclopropyl-2,2-dimethyl-3H-benzofuran-5-amine
##STR01460##
[1561] The title compound was made in a manner analogous to Example
2, Step B to afford
6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-amine (100 mg, 96%
yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.=6.54 (s, 1H),
6.46 (s, 1H), 2.93 (s, 2H), 1.75-1.60 (m, 1H), 1.44 (s, 6H),
0.96-0.82 (m, 2H), 0.65-0.53 (m, 2H).
Step C.
N-(6-Cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide
##STR01461##
[1563] The title compound was made in a manner analogous to Example
378, Step C to afford
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide (120 mg, 47% yield). .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.04 (s, 1H), 9.38 (dd, J=7.0, 1.6 Hz,
1H), 8.89 (dd, J=4.3, 1.6 Hz, 1H), 8.69 (s, 1H), 8.02 (s, 1H), 7.32
(dd, J=7.0, 4.2 Hz, 1H), 6.49 (s, 1H), 3.00 (s, 2H), 1.92 (td,
J=8.4, 4.4 Hz, 1H), 1.40 (s, 6H), 1.10-0.99 (m, 2H), 0.73-0.62 (m,
2H). MS (ESI): m/z=349.2 [M+1].sup.+.
Example 385.
N-(2-methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR01462##
[1564] Step A. 6-Chloro-1,1-dioxo-1,2-benzothiazol-3-one
##STR01463##
[1566] To a mixture of methyl 4-chloro-2-(chlorosulfonyl)benzoate
(500 mg, 1.86 mmol) in tetrahydrofuran (10 ml) was added ammonium
hydroxide (2 ml, 28%). The mixture was stirred at room temperature
for 1 h and then concentrated to afford
6-chloro-1,1-dioxo-1,2-benzothiazol-3-one (400 mg) as a white
solid, which was used without further purification. MS (ESI):
m/z=218.1 [M+1].sup.+.
Step B. 6-Chloro-2-methyl-1,1-dioxo-1,2-benzothiazol-3-one
##STR01464##
[1568] A mixture of 6-chloro-1,1-dioxo-1,2-benzothiazol-3-one (400
mg, 1.84 mmol), iodomethane (391 mg, 2.76 mmol) and cesium
carbonate (898 mg, 2.76 mmol) in N,N-dimethylformamide (6 ml) was
stirred at 80.degree. C. in a sealed tube for 12 h. Water was added
and the reaction was extracted with ethyl acetate (20 ml). The
organic phase was isolated, washed with brine, dried over sodium
sulfate and concentrated to afford
6-chloro-2-methyl-1,1-dioxo-1,2-benzothiazol-3-one (340 mg) as a
brown solid, which was used without further purification. MS (ESI):
m/z=232.1 [M+1].sup.+.
Step C. 1
6-Chloro-2-methyl-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one
##STR01465##
[1570] To a mixture of
6-chloro-2-methyl-1,1-dioxo-1,2-benzothiazol-3-one (500 mg, 2.16
mmol) in fuming sulfuric acid (6 ml) was added drop-wise fuming
nitric acid (2 ml). The mixture was stirred at 70.degree. C. for 12
h. The reaction was cooled to room temperature and poured into ice
water. The reaction was extracted with ethyl acetate (2.times.20
ml). The organic phases were combined, dried over sodium sulfate
and concentrated. The residue was purified by column chromatography
(eluent 1:5 ethyl acetate: petroleum ether) to afford
6-chloro-2-methyl-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (52 mg,
9% yield over 3 steps) as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.44 (s, 1H), 8.14 (s, 1H), 3.32 (s, 3H).
Step D.
2-Methyl-6-morpholino-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one
##STR01466##
[1572] A mixture of
6-chloro-2-methyl-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (38 mg,
0.14 mmol) in acetonitrile (3 ml) was treated with morphine (20 mg,
0.21 mmol) and stirred for 2 h at ambient temperature. Water was
added and the reaction was washed with ethyl acetate. The organic
phase was isolated, dried over sodium sulfate and concentrated to
afford
2-methyl-6-morpholino-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (43
mg, 96%) as a yellow solid. MS (ESI): m/z=328.1 [M+1].sup.+.
Step E.
2-Methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine
##STR01467##
[1574] To a mixture of
2-methyl-6-morpholino-5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (43
mg, 0.13 mmol) in tetrahydrofuran (8 ml) was added drop-wise
borane-tetrahydrofuran complex (1 M in tetrahydrofuran, 3 ml, 3
mmol). The mixture was stirred at 65.degree. C. for 12 h. Methanol
was added and the mixture was stirred at room temperature for 30
min. The mixture was concentrated to afford
2-methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine (35 mg)
as a colorless oil, which was used without further purification. MS
(ESI): m/z=284.1 [M+1].sup.+.
Step F.
N-(2-Methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide
##STR01468##
[1576] To a mixture of potassium carbonate (30 mg, 0.21 mmol),
2-methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-amine (35 mg,
0.12 mmol) in toluene (10 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (24 mg, 0.13 mmol,
Example 3, Step B). The mixture was stirred at 110.degree. C. for 4
h, concentrated and purified by preparative HPLC (Waters, XBridge
C18, 4.6.times.150 mm, 3.5 m, A: acetonitrile, 30%-45%; B: 10 mM
ammonium hydrogen carbonate in water) to afford
N-(2-methyl-6-morpholino-1,1-dioxo-3H-1,2-benzothiazol-5-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide (15 mg, 28%) as a white solid. .sup.1H
NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.91 (s, 1H),
9.41 (dd, J=1.2, 6.8 Hz, 1H), 9.00 (dd, J=1.2, 4.0 Hz, 1H), 8.76
(s, 1H), 8.71 (s, 1H), 7.40 (dd, J=4.0, 6.8 Hz, 1H), 4.39 (s, 2H),
3.91-3.88 (m, 4H), 2.95-2.93 (m, 4H), 2.81 (s, 3H). MS (ESI):
m/z=429.2 [M+1].sup.+.
Example 386.
N-[2-(Cyanomethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyrazolo[1,5--
a]pyrimidine-3-carboxamide
##STR01469##
[1577] Step A. 2-(2,4-Difluoro-5-nitrophenyl)acetic acid
##STR01470##
[1579] To a solution of (2,4-difluoro-phenyl)acetic acid (200.0 g,
1.16 mol) in sulfuric acid (825 ml) was added dropwise nitric acid
(69%, 82.5 ml) at 0.degree. C. The reaction mixture was stirred at
0.degree. C. for 45 min and then poured into ice water. The
resulting precipitate was collected by filtration, washed with
water and dried to afford 2-(2,4-difluoro-5-nitrophenyl)acetic acid
(216.0 g, 85% yield) as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.13 (t, J=8.0 Hz, 1H), 7.08 (dd, J=8.8, 10.0
Hz, 1H), 3.78 (s, 2H). .sup.19F NMR (376 MHz, CDCl.sub.3):
.delta.-100.6 (d, J=15.0 Hz, 1F), -111.9 (d, J=15.0 Hz, 1F).
Step B. 1-(2,4-Difluoro-5-nitrophenyl)propan-2-one
##STR01471##
[1581] To a solution of 2-(2,4-difluoro-5-nitrophenyl)acetic acid
(216.0 g, 996 mmol) in acetic anhydride (562 ml) was added
1-methylimidazole (79.4 ml, 996 mmol) dropwise at 0.degree. C. The
reaction mixture was stirred at 0.degree. C. for 90 min. The
reaction was quenched with ice water and then adjusted to pH=7-8
with saturated aqueous sodium bicarbonate. The resulting mixture
was extracted with ethyl acetate (500 ml.times.4) and the combined
organic phases were isolated and dried over anhydrous sodium
sulfate and concentrated to a small volume under reduced pressure
and purified by column chromatography to give compound
1-(2,4-difluoro-5-nitrophenyl)propan-2-one (34 g, 64% yield).
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.00 (t, J=8.0 Hz, 1H),
7.05 (dd, J=8.8, 10.4 Hz, 1H), 3.83 (s, 2H), 2.31 (s, 3H).
Step C. 1-(2-Fluoro-4-morpholino-5-nitrophenyl)propan-2-one
##STR01472##
[1583] To a solution of 1-(2,4-difluoro-5-nitrophenyl)propan-2-one
(105.0 g, 0.49 mol) in dimethylformamide (1.0 L) were added
potassium carbonate (135 g, 0.98 mol) and morpholine (51.0 g, 0.59
mol) at room temperature. The reaction mixture was stirred at room
temperature for 1.5 h and water (5 L) was added. The resulting
mixture was extracted with ethyl acetate (1 L.times.3). The
combined organic phases were isolated, washed with brine (1 L),
dried over anhydrous sodium sulfate and concentrated under reduced
pressure. The resulting semi-solid was suspended in a mixture of
ethyl acetate: petroleum ether (1:2, 300 ml) and stirred for 30
min. 1-(2-Fluoro-4-morpholino-5-nitrophenyl)propan-2-one (105 g,
76% yield) was obtained after filtration as a yellow solid. .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 7.77 (d, J=8.0 Hz, 1H), 6.80 (d,
J=11.2 Hz, 1H), 3.86 (t, J=4.8 Hz, 4H), 3.74 (s, 2H), 3.06 (t,
J=4.8 Hz, 4H), 2.27 (s, 3H).
Step D.
4-(5-Fluoro-4-((2-methyl-1,3-dioxolan-2-yl)methyl)-2-nitrophenyl)m-
orpholine
##STR01473##
[1585] A mixture of
1-(2-fluoro-4-morpholino-5-nitrophenyl)propan-2-one (132.0 g, 0.468
mol), ethan-1,2-diol (86.8 g, 1.404 mol) and p-toluenesulphonic
acid (8.8 g, 46.8 mmol) in toluene (1 L) was refluxed under a
Dean-Stark apparatus to remove water overnight. The reaction
mixture was cooled to room temperature and aqueous sodium
bicarbonate (500 ml) was added. The resulting mixture was extracted
with ethyl acetate (500 ml.times.3). The combined organic layers
were dried over anhydrous sodium sulfate and concentrated under
reduced pressure to afford
4-(5-fluoro-4-((2-methyl-1,3-dioxolan-2-yl)methyl)-2-nitrophenyl)m-
orpholine (150 g, 98% yield) as a yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 7.90 (d, J=7.6 Hz, 1H), 6.77 (d, J=11.2
Hz, 1H), 3.92-3.97 (m, 2H), 3.80-3.87 (m, 6H), 3.04 (t, J=4.8 Hz,
4H), 2.94 (s, 2H), 1.34 (s, 3H).
Step E.
2-((2-Methyl-1,3-dioxolan-2-yl)methyl)-5-morpholino-4-nitrophenol
##STR01474##
[1587] To a solution of
4-(5-fluoro-4-((2-methyl-1,3-dioxolan-2-yl)methyl)-2-nitrophenyl)morpholi-
ne (15 g, 46 mmol) in dimethyl sulfoxide (100 ml) was added
potassium hydroxide (5.1 g, 92 mmol) under an atmosphere of
nitrogen. The reaction mixture was stirred at 100.degree. C. for 4
h and then cooled to room temperature. The mixture was poured into
ice water (1000 ml) and the pH was adjusted to pH=5-6 with 4N
aqueous HCl. The resulting mixture was extracted with ethyl acetate
(200 ml.times.4) and the combined organic layers were dried over
anhydrous sodium sulfate and concentrated under reduced pressure to
give
2-((2-methyl-1,3-dioxolan-2-yl)methyl)-5-morpholino-4-nitrophenol
(15 g), which was used without further purification.
Step F. 1-(2-Hydroxy-4-morpholino-5-nitrophenyl)propan-2-one
##STR01475##
[1589] To a solution of
2-((2-methyl-1,3-dioxolan-2-yl)methyl)-5-morpholino-4-nitrophenol
(15.0 g, 46 mmol) in tetrahydrofuran (100 ml) and water (100 ml)
was added p-toluenesulphonic acid (8.4 g, 49 mmol). The reaction
mixture was stirred at 50.degree. C. for 4 h and then cooled to
room temperature. Saturated aqueous sodium bicarbonate (200 ml) was
added and the resulting mixture was extracted with ethyl acetate
(200 ml.times.3). The combined organic layers were isolated, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure. The residue was purified by column chromatography (eluent
1:2 ethyl acetate: petroleum ether) to afford
1-(2-hydroxy-4-morpholino-5-nitrophenyl)propan-2-one (4.8 g, 37%
yield over two steps) as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.57 (br s, 1H), 7.83 (s, 1H), 6.63 (s, 1H),
3.87 (t, J=4.8 Hz, 4H), 3.75 (s, 2H), 3.05 (t, J=4.8 Hz, 4H), 2.39
(s, 3H).
Step G.
2-(2-Methyl-5-morpholino-6-nitro-3H-benzofuran-2-yl)acetonitrile
##STR01476##
[1591] A mixture of
1-(2-hydroxy-5-morpholino-4-nitro-phenyl)propan-2-one (300.0 mg,
1.07 mmol) (triphenylphosphoranylidene)acetonitrile (338.7 mg, 1.12
mmol) in chloroform (15 ml) was stirred at 60.degree. C. for 3 h.
triethylamine (4 ml) was added and the mixture was stirred at
60.degree. C. for 12 h. The reaction was then concentrated and
purified by column chromatography (eluent 33% ethyl acetate:
petroleum ether) to afford
2-(2-methyl-5-morpholino-6-nitro-3H-benzofuran-2-yl)acetonitrile
(71 mg, 18% yield) as a yellow solid. MS (ESI): m/z=304.1
[M+1].sup.+.
Step H.
2-(5-Amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)acetonitrile
##STR01477##
[1593] The title compound was made in a manner analogous to Example
2, Step B to afford
2-(5-amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)acetonitrile
(70 mg, 90% yield) as a brown oil. (ESI): m/z=274.2
[M+1].sup.+.
Step I.
N-[2-(Cyanomethyl)-2-methyl-6-morpholino-3H-benzofuran-5-yl]pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide
##STR01478##
[1595] The title compound was made in a manner analogous to Example
1, Step C to afford 2
N-[1'-(2-hydroxyethyl)-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]--
5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (91 mg, 40% yield) as
a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.49 (s,
1H), 8.84 (d, J=6.8 Hz, 1H), 8.77-8.78 (m, 2H), 8.47 (s, 1H), 7.08
(dd, J=4.0, 6.8 Hz, 1H), 6.70 (s, 1H), 3.94-3.97 (m, 4H), 3.22 (d,
J=16.0 Hz, 1H), 3.16 (d, J=15.6 Hz, 1H), 2.91-2.93 (m, 4H), 2.79
(d, J=16.8 Hz, 1H), 2.73 (d, J=16.4 Hz, 1H), 1.68 (s, 3H). (ESI):
m/z=419.1 [M+1].sup.+.
Examples 387 and 388.
(S)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01479##
[1596] Step A.
2-(2-Methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)ethanol
##STR01480##
[1598] To sodium borohydride (113.0 mg, 2.97 mmol) in a mixture of
tetrahydrofuran (12 ml) and ethanol (3 ml) was added lithium
chloride (124.9 mg, 2.97 mmol) followed by methyl
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)acetate
(Examples 367 and 368, Step E; 200.0 mg, 0.59 mmol) at 0.degree. C.
The mixture was stirred at 25.degree. C. for 2 h and quenched with
aqueous ammonium chloride (20 ml). The organic phase was isolated,
dried over magnesium sulfate, filtered and concentrated to afford
2-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)ethanol (180
mg, 82% yield) as a yellow solid. (ESI): m/z=309.2.
Step B.
2-(5-Amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)ethanol
##STR01481##
[1600] The title compound was made in a manner analogous to Example
2, Step B to afford
2-(5-amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)ethanol (130
mg, 70% yield) as a white oil. (ESI): m/z=279.3 [M+1].sup.+.
Step C.
(R)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzof-
uran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01482##
[1602] The title compounds were made in a manner analogous to
Example 1, Step C to afford
(R)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (91 mg, 40% yield) as
yellow solids with stereochemistry assigned arbitrarily.
[1603] Example 387, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.48 (s, 1H), 8.90-8.70 (m, 3H), 8.45 (s, 1H), 7.07 (dd,
J=7.0, 4.1 Hz, 1H), 6.65 (s, 1H), 5.35 (s, 1H), 3.98-3.80 (m, 6H),
3.18 (d, J=15.5 Hz, 1H), 3.02 (d, J=15.6 Hz, 1H), 2.94-2.90 (m,
4H), 1.99 (dt, J=14.6, 5.6 Hz, 1H), 1.50 (s, 3H), 1.26 (s, 2H).
(ESI): m/z=424.2 [M+1].sup.+.
[1604] Example 388, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.48 (s, 1H), 8.98-8.70 (m, 3H), 8.45 (s, 1H), 7.07 (dd,
J=7.0, 4.1 Hz, 1H), 6.65 (s, 1H), 5.35 (s, 1H), 3.92 (dd, J=26.9,
22.3 Hz, 6H), 3.18 (d, J=15.7 Hz, 1H), 3.02 (d, J=15.5 Hz, 1H),
2.94-2.90 (m, 4H), 2.07-1.95 (m, 1H), 1.50 (s, 3H), 1.25 (s, 2H).
(ESI): m/z=424.2 [M+1].sup.+.
Example 389.
N-[6-[4-(Aminomethyl)-4-fluoro-1-piperidyl]-2,2-dimethyl-3H-benzofuran-5--
yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01483##
[1605] Step A. tert-Butyl
N-[[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-fluoro-4-piperidyl]meth-
yl]carbamate
##STR01484##
[1607] The title compound was made in a manner analogous to Example
13, Step A to afford tert-butyl
N-[[1-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-4-fluoro-4-piperidyl]meth-
yl]carbamate (416 mg, 94% yield) as a yellow solid. (ESI):
m/z=424.2 [M+1].sup.+.
Step B. tert-Butyl
N-[[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-fluoro-4-piperidyl]meth-
yl]carbamate
##STR01485##
[1609] The title compound was made in a manner analogous to Example
2, Step B to afford tert-butyl
N-[[1-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-4-fluoro-4-piperidyl]meth-
yl]carbamate (370 mg, 80% yield) as a yellow oil. (ESI): m/z=394.3
[M+1].sup.+.
Step C. tert-Butyl
N-[[1-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-4-fluoro-4-piperidyl]methyl]carbamate
##STR01486##
[1611] The title compound was made in a manner analogous to Example
1, Step C to afford tert-butyl
N-[[1-[2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-3H-benz-
ofuran-6-yl]-4-fluoro-4-piperidyl]methyl]carbamate (487 mg, 96%
yield) as a yellow solid. (ESI): m/z=539.3 [M+1].sup.+.
Step D.
N-[6-[4-(Aminomethyl)-4-fluoro-1-piperidyl]-2,2-dimethyl-3H-benzof-
uran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01487##
[1613] The title compound was made in a manner analogous to Example
3, Step M to afford
N-[6-[4-(aminomethyl)-4-fluoro-1-piperidyl]-2,2-dimethyl-3H-benzofuran-5--
yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (300 mg, 76% yield) as a
light yellow foam. .sup.1H NMR (400 MHz, Chloroform-d) .delta.
10.42 (s, 1H), 8.86-8.76 (m, 2H), 8.68 (dt, J=3.4, 1.5 Hz, 1H),
8.40 (s, 1H), 7.07-6.99 (m, 1H), 6.67 (s, 1H), 3.07-2.85 (m, 8H),
2.11-1.87 (m, 4H), 1.48 (d, J=1.2 Hz, 6H). (ESI): m/z=439.3
[M+1].sup.+.
Examples 390 and 391.
(R)--N-(1'-methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin]-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(1'-methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin]-5-yl)-
pyrazol[1,5-a]pyrimidine-3-carboxamide
##STR01488##
[1614] Step A.
1'-Methyl-6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]
##STR01489##
[1616] A mixture of
6-fluoro-1'-methyl-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]
(304.0 mg, 1.21 mmol), morpholine (0.31 ml, 3.62 mmol) and
potassium carbonate (415.5 mg, 3.0 mmol) in acetonitrile (15 ml)
was stirred 25.degree. C. overnight. The reaction was filtered and
dried under reduced pressure to afford
1'-methyl-6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidin-
e](323 mg, 80% yield) as a yellow oil. MS-ESI: [M+H].sup.+
320.2.
Step B.
1'-Methyl-6-morpholino-spiro[3H-benzofuran-2,3'-pyrrolidine]-5-ami-
ne
##STR01490##
[1618] The title compound was made in a manner analogous to Example
2, Step B to afford
1'-methyl-6-morpholino-spiro[3H-benzofuran-2,3'-pyrrolidine]-5-amine
(310 mg, 76% yield) as a yellow oil. MS-ESI: [M+H].sup.+ 290.2.
Step C.
(R)--N-(1'-Methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin-
]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(1'-Methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin]-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01491##
[1620] The title compounds were made in a manner analogous to
Example 1, Step C to afford
(R)--N-(1'-methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin]-5-yl)-
pyrazzolo[1,5-a]pyrimidine-3-carboxamide (98.8 mg, 21% yield) and
(S)--N-(1'-methyl-6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidin]-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide (108.5 mg, 23% yield) as
yellow solids upon resolution via chiral HPLC with stereochemistry
assigned arbitrarily.
[1621] Example 390, Peak 1: .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 10.48 (s, 1H), 8.84 (dd, J=7.0, 1.7 Hz, 1H), 8.79-8.72 (m,
2H), 8.45 (s, 1H), 7.07 (dd, J=7.0, 4.1 Hz, 1H), 6.69 (s, 1H),
4.01-3.90 (m, 4H), 3.34-3.20 (m, 2H), 3.09 (d, J=10.6 Hz, 1H), 3.02
(q, J=8.0 Hz, 1H), 2.91 (t, J=4.5 Hz, 4H), 2.77 (s, 2H), 2.51 (s,
3H), 2.41 (dt, J=13.3, 6.5 Hz, 1H), 2.13 (dt, J=14.0, 7.7 Hz, 1H).
MS-ESI: [M+H].sup.+ 435.3.
[1622] Example 391, Peak 2: .sup.1H NMR (400 MHz, Chloroform-d)
.delta. 10.48 (s, 1H), 8.83 (dd, J=7.0, 1.7 Hz, 1H), 8.80-8.75 (m,
2H), 8.44 (s, 1H), 7.07 (dd, J=7.0, 4.1 Hz, 1H), 6.69 (s, 1H), 3.95
(t, J=4.5 Hz, 4H), 3.33-3.18 (m, 2H), 3.05 (d, J=10.4 Hz, 1H), 2.97
(q, J=8.3 Hz, 1H), 2.91 (dd, J=5.6, 3.5 Hz, 4H), 2.60 (d, J=10.5
Hz, 2H), 2.43 (s, 3H), 2.41-2.35 (m, 1H), 2.10 (ddd, J=14.2, 8.6,
6.0 Hz, 1H). MS-ESI: [M+H].sup.+ 435.3.
Example 392.
N-[2-(1-fluoro-2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzof-
uran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01492##
[1623] Step A.
1-(2,4-Difluorophenyl)-3-fluoro-2,4-dimethyl-pentane-2,4-diol
##STR01493##
[1625] To a solution of ethyl
4-(2,4-difluorophenyl)-2-fluoro-3-hydroxy-3-methyl-butanoate (1000
mg, 3.62 mmol) in tetrahydrofuran (36 ml) at -78.degree. C. was
added methyl lithium (6.03 ml, 18.1 mmol) and the reaction was
stirred for 3 h at room temperature. Saturated aqueous ammonium
chloride and ethyl acetate were added. The organic phase was
separated, dried over sodium sulfate and concentrated. The residue
was purified by column chromatography (eluent 25% ethyl acetate:
petroleum ether) to afford
1-(2,4-difluorophenyl)-3-fluoro-2,4-dimethyl-pentane-2,4-diol (310
mg, 33% yield) as a colorless oil.
Step B.
1-Fluoro-1-(6-fluoro-2-methyl-3H-benzofuran-2-yl)-2-methyl-propan--
2-ol
##STR01494##
[1627]
1-(2,4-Difluorophenyl)-3-fluoro-2,4-dimethyl-pentane-2,4-diol (310
mg, 1.2 mmol) in tetrahydrofuran (20 ml) was treated with potassium
tert-butoxide (331 mg, 3.0 mmol) at 0.degree. C. and warmed to
60.degree. C. with stirring for 24 h. After cooling to room
temperature, the mixture was diluted with water. The organic phase
was isolated and concentrated to afford
1-fluoro-1-(6-fluoro-2-methyl-3H-benzofuran-2-yl)-2-methyl-prop-
an-2-ol (210 mg, 65% yield) which was used directly without further
purification. MS-ESI: [M-H.sub.2O+H].sup.+225.2.
Step C.
1-Fluoro-1-(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)-2-methyl-
-propan-2-ol
##STR01495##
[1629] The title compound was made in a manner analogous to
Intermediate 1, Step D to afford
1-fluoro-1-(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)-2-methyl-propan-
-2-ol (200 mg, 21% yield) as a brown oil. MS-ESI: [M+H].sup.+
288.
Step D.
1-Fluoro-2-methyl-1-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-
-yl)propan-2-ol
##STR01496##
[1631] The title compound was made in a manner analogous to Example
50, Step A to afford
1-fluoro-2-methyl-1-(2-methyl-6-morpholino-5-nitro-3H-benzofuran-2-yl)pro-
pan-2-ol (59 mg, 60% yield) as a yellow oil. MS-ESI: [M+H].sup.+
355.1.
Step E.
1-(5-Amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)-1-fluoro-2-me-
thyl-propan-2-ol
##STR01497##
[1633] The title compound was made in a manner analogous to Example
2, Step B to afford
1-(5-amino-2-methyl-6-morpholino-3H-benzofuran-2-yl)-1-fluoro-2-methyl-pr-
opan-2-ol (39 mg, 72% yield) as a brown oil. MS-ESI: [M+H].sup.+
325.1.
Step F.
N-[2-(1-Fluoro-2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-
-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01498##
[1635] The title compound was made in a manner analogous to Example
1, Step C to afford
N-(2-(1-fluoro-2-hydroxy-2-methylpropyl)-2-methyl-6-morpholino-2,3-dihydr-
obenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (10 mg,
18%) as a light yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3):
10.48 (s, 1H), 8.83 (dd, J=1.2, 6.8 Hz, 1H), 8.79 (s, 1H), 8.77
(dd, J=1.2, 4.4 Hz, 1H), 8.47 (s, 1H), 7.07 (dd, J=4.4, 6.8 Hz,
1H), 6.69 (s, 1H), 4.37 (d, J=44.4 Hz, 1H), 3.96-3.94 (m, 4H),
3.68-3.65 (m, 2H), 2.93-2.83 (m, 4H), 2.64 (s, 1H), 1.57 (s, 3H),
1.35-1.32 (m, 6H). MS-ESI: [M+H].sup.+ 470.
Example 393.
N-(6-Morpholinospiro[3H-benzofuran-2,3'-pyrrolidine]-5-yl)pyrazolo[1,5-a]-
pyrimidine-3-carboxamide
##STR01499##
[1636] Step A. tert-Butyl
3-[(2,4-difluorophenyl)methyl]-3-hydroxy-pyrrolidine-1-carboxylate
##STR01500##
[1638] To a solution of magnesium (2.90 g, 120.8 mmol) and iodine
(80 mg, 0.31 mmol) in ether (25 ml) was added 2,4-difluorobenzyl
bromide (9.94 g, 48 mmol) dropwise at reflux and the resulting
mixture was stirred for 30 min. This mixture was then added to a
solution of N-boc-3-pyrrolidone (7.41 g, 40 mmol) in ether (100 ml)
at -78 C and the reaction was stirred at room temperature for 2 h.
Saturated aqueous ammonium chloride and ethyl acetate (200 ml) were
added and the organic phase was isolated, dried over sodium sulfate
and concentrated. The residue was purified by column chromatography
(eluting gradient 1:10 to 1:5 ethyl acetate: petroleum ether) to
afford tert-butyl
3-[(2,4-difluorophenyl)methyl]-3-hydroxy-pyrrolidine-1-carboxylate
(2.30 g, 15% yield) as a yellow oil. MS-ESI: [M+H].sup.+ 258.
Step B. tert-Butyl
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
##STR01501##
[1640] The title compound was made in a manner analogous to Example
3, Step E to afford tert-butyl
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate (552
mg, 71% yield) as an off-white solid.
Step C. 6-Fluorospiro[3H-benzofuran-2,3'-pyrrolidine]
##STR01502##
[1642] To tert-butyl
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate (552.0
mg, 1.9 mmol) in dichloromethane (11 ml) was added trifluoroacetic
acid (2 ml) and the mixture was stirred at 25.degree. C. for 4 h.
To the reaction was added aqueous saturated sodium bicarbonate (20
ml) and the aqueous layer was isolated and extracted with
dichloromethane (2.times.). The combined organic phases were washed
with saturated brine, dried over anhydrous magnesium sulfate,
filtered and concentrated to afford
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine] (303 mg, 1.5 mmol) as
a yellow oil. MS-ESI: [M+H].sup.+ 194.1.
Step D. Benzyl
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
##STR01503##
[1644] To a mixture of benzyl chloroformate (469.4 mg, 2.8 mmol)
and 6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine] (409 mg, 2.1
mmol) in dichloromethane (15 ml) was added trimethylamine (4.23
mmol) and the reaction was stirred at Then stirred at 25.degree. C.
for 2 h. The reaction was concentrated and purified by column
chromatography (eluent 1:1 ethyl acetate: petroleum ether) to
afford benzyl
6-fluorospiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate (739
mg, 78% yield) as a yellow oil. MS-ESI: [M+Na].sup.+328.2.
Step E. Benzyl
6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
##STR01504##
[1646] A mixture of benzyl
6-fluoro-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
(589 mg, 1.6 mmol), morpholine (0.41 ml, 4.75 mmol) and potassium
carbonate (545.4 mg, 3.95 mmol) in acetonitrile (18 ml) was stirred
at 25.degree. C. overnight. The reaction was filtered and dried
under reduced pressure to afford benzyl
6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
(451 mg, 56% yield) as a yellow oil. MS-ESI: [M+H].sup.+ 440.2.
Step F. Benzyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
##STR01505##
[1648] A solution of benzyl
6-morpholino-5-nitro-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
(451.0 mg, 1.0 mmol), ammonium chloride (549 mg, 10.3 mmol), iron
(574.7 mg, 10.3 mmol) and ammonium chloride (549 mg, 10.3 mmol) in
ethanol (40 ml) and water (8 ml) was stirred for 2 h at 78.degree.
C. The reaction mixture was filtered and the precipitate was washed
with dichloromethane. The filtrate was extracted with
dichloromethane, the organic phase was isolated and dried under
reduced pressure to afford benzyl
5-amino-6-morpholino-spiro[3H-benzofuran-2,3'-pyrrolidine]-1'-carboxylate
(421 mg, 95% yield) as a brown solid.
Step G. Benzyl
6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)spiro[3H-benzof-
uran-2,3'-pyrrolidine]-1'-carboxylate
##STR01506##
[1650] The title compound was made in a manner analogous to Example
1, Step C to afford benzyl
6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)spiro[3H-benzof-
uran-2,3'-pyrrolidine]-1'-carboxylate (464 mg). MS-ESI: [M+H].sup.+
555.3.
Step H.
N-(6-Morpholinospiro[3H-benzofuran-2,3'-pyrrolidine]-5-yl)pyrazolo-
[1,5-a]pyrimidine-3-carboxamide
##STR01507##
[1652] A mixture of benzyl
6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)spiro[3H-benzof-
uran-2,3'-pyrrolidine]-1'-carboxylate (434 mg, 0.8 mmol) and
trifluoroacetic acid (3 ml) was stirred at 50.degree. C. for 2 h.
The reaction was concentrated and purified by HPLC (Xbridge
21.2*250 mm c18, 10 um, A: 10 mM aqueous ammonium bicarbonate, B:
acetonitrile) to afford
N-(6-morpholino-3H-spiro[benzofuran-2,3'-pyrrolidine]-5-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide (59.4 mg, 18%) as a yellow solid. .sup.1H
NMR (400 MHz, CDCl.sub.3): 10.48 (s, 1H), 8.84 (d, J=3.4 Hz, 1H),
8.79 (s, 1H), 8.78 (d, J=6.6 Hz, 1H), 8.45 (s, 1H), 7.08 (s, J=4.4,
6.6 Hz, 1H), 7.35 (dd, J=4.4, 6.6 Hz, 1H), 6.65 (s, 1H), 3.94-3.95
(m, 4H), 3.21-3.33 (m, 4H), 3.12-3.13 (m, 1H), 2.90-2.92 (m, 4H),
2.84 (d, J=12 Hz, 1H), 1.26 (s, 2H).
Example 394.
N-(2,2-bis(hydroxymethyl)-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01508##
[1653] Step A.
5-[(4-Chloro-2-fluoro-phenyl)methyl]-2,2-dimethyl-1,3-dioxan-5-ol
##STR01509##
[1655] A mixture of potassium tert-butoxide (2700.0 mg, 24.11 mmol)
and
5-[(4-chloro-2-fluoro-phenyl)methyl]-2,2-dimethyl-1,3-dioxan-5-ol
(3000.0 mg, 10.92 mmol) in tetrahydrofuran (60 mL) was stirred at
50.degree. C. for 12 h. Upon cooling to room temperature and
concentration, the residue was purified by silica gel
chromatography (eluent: 1:1 ethyl acetate: petroleum ether) to
afford 6'-chloro-2,2-dimethyl-spiro[1,3-dioxane-5,2'-3H-benzofuran]
(930 mg, 3.6512 mmol, 33.4% yield) as a colorless oil.
Step B.
6'-Chloro-2,2-dimethyl-spiro[1,3-dioxane-5,2'-3H-benzofuran]
##STR01510##
[1657] The title compound was made in a manner analogous to Example
3, Step E to afford
6'-chloro-2,2-dimethyl-spiro[1,3-dioxane-5,2'-3H-benzofuran] (930
mg, 33% yield) as a colorless oil. MS-ESI: [M+H].sup.+ 255.1.
Step C.
6'-Chloro-2,2-dimethyl-5'-nitro-spiro[1,3-dioxane-5,2'-3H-benzofur-
an]
##STR01511##
[1659] A mixture of
6'-chloro-2,2-dimethyl-spiro[1,3-dioxane-5,2'-3H-benzofuran] (930
mg, 3.7 mmol) and copper(II) nitrate (2200 mg, 11.7 mmol) in acetic
acid (5 ml) and acetic anhydride (5 ml) was stirred at room
temperature. Upon concentration, the residue was purified by column
chromatography (eluent 50% ethyl acetate: petroleum ether) to
afford
6'-chloro-2,2-dimethyl-5'-nitro-spiro[1,3-dioxane-5,2'-3H-benzofuran]
(900 mg, 82% yield) as a yellow oil.
Step D.
4-(2,2-Dimethyl-5'-nitro-spiro[1,3-dioxane-5,2'-3H-benzofuran]-6'--
yl)morpholine
##STR01512##
[1661]
6'-Chloro-2,2-dimethyl-5'-nitro-spiro[1,3-dioxane-5,2'-3H-benzofura-
n] (600 mg, 2 mmol) and morpholine (3 ml, 35 mmol) was stirred at
90.degree. C. for 12 h. The reaction was concentrated and purified
by column chromatography (eluent 30% ethyl acetate: petroleum
ether) to afford
4-(2,2-dimethyl-5'-nitro-spiro[1,3-dioxane-5,2'-3H-benzofuran]-6'--
yl)morpholine (65 mg, 9% yield).
[1662] MS-ESI: [M+H].sup.+ 351.
Step E.
2,2-dimethyl-6'-morpholino-spiro[1,3-dioxane-5,2'-3H-benzofuran]-5-
'-amine
##STR01513##
[1664] The title compound was made in a manner analogous to Example
2, Step B to afford
2,2-dimethyl-6'-morpholino-spiro[1,3-dioxane-5,2'-3H-benzofuran]-5'-amine
(90 mg) which was used directly without further purification.
Step F.
N-(2',2'-Dimethyl-6-morpholino-3H-spiro[benzofuran-2,5'-[1,3]dioxa-
n]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01514##
[1666]
2,2-Dimethyl-6'-morpholino-spiro[1,3-dioxane-5,2'-3H-benzofuran]-5'-
-amine (90 mg, 0.28 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (100 mg, 0.61 mmol), HATU (180 mg, 0.47 mmol) and
N,N-diisopropylamine (0.2 ml, 1.22 mmol) was stirred in
N,N-dimethylformamide (5 ml) at 25.degree. C. for 12 h. The mixture
was concentrated and purified by column chromatography (eluent 40%
ethyl acetate: petroleum ether) to afford
N-(2,2-dimethyl-6'-morpholino-spiro[1,3-dioxane-5,2'-3H-benzofuran-
]-5'-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (110 mg, 84%
yield).
Step G.
N-(2,2-Bis(hydroxymethyl)-6-morpholino-2,3-dihydrobenzofuran-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01515##
[1668] A mixture of
N-(2,2-dimethyl-6'-morpholino-spiro[1,3-dioxane-5,2'-3H-benzofuran]-5'-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (90 mg, 0.19 mmol) and
concentrated hydrochloric acid (2 ml) in methanol (10 ml) was
stirred at 25.degree. C. for 3 h, concentrated and purified by HPLC
(Xbridge 21.2*250 mm c18, 10 um 20-30% 10 mM aqueous ammonium
bicarbonate in acetonitrile) to afford
N-[2,2-bis(hydroxymethyl)-6-morpholino-3H-benzofuran-5-yl]pyrazolo[1,5-a]-
pyrimidine-3-carboxamide (41.5 mg, 51% yield). .sup.1H NMR (400
MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.39 (s, 1H), 9.38 (dd,
J=7.1, 1.6 Hz, 1H), 8.96 (dd, J=4.3, 1.6 Hz, 1H), 8.68 (s, 1H),
8.19 (s, 1H), 7.35 (dd, J=7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 4.85 (t,
J=5.8 Hz, 1H), 4.77 (s, 1H), 3.92 (d, J=10.8 Hz, 1H), 3.87-3.77 (m,
5H), 3.35 (d, J=6.5 Hz, 3H), 2.92-2.78 (m, 5H).
Example 395.
N-(2,2-dimethyl-6-(2-(methylcarbamoyl)cyclopropyl)-2,3-dihydrobenzofuran--
5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01516##
[1669] Step A. 2,2-Dimethyl-5-nitro-6-vinyl-3H-benzofuran
##STR01517##
[1671] 6-Bromo-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran
(Intermediate 4, 200 mg, 0.74 mmol), vinylboronic acid pinacol
ester (0.38 ml, 2.24 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (270
mg, 0.37 mmol) and potassium phosphate (314.0 mg, 1.48 mmol) in
1,4-dioxane (5 ml) and water (2 ml) was heated at 110.degree. C.
under microwave conditions for 2 h. The solvent was removed and the
crude reaction was purified by preparatory TLC (eluent 1:3 ethyl
acetate: petroleum ether) to afford
2,2-dimethyl-5-nitro-6-vinyl-3H-benzofuran (81 mg, 45% yield) as a
yellow solid. MS-ESI: [M+H].sup.+ 220.1.
Step B. Ethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylate
##STR01518##
[1673] To a mixture of rhodium(II) acetate dimer (163.3 mg, 0.37
mmol) and 2,2-dimethyl-5-nitro-6-vinyl-3H-benzofuran (1.62 g, 7.4
mmol) in dichloromethane (60 ml) under nitrogen was added ethyl
diazoacetate (1.2 ml, 11.1 mmol) dropwise. The mixture was stirred
for 12 h, concentrated to dryness and purified by column
chromatography (eluent 20% ethyl acetate: petroleum ether) to
afford ethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylate
(480 mg, 21% yield) as a white solid. MS-ESI: [M+H].sup.+
306.2.
Step C.
2-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid
##STR01519##
[1675] A solution of ethyl
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylate
(60 mg, 0.2 mmol) and lithium hydroxide (23.5 mg, 0.98 mmol) in
methanol (5 ml) was stirred for 16 h, diluted with water, acidified
with 1M hydrochloric acid, and extracted with ethyl acetate. The
organic phase was isolated, washed with saturated brine, dried over
anhydrous sodium sulfate, filtered and concentrated under reduced
pressure to give
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid (50 mg, 92% yield) as a colorless oil.
Step D.
2-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)cyclopropane-1--
carboxylic acid
##STR01520##
[1677] The title compound was made in a manner analogous to Example
394, Step F to afford
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-N-methyl-cyclopropanecarboxam-
ide (45 mg, 86% yield) as a yellow solid. MS-ESI: [M+H].sup.+
291.1.
Step E.
2-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-N-methylcyclop-
ropane-1-carboxamide
##STR01521##
[1679] The title compound was made in a manner analogous to Example
2, Step B to afford
2-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)-N-methyl-cyclopropanecarboxam-
ide (35 mg, 87% yield) as a yellow solid.
Step F.
N-(2,2-Dimethyl-6-(2-(methylcarbamoyl)cyclopropyl)-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01522##
[1681] The title compound was made in a manner analogous to Example
394, Step F to afford
N-[2,2-dimethyl-6-[2-(methylcarbamoyl)cyclopropyl]-3H-benzofuran-5-yl]pyr-
azolo[1,5-a]pyrimidine-3-carboxamide (10 mg, 18% yield) as a light
yellow solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 9.96 (s, 1H), 9.38 (d, J=6.8 Hz, 1H), 8.86-8.76 (m, 1H),
8.68 (s, 1H), 7.97 (d, J=4.4 Hz, 2H), 7.35 (dd, J=7.0, 4.2 Hz, 1H),
6.50 (s, 1H), 3.00 (s, 2H), 2.42 (d, J=4.6 Hz, 3H), 2.40-2.31 (m,
1H), 1.79 (dt, J=8.8, 4.7 Hz, 1H), 1.40 (s, 7H), 1.17 (d, J=9.5 Hz,
1H).
[1682] MS-ESI: [M+H].sup.+ 406.3.
Example 396.
N-(6-((1R,2R)-2-Carbamoylcyclopropyl)-2,2-dimethyl-2,3-dihydrobenzofuran--
5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01523##
[1683] Step A.
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid
##STR01524##
[1685] The title compound was made in a manner analogous to Example
395, Step C to afford
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid as a white solid. (140 mg, quantitative) as a white solid.
MS-ESI: [M+H].sup.+ 278.1.
Step B.
(1R,2R)-2-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecar-
bonyl chloride
##STR01525##
[1687] A mixture of
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid (45 mg, 0.16 mmol) and thionyl chloride (10 ml, 0.16 mmol) was
heated to 80.degree. C. and stirred for 3 h. The reaction was then
concentrated to afford
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarbonyl
chloride (50 mg, quantitative). MS-ESI: [M+H].sup.+ 292.2.
Step C.
(1R,2R)-2-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)cyclopr-
opane-1-carboxamide
##STR01526##
[1689] A solution of
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarbonyl
chloride (45 mg, 0.15 mmol) and ammonium hydroxide (5 ml) was
stirred for 12 h and concentrated to afford
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxamid-
e (40 mg, 95% yield) as a white solid. MS-ESI: [M+H].sup.+
277.2
Step D.
(1R,2R)-2-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)cyclopr-
opane-1-carboxamide
##STR01527##
[1691] The title compound was made in a manner analogous to Example
2, Step B to afford
(1R,2R)-2-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)cyclopropanecarboxamid-
e (10 mg, 28% yield), which was used directly without further
purification. MS-ESI: [M+H].sup.+ 247.3.
Step E.
N-(6-((1R,2R)-2-Carbamoylcyclopropyl)-2,2-dimethyl-2,3-dihydrobenz-
ofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01528##
[1693] The title compound was made in a manner analogous to Example
395, Step C to afford
N-[6-(1R,2R)-2-carbamoylcyclopropyl]-2,2-dimethyl-3H-benzofuran-5-yl]pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (3 mg, 19% yield) as a yellow
solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
9.96 (s, 1H), 9.38 (d, J=6.9 Hz, 1H), 8.86 (d, J=4.2 Hz, 1H), 8.68
(s, 1H), 7.97 (s, 1H), 7.58 (s, 1H), 7.33 (dd, J=7.0, 4.3 Hz, 1H),
6.87 (s, 1H), 6.50 (s, 1H), 3.00 (s, 2H), 2.33 (s, 1H), 1.91-1.75
(m, 1H), 1.41 (d, J=2.9 Hz, 6H), 1.38-1.12 (m, 2H). MS-ESI:
[M+H].sup.+392.3.
Example 397.
N-(6-((1R,2R)-2-(Hydroxymethyl)cyclopropyl)-2,2-dimethyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01529##
[1694] Step A.
((1R,2R)-2-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)cyclopropyl)m-
ethanol
##STR01530##
[1696] A mixture of
(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropanecarboxylic
acid (Example 396, Step A; 50 mg, 0.18 mmol) in
borane-tetrahydrofuran complex (5 ml, 10 mmol) was stirred for 2 h
at 25.degree. C. Methanol (20 ml) was added and the reaction was
concentrated to afford
[(1R,2R)-2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)cyclopropyl]methanol
(40 mg, 84% yield) as a yellow solid. MS-ESI: [M+H].sup.+
264.1.
Step B.
((1R,2R)-2-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)
cyclopropyl)methanol
##STR01531##
[1698] The title compound was made in a manner analogous to Example
2, Step B to afford
[(1R,2R)-2-(5-amino-2,2-dimethyl-3H-benzofuran-6-yl)cyclopropyl]methanol
(36 mg, 100% yield), which was used directly without further
purification. MS-ESI: [M+H].sup.+ 234.2.
Step C.
N-(6-((1R,2R)-2-(Hydroxymethyl)cyclopropyl)-2,2-dimethyl-2,3-dihyd-
robenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01532##
[1700] The title compound was made in a manner analogous to Example
395, Step C to afford
N-[6-(1R,2R)-2-(hydroxymethyl)cyclopropyl]-2,2-dimethyl-3H-benzofuran-5-y-
l]pyrazolo[1,5-a]pyrimidine-3-carboxamide (38.2 mg, 65% yield) as a
yellow solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 9.91 (s, 1H), 9.43-9.32 (m, 1H), 8.86 (dd, J=4.3, 1.6 Hz,
1H), 8.69 (s, 1H), 7.90 (s, 1H), 7.33 (dd, J=7.1, 4.2 Hz, 1H), 6.46
(s, 1H), 3.55-3.36 (m, 2H), 2.99 (s, 2H), 1.86 (dt, J=9.7, 4.9 Hz,
1H), 1.40 (s, 6H), 1.32 (q, J=6.1 Hz, 1H), 1.00 (dt, J=9.1, 4.7 Hz,
1H), 0.78 (dt, J=9.2, 4.9 Hz, 1H). MS-ESI: [M+H].sup.+ 379.2.
Example 398.
N-(2-Isopropyl-6-morpholino-1-oxoisoindolin-5-yl)-6-(methylamino)pyrazolo-
[1,5-a]-pyrimidine-3-carboxamide
##STR01533##
[1702] The title compound was made in a manner analogous to Example
381 using 5-amino-2-isopropyl-6-morpholinoisoindolin-1-one (Example
138, Step C) to afford
N-(2-isopropyl-6-morpholino-1-oxoisoindolin-5-yl)-6-(methylamino)pyrazolo-
[1,5-a]-pyrimidine-3-carboxamide (15 mg, 26% yield) as a yellow
solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
10.78 (s, 1H), 8.76 (s, 1H), 8.68 (s, 1H), 8.43 (s, 1H), 8.34 (s,
1H), 7.55 (s, 1H), 6.37 (s, 1H), 4.41 (s, 3H), 3.89 (m, 4H), 2.89
(m, 4H), 2.76 (m, 3H), 1.22 (s, 6H). LCMS (ESI): m/z=450.0
[M+H].sup.+.
Examples 399 and 400.
N-[2-[(3R,4S)-3-Fluorotetrahydropyran-4-yl]-6-morpholino-1-oxo-isoindolin-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[2-[(3S,4R)-3-fluorotetrahydro
pyran-4-yl]-6-morpholino-1-oxo-isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine--
3-carboxamide
##STR01534##
[1703] Step A. Ethyl
2-(dibromomethyl)-5-fluoro-4-nitro-benzoate
##STR01535##
[1705] To a solution of 1-bromo-2,5-pyrrolidinedione (7.83 g, 44.02
mmol) in carbon tetrachloride (100 ml) was added benzoyl peroxide
(0.43 mg, 1.76 mmol) and ethyl 5-fluoro-2-methyl-4-nitro-benzoate
(2.0 g, 8.8 mmol). The mixture was stirred at 100.degree. C. for 16
h, concentrated and purified by silica gel column chromatography
(eluent 5% ethyl acetate: petroleum ether) to afford ethyl
2-(dibromomethyl)-5-fluoro-4-nitro-benzoate (2.80 g, 82% yield) as
a yellow oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.84 (d,
J=7.2 Hz, 1H), 7.92 (s, 1H), 7.83 (d, J=10.4 Hz, 1H), 4.48 (q,
J=7.2 Hz, 1H), 1.46 (t, J=7.2 Hz, 3H).
Step B. Ethyl 5-fluoro-2-formyl-4-nitro-benzoate
##STR01536##
[1707] To a solution of ethyl
2-(dibromomethyl)-5-fluoro-4-nitro-benzoate (2.50 g, 6.49 mmol) in
tetrahydrofuran (30 ml) was added silver nitrate (4.41 g, 25.98
mmol) in water (30 ml) and the mixture was stirred at 25.degree. C.
for 16 h. Sodium bicarbonate (1.0 g) was added in portions to the
reaction and the reaction was stirred for 48 h. The reaction was
filtered and diluted with ethyl acetate (200 ml). The organic phase
was separated and the aqueous phase was extracted with ethyl
acetate (100 ml). The combined organic phases were washed with
saturated sodium bicarbonate solution and brine, and dried over
sodium sulfate. After concentration, the crude oil was purified by
silica gel column chromatography (eluent 10% ethyl acetate:
petroleum ether) to give ethyl 5-fluoro-2-formyl-4-nitro-benzoate
(0.85 g, 54% yield) as a yellow oil. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.59 (s, 1H), 8.63 (d, J=7.2 Hz, 1H), 7.91 (d,
J=10.8 Hz, 1H), 4.51 (q, J=7.2 Hz, 1H), 1.46 (t, J=7.2 Hz, 3H).
Step C. Ethyl 2-formyl-5-morpholino-4-nitro-benzoate
##STR01537##
[1709] To a solution of ethyl 5-fluoro-2-formyl-4-nitro-benzoate
(850 mg, 3.52 mmol) in dichloromethane (5 ml) was added
N,N-diisopropylethylamine (911 mg, 7.05 mmol) and morpholine (399
mg, 4.58 mmol) at 0.degree. C. and stirred for 2 h. Upon reaction
completion, the mixture was diluted with water (20 ml) and
extracted with dichloromethane (80 ml.times.2). The organic phases
were combined and washed with brine (50 ml), dried over sodium
sulfate, and concentrated under reduced pressure. The residue was
purified on silica gel column (eluent 30% ethyl acetate: petroleum
ether) to obtain ethyl 2-formyl-5-morpholino-4-nitro-benzoate (540
mg, 49% yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.38 (s, 1H), 8.37 (s, 1H), 7.50 (s, 1H), 4.48 (q, J=7.2
Hz, 2H), 3.86 (t, J=4.4 Hz, 4H), 3.26 (t, J=4.4 Hz, 4H), 1.44 (t,
J=7.2 Hz, 3H). LCMS (ESI): m/z=308.9 [M+H].sup.+.
Step D. Ethyl 4-amino-2-formyl-5-morpholino-benzoate
##STR01538##
[1711] To a solution of ethyl
2-formyl-5-morpholino-4-nitro-benzoate (0.5 g, 1.6 mmol) in ethanol
(10 ml) and water (2 ml) was added iron (0.45 g, 8.1 mmol) and
ammonium chloride (0.43 g, 8.1 mmol). The reaction was stirred at
80.degree. C. for 1 h, filtered and the filtrate was concentrated.
The residue was dissolved in dichloromethane (90 ml) and washed
with water (50 ml) and brine (50 ml). The organic phase was dried
over sodium sulfate and concentrated to dryness to give ethyl
4-amino-2-formyl-5-morpholino-benzoate (0.42 g, 93% yield) as a
yellow solid. LCMS (ESI): m/z=278.9 [M+H].sup.+.
Step E. trans-Ethyl
4-amino-2-(((3-fluorotetrahydro-2H-pyran-4-yl)amino)methyl)-5-morpholinob-
enzoate
##STR01539##
[1713] To a solution of trans-3-fluorotetrahydropyran-4-amine (77
mg, 0.65 mmol) in methanol (5 ml) was added ethyl
4-amino-2-formyl-5-morpholino-benzoate (150 mg, 0.54 mmol). The
mixture was stirred at 20.degree. C. for 1 h. Sodium
cyanoborohydride (67 mg, 1.08 mmol) was added and the reaction was
stirred at 20.degree. C. for 16 h. The reaction was concentrated
and purified by preparatory TLC (eluent: 100% ethyl acetate) to
afford trans-ethyl 4-amino-2-(((3-fluoro
tetrahydro-2H-pyran-4-yl)amino)methyl)-5-morpholinobenzoate (100
mg, 48% yield) as a yellow solid. LCMS (ESI): m/z=382.0
[M+H].sup.+.
Step F.
trans-5-Amino-2-(3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino
isoindolin-1-one
##STR01540##
[1715] To a solution of triethylamine (53 mg, 0.52 mmol) in toluene
(5 ml) under nitrogen was added trans-ethyl
4-amino-2-(((3-fluorotetrahydro-2H-pyran-4-yl)amino)methyl)-5-morpholinob-
enzoate (100 mg, 0.26 mmol). The mixture was stirred at 110.degree.
C. for 24 h, concentrated and purified by preparatory TLC (eluent:
100% ethyl acetate) to afford
trans-5-amino-2-(3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino
isoindolin-1-one (75 mg, 85% yield) as a yellow solid. LCMS (ESI):
m/z=358.0 [M+Na].sup.+.
Step G.
trans-N-(2-(3-Fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxo
isoindolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01541##
[1717] To a solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (48 mg, 0.27 mmol) in dichloromethane (10 ml) was added
trans-5-amino-2-(3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino
isoindolin-1-one (75 mg, 0.22 mmol) and N,N-diisopropylethyl amine
(86 mg, 0.67 mmol). The reaction was stirred at 40.degree. C. for
12 h, concentrated and purified by preparatory TLC (eluent 10%
methanol: dichloromethane) to give
trans-N-(2-(3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxoisoindoli-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 32% yield)
as a white solid. LCMS (ESI): m/z=481.1 [M+H].sup.+.
Step H.
N-(2-((3R,4S)-3-Fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxo
isoindolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-(2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxoisoindo-
lin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01542##
[1719]
trans-N-(2-(3-Fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxoiso-
indolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 0.07
mmol) was separated by preparatory SFC (AD (250 mm*30 mm, 10 um),
55%, 0.1% ammonium hydroxide in methanol) to give
N-(2-((3R,4S)-3-Fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxo
isoindolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (10 mg, 30%
yield) and
N-(2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-6-morpholino-1-oxoisoindo-
lin-5-yl) pyrazolo[1,5-a]pyrimidine-3-carboxamide (11 mg, 31%
yield) as white solids with absolute stereochemistry assigned
arbitrarily.
[1720] Example 399, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.94 (s, 1H), 8.96-8.69 (m, 4H), 7.76 (s, 1H), 7.13 (dd,
J=6.8, 4.4 Hz, 1H), 4.88-4.66 (m, 1H), 4.56-4.44 (m, 2H), 4.30-4.22
(m, 1H), 4.02 (t, J=4.4 Hz, 4H), 3.59-3.39 (m, 2H), 3.00 (t, J=4.4
Hz, 4H), 2.04-1.96 (m, 2H). LCMS (ESI): m/z=481.1 [M+H].sup.+.
[1721] Example 400, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.94 (s, 1H), 8.97-8.73 (m, 4H), 7.76 (s, 1H), 7.13 (dd,
J=6.8, 4.4 Hz, 1H), 4.86-4.65 (m, 1H), 4.55-4.44 (m, 2H), 4.30-4.22
(m, 1H), 4.03-4.01 (m, 4H), 3.59-3.39 (m, 2H), 3.05-2.90 (m, 4H),
2.04-1.96 (m, 2H). LCMS (ESI): m/z=481.1 [M+H].sup.+.
Example 401.
N-(2-Methyl-7-morpholino-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01543##
[1722] Step A. Ethyl 2-methyl-5-morpholino-4-nitro-benzoate
##STR01544##
[1724] A mixture of ethyl 5-fluoro-2-methyl-4-nitro-benzoate (1.4
g, 6.16 mmol) and morpholine (2.15 g, 24.65 mmol) was stirred at
110.degree. C. for 2 h. The reaction mixture was concentrated to
dryness and purified by silica gel column chromatography (eluting
gradient 10-50% ethyl acetate: petroleum ether) to afford ethyl
2-methyl-5-morpholino-4-nitro-benzoate (1.6 g, 88% yield) as a red
oil.
Step B. Ethyl 5-morpholino-4-nitro-2-(2-oxoethyl)benzoate
##STR01545##
[1726] To a solution of ethyl
2-methyl-5-morpholino-4-nitro-benzoate (0.5 g, 1.70 mmol) in
N,N-dimethylformamide (5 ml) was added Bredereck's reagent (0.3 g,
1.70 mmol). The mixture was at 140.degree. C. for 3 h, cooled to
room temperature, concentrated to dryness and purified by silica
gel column chromatography (eluting gradient 10-50% ethyl acetate:
petroleum ether) to afford ethyl
5-morpholino-4-nitro-2-(2-oxoethyl)benzoate (0.2 g, 36% yield) as a
red oil. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 9.80 (s, 1H),
7.80 (s, 1H), 7.61 (s, 1H), 4.37 (q, J=6.8 Hz, 2H), 4.08 (s, 2H),
3.85 (t, J=4.4 Hz, 4H), 3.10 (t, J=4.4 Hz, 4H), 1.40 (t, J=7.2 Hz,
3H).
Step C. 2-Methyl-7-morpholino-6-nitro-isoquinolin-1-one
##STR01546##
[1728] To a solution of methylamine (135 mg, 4.34 mmol) in
N,N-dimethylformamide (5 ml) was added ethyl
5-morpholino-4-nitro-2-(2-oxoethyl)benzoate (200 mg, 0.62 mmol) and
the reaction was irradiated under microwave conditions at
140.degree. C. for 30 min. The reaction mixture was concentrated to
dryness and purified by preparatory TLC (eluent 50% ethyl acetate:
petroleum ether) to afford
2-methyl-7-morpholino-6-nitro-isoquinolin-1-one (60 mg, 33% yield)
as a red oil. .sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 8.15 (s,
1H), 7.83 (s, 1H), 7.09 (d, J=7.6 Hz, 1H), 6.47 (d, J=7.6 Hz, 1H),
3.86 (t, J=4.4 Hz, 4H), 3.63 (s, 3H), 3.12 (t, J=4.4 Hz, 4H).
Step D.
6-Amino-2-methyl-7-morpholino-3,4-dihydroisoquinolin-1-one
##STR01547##
[1730] To a solution of
2-methyl-7-morpholino-6-nitro-isoquinolin-1-one (150 mg, 0.52 mmol)
in methanol (5 ml) was added 10% palladium on carbon (55 mg, 0.05
mmol). The reaction mixture was stirred at 65.degree. C. for 1 h
under hydrogen gas (15 psi), filtered and the filtrate was
concentrated to obtain
6-amino-2-methyl-7-morpholino-3,4-dihydroisoquinolin-1-one (120 mg,
88% yield) as a white solid. The crude was used directly without
further purification. LCMS (ESI): m/z=262.0 [M+H].sup.+.
Step E.
6-Amino-2-methyl-7-morpholino-3,4-dihydroisoquinolin-1-one
##STR01548##
[1732] To a solution of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid
(82 mg, 0.51 mmol) and
6-amino-2-methyl-7-morpholino-3,4-dihydroisoquinolin-1-one (120 mg,
0.46 mmol) in pyridine (6 ml) was added phosphorus oxychloride
(0.21 ml, 2.3 mmol) and the reaction was stirred at 25.degree. C.
for 2 h. The reaction mixture was quenched with aqueous 10% sodium
bicarbonate (5 ml) solution at 0.degree. C. and extracted with
ethyl acetate (10 ml*2). The organic phases were isolated, dried
over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by reverse phase chromatography (acetonitrile
45-75% 0.05% ammonia in water) to give
N-(2-methyl-7-morpholino-1-oxo-3,4-dihydroisoquinolin-6-yl)pyrazolo[1,5-a-
]pyrimidine-3-carboxamide (17 mg, 9% yield) as a white solid.
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 10.86 (s, 1H), 8.87-8.70
(m, 3H), 8.56 (s, 1H), 7.98 (s, 1H), 7.12 (s, 1H), 4.03-3.95 (m,
4H), 3.59-3.56 (m, 2H), 3.16 (s, 3H), 3.04-2.99 (m, 6H). LCMS
(ESI): m/z=407.0 [M+H].sup.+.
Example 402.
N-(7-Morpholino-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01549##
[1733] Step A. 2-Amino-5-chloro-4-nitrobenzene-1-sulfonyl
chloride
##STR01550##
[1735] 4-Chloro-3-nitroaniline (10.0 g, 57.95 mmol) was added in
small portions to a well-stirred solution of chlorosulfonic acid
(28 ml, 406.3 mmol) maintained at 10.degree. C., and then raised to
150.degree. C. for 1 h. The reaction was cooled to room
temperature, thionyl chloride (7.5 ml, 102.41 mmol) was added
dropwise, and the reaction was returned to 150.degree. C. for 1 h.
The reaction was cooled to room temperature, poured onto chopped
ice (50 g) and extracted with ethyl acetate (150 ml.times.3). The
organic phases were combined, dried over sodium sulfate,
concentrated and purified by column chromatography (eluting
gradient 15-20% ethyl acetate: petroleum ether) to afford
2-amino-5-chloro-4-nitro-benzenesulfonyl chloride (6.0 g, 38%
yield) as a brown solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.97 (s, 1H), 7.27 (s, 1H), 5.57 (s, 2H).
Step B. 2-Amino-5-chloro-4-nitrobenzenethiol
##STR01551##
[1737] To a solution of triphenyl phosphine (8.7 g, 33.20 mmol) in
toluene (60 ml) in a 100 ml three-neck round-bottom flask with a
nitrogen inlet, reflux condenser, and calcium chloride guard tube,
was added 2-amino-5-chloro-4-nitro-benzenesulfonyl chloride (3.0 g,
11.07 mmol) in portions. The reaction was stirred at 15.degree. C.
for 1 h, water (50 ml) was added, and the reaction was stirred for
30 min. Upon completion, the organic phase was isolated and washed
with 10% aqueous sodium hydroxide (15 ml.times.2). The alkaline
aqueous extracts were washed with ethyl acetate (30 ml.times.2),
acidified with 2M hydrogen chloride and extracted with
dichloromethane (30 ml.times.2). The combined organic extracts were
then washed with brine (15 ml), dried over sodium sulfate and
concentrated to dryness to afford
2-amino-5-chloro-4-nitro-benzenethiol (1.7 g, 75% yield) as an
orange solid which was used directly without further purification.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.19 (s, 1H), 7.81 (s,
1H).
Step C. 7-Chloro-6-nitro-2H-benzo[b][1,4]thiazin-3(4H)-one
##STR01552##
[1739] To the solution of 2-amino-5-chloro-4-nitro-benzenethiol
(1.7 g, 8.31 mmol), ethanethiol (1.8 ml, 24.92 mmol) and ethyl
bromoacetate (4.2 g, 24.92 mmol) in tetrahydrofuran (30 ml) was
added 1,8-diazabicyclo[5.4.0]undec-7-ene (3.8 g, 24.92 mmol). The
reaction was stirred at 20.degree. C. for 2 min, concentrated to
dryness, taken up in ethyl acetate (30 ml) and washed with water
(30 ml.times.2) and brine (30 ml). The organic phase was then dried
over sodium sulfate and concentrated. The material was then brought
up in acetic acid (10 ml), stirred at 100.degree. C. for 10 min,
concentrated, and purified by flash column chromatography (eluent
60% ethyl acetate: petroleum ether) to afford
7-chloro-6-nitro-4H-1,4-benzothiazin-3-one (1.3 g, 64% yield) as a
yellow solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 10.98 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 3.63 (s,
2H).
Step D. 7-Morpholino-6-nitro-2H-benzo[b][1,4]thiazin-3-one
##STR01553##
[1741] A mixture of 7-chloro-6-nitro-4H-1,4-benzothiazin-3-one (1.2
g, 4.90 mmol) in morpholine (17 ml, 198.17 mmol) was stirred at
120.degree. C. for 18 h. The reaction was extracted with ethyl
acetate (40 ml.times.3) and the organic phases were combined,
washed with water (40 ml.times.2) and brine (40 ml), dried over
sodium sulfate, concentrated and purified by silica gel column
chromatography (eluent 50% ethyl acetate in petroleum ether) to
afford 7-morpholino-1-nitro-4H-1,4-benzothiazin-3-one (700 mg, 48%
yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.19 (s, 1H), 7.42 (s, 1H), 7.11 (s, 1H), 3.87-3.85 (m, 4H), 3.50
(s, 2H), 3.04-3.03 (m, 4H).
Step E. 7-Morpholino-6-nitro-2H-benzo[b][1,4]thiazin-3-one
1,1-dioxide
##STR01554##
[1743] 7-Morpholino-6-nitro-4H-1,4-benzothiazin-3-one (700 mg, 2.37
mmol) in 1,4-dioxane (10 ml) was treated with 3-chloroperoxybenzoic
acid (1.4 g, 7.11 mmol) and stirred at 40.degree. C. for 12 h. The
reaction was concentrated to dryness and the residue was brought up
in ethyl acetate (30 ml) and water (30 ml). The organic phase was
isolated, washed with water (30 ml) and brine (30 ml), dried over
sodium sulfate, concentrated, and purified by silica gel column
chromatography (eluting gradient 0-33% ethyl acetate: petroleum
ether) to afford 7-morpholino-6-nitro-2H-benzo b][1,4]thiazin-3-one
1,1-dioxide (500 mg, 64% yield) as a yellow solid. .sup.1H NMR (400
MHz, dimethyl sulfoxide-d.sub.6) .delta. 7.71 (s, 1H), 7.63 (s,
1H), 5.75 (s, 1H), 4.83 (s, 2H), 3.67 (t, J=4.4 Hz, 4H), 2.99 (t,
J=4.4 Hz, 4H).
Step F. 7-Morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide
##STR01555##
[1745] To a solution of
7-morpholino-6-nitro-2H-benzo[b][1,4]thiazin-3-one 1,1-dioxide (500
mg, 1.53 mmol) in tetrahydrofuran (60 ml) was added borane (1M in
tetrahydrofuran, 7.64 ml, 7.64 mmol) at 20.degree. C. The mixture
was stirred at 65.degree. C. for 2 h, cooled to 0.degree. C.,
treated with methanol (10 ml) dropwise and stirred at 65.degree. C.
for 1 h. After concentration, it was afforded
7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (400 mg, 84% yield) as a red oil, which was used to
next step without further purification. .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 7.56 (s, 1H), 7.37 (s, 1H),
7.14 (s, 1H), 3.75-3.74 (m, 2H), 3.63-3.60 (m, 4H), 3.49-3.46 (m,
2H), 2.83-2.80 (m, 4H).
Step G. 6-Amino-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide
##STR01556##
[1747] To the solution of
7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (400 mg, 1.28 mmol) in methanol (50 ml) was added 10%
palladium on carbon (1.4 g, 1.28 mmol). The mixture was stirred at
25.degree. C. for 2 h under hydrogen (15 psi). The reaction was
filtered and the filtrate was concentrated to afford
6-amino-7-morpholino-3,4-dihydro-2H-benzo b][1,4]thiazine
1,1-dioxide (350 mg, 97% yield) as a white solid. LCMS (ESI):
m/z=283.8 [M+H].sup.+.
Step H.
N-(7-Morpholino-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4]thiazin-6--
yl) pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01557##
[1749] To a solution of
6-amino-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (260 mg, 0.92 mmol),
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (150 mg, 0.92 mmol),
and
((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)oxy)tri(pyrrolidin-1-yl)
phosphonium hexafluorophosphate (574 mg, 1.1 mmol) in
N,N-dimethylformamide (5 ml) was added N,N-diisopropylethylamine
(237 mg, 1.84 mmol). The mixture was stirred at 90.degree. C. for
48 h, concentrated to dryness and residue was brought up in ethyl
acetate (30 ml) and water (30 ml). The organic phase was isolated,
washed with water (30 ml) and brine (30 ml), dried over sodium
sulfate, concentrated, and purified by silica gel column
chromatography (eluting gradient 0-60% ethyl acetate in petroleum
ether). The crude solid was washed with methanol (10 ml) and dried
in vacuum to afford
N-(7-morpholino-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide (104 mg, 25% yield) as a yellow
solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta.
10.83 (s, 1H), 9.40-9.38 (m, 1H), 8.96 (m, 1H), 8.72 (s, 1H), 8.10
(s, 1H), 7.38-7.36 (m, 2H), 7.10 (s, 1H), 3.87-3.85 (m, 4H),
3.71-3.69 (m, 2H), 3.33-3.31 (m, 2H), 2.80-2.78 (m, 4H). LCMS
(ESI): m/z=428.9 [M+H].sup.+.
Example 403.
N-(3,3-Dimethyl-7-morpholino-1,1-dioxido-3,4-dihydro-2H-benzo
b][1,4]thiazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01558##
[1750] Step A.
1-(2-Amino-5-fluoro-4-nitro-phenyl)sulfanyl-2-methyl-propan-2-ol
##STR01559##
[1752] To 2-amino-5-fluoro-4-nitro-benzenethiolate (Example 402,
Step B; 1.82 g, 8.6 mmol) in water (10 ml) was added
1,2-epoxy-2-methylpropane (6.2 g, 86.0 mmol) and dichloromethane
(10 ml) and the mixture was stirred vigorously at 10.degree. C. for
2 h. The organic layer was then isolated, washed with brine (5
ml.times.2), and concentrated to afford
1-(2-amino-5-fluoro-4-nitro-phenyl)sulfanyl-2-methyl-propan-2-ol
(0.86 g, 38% yield) as an orange solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.37-7.35 (m, 1H), 7.30-7.27 (m, 1H), 4.33 (s,
2H), 3.09 (s, 2H), 1.99 (s, 1H), 1.37 (s, 6H).
Step B.
7-Fluoro-3,3-dimethyl-6-nitro-2,4-dihydro-1,4-benzothiazine
##STR01560##
[1754]
1-(2-Amino-5-fluoro-4-nitro-phenyl)sulfanyl-2-methyl-propan-2-ol
(0.76 g, 2.9 mmol) in xylene (10 ml) was treated with phosphoric
acid (5.69 g, 58.09 mmol) and heated to 120.degree. C. for 1 h
under nitrogen atmosphere. The mixture was diluted with 1:1 ethyl
acetate:water (10 ml) and the organic phase was isolated, washed
with water (5 ml.times.2), concentrated and purified by silica gel
column (eluent 20% ethyl acetate: petroleum ether) to afford
7-fluoro-3,3-dimethyl-6-nitro-2,4-dihydro-1,4-benzothiazine (0.53
g, 75% yield) as an orange solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.16 (d, J=6.4, 1H), 6.95 (d, J=10.8, 1H), 3.94 (s, 1H),
2.83 (s, 2H), 1.38 (s, 6H).
Step C.
7-Fluoro-3,3-dimethyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide
##STR01561##
[1756] To a solution of
7-fluoro-3,3-dimethyl-6-nitro-2,4-dihydro-1,4-benzothiazine (0.5 g,
2.06 mmol) in dichloromethane (20 ml) was added
3-chloroperoxybenzoic acid (2.09 g, 10.32 mmol) and the mixture was
stirred at 10.degree. C. for 1 h. The reaction was quenched with a
saturated solution of 1:1 sodium bicarbonate:sodium sulfite (30 ml)
and the organic phase was isolated. The organic phase was washed
with brine (20 ml.times.2), filtered and the filtrate was
concentrated under reduced pressure to afford
7-fluoro-3,3-dimethyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4] thiazine
1,1-dioxide (0.5 g, 88% yield) as a yellow solid.
Step D.
3,3-Dimethyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thia-
zine 1,1-dioxide
##STR01562##
[1758] To a solution of
7-fluoro-3,3-dimethyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (0.4 g, 1.46 mmol) in dimethyl sulfoxide (10 ml) was
added morpholine (1.27 g, 14.58 mmol) and N,N-diiso
propylethylamine (0.95 g, 7.29 mmol) and the mixture was stirred at
90.degree. C. for 2 h. Upon cooling to 20.degree. C., the reaction
was diluted with 3:2 ethyl acetate:water (25 ml). The organic phase
was isolated, washed with brine (5 ml.times.2), dried over sodium
sulfate, and concentrated under reduced pressure to give the crude
residue, which was purified by silica gel column (eluent 5%
methanol: dichloromethane) to afford
3,3-dimethyl-7-morpholino-6-nitro-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (160 mg, 32% yield) as an orange solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.59 (s, 1H), 6.91 (s, 1H), 4.36 (s,
1H), 3.76 (t, J=4.4 Hz, 4H), 3.33 (s, 2H), 2.94 (t, J=4.4 Hz, 4H),
1.53 (s, 6H). LCMS (ESI): m/z=341.9 [M+H].sup.+.
Step E.
6-Amino-3,3-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]thia-
zine 1,1-dioxide
##STR01563##
[1760] The title compound was made in a manner analogous to Example
402, Step G to afford
6-amino-3,3-dimethyl-7-morpholino-3,4-dihydro-2H-benzo[b][1,4]thiazine
1,1-dioxide (0.14 g, 100% yield) as a white solid. .sup.1H NMR (400
MHz, dimethyl sulfoxide-d.sub.6) .delta. 6.94 (s, 1H), 6.26 (s,
1H), 5.94 (s, 1H), 5.44 (s, 2H), 3.72 (t, J=4.4 Hz, 4H), 3.26 (s,
2H), 2.68 (t, J=4.4 Hz, 4H), 1.33 (s, 6H).
Step F.
N-(3,3-Dimethyl-7-morpholino-1,1-dioxido-3,4-dihydro-2H-benzo[b][1-
,4] thiazin-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01564##
[1762] The title compound was made in a manner analogous to Example
287, Step G to afford
N-(3,3-dimethyl-7-morpholino-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4]thia-
zin-6-yl) pyrazolo[1,5-a]pyrimidine-3-carboxamide (50 mg, 28%
yield) as a pale solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.83 (s, 1H), 9.40-9.39 (m, 1H), 8.98-8.97 (m, 1H), 8.73 (s, 1H),
8.11 (s, 1H), 7.39-7.37 (m, 1H), 7.37 (s, 1H), 6.94 (s, 1H),
3.88-3.86 (m, 4H), 3.43 (s, 2H), 2.82-2.80 (m, 4H), 1.40 (s, 6H).
LCMS (ESI): m/z=457 [M+H].sup.+.
Example 404.
N-(2,2-Dimethyl-6-(1-methyl-1H-pyrazol-4-yl)-2,3-dihydrobenzofuran-5-yl)p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01565##
[1763] Step A.
4-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1-methyl-1H-pyrazole
##STR01566##
[1765] To a mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(0.2 g, 0.88 mmol), 1,1'-bis (diphenylphosphino)ferrocene palladium
dichloride (64.3 mg, 0.09 mmol) and cesium carbonate (0.57 g, 1.76
mmol) in 1,4-dioxane (2 ml) and water (0.2 ml) was added
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(0.37 g, 1.76 mmol). The mixture was purged with nitrogen
(3.times.) and stirred at 120.degree. C. for 24 h. After being
cooled to 20.degree. C., the mixture was filtered through celite
and purified by preparatory TLC (eluent 50% ethyl acetate:
petroleum ether) to afford
4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)-1-methyl-1H-pyrazole
(0.2 g, 83% yield) as a yellow solid. LCMS (ESI): m/z=273.9
[M+H].sup.+.
Step B.
2,2-Dimethyl-6-(1-methyl-1H-pyrazol-4-yl)-2,3-dihydrobenzofuran-5--
amine
##STR01567##
[1767] The title compound was made in a manner analogous to Example
402, Step G to afford
2,2-dimethyl-6-(1-methyl-1H-pyrazol-4-yl)-2,3-dihydrobenzofuran-5-amine
(0.16 g, 90% yield) as a dark-green oil. LCMS (ESI): m/z=244.0
[M+H].sup.+
Step C.
N-(2,2-Dimethyl-6-(1-methyl-1H-pyrazol-4-yl)-2,3-dihydrobenzofuran-
-5-yl) pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01568##
[1769] The title compound was made in a manner analogous to Example
138, Step D to afford
N-(2,2-dimethyl-6-(1-methyl-1H-pyrazol-4-yl)-2,3-dihydrobenzofuran-5-yl)p-
yrazolo[1,5-a]pyrimidine-3-carboxamide (180 mg, 81% yield) as a
green solid. .sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6)
.delta. 9.68 (s, 1H), 9.33 (m, 1H), 8.65 (s, 1H), 8.63-8.62 (m,
1H), 7.94 (s, 1H), 7.91 (s, 1H), 7.62 (s, 1H), 7.28-7.25 (m, 1H),
6.72 (s, 1H), 3.84 (s, 3H), 3.04 (s, 2H), 1.44 (s, 6H).
Example 405.
N-(6-(5-Cyanopyridin-3-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide
##STR01569##
[1771] The title compound was made in a manner analogous to Example
404 to afford
N-(6-(5-cyanopyridin-3-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide. .sup.1H NMR (400 MHz,
CDCl.sub.3): 9.40 (s, 1H), 8.92-8.88 (m, 2H), 8.77 (d, J=6.4 Hz,
1H), 8.70 (s, 1H), 8.35 (s, 1H), 8.15-8.05 (m, 2H), 7.01-6.97 (m,
1H), 6.64 (s, 1H), 3.13 (s, 2H), 1.54 (s, 6H). LCMS (ESI):
m/z=411.2 [M+H].sup.+.
Example 406.
N-[2,2-Dimethyl-6-(1-methylimidazol-2-yl)-3H-benzofuran-5-yl]pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR01570##
[1772] Step A.
2-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole
##STR01571##
[1774] A solution of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(100.0 mg, 0.44 mmol) and 1-methyl-2-(tributylstannyl)imidazole
(245 mg, 0.66 mmol) in N,N-dimethyl formamide (4 ml) was purged
with nitrogen for 15 min at 20.degree. C.
Tetrakis(triphenylphosphine)palladium(0) (51 mg, 0.04 mmol) was
added and the mixture was stirred at 55.degree. C. for 16 h. Acetic
acid (0.6 ml) was added followed by water (20 ml) and the reaction
mixture was extracted with ethyl acetate (20 ml.times.2). The
combined organic phases were isolated, washed with water (40
ml.times.4) and brine (40 ml), dried over anhydrous sodium sulfate
and concentrated in vacuum to give
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole (34
mg, 28% yield) as a yellow solid.
[1775] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.02 (s, 1H), 7.55
(s, 1H), 6.97 (s, 1H), 6.67 (s, 1H), 3.45 (s, 3H), 3.13 (s, 2H),
1.56 (s, 6H). LCMS (ESI): m/z=273.9 [M+H].sup.+.
Step B.
N-[2,2-Dimethyl-6-(1-methylimidazol-2-yl)-3H-benzofuran-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR01572##
[1777]
N-[2,2-Dimethyl-6-(1-methylimidazol-2-yl)-3H-benzofuran-5-yl]pyrazo-
lo[1,5-a]pyrimidine-3-carboxamide was prepared following the
procedure described for Example 404, Step B-C from
2-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole as a
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.68 (s,
1H), 8.73-8.68 (m, 2H), 8.48-8.45 (m, 2H), 7.56 (s, 1H), 7.18 (s,
1H), 6.95-6.92 (m, 1H), 6.65 (s, 1H), 3.40 (s, 3H), 3.12 (s, 2H),
1.52 (s, 6H). LCMS (ESI): m/z=389.2 [M+H].sup.+.
Example 407.
6-Cyano-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide
##STR01573##
[1778] Step A. 6-Formylpyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR01574##
[1780] A mixture of 5-amino-1H-pyrazole-4-carboxylic acid (0.5 g,
3.93 mmol), methane tricarbaldehyde (0.47 g, 4.7 mmol) and acetic
acid (1 ml) in ethanol (6 ml) was stirred under an atmosphere of
nitrogen at 15.degree. C. for 1 h followed by 70.degree. C. for 15
h. The suspension was filtered and the precipitate was washed with
ethanol (10 ml). The solid was collected and dried to give
6-formylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.47 g, 63%
yield) as a white solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6): .delta. 12.68 (s, 1H), 10.06 (s, 1H), 9.92 (s,
1H), 9.11 (d, J=2.4 Hz, 1H), 8.78 (s, 1H).
Step B.
N-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-formyl
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01575##
[1782] The title compound was made in a manner analogous to Example
1, Step C to afford to afford
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-formylpyrazolo-
[1,5-a]pyrimidine-3-carboxamide (0.21 g, 62% yield) as a yellow
solid. LCMS (ESI): m/z=421.9 [M+H].sup.+.
Step C.
N-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-((hydro-
xyl imino)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01576##
[1784] To a stirred solution of
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-formylpyrazolo-
[1,5-a]pyrimidine-3-carboxamide (0.15 g, 0.35 mmol) in ethanol (5
ml) was added hydroxylamine hydrochloride (97 mg, 1.4 mmol) and
sodium acetate (0.11 g, 1.4 mmol). The mixture was stirred at
20.degree. C. for 2 h under an atmosphere of nitrogen. Water (10
ml) was added and the mixture was extracted with dichloromethane
(50 ml.times.4), dried over sodium sulfate and concentrated under
reduced pressure to give
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-((hydroxyimino-
)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (155 mg, 99% yield)
as a yellow solid. LCMS (ESI): m/z=437.0 [M+H].sup.+.
Step D.
6-Cyano-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)
pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01577##
[1786] To a stirred solution of
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-((hydroxyimino-
)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (180 mg, 0.41 mmol)
in carbon tetrachloride (5 ml) was added thionylchloride (0.15 ml,
2.06 mmol). The mixture was stirred at 65.degree. C. for 2 h under
an atmosphere of nitrogen. Water (10 ml) was added and the mixture
was extracted with dichloromethane (20 ml.times.3). The combined
organic phases were washed with saturated sodium bicarbonate (20
ml), dried over sodium sulfate and concentrated to dryness. The
residue was purified by column chromatography (eluent 3% methanol:
dichloromethane) followed by recrystallization in methanol to give
6-cyano-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide (53 mg, 29% yield) as a yellow
solid. H NMR (400 MHz, CDCl.sub.3): .delta. 10.33 (s, 1H), 9.20 (d,
J=2.0 Hz, 1H), 8.95 (s, 1H), 8.85 (d, J=2.0 Hz, 1H), 8.40 (s, 1H),
6.68 (s, 1H), 3.94 (t, J=4.0 Hz, 4H), 3.05 (s, 2H), 2.91 (t, J=4.0
Hz, 4H), 1.50 (s, 6H). LCMS (ESI): m/z=419.1 [M+H].sup.+.
Example 408.
1-(2-Amino-2-oxoethyl)-4-(2,2-dimethyl-5-(pyrazolo[1,5-a]pyrimidine-3-car-
boxamido)-2,3-dihydrobenzofuran-6-yl)-1-methylpiperazin-1-ium
##STR01578##
[1788] A solution of
N-(6-(4-(2-amino-2-oxoethyl)piperazin-1-yl)-2,2-dimethyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (27 mg, 0.06
mmol) in tetrahydrofuran (1 ml) was added to a solution of sodium
hydride (60 mass % in oil, 2.8 mg, 0.069 mmol) in tetrahydrofuran
(0.3 ml) at ambient temperature and then heated at 60.degree. C.
for 2 h. The mixture was cooled to room temperature and treated
with a solution of iodomethane (4.3 ml, 0.069 mmol) in
dimethylformamide N,N-dimethylformamide (0.5 ml). After 12 h at
40.degree. C., the reaction was quenched with water (1 ml). The
reaction mixture was concentrated under reduced pressure and
purified in a manner similar to Example 145 to obtain the title
compound as a solid (7.6 mg, 27% yield). .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d6) .delta. 10.05 (s, 1H), 9.39 (dd, J=7.0, 1.3
Hz, 1H), 9.10 (d, J=2.9 Hz, 1H), 8.69 (s, 1H), 8.48 (s, 1H), 8.29
(s, 1H), 7.80 (s, 1H), 7.36 (dd, J=6.9, 4.2 Hz, 1H), 6.95 (s, 1H),
4.38 (s, 2H), 3.88 (d, J=12.6 Hz, 2H), 3.74 (d, J=12.4 Hz, 3H),
3.42 (s, 3H), 3.27 (m, 4H), 3.02 (s, 2H), 1.43 (s, 6H). LCMS (ESI)
m/z: 464.2 [M+H].sup.+.
Examples 409, 410, 411 and 412.
N--((R)-2-(hydroxymethyl)-2-methyl-6-(4-((R)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide;
N--((R)-2-(hydroxymethyl)-2-methyl-6-(4-((S)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide;
N--((S)-2-(hydroxymethyl)-2-methyl-6-(4-((R)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide; and
N--((S)-2-(hydroxymethyl)-2-methyl-6-(4-((S)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide
##STR01579##
[1789] Step A.
1,1,1-trifluoro-2-(1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzo-
furan-6-yl)piperidin-4-yl)propan-2-ol
##STR01580##
[1791] A mixture of
(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol
(Intermediate 3) (250 mg, 1.10 mmol),
1,1,1-trifluoro-2-(4-piperidyl)propan-2-ol (250 mg, 1.27 mmol) and
cesium carbonate (1.18 g, 3.63 mmol) in acetonitrile (5 ml) was
stirred at 80.degree. C. for 18 h. Isopropyl acetate, water, and
brine were added and the organic phase was separated and dried over
sodium sulfate. After filtration and concentration under reduced
pressure, the residue was purified by silica gel chromatography
(eluting gradient 0%-100% isopropyl acetate: heptane) to afford
1,1,1-trifluoro-2-(1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzo-
furan-6-yl)piperidin-4-yl)propan-2-ol compound with
3-methyl-6-nitro-7-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)piperidin-1-y-
l)chroman-3-ol (359 mg, 81% yield) as an orange oil. MS (ESI):
m/z=405.1 [M+1].sup.+.
Step B.
2-(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-y-
l)piperidin-4-yl)-1,1,1-trifluoropropan-2-ol
##STR01581##
[1793] A mixture of
1,1,1-trifluoro-2-(1-(2-(hydroxymethyl)-2-methyl-5-nitro-2,3-dihydrobenzo-
furan-6-yl)piperidin-4-yl)propan-2-ol (357 mg, 0.883 mmol), iron
powder (247 mg, 4.41 mmol) and ammonium chloride (236 mg, 4.41
mmol) in ethanol (18 ml) and water (6 ml) was stirred at 50.degree.
C. for 3 h. The reaction was filtered, the filtrate was
concentrated under reduced pressure and the residue was purified by
silica gel column chromatography (eluting gradient 0%-20% methanol:
dichloromethane) to afford
2-(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piper-
idin-4-yl)-1,1,1-trifluoropropan-2-ol compound with
6-amino-3-methyl-7-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)piperidin-1-y-
l)chroman-3-ol (253 mg, 77% yield). MS (ESI): m/z=375.1
[M+1].sup.+.
Step C.
N-(2-(hydroxymethyl)-2-methyl-6-(4-(1,1,1-trifluoro-2-hydroxypropa-
n-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidin-
e-3-carboxamide
##STR01582##
[1795] A mixture
2-(1-(5-amino-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-6-yl)piper-
idin-4-yl)-1,1,1-trifluoropropan-2-ol (253 mg, 0.676 mmol),
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (135 mg, 0.744 mmol),
4-dimethylaminopyridine (16.7 mg, 0.135 mmol) and
diisopropyethylamine (0.35 ml, 2.03 mmol) in 1,2-dichloroethane
(5.00 ml) was stirred at 25.degree. C. for 18 h. The crude reaction
was concentrated under reduced pressure to afford
N-(2-(hydroxymethyl)-2-methyl-6-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)-
piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-car-
boxamide and
N-(3-hydroxy-3-methyl-7-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)piperidi-
n-1-yl)chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. MS
(ESI): m/z=520.2 [M+1].sup.+.
Step D.
N--((R)-2-(hydroxymethyl)-2-methyl-6-(4-((R)-1,1,1-trifluoro-2-hyd-
roxypropan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]-
pyrimidine-3-carboxamide;
N--((R)-2-(hydroxymethyl)-2-methyl-6-(4-((S)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide;
N--((S)-2-(hydroxymethyl)-2-methyl-6-(4-((R)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide; and
N--((S)-2-(hydroxymethyl)-2-methyl-6-(4-((S)-1,1,1-trifluoro-2-hydroxypro-
pan-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide
##STR01583##
[1797]
N-(2-(hydroxymethyl)-2-methyl-6-(4-(1,1,1-trifluoro-2-hydroxypropan-
-2-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-
-3-carboxamide and
N-(3-hydroxy-3-methyl-7-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)piperidi-
n-1-yl)chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
(Example X) were resolved via chiral SFC: (Jasco 2088 SFC(Chiralpak
AD, 250*21.2 mm, Sum) at 25% Methanol with/0.1% ammonium hydroxide
at 70 ml/min, 100 bar, 40 degC, 22 nm) followed by (Jasco 2088
SFC(Whelk-O1, 150*21.2 mm, 5 um) at 35% Methanol with 0.1% ammonium
hydroxide at 70 ml/min, 100 bar, 40 degC, 220 nm); (PIC 100 SFC
(Chiralpak AD, 250*21.2 mm, 5 um), 25% IPA 2 with 0.1% ammonium
hydroxide at 70 ml/min, 100 bar, 40 degC, 220 nm. Absolute and
relative stereochemistry arbitrarily assigned
[1798] Example 409, Peak 5: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.33 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.3, 1.6
Hz, 1H), 8.68 (s, 1H), 8.24 (s, 1H), 7.33 (dd, J=7.0, 4.2 Hz, 1H),
6.65 (s, 1H), 5.85 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.49-3.38 (m,
2H), 3.26-3.15 (m, 2H), 3.00 (d, J=11.6 Hz, 2H), 2.82 (d, J=15.7
Hz, 1H), 2.64 (d, J=24.0 Hz, 2H), 1.88-1.60 (m, 6H), 1.34 (s, 3H),
1.27 (s, 4H). MS (ESI): m/z=520.2 [M+1].sup.+.
[1799] Example 410, Peak 4: 1H NMR (400 MHz, DMSO-d6) .delta. 10.33
(s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.2, 1.6 Hz,
1H), 8.68 (s, 1H), 8.24 (s, 1H), 7.33 (dd, J=7.0, 4.2 Hz, 1H), 6.65
(s, 1H), 5.85 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.50-3.37 (m, 2H),
3.25-3.10 (d, J=15.7 Hz, 1H), 2.99 (m, 2H), 2.82 (d, J=15.7 Hz,
1H), 2.73-2.56 (m, 2H), 1.91-1.63 (m, 5H), 1.34 (s, 3H), 1.27 (s,
3H). MS (ESI): m/z=520.2 [M+1].sup.+.
[1800] Example 411, Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.33 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.24 (s, 1H), 7.33 (dd, J=7.0, 4.2 Hz, 1H),
6.65 (s, 1H), 5.85 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.43 (p, J=5.5
Hz, 2H), 3.19 (d, J=15.7 Hz, 1H), 3.00 (m, 2H), 2.82 (d, J=15.7 Hz,
1H), 2.64 (m 2H), 1.86-1.65 (m, 5H), 1.34 (s, 3H), 1.27 (s, 3H). MS
(ESI): m/z=520.2 [M+1].sup.+.
[1801] Example 412, Peak 3: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.33 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.24 (s, 1H), 7.33 (dd, J=7.0, 4.2 Hz, 1H),
6.65 (s, 1H), 5.86 (s, 1H), 5.03 (t, J=5.8 Hz, 1H), 3.47-3.38 (m,
2H), 3.19 (d, J=16.1 Hz, 1H), 3.11-2.88 (m, 2H), 2.82 (d, J=16.0
Hz, 1H), 2.62 (m, 2H), 1.92-1.59 (m, 5H), 1.34 (s, 3H), 1.27 (s,
3H). MS (ESI): m/z=520.2 [M+1].sup.+.
TABLE-US-00013 TABLE 13 The following examples were made in a
manner similar to that for Examples 409-412 Ex. Name Structure NMR,
MS 413 and 414 N-((R)-6- ((1R,5S,6R)-6- carbamoyl-3-
azabicyclo[3.1.0] hexan-3-yl)-2- (hydroxymethyl)- 2-methyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
and ##STR01584## Example 414, Peak 1: .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 9.58 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.97
(dd, J = 4.3, 1.6 Hz, 1H), 8.68 (s, 1H), 8.00 (s, 1H), 7.33 (dd, J
= 7.0, 4.2 Hz, 2H), 6.77 (s, 1H), 6.59 (s, 1H), 5.03 (t, J = 5.8
Hz, 1H), 3.42 (m, 4H), 3.17 (d, J = 15.9 Hz, 1H), 3.07 (m, 2H),
2.79 (d, J = 15.8 Hz, 1H), 2.21 (t, J = 2.9 Hz, 1H), 1.90 (s, 2H),
1.33 (s, 3H). MS (ESI): m/z = 449.2 [M + 1].sup.+. N-((S)-6-
((1R,5S,6S)-6- carbamoyl-3- azabicyclo[3.1.0] hexan-3-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01585## Example 413,
Peak 2: .sup.1H NMIR (400 MHz, DMSO-d6) .delta. 9.58 (s, 1H), 9.36
(dd, J = 7.0, 1.6 Hz, 1H), 8.97 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s,
1H), 8.00 (s, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 2H), 6.77 (s, 1H),
6.59 (s, 1H), 5.03 (t, J = 5.8 Hz, 1H), 3.42 (m, 4H), 3.17 (d, J =
16.1 Hz, 1H), 3.07 (m, 2H), 2.79 (d, J = 15.8 Hz, 1H), 2.21 (t, J =
2.9 Hz, 1H), 1.90 (s, 2H), 1.33 (s, 3H). MS (ESI): m/z = 449.2 [M +
1].sup.+. 415 and 416 (R)-N-(6-(4-(2- amino-2- oxoethyl)piperazin-
1-yl)-2- (hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01586##
Example 416, Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.42
(s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.97 (dd, J = 4.2, 1.6 Hz,
1H), 8.67 (s, 1H), 8.32 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H),
7.19 (d, J = 28.2 Hz, 2H), 6.67 (s, 1H), 5.03 (t, J = 5.8 Hz, 1H),
3.42 (m, 2H), 3.19 (d, J = 16.2 Hz, 1H), 3.01 (s, 2H), 2.93-2.78
(m, 5H), 2.73 (s, 4H), 1.34 (s, 3H). MS (ESI): m/z = 466.2 [M +
1].sup.+. (S)-N-(6-(4-(2- amino-2- oxoethyl)piperazin- 1-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned ##STR01587## Example 415, Peak 2: .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 10.42 (s, 1H), 9.36 (dd, J = 7.0,
1.6 Hz, 1H), 8.97 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.32 (s,
1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 7.23 (s, 1H), 7.16 (s, 1H),
6.67 (s, 1H), 5.03 (t, J = 5.8 Hz, 1H), 3.49-3.37 (m, 2H), 3.19 (d,
J = 15.7 Hz, 1H), 3.01 (s, 2H), 2.84 (m, 5H), 2.73 (s, 4H), 1.34
(s, 3H). MS (ESI): m/z = 466.2 [M + 1].sup.+. arbitrarily) 417 and
418 (R)-N-(2- (hydroxymethyl)- 2-methyl-6-(3- oxo-2,8-
diazaspiro[4.5] decan-8-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01588##
Example 417, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.46
(s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.6 Hz,
1H), 8.67 (s, 1H), 8.30 (s, 1H), 7.58 (s, 1H), 7.34 (dd, J = 7.0,
4.2 Hz, 1H), 6.72 (s, 1H), 5.02 (t, J = 5.8 Hz, 1H), 3.42 (m, 2H),
3.17 (m, 3H), 2.82 (d, J = 16.0 Hz, 1H), 2.77 (m, 4H), 2.18 (s,
2H), 1.80 (m, 4H), 1.34 (s, 3H). MS (ESI): m/z = 477.2 [M +
1].sup.+. (S)-N-(2- (hydroxymethyl)- 2-methyl-6-(3- oxo-2,8-
diazaspiro[4.5] decan-8-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01589## Example 418 Peak
1: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.46 (s, 1H), 9.36 (dd,
J = 7.0, 1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H),
8.30 (s, 1H), 7.58 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.72
(s, 1H), 5.02 (t, J = 5.8 Hz, 1H), 3.43 (m, 2H), 3.19 (m, 3H), 2.82
(d, J = 16.1 Hz, 1H), 2.79-2.73 (m, 4H), 2.18 (s, 2H), 1.80 (m,
4H), 1.34 (s, 3H). MS (ESI): m/z = 477.2 [M + 1].sup.+. 419 and 420
(R)-N-(6-(5,7- dihydro-6H- pyrrolo[3,4- b]pyridin-6-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01590##
Example 419, Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.39
(s, 1H), 9.29 (dd, J = 7.0, 1.7 Hz, 1H), 8.67 (s, 1H), 8.45 (d, J =
4.9 Hz, 1H), 8.13 (s, 1H), 7.82 (dd, J = 4.2, 1.7 Hz, 1H), 7.75 (d,
J = 6.3 Hz, 1H), 7.32 (dd, J = 7.6, 5.0 Hz, 1H), 7.16 (dd, J = 7.0,
4.2 Hz, 1H), 6.90 (s, 1H), 5.05 (t, J = 5.8 Hz, 1H), 4.51 (s, 2H),
4.47 (s, 2H), 3.44 (m, 2H), 3.25- 3.18 (m, 1H), 2.84 (d, J = 16.1
Hz, 1H), 1.36 (s, 3H). MS (ESI): m/z = 443.1 [M + 1].sup.+.
(S)-N-(6-(5,7- dihydro-6H- pyrrolo[3,4- b]pyridin-6-yl)-2-
(hydroxymethyl)- 2-methyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01591## Example 420,
Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.39 (s, 1H), 9.29
(dd, J = 7.0, 1.7 Hz, 1H), 8.67 (s, 1H), 8.45 (dd, J = 5.0, 1.4 Hz,
1H), 8.13 (s, 1H), 7.82 (dd, J = 4.2, 1.7 Hz, 1H), 7.75 (d, J = 6.4
Hz, 1H), 7.32 (dd, J = 7.6, 5.0 Hz, 1H), 7.16 (dd, J = 7.0, 4.2 Hz,
1H), 6.90 (s, 1H), 5.05 (t, J = 5.8 Hz, 1H), 4.51 (s, 2H), 4.47 (s,
2H), 3.45 (m, 2H), 3.26- 3.16 (m, 1H), 2.84 (d, J = 16.1 Hz, 1H),
1.36 (s, 3H). MS (ESI): m/z = 443.1 [M + 1].sup.+.
Examples 421, 422 and 423.
N--((S)-3-hydroxy-3-methyl-7-(4-((S)-1,1,1-trifluoro-2-hydroxypropan-2-yl-
)piperidin-1-yl)chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
N--((R)-3-hydroxy-3-methyl-7-(4-((R)-1,1,1-trifluoro-2-hydroxypropan-2-yl-
)piperidin-1-yl)chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-(3-hydroxy-3-methyl-7-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)piperidi-
n-1-yl)chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01592##
[1803] The title compounds were made in the process of generating
Examples 409-412, Step A and isolated during Examples 409-412, Step
D. Absolute and relative stereochemistry arbitrarily assigned.
[1804] Example 421, Peak 3: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.29 (s, 1H), 9.41-9.31 (m, 1H), 8.90 (d, J=2.7 Hz, 1H), 8.68 (s,
1H), 8.12 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H), 6.66 (s, 1H), 5.86
(s, 1H), 4.82 (s, 1H), 3.75 (s, 2H), 3.03 (m, 2H), 2.68 (d, J=7.7
Hz, 2H), 2.65-2.55 (m, 2H), 1.77 (m, 5H), 1.28 (s, 3H), 1.19 (s,
3H). MS (ESI): m/z=520.2 [M+1].sup.+.
[1805] Example 422, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.29 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.12 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H),
6.66 (s, 1H), 5.87 (s, 1H), 4.82 (s, 1H), 3.74 (s, 2H), 3.02 (m,
2H), 2.76-2.65 (m, 2H), 2.66-2.54 (m, 2H), 1.78 (m, 5H), 1.28 (s,
3H), 1.19 (s, 3H). MS (ESI): m/z=520.2 [M+1].sup.+.
[1806] Example 423, Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.29 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H), 8.90 (dd, J=4.2, 1.6
Hz, 1H), 8.68 (s, 1H), 8.12 (s, 1H), 7.34 (dd, J=7.0, 4.2 Hz, 1H),
6.66 (s, 1H), 5.87 (s, 1H), 4.82 (s, 1H), 3.74 (s, 2H), 3.01 (m,
2H), 2.78-2.53 (m, 2H), 2.66-2.54 (m, 2H), 1.78 (m, 5H), 1.28 (s,
3H), 1.19 (s, 3H). MS (ESI): m/z=520.2 [M+1].sup.+.
TABLE-US-00014 TABLE 14 The following examples were made in a
manner similar to that for Examples 423-425 Ex. Name Structure NMR,
MS 424 and 425 (R)-N-(7-(4-(2- amino-2- oxoethyl)piperazin-
1-yl)-3-hydroxy- 3-methylchroman- 6-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01593## Example 424, Peak 1:
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.37 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.97 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.19 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 7.24 (s, 1H), 7.16
(s, 1H), 6.68 (s, 1H), 4.83 (s, 1H), 3.75 (s, 2H), 3.02 (s, 2H),
2.90-2.82 (m, 4H), 2.79-2.63 (m, 6H), 1.20 (s, 3H). MS (ESI): m/z =
466.2 [M + 1].sup.+. (S)-N-(7-(4-(2- amino-2- oxoethyl)piperazin-
1-yl)-3-hydroxy- 3-methylchroman- 6-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01594## Example 425, Peak 2: .sup.1H NMR (400
MHz, DMSO-d6) .delta. 10.37 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.97 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.19 (s, 1H),
7.35 (dd, J = 7.0, 4.2 Hz, 1H), 7.24 (s, 1H), 7.16 (s, 1H), 6.68
(s, 1H), 4.83 (s, 1H), 3.75 (s, 2H), 3.02 (s, 2H), 2.92-2.79 (m,
4H), 2.69 (m, 6H), 1.20 (s, 3H). MS (ESI): m/z = 466.2 [M +
1].sup.+. 426 and 427 (R)-N-(7-(4- cyanopiperidin-1-
yl)-3-hydroxy-3- methylchroman-6- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide and ##STR01595## Example 426, Peak 1: .sup.1H NMR (400
MHz, DMSO-d6) .delta. 10.33 (s, 1H), 9.39 (dd, J = 7.0, 1.6 Hz,
1H), 8.87 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.17 (s, 1H),
7.39 (dd, J = 7.0, 4.2 Hz, 1H), 6.66 (s, 1H), 4.83 (s, 1H), 3.75
(s, 2H), 3.10 (m, 1H), 2.97-2.86 (m, 2H), 2.85-2.73 (m, 2H), 2.72-
2.62 (m, 2H), 2.10 (m, 2H), 2.06- 1.95 (m, 2H), 1.19 (s, 3H). MS
(ESI): m/z = 433.1 [M + 1].sup.+. (S)-N-(7-(4- cyanopiperidin-1-
yl)-3-hydroxy-3- methylchroman-6- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide (absolute stereochemistry assigned arbitrarily)
##STR01596## Example 427, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.33 (s, 1H), 9.39 (dd, J = 7.0, 1.6 Hz, 1H), 8.87 (dd, J
= 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.17 (s, 1H), 7.39 (dd, J = 7.0,
4.2 Hz, 1H), 6.66 (s, 1H), 4.83 (s, 1H), 3.75 (s, 2H), 3.10 (m,
1H), 2.97-2.86 (m, 2H), 2.85-2.73 (m, 2H), 2.72- 2.62 (m, 2H), 2.10
(m, 2H), 2.06- 1.95 (m, 2H), 1.19 (s, 3H). MS (ESI): m/z = 433.1 [M
+ 1].sup.+. 428 and 429 (R)-N-(7-(4-(1H- imidazol-1-
yl)piperidin-1-yl)- 3-hydroxy-3- methylchroman-6- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide and ##STR01597## Example 428, Peak 2:
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.26 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.82 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H),
8.11 (s, 1H), 7.78 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 7.30
(s, 1H), 6.95 (s, 1H), 6.71 (s, 1H), 4.84 (s, 1H), 4.24 (dt, J =
11.0, 6.1 Hz, 1H), 3.76 (s, 2H), 3.09 (d, J = 11.7 Hz, 2H),
2.90-2.77 (m, 2H), 2.77- 2.62 (m, 2H), 2.27-2.08 (m, 4H), 1.20 (s,
3H). MS (ESI): m/z = 474.2 [M + 1].sup.+. (S)-N-(7-(4-(1H-
imidazol-1- yl)piperidin-1-yl)- 3-hydroxy-3- methylchroman-6-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01598## Example 429,
Peak 1: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.26 (s, 1H), 9.36
(dd, J = 7.0, 1.6 Hz, 1H), 8.82 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s,
1H), 8.11 (s, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 7.30 (s, 1H),
6.95 (s, 1H), 6.71 (s, 1H), 4.84 (s, 1H), 4.24 (dt, J = 10.9, 6.1
Hz, 1H), 3.76 (s, 2H), 3.09 (d, J = 11.8 Hz, 2H), 2.91- 2.77 (m,
2H), 2.77-2.60 (m, 2H), 2.28-2.05 (m, 4H), 1.20 (s, 3H). MS (ESI):
m/z = 474.2 [M + 1].sup.+. 430 and 431 (R)-N-(3-hydroxy-
3-methyl-7-((1- methyl-1H- pyrazol-4- yl)methoxy) chroman-6-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide and ##STR01599##
Example 430, Peak 3: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.15
(s, 1H), 9.34 (dd, J = 7.0, 1.7 Hz, 1H), 8.64 (s, 1H), 8.33 (dd, J
= 4.2, 1.7 Hz, 1H), 8.13 (s, 1H), 7.84 (s, 1H), 7.66-7.59 (m, 1H),
7.38-7.29 (m, 1H), 6.66 (s, 1H), 5.02 (s, 2H), 4.82 (s, 1H), 3.87
(s, 3H), 3.76 (s, 2H), 2.66 (d, J = 3.9 Hz, 2H), 1.20 (s, 3H). MS
(ESI): m/z = 435.1 [M + 1].sup.+. (S)-N-(3-hydroxy- 3-methyl-7-((1-
methyl-1H- pyrazol-4- yl)methoxy) chroman-6- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01600## Example 431, Peak 1: .sup.1H NMR (400
MHz, DMSO-d6) .delta. 10.15 (s, 1H), 9.34 (dd, J = 7.0, 1.7 Hz,
1H), 8.64 (s, 1H), 8.33 (dd, J = 4.2, 1.7 Hz, 1H), 8.13 (s, 1H),
7.84 (s, 1H), 7.63 (d, J = 0.6 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz,
1H), 6.66 (s, 1H), 5.02 (s, 2H), 4.82 (s, 1H), 3.87 (s, 3H), 3.76
(s, 2H), 2.66 (d, J = 4.0 Hz, 2H), 1.20 (s, 3H). MS (ESI): m/z =
435.1 [M + 1].sup.+. 432 and 433 (R)-N-(2- (hydroxymethyl)-
2-methyl-7- morpholinochroman-6- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide and ##STR01601## Example 433, Peak 1: .sup.1H NMR (400
MHz, DMSO-d6) .delta. 10.35 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz,
1H), 8.95 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.21 (s, 1H),
7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.62 (s, 1H), 4.90 (t, J = 5.8 Hz,
1H), 3.90-3.73 (m, 4H), 3.49- 3.35 (m, 2H), 2.87-2.76 (m, 4H),
2.76-2.65 (m, 2H), 1.89 (dt, J = 14.0, 7.2 Hz, 1H), 1.68 (dt, J =
12.9, 6.1 Hz, 1H), 1.20 (s, 3H). MS (ESI): m/z = 424.1 [M +
1].sup.+. (S)-N-(2- (hydroxymethyl)- 2-methyl-7-
morpholinochroman-6- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01602##
Example 432, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.35
(s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.95 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.21 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H),
6.62 (s, 1H), 4.97-4.82 (m, 1H), 3.83 (m, 4H), 3.48-3.36 (m, 2H),
2.89-2.75 (m, 4H), 2.70 (m, 2H), 1.89 (dt, J = 14.0, 7.2 Hz, 1H),
1.68 (dt, J = 12.9, 6.1 Hz, 1H), 1.20 (s, 3H). MS (ESI): m/z =
424.2 [M + 1].sup.+.
Example 434.
N-(6-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)-2,2-dimethyl-2,3-dihydr-
obenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01603##
[1807] Step A.
1-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazine
##STR01604##
[1809] A mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(10.0 g, 43.9 mmol), piperazine (4.16 g, 48.3 mmol) and
N,N-diisopropylethylamine (25.4 ml, 154 mmol) in dimethylsulfoxide
(133 mL) was heated at 45.degree. C. for 12 h. The mixture was
diluted with water, brine, and dichloromethane. The phases were
separated and the aqueous phase was extracted into dichloromethane.
The combined organic phases were dried over sodium sulfate,
concentrated under reduced pressure and purified by silica gel
chromatography (eluting gradient 0%-20% methanol: dichloromethane)
to afford
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazine (5.96
g, 49% yield) as a bright orange foam. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 7.83 (s, 1H), 6.57 (s, 1H), 3.00 (d, J=1.1 Hz,
2H), 2.91 (d, J=10.5 Hz, 8H), 1.44 (s, 6H).
Step B. Ethyl
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate
##STR01605##
[1811] A mixture of
1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazine (5.96
g, 21.5 mmol), potassium carbonate (4.46 g, 32.3 mmol) and ethyl
2-bromoacetate(2.55 ml, 22.6 mmol) in dimethylformamide (100 ml)
was stirred at ambient temperature for 18 h. The mixture was
diluted with water, brine, and isopropyl acetate. The layers were
separated and the aqueous phase was extracted with isopropyl
acetate. The combined organic phases were dried over sodium
sulfate, concentrated under reduced pressure and purified by silica
gel chromatography (eluting gradient 0%-100% isopropyl acetate:
heptane) to afford ethyl
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate (7.74 g, 99% yield) as an orange oil. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 7.82 (t, J=1.2 Hz, 1H), 6.59 (s, 1H), 4.09 (q,
J=7.1 Hz, 2H), 3.27 (s, 2H), 3.00 (d, J=1.0 Hz, 2H), 2.99-2.93 (m,
4H), 2.68-2.58 (m, 4H), 1.44 (s, 6H), 1.24-1.14 (m, 4H).
Step C. Ethyl
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate
##STR01606##
[1813] A mixture of ethyl
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate (7.74 g, 21.3 mmol) and 10% palladium on carbon (2.27 g, 2.13
mmol) in ethanol (100 ml) was stirred for 18 h under an atmosphere
of hydrogen. The mixture was filtered and the filtrate was
concentrated under reduced pressure and purified by silica gel
chromatography (eluting gradient 0%-5% methanol: dichloromethane)
to afford ethyl
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate (6.36 g, 90% yield). .sup.1H NMR (400 MHz, DMSO-d6) .delta.
6.52 (s, 1H), 6.34 (s, 1H), 4.17 (s, 2H), 4.10 (q, J=7.1 Hz, 2H),
3.25 (s, 2H), 2.83 (s, 2H), 2.74 (d, J=4.4 Hz, 4H), 2.63 (s, 4H),
1.34 (s, 6H), 1.24-1.14 (m, 3H).
Step D. Ethyl
2-(4-(5-(bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzofuran-6--
yl)piperazin-1-yl)acetate
##STR01607##
[1815] A mixture of ethyl
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acet-
ate (6.36 g, 19.1 mmol), potassium carbonate (5.28 g, 38.2 mmol),
potassium iodide (634 mg, 3.82 mmol) and 4-methoxybenxyl chloride
(2.64 ml, 20.0 mmol) in dimethylformamide (38 ml) was stirred at
ambient temperature for 18 h. Additional potassium carbonate (5.28
g, 38.2 mmol) and 4-methoxybenxyl chloride (2.64 ml, 20.0 mmol)
were added. After 18 h, the reaction was filtered and the filtrate
was concentrated in vacuo. The residue was purified by silica gel
chromatography (eluting gradient 0%-50% isopropyl acetate: heptane)
to afford ethyl
2-(4-(5-(bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzofuran-6--
yl)piperazin-1-yl)acetate (4.66 g, 47% yield) as a tan solid.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.04 (d, J=8.7 Hz, 4H), 6.82
(d, J=8.7 Hz, 4H), 6.62 (s, 1H), 6.36 (s, 1H), 4.09 (q, J=7.1 Hz,
2H), 4.05 (s, 4H), 3.71 (s, 6H), 3.29-3.25 (m, 2H), 3.07 (s, 4H),
2.80 (s, 2H), 2.72 (d, J=12.1 Hz, 4H), 1.35 (s, 6H), 1.24-1.13 (m,
3H).
Step E.
1-(4-(5-(Bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzof-
uran-6-yl)piperazin-1-yl)-2-methylpropan-2-ol
##STR01608##
[1817] Methylmagnesium bromide in diethyl ether (3M, 0.150 ml,
0.442 mmol) was added to ethyl
2-(4-(5-(bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzofuran-6--
yl)piperazin-1-yl)acetate (102 mg, 0.177 mmol) in tetrahydrofuran
(2.1 ml) at ambient temperature and the reaction was stirred for 18
h. The mixture was diluted with water, saturated ammonium chloride,
and isopropyl acetate. The layers were separated and the aqueous
phase was extracted into isopropyl acetate. The combined organic
phases were dried over sodium sulfate, concentrated under reduced
pressure and purified by silica gel chromatography (eluting
gradient 0%-100% isopropyl acetate: heptane) to afford
1-(4-(5-(bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzofuran-6--
yl)piperazin-1-yl)-2-methylpropan-2-ol (90 mg, 91% yield). .sup.1H
NMR (400 MHz, Chloroform-d) .delta. 6.99 (d, J=8.7 Hz, 4H),
6.83-6.77 (m, 4H), 6.51 (s, 1H), 6.44 (s, 1H), 4.99 (p, J=6.3 Hz,
OH), 4.08 (s, 4H), 3.79 (s, 7H), 3.23 (s, 5H), 2.86 (s, 2H), 2.82
(t, J=4.2 Hz, 4H), 2.39 (s, 2H), 1.45 (s, 7H), 1.21 (s, 6H).
Step F.
1-(4-(5-Amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1--
yl)-2-methylpropan-2-ol
##STR01609##
[1819] A mixture of
1-(4-(5-(bis(4-methoxybenzyl)amino)-2,2-dimethyl-2,3-dihydrobenzofuran-6--
yl)piperazin-1-yl)-2-methylpropan-2-ol (90 mg, 0.161 mmol) and 10%
palladium on carbon (17.1 mg, 0.0161 mmol) in ethanol (5 ml) was
stirred for 18 h under an atmosphere of hydrogen. The mixture was
filtered through a pad of celite and the filtrate was concentrated
under reduced pressure to afford
1-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-2-m-
ethylpropan-2-ol (37.4 mg, 73% yield) which was used without
further purification.
Step G.
N-(6-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)-2,2-dimethyl-2,3-
-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01610##
[1821] A mixture of
1-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-2-m-
ethylpropan-2-ol (37.4 mg, 0.117 mmol),
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (31.9 mg, 0.176
mmol), and 4-dimethylaminopyridine (2.86 mg, 0.0234 mmol) in
pyridine (5 ml) was stirred at ambient temperature for 36 h. The
reaction was then concentrated under reduced pressure and purified
by preparative HPLC ((Xbridge 21.2*250 mm c18, 10 um; A:
acetonitrile 10-20%; B: 10 mM ammonium bicarbonate in water) to
afford the title compound (33.6 mg, 62% yield) as a solid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.42 (s, 1H), 9.37 (dd, J=7.0,
1.6 Hz, 1H), 8.91 (dd, J=4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.31 (s,
1H), 7.39 (dd, J=7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 4.10 (s, 1H), 3.00
(s, 2H), 2.79 (m, 8H), 2.32 (s, 2H), 1.42 (s, 6H), 1.13 (s, 6H). MS
(ESI): m/z=465.3 [M+1].sup.+.
Example 435.
N-(6-(4-(2-Ethyl-2-hydroxybutyl)piperazin-1-yl)-2,2-dimethyl-2,3-dihydrob-
enzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01611##
[1823] The title compound was made in a manner analogous to Example
434 to give
N-(6-(4-(2-ethyl-2-hydroxybutyl)piperazin-1-yl)-2,2-dimethyl-2,3-dih-
ydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (70.4
mg, 33% yield) as a solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.41 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.91 (dd,
J=4.3, 1.6 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.39 (dd, J=7.0,
4.2 Hz, 1H), 6.68 (s, 1H), 3.79 (s, 1H), 3.00 (s, 2H), 2.79 (m,
8H), 2.32 (s, 2H), 1.54-1.29 (m, 10H), 0.80 (t, J=7.4 Hz, 6H). MS
(ESI): m/z=493.3 [M+1].sup.+.
Examples 436 and 437.
(S)--N-(2-(hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide and
(R)--N-(2-(hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide were generated upon chiral resolution of
Example 141
##STR01612##
[1825] A mixture of
N-(2-(hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5-a]pyr-
imidine-3-carboxamide was resolved by chiral SFC (Amylose-1 15*2.1
cm, 5 um (PIC), A=CO.sub.2, B=methanol {0.1% ammonium hydroxide}
40% isocratic) to obtain
(R)--N-(2-(hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyr-
azolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(hydroxymethyl)-2-methyl-7-morpholinochroman-6-yl)pyrazolo[1,5--
a]pyrimidine-3-carboxamide (16 mg, 38%) (16 mg, 38%) as off white
solids with absolute stereochemistry assigned arbitrarily.
[1826] Example 436 (S), Peak 2: .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.35 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95 (dd,
J=4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.21 (s, 1H), 7.34 (dd, J=7.0,
4.2 Hz, 1H), 6.62 (s, 1H), 4.97-4.82 (m, 1H), 3.83 (m, 4H),
3.48-3.36 (m, 2H), 2.89-2.75 (m, 4H), 2.70 (m, 2H), 1.89 (dt,
J=14.0, 7.2 Hz, 1H), 1.68 (dt, J=12.9, 6.1 Hz, 1H), 1.20 (s, 3H).
MS (ESI): m/z=424.2 [M+1].sup.+.
[1827] Example 437 (R), Peak 1: .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.35 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95 (dd,
J=4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.21 (s, 1H), 7.34 (dd, J=7.0,
4.2 Hz, 1H), 6.62 (s, 1H), 4.90 (t, J=5.8 Hz, 1H), 3.90-3.73 (m,
4H), 3.49-3.35 (m, 2H), 2.87-2.76 (m, 4H), 2.76-2.65 (m, 2H), 1.89
(dt, J=14.0, 7.2 Hz, 1H), 1.68 (dt, J=12.9, 6.1 Hz, 1H), 1.20 (s,
3H). MS (ESI): m/z=424.1 [M+1].sup.+.
Examples 438 and 439.
(S)--N-(2-(dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(2-(dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide were generated upon
chiral resolution of Example 23
##STR01613##
[1829] A mixture of
N-(2-(dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide was resolved by chiral SFC
(Amylose-1 15*2.1 cm, 5 um (PIC), A=CO.sub.2, B=methanol{0.1%
ammonium hydroxide} 40% isocratic) to obtain
(R)--N-(2-(dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(2-(dimethylcarbamoyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-
-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (14 mg, 34%) (15 mg,
34%) as yellow solids with absolute stereochemistry assigned
arbitrarily.
[1830] Example 438, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.45 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95 (dd,
J=4.2, 1.7 Hz, 1H), 8.69 (s, 1H), 8.35 (d, J=1.0 Hz, 1H), 7.35 (dd,
J=7.0, 4.2 Hz, 1H), 6.84 (s, 1H), 3.84 (m, 5H), 3.16 (m, 3H),
3.09-3.01 (m, 1H), 2.90-2.86 (m, 3H), 2.85-2.79 (m, 4H), 1.58 (s,
3H). MS (ESI): m/z=451.2 [M+1].sup.+.
[1831] Example 439, Peak 2: 1H NMR (400 MHz, DMSO-d6) .delta. 10.45
(s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.95 (dd, J=4.2, 1.7 Hz,
1H), 8.69 (s, 1H), 8.35 (s, 1H), 7.35 (dd, J=7.0, 4.2 Hz, 1H), 6.84
(s, 1H), 3.91-3.76 (m, 5H), 3.20-3.12 (m, 3H), 3.10-2.98 (m, 1H),
2.88 (s, 3H), 2.85-2.80 (m, 4H), 1.57 (d, J=2.0 Hz, 3H). MS (ESI):
m/z=451.1 [M+1].sup.+.
Example 440.
N-(2,2-dimethyl-6-(4-(2-oxo-2-(((tetrahydrofuran-2-yl)methyl)amino)ethyl)-
piperazin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-car-
boxamide
##STR01614##
[1832] Step A.
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-N-(-
tetrahydrofuran-2-yl)acetamide
##STR01615##
[1834] A mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran
(Intermediate 1) (200 mg, 0.88 mmol) and
2-piperazin-1-yl-N-(tetrahydrofuran-2-ylmethyl)acetamide (220 mg,
0.97 mmol) in dimethyl sulfoxide (1.3 ml) was treated with
N,N-diisopropylethylamine (0.17 ml, 0.97 mmol) and stirred at
60.degree. C. for 24 h. The mixture was poured into water and the
reaction was extracted by ethyl acetate (100 ml). The organic phase
was washed with water and brine, dried over sodium sulfate and
filtered before concentration to dryness. The residue was purified
by purified by silica gel chromatography (eluting gradient 0-100%
IPAC in heptanes) to afford
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-N-(-
tetrahydrofuran-2-yl)acetamide (347 mg, 94%) as a solid. .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 7.82 (s, 1H), 7.72 (t, J=6.0 Hz,
1H), 6.59 (s, 1H), 4.08 (q, J=5.3 Hz, 1H), 3.86 (p, J=6.5 Hz, 1H),
3.80-3.70 (m, 1H), 3.66-3.56 (m, 1H), 3.17 (dd, J=5.5, 2.2 Hz, 4H),
3.05-2.93 (m, 8H), 2.56 (dtdt, J=4.5, 2.0, 1.0, 0.5 Hz, 4H),
1.93-1.73 (m, 3H), 1.50 (ddd, J=10.1, 7.8, 5.4 Hz, 1H), 1.44 (s,
6H). LCMS (ESI): m/z=419.2 [M+H].sup.+.
Step B.
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1--
yl)-N-(tetrahydrofuran-2-yl)acetamide
##STR01616##
[1836] A mixture of
2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-N-(-
tetrahydrofuran-2-yl)acetamide (342 mg, 0.82 mmol), iron powder
(245 mg, 4.39 mmol) and ammonium chloride (235 mg, 4.39 mmol) in
ethanol (25 ml) and water (5 ml), was heated at 60.degree. C. for 2
h. The reaction mixture was cooled to room temperature then
filtered through celite and concentrated. The crude product was
purified by silica gel chromatography (eluting gradient 0-20%
methanol: dichloromethane) to afford
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-N-(-
tetrahydrofuran-2-yl)acetamide (210 mg, 0.54 mmol, 62% yield) as a
solid, which was used without further purification. MS (ESI):
m/z=389.2 [M+1].sup.+.
Step C. Example X.
N-(2,2-dimethyl-6-(4-(2-oxo-2-(((tetrahydrofuran-2-yl)methyl)amino)ethyl)-
piperazin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-car-
boxamide
##STR01617##
[1838] A mixture of
2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)-N-(-
tetrahydrofuran-2-yl)acetamide (210 mg, 0.54 mmol),
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (240 mg, 1.32 mmol),
and 4-dimethylaminopyridine (21.5 mg, 0.175 mmol) in pyridine (5
ml) was stirred at ambient temperature for 36 h. The reaction was
then concentrated under reduced pressure and purified by
preparative HPLC ((Gemini NX, 5*3 cm c18, 5 um; A: acetonitrile
20-60%; B: 0.1% ammonium hydroxide in water) to afford the title
compound (108 mg, 0.202 mmol, 23% yield) as a solid. H NMR (400
MHz, DMSO-d6) .delta. 10.41 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz, 1H),
8.97 (dd, J=4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.74 (t,
J=6.0 Hz, 1H), 7.35 (dd, J=7.0, 4.2 Hz, 1H), 6.69 (s, 1H),
3.92-3.80 (m, 1H), 3.80-3.69 (m, 1H), 3.68-3.54 (m, 1H), 3.26-3.13
(m, 2H), 3.08 (d, J=3.2 Hz, 2H), 3.00 (s, 2H), 2.89-2.80 (m, 4H),
2.72 (s, 4H), 1.92-1.73 (m, 3H), 1.56-1.45 (m, 1H), 1.41 (s, 6H).
MS (ESI): m/z=534.2 [M+1].sup.+.
TABLE-US-00015 TABLE 15 The following examples were made in a
manner similar to that for Example 440: Ex. Name Structure NMR, MS
441. N-(2,2-dimethyl-6-(4-(2- oxo-2-(thiazol-2-
ylamino)ethyl)piperazin- 1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyridine-3- carboxamide ##STR01618## .sup.1H NMR
(400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 11.94 (s, 1H), 10.42
(s, 1H), 9.45-9.26 (m, 1H), 8.98 (dd, J = 4.2, 1.7 Hz, 1H), 8.67
(s, 1H), 8.34 (s, 1H), 7.50 (d, J = 3.6 Hz, 1H), 7.32-7.21 (m, 2H),
6.72 (s, 1H), 3.52-3.38 (m, 2H), 3.00 (s, 2H), 2.85 (s, 8H), 1.41
(s, 6H). MS (ESI): m/z = 533.2 [M + 1].sup.+. 442. and 443.
(S)-N-(6- (hexahydropyrrolo[1,2- a]pyrazin-2(1H)-yl)-2,2-
dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide and (R)-N- (6- (hexahydropyrrolo[1,2-
a]pyrazin-2(1H)-yl)-2,2- dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01619## ##STR01620##
Example 442, Peak 2: .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.44 (s, 1H), 9.35 (dd, J = 7.0, 1.6
Hz, 1H), 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.34 (s,
1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.09-2.91 (m,
5H), 2.88-2.73 (m, 2H), 2.63- 2.53 (m, 1H), 2.45-2.35 (m, 1H), 2.20
(d, J = 8.3 Hz, 1H), 1.80-1.65 (m, 3H), 1.41 (s, 6H), 1.39-1.23 (m,
1H). MS (ESI): m/z = 433.2 [M + 1].sup.+. Example 443, Peak 1:
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.44 (s,
1H), 9.35 (dd, J = 7.0, 1.7 Hz, 1H), 8.84 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.34 (s, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H),
6.71 (s, 1H), 3.09-2.91 (m, 5H), 2.88-2.73 (m, 2H), 2.63- 2.53 (m,
1H), 2.45-2.35 (m, 1H), 2.20 (d, J = 8.3 Hz, 1H), 1.80-1.65 (m,
3H), 1.41 (s, 6H), 1.39-1.23 (m, 1H). MS (ESI): m/z = 433.2 [M +
1].sup.+.
Example 444.
(R)--N-(2-methyl-2-(2-(methylthio)ethyl)-6-morpholino-2,3-dihydrobenzofur-
an-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01621##
[1839] Step A.
(R)-2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)--
2,3-dihydrobenzofuran-2-yl)ethyl methanesulfonate
##STR01622##
[1841] To a mixture of
(R)--N-(2-(2-hydroxyethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 388) (32 mg,
0.076 mmol) and triethylamine (0.016 ml, 0.11 mmol) in
dichloromethane (1.0 ml) at 0.degree. C. was added methanesulfonyl
chloride (0.0070 ml, 0.091 mmol). After 15 min, the mixture was
diluted with water and extracted with dichloromethane. The combined
organics were dried over sodium sulfate, filtered, and concentrated
in vacuo to afford
(R)-2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)--
2,3-dihydrobenzofuran-2-yl)ethyl methanesulfonate (38 mg, 0.076
mmol), which was used crude without further purification. MS (ESI):
m/z=502.2 [M+1].sup.+.
Step B.
(R)--S-(2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-ca-
rboxamido)-2,3-dihydrobenzofuran-2-yl)ethyl) ethanethioate
##STR01623##
[1843] A solution of
(R)-2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)--
2,3-dihydrobenzofuran-2-yl)ethyl methanesulfonate (38 mg, 0.076
mmol) in N,N-dimethylformamide (5 ml) was treated with sodium
thiomethoxide (8.4 mg, 0.11 mmol) and heated to 60.degree. C. for 4
h. Potassium carbonate (52 mg, 0.38 mmol) was added to the mixture
at 60.degree. C. After 2 h, potassium thioacetate (43 mg, 0.38
mmol) was added and heated at 90.degree. C. for 18 h. The mixture
was diluted with water and extracted with isopropyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate, and concentrated. The residue was purified by silica gel
chromatography (eluting gradient 0-100% isopropyl acetate in
heptanes) to afford
(R)--S-(2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxami-
do)-2,3-dihydrobenzofuran-2-yl)ethyl) ethanethioate (24 mg, 0.050
mmol, 66% yield) as a solid. MS (ESI): m/z=482 [M+1].sup.+.
Step C.
(R)--N-(2-methyl-2-(2-(methylthio)ethyl)-6-morpholino-2,3-dihydrob-
enzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01624##
[1845] A solution of
(R)--S-(2-(2-methyl-6-morpholino-5-(pyrazolo[1,5-a]pyrimidine-3-carboxami-
do)-2,3-dihydrobenzofuran-2-yl)ethyl) ethanethioate (24 mg, 0.050
mmol) in methanol (3 ml) was treated with sodium hydroxide (3.0 mg,
0.075 mmol) at ambient temperature for 1 h. Iodomethane (4.0 ul,
0.061 mmol) was added and the reaction mixture continued to stir
for 2 h at this temperature. The mixture was diluted with water and
extracted with dichloromethane. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated. The
residue was purified by preparative HPLC ((Gemini NX, 5*3 cm c18, 5
um; A: acetonitrile 30-70%; B: 0.1% ammonium hydroxide in water) to
afford
(R)--N-(2-methyl-2-(2-(methylthio)ethyl)-6-morpholino-2,3-dihydrobenzofur-
an-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (2.6 mg, 0.0057
mmol, 11% yield) as a solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.43 (s, 1H), 9.37 (dd, J=7.0, 1.6 Hz, 1H), 8.94 (dd,
J=4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.34 (dd, J=7.0,
4.2 Hz, 1H), 6.73 (s, 1H), 3.88-3.78 (m, 4H), 3.14 (d, J=16.6 Hz,
1H), 2.94 (d, J=16.6 Hz, 1H), 2.85-2.77 (m, 4H), 2.57-2.52 (m, 2H),
2.07 (s, 3H), 2.00-1.90 (m, 2H), 1.39 (s, 3H). MS (ESI): m/z=454.1
[M+1].sup.+.
Example 445.
(R)--N-(6-((1-(2-amino-2-oxoethyl)pyrrolidin-3-yl)oxy)-2,2-dimethyl-2,3-d-
ihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01625##
[1846] Step A. tert-butyl
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidine-1-
-carboxylate
##STR01626##
[1848] A mixture of 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran (50
mg, 0.22 mmol) and tert-butyl
(R)-3-hydroxypyrrolidine-1-carboxylate (82 mg, 0.44 mmol) in DMSO
(1.7 ml) was treated with sodium hydride (60% in oil, 18 mg, 0.44
mmol) at room temperature for 1 h. The reaction mixture was diluted
with saturated sodium bicarbonate solution, brine, and isopropyl
acetate. The layers were separated and the aqueous phase extracted
into isopropyl acetate (3.times.). The combined organic layers were
dried over sodium sulfate, filtered and absorbed under reduced
pressure onto celite. The crude product was purified by silica gel
chromatography (eluting gradient 0-100% isopropyl acetate in
heptanes) to afford tert-butyl
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidine-1-
-carboxylate (64 mg, 0.17 mmol, 77% yield) as a solid.
Step B.
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrol-
idine
##STR01627##
[1850] A solution of tert-butyl
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidine-1-
-carboxylate (64 mg, 0.17 mmol) in dichloromethane (6 ml) was
treated with trifluoroacetic acid (0.50 ml) at room temperature.
After 30 minutes the solvent was removed in vacuo to afford the
crude residue
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidine,
which was carried on without further purification.
Step C.
(R)-2-(3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyr-
rolidin-1-yl)acetamide
##STR01628##
[1852] A mixture of
(R)-3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidine
(47 mg, 0.17 mmol) in 1,4-dioxane (13 ml, 0.013M) was treated with
N,N-diisopropylethylamine (0.088 ml, 0.50 mmol) and
2-bromoacetamide (26 mg, 0.19 mmol) and heated at 60.degree. C. for
18 h. The reaction mixture was absorbed onto celite and the crude
product was purified by silica gel chromatography (eluting gradient
0-100% isopropyl acetate in heptanes) to afford
(R)-2-(3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyr-
rolidin-1-yl)acetamide (82 mg, 0.17 mmol).
Step D.
(R)-2-(3-((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)pyr-
rolidin-1-yl)acetamide
##STR01629##
[1854] A mixture of
(R)-2-(3-((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidin-
-1-yl)acetamide (82 mg, 0.17 mmol), iron powder (68 mg, 1.22 mmol)
and ammonium chloride (65 mg, 1.22 mmol) in ethanol (5 ml) and
water (1.5 ml), was heated at 60.degree. C. for 4 h. The reaction
mixture was cooled to room temperature then filtered through celite
and concentrated. The crude product was purified by silica gel
chromatography (eluting gradient 0-20% methanol: dichloromethane)
to afford
(R)-2-(3-((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidin-
-1-yl)acetamide (52 mg, 0.17 mmol) as a solid, which was used
without further purification. MS (ESI): m/z=306.1 [M+1].sup.+.
Step E.
(R)--N-(6-((1-(2-amino-2-oxoethyl)pyrrolidin-3-yl)oxy)-2,2-dimethy-
l-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01630##
[1856] A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (31
mg, 0.19 mmol),
(R)-2-(3-((5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)oxy)pyrrolidin-
-1-yl)acetamide (52 mg, 0.17 mmol), and
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(98 mg, 0.19 mmol) in dimethylformamide (5 ml) was treated with
collidine (0.025 ml, 0.19 mmol) and the resulting mixture was
stirred at room temperature for 18 h. The reaction was concentrated
under reduced pressure and the residue was purified by preparative
((Gemini NX, 5*3 cm c18, 5 um; A: acetonitrile 5-50%; B: 0.1%
formic acid in water) to afford
N-(6-(2,2-dimethylmorpholino)-2-(hydroxymethyl)-2-methyl-2,3-dihydrobenzo-
furan-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide as a solid (12
mg, 0.026 mmol, 15%). .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.20 (s, 1H), 9.36 (dd, J=7.0, 1.6 Hz,
1H), 8.85 (dd, J=4.2, 1.6 Hz, 1H), 8.66 (s, 1H), 8.30 (s, 1H), 7.32
(dd, J=7.0, 4.2 Hz, 1H), 7.15 (s, 1H), 7.03 (s, 1H), 6.49 (s, 1H),
5.04-4.89 (m, 1H), 3.13 (dd, J=10.5, 6.1 Hz, 1H), 3.05 (s, 2H),
2.97 (s, 2H), 2.87-2.77 (m, 2H), 2.72-2.61 (m, 1H), 2.41-2.27 (m,
1H), 2.03 (dd, J=8.0, 5.7 Hz, 1H), 1.41 (s, 6H).
[1857] MS (ESI): m/z=451.2 [M+1].sup.+.
TABLE-US-00016 TABLE 16 The following examples were made in a
manner similar to that for Example 445: Ex. Name Structure NMR, MS
446. N-(6-((1-(2- hydroxyethyl)azetidin-3- yl)oxy)-2,2-dimethyl-
2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01631## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.26 (s, 1H), 9.38 (dd, J = 7.0, 1.6
Hz, 1H), 8.87 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.29 (d, J =
1.0 Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.33 (s, 1H), 4.86 (q,
J = 5.6 Hz, 1H), 4.48- 4.35 (m, 1H), 3.90-3.76 (m, 2H), 3.46-3.39
(m, 2H), 3.20-3.12 (m, 2H), 2.97 (d, J = 1.1 Hz, 2H), 2.61-2.52 (m,
2H), 1.41 (s, 6H). MS (ESI): mz = 424.1 [M + 1].sup.+. 447.
(S)-N-(6-((1-(2-amino- 2-oxoethyl)pyrrolidin-3-
yl)oxy)-2,2-dimethyl- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01632## .sup.1H NMR (400 MHz,
dimethyl sulfoxide-d.sub.6) .delta. 10.20 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.85 (dd, J = 4.2, 1.6 Hz, 1H), 8.66 (s, 1H),
8.30 (s, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H), 7.14 (s, 1H), 7.03
(s, 1H), 6.49 (s, 1H), 5.02-4.90 (m, 1H), 3.13 (dd, J = 10.5, 6.2
Hz, 1H), 3.05 (s, 2H), 2.97 (s, 2H), 2.89-2.77 (m, 2H), 2.71-2.62
(m, 1H), 2.40- 2.29 (m, 1H), 2.03 (dd, J = 8.1, 5.6 Hz, 1H), 1.41
(s, 6H). MS (ESI): m/z = 451.2 [M + 1].sup.+.
Example 448.
N-(6-((1-ethyl-1H-pyrazol-4-yl)methoxy)-2,2-dimethyl-2,3-dihydrobenzofura-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01633##
[1858] Step A. (1-ethyl-1H-pyrazol-4-yl)methanol
##STR01634##
[1860] A mixture of 1-ethylpyrazole-4-carboxylic acid (200 mg, 1.43
mmol) was dissolved in tetrahydrofuran (20 ml, 0.07M) and treated
with borane-tetrahydrofuran complex (4.4 ml, 4.4 mmol) for 4 h at
25.degree. C. Methanol was added and the mixture was stirred at
room temperature for 30 min. The mixture was concentrated to afford
(1-ethyl-1H-pyrazol-4-yl)methanol (180 mg, 1.43 mmol), which was
used without further purification. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 8.00 (s, 1H), 7.67 (s, 1H), 5.06 (t,
J=5.5 Hz, 1H), 4.38-4.28 (m, 4H), 1.34 (m, 3H), MS (ESI): m/z=127
[M+1].sup.+.
Step B. 2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-ol
##STR01635##
[1862] 6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran (2.00 g, 8.79
mmol) was dissolved in tert-butanol (67.6 ml) and treated with
potassium hydroxide (567 mg, 10.1 mmol). The reaction mixture was
heated at 80.degree. C. for 24 h. Potassium hydroxide was added
(1.13 g, 20.2 mmol) and the reaction was stirred at 85.degree. C.
for an additional 24 h. After cooling to room temperature, the pH
was adjusted to 6 with 5% aqueous potassium bisulfate solution. The
mixture was diluted with water (100 mL) and extracted with ethyl
acetate (200 mL.times.3). The combined organic layers were washed
with brine (300 mL), dried over sodium sulfate and concentrated.
The residue was purified by silica gel chromatography (eluting
gradient 0-100% isopropyl acetate in heptanes) to afford
2,2-dimethyl-5-nitro-3H-benzofuran-6-ol (1.54 g, 7.36 mmol, 84%
yield) as a yellow solid. .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.96 (s, 1H), 7.89 (t, J=1.3 Hz, 1H),
6.44 (s, 1H), 2.99 (d, J=1.2 Hz, 2H), 1.44 (s, 6H).
Step C.
4-(((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)methyl)-1-
-ethyl-1H-pyrazole
##STR01636##
[1864] To a mixture of 2,2-dimethyl-5-nitro-3H-benzofuran-6-ol (200
mg, 0956 mmol), (1-ethyl-1H-pyrazol-4-yl)methanol (180 mg, 1.43
mmol), and triphenylphosphine (326 mg, 1.24 mmol) in
tetrohydrofuran (7.35 ml) was added diisopropylazodicarboxylate
(0.25 ml, 1.2 mmol) dropwise. The reaction mixture was stirred at
ambient temperature for an overnight period. The reaction was
quenched with 1 N HCl and extracted with isopropyl acetate. The
combined organics were dried over sodium sulfate, filtered and
concentrated. The crude product was purified by silica gel
chromatography (eluting gradient 0-100% methanol: dichloromethane)
to afford
4-(((2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)oxy)methyl)-1-
-ethyl-1H-pyrazole (45 mg, 0.142 mmol, 15% yield). MS (ESI):
m/z=318 [M+1].sup.+.
Step D.
6-((1-ethyl-1H-pyrazol-4-yl)methoxy)-2,2-dimethyl-2,3-dihydrobenzo-
furan-5-amine
##STR01637##
[1866]
6-((1-ethyl-1H-pyrazol-4-yl)methoxy)-2,2-dimethyl-2,3-dihydrobenzof-
uran-5-amine was made in a manner analogous to Example 445, Step D
to give the desired product (41 mg, quant.) which was used without
further purification. MS (ESI): m/z=288 [M+1].sup.+.
Step E.
N-(6-((1-ethyl-1H-pyrazol-4-yl)methoxy)-2,2-dimethyl-2,3-dihydrobe-
nzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01638##
[1868] The title compound was made in a manner analogous to Example
445, Step E to give
N-(6-((1-ethyl-1H-pyrazol-4-yl)methoxy)-2,2-dimethyl-2,3-dihydrobenzofura-
n-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (19 mg, 31% yield).
.sup.1H NMR (400 MHz, dimethyl sulfoxide-d.sub.6) .delta. 10.16 (s,
1H), 9.33 (dd, J=7.1, 1.4 Hz, 1H), 8.63 (s, 1H), 8.27 (t, J=2.8 Hz,
2H), 7.88 (s, 1H), 7.64 (s, 1H), 7.30 (dd, J=7.0, 4.2 Hz, 1H), 6.70
(s, 1H), 5.02 (s, 2H), 4.15 (q, J=7.3 Hz, 2H), 2.98 (s, 2H), 1.42
(s, 6H), 1.36 (t, J=7.3 Hz, 3H). MS (ESI): m/z=433.2
[M+1].sup.+.
Example 449.
N-(2-(((2R,5R)-5-amino-1,3-dioxan-2-yl)methyl)-6-morpholino-1-oxoisoindol-
in-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01639##
[1869] Step A.
2-((2R,5R)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-
-yl)isoindoline-1,3-dione
##STR01640##
[1871] To methyl 2-(bromomethyl)-5-chloro-4-nitro-benzoate
(preparation 5, WO 2013079505 (300 mg, 0.97 mmol) in methanol (10
ml) was added triethylamine (0.16 ml, 1.2 mmol) and
2-[2-(aminomethyl)-1,3-dioxan-5-yl]isoindoline-1,3-dione (306 mg,
1.2 mmol). The reaction was heated to 70.degree. C. for 18 h,
concentrated and purified by silica gel chromatography (eluting
gradient 0-20% methanol: dichloromethane) to afford
2-((2r,5r)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-
-yl)isoindoline-1,3-dione (301 mg, 68%). .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.36 (s, 1H), 8.05 (s, 1H), 7.85 (td, J=4.3, 2.5
Hz, 4H), 4.91 (t, J=4.3 Hz, 1H), 4.70 (s, 2H), 4.29 (d, J=8.4 Hz,
3H), 4.11-4.06 (m, 2H), 3.74 (d, J=4.5 Hz, 2H). LCMS (ESI) m/z:
458.0 [M+H]+.
Step B.
2-(((2R,5R)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3--
dioxan-5-yl)carbamoyl)benzoic acid
##STR01641##
[1873] The title compound was made in a manner analogous to Example
173, Step B to give the desired product
2-(((2r,5r)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan--
5-yl)carbamoyl)benzoic acid (390 mg, quant) which was used without
further purification. MS (ESI): m/z=596.1 [M+1].sup.+.
Step C.
2-(((2R,5R)-5-amino-1,3-dioxan-2-yl)methyl)-6-chloro-5-nitroisoind-
olin-1-one
##STR01642##
[1875] 2-(((2r,
5r)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-yl)car-
bamoyl)benzoic acid (390 mg, 0.66 mmol) was dissolved in methanol
(20 ml) and treated with hydrazine (5 ml) and stirred at ambient
temperature for 1 week. The reaction mixture was concentrated in
vacuo and the crude product purified by silica gel chromatography
(eluting gradient 0-20% methanol: dichloromethane) to afford
2-(((2r,
5r)-5-amino-1,3-dioxan-2-yl)methyl)-6-chloro-5-nitroisoindolin-1-one
(164 mg, 0.432 mmol, 66% yield). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.06 (s, 1H), 7.58 (s, 1H), 4.61 (t, J=4.7 Hz, 1H), 4.55
(s, 2H), 3.94 (dd, J=11.2, 5.0 Hz, 2H), 3.72-3.66 (m, 4H), 3.63 (d,
J=4.7 Hz, 2H), 3.18 (t, J=10.9 Hz, 2H), 3.03-2.97 (m, 4H), 2.78
(dt, J=10.4, 5.1 Hz, 1H), 1.40 (s, 2H).
Step D. tert-butyl
((2R,5R)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-y-
l)carbamate
##STR01643##
[1877] To a mixture of
2-(((2r,5r)-5-amino-1,3-dioxan-2-yl)methyl)-6-chloro-5-nitroisoindolin-1--
one (163 mg, 0.43 mmol), 4-dimethylaminopyridine (10 mg, 0.086
mmol), and trimethylamine (0.090 ml, 0.644 mmol) in tetrahydrofuran
(3 ml) was added di-tert-butyl dicarbonate (145 mg, 0.644 mmol) at
ambient temperature. After 16 h, the mixture was diluted with water
and extracted with isopropyl acetate. The combined organics were
dried over sodium sulfate, filtered and concentrated. The crude
product was purified by silica gel chromatography (eluting gradient
0-100% methanol: dichloromethane) to afford tert-butyl ((2r,
5r)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-yl)car-
bamate (33 mg, 0.069 mmol, 16% yield). (ESI): m/z=479.1
[M+1].sup.+.
Step E. tert-butyl
((2R,5R)-2-((5-amino-6-chloro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-y-
l)carbamate
##STR01644##
[1879] A mixture of tert-butyl
((2r,5r)-2-((6-chloro-5-nitro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-y-
l)carbamate (33 mg, 0.069 mmol) and 10% palladium on carbon (1.5
mg) in methanol (5.3 ml) was stirred at 25.degree. C. under a
hydrogen atmosphere for 3 h. The reaction was filtered through a
pad pf celite and concentrated under reduced pressure to afford
tert-butyl
((2r,5r)-2-((5-amino-6-chloro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-y-
l)carbamate (31 mg), which was used without further purification.
MS (ESI): m/z=449 [M+1].sup.+.
Step F. tert-butyl
((2R,5R)-2-((6-morpholino-1-oxo-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamid-
o)isoindolin-2-yl)methyl)-1,3-dioxan-5-yl)carbamate
##STR01645##
[1881] The title compound was made in a manner analogous to Example
173, Step D using tert-butyl
((2r,5r)-2-((5-amino-6-chloro-1-oxoisoindolin-2-yl)methyl)-1,3-dioxan-5-y-
l)carbamate, Step E) to give the desired product tert-butyl
((2r,5r)-2-((6-morpholino-1-oxo-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamid-
o)isoindolin-2-yl)methyl)-1,3-dioxan-5-yl)carbamate, which was used
crude without further purification. MS (ESI): m/z=594
[M+1].sup.+.
Step G.
N-(2-(((2R,5R)-5-amino-1,3-dioxan-2-yl)methyl)-6-morpholino-1-oxoi-
soindolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01646##
[1883] A mixture of tert-butyl
((2R,5R)-2-((6-morpholino-1-oxo-5-(pyrazolo[1,5-a]pyrimidine-3-carboxamid-
o)isoindolin-2-yl)methyl)-1,3-dioxan-5-yl)carbamate (40 mg, 0.067
mmol) in dichloromethane (5 ml) was treated with trifluoroacetic
acid (0.5 ml) at ambient temperature. After 72 h, the mixture was
concentrated and the crude residue purified by preparative HPLC
((Gemini NX, 5*3 cm c18, 5 um; A: acetonitrile 5-50%; B: 0.1%
ammonium hydroxide in water) to afford
N-(2-(((2r,5r)-5-amino-1,3-dioxan-2-yl)methyl)-6-morpholino-1-oxoisoindol-
in-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (3 mg, 0.0061 mmol,
9% yield) as a solid. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.90
(s, 1H), 9.41 (dd, J=7.0, 1.6 Hz, 1H), 9.00 (dd, J=4.2, 1.6 Hz,
1H), 8.76 (s, 1H), 8.74 (s, 1H), 7.58 (s, 1H), 7.39 (dd, J=7.0, 4.2
Hz, 1H), 4.60 (t, J=4.8 Hz, 1H), 4.52 (s, 2H), 3.95 (dd, J=11.2,
4.8 Hz, 2H), 3.92-3.88 (m, 4H), 3.60 (d, J=4.8 Hz, 2H), 3.18 (t,
J=10.9 Hz, 2H), 2.95-2.88 (m, 4H), 2.80 (dt, J=10.4, 5.2 Hz, 1H).
MS (ESI): m/z=494.2 [M+1].sup.+.
Example 450.
N-(2,2-dimethyl-6-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01647##
[1885] Potassium peroxymonosulfate (81 mg, 0.13 mmol) was added to
a solution of
N-[2,2-dimethyl-6-[4-(2-methylsulfanylethyl)piperazin-1-yl]-3H-benzofuran-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (30.8 mg, 0.066 mmol)
in N,N-dimethylformamide (2.2 ml) at 0.degree. C. for 2 h. The
reaction mixture was warmed to room temperature and stirred
overnight. The crude reside was purified by preparative HPLC
((Gemini NX, 5*3 cm c18, 5 um; A: acetonitrile 30-70%; B: 0.1%
ammonium hydroxide in water) to afford
N-(2,2-dimethyl-6-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)-2,3-dihydro-
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (1.3 mg,
0.0026 mmol, 4% yield). MS (ESI): m/z=499.2 [M+1].sup.+.
Example 451. 5-[[(1R,2S)-2-aminocyclohexyl]
amino]-N-(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide
##STR01648##
[1886] Step A. methyl
5-[[(1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]pyrazolo[1,5-a]p-
yrimidine-3-carboxylate
##STR01649##
[1888] A microwave vial was charged with methyl
5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (500 mg, 2.36
mmol), tert-butyl N-[(1S,2R)-2-aminocyclohexyl]carbamate (506 mg,
2.36 mmol), and methanol (4.7 mL). The vial was sealed and stirred
at 90.degree. C. for 30 min in the microwave, resulting in a
suspension. The reaction mixture was concentrated in vacuo and the
crude product was purified by column chromatography (0-100%
isopropyl acetate/heptane) to afford methyl
5-[[(1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]
amino]pyrazolo[1,5-a]pyrimidine-3-carboxylate (420.2 mg, 1.08 mmol,
46% yield) as a white solid. MS: m/z=390 (M+1).
Step B.
5-[[(1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]pyrazolo[-
1,5-a]pyrimidine-3-carboxylic acid
##STR01650##
[1890] To a mixture of methyl
5-[[(1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]pyrazolo[1,5-a]p-
yrimidine-3-carboxylate (330 mg, 0.85 mmol) in tetrahydrofuran (1.7
mL) and water (3.40 mL) was added lithium hydroxide (61 mg, 2.54
mmol). The mixture was stirred at reflux for 2 days, after which a
second portion of lithium hydroxide (61 mg, 2.54 mmol) was added.
After an additional 3 h, the reaction was brought to room
temperature and partitioned between dichloromethane and water. The
aqueous phase was acidified to pH 2 with 1 N hydrochloric acid and
extracted with dichloromethane (3.times.). The combined organic
phase was dried over sodium sulfate, filtered, and concentrated in
vacuo to afford
5-[[(1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]pyrazolo[1,5-a]p-
yrimidine-3-carboxylic acid (196.4 mg, 0.5232 mmol) as a white
solid. MS: m/z=376 (M+1).
Step C. tert-butyl
N-[(1S,2R)-2-[[3-[(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)carbamoyl]py-
razolo[1,5-a] pyrimidin-5-yl] amino] cyclohexyl]carbamate
##STR01651##
[1892] The title compound was made in a manner analogous to Example
12 from 6-methoxy-2,2-dimethyl-3H-benzofuran-5-amine (Example 34,
Step B) to afford tert-butyl
N-[(1S,2R)-2-[[3-[(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)carbamoyl]py-
razolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]carbamate (97.3 mg,
0.177 mmol, 68.3% yield). MS: m/z=551 (M+1).
Step D.
5-[[(1R,2S)-2-aminocyclohexyl]amino]-N-(6-methoxy-2,2-dimethyl-3H--
benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01652##
[1894] To a solution of tert-butyl
N-[(1S,2R)-2-[[3-[(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)carbamoyl]py-
razolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]carbamate (97.3 mg,
0.177 mmol) in dichloromethane(1.77 mL) at 0.degree. C. was added
trifluoroacetic acid (0.442 mL, 5.84 mmol). The resulting solution
was brought to room temperature and stirred for 3 h. The reaction
mixture was concentrated in vacuo and purified by HPLC to afford
5-[[(1R,2S)-2-aminocyclohexyl]
amino]-N-(6-methoxy-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimi-
dine-3-carboxamide (37 mg, 0.082 mmol, 46.5% yield) as a white
solid. .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 9.64 (s, 1H),
8.55 (d, J=7.6 Hz, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.71 (s, 1H),
6.63-6.53 (m, 2H), 4.22 (s, 1H), 3.83 (s, 3H), 3.09 (s, 1H), 2.96
(s, 2H), 1.78 (s, 1H), 1.62-1.49 (m, 7H), 1.41 (s, 6H), 1.31 (s,
3H). MS: m/z=451.2 (M+1).
Example 452.
N-(6-carbamoyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine--
3-carboxamide
##STR01653##
[1895] Step A.
2,2-dimethyl-5-nitro-3H-benzofuran-6-carbonitrile
##STR01654##
[1897] To a microwave vial containing
6-chloro-2,2-dimethyl-5-nitro-3H-benzofuran (100 mg, 0.44 mmol),
tris(dibenzylideneacetone)dipalladium(0) (20.1 mg, 0.022 mmol),
S-Phos (18.6 mg, 0.044 mmol), and zinc cyanide (56.7 mg, 0.48 mmol)
were added N,N-dimethylformamide (2.2 mL) and water (0.021 mL). The
mixture was sparged with nitrogen for 5 min, after which the vial
was sealed and stirred in the microwave at 150.degree. C. for 30
min. The crude reaction mixture was partitioned between 1 N sodium
hydroxide and dichloromethane. The aqueous phase was extracted with
dichloromethane (2.times.). The combined organic phase was dried
over sodium sulfate, filtered, and concentrated to afford an orange
solid. The crude residue was purified on silica (0-70% isopropyl
acetate/heptane) to afford
2,2-dimethyl-5-nitro-3H-benzofuran-6-carbonitrile (75 mg, 0.34
mmol, 95% yield) as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.14 (t, J=1.2 Hz, 1H), 7.10 (s, 1H), 3.16 (d,
J=1.2 Hz, 2H), 1.56 (s, 6H).
Step B. 2,2-dimethyl-5-nitro-3H-benzofuran-6-carboxamide
##STR01655##
[1899] A mixture of
2,2-dimethyl-5-nitro-3H-benzofuran-6-carbonitrile (41.4 mg, 0.190
mmol) and potassium hydroxide (11.7 mg, 0.209 mmol) in tert-butanol
(0.632 mL) was stirred at 60.degree. C. Upon completion of the
hydrolysis (2 h), the mixture was diluted with water and extracted
with dichloromethane. The aqueous layer was extracted with
dichloromethane (2.times.). The combined organic phase was dried
over sodium sulfate, filtered, and concentrated to afford the crude
product as an orange solid (45 mg, 0.19 mmol, quantitative yield).
MS: m/z=237 [M+1].sup.+.
Step C. 5-amino-2,2-dimethyl-3H-benzofuran-6-carboxamide
##STR01656##
[1901] 2,2-dimethyl-5-nitro-3H-benzofuran-6-carboxamide (45 mg,
0.195 mmol) was suspended in ethanol (1.9 mL).
N,N-dimethylformamide (0.3 mL) was added to solubilize the
substrate. 10% palladium on carbon (2 mg, 0.0019 mmol) was added,
and the atmosphere was exchanged for hydrogen through 3 cycles of
vacuum/H.sub.2. The mixture was stirred under H.sub.2 (1 atm)
overnight.
[1902] The contents were filtered through a 0.45 um syringe filter,
and the filtrate was concentrated in vacuo. Flash column
chromatography (0-100% isopropyl acetate/heptane) gave
5-amino-2,2-dimethyl-3H-benzofuran-6-carboxamide (22.6 mg, 0.110
mmol, 57% yield) as a white solid.
[1903] MS: m/z=207 [M+1].sup.+.
Step D.
N-(6-carbamoyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyri-
midine-3-carboxamide
##STR01657##
[1905] The title compound was made in a manner analogous to Example
4, Step C to afford
N-(6-carbamoyl-2,2-dimethyl-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidine--
3-carboxamide (5 mg, 4.5% yield). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.60 (s, 1H), 9.31 (dd, J=7.0, 1.7 Hz, 1H),
8.81 (dd, J=4.1, 1.7 Hz, 1H), 8.63 (s, 1H), 8.18 (s, 1H), 7.97 (s,
1H), 7.47 (s, 1H), 7.27 (dd, J=7.0, 4.2 Hz, 1H), 7.02 (s, 1H), 3.08
(d, J=1.2 Hz, 2H), 2.62 (s, 1H), 1.44 (s, 6H). MS: m/z=352.1
[M+1]+.
Example 453.
N-(6-(4-ethylpiperazin-1-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01658##
[1907]
N-(2,2-dimethyl-6-piperazin-1-yl-3H-benzofuran-5-yl)pyrazolo[1,5-a]-
pyrimidine-3-carboxamide (Example 533) (50 mg, 0.127 mmol) and
bromoethane (0.255 mmol) were dissolved in 1,4-dioxane (1.27 ml,
0.1M) and treated with N,N-diisopropylethylamine (0.067 ml, 0.382
mmol). The reaction mixture was stirred for 16 h at 100.degree. C.,
concentrated under reduced pressure and the crude residue purified
by preparative HPLC to afford
N-(6-(4-ethylpiperazin-1-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (7.7 mg, 0.018 mmol, 14%
yield) as a solid. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.41 (s,
1H), 9.36 (dd, J=7.0, 1.7 Hz, 1H), 8.89 (dd, J=4.2, 1.7 Hz, 1H),
8.67 (s, 1H), 8.30 (d, J=1.0 Hz, 1H), 7.35 (dd, J=7.0, 4.2 Hz, 1H),
6.69 (s, 1H), 3.17 (d, J=5.2 Hz, 2H), 3.00 (dq, J=1.0, 0.5 Hz, 2H),
2.82 (m, 4H), 2.61 (m, 2H), 2.45 (m, 2H), 1.41 (s, 6H), 1.04 (t,
J=7.2 Hz, 3H). MS (ESI): m/z=421.2 [M+1].sup.+.
TABLE-US-00017 TABLE 17 The following examples were made in a
manner similar to that for Example 453: Ex. Name Structure NMR, MS
454. N-(2,2-dimethyl-6-(4-(2- (methylthio)ethyl)piperazin-
1-yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01659## .sup.1H NMR (400 MHz, dimethyl
sulfoxide-d.sub.6) .delta. 10.39 (s, 1H), 9.36 (ddd, J = 7.0, 1.6,
0.5 Hz, 1H), 8.91 (ddd, J = 4.2, 1.7, 0.5 Hz, 1H), 8.67 (s, 1H),
8.30 (d, J = 1.0 Hz, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s,
1H), 3.00 (s, 2H), 2.81 (t, J = 4.7 Hz, 4H), 2.69-2.64 (m, 6H),
2.09 (d, J = 0.5 Hz, 3H), 2.07 (d, J = 0.5 Hz, 2H), 1.41 (s, 6H).
MS (ESI): m/z = 467.2 [M + 1].sup.+. 455. N-(6-(4-(3-amino-3-
oxopropyl)piperazin-1- yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01660## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.40 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.91 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.31 (d, J = 1.0 Hz, 1H), 7.36 (m, 2H), 6.77 (s, 1H), 6.69 (s, 1H),
3.29- 3.22 (m, 2H), 2.99 (s, 2H), 2.81 (m, 4H), 2.63 (m, 4H), 2.26
(t, J = 7.2 Hz, 2H), 1.41 (s, 6H). MS (ESI): m/z = 464.2 [M +
1].sup.+. 456. N-(6-(4- (cyanomethyl)piperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01661## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.29 (s, 1H), 9.35 (dd, J = 7.0, 1.6 Hz,
1H), 9.06 (dd, J = 4.2, 1.7 Hz, 1H), 8.68 (s, 1H), 8.30 (d, J = 1.1
Hz, 1H), 7.29 (dd, J = 7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.84 (s,
2H), 3.00 (d, J = 1.1 Hz, 2H), 2.87 (dd, J = 5.8, 3.6 Hz, 4H), 2.75
(dd, J = 6.0, 3.4 Hz, 4H), 1.41 (s, 6H). MS (ESI): m/z = 432.2 [M +
1].sup.+. 457. N-(6-(4-(2- cyanoethyl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01662## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.38 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.92 (dd, J = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.30 (d, J = 1.1
Hz, 1H), 7.34 (dd, J = 7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.00 (d, J =
1.1 Hz, 2H), 2.83 (t, J = 4.7 Hz, 4H), 2.75- 2.63 (m, 8H), 1.41 (s,
6H). MS (ESI): m/z = 446.2 [M + 1].sup.+. 458. N-(6-(4-
(cyclopropylmethyl) piperazin-1-yl)-2,2-dimethyl-
2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01663## .sup.1H NMR (400 MHz, DMSO- d.sub.6)
.delta. 10.41 (s, 1H), 9.35 (dd, J = 7.0, 1.6 Hz, 1H), 8.87 (dd, J
= 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.35
(dd, J = 7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.00 (s, 2H), 2.83 (m,
4H), 2.75-2.62 (m, 4H), 2.29 (d, J = 6.6 Hz, 2H), 1.41 (s, 6H),
0.93-0.82 (m, 1H), 0.51-0.43 (m, 2H), 0.16- 0.07 (m, 2H). MS (ESI):
m/z = 447.2 [M + 1].sup.+. 459. N-(2,2-dimethyl-6-(4-
((3-methyl-1,2,4- oxadiazol-5- yl)methyl)piperazin-1- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01664## .sup.1H NMR (400 MHz, DMSO- d.sub.6) .delta. 10.35 (s,
1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.81 (dd, J = 4.2, 1.7 Hz,
1H), 8.67 (s, 1H), 8.29 (d, J = 1.0 Hz, 1H), 7.33 (dd, J = 7.0, 4.2
Hz, 1H), 6.71 (s, 1H), 3.99 (s, 2H), 3.01-2.98 (s, 2H), 2.86-2.80
(m, 4H), 2.81-2.73 (m, 4H), 2.38 (s, 3H), 1.41 (s, 6H). MS (ESI):
m/z = 489.2 [M + 1].sup.+. 460. N-(2,2-dimethyl-6-(4-
((1-methyl-1H-pyrazol- 4-yl)methyl)piperazin-1- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01665## .sup.1H NMR (400 MHz, DMSO- d.sub.6) .delta. 10.41 (s,
1H), 9.35 (dd, J = 7.0, 1.6 Hz, 1H), 8.66 (s, 1H), 8.47 (dd, J =
4.2, 1.6 Hz, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.60 (d, J = 0.8 Hz,
1H), 7.33 (d, J = 0.8 Hz, 1H), 7.30 (dd, J = 7.0, 4.2 Hz, 1H), 6.69
(s, 1H), 3.83 (s, 3H), 3.49 (s, 2H), 2.99 (s, 2H), 2.80 (m, 4H),
2.60 (m, 4H), 1.40 (s, 6H). MS (ESI): m/z = 487.2 [M + 1].sup.+.
461. N-(2,2-dimethyl-6-(4- ((5-methyl-1,2,4- oxadiazol-3-
yl)methyl)piperazin-1- yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01666## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.36 (s, 1H), 9.37 (dd, J =
7.0, 1.6 Hz, 1H), 8.83 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.30 (s, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 3.74
(s, 2H), 2.99 (m, 2H), 2.83 (m, 3H), 2.77-2.69 (m, 3H), 2.60 (s,
2H), 1.41 (s, 6H). MS (ESI): m/z = 489.2 [M + 1].sup.+. 462.
N-(6-(4-(2-(1H-pyrazol- 1-yl)ethyl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01667## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.38 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.91 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.30 (d, J = 1.1
Hz, 1H), 7.75 (dd, J = 2.2, 0.7 Hz, 1H), 7.42 (dd, J = 1.8, 0.7 Hz,
1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 6.22 (t, J = 2.0
Hz, 1H), 4.26 (t, J = 6.8 Hz, 2H), 3.00 (s, 2H), 2.87-2.78 (m, 6H),
2.73-2.63 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 487.2 [M +
1].sup.+. 463. N-(2,2-dimethyl-6-(4- ((5-methyl-1,3,4- oxadiazol-2-
yl)methyl)piperazin-1- yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01668## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.36 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.30 (d, J = 0.9 Hz, 1H), 7.33 (dd, J = 7.0, 4.2 Hz, 1H), 6.70 (s,
1H), 3.88 (s, 2H), 2.99 (d, J = 1.1 Hz, 2H), 2.84 (d, J = 4.8 Hz,
3H), 2.73 (s, 4H), 1.41 (s, 7H). MS (ESI): m/z = 489.2 [M +
1].sup.+. 464. N-(2,2-dimethyl-6-(4- ((tetrahydro-2H-pyran-
4-yl)methyl)piperazin-1- yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01669## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.39 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.90 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H),
8.30 (d, J = 0.9 Hz, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.68 (s,
1H), 3.88-3.79 (m, 2H), 3.02- 2.97 (m, 2H), 2.81 (t, J = 4.7 Hz,
4H), 2.60 (s, 4H), 2.25 (d, J = 7.3 Hz, 2H), 1.77 (m, 1H),
1.69-1.60 (m, 2H), 1.41 (s, 6H), 1.21-1.07 (m, 2H). MS (ESI): m/z =
491.2 [M + 1].sup.+. 465. N-(6-(4-(3- methoxypropyl)piperazin-
1-yl)-2,2-dimethyl- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01670## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.39 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.89 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.30 (d, J = 1.0
Hz, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H), 3.41-3.34
(m, 2H), 3.23 (s, 3H), 3.03-2.95 (m, 2H), 2.81 (t, J = 4.7 Hz, 4H),
2.66- 2.56 (m, 4H), 2.42 (dd, J = 8.0, 6.7 Hz, 2H), 1.75-1.64 (m,
2H), 1.41 (s, 6H). MS (ESI): m/z = 465.2 [M + 1].sup.+. 466.
N-(6-(4- (cyclobutylmethyl)piperazin- 1-yl)-2,2-dimethyl-
2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01671## .sup.1H NMR (400 MHz, DMSO- d.sub.6)
.delta. 10.39 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.90 (dd, J
= 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.30 (d, J = 0.9 Hz, 1H), 7.38
(dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H), 3.02-2.97 (m, 2H), 2.79
(ddt, J = 5,3, 4.4, 0.9 Hz, 4H), 2.62-2.54 (m, 4H), 2.44 (d, J =
6.7 Hz, 2H), 2.02 (dddd, J = 9.8, 8.6, 5.0, 2.7 Hz, 2H), 1.95-1.75
(m, 2H), 1.73-1.61 (m, 2H), 1.41 (s, 6H). MS (ESI): m/z = 461.2 [M
+ 1].sup.+. 467. N-(2,2-dimethyl-6-(4-(2- oxopyrrolidin-3-
yl)piperazin-1-yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01672## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.41 (s, 1H), 9.34 (dd, J = 7.0, 1.6 Hz,
1H), 9.19 (dd, J = 4.2, 1.7 Hz, 1H), 8.66 (s, 1H), 8.36 (d, J = 1.0
Hz, 1H), 7.76 (s, 1H), 7.31 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s,
1H), 3.22-3.06 (m, 5H), 3.03-2.98 (m, 2H), 2.89-2.70 (m, 6H), 2.27-
2.14 (m, 1H), 1.95 (m, 1H), 1.41 (s, 6H), 1.24 (s, 1H). MS (ESI):
m/z = 476.2 [M + 1].sup.+. 468. N-(2,2-dimethyl-6-(4-
((5-oxopyrrolidin-2- yl)methyl)piperazin-1- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01673## .sup.1H NMR (400 MHz, DMSO- d.sub.6) .delta. 10.38 (s,
1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.89 (dd, J = 4.2, 1.7 Hz,
1H), 8.68 (s, 1H), 8.30-8.26 (m, 1H), 7.53 (s, 1H), 7.35 (dd, J =
7.0, 4.2 Hz, 1H), 6.67 (s, 1H), 3.79-3.69 (m, 1H), 3.02-2.97 (m,
2H), 2.82 (m, 4H), 2.75-2.59 (m, 4H), 2,41 (m, 2H), 2.24- 2.03 (m,
3H), 1.78-1.66 (m, 1H), 1.41 (s, 7H). MS (ESI): m/z = 490.2 [M +
1].sup.+. 469. N-(6-(4-(2,3- dihydroxypropyl)piperazin-
1-yl)-2,2-dimethyl- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01674## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.38 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz,
1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.37
(dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H), 4.40 (d, J = 25.2 Hz, 1H),
3.67 (s, 1H), 3.46- 3.34 (m, 2H), 3.29-3.14 (m, 2H), 3.00 (d, J =
1.0 Hz, 2H), 2.95-2.60 (m, 5H), 1.41 (s, 6H). MS (ESI): m/z = 467.2
[M + 1].sup.+. 470. N-(2,2-dimethyl-6-(4-(2- (2-oxopyrrolidin-1-
yl)ethyl)piperazin-1-yl)- 2,3-dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01675## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.38 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.91 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.30 (d, J = 1.0
Hz, 1H), 7.35 (dd, J = 7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 3.49-3.36
(m, 4H), 3.17 (d, J = 5.2 Hz, 1H), 3.03-2.95 (m, 2H), 2.85-2.78 (m,
4H), 2.70-2.61 (m, 3H), 2.21 (dd, J = 8.8, 7.6 Hz, 2H), 2.01-1.85
(m, 2H), 1.41 (s, 7H). MS (ESI): m/z = 504.2 [M + 1].sup.+.
Example 471.
N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-(hydroxymethyl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01676##
[1909] To a solution of
6-bromo-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (100 mg, 0.21 mmol) in 1,4-dioxane (3 ml)
and water (0.30 ml) was added potassium
acetoxymethyl(trifluoro)boron (115 mg, 0.64 mmol), sodium carbonate
(68 mg, 0.64 mmol),
2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl (60 mg,
0.13 mmol) and Ruphos-Pd-G2 (44 mg, 0.06 mmol). The reaction
mixture was stirred at 120.degree. C. for 0.5 h under microwave
irradiation. The reaction mixture was filtered and concentrated.
The residue was purified by prep-TLC (5% methanol in
dichloromethane) to afford
N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-6-(hydroxymethyl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide (48 mg, 53%) as a yellow solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.42 (s, 1H), 9.22 (s, 1H),
8.95 (s, 1H), 8.65 (s, 1H), 8.32 (s, 1H), 6.72 (s, 1H), 5.64 (t,
J=5.6 Hz, 1H), 4.70 (d, J=5.6 Hz, 2H), 3.90-3.80 (m, 4H), 3.00 (s,
2H), 2.90-2.80 (m, 4H), 1.41 (s, 6H). LCMS (ESI): m/z=424.1
[M+H].sup.+.
Examples 472 and 473.
N-[6-[4-[(1R)-2-amino-1-methyl-2-oxo-ethyl]piperazin-1-yl]-2,2-dimethyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-[6-[4-[(1S)-2-amino-1-methyl-2-oxo-ethyl]piperazin-1-yl]-2,2-dimethyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01677##
[1910] Step A:
N-[6-[4-(2-amino-1-methyl-2-oxo-ethyl)piperazin-1-yl]-2,2-dimethyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01678##
[1912] To a solution of
N-(2,2-dimethyl-6-piperazin-1-yl-3H-benzofuran-5-yl)
pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example 533) (200 mg, 0.51
mmol) in 1,4-dioxane (5 ml) was added N,N-diisopropylethylamine
(197.6 mg, 1.53 mmol) and 2-bromopropanamide (85.2 mg, 0.56 mmol).
The reaction was stirred at 100.degree. C. for 16 h. The reaction
was concentrated and purified by pre-TLC (10% methanol in
dichloromethane) to afford
N-[6-[4-(2-amino-1-methyl-2-oxo-ethyl)piperazin-1-yl]-2,2-dimethyl-3H-ben-
zofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (162.0 mg,
68.6% yield) as a yellow solid. LCMS (ESI): m/z=464.2
[M+H].sup.+
Step B: N-[6-[4-[(1R)-2-amino-1-methyl-2-oxo-ethyl]
piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-
-3-carboxamide and N-[6-[4-[(1S)-2-amino-1-methyl-2-oxo-ethyl]
piperazin-1-yl]-2,2-dimethyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-
-3-carboxamide
##STR01679##
[1914]
N-[6-[4-(2-amino-1-methyl-2-oxo-ethyl)piperazin-1-yl]-2,2-dimethyl--
3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (162 mg,
0.35 mmol) was resolved by chiral SFC to afford
N-[6-[4-[(1R)-2-amino-1-methyl-2-oxo-ethyl]piperazin-1-yl]-2,2-dimethyl-3-
H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (45 mg,
27%; RT=2.97 min) and N-[6-[4-[(1
S)-2-amino-1-methyl-2-oxo-ethyl]piperazin-1-yl]-2,2-dimethyl-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 21%; RT=3.45
min) as yellow solids with absolute stereochemistry assigned
arbitrarily.
[1915] Example 472, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.38 (s, 1H), 9.34-9.33 (m, 1H), 8.94-8.93 (m, 1H), 8.65
(s, 1H), 8.31 (s, 1H), 7.33 (dd, J=7.2, 4.4 Hz, 1H), 7.28 (s, 1H),
7.06 (s, 1H), 6.66 (s, 1H), 3.09-3.07 (m, 1H), 2.98 (s, 2H),
2.81-2.80 (m, 4H), 2.79-2.73 (m, 4H), 1.39 (s, 6H), 1.13 (d, J=6.8
Hz, 3H). LCMS (ESI): m/z=464.2 [M+H].sup.+
[1916] Example 473, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.40 (s, 1H), 9.37-9.35 (m, 1H), 8.96-8.95 (m, 1H), 8.67
(s, 1H), 8.33 (s, 1H), 7.35 (dd, J=7.2, 4.4 Hz, 1H), 7.30 (s, 1H),
7.10 (s, 1H), 6.68 (s, 1H), 3.12-3.07 (m, 1H), 2.99 (s, 2H), 2.82
(s, 4H), 2.75 (s, 4H), 1.40 (s, 6H), 1.15 (d, J6.8 Hz, 3H). LCMS
(ESI): m/z=464.3 [M+H].sup.+
TABLE-US-00018 TABLE 18 The following examples were made in a
manner similar to that for Example 472: Ex. Name Structure NMR, MS
474 (S)-N-(6-(4-(2- hydroxypropyl) piperazin-1-yl)-
2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01680## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.40 (s, 1H), 9.36- 9.34 (m, 1H), 8.90-8.88
(m, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.36-7.34 (m, 1H), 6.68 (s,
1H), 4.37-4.35 (m, 1H), 3.80-3.78 (m, 1H), 2.98 (s, 2H), 2.81-2.79
(m, 4H), 2.68-2.66 (m, 4H), 2.36-2.34 (m, 1H), 1.40 (s, 6H),
1.09-1.05 (m, 3H). LCMS (ESI): m/z = 451.3 [M + 1].sup.+. 475
(R)-N-(6-(4-(2- hydroxypropyl) piperazin-1-yl)- 2,2-dimethyl-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01681## .sup.1H NMR (400 MHz, DMSO- d.sub.6) .delta. 10.40 (s,
1H), 9.36- 9.34 (m, 1H), 8.90-8.88 (m, 1H), 8.67 (s, 1H), 8.29 (s,
1H), 7.36-7.34 (m, 1H), 6.68 (s, 1H), 4.37-4.35 (m, 1H), 3.80-3.78
(m, 1H), 2.98 (s, 2H), 2.81-2.79 (m, 4H), 2.68-2.66 (m, 4H),
2.36-2.34 (m, 1H), 1.40 (s, 6H), 1.09-1.05 (m, 3H). LCMS (ESI): m/z
= 451.3 [M + 1].sup.+. 476 N-(6-(4-(2- amino-2- methylpropyl)
piperazin-1-yl)- 2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01682## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.39 (s, 1H), 9.39- 9.34 (m,
1H), 8.91-8.80 (m, 1H), 8.68 (s, 1H), 8.29 (s, 1H), 7.38-7.35 (m,
1H), 6.65 (s, 1H), 2.99 (s, 2H), 2.85-2.80 (m, 8H), 2.40 (s, 2H),
1.41 (s, 6H), 1.13 (s, 6H). LCMS (ESI): m/z = 486.2 [M + Na].sup.+.
477 N-[6-[4-[(2R)-2- Aminopropyl] piperazin-1-yl]- 2,2-dimethyl-
3H-benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01683## .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.11-9.10
(m, 1H), 8.88-8.87 (m, 1H), 8.64 (s, 1H), 8.19 (s, 1H), 7.27 (dd, J
= 6.0, 4.4 Hz, 1H), 6.65 (s, 1H), 3.15-3.10 (m, 1H), 3.03 (s, 2H),
2.95- 2.85 (m, 4H), 2.85-2.75 (m, 2H), 2.70-2.60 (m, 2H), 2.45-2.30
(m, 2H), 1.46 (s, 6H), 1.10 (d, J = 6.0, 3H). LCMS (ESI): m/z =
472.1 [M + Na].sup.+. 478 N-[6-[4-[(2S)-2- Aminopropyl]
piperazin-1-yl]- 2,2-dimethyl- 3H-benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01684## .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 9.12 (dd, J = 6.8, 1.6 Hz, 1H), 8.90 (dd, J =
4.0, 1.6 Hz, 1H), 8.66 (s, 1H), 8.19 (s, 1H), 7.27 (dd, J = 6.8,
4.0 Hz, 1H), 6.66 (s, 1H), 3.15-3.10 (m, 1H), 3.03 (s, 2H),
2.95-2.85 (m, 4H), 2.85-2.75 (m, 2H), 2.70-2.60 (m, 2H), 2.45- 2.30
(m, 2H), 1.56 (s, 6H), 1.14 (d, J = 6.4, 3H). LCMS (ESI): m/z =
472.1 [M + Na].sup.+. 479 N-[2,2- Dimethyl-6-[4- [(5-methyl-2-
oxo-3H-oxazol- 4-yl)methyl] piperazin-1-yl]-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01685## .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 10.31 (s, 1H), 8.85 (dd, J = 7.2,
2.0 Hz, 1H), 8.79 (s, 1H), 8.65 (dd, J = 4.0, 1.6 Hz, 1H), 8.35 (s,
1H). 7.10 (dd, J = 6.8, 4.0 Hz, 1H), 6.64 (s, 1H), 3.32 (s, 2H),
3.04 (s, 2H), 2.99-2.89 (m, 4H), 2.74-2.64 (m, 4H), 2.07 (s, 3H),
1.49 (s, 6H). LCMS (ESI): m/z = 504.2 [M + H].sup.+ 480 and 481
(S)-N-(2,2- dimethyl-6-(4- (1-(methylamino)- 1-oxopropan-2-
yl)piperazin-1- yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide (R)-N-(2,2- dimethyl-6-(4-
(1-(methylamino)- 1-oxopropan-2- yl)piperazin-1- yl)-2,3-
dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01686##
##STR01687## Example 480, Peak 1: .sup.1H NMR (400 MHz,
CDCl.sub.3): 10.32 (s, 1H), 8.83-8.82 (m, 1H), 8.77 (s, 1H),
8.71-8.70 (m, 1H), 8.38 (s, 1H), 7.15- 7.03 (m, 2H), 6.64 (s, 1H),
3.12-3.06 (m, 1H), 3.03 (s, 2H), 2.94-2.93 (m, 4H), 2.85 (d, J =
4.8 Hz, 3H), 2.83- 2.75 (m, 2H), 2.70-2.69 (m, 2H), 1.49 (s, 6H),
1.31 (d, J = 7.2 Hz, 3H). LCMS (ESI): m/z = 478.1 [M + H].sup.+
Example 481, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3): 10.32 (s,
1H), 8.83-8.82 (m, 1H), 8.77 (s, 1H), 8.71-8.70 (m, 1H), 8.38 (s,
1H), 7.15- 7.03 (m, 2H), 6.64 (s, 1H), 3.12-3.06 (m, 1H), 3.03 (s,
2H), 2.94-2.93 (m, 4H), 2.85 (d, J = 4.4 Hz, 3H), 2.83- 2.75 (m,
2H), 2.70-2.69 (m, 2H), 1.49 (s, 6H), 1.31 (d, J = 6.8 Hz, 3H).
LCMS (ESI): m/z = 478.1 [M + H].sup.+ 482 and 483 N-[6-[4-[(1S)-1-
carbamoyl-3- hydroxy- propyl]piperazin- 1-yl]-2,2- dimethyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and
N-[6-[4-[(1R)-1- carbamoyl-3- hydroxy- propyl]piperazin- 1-yl]-2,2-
dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide (absolute stereochemistry assigned arbitrarily)
##STR01688## ##STR01689## Example 482, Peak 1: .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 10.41 (s, 1H), 9.35-9.33 (m, 1H), 8.99
(dd, J = 4.0, 1.6 Hz, 1H), 8.66 (s, 1H), 8.36 (s, 1H), 7.41 (s,
1H), 7.34 (dd, J = 7.2, 4.4 Hz, 1H), 7.14 (s, 1H), 6.67 (s, 1H),
4.47 (t, J = 5.2 Hz, 1H). 3.51-3.38 (m, 2H), 3.23 (t, J = 7.2 Hz,
1H), 2.99 (s, 2H), 2.83-2.75 (m, 8H), 1.79-1.68 (m, 2H), 1.41 (s,
6H). LCMS (ESI): m/z = 494.2 [M + H].sup.+. Example 483, Peak 2:
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.41 (s, 1H),
9.36-9.34 (m, 1H), 8.99-8.98 (m, 1H), 8.66 (s, 1H), 8.36 (s, 1H),
7.41 (s, 1H), 7.34 (dd, J = 6.8, 4.0 Hz, 1H), 7.14 (s, 1H), 6.67
(s, 1H), 4.47 (t, J = 5.2 Hz, 1H), 3.52-3.40 (m, 2H), 3.23 (t, J =
7.2 Hz, 1H), 2.99 (s, 2H), 2.85-2.74 (m, 8H), 1.80-1.67 (m, 2H),
1.41 (s, 6H). LCMS (ESI): m/z = 494.2 [M + H].sup.+
Example 484.
5-(Difluoromethyl)-N-(2-isopropyl-6-morpholino-1-oxo-isoindolin-5-yl)pyra-
zolo[1,5-a]pyrimidine-3-carboxamide
##STR01690##
[1917] Step A: Methyl
5-[(E)-2-(dimethylamino)vinyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01691##
[1919] To a solution of ethyl
5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (1.30 g, 6.33 mmol)
in N,N-dimethylformamide (20 ml) was added lithium hydroxide (75
mg, 3.17 mmol) and N,N-dimethylformamide dimethyl acetal (2.26 g,
19 mmol). The mixture was stirred at 120.degree. C. for 16 h. The
reaction was concentrated and purified by flash column
chromatography (ethyl acetate) to afford methyl
5-[(E)-2-(dimethylamino)vinyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate
(950 mg, 60% yield) as a dark yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.32 (s, 1H), 8.23 (d, J=7.6 Hz, 1H), 7.90 (d,
J=12.8 Hz, 1H), 6.53 (d, J=7.6 Hz, 1H), 5.18 (d, J=12.8 Hz, 1H),
3.91 (s, 3H), 3.04 (br s, 6H).
Step B: Methyl 5-formylpyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01692##
[1921] To a solution of methyl
5-[(E)-2-(dimethylamino)vinyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate
(950.0 mg, 3.86 mmol) in methyl alcohol (20 ml) was added sodium
periodate (1.65 g, 7.72 mmol) in water (20 ml). The mixture was
stirred at 60.degree. C. for 16 h. Methyl alcohol was removed and
the aqueous solution was extracted with ethyl acetate (150
ml.times.2). The combined organic phase was washed with saturated
sodium bicarbonate solution (100 ml) and brine (150 mL), dried over
sodium sulfate and concentrated. The crude product was purified by
flash column chromatography (ethyl acetate) to give methyl
5-formylpyrazolo[1,5-a]pyrimidine-3-carboxylate (630 mg, 79% yield)
as a yellow solid.
[1922] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.17 (s, 1H),
8.92 (d, J=6.4 Hz, 1H), 8.73 (s, 1H), 7.62 (d, J=7.2 Hz, 1H), 4.02
(s, 3H).
Step C: Methyl
5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01693##
[1924] To a solution of methyl
5-formylpyrazolo[1,5-a]pyrimidine-3-carboxylate (600 mg, 2.92 mmol)
in dichloromethane (10 ml) was added diethylaminosulfur trifluoride
(943 mg, 5.85 mmol) dropwise at 0.degree. C. The reaction was
stirred at 25.degree. C. for 16 h. The reaction was concentrated
and purified by flash column chromatography (33% ethyl acetate in
petroleum ether) to afford methyl
5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (430 mg,
64% yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.91 (d, J=7.2 Hz, 1H), 8.67 (s, 1H), 7.35 (d, J=7.2 Hz,
1H), 6.76 (t, J=54.4 Hz, 1H), 3.98 (s, 3H).
Step D: 5-(Difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid
##STR01694##
[1926] A mixture of methyl
5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (100 mg,
0.44 mmol) and lithium hydroxide monohydrate (24 mg, 0.57 mmol) in
tetrahydrofuran (1 ml) and methyl alcohol (1 ml) was stirred at
100.degree. C. under microwave irradiation for 100 min. The
reaction was acidified with hydrochloric acid (1 M, 0.6 mL) and
concentrated to afford 5-(difluoromethyl)
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (90 mg, 95% yield) as a
red solid, which was directly used in the next step without further
purification. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.31 (d,
J=7.2 Hz, 1H), 8.40 (s, 1H), 7.27 (d, J=7.2 Hz, 1H), 7.02 (t,
J=54.4 Hz, 1H).
Step E: 5-(Difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride
##STR01695##
[1928] To a solution of
5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (70
mg, 0.33 mmol) in oxalyl chloride (2.8 ml, 32 mmol) was added
N,N-dimethylformamide (24 mg, 0.33 mmol). The mixture was stirred
at 25.degree. C. for 1 h. The reaction mixture was concentrated to
obtain 5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (70 mg, 92% yield) as a yellow solid, which was used
directly.
Step F:
5-(Difluoromethyl)-N-(2-isopropyl-6-morpholino-1-oxo-isoindolin-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01696##
[1930] To a solution of
5-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (70
mg, 0.30 mmol) in pyridine (5 ml) was added
5-amino-2-isopropyl-6-morpholino-isoindolin-1-one (65 mg, 0.24
mmol). The reaction mixture was stirred at 50.degree. C. for 6 h.
The reaction was concentrated and purified by prep-TLC (10%
methanol in dichloromethane) to give the crude product, which was
triturated with methanol (5 mL) to give
5-(difluoromethyl)-N-(2-isopropyl-6-morpholino-1-oxo-isoindolin-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (39 mg, 35% yield) as a
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.04 (s,
1H), 9.01 (d, J=7.2 Hz, 1H), 8.92 (s, 1H), 8.60 (s, 1H), 7.69 (s,
1H), 7.41 (d, J=7.6 Hz, 1H), 6.84 (t, J=54.4 Hz, 1H), 4.72-4.64 (m,
1H), 4.35 (s, 2H), 3.92-3.83 (m, 4H), 3.04-2.95 (m, 4H), 1.31 (d,
J=6.4 Hz, 6H). LCMS (ESI): m/z=471.2 [M+H].sup.+.
TABLE-US-00019 TABLE 19 The following examples were made in a
manner similar to that for Example 484: Ex. Name Structure NMR, MS
485 6-cyano-N-(2- isopropyl-6- morpholino-1- oxo-isoindolin-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01697## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.74 (s, 1H), 10.28- 10.24
(m, 1H), 9.32 (d, J = 1.9 Hz, 1H), 8.95 (s, 1H), 8.73 (s, 1H), 7.58
(s, 1H), 4.48-4.32 (m, 3H), 3.92- 3.82 (m, 4H), 2.93-2.86 (m, 4H),
1.22 (d, J = 6.8 Hz, 6H). MS: m/z = 446.2 [M + H].sup.+. 486
N3-(2-isopropyl- 6-morpholino-1- oxo-isoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine- 3,6- dicarboxamide ##STR01698## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.74 (s, 1H), 10.28- 10.24 (m, 1H), 9.32
(d, J = 1.9 Hz, 1H), 8.95 (s, 1H), 8.73 (s, 1H), 7.58 (s, 1H),
4.48-4.32 (m, 3H), 3.92- 3.82 (m, 4H), 2.93-2.86 (m, 4H), 1.22 (d,
J = 6.8 Hz, 6H). MS: m/z = 464.2 [M + H].sup.+.
Example 487.
N-[6-Cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindo-
lin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01699##
[1931] Step A:
6-Cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-iso
indolin-1-one
##STR01700##
[1933] To a solution of
6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-isoindolin-1--
one (200 mg, 0.63 mmol), cyclopropyl boronic acid (82 mg, 0.95
mmol), potassium phosphate, tribasic (536 mg, 2.53 mmol) and
triphenylphosphine (50 mg, 0.19 mmol) in toluene (5 ml) and water
(1 ml) was added palladium(II) acetate (21 mg, 0.09 mmol) under the
protection of nitrogen. The reaction was stirred at 120.degree. C.
for 2 h with microwave irradiation. The reaction was diluted with
water (5 ml) and extracted with dichloromethane (50 ml.times.3).
The combined organic phase was washed with brine (50 ml.times.2),
dried over sodium sulfate, filtered and concentrated. The residue
was purified by prep-TLC (50% ethyl acetate in petroleum ether) to
afford
6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-isoindol-
in-1-one (with some triphenylphosphine oxide; 200 mg, 98% yield) as
a yellow solid.
Step B:
5-Amino-6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]is-
oindolin-1-one
##STR01701##
[1935] To a solution of
6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-isoindol-
in-1-one (200 mg, 0.62 mmol) and iron (173 mg, 3.1 mmol) in ethanol
(5 ml) and water (1 ml) was added ammonium chloride (166 mg, 3.1
mmol). The reaction was stirred at 80.degree. C. for 2 h. The
reaction was filtered and concentrated. The residue was dissolved
in ethyl acetate (20 ml), diluted with water (20 ml) and extracted
with ethyl acetate (100 ml.times.3). The combined organic phase was
washed with brine (100 ml.times.2), dried over sodium sulfate,
filtered and concentrated to afford
5-amino-6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]is-
oindolin-1-one (110 mg, 61% yield) as a yellow solid.
Step C:
N-[6-Cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo--
isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01702##
[1937] To a solution of
5-amino-6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]isoindoli-
n-1-one (100 mg, 0.34 mmol) in pyridine (10 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (75 mg, 0.41 mmol).
The reaction was stirred at 25.degree. C. for 2 h and concentrated.
The residue was purified by prep-TLC (10% methanol in
dichloromethane) to afford
N-[6-cyclopropyl-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo--
isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (92.2 mg,
59% yield) as a yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.58 (s, 1H), 9.40 (dd, J=6.8, 1.6 Hz, 1H), 8.94 (dd,
J=4.0, 1.2 Hz, 1H), 8.76 (s, 1H), 8.68 (s, 1H), 7.46 (s, 1H), 7.36
(dd, J=6.8, 4.0 Hz, 1H), 4.87 (s, 1H), 4.59-4.37 (m, 3H), 4.01-3.88
(m, 1H), 3.74-3.64 (m, 1H), 2.12-2.04 (m, 1H), 1.24-1.15 (m, 8H),
0.79-0.75 (m, 2H). LCMS (ESI): m/z=438.1 [M+H].sup.+.
Example 488.
N-[2,2-Dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-yl]pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR01703##
[1938] Step A:
4-(2,2-Dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole
##STR01704##
[1940] To a solution of 6-bromo-2,2-dimethyl-5-nitro-3H-benzofuran
(200 mg, 0.74 mmol) bis(triphenylphosphine)palladium(II) dichloride
(103 mg, 0.15 mmol) in N,N-dimethylformamide (5 ml) was added
tributyl-(1-methylimidazol-4-yl)stannane (382 mg, 1.03 mmol) under
nitrogen. The mixture was stirred at 100.degree. C. for 16 h. The
reaction mixture was filtered, diluted with water (20 ml) and
extracted with ethyl acetate (20 ml.times.2). The organic phase was
washed with brine (10 ml.times.2), dried over sodium sulfate,
filtered and concentrated. The residue was purified by flash
chromatography (5-10% ethyl acetate in petroleum ether) to afford
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole (113
mg, 56%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.62 (s, 1H), 7.47 (s, 1H), 7.13 (s, 1H), 7.07 (s, 1H),
3.73 (s, 3H), 3.06 (s, 2H), 1.52 (s, 6H). LCMS (ESI): m/z=274.0
[M+H].sup.+.
Step B:
2,2-Dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-amine
##STR01705##
[1942] To a solution of
4-(2,2-dimethyl-5-nitro-3H-benzofuran-6-yl)-1-methyl-imidazole (120
mg, 0.44 mmol) in methanol (4 ml) was added 10% palladium on carbon
(46 mg, 0.22 mmol). The reaction mixture was stirred under hydrogen
atmosphere (15 psi) at 25.degree. C. for 2 h. The reaction was
filtered, and the filtrate was concentrated. The residue was
purified by prep-TLC (5% methanol in dichloromethane) to afford
2,2-dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-amine (85
mg, 80%) as a yellow solid. LCMS (ESI): m/z=243.9 [M+H].sup.+.
Step C:
N-[2,2-Dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR01706##
[1944] To a solution of
2,2-dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-amine (85
mg, 0.35 mmol) in pyridine (2 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (95 mg, 0.52 mmol).
The reaction mixture was stirred at 25.degree. C. for 2 h. The
reaction was concentrated and the residue was purified by prep-TLC
(10% ethyl acetate in petroleum ether) to give
N-[2,2-dimethyl-6-(1-methylimidazol-4-yl)-3H-benzofuran-5-yl]pyrazolo[1,5-
-a]pyrimidine-3-carboxamide (45 mg, 33.2%) as a yellow solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.45 (s, 1H), 8.78-8.76
(m, 2H), 8.67-8.65 (m, 1H), 8.28 (s, 1H), 7.48 (s, 1H), 7.11 (s,
1H), 6.98 (dd, J=7.2, 4.0 Hz, 1H), 6.92 (s, 1H), 3.71 (s, 3H), 3.08
(s, 2H), 1.51 (s, 6H). LCMS (ESI): m/z=389.0 [M+H].sup.+.
TABLE-US-00020 TABLE 20 The following examples were made in a
manner similar to that for Example 488: Ex. Name Structure NMR, MS
489 N-[2,2- dimethyl-6-(1- methylpyrazol- 3-yl)-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01707## .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 5 11.10 (s, 1H), 8.78 (dd, J =
7.2, 1.6 Hz, 1H), 8.76 (s, 1H), 8.66-8.65 (m, 1H), 8.27 (s, 1H),
7.37 (d, J = 2.4 Hz, 1H), 6.99 (dd, J = 7.2, 4.0 Hz, 1H), 6.96 (s,
1H), 6.48 (d, J = 2.0 Hz, 1H), 3.90 (s, 3H), 3.09 (s, 2H), 1.51 (s,
6H). LCMS (ESI): m/z = 389.0 [M + H].sup.+.
Example 490.
6-(Azetidin-3-yl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01708##
[1945] Step A: tert-Butyl
3-[3-[(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)carbamoyl]pyrazolo[1,-
5-a] pyrimidin-6-yl] azetidine-1-carboxylate
##STR01709##
[1947] To a mixture of zinc (211 mg, 3.23 mmol) in N,
N-dimethylacetamide (2.5 ml) was added chlorotrimethylsilane (0.03
ml, 0.40 mmol) and 1,2-dibromoethane (0.03 ml, 0.40 mmol) at
20.degree. C. under nitrogen. The resulting mixture was stirred for
15 min. A solution of 1-Boc-3-iodoazetidine (700 mg, 2.47 mmol) in
N, N-dimethylacetamide (1 ml) was added portion wise. The reaction
mixture was stirred for 30 min to give a solution of zinc
reagent.
[1948] In another reaction vessel, to a solution of
6-bromo-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (200 mg, 0.42 mmol) in N,
N-dimethylacetamide (2 ml) was added
1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (75 mg,
0.10 mmol), cuprous iodide (39 mg, 0.20 mmol) and the freshly
prepared (1-tert-butoxycarbonylazetidin-3-yl)-iodo-zinc (3.03 ml,
2.12 mmol). The reaction mixture was stirred at 80.degree. C. for
16 h under nitrogen. The reaction mixture was quenched by water (50
ml) and extracted with dichloromethane (50 ml.times.3). The
combined organic layers were washed with water (150 ml.times.3),
brine (150 ml), dried over anhydrous sodium sulfate, filtered and
concentrated. The residue was purified by flash column
chromatography on silica gel (eluting with 0-20-50-100% ethyl
acetate in petroleum ether) to afford a crude product which was
further purified by prep-TLC (5% methanol in dichloromethane) twice
to afford tert-butyl
3-[3-[(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)carbamoyl]pyrazolo[1,-
5-a] pyrimidin-6-yl]azetidine-1-carboxylate (100 mg, 43%) as a
yellow solid. LCMS (ESI): m/z=549.3[M+H].sup.+.
Step B:
6-(azetidin-3-yl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)-
pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride
##STR01710##
[1950] A mixture of tert-butyl
3-[3-[(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)carbamoyl]pyrazolo[1,-
5-a]pyrimidin-6-yl]azetidine-1-carboxylate (90 mg, 0.16 mmol) in 4
M hydrochloric acid in methanol (2 ml, 8 mmol) was stirred at
28.degree. C. for 30 min. The reaction mixture was concentrated to
obtain a residue which was triturated with methanol to afford
6-(azetidin-3-yl)-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)
pyrazolo[1,5-a]pyrimidine-3-carboxamide (35 mg, 42%, HCl salt) as a
yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.34 (s, 1H),
9.60-9.50 (m, 1H), 9.05-8.95 (m, 1H), 8.70 (s, 1H), 8.31 (s, 1H),
6.72 (s, 1H), 4.50-4.25 (m, 5H), 3.95-3.75 (m, 4H), 3.00 (s, 2H),
2.95-2.75 (m, 4H), 1.42 (s, 6H). LCMS (ESI): m/z=449.1
[M+H].sup.+.
Example 491.
N.sup.3-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,-
5-a]pyrimidine-3,6-dicarboxamide
##STR01711##
[1951] Step A: ethyl
3-((2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)carbamoyl)
pyrazolo[1,5-a]pyrimidine-6-carboxylate
##STR01712##
[1953] A solution of
6-bromo-N-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (150 mg, 0.3 mmol), triethylamine (96 mg,
1.0 mmol) and 1,1'-bis(diphenylphosphino) ferrocene palladium
dichloride (23 mg, 0.03 mmol) in anhydrous ethanol (25 ml) was
stirred at 80.degree. C. for 20 h under CO atmosphere (40 psi). The
reaction mixture was concentrated and the residue was purified by
prep-TLC (4% methanol in dichloromethane) to afford ethyl
3-[(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)carbamoyl]pyrazolo[1,5-a-
]pyrimidine-6-carboxylate (120.0 mg, 81%) as a yellow solid. LCMS
(ESI): m/z=466.1 [M+H].sup.+.
Step B:
N.sup.3-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyra-
zolo[1,5-a]pyrimidine-3,6-dicarboxamide
##STR01713##
[1955] To ethyl
3-[(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)carbamoyl]pyrazolo[1,5-a-
]pyrimidine-6-carboxylate (120.0 mg, 0.3 mmol) was added anhydrous
ethanol (30 ml) saturated with ammonia (22.0 mg, 1.3 mmol). The
mixture was stirred at 100.degree. C. for 48 h and concentrated.
The crude product was triturated with 10% methanol in
dichloromethane twice to give
N-3-(2,2-dimethyl-6-morpholino-3H-benzofuran-5-yl)pyrazolo[1,5-a]pyrimidi-
ne-3,6-dicarboxamide (37.1 mg, 32%) as a reddish purple solid.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.42 (s, 1H), 9.76 (d,
J=2.0 Hz, 1H), 9.26 (d, J=2.0 Hz, 1H), 8.79 (s, 1H), 8.41 (s, 1H),
8.32 (s, 1H), 7.92 (s, 1H), 6.73 (s, 1H), 3.87-3.84 (m, 4H), 3.01
(s, 2H), 2.83-2.81 (m, 4H), 1.41 (s, 6H). LCMS (ESI): m/z=437.2
[M+H].sup.+.
Example 492.
N3-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]-N.sup.6-methyl-pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide
##STR01714##
[1956] Step A: Methyl
3-[[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylate
##STR01715##
[1958] To a solution of
6-bromo-N-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo--
isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Example
269 (100 mg, 0.18 mmol) in methanol (15 ml) was added triethylamine
(54 mg, 0.53 mmol) and 1,1'-bis(diphenylphosphino)ferrocene
palladium dichloride (7 mg, 0.01 mmol). The reaction was stirred at
80.degree. C. for 16 h under CO (50 psi). The reaction was diluted
with water (50 ml) and extracted with dichloromethane (100
ml.times.3). The organic phase was washed with brine (100
ml.times.2), dried over sodium sulfate, filtered and concentrated.
The residue was purified by prep-TLC (10% methanol in
dichloromethane) to afford methyl
3-[[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylate (90 mg,
94% yield) as a brown solid. LCMS (ESI): m/z=541.1 [M+H].sup.+.
Step B:
3-[[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo--
isoindolin-5-yl] carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylic
acid
##STR01716##
[1960] To a solution of methyl
3-[[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylate (80 mg,
0.15 mmol) in methanol (2 ml) and water (1 ml) was added lithium
hydroxide (18 mg, 0.74 mmol). The reaction was stirred at
30.degree. C. for 2 h. The reaction was diluted with water (10 ml)
and washed with ethyl acetate (50 ml.times.3). The aqueous phase
was adjusted to pH 5 with hydrochloric acid (2 M) and extracted
with dichloromethane (50 ml.times.3). The organic phase was washed
with brine (50 ml.times.2), dried over sodium sulfate, filtered and
concentrated to afford
3-[[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl] carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylic acid (72
mg, 92%) as a brown solid. LCMS (ESI): m/z=527.1 [M+H].
Step C:
N3-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo--
isoindolin-5-yl]-N.sup.6-methyl-pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamid-
e
##STR01717##
[1962] To a solution of
3-[[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-isoindo-
lin-5-yl]carbamoyl]pyrazolo[1,5-a]pyrimidine-6-carboxylic acid
(72.0 mg, 0.14 mmol), methanamine hydrochloride (19 mg, 0.27 mmol)
and HATU (78 mg, 0.21 mmol) in N,N-dimethylformamide (5 ml) was
added N,N-diisopropylethylamine (0.05 ml, 0.27 mmol). The reaction
was stirred at 30.degree. C. for 30 min. The reaction was filtered
and purified by reverse phase chromatography (Waters Xbridge Prep
OBD C18 150 mm*30 mm, 5 m, acetonitrile 20-50%/0.05% ammonia
hydroxide in water) to afford
N.sup.3-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-6-morpholino-1-oxo-is-
oindolin-5-yl]-N.sup.6-methyl-pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide
(14.1 mg, 18.5% yield) as a yellow solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.85 (s, 1H), 9.71 (d, J=2.0 Hz, 1H), 9.29
(d, J=2.0 Hz, 1H), 8.96-8.95 (m, 1H), 8.86 (s, 1H), 8.76 (s, 1H),
7.61 (s, 1H), 4.92 (s, 1H), 4.56-4.37 (m, 3H), 3.97-3.86 (m, 5H),
3.76-3.66 (m, 1H), 2.94-2.88 (m, 7H), 1.18 (s, 6H). LCMS (ESI):
m/z=540.1 [M+H].sup.+.
Example 493.
6-(difluoromethoxy)-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01718##
[1964] To a solution of
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazol-
o[1,5-a]pyrimidine-3-carboxamide (Example 530) (180 mg, 0.44 mmol)
in DMF (8 ml) and water (0.8 ml) was added cesium carbonate (172
mg, 0.53 mmol) and sodium chlorodifluoroacetate (134 mg, 0.88
mmol). The mixture was heated at 100.degree. C. for 16 h. The
reaction mixture was cooled to room temperature, diluted with ethyl
acetate (50 ml), and washed with H.sub.2O (20 ml.times.2). The
organic phase was dried over anhydrous sodium sulfate, filtered and
concentrated. The residue was purified by prep-TLC (2% methanol in
dichloromethane) to afford
6-(difluoromethoxy)-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (26 mg, 12%) as a yellow
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.37 (s, 1H),
8.82-8.81 (m, 2H), 8.72 (d, J=2.4 Hz, 1H), 8.43 (s, 1H), 6.90-6.43
(m, 2H), 4.09-3.88 (m, 4H), 3.05 (s, 2H), 2.99-2.86 (m, 4H), 1.49
(s, 6H). LCMS (ESI): m/z=460.0 [M+H].sup.+.
Examples 494 and 495.
N-[(2R)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-[(2S)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01719##
[1966]
N-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-meth-
yl-3H-benzofuran-5-yl]-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxamide
(Example 131, 155 mg, 0.32 mmol) was resolved by chiral SFC to
afford
N-[(2S)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]-6-fluoro-pyrazzolo[1,5-a]pyrimidine-3-carboxamide
(70.44 mg, 44.1%) and
N-[(2R)-6-[4-(2,2-difluoroethyl)piperazin-1-yl]-2-(hydroxymethyl)-2-methy-
l-3H-benzofuran-5-yl]-6-fluoro-pyrazolo[1,5-a]pyrimidine-3-carboxamide
(71.18 mg, 44.5%) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[1967] Example 494, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.24 (s, 1H), 9.85-9.75 (m, 1H), 9.20-9.10 (m, 1H), 8.71
(s, 1H), 8.27 (s, 1H), 6.70 (s, 1H), 6.40-6.05 (m, 1H), 5.10-4.95
(m, 1H), 3.50-3.40 (m, 2H), 3.25-3.10 (m, 1H), 3.00-2.70 (m, 11H),
1.34 (s, 3H). LCMS (ESI): m/z=491.2 [M+H].sup.+.
[1968] Example 495, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.24 (s, 1H), 9.85-9.75 (m, 1H), 9.20-9.10 (m, 1H), 8.71
(s, 1H), 8.27 (s, 1H), 6.70 (s, 1H), 6.40-6.05 (m, 1H), 5.06 (s,
1H), 3.50-3.40 (m, 2H), 3.25-3.10 (m, 1H), 3.00-2.70 (m, 11H), 1.34
(s, 3H). LCMS (ESI): m/z=491.2 [M+H].sup.+.
Example 496.
N-[6-(Cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-ox-
o-isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01720##
[1969] Step A:
1-Bromo-5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzene
##STR01721##
[1971] To a solution of cyclopropanemethanol (0.92 g, 12.82 mmol)
and 1-bromo-5-fluoro-2-methyl-4-nitrobenzene (1.5 g, 6.41 mmol) in
tetrahydrofuran (50 ml) was added sodium tert-butoxide (0.74 g,
7.69 mmol). The mixture was stirred at 50.degree. C. for 16 h. The
mixture was filtered and concentrated. The crude product was
purified by flash column chromatography (5% ethyl acetate in
petroleum ether) to give
1-bromo-5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzene (1.1 g, 60%
yield) as a white solid.
[1972] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.74 (s, 1H), 7.25
(s, 1H), 3.95 (d, J=6.4 Hz, 2H), 2.38 (s, 3H), 1.32-1.26 (m, 1H),
0.71-0.64 (m, 2H), 0.42-0.38 (m, 2H).
Step B: Ethyl 5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzoate
##STR01722##
[1974] To a solution of
1-bromo-5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzene (500 mg,
1.75 mmol) in triethylamine (10 ml, 72 mmol) and ethanol (20 ml)
was added bis(triphenylphosphine)palladium(II) dichloride (122 mg,
0.17 mmol). The reaction was stirred at 80.degree. C. for 16 h
under CO (40-50 psi). The reaction was filtered and concentrated.
The crude product was purified by flash column chromatography (3%
ethyl acetate in petroleum ether) to give ethyl
5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzoate (340 mg, 69%
yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.65 (s, 1H), 7.57 (s, 1H), 4.40 (q, J=7.2 Hz, 2H), 4.00 (d, J=6.8
Hz, 2H), 2.55 (s, 3H), 1.42 (t, J=7.2 Hz, 3H), 1.31-1.27 (m, 1H),
0.70-0.62 (m, 2H), 0.43-0.36 (m, 2H).
Step C: Ethyl
2-(bromomethyl)-5-(cyclopropylmethoxy)-4-nitro-benzoate
##STR01723##
[1976] To a solution of ethyl
5-(cyclopropylmethoxy)-2-methyl-4-nitro-benzoate (400 mg, 1.43
mmol) in acetonitrile (10 ml) was added
1-bromo-2,5-pyrrolidinedione (305 mg, 1.72 mmol) and
2,2'-azobis(2-methylpropionitrile) (35 mg, 0.21 mmol). The mixture
was stirred at 80.degree. C. for 16 h under nitrogen and
concentrated. The crude product was purified by flash column
chromatography (2% ethyl acetate in petroleum ether) to afford
ethyl 2-(bromomethyl)-5-(cyclopropylmethoxy)-4-nitro-benzoate (260
mg, 50% yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.88 (s, 1H), 7.61 (s, 1H), 4.87 (s, 2H), 4.46 (q, J=7.2
Hz, 2H), 4.04 (d, J=6.8 Hz, 2H), 1.46 (t, J=7.2 Hz, 3H), 1.34-1.29
(m, 1H), 0.73-0.64 (m, 2H), 0.45-0.37 (m, 2H).
Step D:
6-(Cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]--
5-nitro-isoindolin-1-one
##STR01724##
[1978] To a solution of ethyl
2-(bromomethyl)-5-(cyclopropylmethoxy)-4-nitro-benzoate (370 mg,
1.03 mmol) in methyl alcohol (15 ml) was added
(3R)-4-amino-3-fluoro-2-methyl-butan-2-ol (187 mg, 1.55 mmol) and
triethylamine (209 mg, 2.07 mmol). The reaction was stirred at
60.degree. C. for 5 h. The reaction was concentrated and purified
by flash chromatography (70% ethyl acetate in petroleum ether) to
afford
6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-
-isoindolin-1-one (190 mg, 52% yield) as a yellow solid. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.84 (s, 1H), 7.51 (s, 1H),
4.69-4.42 (m, 3H), 4.35-4.15 (m, 1H), 4.05 (d, J=6.4 Hz, 2H),
3.73-3.63 (m, 1H), 2.31-2.15 (m, 1H), 1.36-1.32 (m, 6H), 1.31-1.28
(m, 1H), 0.71-0.63 (m, 2H), 0.45-0.35 (m, 2H).
Step E:
5-Amino-6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-
-butyl] isoindolin-1-one
##STR01725##
[1980] To a solution of
6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-
-isoindolin-1-one (190 mg, 0.54 mmol) in ethanol (10 ml) and water
(2 ml) was added iron (150 mg, 2.7 mmol) and ammonium chloride (144
mg, 2.7 mmol). The reaction was stirred at 80.degree. C. for 2 h.
The reaction was filtered, then concentrated. The reaction was
taken up in dichloromethane (80 ml.times.2), washed with brine (80
ml), dried over sodium sulfate, and concentrated to give
5-amino-6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-
isoindolin-1-one (170 mg, 97% yield) as a yellow solids. LCMS
(ESI): m/z=323.0 [M+H].sup.+.
Step F:
N-[6-(Cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-buty-
l]-1-oxo-isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01726##
[1982] To a solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (148 mg, 0.82 mmol) in pyridine (5 ml) was added
5-amino-6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-
isoindolin-1-one (220 mg, 0.68 mmol). The reaction mixture was
stirred at 50.degree. C. for 16 h. The reaction was concentrated
and purified by flash column chromatography (75% ethyl acetate in
dichloromethane) to give
N-[6-(cyclopropylmethoxy)-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-
-1-oxo-isoindolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (252
mg, 77% yield) as a yellow solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.80 (s, 1H), 9.38 (d, J=7.2 Hz, 1H), 8.87
(d, J=3.2 Hz, 1H), 8.76-8.68 (m, 2H), 7.35-7.30 (m, 1H), 7.25 (s,
1H), 4.91 (s, 1H), 4.55-4.35 (m, 3H), 4.09-3.84 (m, 3H), 3.75-3.61
(m, 1H), 1.49-1.43 (m, 1H), 1.23-1.13 (m, 6H), 0.73-0.65 (m, 2H),
0.49-0.41 (m, 2H). LCMS (ESI): m/z=468.1 [M+H].sup.+.
Examples 497 and 498.
N-((2R,3'S)-1',3'-dimethyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidi-
n]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
N-((2R,3'R)-1',3'-dimethyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidi-
n]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01727##
[1984] To a solution of
1',3'-dimethyl-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-5-amine
(900 mg, 2.84 mmol; prepared following the procedure described for
Example 152 from 1,3-dimethylpiperidin-4-one) in pyridine (50 ml)
was added pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (669 mg,
3.69 mmol). The mixture was stirred at 60.degree. C. for 3 h. The
reaction was concentrated, and the residue was triturated with
methanol (5 ml) to afford
N-(1',3'-dimethyl-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine-
]-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (1.0 g, 76% yield)
as a yellow solid. It was resolved by chiral preparatory SFC to
afford
N-[(2R,3'S)-1',3'-dimethyl-6-morpholino-spiro[3H-benzofuran-2,4'-piperidi-
ne]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (325 mg, 25%;
RT=2.105 min) and
N-[(2R,3'R)-1',3'-dimethyl-6-morpholino-spiro[3H-benzofuran-2,4'-
-piperidine]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (350 mg,
26.4%; RT=2.822 min) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[1985] Example 497, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.46 (s, 1H), 8.89-8.81 (m, 1H), 8.79 (s, 1H), 8.78-8.76
(m, 1H), 8.41 (s, 1H), 7.07 (dd, J=6.8, 4.0 Hz, 1H), 6.68 (s, 1H),
3.96-3.94 (m, 4H), 3.22 (d, J=15.6 Hz, 1H), 2.93-2.89 (m, 5H),
2.70-2.63 (m, 2H), 2.42-2.39 (m, 1H), 2.34 (s, 3H), 2.22-2.18 (m,
1H), 2.05-2.01 (m, 1H), 1.93-1.84 (m, 1H), 1.82-1.81 (m, 1H), 0.87
(d, J=6.4 Hz, 3H). LCMS (ESI): m/z=463.3 [M+H].sup.+.
[1986] Example 498, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.44 (s, 1H), 8.85 (dd, J=6.8, 1.6 Hz, 1H), 8.79 (s, 1H),
8.77 (dd, J=4.0, 1.6 Hz, 1H), 8.45 (s, 1H), 7.08 (dd, J=6.8, 4.0
Hz, 1H), 6.64 (s, 1H), 3.96-3.94 (m, 4H), 3.42-3.37 (m, 1H), 3.30
(d, J=16.8 Hz, 1H), 3.27-3.22 (m, 1H), 3.20-3.12 (m, 1H), 2.94 (d,
J=16.8 Hz, 1H), 2.93-2.90 (m, 5H), 2.82 (s, 3H), 2.68-2.62 (m, 1H),
2.61-2.55 (m, 1H), 2.17-2.13 (m, 1H), 0.92 (d, J=6.8 Hz, 3H). LCMS
(ESI): m/z=463.1 [M+H].sup.+.
Example 499.
N-(2,2-Dimethyl-6-morpholino-1-oxo-2,3-dihydro-1H-inden-5-yl)pyrazolo[1,5-
-a]pyrimidine-3-carboxamide
##STR01728##
[1987] Step A: N-(2,3-Dihydro-1H-inden-5-yl)acetamide
##STR01729##
[1989] To a stirred solution of 2,3-dihydro-1H-inden-5-ylamine
(15.0 g, 112.6 mmol) and triethylamine (17.1 g, 168.9 mmol) in
dichloromethane (300 ml) was added acetyl chloride (26.5 g, 337.9
mmol) dropwise. The mixture was stirred at 26.degree. C. for 2.5 h,
quenched with methanol (20 ml) and water (100 ml), and extracted
with dichloromethane (150 mL.times.3). The combined organic phase
was dried over anhydrous sodium sulfate, filtered and concentrated.
The residue was purified by flash column chromatography (20-45%
ethyl acetate in petroleum ether) to afford
N-(2,3-dihydro-1H-inden-5-yl)acetamide (19.0 g, 96%) as a light
brown solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.65 (s,
1H), 7.43 (s, 1H), 7.17-7.12 (m, 2H), 2.89-2.83 (m, 4H), 2.14 (s,
3H), 2.06 (quint, J=7.2 Hz, 2H).
Step B: N-(6-bromoindan-5-yl)acetamide
##STR01730##
[1991] To a stirred solution of
N-(2,3-dihydro-1H-inden-5-yl)acetamide (19.0 g, 108.4 mmol) in
acetic acid (350 ml) was added bromine (6.83 ml, 133.4 mmol) in
acetic acid (3 ml) at 0.degree. C. over a period of 20 min. The
mixture was stirred at 26.degree. C. for 1 h under nitrogen, and
diluted with water until no more precipitate formed. The
precipitate was collected, washed with water, and dried under
vacuum to give N-(6-bromoindan-5-yl)acetamide (27.0 g, 98%) as a
light yellow solid. LCMS (ESI): m/z=255.8 [M+H].sup.+.
Step C: N-(6-bromo-1-oxo-indan-5-yl)acetamide
##STR01731##
[1993] To a stirred solution of N-(6-bromoindan-5-yl)acetamide
(27.0 g, 106.3 mmol) in acetic acid (300 ml) was added dropwise
chromium trioxide (44.0 g, 439.9 mmol) in 50% aqueous acetic acid
(34 ml) at 50.degree. C. and stirred for another 20 min. Then it
was cooled to 0.degree. C. when the reaction was quenched with
2-propanol (10 ml). The solvent was removed in vacuo, and the
residue was diluted with water (100 ml) and extracted with ethyl
acetate (100 ml.times.3). The combined organic phase was washed
with 0.5 M aqueous NaOH (50 ml) and brine, dried over anhydrous
sodium sulfate, and concentrated. The residue was purified by flash
column chromatography (0-4% methanol in dichloromethane) to afford
N-(6-bromo-1-oxo-indan-5-yl)acetamide (13.1 g, 46%) as a light
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.59 (s,
1H), 7.94 (s, 1H), 7.91 (br s, 1H), 3.11 (t, J=6.0 Hz, 2H), 2.71
(t, J=6.0 Hz, 2H), 2.30 (s, 3H).
Step D: 5-Amino-6-bromo-indan-1-one
##STR01732##
[1995] A mixture of N-(6-bromo-1-oxo-indan-5-yl)acetamide (13.1 g,
48.9 mmol) and 6 M aqueous hydrochloric acid (260 ml, 1.560 mol)
was stirred at 100.degree. C. for 1 h under nitrogen. The solution
was cooled to 0.degree. C. and adjusted to pH=8 with 10 M aqueous
sodium hydroxide solution. The precipitate formed was collected,
washed with water, and dried under vacuum to afford
5-amino-6-bromo-indan-1-one (10.8 g, 98%) as a light brown powder.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.86 (s, 1H), 6.74 (s,
1H), 4.68 (s, 2H), 2.98 (t, J=6.0 Hz, 2H), 2.64 (t, J=6.0 Hz,
2H).
Step E: 6-Bromo-5-nitro-indan-1-one
##STR01733##
[1997] To a suspension of 5-amino-6-bromo-indan-1-one (4.0 g, 17.7
mmol) in 20% aqueous HBF.sub.4 (16 ml) at 0.degree. C. was added 4
M aqueous sodium nitrite (1.9 g, 27.3 mmol) drop wise over a period
of 5 min. The mixture was stirred for 50 min after the addition was
completed. The resulting foamy suspension was added portion wise to
a vigorously stirred mixture of copper (5.3 g, 83.2 mmol) and
sodium nitrite (16.3 g, 236.7 mmol) in water (32 ml) at 26.degree.
C. over a period of 30 min. During the addition, excessive foaming
was broken up by the addition of small amounts of diethyl ether.
After the mixture was stirred for a further 50 min, it was filtered
through Celite pad and washed with ethyl acetate (300 ml). The
organic phase was separated, washed with brine, dried over
anhydrous sodium sulfate, filtered and concentrated. The residue
was purified by flash column chromatography (10-20% ethyl acetate
in petroleum ether) to afford 6-bromo-5-nitro-indan-1-one (2.1 g,
47%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.08 (s, 1H), 7.85 (s, 1H), 3.21 (t, J=6.0 Hz, 2H), 2.83 (t, J=6.0
Hz, 2H).
Step F: 6-Bromo-2,2-dimethyl-5-nitro-indan-1-one
##STR01734##
[1999] To a mixture of 6-bromo-5-nitro-indan-1-one (1.2 g, 4.5
mmol) and iodomethane (1.4 ml, 22.9 mmol) in N, N-dimethylformamide
(40 ml) was added 60% sodium hydride mineral oil (544 mg, 13.6
mmol) in batches at 0.degree. C. The mixture was stirred at
0.degree. C. for 10 min, quenched by saturated ammonium chloride
solution (10 mL) and extracted with ethyl acetate (100 ml.times.3).
The combined organic phase was dried over sodium sulfate, filtered
and concentrated. The residue was purified by flash column
chromatography (2-5% ethyl acetate in petroleum ether) to afford
6-bromo-2,2-dimethyl-5-nitro-indan-1-one (450 mg, 35%) as a yellow
solid. LCMS (ESI): m/z=284.1 [M+H].sup.+.
Step G: 2,2-Dimethyl-6-morpholino-5-nitro-indan-1-one
##STR01735##
[2001] To a stirred solution of
6-bromo-2,2-dimethyl-5-nitro-indan-1-one (450 mg, 1.6 mmol) in
dimethyl sulfoxide (18 ml) was added morpholine (276 mg, 3.2 mmol)
and N,N-diisopropylethylamine (614 mg, 4.8 mmol). The mixture was
stirred at 110.degree. C. for 16 h, diluted with water (50 ml), and
extracted with ethyl acetate (100 ml.times.3). The combined organic
phase was washed with brine (30 ml), dried over sodium sulfate,
filtered and concentrated. The residue was purified by flash column
chromatography (10% ethyl acetate in petroleum ether) to give the
mixture of 2,2-dimethyl-6-morpholino-5-nitro-indan-1-one and
6-bromo-2,2-dimethyl-5-morpholino-indan-1-one (340 mg, 74%) as a
yellow solid which was used directly for next step.
[2002] LCMS (ESI): m/z=290.9 [M+H].sup.+.
Step H: 5-Amino-2,2-dimethyl-6-morpholino-indan-1-one
##STR01736##
[2004] To a stirred mixture of
2,2-dimethyl-6-morpholino-5-nitro-indan-1-one and
6-bromo-2,2-dimethyl-5-morpholino-indan-1-one (340 mg) in ethanol
(25 ml) and water (5 ml) was added iron (327 mg, 5.9 mmol) and
ammonium chloride (313 mg, 5.9 mmol). The mixture was stirred at
80.degree. C. for 2 h under nitrogen. The reaction mixture was
filtered and concentrated. The residue was purified by flash column
chromatography (20-60% ethyl acetate in petroleum ether) to afford
5-amino-2,2-dimethyl-6-morpholino-indan-1-one (190 mg, 62%) as
light a yellow solid. LCMS (ESI): m/z=261.0 [M+H].sup.+.
Step I:
N-(2,2-dimethyl-6-morpholino-1-oxo-2,3-dihydro-1H-inden-5-yl)pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR01737##
[2006] A mixture of 5-amino-2,2-dimethyl-6-morpholino-indan-1-one
(50 mg, 0.2 mmol) and pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(52 mg, 0.3 mmol) in pyridine (5 ml) was stirred at 28.degree. C.
for 20 h and concentrated. The residue was purified by flash column
chromatography (eluting 0-1% methanol in dichloromethane) followed
by prep-TLC (100% ethyl acetate). The crude product was further
triturated with methanol to afford
N-(2,2-dimethyl-6-morpholino-1-oxo-indan-5-yl)pyrazolo[1,5-a]pyrim-
idine-3-carboxamide (54 mg, 68%) as a white solid. 1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 10.94 (s, 1H), 9.40 (d, J=6.8 Hz, 1H), 8.98
(d, J=4.4 Hz, 1H), 8.75 (s, 1H), 8.68 (s, 1H), 7.53 (s, 1H), 7.38
(dd, J=6.8, 4.4 Hz, 1H), 3.91-3.85 (m, 4H), 2.98 (s, 2H), 2.91-2.86
(m, 4H), 1.14 (s, 6H). LCMS (ESI): m/z=406.1 [M+H].sup.+.
Example 500.
N-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindolin-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide
##STR01738##
[2007] Step A: 5-amino-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]
isoindolin-1-one
##STR01739##
[2009] To a solution of
6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-isoindolin-1--
one (100 mg, 0.32 mmol) in methanol (30 ml) was added 10% palladium
on carbon (7 mg, 0.06 mmol). The reaction mixture was stirred at
25.degree. C. for 6 h under a hydrogen atmosphere (15 psi). The
mixture was filtered and the filtrate was concentrated. The residue
was purified by flash chromatography (0-50% ethyl acetate in
petroleum ether) to afford
5-amino-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]isoindolin-1-one
(50 mg, 63%) as a white solid. LCMS (ESI): m/z=253.1
[M+H].sup.+.
Step B:
N-[2-[(2R)-2-Fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindolin-5-y-
l]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01740##
[2011] To a solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (47 mg, 0.26 mmol) in pyridine (2 ml) was added
5-amino-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]isoindolin-1-one
(55 mg, 0.22 mmol). The reaction mixture was stirred at 50.degree.
C. for 16 h and concentrated. The residue was purified by flash
column chromatography (3% methyl alcohol in dichloromethane) to
give
N-[2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindolin-5-yl]pyraz-
olo[1,5-a]pyrimidine-3-carboxamide (29 mg, 32%) as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.13 (s, 1H), 8.88-8.85
(m, 1H), 8.79 (s, 1H), 8.77-8.75 (m, 1H), 8.33 (s, 1H), 7.84 (d,
J=8.0 Hz, 1H), 7.53-7.50 (m, 1H), 7.11 (dd, J=6.8, 4.0 Hz, 1H),
4.69-4.45 (m, 3H), 4.25-4.15 (m, 1H), 3.68-3.64 (m, 1H), 2.42 (s,
1H), 1.35 (s, 3H), 1.33 (s, 3H). LCMS (ESI): m/z=398.2
[M+H].sup.+.
Example 501.
N-(1'-(2-fluoroethyl)-6-morpholino-3H-spiro[benzofuran-2,4'-piperidin]-5--
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01741##
[2013] To a solution of
N-(6-morpholinospiro[3H-benzofuran-2,4'-piperidine]-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide (80 mg, 0.18 mmol), 1-bromo-2-fluoroethane
(70 mg, 0.55 mmol) in acetonitrile (10 ml) was added
N,N-diisopropylethylamine (71 mg, 0.55 mmol). The reaction was
stirred at 60.degree. C. for 16 h. The reaction was diluted with
water (10 ml) and extracted with dichloromethane (20 ml.times.3).
The combined organic phase was washed with brine (20 ml.times.2),
dried over sodium sulfate, filtered and concentrated. The residue
was triturated with acetonitrile (3 ml) to afford
N-[1'-(2-fluoroethyl)-6-morpholino-spiro[3H-benzofuran-2,4'-piperi-
dine]-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (48 mg, 54%
yield) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.48 (s, 1H), 8.84 (dd, J=6.8 Hz, 1.6 Hz, 1H), 8.79 (s, 1H), 8.78
(dd, J=4.0 Hz, 1.6 Hz, 1H), 8.43 (s, 1H), 7.07 (dd, J=6.8 Hz, 4.0
Hz, 1H), 6.69 (s, 1H), 4.71-4.68 (m, 1H), 4.60-4.57 (m, 1H),
3.97-3.94 (m, 4H), 3.03 (s, 2H), 2.94-2.90 (m, 4H), 2.86-2.83 (m,
1H), 2.80-2.70 (m, 5H), 2.05-2.01 (m, 2H), 2.00-1.91 (m, 2H). LCMS
(ESI): m/z=481.3 [M+H].sup.+.
Example 502.
N-(1'-ethyl-6-morpholino-3H-spiro[benzofuran-2,4'-piperidin]-5-yl)pyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01742##
[2015] To a solution of
N-(6-morpholinospiro[3H-benzofuran-2,4'-piperidine]-5-yl)pyrazolo[1,5-a]p-
yrimidine-3-carboxamide (200 mg, 0.46 mmol), acetaldehyde (61 mg,
1.38 mmol) and acetic acid (0.6 ml) in methanol (20 ml) was added
sodium cyanoborohydride (34.7 mg, 0.55 mmol).
[2016] The solution was stirred at 20.degree. C. for 3 h. The
reaction was concentrated. The residue was taken up in ethyl
acetate (20 ml) and washed with water (20 ml.times.2) and brine (20
ml). The organic phase was dried over sodium sulfate, filtered and
concentrated. The crude product was purified by prep-TLC (5%
methanol in dichloromethane) to afford
N-(1'-ethyl-6-morpholino-spiro[3H-benzofuran-2,4'-piperidine]-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide (32 mg, 15% yield) as a
white solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.43 (s,
1H), 9.36 (d, J=6.0 Hz, 1H), 8.96-8.91 (m, 1H), 8.67 (s, 1H), 8.30
(s, 1H), 7.34 (dd, J=6.8, 4.0 Hz, 1H), 6.75 (s, 1H), 3.90-3.81 (m,
4H), 2.98 (s, 2H), 2.81-2.79 (m, 4H), 2.60-2.55 (m, 2H), 2.40-2.37
(m, 4H), 1.84-1.74 (m, 4H), 1.01 (t, J=6.8 Hz, 3H). LCMS (ESI):
m/z=463.3 [M+H].sup.+.
TABLE-US-00021 TABLE 21 The following examples were made in a
manner similar to that for Example 502: Ex. Name Structure NMR, MS
503. N-(6-(4-((1H- imidazol-2- yl)methyl)piperazin-1-
yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01743## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 11.91 (s, 1H), 10.41 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.66 (s, 1H), 8.61 (dd, J = 4.2, 1.7 Hz, 1H),
8.32 (d, J = 1.0 Hz, 1H), 7.95 (s, 0H), 7.36 (dd, J = 7.0, 4.2 Hz,
1H), 7.09 (s, 1H), 6.89 (s, 1H), 6.68 (s, 1H), 3.66 (s, 2H), 3.17
(d, J = 5.2 Hz, 1H), 2.99 (d, J = 1.1 Hz, 2H), 2.85-2.79 (m, 4H),
2.70-2.61 (m, 4H), 1.41 (s, 6H). MS (ESI): m/z = 473.2 [M +
H].sup.+. 504. N-(6-(4- (isoxazol-4- ylmethyl)piperazin-
1-yl)-2,2-dimethyl- 2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01744## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.38 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.88 (s, 1H), 8.67 (s, 1H), 8.63 (dd, J = 4.2, 1.7 Hz, 1H),
8.59 (s, 1H), 8.29 (d, J = 1.0 Hz, 1H), 7.30 (dd, J = 7.0, 4.2 Hz,
1H), 6.69 (s, 1H), 3.55 (d, J = 0.8 Hz, 2H), 3.04- 2.93 (m, 2H),
2.82 (t, J = 4.6 Hz, 4H), 2.62 (d, J =5.9 Hz, 4H), 1.41 (s, 6H). MS
(ESI): m/z = 474.2 [M + H].sup.+. 505. N-(6-(4-((1H- pyrazol-5-
yl)methyl)piperazin- 1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01745## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.41 (s, 1H), 9.36 (dd, J =
7.3, 1.6 Hz, 1H), 8.66 (s, 1H), 8.42 (d, J = 33.5 Hz, 1H), 8.32 (d,
J = 1.0 Hz, 1H), 7.80-7.19 (m, 2H), 6.69 (s, 1H), 6.19 (s, 1H),
3.66 (d, J = 22.3 Hz, 2H), 3.17 (d, J = 5.3 Hz, 1H), 2.99 (d, J =
1.1 Hz, 2H), 2.81 (t, J = 4.7 Hz, 4H), 2.71-2.60 (m, 4H), 1.41 (s,
6H). MS (ESI): m/z = 73.2 [M + H].sup.+. 506. N-(2,2-
dimethyl-6-(4- ((1-methyl-1H- imidazol-5- yl)methyl)piperazin-
1-yl)-2,3- dihydrobenzofuran-5- yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01746## .sup.1H NMR (400 MHz, DMSO- d.sub.6)
.delta. 10.39 (s, 1H), 9.37 (dd, J = 7.0, 1.6 Hz, 1H), 8.80 (dd, J
= 4.2, 1.6 Hz, 1H), 8.67 (s, 1H), 8.31 (d, J = 1.0 Hz, 1H), 7.57
(dd, J = 1.1, 0.5 Hz, 1H), 7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.80 (d,
J = 1.1 Hz, 1H), 6.67 (s, 1H), 3.64 (d, J = 0.5 Hz, 3H), 3.58 (d, J
= 0.8 Hz, 2H), 2.99 (dd, J = 1.1, 0.6 Hz, 2H), 2.84-2.75 (m, 4H),
2.69-2.57 (m, 3H), 1.40 (s, 6H). MS (ESI): m/z = 487.2 [M +
H].sup.+. 507. N-(2,2- dimethyl-6-(4- ((2-methyl-1H- imidazol-4-
yl)methyl)piperazin- 1-yl)-2,3- dihydrobenzofuran-5-
yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01747## .sup.1H
NMR (400 MHz, DMSO- d.sub.6) .delta. 10.44 (s, 1H), 9.36 (dd, J =
7.0, 1.6 Hz, 1H), 8.66 (s, 1H), 8.46 (dd, J = 4.2, 1.6 Hz, 1H),
8.32 (d, J = 1.1 Hz, 1H), 7.30 (dd, J = 7.0, 4.2 Hz, 1H), 6.69 (s,
1H), 4.09 (m, 2H), 3.49 (s, 2H), 3.17 (d, J = 4.9 Hz, 3H), 2.79 (t,
J = 4.5 Hz, 4H), 2.64 (s, 4H), 2.25 (s, 3H), 1.41 (s, 6H). MS
(ESI): m/z = 487.2 [M + H].sup.+. 508. N-(6-(4- isopropylpiperazin-
1-yl)-2,2-dimethyl-2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01748## .sup.1H NMR (400 MHz,
DMSO- d.sub.6) .delta. 10.33 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz,
1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.25 (s, 1H),
7.36 (dd, J = 7.0, 4.2 Hz, 1H), 6.67 (s, 1H), 3.04- 2.96 (m, 2H),
2.85-2.75 (m, 3H), 2.72-2.61 (m, 5H), 1.41 (s, 6H), 1.02 (d, J =
6.5 Hz, 6H). MS (ESI): m/z = 435.2 [M + H].sup.+. 509.
N-(6-(4-((1H- imidazol-4- yl)methyl)piperazin- 1-yl)-2,2-dimethyl-
2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01749## .sup.1H NMR (400 MHz, DMSO- d.sub.6)
.delta. 10.43 (s, 1H), 9.36 (dd, J = 7.0, 1.6 Hz, 1H), 8.66 (s,
1H), 8.43 (dd, J = 4.2, 1.6 Hz, 1H), 8.34-8.26 (m, 1H), 7.62 (d, J
= 1.1 Hz, 1H), 7.32 (dd, J = 7.0, 4.2 Hz, 1H), 6.68 (s, 1H), 4.08
(s, 1H), 3.58 (s, 2H), 3.17 (d, J = 2.7 Hz, 2H), 2.99 (s, 2H),
2.84-2.71 (m, 4H), 2.70-2.59 (m, 4H), 1.40 (s, 6H). MS (ESI): m/z =
473.2 [M + H].sup.+.
Examples 510 and 511.
(R)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methylchroman-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methylchroman-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01750##
[2017] Step A:
7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-methyl-6-nitrochroman-3-ol
##STR01751##
[2019] To a stirred solution of
(6-fluoro-2-methyl-5-nitro-3H-benzofuran-2-yl)methanol (440 mg,
1.94 mmol) in dimethyl sulfoxide (8 ml) was added potassium
carbonate (669 mg, 4.84 mmol) and 1-(2,2-difluoroethyl)piperazine
(349 mg, 2.32 mmol). The mixture was stirred at 140.degree. C. for
72 h, diluted with water (30 ml) and extracted with ethyl acetate
(50 ml.times.3). The organic phase was separated and concentrated
to dryness. The crude product was purified by flash column
chromatography (0-50% ethyl acetate in petroleum ether) to give
7-(4-(2,2-difluoroethyl)
piperazin-1-yl)-3-methyl-6-nitrochroman-3-ol (600 mg, 86.7%) as a
yellow solid. LCMS (ESI): m/z=358.1 [M+H].sup.+.
Step B:
6-amino-7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-methylchroman-3--
ol
##STR01752##
[2021] To a solution of
7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-methyl-6-nitrochroman-3-ol
(600 mg, 1.68 mmol) in methanol (20 ml) was added 10% palladium on
carbon (268 mg, 0.25 mmol) at 25.degree. C. under H.sub.2 (15 psi).
The mixture was stirred for 12 h. The solution was filtered and
concentrated to afford
6-amino-7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-methylchroman-3-ol
(320 mg, 58%) as a white solid. LCMS (ESI): m/z=328.1
[M+H].sup.+.
Step C:
(S)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methyl-
chroman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methylchroman-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01753##
[2023] To a solution of
6-amino-7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-methylchroman-3-ol
(270 mg, 0.82 mmol) in pyridine (2 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (173 mg, 0.95 mmol).
The mixture was stirred at 28.degree. C. for 16 h. The solution was
concentrated and purified by chromatography on silica (solvent
gradient: 0-50% ethyl acetate in petroleum ether) and was further
resolved by chiral preparatory SFC to afford
(S)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methylchroman-
-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (98 mg, 22.1%;
RT=4.715 min) and
(R)--N-(7-(4-(2,2-difluoroethyl)piperazin-1-yl)-3-hydroxy-3-methylchr-
oman-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (100 mg, 24%;
RT=5.362 min) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[2024] Example 510, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.35 (s, 1H), 8.84 (dd, J=7.2, 1.6 Hz, 1H), 8.78 (s, 1H),
8.73 (dd, J=4.0, 2.0 Hz, 1H), 8.32 (s, 1H), 7.08 (dd, J=6.8, 4.4
Hz, 1H), 6.75 (s, 1H), 5.96 (tt, J=56.0, 4.4 Hz, 1H), 3.94 (d,
J=12.8 Hz, 1H), 3.83 (d, J=11.2 Hz, 1H), 3.00-2.80 (m, 12H), 2.18
(br s, 1H), 1.37 (s, 3H). LCMS (ESI): m/z=473.1 [M+H].sup.+.
[2025] Example 511, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.35 (s, 1H), 8.85 (dd, J=7.2, 1.6 Hz, 1H), 8.79 (s, 1H),
8.74 (dd, J=4.4, 2.0 Hz, 1H), 8.33 (s, 1H), 7.09 (dd, J=7.2, 4.8
Hz, 1H), 6.76 (s, 1H), 5.98 (tt, J=52.0, 4.4 Hz, 1H), 3.95 (d,
J=10.4 Hz, 1H), 3.84 (d, J=10.4 Hz, 1H), 3.00-2.80 (m, 12H), 2.13
(s, 1H), 1.38 (s, 3H). LCMS (ESI): m/z=473.1 [M+H].sup.+.
Examples 512 and 513.
(S)--N-(6-Cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((5-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(R)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((5-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01754##
[2026] Step A: Methyl
1-(2,4-dimethoxybenzyl)-5-oxopyrrolidine-3-carboxylate
##STR01755##
[2028] A solution of 2,4-dimethoxybenzylamine (7.0 g, 41.86 mmol)
and dimethyl itaconate (7.94 g, 50.24 mmol) in methanol (100 ml)
was stirred at 28.degree. C. for 14 h. The reaction mixture was
concentrated and the residue was purified by silica gel column
(10-20% ethyl acetate in petroleum ether) to afford methyl
1-(2,4-dimethoxybenzyl)-5-oxopyrrolidine-3-carboxylate (8 g, 65%)
as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.12 (d,
J=8.8 Hz, 1H), 6.45-6.42 (m, 2H), 4.45-4.40 (m, 2H), 3.79 (s, 6H),
3.69 (s, 3H), 3.46 (d, J=8.0 Hz, 2H), 3.18-3.14 (m, 1H), 2.70-2.63
(m, 2H).
Step B:
1-(2,4-Dimethoxybenzyl)-4-(hydroxymethyl)pyrrolidin-2-one
##STR01756##
[2030] To a solution of methyl
1-(2,4-dimethoxybenzyl)-5-oxopyrrolidine-3-carboxylate (5.0 g,
17.05 mmol) in tetrahydrofuran (60 ml) and methanol (30 ml) was
added lithium borohydride (928 mg, 42.62 mmol). The reaction was
stirred at 25.degree. C. for 2.5 h. The reaction was quenched with
water (50 ml) and extracted with ethyl acetate (150 ml.times.3).
The combined organic phase was washed with brine (60 ml.times.2),
dried over anhydrous sodium sulfate, filtered and concentrated to
afford 1-(2,4-dimethoxybenzyl)-4-(hydroxymethyl)pyrrolidin-2-one
(4.1 g, 91%) as a white solid. LCMS (ESI): m/z=266.2
[M+H].sup.+.
Step C: 1-(2,4-Dimethoxybenzyl)-4-(iodomethyl)pyrrolidin-2-one
##STR01757##
[2032] To a solution of
1-(2,4-dimethoxybenzyl)-4-(hydroxymethyl)pyrrolidin-2-one (4.1 g,
15.45 mmol), triphenylphosphine (6.1 g, 23.18 mmol) and imidazole
(3.16 g, 46.36 mmol) in dichloromethane (50 ml) was added iodine
(5.9 g, 23.18 mmol) at 26.degree. C. The mixture was stirred at
26.degree. C. under nitrogen for 16 h. The reaction was quenched
with saturated sodium sulfite solution (20 ml) and extracted with
dichloromethane (50 ml.times.3). The combined organic phase was
dried over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by flash column chromatography (0-5% Ethyl
acetate in dichloromethane) to afford
1-(2,4-dimethoxybenzyl)-4-(iodomethyl)pyrrolidin-2-one (1.6 g,
27.6%) as a yellow oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.13 (d, J=9.2 Hz, 1H), 6.46-6.43 (m, 2H), 4.41 (s, 2H), 3.81 (s,
3H), 3.80 (s, 3H), 3.42-3.38 (m, 1H), 3.22-3.14 (m, 2H), 3.02-2.98
(m, 1H), 2.62-2.57 (m, 2H), 2.24-2.18 (m, 1H).
Step D: Ethyl
5-((1-(2,4-Dimethoxybenzyl)-5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]py-
rimidine-3-carboxylate
##STR01758##
[2034] To a solution of zinc (362 mg, 5.54 mmol) in N,
N-dimethylacetamide (10 ml) was added chlorotrimethylsilane (0.11
ml, 0.85 mmol) and 1,2-dibromoethane (0.06 ml, 0.85 mmol) at
20.degree. C. under nitrogen. The resulting mixture was stirred at
20.degree. C. for 15 min. A solution of
1-[(2,4-dimethoxyphenyl)methyl]-4-(iodomethyl)pyrrolidin-2-one (1.6
g, 4.26 mmol) in N,N-dimethylacetamide (12 ml) was added
portionwise. The reaction mixture was stirred for 30 min to give a
solution of zinc reagent.
[2035] In another reaction vessel, to a solution of ethyl
5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate (520 mg, 1.94 mmol)
in N,N-dimethylacetamide (10 ml) was added cuprous iodide (74 mg,
0.39 mmol), 1,1'-Bis(diphenylphosphino)ferrocene palladium
dichloride (142 mg, 0.19 mmol). The mixture was purged with
nitrogen atmosphere three times and the freshly prepared
(1-(2,4-dimethoxybenzyl)-5-oxopyrrolidin-3-yl)zinc(II) iodide
solution was added dropwise. The reaction mixture was stirred at
80.degree. C. for 16 h under nitrogen. The reaction was quenched
with water (20 ml) and extracted with dichloromethane (20
ml.times.3). The combined organic phase was dried over anhydrous
sodium sulfate, filtered and concentrated. The residue was purified
by flash column chromatography (0-2% methanol in dichloromethane)
to afford ethyl
5-((1-(2,4-dimethoxybenzyl)-5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]py-
rimidine-3-carboxylate (800 mg, 94%) as a brown solid. LCMS (ESI):
m/z=439.0 [M+H].sup.+.
Step E: Ethyl
5-((5-Oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01759##
[2037] To ethyl
5-((1-(2,4-dimethoxybenzyl)-5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]py-
rimidine-3-carboxylate (400 mg, 0.91 mmol) was added
trifluoroacetic acid (8.0 ml, 107.70 mmol). The mixture was stirred
at 50.degree. C. for 16 h. The reaction was quenched with saturated
sodium bicarbonate solution to adjust pH to 7 and extracted with
dichloromethane (30 ml.times.3). The combined organic phase was
dried over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by flash column chromatography (0-10% methanol
in dichloromethane) to afford ethyl
5-((5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
(330 mg, 99%) as a white solid. LCMS (ESI): m/z=289.0
[M+H].sup.+.
Step F:
5-((5-Oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carbox-
ylic acid
##STR01760##
[2039] A mixture of lithium hydroxide hydrate (67 mg, 1.60 mmol)
and ethyl
5-((5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
(230 mg, 0.80 mmol) in tetrahydrofuran (6 ml), water (6 ml) and
methanol (3 ml) was stirred at 30.degree. C. for 1 h. The solution
was concentrated in vacuo to afford
5-((5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (200 mg, 96%) as a yellow solid which was used directly for
the next step without further purification. LCMS (ESI): m/z=261.0
[M+H].sup.+.
Step G:
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(5-oxopyrroli-
din-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01761##
[2041] To a solution of
5-((5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (200 mg, 0.77 mmol),
6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-amine (234 mg, 1.15
mmol) and
(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate
(481 mg, 0.92 mmol) in N,N-dimethylformamide (5 ml) was added
N,N-diisopropylethylamine (0.27 ml, 1.54 mmol). The mixture was
stirred at 25.degree. C. for 12 h. The reaction mixture was
concentrated and the residue was purified by flash column
chromatography (0-9% methanol in dichloromethane) to afford
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(5-oxopyrrolidin-3-y-
l)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (130 mg, 38%) as a
colorless oil.
Step H:
(S)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-(-
(5-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(R)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((5-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01762##
[2043]
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(5-oxopyrrolid-
in-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (130 mg,
0.29 mmol) was separated by chiral SFC (Chiralpak OJ 250
mm.times.30 mm.times.5 m; Supercritical
CO.sub.2/MeOH+NH.sub.3*H.sub.2O=30/30; 50 ml/min) to afford
(S)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((5-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (19
mg, 14%, RT=5.15 min) and
(R)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((5-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (15
mg, 11%, RT=5.58 min) as white solids with absolute stereochemistry
assigned arbitrarily.
[2044] Example 512, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.60 (s, 1H), 8.78-8.70 (m, 2H), 7.84 (s, 1H), 6.89 (d,
J=7.2 Hz, 1H), 6.48 (s, 1H), 5.58 (br s, 1H), 3.59-3.51 (m, 1H),
3.24-3.17 (m, 1H), 3.12-3.01 (m, 5H), 2.56-2.52 (m, 1H), 2.20-2.11
(m, 1H), 2.03-1.93 (m, 1H), 1.48 (s, 6H), 0.98-0.90 (m, 2H),
0.76-0.69 (m, 2H). LCMS (ESI): m/z=446.2 [M+H].sup.+.
[2045] Example 513, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.60 (s, 1H), 8.80-8.70 (m, 2H), 7.84 (s, 1H), 6.89 (d,
J=7.2 Hz, 1H), 6.48 (s, 1H), 5.48 (br s, 1H), 3.57-3.50 (m, 1H),
3.20-3.15 (m, 1H), 3.12-3.00 (m, 5H), 2.59-2.48 (m, 1H), 2.22-2.12
(m, 1H), 2.00-1.91 (m, 1H), 1.48 (s, 6H), 0.96-0.92 (m, 2H),
0.74-0.70 (m, 2H). LCMS (ESI): m/z=446.3 [M+H].sup.+.
Examples 514 and 515.
(R)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((2-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(S)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((2-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01763##
[2046] Step A: 1-tert-Butyl 3-methyl
2-oxopyrrolidine-1,3-dicarboxylate
##STR01764##
[2048] To a solution of 1-(tert-butoxycarbonyl)-2-pyrrolidinone
(2.3 g, 12.4 mmol) in tetrahydrofuran (100 ml) was added lithium
bis(trimethylsilyl)amide (1.0 M in THF, 16.1 ml, 16.14 mmol) at
-78.degree. C. dropwise under nitrogen. The reaction was stirred at
-78.degree. C. for 30 min. To the above solution was added methyl
chloroformate (1.72 ml, 22.22 mmol) dropwise. The mixture was
stirred at -78.degree. C. for 1 h, quenched with saturated ammonium
chloride solution (40 ml), and extracted with ethyl acetate (100
ml.times.3). The combined organic phase was washed with brine (100
ml.times.2), dried over sodium sulfate, filtered and concentrated.
The residue was purified by flash column chromatography (eluting
0-30% ethyl acetate in petroleum ether) to afford 1-tert-butyl
3-methyl 2-oxopyrrolidine-1,3-dicarboxylate (1.9 g, 63%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 3.89-3.78 (m, 1H), 3.74 (s, 3H),
3.72-3.69 (m, 1H), 3.56-3.53 (m, 1H), 2.41-2.37 (m, 1H), 2.26-2.21
(m, 1H), 1.53 (s, 9H).
Step B: Ethyl
5-(bromomethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01765##
[2050] To a solution of ethyl
5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (1.0 g, 4.87 mmol)
in carbon tetrachloride (20 ml) was added benzoylperoxide (118 mg,
0.49 mmol) and 1-bromo-2,5-pyrrolidinedione (954 mg, 5.36 mmol).
The mixture was stirred at 80.degree. C. for 16 h under nitrogen
protection and concentrated. The crude product was purified by
flash column chromatography (eluting 0-10% ethyl acetate in
petroleum ether) to afford ethyl
5-(bromomethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (580 mg,
42%) as a yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.72 (d, J=7.2 Hz, 1H), 8.57 (s, 1H), 7.21 (d, J=7.2 Hz, 1H), 4.65
(s, 2H), 4.42 (q, J=7.2 Hz, 2H), 1.42 (t, J=7.2 Hz, 3H).
Step C: 1-tert-Butyl 3-methyl 3-((3-(ethoxycarbonyl)pyrazolo[1,5-a]
pyrimidin-5-yl)methyl)-2-oxopyrrolidine-1,3-dicarboxylate
##STR01766##
[2052] To the solution of 1-tert-butyl 3-methyl
2-oxopyrrolidine-1,3-dicarboxylate (1.0 g, 4.12 mmol) and ethyl
5-(bromomethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (780 mg,
2.75 mmol) in acetonitrile (50 ml) was added potassium carbonate
(759 mg, 5.49 mmol). The mixture was stirred at 100.degree. C. for
2 h, diluted with water (150 ml) and extracted with dichloromethane
(50 ml.times.3). The combined organic phase was washed with brine
(50 ml.times.2), dried over anhydrous sodium sulfate, filtered and
concentrated. The residue was purified by flash column
chromatography (eluting 0-50% ethyl acetate in petroleum ether) to
afford 1-tert-butyl 3-methyl
3-((3-(ethoxycarbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)-2-oxopyrrolid-
ine-1,3-dicarboxylate (750 mg, 61%) as a yellow solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.59 (d, J=6.8 Hz, 1H), 8.49 (s, 1H),
6.94 (d, J=7.6 Hz, 1H), 4.38 (q, J=6.8 Hz, 2H), 3.91-3.80 (m, 3H),
3.72 (s, 3H), 3.32 (d, J=16.8 Hz, 1H), 2.93-2.89 (m, 1H), 2.42-2.36
(m, 1H), 1.52 (s, 9H), 1.39 (d, J=7.2 Hz, 3H).
Step D: Ethyl
5-((2-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate
##STR01767##
[2054] To a solution of 1-tert-butyl 3-methyl
3-((3-(ethoxycarbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)-2-oxopyrrolid-
ine-1,3-dicarboxylate (500.0 mg, 1.12 mmol) in
N,N-dimethylformamide (5 ml) was added lithium iodide (1.5 g, 11.2
mmol). The mixture was stirred at 150.degree. C. for 3 h, diluted
with water (30 ml) and extracted with dichloromethane (30
ml.times.3). The combined organic phase was washed with brine (30
ml.times.2), dried over sodium sulfate, filtered and concentrated.
The residue was purified by flash column chromatography (eluting 5%
methanol in dichloromethane) to afford ethyl
5-[(2-oxopyrrolidin-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate
(300 mg, 93%) as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.61 (d, J=6.8 Hz, 1H), 8.53 (s, 1H), 6.99 (d, J=7.2 Hz,
1H), 5.58 (br s, 1H), 4.40 (q, J=6.8 Hz, 2H), 3.53-3.50 (m, 1H),
3.41-3.38 (m, 2H), 3.11-3.06 (m, 2H), 2.61-2.58 (m, 1H), 2.09-2.03
(m, 1H), 1.42 (t, J=6.8 Hz, 3H).
Step E:
5-((2-Oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carbox-
ylic acid
##STR01768##
[2056] To a solution of ethyl
5-[(2-oxopyrrolidin-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxylate
(300 mg, 1.04 mmol) in ethanol (2 ml), water (2 ml) and
tetrahydrofuran (2 ml) was added lithium hydroxide monohydrate (131
mg, 3.12 mmol). The mixture was stirred at 30.degree. C. for 1 h
and concentrated in vacuo to afford
5-[(2-oxopyrrolidin-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carbox-
ylic acid (230 mg, 85%) as a white solid.
Step F:
N-(6-Cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(2-oxopyrroli-
din-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01769##
[2058] To a solution of
5-[(2-oxopyrrolidin-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxylic
acid (200.0 mg, 0.77 mmol),
6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-amine (187.46 mg, 0.92
mmol), and PyAOP (480.81 mg, 0.92 mmol) in N,N-dimethylformamide
(10 ml) was added N,N-diisopropylethylamine (198.64 mg, 1.54 mmol).
The mixture was stirred at 20.degree. C. for 12 h, diluted with
water (30 ml) and extracted with dichloromethane (30 ml.times.3).
The combined organic phase was washed with brine (30 ml.times.2),
dried over sodium sulfate, filtered and concentrated. The residue
was purified by flash column chromatography (eluting 0-10% methanol
in dichloromethane) to afford
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(2-oxopyrrolidin-3-y-
l)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (220 mg, 64%) as a
white solid. LCMS (ESI): m/z=446.3 [M+H].sup.+.
Step G:
(R)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-(-
(2-oxopyrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
(S)--N-(6-cyclopropyl-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)-5-((2-oxop-
yrrolidin-3-yl)methyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01770##
[2060]
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[(2-oxopyrrolid-
in-3-yl)methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (220 mg,
0.49 mmol) was resolved by chiral SFC (AD, 250 mm.times.30 mm, 10
.mu.m, supercritical CO.sub.2/ammonium hydroxide in ethanol=40/40,
60 ml/min) to give
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[[(3S)-2-oxopyrr-
olidin-3-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (38.34
mg, 17%; RT=4.633 min) and
N-(6-cyclopropyl-2,2-dimethyl-3H-benzofuran-5-yl)-5-[[(3R)-2-oxopyrrolidi-
n-3-yl]methyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (36.75 mg,
17%; RT=5.202 min) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[2061] Example 514, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.69 (s, 1H), 8.74 (s, 1H), 8.70 (d, J=7.2 Hz, 1H), 7.88
(s, 1H), 7.01 (d, J=7.2 Hz, 1H), 6.48 (s, 1H), 5.55 (s, 1H),
3.43-3.38 (m, 1H), 3.35-3.31 (m, 2H), 3.06-3.05 (m, 3H), 3.04-3.02
(m, 1H), 2.30-2.24 (m, 1H), 2.01-1.95 (m, 2H), 1.48 (s, 6H),
0.98-0.95 (m, 2H), 0.73-0.70 (m, 2H). LCMS (ESI): m/z=446.3
[M+H].sup.+.
[2062] Example 515, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.69 (s, 1H), 8.74 (s, 1H), 8.70 (d, J=7.2 Hz, 1H), 7.88
(s, 1H), 7.01 (d, J=7.2 Hz, 1H), 6.48 (s, 1H), 5.53 (s, 1H),
3.43-3.38 (m, 1H), 3.35-3.31 (m, 2H), 3.06-3.05 (m, 3H), 3.04-3.02
(m, 1H), 2.30-2.24 (m, 1H), 2.01-1.95 (m, 2H), 1.48 (s, 6H),
0.98-0.94 (m, 2H), 0.73-0.70 (m, 2H). LCMS (ESI): m/z=446.3
[M+H].sup.+.
Examples 516 and 517.
N-[(1S)-1-Hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,5-a]pyr-
imidine-3-carboxamide and
N-[(1R)-1-Hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,5-a]pyr-
imidine-3-carboxamide
##STR01771##
[2063] Step A: 5-Amino-2,2-dimethyl-6-morpholino-indan-1-ol
##STR01772##
[2065] To a stirred solution of
5-amino-2,2-dimethyl-6-morpholino-indan-1-one (150 mg, 0.6 mmol)
(Example 499, Step H) in tetrahydrofuran (9 ml) and methanol (3 ml)
was added sodium borohydride (65 mg, 1.7 mmol) at 0.degree. C. The
mixture was stirred under nitrogen at 0.degree. C. for 10 min, then
at 28.degree. C. for 8.5 h. The reaction mixture was quenched with
water (15 ml) and extracted with dichloromethane (50 ml.times.3).
The combined organic phase was dried over sodium sulfate, filtered
and concentrated to afford crude
5-amino-2,2-dimethyl-6-morpholino-indan-1-ol (150 mg, 99%) as a
light brown solid, which was used for the next step directly
without further purification.
[2066] LCMS (ESI): m/z=263.1 [M+H].sup.+.
Step B:
N-(1-Hydroxy-2,2-dimethyl-6-morpholino-2,3-dihydro-1H-inden-5-yl)p-
yrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01773##
[2068] A mixture of 5-amino-2,2-dimethyl-6-morpholino-indan-1-ol
(150.0 mg, 0.6 mmol) and pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (135.0 mg, 0.7 mmol) in pyridine (15 ml) was stirred at
28.degree. C. for 18 h and concentrated. The residue was purified
by flash column chromatography (0-2% methanol in dichloromethane)
to afford
N-(1-hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl)pyrazolo[1,5-a]pyrimidi-
ne-3-carboxamide (220.0 mg, 94%) as a light yellow solid. LCMS
(ESI): m/z=408.1 [M+H].sup.+.
Step C:
N-[(1S)-1-Hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,-
5-a]pyrimidine-3-carboxamide and
N-[(1R)-1-Hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,5-a]pyr-
imidine-3-carboxamide
##STR01774##
[2070]
N-(1-hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl)pyrazolo[1,5-a]py-
rimidine-3-carboxamide (220 mg, 0.5 mmol) was resolved by chiral
SFC (AD (250 mm.times.30 mm, 10 m); supercritical CO.sub.2 35%/0.1%
ammonium hydroxide in ethanol) to afford
N-[(1S)-1-hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,5-a]pyr-
imidine-3-carboxamide (59.4 mg, 27%; RT=4.667 min) and
N-[(1R)-1-hydroxy-2,2-dimethyl-6-morpholino-indan-5-yl]pyrazolo[1,5-a]pyr-
imidine-3-carboxamide (56.6 mg, 26%; RT=4.955 min) as light yellow
solids with absolute stereochemistry assigned arbitrarily.
[2071] Example 516, Peak 1: .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.13 (dd, J=7.2, 1.6 Hz, 1H), 8.93 (dd, J=4.0, 1.6 Hz, 1H),
8.66 (s, 1H), 8.31 (s, 1H), 7.31-7.27 (m, 2H), 4.61 (s, 1H),
3.99-3.95 (m, 4H), 2.95-2.90 (m, 4H), 2.77 (d, J=15.2 Hz, 1H), 2.64
(d, J=15.2 Hz, 1H), 1.18 (s, 3H), 1.03 (s, 3H). LCMS (ESI):
m/z=408.2 [M+H].sup.+.
[2072] Example 517, Peak 2: .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.13 (dd, J=7.2, 1.6 Hz, 1H), 8.94 (dd, J=4.0, 1.6 Hz, 1H),
8.67 (s, 1H), 8.32 (s, 1H), 7.32-7.28 (m, 2H), 4.61 (s, 1H),
3.99-3.95 (m, 4H), 2.95-2.90 (m, 4H), 2.77 (d, J=15.6 Hz, 1H), 2.64
(d, J=15.2 Hz, 1H), 1.18 (s, 3H), 1.03 (s, 3H). LCMS (ESI):
m/z=408.2 [M+H].sup.+.
Example 518.
N-(4-dimethylphosphoryl-2-morpholino-phenyl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide
##STR01775##
[2073] Step A: 4-(5-chloro-2-nitro-phenyl)morpholine
##STR01776##
[2075] To a solution of 4-chloro-2-fluoronitrobenzene (3.0 g, 17.09
mmol) in toluene (40 ml) was added potassium carbonate (2.36 g,
17.09 mmol) and morpholine (1.50 ml, 17.09 mmol). The reaction
mixture was stirred at 30.degree. C. for 16 h. The reaction was
quenched with water (200 ml) and extracted with ethyl acetate (200
ml.times.2). The combined organic phase was washed with water (400
ml.times.3) and brine (400 ml). The organic layer was separated,
dried over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by flash column chromatography on silica gel
(eluting with 0-9% ethyl acetate in petroleum ether) to afford
4-(5-chloro-2-nitro-phenyl) morpholine (3.9 g, 94%) as a red solid.
LCMS (ESI): m/z=242.9 [M+H].sup.+.
Step B: 4-(5-dimethylphosphoryl-2-nitro-phenyl)morpholine
##STR01777##
[2077] To a solution of 4-(5-chloro-2-nitro-phenyl)morpholine (500
mg, 2.06 mmol) in N,N-dimethyl formamide (5 ml) was added methyl
phosphonoylmethane (193 mg, 2.47 mmol), potassium phosphate
tribasic (481 mg, 2.27 mmol),
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (60 mg, 0.10 mmol)
and palladium(II) acetate (23 mg, 0.10 mmol). The reaction mixture
was stirred at 120.degree. C. for 16 h under nitrogen. The reaction
mixture was filtered and the filtrate was diluted with water (50
ml). The mixture was extracted with ethyl acetate (50 ml.times.3).
The combined organic phase was dried over anhydrous sodium sulfate,
filtered and concentrated. The residue was purified by flash column
chromatography (eluting with 0-100% ethyl acetate in petroleum
ether, then 0-10% methanol in dichloromethane) to afford
4-(5-dimethylphosphoryl-2-nitro-phenyl) morpholine (150 mg, 26%) as
a yellow solid. LCMS (ESI): m/z=285.0 [M+H].sup.+.
Step C: 4-dimethylphosphoryl-2-morpholino-aniline
##STR01778##
[2079] To a solution of
4-(5-dimethylphosphoryl-2-nitro-phenyl)morpholine (250 mg, 0.88
mmol) in ethanol (10 ml) and water (2 ml) was added iron (246 mg,
4.4 mmol) and ammonium chloride (0.15 mL, 4.4 mmol). The reaction
mixture was stirred at 80.degree. C. for 16 h under nitrogen. The
mixture was filtered and the filtrate was concentrated. The residue
was purified by prep-TLC (10% methanol in dichloromethane) to
afford 4-dimethylphosphoryl-2-morpholino-aniline (160 mg, 72%) as a
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.50-7.40
(m, 1H), 7.25-7.10 (m, 1H), 6.85-6.75 (m, 1H), 4.30 (s, 2H),
3.95-3.75 (m, 4H), 3.00-2.85 (m, 4H), 1.70 (s, 3H), 1.66 (s,
3H).
Step D:
N-(4-dimethylphosphoryl-2-morpholino-phenyl)pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide
##STR01779##
[2081] A mixture of pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride
(120 mg, 0.66 mmol) and 4-dimethylphosphoryl-2-morpholino-aniline
(120 mg, 0.47 mmol) in pyridine (2 ml) was stirred at 28.degree. C.
for 16 h. The reaction was concentrated and the residue was
purified by prep-TLC (10% methanol in dichloromethane) to obtain a
crude product which was triturated with methanol (5 ml) to afford
N-(4-dimethylphosphoryl-2-morpholino-phenyl)pyrazolo[1,5-a]pyrimidine-3-c-
arboxamide (97 mg, 51%) as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) 10.81 (s, 1H), 8.95-8.60 (m, 4H), 7.85-7.70 (m, 1H),
7.45-7.30 (m, 1H), 7.20-7.05 (m, 1H), 4.05-3.95 (m, 4H), 3.05-3.95
(m, 4H), 1.76 (s, 3H), 1.73 (s, 3H). LCMS (ESI): m/z=400.1
[M+H].sup.+.
Examples 519 and 520.
N-[(3R)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a-
]pyrimidine-3-carboxamide and
N-[(3S)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
##STR01780##
[2082] Step A: diethyl 2-(2,4-difluorobenzyl)-2-methylmalonate
##STR01781##
[2084] To a suspension of 60% sodium hydride (1.4 g, 34.5 mmol) in
N,N-dimethylformamide (100 ml) was added diethyl methyl malonate
(5.0 g, 28.7 mmol) dropwise at 0.degree. C. The mixture was stirred
at 0.degree. C. for 30 min, then 2,4-difluorobenzyl bromide (6.5 g,
31.6 mmol) in N, N-dimethylformamide (6 ml) was added dropwise. The
mixture was stirred from 0.degree. C. to 28.degree. C. for 2.5 h.
The reaction was quenched with saturated ammonium chloride solution
(10 ml) and extracted with ethyl acetate (100 ml.times.3). The
combined organic phase was dried over sodium sulfate, filtered and
concentrated. The residue was purified by flash column
chromatography (eluting 3-7% ethyl acetate in petroleum ether) to
give diethyl 2-[(2,4-difluorophenyl)methyl]-2-methyl-propanedioate
(8.4 g, 97%) as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 7.14-7.09 (m, 1H), 6.80-6.74 (m, 2H), 4.23-4.17 (m, 4H),
3.25 (s, 2H), 1.34 (s, 3H), 1.26 (t, J=7.2 Hz 6H).
Step B: 2-(2,4-difluorobenzyl)-2-methylpropane-1,3-diol
##STR01782##
[2086] To a stirred solution of diethyl
2-[(2,4-difluorophenyl)methyl]-2-methyl-propanedioate (6.4 g, 21.2
mmol) in tetrahydrofuran (70 ml) was added lithium aluminum hydride
(2.0 g, 53.0 mmol) in batches at -10.degree. C. The mixture was
stirred from -10.degree. C. to 25.degree. C. for 3.5 h. The
reaction was quenched with water (30 ml) and extracted with ethyl
acetate (100 ml.times.3). The combined organic phase was dried over
sodium sulfate, filtered and concentrated. The residue was purified
by flash column chromatography (eluting 20-60% ethyl acetate in
petroleum ether) to give
2-[(2,4-difluorophenyl)methyl]-2-methyl-propane-1,3-diol (4.5 g,
97%) as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.31-7.25 (m, 1H), 6.87-6.80 (m, 2H), 3.61-3.54 (m, 4H), 2.77 (s,
2H), 2.56 (s, 2H), 0.77 (s, 3H).
Step C: (7-fluoro-3-methylchroman-3-yl)methanol
##STR01783##
[2088] To a stirred solution of
2-[(2,4-difluorophenyl)methyl]-2-methyl-propane-1,3-diol (4.7 g,
21.6 mmol) in N,N-dimethylformamide (20 ml) and toluene (80 ml) was
added 60% sodium hydride in mineral oil (1.9 g, 47.6 mmol) at
0.degree. C. The reaction was heated at 100.degree. C. for 2 h
under nitrogen. The reaction was quenched with a saturated ammonium
chloride solution (25 ml) and extracted with dichloromethane (100
ml.times.3). The combined organic phase was dried over sodium
sulfate, filtered and concentrated. The residue was purified by
flash column chromatography (eluting 0-15% ethyl acetate in
petroleum ether) to afford (7-fluoro-3-methyl-chroman-3-yl)methanol
(3.9 g, 92%) as a light yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 6.98-6.94 (m, 1H), 6.61-6.53 (m, 2H), 4.06-4.03
(m, 1H), 3.80-3.77 (m, 1H), 3.55 (d, J=10.8 Hz, 1H), 3.46 (d,
J=10.8 Hz, 1H), 2.64 (d, J=16.8 Hz, 1H), 2.48 (d, J=16.0 Hz, 1H),
1.65 (s, 1H), 1.05 (s, 3H).
Step D: (7-fluoro-3-methylchroman-3-yl)methyl methanesulfonate
##STR01784##
[2090] To a stirred solution of
(7-fluoro-3-methyl-chroman-3-yl)methanol (3.4 g, 17.3 mmol) in
dichloromethane (60 ml) was added triethylamine (4.4 g, 43.3 mmol)
and methanesulfonyl chloride (3.2 g, 28.3 mmol) at 0.degree. C. The
mixture was stirred at 28.degree. C. for 2 h. The reaction was
quenched with water (50 ml) and extracted with dichloromethane (100
ml.times.3). The combined organic phases was dried over sodium
sulfate, filtered and concentrated to afford crude
(7-fluoro-3-methyl-chroman-3-yl)methyl methanesulfonate (4.9 g,
99%) as an orange oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
6.99-6.96 (m, 1H), 6.65-6.55 (m, 2H), 4.10 (d, J=10.4 Hz, 1H),
4.07-4.01 (m, 2H), 3.79 (d, J=10.8 Hz, 1H), 3.00 (s, 3H), 2.68 (d,
J=16.4 Hz, 1H), 2.61 (d, J=16.4 Hz, 1H), 1.14 (s, 3H).
Step E: 2-(7-fluoro-3-methylchroman-3-yl)acetonitrile
##STR01785##
[2092] To a stirred solution of
(7-fluoro-3-methyl-chroman-3-yl)methyl methanesulfonate (4.9 g,
17.9 mmol) in dimethyl sulfoxide (80 ml) was added potassium
cyanide (3.5 g, 53.4 mmol). The mixture was stirred at 110.degree.
C. for 17 h under nitrogen. The reaction was quenched with water
(100 ml) and extracted with ethyl acetate (100 ml.times.3). The
combined organic phase was dried over sodium sulfate, filtered and
concentrated. The residue was purified by flash column
chromatography (eluting 0-10% ethyl acetate in petroleum ether) to
afford 2-(7-fluoro-3-methyl-chroman-3-yl)acetonitrile (3.3 g, 90%)
as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.00-6.97 (m, 1H), 6.66-6.56 (m, 2H), 3.99-3.96 (m, 1H), 3.81 (d,
J=11.2 Hz, 1H), 2.70 (s, 2H), 2.40 (s, 2H), 1.24 (s, 3H).
Step F: 2-(7-fluoro-3-methyl-6-nitrochroman-3-yl)acetonitrile
##STR01786##
[2094] To a stirred solution of
2-(7-fluoro-3-methyl-chroman-3-yl)acetonitrile (1.5 g, 7.31 mmol)
in acetic acid (5 ml) and acetic anhydride (10 ml) was added
copper(II) nitrate (4.1 g, 21.9 mmol) at 0.degree. C. The mixture
was stirred at 0.degree. C. for 15 min and at 28.degree. C. for 0.5
h. Water (100 ml) was added and extracted with ethyl acetate (100
ml.times.3). The combined organic phase was washed with saturated
sodium bicarbonate solution (100 ml.times.3), dried over sodium
sulfate, filtered and concentrated. The residue was purified by
flash column chromatography (eluting 15-30% ethyl acetate in
petroleum ether) to give 2-(7-fluoro-3-methyl-6-nitro-chroman-3-yl)
acetonitrile (1.8 g, 98%) as a light yellow solid.
Step G:
2-(3-methyl-7-morpholino-6-nitrochroman-3-yl)acetonitrile
##STR01787##
[2096] To a stirred solution of
2-(7-fluoro-3-methyl-6-nitro-chroman-3-yl)acetonitrile (1.5 g, 6.1
mmol) in dimethyl sulfoxide (30 ml) was added
N,N-diisopropylethylamine (2.4 g, 18.4 mmol) and morpholine (1.1 g,
12.3 mmol). The mixture was stirred at 90.degree. C. for 16 h under
nitrogen. Water (100 ml) was added, and the mixture was extracted
with ethyl acetate (200 ml.times.3), dried over sodium sulfate,
filtered and concentrated. The residue was purified by flash column
chromatography (10-20% ethyl acetate in petroleum ether) to give
2-(3-methyl-7-morpholino-6-nitro-chroman-3-yl)acetonitrile (640 mg,
33%) as a yellow oil. .sup.1H NMR (400 MHz, CDl.sub.3) .delta. 7.75
(s, 1H), 6.53 (s, 1H), 4.07 (d, J=11.2 Hz, 1H), 3.87 (d, J=12.4 Hz,
1H), 3.86-3.83 (m, 4H), 3.02-2.99 (m, 4H), 2.71 (s, 2H), 2.45-2.33
(m, 2H), 1.25 (s, 3H).
Step H:
2-(6-amino-3-methyl-7-morpholinochroman-3-yl)acetonitrile
##STR01788##
[2098] To a stirred solution of
2-(3-methyl-7-morpholino-6-nitro-chroman-3-yl)acetonitrile (300 mg,
1.0 mmol) in ethanol (20 ml) and water (4 ml) was added iron (264
mg, 4.7 mmol) and ammonium chloride (253 mg, 4.7 mmol). The mixture
was stirred at 80.degree. C. for 2 h under nitrogen. The mixture
was filtered and the filtrate was concentrated. The residue was
purified by column chromatography (eluting 20-70% ethyl acetate in
petroleum ether) to afford
2-(6-amino-3-methyl-7-morpholino-chroman-3-yl)acetonitrile (270 mg,
99%) as a reddish purple solid. LCMS (ESI): m/z=288.0
[M+H].sup.+.
Step I:
2-(3-methyl-7-morpholino-6-nitrochroman-3-yl)acetonitrile
##STR01789##
[2100] To a stirred solution of
2-(6-amino-3-methyl-7-morpholino-chroman-3-yl)acetonitrile (220.0
mg, 0.8 mmol) in pyridine (25 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (167 mg, 0.9 mmol).
The mixture was stirred at 25.degree. C. for 2 h and concentrated.
The residue was purified by column chromatography (eluting 0-1%
methanol in dichloromethane) to give
N-[3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a]pyri-
midine-3-carboxamide (340.0 mg, 99%) as a yellow solid. LCMS (ESI):
m/z=433.2 [M+H].sup.+.
Step J:
N-[(3R)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazol-
o[1,5-a]pyrimidine-3-carboxamide and
N-[(3S)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a-
]pyrimidine-3-carboxamide
##STR01790##
[2102]
N-[3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5--
a]pyrimidine-3-carboxamide (340 mg, 0.8 mmol) was resolved by
chiral preparatory SFC to afford
N-[(3R)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a-
]pyrimidine-3-carboxamide (124.8 mg, 36%; RT=3.341 min) and
N-[(3S)-3-(cyanomethyl)-3-methyl-7-morpholino-chroman-6-yl]pyrazolo[1,5-a-
]pyrimidine-3-carboxamide (113.1 mg, 33%; RT=4.977 min) as light
yellow solids with absolute stereochemistry assigned
arbitrarily.
[2103] Example 519, Peak 1: .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.14 (d, J=6.8 Hz, 1H), 8.93 (s, 1H), 8.67 (s, 1H), 8.17
(s, 1H), 7.29 (s, 1H), 6.77 (s, 1H), 4.05-3.91 (m, 5H), 3.83 (d,
J=10.8 Hz, 1H), 3.00-2.84 (m, 4H), 2.77 (d, J=16.4 Hz, 1H), 2.71
(d, J=17.6 Hz, 1H), 2.54 (s, 2H), 1.21 (s, 3H). LCMS (ESI):
m/z=433.2 [M+H].sup.+.
[2104] Example 520, Peak 2: .sup.1H NMR (400 MHz, CD.sub.3OD) for
second peak on SFC: 9.14 (d, J=5.6 Hz, 1H), 8.92 (s, 1H), 8.67 (s,
1H), 8.17 (s, 1H), 7.29 (s, 1H), 6.77 (s, 1H), 4.00-3.91 (m, 5H),
3.84 (d, J=11.2 Hz, 1H), 2.96-2.86 (m, 4H), 2.77 (d, J=17.2 Hz,
1H), 2.71 (d, J=17.2 Hz, 1H), 2.54 (s, 2H), 1.21 (s, 3H). LCMS
(ESI): m/z=433.2 [M+H].sup.+.
Example 521.
N-[6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindolin-5-
-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01791##
[2105] Step A: Methyl 4-amino-5-chloro-2-methyl-benzoate
##STR01792##
[2107] To a solution of methyl 5-chloro-2-methyl-4-nitro-benzoate
(600 mg, 2.61 mmol) in ethanol (10 ml) and water (2 ml) was added
iron (729.7 mg, 13.07 mmol) and ammonium chloride (699 mg, 13.07
mmol). The mixture was stirred at 80.degree. C. for 2 h. The
reaction mixture was filtered and concentrated. The residue was
purified by flash column chromatography (0-10% ethyl acetate in
petroleum ether) to afford methyl
4-amino-5-chloro-2-methyl-benzoate (450 mg, 86%) as a white solid.
LCMS (ESI): m/z=199.8 [M+H].sup.+.
Step B: Methyl
5-chloro-2-methyl-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)benzoate
##STR01793##
[2109] To a solution of methyl 4-amino-5-chloro-2-methyl-benzoate
(400 mg, 2.0 mmol) in tetrahydrofuran (20 ml) was added sodium
hydride (60% in mineral oil, 160 mg, 4.0 mmol) at 25.degree. C.
After stirring at 25.degree. C. for 30 min,
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (546 mg, 3.0 mmol)
was added to the solution. The reaction mixture was stirred at
25.degree. C. for 4 h. The reaction was diluted with water (10 ml)
and extracted with dichloromethane (20 ml.times.3). The combined
organic phase was washed with brine (20 ml.times.3), dried over
anhydrous sodium sulfate, filtered and concentrated. The residue
was triturated with methanol to afford methyl
5-chloro-2-methyl-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)benzoate
(77 mg, 11%) as a yellow solid. LCMS (ESI): m/z=345.0
[M+H].sup.+.
Step C: Methyl
2-(bromomethyl)-5-chloro-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)ben-
zoate
##STR01794##
[2111] To a solution of methyl
5-chloro-2-methyl-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)benzoate
(77 mg, 0.22 mmol) in acetonitrile (10 ml) was added
2,2'-azobis(2-methylpropionitrile) (4 mg, 0.02 mmol) and
1-bromo-2,5-pyrrolidinedione (44 mg, 0.25 mmol) under nitrogen. The
mixture was stirred at 80.degree. C. for 16 h and concentrated. The
residue was purified by flash column chromatography (0-10% methanol
in dichloromethane) to afford methyl
2-(bromomethyl)-5-chloro-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)ben-
zoate (40 mg, 42% yield) as a white solid. LCMS (ESI): m/z=424.8
[M+H].sup.+.
Step D:
N-[6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoin-
dolin-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01795##
[2113] To a solution of methyl
2-(bromomethyl)-5-chloro-4-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)ben-
zoate (40 mg, 0.09 mmol) and
(3R)-4-amino-3-fluoro-2-methyl-butan-2-ol (14 mg, 0.11 mmol) in
methanol (10 ml) was added triethylamine (0.04 ml, 0.28 mmol). The
reaction was stirred at 70.degree. C. for 2 h and concentrated. The
residue was purified by prep-TLC (10% methanol in dichloromethane)
to afford
N-[6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-1-oxo-isoindolin-5-
-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (20 mg, 47%) as a white
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.63 (s, 1H),
8.88-8.85 (m, 2H), 8.79-8.77 (m, 2H), 7.91 (s, 1H), 7.13-7.09 (m,
1H), 4.67-4.46 (m, 3H), 4.28-4.15 (m, 1H), 3.71-3.60 (m, 1H), 2.44
(s, 1H), 1.35 (s, 3H), 1.33 (s, 3H). LCMS (ESI): m/z=432.0
[M+H].sup.+.
Examples 522 and 523.
N-[(2R)-2-(1-Hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)piperaz-
in-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxami-
de and
N-[(2S)-2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)p-
iperazin-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-car-
boxamide
##STR01796##
[2114] Step A:
2-[6-[4-(1H-Imidazol-4-ylmethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzo-
furan-2-yl]propan-2-ol
##STR01797##
[2116] To a solution of 1H-imidazole-4-carbaldehyde (44 mg, 0.47
mmol) in methanol (5 ml), acetic acid (0.25 ml) and dichloromethane
(5 ml) was added
2-(2-methyl-5-nitro-6-piperazin-1-yl-3H-benzofuran-2-yl)propan-2-ol
(100 mg, 0.31 mmol). The mixture was stirred at 25.degree. C. for 1
h when sodium cyanoborohydride (29 mg, 0.47 mmol) was added. The
reaction was stirred at 25.degree. C. for 16 h. The reaction was
diluted with water (20 ml) and extracted with dichloromethane (50
ml.times.2). The organic phase was washed with brine (50
ml.times.2), dried over sodium sulfate, filtered and concentrated.
The residue was purified by flash column chromatography (10%
methanol in dichloromethane) to afford
2-[6-[4-(1H-imidazol-4-ylmethyl)
piperazin-1-yl]-2-methyl-5-nitro-3H-benzofuran-2-yl]propan-2-ol
(100 mg, 80% yield) as a yellow solid. LCMS (ESI): m/z=402.3
[M+H].sup.-.
Step B:
2-[5-Amino-6-[4-(1H-imidazol-4-ylmethyl)piperazin-1-yl]-2-methyl-3-
H-benzofuran-2-yl] propan-2-ol
##STR01798##
[2118] To a solution of
2-[6-[4-(1H-imidazol-4-ylmethyl)piperazin-1-yl]-2-methyl-5-nitro-3H-benzo-
furan-2-yl]propan-2-ol (510 mg, 1.27 mmol) in ethanol (10 ml) and
water (2 ml) was added iron (354 mg, 6.35 mmol) and ammonium
chloride (339 mg, 6.35 mmol). The reaction was stirred at
80.degree. C. for 2 h. The reaction was filtered and concentrated.
The residue was taken up in dichloromethane (80 ml.times.2), washed
with saturated brine solution (80 ml), dried over sodium sulfate
and concentrated to give
2-[5-amino-6-[4-(1H-imidazol-4-ylmethyl)piperazin-1-yl]-2-methyl-3H-benzo-
furan-2-yl]propan-2-ol (450 mg, 95% yield) as a yellow solid. LCMS
(ESI): m/z=372.0 [M+H].sup.+.
Step C:
N-[2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)piper-
azin-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxa-
mide
##STR01799##
[2120] To a solution of pyrazolo[1,5-a]pyrimidine-3-carbonyl
chloride (263 mg, 1.45 mmol) in pyridine (10 ml) was added
2-[5-amino-6-[4-(1H-imidazol-4-ylmethyl)piperazin-1-yl]-2-methyl-3H-benzo-
furan-2-yl]propan-2-ol (450 mg, 1.21 mmol). The reaction mixture
was stirred at 50.degree. C. for 16 h. The reaction were
concentrated and purified by flash column chromatography (10%
methanol in dichloromethane) to give
N-[2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-yl
methyl)piperazin-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimid-
ine-3-carboxamide (480 mg, 76% yield) as a yellow solid. LCMS
(ESI): m/z=517.3 [M+H].sup.+.
Step D:
N-[(2R)-2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)-
piperazin-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-ca-
rboxamide and
N-[(2S)-2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)piperaz-
in-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxami-
de
##STR01800##
[2122]
N-[2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)pipera-
zin-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide (480 mg, 0.93 mmol) was resolved by chiral preparatory SFC to
afford
N-[(2R)-2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)piperaz-
in-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxami-
de (121 mg, 25%) and
N-[(2S)-2-(1-hydroxy-1-methyl-ethyl)-6-[4-(1H-imidazol-4-ylmethyl)piperaz-
in-1-yl]-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxami-
de (161 mg, 33%) as yellow solids with absolute stereochemistry
assigned arbitrarily.
[2123] Example 522, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.37 (s, 1H), 8.78 (d, J=6.8 Hz, 1H), 8.71 (s, 1H),
8.49-8.44 (m, 1H), 8.35 (s, 1H), 7.60 (s, 1H), 7.11-7.01 (m, 1H),
6.93 (s, 1H), 6.60 (s, 1H), 3.63 (s, 2H), 3.51 (d, J=15.6 Hz, 1H),
2.97-2.59 (m, 10H), 1.40 (s, 3H), 1.38 (s, 3H), 1.25 (s, 3H). LCMS
(ESI): m/z=517.2 [M+H].sup.+.
[2124] Example 523, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.40 (s, 1H), 8.80 (d, J=6.8 Hz, 1H), 8.75 (s, 1H),
8.57-8.51 (m, 1H), 8.38 (s, 1H), 7.62 (s, 1H), 7.11-7.02 (m, 1H),
6.97 (s, 1H), 6.64 (s, 1H), 3.65 (s, 2H), 3.51 (d, J=15.6 Hz, 1H),
2.98-2.58 (m, 10H), 1.41 (s, 3H), 1.38 (s, 3H), 1.26 (s, 3H). LCMS
(ESI): m/z=517.1 [M+H].sup.+.
Examples 524 and 525.
N-[(2S)-6-[4-(2-amino-2-oxo-ethyl)piperazin-1-yl]-2-(1-hydroxy-1-methyl-e-
thyl)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
and
N-[(2R)-6-[4-(2-amino-2-oxo-ethyl)piperazin-1-yl]-2-(1-hydroxy-1-meth-
yl-ethyl)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxam-
ide
##STR01801##
[2126]
N-[6-[4-(2-amino-2-oxo-ethyl)piperazin-1-yl]-2-(1-hydroxy-1-methyl--
ethyl)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
(Example 356) (650 mg, 1.32 mmol) was resolved by chiral SFC (OD
(250 mm.times.30 mm, 5 .mu.m), 45%/0.1% NH.sub.3H.sub.2O in MeOH)
to afford
N-[(2S)-6-[4-(2-amino-2-oxo-ethyl)piperazin-1-yl]-2-(1-hydroxy-1-methyl-e-
thyl)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
(271.7 mg, 41.4%; RT=5.11 min) and
N-[(2R)-6-[4-(2-amino-2-oxo-ethyl)piperazin-1-yl]-2-(1-hydroxy-1-methyl-e-
thyl)-2-methyl-3H-benzofuran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
(278.4 mg, 42.4%; RT=5.99 min) as yellow solids with absolute
stereochemistry assigned arbitrarily.
[2127] Example 524, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.40 (s, 1H), 9.36 (dd, J=6.8, 1.6 Hz, 1H), 8.97 (dd,
J=4.0, 1.6 Hz, 1H), 8.67 (s, 1H), 8.31 (s, 1H), 7.35 (dd, J=6.8,
4.0 Hz, 1H), 7.23 (s, 1H), 7.17 (s, 1H), 6.68 (s, 1H), 4.52 (s,
1H), 3.45 (d, J=15.6 Hz, 1H), 3.01 (s, 2H), 2.90-2.80 (m, 4H),
2.75-2.65 (m, 5H), 1.32 (s, 3H), 1.17 (s, 3H), 1.15 (s, 3H). LCMS
(ESI): m/z=494.2 [M+H].sup.+.
[2128] Example 525, Peak 2: .sup.1H NMR (400 MHz, DMSO-d6) .delta.
10.38 (s, 1H), 9.34 (dd, J=7.2, 1.6 Hz, 1H), 8.95 (dd, J=4.4, 1.6
Hz, 1H), 8.65 (s, 1H), 8.29 (s, 1H), 7.33 (dd, J=7.2, 4.4 Hz, 1H),
7.21 (s, 1H), 7.15 (s, 1H), 6.66 (s, 1H), 4.50 (s, 1H), 3.43 (d,
J=16.0 Hz, 1H), 2.99 (s, 2H), 2.90-2.80 (m, 4H), 2.75-2.65 (m, 5H),
1.30 (s, 3H), 1.15 (s, 3H), 1.14 (s, 3H). LCMS (ESI): m/z=494.2
[M+H].sup.+.
Examples 526 and 527.
(N-[(2R)-2-(2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide and
(N-[(2S)-2-(2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01802##
[2130]
N-[2-(2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzofura-
n-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (180 mg, 0.40 mmol)
was prepared following the procedure described for Example 6, from
1-(2,4-difluorophenyl)-2,4-dimethyl-pentane-2,4-diol. It was
resolved by chiral SFC (Chiralpak AD 100.times.4.6 mm.times.3 m;
40%/0.05% DEA in ethanol) to afford
N-[(2R)-2-(2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzofuran-
-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (60 mg, 33.3%;
RT=4.731 min) and
N-[(2S)-2-(2-hydroxy-2-methyl-propyl)-2-methyl-6-morpholino-3H-benzof-
uran-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (50 mg, 27.8%;
RT=5.207 min) as light yellow solids with absolute stereochemistry
assigned arbitrarily.
[2131] Example 526, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.46 (s, 1H), 8.85-8.81 (m, 1H), 8.80-8.76 (m, 2H), 8.42
(s, 1H), 7.06 (dd, J=6.8, 4.4 Hz, 1H), 6.66 (s, 1H), 3.99-3.88 (m,
4H), 3.31 (d, J=15.6 Hz, 1H), 3.05 (br s, 1H), 2.98 (d, J=15.6 Hz,
1H), 2.92-2.90 (m, 4H), 2.05 (s, 2H), 1.52 (s, 3H), 1.32 (s, 3H),
1.27 (s, 3H). LCMS (ESI): m/z=452.1 [M+H].sup.+.
[2132] Example 527, Peak 2: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.46 (s, 1H), 8.83 (dd, J=6.8, 2.0 Hz, 1H), 8.80-8.76 (m,
2H), 8.42 (s, 1H), 7.06 (dd, J=7.2, 4.0 Hz, 1H), 6.66 (s, 1H),
3.98-3.90 (m, 4H), 3.31 (d, J=15.6 Hz, 1H), 3.04 (s, 1H), 2.98 (d,
J=15.6 Hz, 1H), 2.92-2.90 (m, 4H), 2.06 (s, 2H), 1.52 (s, 3H), 1.33
(s, 3H), 1.27 (s, 3H). LCMS (ESI): m/z=452.1 [M+H].sup.+.
Example 528.
(R)--N-(6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)-1-oxoisoindolin-5-yl-
)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01803##
[2133] Step A:
(R)-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitro-6-vinylisoindolin-1-one
##STR01804##
[2135] To a solution of
6-chloro-2-[(2R)-2-fluoro-3-hydroxy-3-methyl-butyl]-5-nitro-isoindolin-1--
one (100 mg, 0.32 mmol) in 1,4-dioxane (3 ml) and water (0.5 ml)
was added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (80 mg,
0.47 mmol), palladium(II) acetate (7 mg, 0.03 mmol),
2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (26 mg, 0.06 mmol)
and potassium phosphate (201 mg, 0.95 mmol). The mixture was
stirred at 90.degree. C. for 30 min under microwave condition and
concentrated. The residue was dissolved in ethyl acetate (50 ml),
and washed with water (40 ml) and brine (40 ml). The organic phase
was dried over anhydrous sodium sulfate, filtered and concentrated.
The residue was purified by flash column chromatography (50% ethyl
acetate in petroleum ether) to afford
(R)-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitro-6-vinylisoindolin-1-one
(90 mg, 93%) as colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.11 (s, 1H), 7.98 (s, 1H), 7.13 (dd, J=17.6, 11.2 Hz, 1H),
5.89 (d, J=16.8 Hz, 1H), 5.58 (d, J=11.2 Hz, 1H), 4.74 (d, J=18.0
Hz, 1H), 4.63-4.45 (m, 2H), 4.35-4.21 (m, 1H), 3.72-3.64 (m, 1H),
2.15 (s, 1H), 1.35 (s, 6H).
[2136] LCMS (ESI): m/z=309 [M+H].sup.+.
Step B:
(R)-5-amino-6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)isoindolin-
-1-one
##STR01805##
[2138] To a stirred solution of
(R)-5-amino-2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-vinylisoindolin-1-one
(90 mg, 0.29 mmol) in methanol (10 ml) was added 10% palladium on
carbon (31 mg, 0.029 mmol). The mixture was stirred at 26.degree.
C. under hydrogen atmosphere (15 psi) for 2 h. The mixture was
filtered and the filtrate was concentrated to afford
(R)-5-amino-6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)isoindolin-1-one
(75 mg, 92%) as colorless oil. LCMS (ESI): m/z=281 [M+H].sup.+.
Step C:
(R)--N-(6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)-1-oxoisoindol-
in-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01806##
[2140] To a solution of
(R)-5-amino-6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)
isoindolin-1-one (75 mg, 0.27 mmol) in pyridine (2 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (63 mg, 0.35 mmol).
The mixture was stirred at 26.degree. C. for 16 h and concentrated.
The residue was purified by prep-TLC (9% methanol in
dichloromethane) to afford
(R)--N-(6-ethyl-2-(2-fluoro-3-hydroxy-3-methylbutyl)-1-oxoisoindol-
in-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (54 mg, 46%) as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.11 (s,
1H), 8.87 (dd, J=7.2, 1.6 Hz, 1H), 8.79 (s, 1H), 8.74 (dd, J=4.4,
2.0 Hz, 1H), 8.64 (s, 1H), 7.72 (s, 1H), 7.10 (dd, J=7.2, 4.4 Hz,
1H), 4.67-4.44 (m, 3H), 4.28-4.12 (m, 1H), 3.73-3.63 (m, 1H), 2.95
(q, J=7.2 Hz, 2H), 2.61 (s, 1H), 1.39 (t, J=7.2 Hz, 3H), 1.34 (s,
3H), 1.32 (s, 3H). LCMS (ESI): m/z=426.1 [M+H].sup.+.
Example 529.
(R)--N-(2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropyl-1-oxoisoindolin--
5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01807##
[2141] Step A:
(R)-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitro-6-(prop-1-en-2-yl)
isoindolin-1-one
##STR01808##
[2143] To a solution of
(R)-6-chloro-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitroisoindolin-1-one
(100 mg, 0.32 mmol) in 1,4-dioxane (3 ml) and water (0.5 ml) was
added 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane
(80 mg, 0.47 mmol), palladium(II) acetate (7 mg, 0.03 mmol),
2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (26 mg, 0.06 mmol)
and potassium phosphate (201 mg, 0.95 mmol). The mixture was
stirred at 90.degree. C. for 30 min under microwave condition and
concentrated. The residue was dissolved in ethyl acetate (50 ml),
washed with water (40 ml) and brine (40 ml). The organic phase was
dried over anhydrous sodium sulfate, filtered and concentrated. The
residue was purified by flash column chromatography (50% ethyl
acetate in petroleum ether) to afford
(R)-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitro-6-(prop-1-en-2-yl)isoind-
olin-1-one (80 mg, 78%) as a colorless oil. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.91 (s, 1H), 7.82 (s, 1H), 5.24 (s, 1H), 4.99
(s, 1H), 4.73 (d, J=17.6 Hz, 1H), 4.65-4.45 (m, 2H), 4.37-4.21 (m,
1H), 3.72-3.65 (m, 1H), 2.13 (s, 3H), 1.35 (s, 6H). LCMS (ESI):
m/z=323.0 [M+H].sup.+.
Step B:
(R)-5-amino-2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropylisoind-
olin-1-one
##STR01809##
[2145] To a stirred solution of
(R)-2-(2-fluoro-3-hydroxy-3-methylbutyl)-5-nitro-6-(prop-1-en-2-yl)isoind-
olin-1-one (120 mg, 0.37 mmol) in methanol (10 ml) was added 10%
palladium on carbon (40 mg, 0.029 mmol). The mixture was stirred at
26.degree. C. under hydrogen atmosphere (15 psi) for 2 h. The
reaction mixture was filtered and the filtrate was concentrated to
afford
(R)-5-amino-2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropylisoindolin-1--
one (96 mg, 88%) as a colorless oil. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.64 (s, 1H), 6.69 (s, 1H), 4.60-4.29 (m, 3H),
4.24-3.98 (m, 3H), 3.70-3.55 (m, 1H), 3.94-2.83 (m, 1H), 2.62 (s,
1H), 1.32-1.29 (m, 12H).
Step C:
(R)--N-(2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropyl-1-oxoisoi-
ndolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
##STR01810##
[2147] To a solution of
(R)-5-amino-2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropylisoindolin-1--
one (96 mg, 0.33 mmol) in pyridine (2 ml) was added
pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (77 mg, 0.42 mmol).
The mixture was stirred at 26.degree. C. for 16 h and concentrated.
The residue was purified by prep-TLC (9% methanol in
dichloromethane) to afford
(R)--N-(2-(2-fluoro-3-hydroxy-3-methylbutyl)-6-isopropyl-1-oxoisoi-
ndolin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (57 mg, 39%) as
a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.14 (s,
1H), 8.88 (dd, J=6.8, 1.6 Hz, 1H), 8.80 (s, 1H), 8.74 (dd, J=4.4,
2.0 Hz, 1H), 8.56 (s, 1H), 7.84 (s, 1H), 7.10 (dd, J=7.2, 4.4 Hz,
1H), 4.68-4.43 (m, 3H), 4.27-4.10 (m, 1H), 3.76-3.65 (m, 1H),
3.51-3.42 (m, 1H), 2.47 (s, 1H), 1.47 (d, J=6.8 Hz, 6H), 1.34 (s,
3H), 1.32 (s, 3H). LCMS (ESI): m/z=440.1 [M+H].sup.+.
Example 530.
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazol-
o[1,5-a]pyrimidine-3-carboxamide
##STR01811##
[2149] To a solution of
6-bromo-N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[-
1,5-a]pyrimidine-3-carboxamide (200 mg, 0.42 mmol) in methanol (10
ml) was added potassium hydroxide (143 mg, 2.54 mmol). The mixture
was stirred at 65.degree. C. for 72 h and concentrated. The residue
was dissolved in water (20 ml) and washed with dichloromethane (30
ml.times.3). The aqueous phase was acidified to pH=3 with 2N HCl
aqueous solution, and extracted with 20% methanol in
dichloromethane (20 ml.times.3). The combined organic phase was
dried over anhydrous sodium sulfate, filtered and concentrated to
afford
N-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazol-
o[1,5-a]pyrimidine-3-carboxamide (40 mg, 22%) as a yellow solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.33 (s, 1H),
8.76-8.72 (m, 2H), 8.49 (s, 1H), 8.29 (s, 1H), 6.70 (s, 1H), 3.82
(s, 4H), 2.99 (s, 2H), 2.80 (s, 4H), 1.41 (s, 6H). LCMS (ESI):
m/z=410.0 [M+H].sup.+.
TABLE-US-00022 TABLE 22 The following examples were made in a
manner similar to that for Example 4: Ex. Name Structure NMR, MS
531 N-[6-(4- carbamoyl-1- piperidyl)-2,2- dimethyl-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01812## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.71 (s,
1H), 9.19 (dd, J = 4.0, 1.6 Hz, 1H), 8.79 - 8.77 (m, 2H), 8.55 (s,
1H), 7.08 (dd, J = 7.2, 4.4 Hz, 1H), 6.63 (s, 1H), 5.54-5.52 (m,
1H), 5.31-5.29 (m, 1H), 3.14-3.11 (m, 2H), 3.04 (s, 2H), 2.73-2.67
(m, 2H), 2.35-2.30 (m, 3H), 1.92-1.90 (m, 2H), 1 49 (s, 6H). LCMS
(ESI): m/z = 435.1 [M + H].sup.+. 532 N-[6-[4- (dimethylamino)-
1-piperidyl]- 2,2-dimethyl- 3H-benzofuran- 5-yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01813## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.43 (s, 1H), 8.83-8.78 (m, 3H), 8.38 (s, 1H),
7.04 (dd, J = 7.2, 4.4 Hz, 1H), 6.64 (s, 1H), 3.16-3.12 (m, 2H),
3.03 (s, 2H), 2.70-2.64 (m, 2H), 2.34 (s, 6H), 2.25-2.18 (m, 1H),
1.98-1.95 (m, 2H), 1.86-1.83 (m, 2H), 1.49 (s, 6H). LCMS (ESI): m/z
= 435.2 [M + H].sup.+. 533 N-(2,2- dimethyl-6- (piperazin-1-yl)-
2,3- dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01814## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.34 (s, 1H), 9.39 (dd, J = 6.8 Hz, 1.6 Hz, 1H), 9.02 (dd,
J = 4.0 Hz, 1.2 Hz, 1H), 8.70 (s, 1H), 8.34 (s, 1H), 7.39 (dd, J =
6.8 Hz, 4.4 Hz, 1H), 6.70 (s, 1H), 4.17-4.13 (m, 1H), 3.32-3.28 (m,
2H), 3.16 (d, J = 5.6 Hz, 2H), 3.07-3.00 (m, 6H), 1.41 (s, 6H).
LCMS (ESI): m/z = 393.0 [M + H].sup.+. 534 N-[6-(4- carbamoyl-4-
fluoro-1- piperidyl)-2,2- dimethyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01815## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.57 (s, 1H), 9.37 (d, J = 7.2
Hz, 1H), 9.27 (s, 1H), 8.67 (s, 1H), 8.46 (s, 1H), 7.72 (s, 1H), 7
49 (s, 1H), 7.40-7.30 (m, 1H), 6.74 (s, 1H), 3.10-2.75 (m, 6H),
2.65-2.55 (m, 2H), 1.95-1.75 (m, 2H), 1.41 (s, 6H). LCMS (ESI): m/z
= 453.3 [M + H].sup.+. 535 N-[6-[4-(2- Amino-2-oxo-
ethyl)-4-methyl- 1-piperidyl]-2,2- dimethyl-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01816## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.37 (s, 1H). 9.35 (dd, J =
6.8, 1.6 Hz, 1H), 8.92 (dd, J = 4.0, 1.2 Hz, 1H), 8.67 (s, 1H),
8.29 (s, 1H), 7.38- 7.30 (m, 2H), 6.78 (s, 2H), 2.99 (s, 2H),
2.83-2.72 (m, 4H), 2.13 (s, 2H), 1.83-1.75 (m, 2H), 1.61-1.54 (m,
2H), 1.41 (s, 6H), 1.12 (s, 3H). LCMS (ESI): m/z = 463.2 [M +
H].sup.+. 536 N-[6-[4-(2- amino-2-oxo ethyl)-4- hydroxy-1-
piperidyl]-2,2- dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01817## .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 10.44 (s, 1H), 8.83-8.78 (m, 3H), 8.42 (s, 1H),
7.06 (dd, J = 6.8 Hz, 4.0 Hz, 1H), 6.67 (s, 1H), 5.94 (s, 1H), 5.46
(s, 1H), 4.00 (br s, 1H), 3.07-3.04 (m, 4H), 2.87-2.83 (m, 2H),
2.53 (s, 2H), 2.02-1.91 (m, 4H), 1.49 (s, 6H). LCMS (ESI): m/z =
465.1 [M + H].sup.+. 537 N-(6- (dimethylamino)- 2,2-dimethyl- 2,3-
dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01818## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.48 (s,
1H), 8.81 (dd, J = 7.2, 1.6 Hz, 1H), 8.77 (s, 1H), 8.71-8.70 (m,
1H), 8.36 (s, 1H), 7.02 (dd, J = 7.2, 4.0 Hz, 1H), 6.64 (s, 1H),
3.04 (s, 2H), 2.72 (s, 6H), 1.49 (s, 6H). LCMS (ESI): m/z = 352.1
[M + H].sup.+.
TABLE-US-00023 TABLE 23 The following examples were made in a
manner similar to that for Example 64: Ex. Name Structure NMR, MS
538 N-(2,2-dimethyl- 6-((1-methyl- 1H-imidazol-4- yl)methoxy)-2,3-
dihydrobenzofuran- 5-yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01819## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.20 (s,
1H), 8.79-8.77 (m, 1H), 8.74 (s, 1H), 8.49-8.47 (m, 1H), 8.35 (s,
1H), 7.45 (s, 1H), 7.00- 6.96 (m, 2H), 6.56 (s, 1H), 5.12 (s, 2H) ,
3.68 (s, 3H), 3.02 (s, 2H), 1.49 (s, 6H). LCMS (ESI): m/z = 419.0
[M + H].sup.+ 539 N-[6-(1H- Imidazol-4- ylmethoxy)-2,2-
dimethyl-3H- benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01820## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.19 (s, 1H), 9.3l(d, J = 6.0 Hz, 1H), 8.64 (s, 1H), 8.33
(br s, 1H), 8.26 (s, 1H), 7.73 (s, 1H), 7.29 (s, 1H), 7.26-7.24 (m,
1H), 6.75 (s, 1H), 5.05 (s, 2H), 2.98 (s, 2H), 1.42 (s, 6H). LCMS
(ESI): m/z = 405.2 [M + H].sup.+ 540 and 541 N-[2,2-dimethyl-
6-[[(2R)-5- oxopyrrolidin-2- yl]methoxy]-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide and N-[2,2-dimethyl-
6-[[(2S)-5- oxopyrrolidin-2- yl]methoxy]-3H- benzofuran-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01821## Example 540,
Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.99 (s, 1H),
9.33 (dd, J = 6.8, 1.6 Hz, 1H), 8.86 (dd, J = 4.0, 1.6 Hz, 1H),
8.65 (s, 1H), 8.20 (s, 1H), 7.72 (s, 1H), 7.31 (dd, J = 6.8, 4.0
Hz, 1H), 6.56 (s, 1H), 4.05-4.01 (m, 2H), 3.96- 3.94 (m, 1H), 2.97
(s, 2H), 2.27- 2.17 (m, 3H), 1.94-1.91 (m, 1H), 1.41 (s, 6H). LCMS
(ESI): m/z = 422.2 [M + H].sup.+. Example 541, Peak 2: .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.01 (s, 1H), 9.37-9.36 (m, 1H),
8.88-8.87 (m, 1H), 8.67 (s, 1H), 8.22 (s, 1H), 7.73 (s, 1H), 7.33
(dd, J = 7.2, 4.4 Hz, 1H), 6.58 (s, 1H), 4.08-4.02 (m, 2H),
3.97-3.95 (m, 1H), 2.98 (s, 2H), 2.28-2.17 (m, 3H), 1.94- 1.93 (m,
1H), 1.42 (s, 6H). LCMS (ESI): m/z = 422.2 [M + H].sup.+. 542
N-[2,2- Dimethyl-6-[(5- methyl-1H- pyrazol-3- yl)methoxy]-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01822## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.95 (s,
1H), 8.82-8.74 (m, 3H), 8.41 (s, 1H), 7.04 (dd, J = 6.8, 4.8 Hz,
1H), 6.49 (s, 1H), 6.16 (s, 1H), 5.16 (s, 2H), 3.03 (s, 2H), 2.35
(s, 3H), 1.50 (s, 6H). LCMS (ESI): m/z = 441.0 [M + Na].sup.+ 543
N-[2,2- Dimethyl-6-[(5- methyl-1H- pyrazol-3- yl)methoxy]-3H-
benzofuran-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
##STR01823## .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.13 (dd, J
= 6.8, 1.6 Hz, 1H), 8.64 (s, 1H), 8.47 (dd, J = 4.0, 1.6 Hz, 1H),
8.03 (s, 1H), 7.57 (s, 1H), 7.24 (dd, J = 7.2, 4.0 Hz, 1H), 6.63
(s, 1H), 5.21 (s, 2H), 3.03 (s, 2H), 2.59 (s, 3H), 1.47 (s, 6H).
LCMS (ESI): m/z = 419.1 [M + H].sup.+
TABLE-US-00024 TABLE 24 The following examples were made in a
manner similar to that for Example 173: Ex. Name Structure NMR, MS
544 and 545 N-[2-[(1S)-3- hydroxy-1,3- dimethyl-butyl]-
6-morpholino-1- oxo-isoindolin- 5-yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide N-[2-[(1R)-3- hydroxy-1,3- dimethyl-butyl]-
6-morpholino-1- oxo-isoindolin- 5-yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide (absolute stereochemistry assigned arbitrarily)
##STR01824## Example 544, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.93 (s, 1H), 8.92-8.75 (m, 4H), 7.71 (s, 1H), 7.13 (dd, J
= 6.0, 4.4 Hz, 1H), 4.83- 4.72 (m, 1H), 4.38 (s, 2H), 4.05- 3.95
(m, 4H), 3.04-2.88 (m, 5H), 1.92-1.86 (m, 1H), 1.70-1.64 (m, 1H),
1.35 (d, J = 6.8 Hz, 3H), 1.29 (s, 3H), 1.13 (s, 3H). LCMS (ESI):
m/z = 479.2 [M + H].sup.+. Example 545, Peak 2: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 10.93 (s, 1H), 8.94-8.74 (m, 4H), 7.72 (s,
1H), 7.13 (dd, J = 6.8, 4.4 Hz, 1H), 4.84- 4.73 (m, 1H), 4.38 (s,
2H), 4.06- 3.96 (m, 4H), 3.03-2.85 (m, 5H), 1.93-1.87 (m, 1H),
1.69- 1.63 (m, 1H), 1.36 (d, J= 6.8 Hz, 3H), 1.30 (s, 3H), 1.13 (s,
3H). LCMS (ESI): m/z = 479.2 [M + H].sup.+ 546 N-[2-(1-
methylazetidin- 3-yl)-6- morpholino-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01825##
.sup.1HNMR (400 MHz, CDCl.sub.3) .delta. 10.93 (s, 1H), 8.88-8.82
(m, 4H), 7.70 (s, 1H), 7.12 (dd, J = 7.2, 4.4 Hz, 1H), 5.02-4.99
(m, 1H), 4.57 (s, 2H), 4.01-3.99 (m, 4H), 3.85- 3.72 (m, 2H),
3.50-3.40 (m, 2H), 3.00-2.97 (m, 4H), 2.48 (s, 3H). LCMS (ESI): m/z
= 479.2 [M + H].sup.+. 547 and 548 Cis-N-[2-[4-(1- Hydroxy-1-
methyl- ethyl)cyclohexyl]- 6-morpholino- 1-oxo- isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide trans-N-[2-[4-
(1-Hydroxy-1- methyl- ethyl)cyclohexyl] 6-morpholino-1-
oxo-isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01826##
Example 547, Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.92 (s, 1H), 8.88-8.82 (m, 4H), 7.74 (s, 1H), 7.13 (dd, J = 6.8,
4.0 Hz, 1H), 4.59 (s, 2H), 4.48-4.47 (m, 1H), 4.03- 4.00 (m, 4H),
3.01-2.99 (m, 4H), 2.19-2.16 (m, 2H), 1.85-1.76 (m, 4H), 1.53-1.50
(m, 3H), 1.25 (s, 6H). LCMS (ESI): m/z = 519.2 [M + H].sup.+.
Example 548, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.89 (s, 1H), 9.40 (dd, J = 7.2, 1.6 Hz, 1H), 8.99 (dd, J = 4.0, 1
6 Hz, 1H), 8.75 (s, 2H), 7.56 (s, 1H), 7.38 (dd, J = 6.8, 4.4 Hz,
1H), 4.42 (s, 2H), 4.08 (s, 1H), 3.98-3.88 (m, 5H), 2.90- 2.89 (m,
4H), 1.91-1.88 (m, 2H), 1.82-1.74 (m, 2H), 1.60-1.50 (m, 2H),
1.25-1.14 (m, 3H), 1.06 (s, 6H). LCMS (ESI): m/z = 519.2 [M +
H].sup.+ 549 and 550 N-[2-[[(1S,2R)-2- hydroxycyclopentyl]-
methyl]-6- morpholino-1- oxo-isoindolin- 5-yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide W-[2-[[(1R,2S)-2- hydroxycyclopentyl]-
methyl]-6- morpholino-1- oxo-isoindolin- 5-yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01827## Example 549, Peak 1: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 10.92 (s, 1H), 8.87-8.81 (m, 4H), 7.72 (s,
1H), 7.12 (dd, J = 7.2, 4.0 Hz, 1H), 4.51- 4.41 (m, 2H), 4.02-4.00
(m, 4H), 3.98-3.97 (m, 1H), 3.64 (d, J = 6.8 Hz, 2H), 3.00-2.98 (m,
4H), 2.66-2.65 (m, 1H), 2.14-1.61 (m, 6H), 1.41-1.34 (m, 1H). LCMS
(ESI): m/z = 477.2 [M + H].sup.+. Example 550, Peak 2: .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 10.92 (s, 1H), 8.87-8.81 (m, 4H),
7.72 (s, 1H), 7.12 (dd, J= 7.2, 4.4 Hz, 1H), 4.52- 4.41 (m, 2H),
4.02-4.00 (m, 4H), 3.98-3.97 (m, 1H), 3.64 (d, J = 6.4 Hz, 2H),
3.00-2.98 (m, 4H), 2.66-2.64 (m, 1H), 2.12-1.66 (m, 6H), 1.41-1.33
(m, 1H). LCMS (ESI): m/z = 477.2 [M + H].sup.+. 551 and 552 N-[6-
morpholino-2- [(2S)-2- morpholinopropyl]- 1-oxo-isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide; and
N-[6-morpholino-2- [(2R)-2- morpholinopropyl]- 1-oxo-isoindolin-5-
yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01828## Example 551,
Peak 1: .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta. 10.90 (s, 1H),
9.42-9.40 (m, 1H), 8.99 (s, 1H), 8.78-8.73 (m, 2H), 7.57 (s, 1H),
7.42-7.36 (m, 1H), 4.61-4.48 (m, 2H), 3.95-3.85 (m, 4H), 3.61- 3.45
(m, 6H), 2.95-2.85 (m, 5H), 2.65-2.53 (m, 2H), 2.48- 2.35 (m, 2H),
0.93 (d, J = 6.4 Hz, 3H). LCMS (ESI): m/z = 506.2 [M + H].sup.+.
Example 552, Peak 2: .sup.1HNMR (400 MHz, DMSO-d.sub.6) .delta.
10.90 (s, 1H), 9.42-9.40 (m, 1H), 9.00 (s, 1H), 8.78-8.73 (m, 2H),
7.57 (s, 1H), 7.42-7.36 (m, 1H), 4.61-4.48 (m, 2H), 3.95-3.85 (m,
4H), 3.61- 3.45 (m, 6H), 2.95-2.85 (m, 5H), 2.65-2.53 (m, 2H),
2.48- 2.35 (m, 2H), 0.93 (d, J = 6.4 Hz, 3H). LCMS (ESI): m/z =
506.2 [M + H].sup.+. 553 and 554 N-[2-[(3R)-1- methyl-2-oxo
pyrrolidin-3-yl]- 6-morpholino-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide; and N-[2-[(3S)-1-
methyl-2-oxo- pyrrolidin-3-yl]- 6-morpholino-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01829## Example 553,
Peak 1: .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.14 (dd, J =
6.8, 1.6 Hz, 1H), .delta. 93 (dd, J = 4.0, 1.6 Hz, 1H), 8.73 (s,
1H), 8.67 (s, 1H), 7.70 (s, 1H), 7.29 (dd, J = 6.8, 4.4 Hz, 1H),
5.09 (t, J = 9.6 Hz, 1H), 4.54 (d, J = 17.2 Hz, 1H), 4.38 (d, J =
17.2 Hz, 1H), 4.03- 3.97 (m, 4H), 3.56-3.53 (m, 2H), 2.99-2.96 (m,
4H), 2.95 (s, 3H), 2.52-2.44 (m, 1H), 2.34-2.24 (m, 1H). LCMS
(ESI): m/z = 476.2 [M + H].sup.+. Example 554, Peak 2: .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 9.15 (dd, J = 7.2, 1.6 Hz, 1H), 8.95
(dd, J = 4.4, 2.0 Hz, 1H), 8.75 (s, 1H), 8.69 (s, 1H), 7.71 (s,
1H), 7.30 (dd, J = 6.8, 4.4 Hz, 1H), 5.09 (t, J = 9.6 Hz, 1H), 4.55
(d, J = 17.2 Hz, 1H), 4.38 (d, J = 17.2 Hz, 1H), 4.03- 3.97 (m,
4H), 3.56-3.53 (m, 2H), 2.99-2.96 (m, 4H), 2.95 (s, 3H), 2.52-2.45
(m, 1H), 2.34-2.26 (m, 1H). LCMS (ESI): m/z = 476.2 [M + H].sup.+.
555 and 556 N-[6- morpholino-1- oxo-2-[[(3S)- tetrahydrofuran-
3-yl]methyl]- isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide N-[6- morpholino-1- oxo-2-[[(3R)- tetrahydrofuran-
3-yl]methyl]- isoindolin-5- yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide (absolute stereochemistry assigned arbitrarily)
##STR01830## Example 555, Peak 1: .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.90 (s, 1H), 9.41 (d, J = 6.8 Hz, 1H), 8.99
(s, 1H), 8.75 (s, 2H), 7.57 (s, 1H), 7.40-7.37 (m, 1H), 4.50 (s,
2H), 3.89 (s, 4H), 3.80-3.69 (m, 2H), 3.66-3.60 (m, 1H), 3.51-3.50
(m, 2H), 3.46-3.42 (m, 1H), 2.91 (s, 4H), 2.66-2.58 (m, 1H), 1.97-
1.93 (m, 1H), 1.60-1.56 (m, 1H). LCMS (ESI): m/z = 463.1 [M +
H].sup.+. Example 556, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.90 (s, 1H), 9.41 (d, J = 6.8 Hz, 1H), 8.99 (s, 1H), 8.76
(s, 2H), 7.58 (s, 1H), 7.41-7.37 (m, 1H), 4.50 (s, 2H), 3.90 (s,
4H), 3.80-3.69 (m, 2H), 3.66-3.60 (m, 1H), 3.52-3.50 (m, 2H),
3.47-3.43 (m, 1H), 2.91 (s, 4H), 2.66-2.58 (m, 1H), 2.00- 1.91 (m,
1H), 1.62-1.54 (m, 1H). LCMS (ESI): m/z = 463.1 [M + H].sup.+. 557
and 558 N-[2-[(2R,2S)-2- fluoro-3- hydroxy-butyl]- 6-morpholino-1-
oxo-isoindolin- 5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide; and
N-[2-[(2S,3R)-2- fluoro-3- hydroxy-butyl]- 6-morpholino-1-
oxo-isoindolin- 5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01831##
Example 557, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.90 (s, 1H), 9.39 (d, J = 6.4 Hz, 1H), 8.98 (s, 1H), 8.74 (s,
2H), 7.59 (s, 1H), 7.40-7.37 (m, 1H), 5.17-5.16 (m, 1H), 4.60-4.41
(m, 3H), 3.97- 3.73 (m, 7H), 2.91 (s, 4H), 1.15 (d, J = 6.0 Hz,
3H). LCMS (ESI): m/z = 469.2 [M + H].sup.+. Example 558, Peak 2:
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.99 (s, 1H), 9.48 (d,
J = 6.8 Hz, 1H), 9.08 (s, 1H), 8.83 (s, 2H), 7.67 (s, 1H),
7.50-7.45 (m, 1H), 5.23 (d, J = 5.6 Hz, 1H), 4.62-4.52 (m, 3H),
4.03-3.81 (m, 7H), 2.99 (s, 4H), 1.23 (d, J = 5.6 Hz, 3H). LCMS
(ESI): m/z = 469.2 [M + H].sup.+. 559 and 560 N-[2-[[(1S,2S)-2-
hydroxycyclopentyl]- methyl]-6- morpholino-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide N-[2-[[(1R,2R)-2-
hydroxycyclopentyl]- methyl]-6- morpholino-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide (absolute
stereochemistry assigned arbitrarily) ##STR01832## Example 559,
Peak 1: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.95 (s, 1H),
8.89-8.82 (m, 4H), 7.73 (s, 1H), 7.14 (dd, J = 6,8, 4.0 Hz, 1H),
4.69 (s, 1H), 4.56 (d, J = 17.2 Hz, 1H), 4.36 (d, J = 17.2 Hz, 1H),
4.16- 4.09 (m, 1H), 4.03-4.01 (m, 4H), 3.99-3.90 (m, 1H), 3.27-3.22
(m, 1H), 3.00-2.99 (m, 4H), 2.03- 1.57 (m, 7H). LCMS (ESI): m/z =
477.2 [M + H].sup.+. Example 560, Peak 2: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.95 (s, 1H), 8.89-8.82 (m, 4H), 7.73 (s, 1H),
7.14 (dd, J = 6.8, 4.0 Hz, 1H), 4.69 (s, 1H), 4.56 (d, J = 17.6 Hz,
1H), 4.36 (d, J = 16.8 Hz, 1H), 4.16- 4.09 (m, 1H), 4.03-4.01 (m,
4H), 3.99-3.96 (m, 1H), 3.27-3.22 (m, 1H), 3.01-2.99 (m, 4H), 2.03-
1.55 (m, 7H). LCMS (ESI): m/z = 477.2 [M + H].sup.+. 561 and 562
N-(2-((2S,3S)-2- fluoro-3- hydroxybutyl)- 6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide; and
N-(2-((2R,3R)- 2-fluoro-3- hydroxybutyl)- 6-morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01833##
Example 561, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.89 (s, 1H), 9.39-9.37 (m, 1H), 8.99- 8.98 (m, 1H), 8.74-8.73 (m,
2H), 7.58 (s, 1H), 7.38 (dd, J = 6.8, 4.4 Hz, 1H), 5.09-5.08 (m,
1H), 4.63- 4.47 (m, 3H), 3.89-3.81 (m, 7H), 2.95-2.85 (m, 4H), 115
(d, J = 6.4 Hz, 3H). LCMS (ESI): m/z = 469.2 [M + H].sup.+ Example
562, Peak 2: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.90 (s,
1H), 9.42-9.40 (m, 1H), 9.00- 8.99 (m, 1H), 8.75 (s, 2H), 7.59 (s,
1H), 7.40-7.37 (m, 1H), 5.01 (d, J = 5.60, 1H), 4.63-4.48 (m, 3H),
3.90-3.66 (m, 7H), 2.92 (s, 4H), 1.16 (d, J = 6.4 Hz, 3H). LCMS
(ESI): m/z = 469.2 [M + H].sup.+. 563 N-[6-(azetidin-1-
yl)-2-[(2R)-2- fluoro-3-hydroxy-3- methyl-butyl]-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01834## .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.86 (s, 1H), 8.96-8.73 (m, 3H),
8.33 (s, 1H), 7.27 (s, 1H), 7.12 (br s, 1H), 4.64-4.35 (m, 3H),
4.29- 4.09 (m, 1H), 4.05-3.89 (m, 4H), 3.78-3.60 (m, IH), 2.75 (s,
1H), 2.35-2.25 (m, 2H), 1.34 (s, 3H), 1.32 (s, 3H). LCMS (ESI): m/z
= 453.1 [M + H].sup.+. 564 and 565 N-(2-((1S,2R)- 2-(hydroxymethyl)
cyclopentyl)-6- morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide; and N-(2-((1R,2S)- 2-(hydroxymethyl)
cyclopentyl)-6- morpholino-1- oxoisoindolin-5- yl)pyrazolo[1,5-
a]pyrimidine-3- carboxamide (absolute stereochemistry assigned
arbitrarily) ##STR01835## Example 564, Peak 1: .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 10.95 (s, 1H), 8.89-8.82 (m, 4H), 7.74 (s,
1H), 7.14 (dd, J = 6.4, 4.0 Hz, 1H), 4.81 (br s, 1H), 4.58 (d, J =
M2 Hz, 1H) , 4.31 (d, J = 16.8 Hz, 1H), 4.21-4.18 (m, 1H), 4.02 (s,
4H), 3.63-3.58 (m, 1H), 3.20 (t, J = 10.8 Hz, 1H), 3.00 (s, 4H),
2.45- 2.35 (m, 1H), 2.11-1.89 (m, 4H), 1.29-1.26 (m, 2H). LCMS
(ESI): m/z = 477.3 [M + H].sup.+. Example 565, Peak 2: .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 10.95 (s, 1H), 8 89-8.82 (m, 4H),
7.74 (s, 1H), 7.14 (dd, ,/= 6.4, 4.4 Hz, 1H), 4.81 (br s, 1H), 4.58
(d, J = 17.2 Hz, 1H) , 4.31 (d, J = 17.2 Hz, 1H), 4.21-4.18 (m,
1H), 4.02 (s, 4H), 3.63-3.58 (m, 1H), 3.20 (t, J = 10.8 Hz, 1H),
3.00 (s, 4H), 2.45- 2.35 (m, 1H), 2.16-1.84 (m, 4H), 1.29-1.26 (m,
2H). LCMS (ESI): m/z = 477.3 [M + H].sup.+. 566 and 567
N-(2-((1S,2S)-2- (hydroxymethyl) cyclopentyl)-6- morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide; and
N-(2-((1R,2R)-2- (hydroxymethyl) cyclopentyl)-6- morpholino-1-
oxoisoindolin-5- yl)pyrazolo[1,5- a]pyrimidine-3- carboxamide
(absolute stereochemistry assigned arbitrarily) ##STR01836##
Example 566, Peak 1: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.89 (s, 1H), 9.40 (dd, J = 7.2, 1.6 Hz, 1H), 9.02-8.96 (m, 1H),
8.75 (s, 2H), 7.55 (s, 1H), 7.38 (dd, J = 7.2, 4.4 Hz, 1H),
4.51-4.41 (m, 3H), 4.29- 4.25 (m, 1H), 3.93-3.86 (m, 4H), 3.45-3.36
(m, 2H), 2.90 (s, 4H), 2.22-2.09 (m, 1H), 1.93- 1.38 (m, 6H). LCMS
(ESI): m/z = 477.3 [M + H].sup.+. Example 567, Peak 2: .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.89 (s, 1H), 9.41-9.40 (m, 1H),
9.00- 8.99 (m, 1H), 8.75 (s, 2H), 7.55 (s, 1H), 7.38 (dd, J = 7.2,
4.0 Hz, 1H), 4.52-4.40 (m, 3H), 4.33-4.22 (m, 1H), 3.90 (s, 4H),
3.46-3.38 (m, 2H), 2.91 (s, 4H), 2.15-1.85 (m, 1H), 1.92-1.38 (m,
6H). LCMS (ESI): m/z = 477.3 [M + H].sup.+. 568 N-[2-[(2R)-2-
Fluoro-3-hydroxy-3- methyl-butyl]-6-[2- hydroxyethyl(methyl)-
amino]-1- oxo-isoindolin- 5-yl]pyrazolo[1,5- a]pyrimidine-3-
carboxamide ##STR01837## .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.91 (s, 1H), 8.85-8.81 (m, 4H), 7.72 (s, 1H), 7.12-7.06 (m, 1H),
4.65-4.46 (m, 3H), 4.25-4.12 (m, 1H), 3.81-3.67 (m, 5H), 3.33- 3.27
(m, 2H), 2.67 (s, 3H), 1.36- 1.30 (m, 6H). LCMS (ESI): m/z = 471.2
[M + H].sup.+
TABLE-US-00025 TABLE 25 The following examples were made in a
manner similar to that for Example 250: Ex. Name Structure NMR, MS
569 N-[6-(4-Cyano- 4-methyl-1- piperidyl)-2- [(2R)-2-fluoro-
3-hydroxy-3- methyl-butyl]-1- oxo-isoindolin- 5-yl]pyrazolo[1,5-
a]pyrimidine-3- carboxamide ##STR01838## .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.75 (s, 1H), 8.98-8.60 (m, 4H), 7.77 (s, 1H),
7.17- 7.09 (m, 1H), 4.71-4.36 (m, 3H), 4.29-4.09 (m, 1H), 3.72-3.64
(m, 1H), 3.15- 3.05 (m, 4H), 2.53 (s, 1H), 2.25-2.17 (m, 2H), 2.01-
1.93 (m, 2H), 1.55 (s, 3H), 1.40-1.28 (m, 6H). LCMS (ESI): m/z =
520.2 [M + H].sup.+. 570 N-[6- (dimethylamino)- 2-[(2R)-2-
fluoro-3- hydroxy-3- methyl-butyl]-1- oxo-isoindolin-
5-yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide ##STR01839## .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 11.03 (s, 1H), 8.86-8.75 (m, 4H),
7.70 (s, 1H), 7.08 (dd, J = 7.2, 4.0 Hz, 1H), 4.64-4.48 (m, 3H),
4.25- 4.12 (m, 1H), 3.75-3.66 (m, 1H), 2.81 (s, 6H), 1.34 (s, 3H),
1.32 (s, 3H). LCMS (ESI): m/z = 441.1 [M + H].sup.+.
Biological Examples
[2150] Compounds were assayed for inhibition of human IRAK4 and
IRAK1 catalytic activity using recombinant enzyme produced from
insect cells. Full-length IRAK4 protein, carrying an N-terminal
His6-Tag, was obtained from Life Technologies (Carlsbad, Calif.,
USA). The IRAK1 construct was produced internally and was comprised
of IRAK1 residues Arg194 to Ser712, preceded by an NH2-terminal
His6 tag and the coding sequence for glutathione-S-transferase.
[2151] Kinase activities were assayed using the
Transcreener-Fluorecescence polarization platform (BelBrook Labs,
Madison, Wis., USA) that measures amounts of the reaction product,
ADP. The IRAK4 reaction conditions were optimized using an
IRAK1-derived peptide (sequence H-KKARFSRFAGSSPSQSSMVAR) to provide
a linear reaction rate over the course of a 90 min incubation,
which resulted in 10-12% conversion of the starting ATP to ADP.
Final IRAK4 assay conditions were 1.25 nM IRAK4; 125 uM ATP; 10 uM
MgCl.sub.2; 125 uM peptide in reaction buffer (25 mM HEPES (pH7.4);
2 mM Dithiothreitol; 0.015% Brij-35; and 0.5% dimethyl sulfoxide.
The IRAK1 activity was optimized similarly, yielding final assay
conditions of 3 mM IRAK1; 62.5 uM ATP; 5 uM MgCl.sub.2, and 62.5 uM
IRAK1 peptide in reaction buffer for 60 min.
[2152] Assays of compounds for kinase inhibition were performed
using inhibitors serially-diluted in dimethyl sulfoxide, which was
accomplished with a LabCyte Echo 555 liquid dispenser. 384 well
assay plates spotted with compound received 4 ul of a 2.times.
substrate (ATP+peptide) mix in reaction buffer, followed by 4 ul of
2.times. enzyme diluted in reaction buffer.
[2153] Reactions were halted at 60 (IRAK1) or 90 (IRAK4) min by
addition of 6 ul of detection buffer, containing EDTA (40 nM final
concentration), 0.95 ug of the ADP-binding antibody ADP2, ADP
tracer (3 nM final concentration), and 25 uM HEPES. Following a 1
hr incubation, fluorescence polarization of the
ADP2-antibody::TRACER complex was read on a Tecan M1000 plate
reader using a 635/20 excitation filter in combination with a
670/20 emission filter. Delta milli-P values were analyzed using
Genedata software to fit dose-response curves and compute compound
Ki values, using ATP Km values of 642 um and 83.2 uM for IRAK4 and
IRAK1, respectively. Tables 15, 16 and 17 provide IRAK4 Ki values
for representative compounds of the present invention.
TABLE-US-00026 TABLE 26 IRAK4 Ki values of representative compounds
of the present invention. Example IRAK4 Ki (uM) 1 0.0047 2 0.026 3
0.15 4 0.0015 5 0.054 6 0.014 7 0.0039 8 0.0023 9 0.098 10 0.27 11
0.072 12 0.002 13 0.0067 14 0.019 15 0.012 16 0.0019 17 0.18 18
0.021 19 0.0033 20 0.78 21 0.0064 22 23 0.031 24 0.0029 25 0.01 26
0.0051 27 0.26 28 0.027 29 0.009 30 0.032 31 0.0054 32 0.015 33
0.005 34 0.038 35 0.69 36 0.15 37 0.37 38 0.36 39 0.011 40 0.001 41
0.084 42 0.2 43 0.13 44 0.0017 45 0.0019 46 0.54 47 0.18 48 0.19 49
0.022 50 0.0062 51 0.0096 52 0.0038 53 0.0027 54 0.016 55 0.034 56
0.021 57 0.06 58 0.036 59 0.0096 60 0.0066 61 0.035 62 0.26 63 0.39
64 0.0087 65 0.0092 66 0.024 67 0.0044 68 0.0098 69 0.027 70 0.028
71 0.92 72 0.45 73 0.36 74 0.75 75 0.065 76 0.025 77 0.013 78 0.84
79 1.5 80 0.034 81 0.1 82 0.19 83 0.062 84 0.024 85 0.017 86 0.049
87 0.019 88 0.0076 89 0.026 90 0.043 91 0.039 92 0.0023 93 0.0018
94 0.029 95 0.025 96 0.014 97 0.0072 98 0.0028 99 0.0033 100 0.021
101 0.032 102 0.19 103 0.088 104 0.022 105 0.72 106 0.0024 107
0.079 108 0.079 109 0.0042 110 0.0025 111 0.0048 112 0.078 113 0.32
114 0.017 115 0.0095 116 0.018 117 0.017 118 0.014 119 0.79 120
0.001 121 0.016 122 0.006 123 1.1 124 0.49 125 0.005 126 0.0057 127
0.026 128 0.034 129 0.0032 130 0.0033 131 132 0.0048 133 0.0041 134
135 136 0.0035 137 0.17 138 0.0068 139 0.0015 140 0.026 141 0.016
142 0.02 143 0.74 144 0.013 145 0.13 146 0.027 147 0.023 148 0.0061
149 0.025 150 0.089 151 0.072 152 0.012 153 0.014 154 0.0093 155
0.022 156 0.027 157 0.0088 158 0.027 159 0.0044 160 0.0048 161
0.0038 162 0.0045 163 0.0039 164 0.0028 165 0.0056 166 0.018 167
0.0028 Blank = not determined
TABLE-US-00027 TABLE 27 IRAK4 Ki values of representative compounds
of the present invention. Example IRAK4 Ki (uM) 168 0.0036 169
0.0025 170 0.003 171 0.038 172 0.016 173 0.029 174 0.02 175 0.0022
176 0.051 177 0.002 178 0.015 179 0.031 180 0.0038 181 0.002 182
0.056 183 0.0051 184 0.0031 185 0.0058 186 0.015 187 0.002 188
0.084 189 0.0055 190 0.63 191 0.027 192 0.044 193 0.1 194 0.41 195
0.02 196 0.013 197 0.033 198 0.14 199 0.17 200 0.022 201 0.028 202
0.69 203 0.015 204 0.73 205 0.086 206 0.0034 207 0.017 208 0.015
209 0.0058 210 0.0031 211 0.0051 212 0.056 213 0.003 214 0.012 215
0.0054 216 0.003 217 0.015 218 0.017 219 0.082 220 0.075 221 0.003
222 0.094 223 0.072 224 0.33 225 0.045 226 0.006 227 0.49 228 0.048
229 0.26 230 0.018 231 0.003 232 0.034 233 0.10 234 0.033 235 0.004
236 0.013 237 0.81 238 0.036 239 0.12 240 0.027 241 0.015 242 0.028
243 0.25 244 0.036 245 0.010 246 0.006 247 0.015 248 0.036 249
0.047 250 0.024 251 0.029 252 0.005 253 0.020 254 0.026 255 0.004
256 0.002 257 0.006 258 0.003 259 0.002 260 261 0.002 262 0.010 263
0.008 264 0.002 265 0.004 266 0.009 267 0.039 268 0.075 269 0.0015
270 0.0097 271 0.0017 272 0.004 273 0.037 274 0.0014 275 0.034 276
0.026 277 0.016 278 0.004 279 0.0018 280 0.002 281 0.0024 282 0.002
283 0.002 284 0.002 285 0.002 286 0.002 287 0.026 288 0.063 289
0.008 290 0.18 291 0.38 292 0.76 293 0.69 294 0.014 295 0.0082 296
0.018 297 0.023 298 0.007 299 0.031 300 0.007 301 0.017 302 0.011
303 0.97 304 0.72 305 0.029 306 0.052 307 0.032 308 0.009 309 0.015
310 0.023 311 0.010 312 0.073 313 0.49 314 0.065 315 0.52 316
0.0052 317 0.0024 318 0.0043 319 0.0031 320 0.0046 321 0.011 322
0.035 323 0.0042 324 0.0048 325 0.006 326 0.0032 327 0.0033 328
0.0027 329 0.006 330 0.006 331 0.012 332 0.006 333 0.003 334 0.003
335 0.002 Blank = not determined
TABLE-US-00028 TABLE 28 IRAK4 Ki values of representative compounds
of the present invention. Example IRAK4 Ki (uM) 336 0.003 337
0.0045 338 0.0077 339 0.005 340 0.008 341 0.004 342 0.0039 343
0.005 344 0.008 345 0.004 346 0.0029 347 0.0036 348 0.89 349 1.1
350 0.005 351 352 0.002 353 354 0.003 355 0.006 356 0.004 357 0.41
358 0.51 359 0.26 360 0.0063 361 0.0092 362 0.0067 363 0.0053 364
0.0037 365 0.0045 366 0.0075 367 0.0058 368 0.021 369 0.0068 370
0.0058 371 0.0014 372 0.013 373 0.0017 374 0.002 375 0.047 376
0.046 377 0.011 378 0.0073 379 0.0051 380 0.0081 381 0.003 382
0.004 383 0.0076 384 0.037 385 0.019 386 0.016 387 0.015 388 0.012
389 0.0013 390 0.016 391 0.031 392 0.018 393 0.024 394 0.075 395
0.34 396 0.11 397 0.088 398 0.007 399 0.005 400 0.001 401 0.097 402
0.019 403 0.68 404 0.064 405 0.52 406 0.15 407 0.006 408 0.046 409
0.0067 410 0.0062 411 0.0076 412 0.0059 413 0.032 414 0.012 415
0.003 416 0.003 417 0.0036 418 0.0048 419 0.009 420 0.014 421 0.10
422 0.11 423 0.0096 424 0.003 425 0.006 426 0.005 427 0.038 428
0.075 429 0.012 430 0.13 431 0.020 432 0.010 433 0.014 434 0.022
435 0.053
TABLE-US-00029 TABLE 29 IRAK4 Ki values of representative compounds
of the present invention. Example IRAK4 Ki (uM) 436 0.01 437 0.014
438 0.055 439 0.034 440 0.053 441 0.006 442 0.096 443 0.038 444
0.0028 445 0.0033 446 0.052 447 0.006 448 0.024 449 0.08 450 451
0.0047 452 0.15 453 0.044 454 0.0088 455 0.0058 456 0.0026 457
0.0044 458 0.037 459 0.016 460 0.0059 461 0.029 462 0.0065 463
0.025 464 0.067 465 0.038 466 0.099 467 0.013 468 0.0051 469 0.0088
470 0.012 471 0.0065 472 0.0025 473 0.005 474 0.02 475 0.0095 476
0.033 477 0.035 478 0.006 479 0.0067 480 481 482 483 484 0.35 485
0.066 486 0.037 487 0.00061 488 0.61 489 0.24 490 0.98 491 0.0011
492 0.0091 493 0.043 494 0.04 495 0.017 496 0.00083 497 0.0026 498
0.029 499 0.03 500 0.084 501 0.0069 502 0.0058 503 0.004 504 0.0031
505 0.0052 506 0.0051 507 0.0032 508 0.043 509 0.0011 510 0.044 511
512 0.15 513 0.21 514 0.81 515 0.42 516 0.0061 517 0.14 518 0.13
519 0.039 520 0.0011 521 0.004 522 0.0034 523 0.0044 524 0.0041 525
0.0042 526 527 528 529 530 531 0.0032 532 0.0072 533 0.013 534
0.002 535 0.0031 536 0.0031 537 0.012 538 0.22 539 0.033 540 0.074
541 0.19 542 0.059 543 0.14 544 0.013 545 0.0059 546 0.011 547
0.038 548 0.0029 549 0.0081 550 0.0021 551 0.0029 552 0.012 553
0.058 554 0.014 555 0.0038 556 0.0045 557 0.0073 558 0.0084 559
0.0022 560 0.0016 561 0.011 562 0.0019 563 0.033 564 0.028 565
0.094 566 0.008 567 0.0059 568 569 0.0031 570 0.00063 Blank = not
determined
[2154] The features disclosed in the foregoing description, or the
following claims, expressed in their specific forms or in terms of
a means for performing the disclosed function, or a method or
process for attaining the disclosed result, as appropriate, may,
separately, or in any combination of such features, be utilized for
realizing the invention in diverse forms thereof.
[2155] The foregoing invention has been described in some detail by
way of illustration and example, for purposes of clarity and
understanding. It will be obvious to one of skill in the art that
changes and modifications may be practiced within the scope of the
appended claims. Therefore, it is to be understood that the above
description is intended to be illustrative and not restrictive. The
scope of the invention should, therefore, be determined not with
reference to the above description, but should instead be
determined with reference to the following appended claims, along
with the full scope of equivalents to which such claims are
entitled.
[2156] The patents, published applications, and scientific
literature referred to herein establish the knowledge of those
skilled in the art and are hereby incorporated by reference in
their entirety to the same extent as if each was specifically and
individually.
* * * * *